

(19) World Intellectual Property Organization  
International Bureau



BS

(43) International Publication Date  
27 December 2001 (27.12.2001)

PCT

(10) International Publication Number  
WO 01/98526 A2

(51) International Patent Classification<sup>7</sup>: C12Q

(21) International Application Number: PCT/US01/20122

(22) International Filing Date: 22 June 2001 (22.06.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/213,812 22 June 2000 (22.06.2000) US  
09/804,291 13 March 2001 (13.03.2001) US

(71) Applicant: SENOMYX, INC. [US/US]; Suite 160, 11099 N. Torrey Pines Road, La Jolla, CA 92037 (US).

(72) Inventors: ZOZULYA, Sergey; 3950 Mahaila Avenue #B22, San Diego, CA 92122 (US). STRYER, Lubert; c/o Senomyx, Inc., 11099 N. Torrey Pines Road, Suite 160, La Jolla, CA 92037 (US).

(74) Agents: TESKIN, Robin, L. et al.; Pillsbury Winthrop LLP, 1600 Tysons Boulevard, McLean, VA 22102 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 01/98526 A2

(54) Title: RECEPTOR FINGERPRINTING, SENSORY PERCEPTION, AND BIOSENSORS OF CHEMICAL SENSANTS

(57) Abstract: The use of sensory G protein-coupled receptors that recognize chemical sensants, particularly those involving olfactory and taste receptors; polypeptide fragments and mutants thereof; classes of such receptors; polynucleotides encoding such receptors, fragments and mutants thereof, and representatives of receptor classes; genetic vectors including such polynucleotides; and cells and non-human organisms engineered to express such receptor complexes, fragments and mutants of an olfactory or taste receptor, and representatives of receptor classes to simulate sensory perception of odorants and tastants is described. The use of such products as a biosensor or a components thereof to detect, identify, measure, or otherwise process the event of binding between the receptor and its cognate ligand (*i.e.*, chemical sensant) is also described. The invention has application, for example, in the design and formulation of odorant and tastant compositions.

## BIOSENSORS OF CHEMICAL SENSANTS

## 5

This application is related to U.S. Provisional Serial No. 60/213,812, filed June 22, 2000, and U.S. Serial No. 09/804,291, filed March 13, 2001, which are incorporated by reference in their entirety.

## 10

### Field of the Invention

The invention relates to the use of sensory G protein-coupled receptor complexes that recognize chemical sensants, particularly those involving olfactory and taste receptors; polypeptide fragments and mutants thereof; classes of such receptors; polynucleotides encoding such receptors, fragments and mutants thereof, and representatives of receptor classes; genetic vectors including such polynucleotides; and cells and non-human organisms engineered to express such receptor complexes, fragments and mutants of an olfactory or taste receptor, and representatives of receptor classes to simulate sensory perception of odorants and tastants. The invention also relates to the use of such products as a biosensor or component thereof to detect, to identify, to measure, or otherwise process the event of binding between the receptor and its cognate ligand (*i.e.*, chemical sensant). The invention has application, for example, in the design and formulation of odorant and tastant compositions.

25 Description of the Related Art

The olfactory and taste systems provide sensory information about the chemical environment. Olfactory receptors and taste receptors recognize, respectively, "odorants" and "tastants," collectively referred to as "sensants" or "sensory receptor ligands" herein. A "primary" sensant is an odorant or tastant ligand that substantially binds to sensory receptors with a ligand-binding site of a single amino acid sequence. Olfactory and taste receptors belong to the superfamily of seven-transmembrane guanyl nucleotide-binding proteins: such receptors are, however, also recognized as distinct families, or sub-genuses, of olfactory or taste

receptors (see Raming *Nature* 361:353, 1993). These receptors control diverse physiological functions such as media-ting signaling from an external chemical stimulus across the membrane containing the receptor into a cell, endocrine function, exocrine function, heart rate, lipolysis, and carbohydrate metabolism. Thus, the  
5 dissection of these diverse functions into component signals is needed.

But the complexities of sensory perception of chemical sensants prevent easy translation of the olfaction and taste systems to a machine sensor. For example, U.S. Patent Nos. 5,675,070; 5,918,257; 5,928,609; and 6,085,576 disclose machine sensors that use various chemistries, but they do not take advantage of the specificity of  
10 olfactory and taste receptors for their cognate ligands to produce a biosensor.

WO 00/15269 discloses methods and apparatus for odor reproduction. The total affinities of a specific odorant with a group of receptors was called the affinity fingerprint of the odorant. This odorant fingerprint was represented by a vector of affinity values. It was proposed to repro-duce an arbitrary odor by inputting its sensed  
15 odorant fingerprint into a device, which has a palate of predetermined odorants and produces a composite odor using predetermined odorant finger-prints by minimizing the difference between vectors representing the sensed odorant fingerprint and the predetermined odorant fingerprints. This reference, however, does not teach or suggest the human olfactory receptors disclosed herein.

20 WO 00/70343 discloses biosensors and sense replication systems using G-protein coupled receptors (GPCR). It was proposed to mimic the response of the G-protein signal transduction system by detecting the affinity of a stimulus to a plurality of GPCR, codifying such information into electronic signals, and reproducing the stimulus by converting the codified information into a combination of stimulant  
25 entities. But this reference also does not teach or suggest the human olfactory receptors disclosed herein.

WO 01/27158 discloses olfactory receptors and their use to determine the correspondence between individual odorant receptors and particular odors. It was proposed that the interactions between an odor and olfactory receptors can be used to  
30 represent the odor and to re-create it. This reference, however, does not teach or suggest the human olfactory receptors disclosed herein.

Dissecting the function of sensory receptors by binding sensory receptors of a clone of cells expressing a single sensory receptor gene, fragmentation of sensory

receptors to provide ligand-binding or signal-transducing domains thereof, and construction of fusion sensory receptor proteins will separate the diverse physiological functions associated with sensory perception at the level of ligand-receptor binding. Furthermore, novel "primary sensants" that are identified and isolated by the methods described herein may be used to further define the function of the cognate sensory receptor by uniquely enhancing or, in the alternative, blocking stimulation of sensory receptors with a single ligand-binding domain.

The present invention addresses the need for better understanding of these ligand-receptor interactions by using a large set of identified sensory receptors. Even if the receptor set used is incomplete (*i.e.*, a partial set of all sensory receptors encoded in the genome), a large number of sensants will be detected. Moreover, redundancy in the chemical structures recognized by the sensory receptors or combinatorial processing of signals from different sensory receptors would allow broad coverage of chemically diverse sensants (*e.g.*, by selection of a representative class of sensory receptors). Also provided are, *inter alia*, methods for utilizing such sensory receptors and biosensors to simulate sensory perception. To analyze ligand-receptor interactions and their effects on cell signaling and the processing of those signals in sensory perception, specific sensants and their cognate receptor complexes are detected, identified, and measured under binding conditions. Fragrances and flavorings can be detected, identified, measured, and/or custom designed by the methods herein described. In addition, drugs that incorporate artificial odors and/or tastes can be formulated.

### Summary of the Invention

Large gene families encoding mammalian olfactory G-protein-coupled receptors (OLFR) and mammalian taste G-protein-coupled receptors (TASR) are known in the prior art or are disclosed herein. An object of the invention to provide fragments and variants of such OLFRs and TASRs which retain odorant- or tastant-binding activity, respectively. The large number of sensory receptors that are made available herein and now amenable to manipulation raises the confidence that a substantially complete, or at least functional, repertoire of sensory receptors is provided.



It is an object of the invention to provide nucleic acid sequences or molecules that encode such sensory receptors, or fragments or variants thereof. Another object is to provide expression vectors which include nucleic acid sequences that encode such sensory receptors, or fragments or variants thereof. It is yet another object of the invention to provide human or non-human cells which functionally express at least one of such sensory receptors, or fragments or variants thereof. Still another object is to provide sensory receptor fusion proteins or other polypeptides which include at least a fragment of at least one of such sensory receptors. In particular, fusions with reporter molecules or other heterologous amino acid sequences may maintain the original ligand-properties while changing the signaling properties to allow easier detection of sensant binding to the receptor (*e.g.*, change in fluorescent signal). Moreover, chimeric proteins or other polypeptides with altered ligand-binding and/or signaling properties can be made from two or more different sensory receptors by mixing domains.

The invention provides methods for representing the sensory perception of one or more chemicals (*e.g.*, a primary sensant or mixture thereof) and/or for predicting the sensory perception of one or more chemicals in a mammal (*e.g.*, human) using the aforementioned products. Given a known member of a ligand-receptor binding pair, one or both members of the pair (*i.e.*, ligand, receptor, or both) may be detected, identified, and/or measured under binding conditions.

Novel molecules or combinations of molecules which elicit a desired and predetermined sensory perception in a mammal (*e.g.*, human) can be generated by determining a value of sensory perception in a mammal for a known molecule or combination thereof; determining a value of sensory perception in a mammal for one or more unknown molecules or combinations thereof; comparing the value of sensory perception in a mammal for one or more unknown compositions to the value of sensory perception in a mammal for one or more known compositions; selecting a molecule or combination of molecules that elicits a predetermined sensory perception in a mammal; and mixing two or more unknown molecules or combinations thereof to form a molecule or combination thereof that elicits a predetermined sensory perception in a mammal. The combining step yields a single molecule or a combination thereof that elicits a predetermined sensory perception in a mammal. In particular, primary odorants that uniquely bind to olfactory receptors with a single

ligand-binding domain may be such novel molecules. Variants thereof may be used (1) to enhance stimulation of a limited response by olfactory receptors with a single ligand-binding domain or (2) to block stimulation of olfactory receptors with a single ligand-binding domain to reduce or inhibit olfactory perception. An alternative method for identifying primary odorants is to identify the mutated receptors in genetic anosmias because that odorant would be expected to be recognized by only one or a few olfactory receptors affected by the mutation.

### Detailed Description of the Invention

#### 10 Perception of Chemical Sensants

U.S. Patent No. 5,691,188 describes how upon binding of ligand to receptor, the receptor presumably undergoes a conformational change leading to activation of the G protein. The G proteins are comprised of three subunits: a guanyl nucleotide binding  $\alpha$  subunit, a  $\beta$  subunit, and a  $\gamma$  subunit. G proteins cycle between two forms, depending on whether GDP or GTP is bound to the  $\alpha$  subunit. When GDP is bound, the G protein exists as a heterotrimer: the  $G\alpha\beta\gamma$  complex. When GTP is bound, the  $\alpha$  subunit dissociates from the heterotrimer, leaving a  $G\beta\gamma$  complex. When a  $G\alpha\beta\gamma$  complex operatively associates with an activated G protein coupled receptor in a cell membrane, the rate of exchange of GTP for bound GDP is increased and the rate of disso-ciation of the bound  $G\alpha$  subunit from the  $G\alpha\beta\gamma$  complex increases. The free  $G\alpha$  subunit and  $G\beta\gamma$  complex are thus capable of transmitting a signal to downstream elements of a variety of signal transduction pathways. These events form the basis for a multiplicity of different cell signaling phenomena, including for example the signaling phenomena that are identified as neurological sensory perceptions such as taste and/or smell. A high-resolution X-ray crystal structure is available for rhodopsin, a guanyl nucleotide binding protein, has been solved (Palczewski *et al.*, *Science* 289:739, 2000). Using this structure, the portions of the amino acid sequence of sensant receptors that are responsible for ligand binding can be identified.

30

#### Sensory Perception - Olfaction

Genes encoding the olfactory receptors are active primarily in olfactory neurons (Axel *Sci. Amer.* 273:154, 1995). Individual olfactory receptor types are expressed in subsets of cells distributed in distinct zones of the olfactory epithelium (Breer *Semin. Cell Biol.* 5:25, 1994). The human genome contains thousands of genes  
5 that encode a diverse repertoire of olfactory receptors (Rouquier *Nat. Genet.* 18:243, 1998; Trask *Hum. Mol. Genet.* 7:2007, 1998). An understanding of an animal's ability to detect and discriminate among the thousands of distinct odorants or tastants, and more particularly to distinguish, for example beneficial tastants or odorants from toxic tastants or odorants, is complicated by the fact that sensory receptors belong to a  
10 multigene family with over a thousand members, and the odorant receptors number at least 500 to 1,000. Moreover, each sensory receptor neuron may express only one or a few of these receptors. With respect to odorant receptors, any given olfactory neuron can respond to a small set of odorant ligands. In addition, odorant discrimination for a given neuron may depend on the ligand specificity of the one or few receptors it  
15 expresses.

#### Sensory Perception - Taste

Mammals are believed to have five basic taste modalities: sweet, bitter, sour, salty, and umami (the taste of monosodium glutamate). See, e.g., Kawamura *et al.*,  
20 *Introduction to Umami: A Basic Taste* (1987); Kinnamon *et al.*, *Ann. Rev. Physiol.*, 54:715, 1992; Lindemann, *Physiol. Rev.*, 76:718, 1996; Stewart *et al.*, *Am. J. Physiol.*, 272:1, 1997. Numerous physiological studies in animals have shown that taste receptor cells may selectively respond to different chemical stimuli. See, e.g., Akabas  
*et al.*, *Science*, 242:1047, 1988; Gilbertson *et al.*, *J. Gen. Physiol.*, 100:803, 1992;  
25 Bernhardt *et al.*, *J. Physiol.*, 490:325, 1996; Cummings *et al.*, *J. Neurophysiol.*, 75:1256, 1996.

In mammals, taste receptor cells are assembled into taste buds that are distributed into different papillae in the tongue epithelium. Circumvallate papillae, found at the very back of the tongue, contain hundreds, e.g., mice, to thousands, e.g.,  
30 human, of taste buds. By contrast, foliate papillae, localized to the posterior lateral edge of the tongue, only contain dozens to hundreds of taste buds. Moreover, fungiform papillae contain only a single or a few taste buds, and are at the front of the tongue.

AC010814, AC018700, AC021304, AC008620, AC011537, AC010760, AC027641, AC017103, AC024729, AC024257, AC025115, AP001524, AP000916, AC010814, AL162254, AC025234, AP001521, AC026090, AC019088, AC016856, AC016787, AC009594, AC026038, AQ628489, AC025942, AL163152, AC026975, AC024654, 5 AP001803, AP001804, AL353767, AP001884, AC026083, AC018793, AP000818, AL353894, AL049734, AL355366, AC011464, AC037472, AC036111, AC019093, AC027239, AC027522, AC009545, AC021333, AC036216, AC021935, AC022762, AL356019, AC055861, AC018375, AC072059, AC068339, AC022891, AL357039, AP002345, AC044810, AC073113, AC024399, AC023564, AL390860, AC074365, 10 AP002826, AL359636, AL391534, AC055731, AC076959, AP002826, AC019088, AC009779, AL445307, AP002512, AP000818, AC079190) by virtue of their sequence homology to some of the known human and other mammalian olfactory receptor genes. Similarly, genes encoding five and thirty-six (36) distinct, novel human T1R and T2R taste receptors, respectively, have been identified in genome 15 sequence databases.

Alternatively, nucleic acids encoding the sensory receptors and other related polypeptides can be isolated from a variety of sources, genetically engineered, amplified, synthesized, and/or expressed recombinantly according to the methods disclosed in WO 00/35374, which is herein incorporated by reference in its entirety.

20 These nucleic acids provide probes for the identification of cells expressing sensory receptors, as the nucleic acids are specifically expressed in such cells. They can also serve as tools for the generation of sensory topographical maps that elucidate the relationship between cells expressing sensory receptors and sensory neurons leading to particular regions of the brain. Furthermore, the nucleic acids and the 25 polypeptides they encode can be used as probes to elucidate olfactant- or tastant-induced behaviors.

Nucleic acid molecules encoding a sensory receptor comprising a nucleic acid sequence that is at least 75%, 85%, 90%, 95%, or 99% identical to a nucleic acid sequence selected from those known in the prior art or disclosed herein are considered 30 variants. Other nucleic acid molecules comprising a nucleic acid sequence that encodes a polypeptide having an amino acid sequence at least 75%, 85%, 90%, 95%, or 99% identical to an amino acid sequence selected from those known in the prior art or disclosed herein are also considered variants. Further variants contain amino acid

sequence differences in at most ten, five, four, three, two, or one amino acid residue(s).

Exemplary nucleic acid sequences may be selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 22, SEQ ID NO: 24, SEQ ID NO: 26, SEQ ID NO: 28, SEQ ID NO: 30, SEQ ID NO: 32, SEQ ID NO: 34, SEQ ID NO: 36, SEQ ID NO: 38, SEQ ID NO: 40, SEQ ID NO: 42, SEQ ID NO: 44, SEQ ID NO: 46, SEQ ID NO: 48, SEQ ID NO: 50, SEQ ID NO: 52, SEQ ID NO: 54, SEQ ID NO: 56, SEQ ID NO: 58, SEQ ID NO: 60, SEQ ID NO: 62, SEQ ID NO: 64, SEQ ID NO: 66, SEQ ID NO: 68, SEQ ID NO: 70, SEQ ID NO: 72, SEQ ID NO: 74, SEQ ID NO: 76, SEQ ID NO: 78, SEQ ID NO: 80, SEQ ID NO: 82, SEQ ID NO: 84, SEQ ID NO: 86, SEQ ID NO: 88, SEQ ID NO: 90, SEQ ID NO: 92, SEQ ID NO: 94, SEQ ID NO: 96, SEQ ID NO: 98, SEQ ID NO: 100, SEQ ID NO: 102, SEQ ID NO: 104, SEQ ID NO: 106, SEQ ID NO: 108, SEQ ID NO: 110, SEQ ID NO: 112, SEQ ID NO: 114, SEQ ID NO: 116, SEQ ID NO: 118, SEQ ID NO: 120, SEQ ID NO: 122, SEQ ID NO: 124, SEQ ID NO: 126, SEQ ID NO: 128, SEQ ID NO: 130, SEQ ID NO: 132, SEQ ID NO: 134, SEQ ID NO: 136, SEQ ID NO: 138, SEQ ID NO: 140, SEQ ID NO: 142, SEQ ID NO: 144, SEQ ID NO: 146, SEQ ID NO: 148, SEQ ID NO: 150, SEQ ID NO: 152, SEQ ID NO: 154, SEQ ID NO: 156, SEQ ID NO: 158, SEQ ID NO: 160, SEQ ID NO: 162, SEQ ID NO: 164, SEQ ID NO: 166, SEQ ID NO: 168, SEQ ID NO: 170, SEQ ID NO: 172, SEQ ID NO: 174, SEQ ID NO: 176, SEQ ID NO: 178, SEQ ID NO: 180, SEQ ID NO: 182, SEQ ID NO: 184, SEQ ID NO: 186, SEQ ID NO: 188, SEQ ID NO: 190, SEQ ID NO: 192, SEQ ID NO: 194, SEQ ID NO: 196, SEQ ID NO: 198, SEQ ID NO: 200, SEQ ID NO: 202, SEQ ID NO: 204, SEQ ID NO: 206, SEQ ID NO: 208, SEQ ID NO: 210, SEQ ID NO: 212, SEQ ID NO: 214, SEQ ID NO: 216, SEQ ID NO: 218, SEQ ID NO: 220, SEQ ID NO: 222, SEQ ID NO: 224, SEQ ID NO: 226, SEQ ID NO: 228, SEQ ID NO: 230, SEQ ID NO: 232, SEQ ID NO: 234, SEQ ID NO: 236, SEQ ID NO: 238, SEQ ID NO: 240, SEQ ID NO: 242, SEQ ID NO: 244, SEQ ID NO: 246, SEQ ID NO: 248, SEQ ID NO: 250, SEQ ID NO: 252, SEQ ID NO: 254, SEQ ID NO: 256, SEQ ID NO: 258, SEQ ID NO: 260, SEQ ID NO: 262, SEQ ID NO: 264, SEQ ID NO: 266, SEQ ID NO: 268, SEQ ID NO: 270, SEQ ID NO: 272, SEQ ID NO: 274, SEQ ID NO: 276, SEQ ID NO: 278, SEQ ID

- NO: 280, SEQ ID NO: 282, SEQ ID NO: 284, SEQ ID NO: 286, SEQ ID NO: 288,  
 SEQ ID NO: 290, SEQ ID NO: 292, SEQ ID NO: 294, SEQ ID NO: 296, SEQ ID  
 NO: 298, SEQ ID NO: 300, SEQ ID NO: 302, SEQ ID NO: 304, SEQ ID NO: 306,  
 SEQ ID NO: 308, SEQ ID NO: 310, SEQ ID NO: 312, SEQ ID NO: 314, SEQ ID  
 5 NO: 316, SEQ ID NO: 318, SEQ ID NO: 320, SEQ ID NO: 322, SEQ ID NO: 324,  
 SEQ ID NO: 326, SEQ ID NO: 328, SEQ ID NO: 330, SEQ ID NO: 332, SEQ ID  
 NO: 334, SEQ ID NO: 336, SEQ ID NO: 338, SEQ ID NO: 340, SEQ ID NO: 342,  
 SEQ ID NO: 344, SEQ ID NO: 346, SEQ ID NO: 348, SEQ ID NO: 350, SEQ ID  
 NO: 352, SEQ ID NO: 354, SEQ ID NO: 356, SEQ ID NO: 358, SEQ ID NO: 360,  
 10 SEQ ID NO: 362, SEQ ID NO: 364, SEQ ID NO: 366, SEQ ID NO: 368, SEQ ID  
 NO: 370, SEQ ID NO: 372, SEQ ID NO: 374, SEQ ID NO: 376, SEQ ID NO: 378,  
 SEQ ID NO: 380, SEQ ID NO: 382, SEQ ID NO: 384, SEQ ID NO: 386, SEQ ID  
 NO: 388, SEQ ID NO: 390, SEQ ID NO: 392, SEQ ID NO: 394, SEQ ID NO: 396,  
 SEQ ID NO: 398, SEQ ID NO: 400, SEQ ID NO: 402, SEQ ID NO: 404, SEQ ID  
 15 NO: 406, SEQ ID NO: 408, SEQ ID NO: 410, SEQ ID NO: 412, SEQ ID NO: 414,  
 SEQ ID NO: 416, SEQ ID NO: 418, SEQ ID NO: 420, SEQ ID NO: 422, SEQ ID  
 NO: 424, SEQ ID NO: 426, SEQ ID NO: 428, SEQ ID NO: 430, SEQ ID NO: 432,  
 SEQ ID NO: 434, SEQ ID NO: 436, SEQ ID NO: 438, SEQ ID NO: 440, SEQ ID  
 NO: 442, SEQ ID NO: 444, SEQ ID NO: 446, SEQ ID NO: 448, SEQ ID NO: 450,  
 20 SEQ ID NO: 452, SEQ ID NO: 454, SEQ ID NO: 456, SEQ ID NO: 458, SEQ ID  
 NO: 460, SEQ ID NO: 462, SEQ ID NO: 464, SEQ ID NO: 466, SEQ ID NO: 468,  
 SEQ ID NO: 470, SEQ ID NO: 472, SEQ ID NO: 474, SEQ ID NO: 476, SEQ ID  
 NO: 478, SEQ ID NO: 480, SEQ ID NO: 482, SEQ ID NO: 484, SEQ ID NO: 486,  
 SEQ ID NO: 488, SEQ ID NO: 490, SEQ ID NO: 492, SEQ ID NO: 494, SEQ ID  
 25 NO: 496, SEQ ID NO: 498, SEQ ID NO: 500, SEQ ID NO: 502, SEQ ID NO: 504,  
 SEQ ID NO: 506, SEQ ID NO: 508, SEQ ID NO: 510; and SEQ ID NO: 512.

Nucleic acid molecule comprising a nucleic acid sequence that encodes a  
 fragment of a polypeptide having an amino acid sequence selected from those known  
 in the prior art or disclosed herein; wherein the fragment is at least ten, 20, 30, 50, 70,  
 30 100, or 150 amino acid residues in length, are useful as probes, primers, and to  
 construct hybrids or chimerae.

Polypeptides comprising an amino acid sequence that is at least 90%, 95%,  
 96%, 97%, 98%, or 99% identical to an amino acid sequence selected from those

known in the prior art or disclosed herein are considered variants. Further variants contain amino acid sequence differences in at most ten, five, four, three, two, or one amino acid residue(s). Other polypeptides comprising a fragment of a polypeptide having an amino acid sequence selected from those known in the prior art or disclosed  
 5 herein; wherein the fragment is at least 40, 60, 80, 100, 150, 200, or 250 amino acid residues in length, are useful as specific binders of sensants, competitive binders, antigens, and to construct hybrids or chimerae.

Exemplary amino acid sequences may be selected from the group consisting of  
 SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ  
 10 ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, SEQ  
 ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 25, SEQ ID NO: 27, SEQ ID NO: 29, SEQ  
 ID NO: 31, SEQ ID NO: 33, SEQ ID NO: 35, SEQ ID NO: 37, SEQ ID NO: 39, SEQ  
 ID NO: 41, SEQ ID NO: 43, SEQ ID NO: 45, SEQ ID NO: 47, SEQ ID NO: 49, SEQ  
 ID NO: 51, SEQ ID NO: 53, SEQ ID NO: 55, SEQ ID NO: 57, SEQ ID NO: 59, SEQ  
 15 ID NO: 61, SEQ ID NO: 63, SEQ ID NO: 65, SEQ ID NO: 67, SEQ ID NO: 69, SEQ  
 ID NO: 71, SEQ ID NO: 73, SEQ ID NO: 75, SEQ ID NO: 77, SEQ ID NO: 79, SEQ  
 ID NO: 81, SEQ ID NO: 83, SEQ ID NO: 85, SEQ ID NO: 87, SEQ ID NO: 89, SEQ  
 ID NO: 91, SEQ ID NO: 93, SEQ ID NO: 95, SEQ ID NO: 97, SEQ ID NO: 99, SEQ  
 ID NO: 101, SEQ ID NO: 103, SEQ ID NO: 105, SEQ ID NO: 107, SEQ ID NO: 109,  
 20 SEQ ID NO: 111, SEQ ID NO: 113, SEQ ID NO: 115, SEQ ID NO: 117, SEQ ID  
 NO: 119, SEQ ID NO: 121, SEQ ID NO: 123, SEQ ID NO: 125, SEQ ID NO: 127,  
 SEQ ID NO: 129, SEQ ID NO: 131, SEQ ID NO: 133, SEQ ID NO: 135, SEQ ID  
 NO: 137, SEQ ID NO: 139, SEQ ID NO: 141, SEQ ID NO: 143, SEQ ID NO: 145,  
 SEQ ID NO: 147, SEQ ID NO: 149, SEQ ID NO: 151, SEQ ID NO: 153, SEQ ID  
 25 NO: 155, SEQ ID NO: 157, SEQ ID NO: 159, SEQ ID NO: 161, SEQ ID NO: 163,  
 SEQ ID NO: 165, SEQ ID NO: 167, SEQ ID NO: 169, SEQ ID NO: 171, SEQ ID  
 NO: 173, SEQ ID NO: 175, SEQ ID NO: 177, SEQ ID NO: 179, SEQ ID NO: 181,  
 SEQ ID NO: 183, SEQ ID NO: 185, SEQ ID NO: 187, SEQ ID NO: 189, SEQ ID  
 NO: 191, SEQ ID NO: 193, SEQ ID NO: 195, SEQ ID NO: 197, SEQ ID NO: 199,  
 30 SEQ ID NO: 201, SEQ ID NO: 203, SEQ ID NO: 205, SEQ ID NO: 207, SEQ ID  
 NO: 209, SEQ ID NO: 211, SEQ ID NO: 213, SEQ ID NO: 215, SEQ ID NO: 217,  
 SEQ ID NO: 219, SEQ ID NO: 221, SEQ ID NO: 223, SEQ ID NO: 225, SEQ ID  
 NO: 227, SEQ ID NO: 229, SEQ ID NO: 231, SEQ ID NO: 233, SEQ ID NO: 235,

- SEQ ID NO: 237, SEQ ID NO: 239, SEQ ID NO: 241, SEQ ID NO: 243, SEQ ID NO: 245, SEQ ID NO: 247, SEQ ID NO: 249, SEQ ID NO: 251, SEQ ID NO: 253, SEQ ID NO: 255, SEQ ID NO: 257, SEQ ID NO: 259, SEQ ID NO: 261, SEQ ID NO: 263, SEQ ID NO: 265, SEQ ID NO: 267, SEQ ID NO: 269, SEQ ID NO: 271, SEQ ID NO: 273, SEQ ID NO: 275, SEQ ID NO: 277, SEQ ID NO: 279, SEQ ID NO: 281, SEQ ID NO: 283, SEQ ID NO: 285, SEQ ID NO: 287, SEQ ID NO: 289, SEQ ID NO: 291, SEQ ID NO: 293, SEQ ID NO: 295, SEQ ID NO: 297, SEQ ID NO: 299, SEQ ID NO: 301, SEQ ID NO: 303, SEQ ID NO: 305, SEQ ID NO: 307, SEQ ID NO: 309, SEQ ID NO: 311, SEQ ID NO: 313, SEQ ID NO: 315, SEQ ID NO: 317, SEQ ID NO: 319, SEQ ID NO: 321, SEQ ID NO: 323, SEQ ID NO: 325, SEQ ID NO: 327, SEQ ID NO: 329, SEQ ID NO: 331, SEQ ID NO: 333, SEQ ID NO: 335, SEQ ID NO: 337, SEQ ID NO: 339, SEQ ID NO: 341, SEQ ID NO: 343, SEQ ID NO: 345, SEQ ID NO: 347, SEQ ID NO: 349, SEQ ID NO: 351, SEQ ID NO: 353, SEQ ID NO: 355, SEQ ID NO: 357, SEQ ID NO: 359, SEQ ID NO: 361, SEQ ID NO: 363, SEQ ID NO: 365, SEQ ID NO: 367, SEQ ID NO: 369, SEQ ID NO: 371, SEQ ID NO: 373, SEQ ID NO: 375, SEQ ID NO: 377, SEQ ID NO: 379, SEQ ID NO: 381, SEQ ID NO: 383, SEQ ID NO: 385, SEQ ID NO: 387, SEQ ID NO: 389, SEQ ID NO: 391, SEQ ID NO: 393, SEQ ID NO: 395, SEQ ID NO: 397, SEQ ID NO: 399, SEQ ID NO: 401, SEQ ID NO: 403, SEQ ID NO: 405, SEQ ID NO: 407, SEQ ID NO: 409, SEQ ID NO: 411, SEQ ID NO: 413, SEQ ID NO: 415, SEQ ID NO: 417, SEQ ID NO: 419, SEQ ID NO: 421, SEQ ID NO: 423, SEQ ID NO: 425, SEQ ID NO: 427, SEQ ID NO: 429, SEQ ID NO: 431, SEQ ID NO: 433, SEQ ID NO: 435, SEQ ID NO: 437, SEQ ID NO: 439, SEQ ID NO: 441, SEQ ID NO: 443, SEQ ID NO: 445, SEQ ID NO: 447, SEQ ID NO: 449, SEQ ID NO: 451, SEQ ID NO: 453, SEQ ID NO: 455, SEQ ID NO: 457, SEQ ID NO: 459, SEQ ID NO: 461, SEQ ID NO: 463, SEQ ID NO: 465, SEQ ID NO: 467, SEQ ID NO: 469, SEQ ID NO: 471, SEQ ID NO: 473, SEQ ID NO: 475, SEQ ID NO: 477, SEQ ID NO: 479, SEQ ID NO: 481, SEQ ID NO: 483, SEQ ID NO: 485, SEQ ID NO: 487, SEQ ID NO: 489, SEQ ID NO: 491, SEQ ID NO: 493, SEQ ID NO: 495, SEQ ID NO: 497, SEQ ID NO: 499, SEQ ID NO: 501, SEQ ID NO: 503, SEQ ID NO: 505, SEQ ID NO: 507, SEQ ID NO: 509 and SEQ ID NO: 511.

Also provided are methods of screening for modulators, *e.g.*, activators, inhibitors, stimu-lators, enhancers, agonists, and antagonists, of the sensory receptors,



or fragments or variants thereof. Such modulators of signal transduction are useful for pharmacological or genetic modulation of signaling pathways. These methods of screening can be used to identify high affinity agonists and antagonists of sensory cell activity. These modulator compounds can then be used in the pharmaceutical, food, and cosmetic industries to customize odorants or tastants.

Thus, the invention provides assays for sensory modulation, where the sensory receptors, or fragments or variants thereof, act as direct or indirect reporter molecules for the effect of modulators on signal transduction. Sensory receptors, or fragments or variants thereof, can be used in assays, *e.g.*, to measure changes in ion concentration, membrane potential, current flow, ion flux, transcription, signal transduction, receptor-ligand interaction, second messenger concentrations, *in vitro*, *in vivo*, and *ex vivo*. In one embodiment, sensory receptors, or fragments or variants thereof, can be used as an indirect reporters via attachment to second reporter molecules, such as green fluorescent protein (*see, e.g., Mistili et al., Nature Biotech., 15:961, 1997*). In another embodiment, the sensory receptors, or fragments or variants thereof, can be expressed in host cells, and modulation of signal transduction via sensory receptor activity can be assayed by measuring changes in  $\text{Ca}^{2+}$  levels.

Methods of assaying for modulators of signal transduction include *in vitro* ligand binding assays using the sensory receptors, or fragments or variants thereof. More particularly, such assays can use the sensory receptors; portions thereof such as the extracellular or transmembrane domains; chimeric proteins comprising one or more of such domains; oocyte receptor expression; tissue culture cell receptor expression; transcriptional activation of the receptor; G-protein binding to the receptor; ligand binding assays; voltage, membrane potential and conductance changes; ion flux assays; changes in intracellular second messengers such as cAMP and inositol triphosphate; changes in intracellular  $\text{Ca}^{2+}$  levels; and neurotransmitter release.

The invention also provides for methods of detecting sensory receptor nucleic acid and protein expression, allowing for the investigation of taste transduction regulation and specific identification of sensory receptor cells. The sensory receptors, fragments, and variants of the invention can also be used to generate monoclonal and polyclonal antibodies useful for identifying a sensory receptor cells. Sensory receptor cells can be identified using techniques such as reverse transcription and amplification

of mRNA, isolation of total RNA or poly A<sup>+</sup> RNA, Northern blotting, dot blotting, *in situ* hybridization, RNase protection, S1 digestion, probing DNA microchip arrays, Western blots, and the like.

A. Identification and Characterization of Sensory Receptors

5 The amino acid sequences of the sensory receptors and polypeptides of the invention can be identified by putative translation of the coding nucleic acid sequences. These various amino acid sequences and the coding nucleic acid sequences may be compared to one another or to other sequences according to a number of methods.

10 For example, in sequence comparison, typically one sequence acts as a reference sequence, to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are entered into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. Default program parameters can be used, as  
15 described below for the BLASTN and BLASTP programs, or alternative parameters can be designated. The sequence comparison algorithm then calculates the percent sequence identities for the test sequences relative to the reference sequence, based on the program parameters.

A "comparison window," as used herein, includes reference to a segment of  
20 any one of the number of contiguous positions selected from the group consisting of from 20 to 600, usually about 50 to about 200, more usually about 100 to about 150 in which a sequence may be compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned. Methods of alignment of sequences for comparison are well-known in the art. Optimal alignment  
25 of sequences for comparison can be conducted, *e.g.*, by the local homology algorithm of Smith & Waterman, *Adv. Appl. Math.* 2:482, 1981, by the homology alignment algorithm of Needleman & Wunsch, *J. Mol. Biol.* 48:443, 1970, by the search for similarity method of Pearson & Lipman, *Proc. Natl. Acad. Sci. USA* 85:2444, 1988, by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and  
30 TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, WI), or by manual alignment and visual inspection (*see, e.g., Current Protocols in Molecular Biology* (Ausubel *et al.*, eds. 1995 supplement)).

A preferred example of an algorithm that is suitable for determining percent sequence identity and sequence similarity are the BLAST and BLAST 2.0 algorithms, which are described in Altschul *et al.*, *Nucl. Acids Res.* 25:3389, 1977 and Altschul *et al.*, *J Mol. Biol.* 215:403, 1990, respectively. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (<http://www.ncbi.nlm.nih.gov/>). This algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence, which either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighborhood word score threshold (Altschul *et al.*, Altschul *et al.*, *Nucl. Acids Res.* 25:3389, 1977 and Altschul *et al.*, *J. Mol. Biol.* 215:403, 1990). These initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them. The word hits are extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Cumulative scores are calculated using, for nucleotide sequences, the parameters M (reward score for a pair of matching residues; always > 0) and N (penalty score for mismatching residues; always < 0). For amino acid sequences, a scoring matrix is used to calculate the cumulative score. Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses as defaults a wordlength (W) of 11, an expectation (E) or 10, M=5, N=-4 and a comparison of both strands. For amino acid sequences, the BLASTP program uses as defaults a wordlength of 3, and expectation (E) of 10, and the BLOSUM62 scoring matrix (see Henikoff & Henikoff, *Proc. Natl. Acad. Sci. USA* 89:10915, 1989) alignments (B) of 50, expectation (E) of 10, M=5, N=-4, and a comparison of both strands.

Another example of a useful algorithm is PILEUP. PILEUP creates a multiple sequence alignment from a group of related sequences using progressive, pairwise alignments to show relationship and percent sequence identity. It also plots a so-called "tree" or "dendrogram" showing the clustering relationships used to create the alignment (see, e.g., Figure 2). PILEUP uses a simplification of the progressive

alignment method of Feng & Doolittle, *J Mol. Evol.* 35:351, 1987. The method used is similar to the method described by Higgins & Sharp, *CABIOS* 5:151, 1989. The program can align up to 300 sequences, each of a maximum length of 5,000 nucleotides or amino acids. The multiple alignment procedure begins with the pairwise alignment of the two most similar sequences, producing a cluster of two aligned sequences. This cluster is then aligned to the next most related sequence or cluster of aligned sequences. Two clusters of sequences are aligned by a simple extension of the pairwise alignment of two individual sequences. The final alignment is achieved by a series of progressive, pairwise alignments. The program is run by designating specific sequences and their amino acid or nucleotide coordinates for regions of sequence comparison and by designating the program parameters. Using PILEUP, a reference sequence is compared to other test sequences to determine the percent sequence identity relationship using the following parameters: default gap weight (3.00), default gap length weight (0.10), and weighted end gaps. PILEUP can be obtained from the GCG sequence analysis software package, e.g., version 7.0 (Devereaux *et al.*, *Nucl. Acids Res.* 12:387, 1984) encoded by the genes were derived by conceptual translation of the corresponding open reading frames. Comparison of these protein sequences to all known proteins in the public sequence databases using BLASTP algorithm revealed their strong homology to the members of the mammalian olfactory receptor family, each of the olfactory receptor sequences having at least 50%, and preferably at least 55%, at least 60%, at least 65%, and most preferably at least 70%, amino acid identity to at least one known member of the family.

The nucleic acid molecules of the present invention are typically intronless and encode putative sensory receptor proteins generally having lengths of about 300 to about 400 amino acid residues that contain seven transmembrane domains, as predicted by hydrophobicity plotting analysis, indicating that they belong to the G protein-coupled receptor superfamily, which includes the subset of taste and olfactory receptors. In addition to the overall structural similarity, each of the 256 sensory receptors identified herein has a characteristic sequence signature of an olfactory receptor. In particular, all 256 sequences contain very close matches to the following consensus amino acid motifs (Mombaerts, 1999; Pilpel, 1999): LHTPMY in intracellular loop 1, MAYDRYVAIC at the end of transmembrane domain 3 and the beginning of intracellular loop 2, SY at the end of transmembrane domain 5,

FSTCSSH in the beginning of transmembrane domain 6, and PMLNPF in transmembrane domain 7. Combination of all the above mentioned structural features of the 256 genes and encoded proteins strongly suggests that they represent novel members of the human olfactory receptor family.

5 As noted above, complete or partial sequences of numerous human and other eukaryotic sensory receptors are currently known. The novel human receptors have amino acid sequences distinctly different from the previously known human sensory receptors, which suggests their different specificity in sensant recognition. Therefore, these novel sensory receptors and their genes can be used, alone or in combination  
10 with known sensory receptors, in developing detection systems and assays for chemically distinct types of sensants not recognized by the known sensory receptors, as well as for diagnostic and research purposes.

#### B. Definitions

The terms "purified," "substantially purified," and "isolated" as used herein  
15 refer to the state of being free of other, dissimilar compounds with which the compound of the invention is normally associated in its natural state, so that the "purified," "substantially purified," and "isolated" subject comprises at least 0.5%, 1%, 5%, 10%, or 20%, and most preferably at least 50% or 75% of the mass, by weight, of a given sample. In one preferred embodiment, these terms refer to the  
20 compound of the invention comprising at least 95% of the mass, by weight, of a given sample. As used herein, the terms "purified," "substantially purified," and "isolated" when referring to a nucleic acid or protein, of nucleic acids or proteins, also refers to a state of purification or concentration different than that which occurs naturally in the mammalian, especially human, body. Any degree of purification or  
25 concentration greater than that which occurs naturally in the mammalian, especially human, body, including (1) the purification from other associated structures or compounds or (2) the association with structures or compounds to which it is not normally associated in the mammalian, especially human, body, are within the meaning of "isolated." The nucleic acid or protein or classes of nucleic acids or  
30 proteins, described herein, may be isolated, or otherwise associated with structures or compounds to which they are not normally associated in nature, according to a variety of methods and processes known to those of skill in the art.

The terms "amplifying" and "amplification" refer to the use of any suitable amplification methodology for generating or detecting recombinant or naturally expressed nucleic acid, as described in detail, below. For example, the invention provides methods and reagents (e.g., specific degenerate oligonucleotide primer pairs) for amplifying (e.g., by polymerase chain reaction, PCR) naturally expressed (e.g., genomic or mRNA) or recombinant (e.g., cDNA) nucleic acids of the invention (e.g., sensant-binding sequences of the invention) *in vivo* or *in vitro*.

The term "7- transmembrane receptor" means a polypeptide belonging to a superfamily of transmembrane proteins that have seven domains that span the plasma membrane seven times (thus, the seven domains are called "transmembrane" or "TM" domains TM I to TM VII). The families of olfactory and taste receptors each belong to this super-family. Seven-transmembrane receptor polypeptides have similar and characteristic primary, secondary and tertiary structures, as discussed in further detail below.

The term "expression vector" refers to any recombinant expression system for the purpose of expressing a nucleic acid sequence of the invention *in vitro* or *in vivo*, constitutively or inducibly, in any cell, including prokaryotic, yeast, fungal, plant, insect or mammalian cell. The term includes linear or circular expression systems. The term includes expression systems that remain episomal or integrate into the host cell genome. The expression systems can have the ability to self-replicate or not, *i.e.*, drive only transient expression in a cell. The term includes recombinant expression "cassettes which contain only the minimum elements needed for transcription of the recombinant nucleic acid.

The term "library" means a preparation that is a mixture of different nucleic acid or polypeptide molecules, such as the library of recombinantly generated sensory, particularly olfactory or taste, receptor ligand-binding domains generated by amplification of nucleic acid with degenerate primer pairs, or an isolated collection of vectors that incorporate the amplified sensant-binding domains, or a mixture of cells each randomly transfected with at least one vector encoding a sensory receptor.

The term "nucleic acid" or "nucleic acid sequence" refers to a deoxy-ribonucleotide or ribonucleotide oligonucleotide in either single- or double-stranded form. The term encompasses nucleic acids, *i.e.*, oligonucleotides, containing known analogs of natural nucleotides. The term also encompasses nucleic-acid-like

structures with synthetic backbones, *see e.g., Oligonucleotides and Analogues, a Practical Approach*, ed. F. Eckstein, Oxford Univ. Press (1991); *Anti-sense Strategies*, Annals of the N.Y. Academy of Sciences, Vol. 600, Eds. Baserga *et al.* (NYAS 1992); Milligan (1993) *J. Med. Chem.* 36:1923-1937; *Antisense Research and Applications* (1993, CRC Press), WO 97/03211; WO 96/39154; Mata (1997) *Toxicol. Appl. Pharmacol.* 144:189-197; Strauss-Soukup (1997) *Biochemistry* 36:8692-8698; Samstag (1996) *Antisense Nucleic Acid Drug Dev* 6:153-156.

The term sensory receptor "ligand-binding region" refers to sequences derived from a sensory receptor that substantially incorporates transmembrane domains II to VII (TM II to VII). The domain may be capable of binding a sensant.

The terms "conservative variant" or "analog" or "mimetic" refer to a polypeptide which has a modified amino acid sequence, such that the change(s) do not substantially alter the poly-peptide's (the conservative variant's) structure and/or activity, as defined herein. These include conservatively modified variations of an amino acid sequence, *i.e.*, amino acid substitutions, additions or deletions of those residues that are not critical for protein activity, or substitution of amino acids with residues having similar properties (*e.g.*, acidic, basic, positively or negatively charged, polar or non-polar, etc.) such that the substitutions of even critical amino acids does not substantially alter structure and/or activity. Conservative substitution tables providing function-ally similar amino acids are well known in the art.

For example, one exemplary guideline to select conservative substitutions includes (original residue followed by exemplary substitution): Ala/Gly or Ser; Arg/Lys; Asn/Gln or His; Asp/Glu; Cys/Ser; Gln/Asn; Gly/Asp; Gly/Ala or Pro; His/Asn or Gln; Ile/Leu or Val; Leu/Ile or val; Lys/Arg or Gln or Glu; Met/Leu or Tyr or Ile; Phe/Met or Leu or Tyr; Ser/Thr; Thr/Ser; Trp/Tyr; Tyr/Trp or Phe; Val/Ile or Leu. An alternative exemplary guideline uses the following six groups, each containing amino acids that are conservative substitutions for one another: 1) Alanine (A), Serine (S), Threonine (T); 2) Aspartic acid (D), Glutamic acid (E); 3) Asparagine (N), Glutamine (Q); 4) Arginine (R), Lysine (I); 5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V); and 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W); (*see also, e.g., Creighton, Proteins*, W.H. Freeman, 1984; Schultz & Schimer, *Principles of Protein Structure*, Springer-Verlag, 1979). One of skill in the art will appreciate that the above-identified substitutions are not the only possible

conservative substitutions. For example, for some purposes, one may regard all charged amino acids as conservative substitutions for each other whether they are positive or negative. In addition, individual substitutions, deletions or additions that alter, add or delete a single amino acid or a small percentage of amino acids in an

5 encoded sequence can also be considered "conservatively modified variations."

The terms "mimetic" and "peptidomimetic" refer to a synthetic chemical compound that has substantially the same structural and/or functional characteristics of the polypeptides, *e.g.*, translocation domains or sensant-binding domains or chimeric receptors of the invention. The mimetic can be either entirely composed of

10 synthetic, non-natural analogs of amino acids, or, is a chimeric molecule of partly natural peptide amino acids and partly non-natural analogs of amino acids. The mimetic can also incorporate any amount of natural amino acid conservative substitutions as long as such substitutions also do not substantially alter the mimetic's structure and/or activity. As with polypeptides of the invention which are

15 conservative variants, routine experimentation will determine whether a mimetic is within the scope of the invention, *i.e.*, that its structure and/or function is not substantially altered. Polypeptide mimetic compositions can contain any combination of non-natural structural components, which are typically from three structural groups:

20 a) residue linkage groups other than the natural amide bond ("peptide bond") linkages; b) non-natural residues in place of naturally occurring amino acid residues; or c) residues which induce secondary structural mimicry, *i.e.*, to induce or stabilize a secondary structure, *e.g.*, a beta turn, gamma turn, beta sheet, alpha helix conformation, and the like. A polypeptide can be characterized as a mimetic when all or some of its residues are joined by chemical means other than natural peptide bonds.

25 Individual peptidomimetic residues can be joined by peptide bonds, other chemical bonds or coupling means, such as, *e.g.*, glutaraldehyde, N-hydroxysuccinimide esters, bifunctional maleimides, N,N'-dicyclohexylcarbodiimide (DCC) or N,N'-diisopropylcarbodiimide (DIC). Linking groups that can be an alternative to the traditional amide bond ("peptide bond") linkages include, *e.g.*, ketomethylene (*e.g.*,

30  $-C(=O)-CH_2-$  for  $-C(=O)-NH-$ ), aminomethylene ( $CH_2-NH$ ), ethylene, olefin ( $CH=CH$ ), ether ( $CH_2-O$ ), thioether ( $CH_2-S$ ), tetrazole ( $CN_4$ ), thiazole, retroamide, thioamide, or ester (see, *e.g.*, Spatola (1983) in *Chemistry and Biochemistry of Amino Acids, Peptides and Proteins*, Vol. 7, pp 267-357, "Peptide Backbone Modifications,"



Marcell Dekker, NY). A polypeptide can also be characterized as a mimetic by containing all or some non-natural residues in place of naturally occurring amino acid residues; non-natural residues are well described in the scientific and patent literature.

As used herein, "recombinant" refers to a polynucleotide synthesized or otherwise manipulated *in vitro* (e.g., "recombinant polynucleotide"), to methods of using recombinant polynucleotides to produce gene products in cells or other biological systems, or to a polypeptide ("recombinant protein") encoded by a recombinant polynucleotide. "Recombinant means" also encompass the ligation of nucleic acids having various coding regions or domains or promoter sequences from different sources into an expression cassette or vector for expression of, e.g., inducible or constitutive expression of a fusion protein comprising a translocation domain of the invention and a nucleic acid sequence amplified using a primer of the invention.

The term "transmembrane domain" means a polypeptide domain that can completely span the plasma membrane. The general secondary and tertiary structure of transmembrane domains, in particular the seven transmembrane domains of 7-transmembrane receptors such as olfactory receptors, are well known in the art. Thus, primary structure sequence can be designed or predicted based on known transmembrane domain sequences, as described in detail below.

#### C. Isolation and Expression of Olfactory Receptors

Isolation and expression of the sensory receptors, or fragments or variants thereof, of the invention can be performed as described below. PCR primers can be used for the amplification of nucleic acids encoding olfactory receptor ligand binding regions and libraries of these nucleic acids can thereby be generated. Libraries of expression vectors can then be used to infect or transfect host cells for the functional expression of these libraries. These genes and vectors can be made and expressed *in vitro* or *in vivo*. One of skill will recognize that desired phenotypes for altering and controlling nucleic acid expression can be obtained by modulating the expression or activity of the genes and nucleic acids (e.g., promoters, enhancers and the like) within the vectors of the invention. Any of the known methods described for increasing or decreasing expression or activity can be used. The invention can be practiced in conjunction with any method or protocol known in the art, which are well described in the scientific and patent literature.

The nucleic acid sequences of the invention and other nucleic acids used to practice this invention, whether RNA, cDNA, genomic DNA, vectors, viruses or hybrids thereof, may be isolated from a variety of sources, genetically engineered, amplified, and/or expressed recombinantly. Any recombinant expression system can be used, including, in addition to mammalian cells, e.g., bacterial, yeast, insect or plant systems.

Alternatively, these nucleic acids can be synthesized *in vitro* by well-known chemical synthesis techniques, as described in, e.g., Carruthers, *Cold Spring Harbor Symp. Quant. Biol.* 47:411-418 (1982); Adams, *Am. Chem. Soc.* 105:661 (1983); Belousov, *Nucleic Acids Res.* 25:3440-3444 (1997); Frenkel, *Free Radic. Biol. Med.* 19:373-380 (1995); Blommers, *Biochemistry* 33:7886-7896 (1994); Narang, *Meth. Enzymol.* 68:90 (1979); Brown, *Meth. Enzymol.* 68:109 (1979); Beaucage, *Tetra. Lett.* 22:1859 (1981); U.S. Patent No. 4,458,066. Double-stranded DNA fragments may then be obtained either by synthesizing the complementary strand and annealing the strands together under appropriate conditions, or by adding the complementary strand using DNA polymerase with an appropriate primer sequence..

Techniques for the manipulation of nucleic acids, such as, for example, for generating mutations in sequences, subcloning, labeling probes, sequencing, hybridization and the like are well described in the scientific and patent literature. See, e.g., Sambrook, ed., *Molecular Cloning: a Laboratory manual* (2nd ed.), Vols. 1-3, Cold Spring Harbor Laboratory (1989); *Current Protocols in Molecular Biology*, Ausubel, ed. John Wiley & Sons, Inc., New York (1997); *Laboratory Techniques in Biochemistry and Molecular Biology: Hybridization With Nucleic Acid Probes, Part I, Theory and Nucleic Acid Preparation*, Tijssen, ed. Elsevier, N.Y. (1993).

Nucleic acids, vectors, capsids, polypeptides, and the like can be analyzed and quantified by any of a number of general means well known to those of skill in the art. These include, e.g., analytical biochemical methods such as NMR, spectrophotometry, radiography, electrophoresis, capillary electrophoresis, high performance liquid chromatography (HPLC), thin layer chromatography (TLC), and hyperdiffusion chromatography, various immunological methods, e.g., fluid or gel precipitin reactions, immunodiffusion, immunoelectrophoresis, radioimmunoassay (RIA), enzyme-linked immunosorbent assay (ELISA), immunofluorescent assay, Southern analysis, Northern analysis, dot-blot analysis, gel electrophoresis (e.g., SDS-PAGE),

RT-PCR, quantitative PCR, other nucleic acid or target or signal amplification methods, radiolabeling, scintillation counting, and affinity chromatography.

Oligonucleotide primers are used to amplify nucleic acid encoding an olfactory receptor ligand-binding region. The nucleic acids described herein can also be cloned  
5 or measured quantitatively using amplification techniques. Using exemplary degenerate primer pair sequences, (see below), the skilled artisan can select and design suitable oligonucleotide amplification primers. Amplification methods are also well known in the art, and include, *e.g.*, polymerase chain reaction, PCR (*PCR Protocols, a Guide to Methods and Applications*, ed. Innis. Academic Press, NY, 1990  
10 and *PCR Strategies*, ed. Innis, Academic Press, NY, 1995), ligase chain reaction (LCR) (*see, e.g.*, Wu, *Genomics* 4:560, 1989; Landegren, *Science* 241:1077, 1988; Barringer, *Gene* 89:117, 1990); transcription amplification (*see, e.g.*, Kwoh, *Proc. Natl. Acad. Sci. USA* 86:1173, 1989); and, self-sustained sequence replication (*see, e.g.*, Guatelli, *Proc. Natl. Acad. Sci. USA* 87:1874, 1990); Q Beta replicase  
15 amplification (*see, e.g.*, Smith, *J. Clin. Microbiol.* 35:1477, 1997); automated Q-beta replicase amplification assay (*see, e.g.*, Burg, *Mol. Cell. Probes* 10:257, 1996) and other RNA polymerase mediated techniques (*e.g.*, NASBA, Cangene, Mississauga, Ontario); see also Berger, *Methods Enzymol.* 152:307, 1987; Sambrook; Ausubel; U.S. Patent Nos. 4,683,195 and 4,683,202; Sooknanan, *Biotechnology* 13:563, 1995.

20 Once amplified, the nucleic acids, either individually or as libraries, may be cloned according to methods known in the art, if desired, into any of a variety of vectors using routine molecular biological methods; methods for cloning *in vitro* amplified nucleic acids are described, *e.g.*, U.S. Patent No. 5,426,039. To facilitate cloning of amplified sequences, restriction enzyme sites can be "built into" the PCR  
25 primer pair. For example, Pst I and Bsp E1 sites were designed into the exemplary primer pairs of the invention. These particular restriction sites have a sequence that, when ligated, are "in-frame" with respect to the 7-membrane receptor "donor" coding sequence into which they are spliced (the sensant-binding region-coding sequence is internal to the 7-membrane polypeptide, thus, if it is desired that the construct be  
30 translated downstream of a restriction enzyme splice site, out of frame results should be avoided; this may not be necessary if the inserted sensant-binding domain comprises substantially most of the transmembrane VII region). The primers can be designed to retain the original sequence of the "donor" 7-membrane receptor (the Pst I

and Bsp E1 sequence in the primers of the invention generate an insert that, when ligated into the Pst I/Bsp E1 cut vector, encode residues found in the "donor" mouse olfactory receptor M4 sequence). Alternatively, the primers can encode amino acid residues that are conservative substitutions (*e.g.*, hydrophobic for hydrophobic residue, see above discussion) or functionally benign substitutions (*e.g.*, do not prevent plasma membrane insertion, cause cleavage by peptidase, cause abnormal folding of receptor, and the like).

The primer pairs are designed to selectively amplify sensant-binding regions of olfactory receptor proteins. These domain regions may vary for different sensants, and more particularly odorants; thus, what may be a minimal binding region for one sensant, and more particularly odorants, may be too limiting for a second potential ligand. Thus, domain regions of different sizes comprising different domain structures may be amplified; for example, transmembrane (TM) domains II through VII, III through VII, III through VI or II through VI, or variations thereof (*e.g.*, only a subsequence of a particular domain, mixing the order of the domains, and the like), of a 7-transmembrane sensory receptor.

As domain structures and sequence of many 7-membrane proteins, particularly olfactory receptors, are known, the skilled artisan can readily select domain-flanking and internal domain sequences as model sequences to design degenerate amplification primer pairs. For example, a nucleic acid sequence encoding domain regions II through VII can be generated by PCR amplification using a primer pair. To amplify a nucleic acid comprising transmembrane domain I (TM I) sequence, a degenerate primer can be designed from a nucleic acid that encodes the amino acid sequence LFLLYL. Such a degenerate primer can be used to generate a binding domain incorporating TM I through TM III, TM I through TM IV, TM I through TM V, TM I through TM VI or TM I through TM VII.

To amplify a nucleic acid comprising a transmembrane domain III (TM III) sequence, a degenerate primer (of at least about 17 residues) can be designed from a nucleic acid that encodes the amino acid sequence M(A/G)(Y/F)DRYVAI (encoded by a nucleic acid sequence such as 5'-ATGG(G/C)CT(A/T)TGACCG(C/A/T)T(AT)(C/T)GT-3'). Such a degenerate primer can be used to generate a binding domain incorporating TM III through TM IV, TM III through TM V, TM III through TM VI or TM III through TM VII.

To amplify a transmembrane domain VI (TM VI) sequence, a degenerate primer (of at least about 17 residues) can be designed from nucleic acid encoding an amino acid sequence TC(G/A)SHL, encoded by a sequence such as 5'-AG(G/A)TGN(G/C)(T/A)N(G/C)C(G/A)CA-NGT-3'. Such a degenerate primer can  
5 be used to generate a binding domain incorporating TM I through TM VI, TM II through TM VI, TM III through TM VI or TM IV through TM VI).

Paradigms to design degenerate primer pairs are well known in the art. For example, a COnsensus-DEgenerate Hybrid Oligonucleotide Primer (CODEHOP) strategy computer program is accessible as <http://blocks.fhcrc.org/codehop.html>, and  
10 is directly linked from the BlockMaker multiple sequence alignment site for hybrid primer prediction beginning with a set of related protein sequences, as known olfactory receptor ligand-binding regions (*see, e.g., Rose, Nucl. Acids Res.* 26:1628, 1998; Singh, *Biotechniques* 24:318, 1998).

Means to synthesize oligonucleotide primer pairs are well known in the art.  
15 "Natural" base pairs or synthetic base pairs can be used. For example, use of artificial nucleobases offers a versatile approach to manipulate primer sequence and generate a more complex mixture of amplification products. Various families of artificial nucleobases are capable of assuming multiple hydrogen bonding orientations through internal bond rotations to provide a means for degenerate molecular recognition.  
20 Incorporation of these analogs into a single position of a PCR primer allows for generation of a complex library of amplification products. *See, e.g., Hoops, Nucleic Acids Res.* 25:4866, 1997. Nonpolar molecules can also be used to mimic the shape of natural DNA bases. A non-hydrogen-bonding shape mimic for adenine can replicate efficiently and selectively against a nonpolar shape mimic for thymine (*see, e.g., Morales, Nat. Struct. Biol.* 5:950, 1998). For example, two degenerate bases can  
25 be the pyrimidine base 6H, 8H-3,4-dihydropyrimido[4,5-c][1,2]oxazin-7-one or the purine base N6-methoxy-2,6-diaminopurine (*see, e.g., Hill, Proc. Natl. Acad. Sci. USA* 95:4258, 1998). Exemplary degenerate primers of the invention incorporate the nucleobase analog 5'-Dimethoxytrityl-N-benzoyl-2'-deoxy-Cytidine, 3'-[(2-  
30 cyanoethyl)-(N,N-diisopropyl)]-phosphoramidite (the term "P" in the sequences, *see above*). This pyrimidine analog hydrogen bonds with purines, including A and G residues.

Exemplary primer pairs for amplification of olfactory receptor transmembrane domains II through VII include:

- (a) 5'-GGGGTCCGGAG(A/G)(C/G)(A/G)TA(A/G/T)AT(A/G/P)A(A/G/P)(A/G/P)GG-  
3' and  
5'-  
5 GGGGCTGCAGACACC(A/C/G/T)ATGTA(C/T)(C/T)T(A/C/G/T)TT(C/T)(C/T)T-  
3'.  
(b) 5'-GGGGTCCGGAG(A/G)(C/G)T(A/G)A(A/G/T)AT(A/G/P)A(A/G/P)(A/G/P)GG-  
3' and  
10 5'-  
GGGGCTGCAGACACC(A/C/G/T)ATGTA(C/T)(C/T)T(A/C/G/T)TT(C/T)(C/T)T-  
3'.  
(c) 5'-  
GGGGTCCGGAG(A/G)(C/G)T(A/G)A(A/G/T)AT(A/G/C/T)A(A/G/C/T)(A/G/C/T)  
GG-3' and  
15 5'-GGGGCTGCAGACACC(A/C/G/T)ATGTA(C/T)(C/T)T(A/C/G/T)  
TT(C/T)(C/T)T-3'.

Nucleic acids that encode ligand-binding regions of olfactory receptors are generated by amplification (*e.g.*, PCR) of appropriate nucleic acid sequences using degenerate primer pairs. The amplified nucleic acid can be genomic DNA from any cell or tissue or mRNA or cDNA derived from olfactory receptor-expressing cells, *e.g.*, olfactory neurons or olfactory epithelium.

Isolation from olfactory receptor-expressing cells is well known in the art (cells expressing naturally or inducibly expressing olfactory receptors can be used to express the hybrid olfactory receptors of the invention to screen for potential odorants and odorant effect on cell physiology, as described below). For example, cells can be identified by olfactory marker protein (OMP), an abundant cytoplasmic protein expressed almost exclusively in mature olfactory sensory neurons (*see, e.g.*, Buiakova, *Proc. Natl. Acad. Sci. USA* 93:9858, 1996). Shirley, *Eur. J. Biochem.* 32:485, 1983), describes a rat olfactory preparation suitable for biochemical studies *in vitro* on olfactory mechanisms. Cultures of adult rat olfactory receptor neurons are described by Vargas, *Chem. Senses* 24:211, 1999). Because these cultured neurons exhibit typical voltage-gated currents and are responsive to application of odorants, they can also be used to express the hybrid olfactory receptors of the invention for odorant screening (endogenous olfactory receptor can be initially blocked, if desired, by, *e.g.*,

antisense, knockout, and the like). U.S. Patent No. 5,869,266 describes culturing human olfactory neurons for neurotoxicity tests and screening. Murrell, *J. Neurosci.* 19:8260, 1999), describes differentiated olfactory receptor-expressing cells in culture that respond to odorants, as measured by an influx of calcium.

5           Hybrid protein-coding sequences comprising nucleic acids sensory receptors fused to the translocation sequences described herein may be constructed. Also provided are hybrid receptors comprising the translocation motifs and ligand-binding domains of sensory receptors. These nucleic acid sequences can be operably linked to transcriptional or translational control elements, *e.g.*, transcription and translation  
10 initiation sequences, promoters and enhancers, transcription and translation terminators, polyadenylation sequences, and other sequences useful for transcribing DNA into RNA. In construction of recombinant expression cassettes, vectors, transgenics, and a promoter fragment can be employed to direct expression of the desired nucleic acid in all tissues. Olfactory cell-specific transcriptional elements can  
15 also be used to express the fusion polypeptide receptor, including, *e.g.*, a 6.7 kb region upstream of the M4 olfactory receptor coding region. This region was sufficient to direct expression in olfactory epithelium with wild type zonal restriction and distributed neuronal expression for endogenous olfactory receptors (Qasba, *J. Neurosci.* 18:227, 1998). Receptor genes are normally expressed in a small subset of  
20 neurons throughout a zonally restricted region of the sensory epithelium. The transcriptional or translational control elements can be isolated from natural sources, obtained from such sources as ATCC or GenBank libraries, or prepared by synthetic or recombinant methods.

          Fusion proteins, either having C-terminal or, more preferably, N-terminal  
25 translocation sequences, may also comprise the translocation motif described herein. However, these fusion proteins can also comprise additional elements for, *e.g.*, protein detection, purification, or other applications. Detection and purification facilitating domains include, *e.g.*, metal chelating peptides such as polyhistidine tracts or histidine-tryptophan modules or other domains that allow purification on immobilized  
30 metals; maltose binding protein; protein A domains that allow purification on immobilized immunoglobulin; or the domain utilized in the FLAGS extension/affinity purification system (Immunex Corp, Seattle WA).

The inclusion of a cleavable linker sequences such as Factor Xa (*see, e.g., Ottavi, Biochimie* 80:289, 1998), subtilisin protease recognition motif (*see, e.g., Polyak, Protein Eng.* 10:615, 1997); enterokinase (Invitrogen, San Diego, CA), and the like, between the translocation domain (for efficient plasma membrane expression) and the rest of the newly translated polypeptide may be useful to facilitate purification. For example, one construct can include a nucleic acid sequence encoding a polypeptide linked to six histidine residues followed by a thioredoxin, an enterokinase cleavage site (*see, e.g., Williams, Biochemistry* 34:1787, 1995), and an amino terminal translocation domain. The histidine residues facilitate detection and purification while the enterokinase cleavage site provides a means for purifying the desired protein(s) from the remainder of the fusion protein. Technology pertaining to vectors encoding fusion proteins and application of fusion proteins are well described in the scientific and patent literature, *see, e.g., Kroll, DNA Cell. Biol.* 12:441, 1993).

Expression vectors, either as individual expression vectors or as libraries of expression vectors, comprising the olfactory binding domain-encoding sequences may be introduced into a genome or into the cytoplasm or a nucleus of a cell and expressed by a variety of conventional techniques, well described in the scientific and patent literature. *See, e.g., Roberts, Nature* 328:731, 1987; Berger *supra*; Schneider, *Protein Expr. Purif.* 6435:10, 1995; Sambrook; Tijssen; Ausubel. Product information from manufacturers of biological reagents and experimental equipment also provide information regarding known biological methods. The vectors can be isolated from natural sources, obtained from such sources as ATCC or GenBank libraries, or prepared by synthetic or recombinant methods.

The nucleic acids can be expressed in expression cassettes, vectors or viruses which are stably or transiently expressed in cells (*e.g., episomal expression systems*). Selection markers can be incorporated into expression cassettes and vectors to confer a selectable phenotype on transformed cells and sequences. For example, selection markers can code for episomal maintenance and replication such that integration into the host genome is not required. For example, the marker may encode antibiotic resistance (*e.g., chloramphenicol, kanamycin, G418, bleomycin, hygromycin*) or herbicide resistance (*e.g., chlorosulfuron or Basta*) to permit selection of those cells transformed with the desired DNA sequences (*see, e.g., Blondelet-Rouault, Gene* 190:315, 1997; Aubrecht, *J. Pharmacol. Exp. Ther.* 281:992, 1997). Because



selectable marker genes conferring resistance to substrates like neomycin or hygromycin can only be utilized in tissue culture, chemoresistance genes are also used as selectable markers *in vitro* and *in vivo*.

A chimeric nucleic acid sequence may encode a sensant-binding domain within any 7-transmembrane polypeptide. Seven-transmembrane receptors belong to a superfamily of trans-membrane (TM) proteins having seven domains that traverse a plasma membrane seven times. Each of the seven domains spans the plasma membrane (TM I to TM VII). Because 7-trans-membrane receptor polypeptides have similar primary sequences and secondary and tertiary structures, structural domains (e.g., TM domains) can be readily identified by sequence analysis. For example, homology modeling, Fourier analysis and helical periodicity detection can identify and characterize the seven domains with a 7-transmembrane receptor sequence. Fast Fourier Transform (FFT) algorithms can be used to assess the dominant periods that characterize profiles of the hydrophobicity and variability of analyzed sequences. To predict TM domains and their boundaries and topology, a "neural network algorithm" by "PHD server" can be used, as done by Pilpel, *Protein Science* 8:969, 1999; Rost, *Protein Sci.* 4:521, 1995. Periodicity detection enhancement and alpha helical periodicity index can be done as by, e.g., Donnelly, *Protein Sci.* 2:55-70 (1993). Other alignment and modeling algorithms are well known in the art, see, e.g., Peitsch, *Receptors Channels* 4:161, 1996; Cronet, *Protein Eng.* 6:59, (1993) (homology and "discover modeling"); <http://bioinfo.weizmann.ac.il/>.

The library sequences include receptor sequences that correspond to TM ligand-binding domains, including, e.g., TM II to VII, TM II to VI, TM III to VII, and TM III to VII, that have been amplified (e.g., PCR) from mRNA of or cDNA derived from, e.g., olfactory receptor-expressing neurons or genomic DNA.

Libraries of sensory receptor ligand-binding TM domain sequences can include a various TM domains or variations thereof, as described above. These sequences can be derived from any 7-transmembrane receptor. Because these polypeptides have similar primary sequences and secondary and tertiary structures, the seven domains can be identified by various analyses well known in the art, including, e.g., homology modeling, Fourier analysis and helical periodicity (see, e.g., Pilpel *supra*), as described above. Using this information sequences flanking the seven

domains can be identified and used to design degenerate primers for amplification of various combinations of TM regions and subsequences.

The present invention also includes not only the DNA and proteins having the specified amino acid sequences, but also DNA fragments, particularly fragments of, for example, 40, 60, 80, 100, 150, 200, or 250 nucleotides, or more, as well as protein fragments of, for example, 10, 20, 30, 50, 70, 100, or 150 amino acids, or more.

Also contemplated are chimeric proteins, comprising at least 10, 20, 30, 50, 70, 100, or 150 amino acids, or more, of one of at least one of the sensory receptors described herein, coupled to additional amino acids representing all or part of another G protein receptor, preferably a member of the 7-transmembrane superfamily. These chimerae can be made from the instant receptors and a G protein receptor described herein, or they can be made by combining two or more of the present proteins. In one preferred embodiment, one portion of the chimera corresponds to and is derived from one or more of the domains of the 7-transmembrane protein described herein, and the remaining portion or portions come from another G protein-coupled receptor. Chimeric receptors are well known in the art, and the techniques for creating them and the selection and boundaries of domains or fragments of G protein-coupled receptors for incorporation therein are also well known. Thus, this knowledge of those skilled in the art can readily be used to create such chimeric receptors. The use of such chimeric receptors can provide, for example, an olfactory selectivity characteristic of one of the receptors specifically disclosed herein, coupled with the signal transduction characteristics of another receptor, such as a well known receptor used in prior art assay systems.

For example, a domain such as a ligand binding domain, an extracellular domain, a transmembrane domain (e.g., one comprising seven transmembrane regions and corresponding extracellular and cytosolic loops), the transmembrane domain and a cytoplasmic domain, an active site, a subunit association region, etc., can be covalently linked to a heterologous protein. For instance, an extracellular domain can be linked to a heterologous GPCR transmembrane domain, or a heterologous CGPCR extracellular domain can be linked to a transmembrane domain. Other heterologous proteins of choice can include, e.g., green fluorescent protein,  $\beta$ -gal, glutamate receptor, and the rhodopsin presequence.

Polymorphic variants, alleles, and interspecies homologs that are substantially identical to a sensory receptor disclosed herein can be isolated using the nucleic acid probes described above. Alternatively, expression libraries can be used to isolate sensory receptors and polymorphic variants, alleles, and interspecies homologs thereof, by detecting expressed homologs immunologically with antisera or purified antibodies made against a sensory receptor-derived polypeptide, which also recognize and selectively bind to the sensory receptor homolog.

Also within the scope of the invention are host cells for expressing the sensory receptors, fragments, or variants of the invention. To obtain high levels of expression of a cloned gene or nucleic acid, such as cDNAs encoding the sensory receptors, fragments, or variants thereof, the nucleic acid sequence of interest is subcloned into an expression vector that contains a strong promoter to direct transcription, a transcription/translation terminator, and if for a nucleic acid encoding a protein, a ribosome binding site for translational initiation. Suitable prokaryotic and eukaryotic expression systems are well known in the art and described, e.g., in Sambrook *et al.*

Any of the well known procedures for introducing foreign nucleotide sequences into host cells may be used. These include the use of calcium phosphate transfection, polybrene, protoplast fusion, electroporation, liposomes, microinjection, plasmid vectors, viral vectors and any of the other well known methods for introducing cloned genomic DNA, cDNA, synthetic DNA or other foreign genetic material into a host cell (*see, e.g., Sambrook et al.*). It is only necessary that the particular genetic engineering procedure used be capable of successfully introducing at least one gene into the host cell capable of expressing the olfactory receptor, fragment, or variant of interest.

After the expression vector is introduced into the cells, the transfected cells are cultured under conditions favoring expression of the receptor, fragment, or variant of interest, which is then recovered from the culture using standard techniques. Examples of such techniques are well known in the art. *See, e.g., WO 00/06593*, which is incorporated by reference in a manner consistent with this disclosure.

D. Immunological Detection of Sensory Receptor Polypeptides

In addition to the detection of sensory receptor genes and gene expression using nucleic acid hybridization technology, one can also use immunoassays to detect

sensory receptors, e.g., to identify olfactory receptor cells, and variants of sensory receptor family members. Immunoassays can be used to qualitatively or quantitatively analyze the sensory receptors. A general overview of the applicable technology can be found in Harlow & Lane, *Antibodies: A Laboratory Manual* (1988).

5           1.     Antibodies to sensory receptor family members

Methods of producing polyclonal and monoclonal antibodies that react specifically with a sensory receptor family member are known to those of skill in the art (see, e.g., Coligan, *Current Protocols in Immunology*, 1991; Goding, *Monoclonal Antibodies: Principles and Practice*, 2d ed., 1986; Harlow & Lane, supra; and Kohler & Milstein, *Nature*, 256:495, 1975). Such techniques include antibody preparation by selection of antibodies from libraries of recombinant antibodies in phage or similar vectors, as well as preparation of polyclonal and monoclonal antibodies by immunizing rabbits or mice (see, e.g., Huse et al., *Science*, 246:1275, 1989; Ward et al., *Nature*, 341:544, 1989).

15           A number of sensory receptor-comprising immunogens may be used to produce antibody specifically reactive with a sensory receptor family member. For example, a recombinant sensory receptor protein, or an antigenic fragment thereof, can be isolated as described herein. Suitable antigenic regions include, e.g., the conserved motifs that are used to identify members of the sensory receptor family.

20           Recombinant proteins can be expressed in eukaryotic or prokaryotic cells as described above, and purified as generally described above. Recombinant protein is the preferred immunogen for the production of monoclonal or polyclonal antibodies. Alternatively, a synthetic peptide derived from the sequences disclosed herein and conjugated to a carrier protein can be used as immunogen. Naturally occurring

25           protein may also be used either in pure or impure form. The product is then injected into an animal capable of producing antibodies. Either monoclonal or polyclonal antibodies may be generated, for subsequent use in immunoassays to measure the protein.

30           Methods of production of polyclonal antibodies are known to those of skill in the art. Mice, hamsters, rats, guinea pigs, rabbits, goats, or chickens is immunized with the protein using an adjuvant (e.g., Freund's adjuvant) and a standard immunization protocol with periodic boosts. The animal's immune response to the immunogen preparation is monitored by taking test bleeds and determining the titer of

reactivity to the sensory receptor. When appropriately high titers of antibody to the immunogen are obtained, blood is collected from the animal and antisera are prepared. Further fractionation of the antisera to enrich for antibodies reactive to the protein can be done if desired (see Harlow & Lane, *supra*).

5 Monoclonal antibodies may be obtained by various techniques familiar to those skilled in the art. Briefly, spleen cells from an animal immunized with a desired antigen are immortalized, commonly by fusion with a myeloma cell (see Kohler & Milstein, *Eur. J. Immunol.*, 6:511, 1976). Alternative methods of immortalization include transformation with Epstein Barr Virus, oncogenes, retroviruses, or other  
10 methods well known in the art. Colonies arising from single clones of immortalized cells are screened for production of antibodies of the desired specificity and affinity for the antigen, and yield of the monoclonal antibodies produced by such cells may be enhanced by various techniques, including injection into the peritoneal cavity of a vertebrate host. Alternatively, one may isolate DNA sequences which encode a  
15 monoclonal antibody or a binding fragment thereof by screening a DNA library from human B cells according to the general protocol outlined by Huse *et al.*, *Science*, 246:1275, 1989.

Monoclonal antibodies or polyclonal sera are collected and titered against antigen in an immunoassay, for example, a solid phase immunoassay with the antigen  
20 immobilized on a solid support. Typically, polyclonal antisera with a titer of  $10^4$  or greater are selected and tested for their cross reactivity against non-sensory receptor proteins, or even other sensory receptor family members or other related proteins from other organisms, using a competitive binding immuno-assay. Specific polyclonal antisera and monoclonal antibodies will usually bind with a  $K_d$  of at least about 0.1  
25 mM, more usually at least about 1 pM, optionally at least about 0.1 pM or better, and optionally 0.01 pM or better.

Once sensory receptor family member specific antibodies are available, individual sensory receptor proteins can be detected by a variety of immunoassay methods. For a review of immuno-nological and immunoassay procedures, see *Basic and Clinical Immunology* (Stites & Terr eds., 7th ed., 1991). Moreover, the  
30 immunoassays of the present invention can be performed in any of several configurations, which are reviewed extensively in *Enzyme Immunoassay* (Maggio, ed., 1980); and Harlow & Lane, *supra*.

## 2. Immunological binding assays

Sensory receptor proteins can be detected and/or quantified using any of a number of well recognized immunological binding assays (see, e.g., U.S. Patent Nos. 4,366,241; 4,376,110; 4,517,288; and 4,837,168). For a review of the general  
5 immunoassays, see also *Methods in Cell Biology: Antibodies in Cell Biology*, volume 37 (Asai, ed. 1993); *Basic and Clinical Immunology* (Stites & Terr, eds., 7th ed., 1991). Immunological binding assays (or immunoassays) typically use an antibody that specifically binds to a protein or antigen of choice (in this case a sensory receptor family member or an antigenic subsequence thereof). The antibody (e.g., anti-sensory  
10 receptor) may be produced by any of a number of means well known to those of skill in the art and as described above.

Immunoassays also often use a labeling agent to specifically bind to and label the complex formed by the antibody and antigen. The labeling agent may itself be one of the moieties comprising the antibody/antigen complex. Thus, the labeling agent  
15 may be a labeled sensory receptor polypeptide or a labeled anti-sensory receptor antibody. Alternatively, the labeling agent may be a third moiety, such a secondary antibody, that specifically binds to the antibody/sensory receptor complex (a secondary antibody is typically specific to antibodies of the species from which the first antibody is derived). Other proteins capable of specifically binding  
20 immunoglobulin constant regions, such as protein A or protein G may also be used as the label agent. These proteins exhibit a strong non-immunogenic reactivity with immunoglobulin constant regions from a variety of species (see, e.g., Kronval *et al.*, *J. Immunol.*, 111:1401, 1973; Akerstrom *et al.*, *J. Immunol.*, 135:2589, 1985). The labeling agent can be modified with a detectable moiety, such as biotin, to which  
25 another molecule can specifically bind, such as streptavidin. A variety of detectable moieties are well known to those skilled in the art.

Throughout the assays, incubation and/or washing steps may be required after each combination of reagents. Incubation steps can vary from about 5 seconds to several hours, optionally from about 5 minutes to about 24 hours. However, the  
30 incubation time will depend upon the assay format, antigen, volume of solution, concentrations, and the like. Usually, the assays will be carried out at ambient temperature, although they can be conducted over a range of temperatures, such as 10°C to 40°C.

a. Non-competitive assay formats

Immunoassays for detecting a sensory receptor protein in a sample may be either competitive or noncompetitive. Noncompetitive immunoassays directly measure the amount of antigen. In one preferred "sandwich" assay, for example, the anti-sensory receptor antibodies are bound directly to a solid substrate on which they are immobilized. These immobilized antibodies then capture the sensory receptor protein present in the test sample. The sensory receptor protein thus immobilized is then bound by a labeling agent, such as a second anti-sensory receptor antibody bearing a label. Alternatively, the second antibody may lack a label, but it may, in turn, be bound by a labeled third antibody specific to antibodies of the species from which the second antibody is derived. The second or third antibody is typically modified with a detectable moiety, such as biotin, to which another molecule specifically binds, *e.g.*, streptavidin, to provide a detectable moiety.

b. Competitive assay formats

In competitive assays, the amount of sensory receptor protein present in the sample is measured indirectly by measuring the amount of a known, added (exogenous) sensory receptor protein displaced (competed away) from an anti-sensory receptor antibody by the unknown sensory receptor protein present in a sample. In one competitive assay, a known amount of sensory receptor protein is added to a sample and the sample is then contacted with an antibody that specifically binds to the sensory receptor. The amount of exogenous sensory receptor protein bound to the antibody is inversely proportional to the concentration of sensory receptor protein present in the sample. In a particularly preferred embodiment, the antibody is immobilized on a solid substrate. The amount of sensory receptor protein bound to the antibody may be determined either by measuring the amount of sensory receptor protein present in a sensory receptor/antibody complex, or alternatively by measuring the amount of remaining uncomplexed protein. The amount of sensory receptor protein may be detected by providing a labeled sensory receptor molecule.

A hapten inhibition assay is another preferred competitive assay. In this assay the known sensory receptor protein is immobilized on a solid substrate. A known amount of anti-sensory receptor antibody is added to the sample, and the sample is then contacted with the immobilized sensory receptor. The amount of anti-sensory receptor antibody bound to the known immobilized sensory receptor protein is

inversely proportional to the amount of sensory receptor protein present in the sample. Again, the amount of immobilized antibody may be detected by detecting either the immobilized fraction of antibody or the fraction of the antibody that remains in solution. Detection may be direct where the antibody is labeled or indirect by the subsequent addition of a labeled moiety that specifically binds to the antibody as described above.

c. Cross-reactivity determinations

Immunoassays in the competitive binding format can also be used for cross-reactivity determinations. For example, a protein at least partially encoded by the nucleic acid sequences disclosed herein can be immobilized to a solid support. Proteins (*e.g.*, sensory receptor proteins and homologs) are added to the assay that compete for binding of the antisera to the immobilized antigen. The ability of the added proteins to compete for binding of the antisera to the immobilized protein is compared to the ability of the sensory receptor polypeptide encoded by the nucleic acid sequences disclosed herein to compete with itself. The percentage cross-reactivity for the above proteins is calculated, using standard calculations. Those antisera with less than 10% cross-reactivity with each of the added proteins listed above are selected and pooled. The cross-reacting antibodies are optionally removed from the pooled antisera by immunoabsorption with the added considered proteins, *e.g.*, distantly related homologs. In addition, peptides comprising amino acid sequences representing conserved motifs that are used to identify members of the sensory receptor family can be used in cross-reactivity determinations.

The immunoabsorbed and pooled antisera are then used in a competitive binding immunoassay as described above to compare a second protein, thought to be perhaps an allele or poly-morphic variant of a sensory receptor family member, to the immunogen protein (*i.e.*, sensory receptor protein encoded by the nucleic acid sequences disclosed herein). In order to make this comparison, the two proteins are each assayed at a wide range of concentrations and the amount of each protein required to inhibit 50% of the binding of the antisera to the immobilized protein is determined. If the amount of the second protein required to inhibit 50% of binding is less than 10 times the amount of the protein encoded by nucleic acid sequences disclosed herein required to inhibit 50% of binding, then the second protein is said to



specifically bind to the polyclonal antibodies generated to a sensory receptor immunogen.

Antibodies raised against sensory receptor conserved motifs can also be used to prepare antibodies that specifically bind only to GPCRs of the sensory receptor family, but not to GPCRs from other families. Polyclonal antibodies that specifically bind to a particular member of the sensory receptor family, can be made by subtracting out cross-reactive antibodies using other sensory receptor family members. Species-specific polyclonal antibodies can be made in a similar way. For example, antibodies specific to human T2R01 can be made by, subtracting out antibodies that are cross-reactive with orthologous sequences, *e.g.*, rat OLFR1 or mouse OLFR1.

d. Other assay formats

Western blot (immunoblot) analysis is used to detect and quantify the presence of sensory receptor protein in the sample. The technique generally comprises separating sample proteins by gel electrophoresis on the basis of molecular weight, transferring the separated proteins to a suitable solid support, (such as a nitrocellulose filter, a nylon filter, or derivatized nylon filter), and incubating the sample with the antibodies that specifically bind the sensory receptor protein. The anti-sensory receptor polypeptide antibodies specifically bind to the sensory receptor poly-peptide on the solid support. These antibodies may be directly labeled or alternatively may be subsequently detected using labeled antibodies (*e.g.*, labeled sheep anti-mouse antibodies) that specifically bind to the anti-sensory receptor antibodies.

Other assay formats include liposome immunoassays (LIA) using liposomes designed to bind specific molecules (*e.g.*, antibodies) and release encapsulated reagents or markers. The released chemicals are then detected according to standard techniques (*see Monroe et al., Amer. Clin. Prod. Rev.*, 5:34, 1986).

e. Reduction of non-specific binding

One of skill in the art will appreciate that it is often desirable to minimize non-specific binding in immunoassays. Particularly, where the assay involves an antigen or antibody immo-bilized on a solid substrate it is desirable to minimize the amount of non-specific binding to the substrate. Means of reducing such non-specific binding are well known to those of skill in the art. Typically, this technique involves coating the substrate with a proteinaceous composition. In particular, protein

compositions such as bovine serum albumin (BSA), nonfat powdered milk, and gelatin are widely used with powdered milk being most preferred.

f. Labels

5 The particular label or detectable group used in the assay is not a critical aspect of the invention, as long as it does not significantly interfere with the specific binding of the antibody used in the assay. The detectable group can be any material having a detectable physical or chemical property. Such detectable labels have been well-developed in the field of immuno-assays and, in general, most any label useful in such methods can be applied to the present invention. Thus, a label is any composition  
10 detectable by spectroscopic, photochemical, bio-chemical, immunochemical, electrical, optical or chemical means. Useful labels in the present invention include magnetic beads (e.g., DYNABEADS™, fluorescent dyes (e.g., fluorescein isothiocyanate, Texas red, rhodamine, and the like), radiolabels (e.g.,  $^3\text{H}$ ,  $^{125}\text{I}$ ,  $^{35}\text{S}$ ,  $^{14}\text{C}$ , or  $^{32}\text{P}$ ), enzymes (e.g., horseradish peroxidase, alkaline phosphatase and others  
15 commonly used in an ELISA), and colorimetric labels such as colloidal gold or colored glass or plastic beads (e.g., polystyrene, polypropylene, latex, etc.).

The label may be coupled directly or indirectly to the desired component of the assay according to methods well known in the art. As indicated above, a wide variety of labels may be used, with the choice of label depending on sensitivity required, ease  
20 of conjugation with the compound, stability requirements, available instrumentation, and disposal provisions.

Non-radioactive labels are often attached by indirect means. Generally, a ligand molecule (e.g., biotin) is covalently bound to the molecule. The ligand then binds to another molecules (e.g., streptavidin) molecule, which is either inherently  
25 detectable or covalently bound to a signal system, such as a detectable enzyme, a fluorescent compound, or a chemiluminescent compound. The ligands and their targets can be used in any suitable combination with antibodies that recognize a sensory receptor protein, or secondary antibodies that recognize anti-sensory receptor.

The molecules can also be conjugated directly to signal generating  
30 compounds, e.g., by conjugation with an enzyme or fluorophore. Enzymes of interest as labels will primarily be hydrolases, particularly phosphatases, esterases and glycosidases, or oxidotases, particularly peroxidases. Fluorescent compounds include fluorescein and its derivatives, rhodamine and its derivatives, dansyl, umbelliferone,

*etc.* Chemiluminescent compounds include luciferin, and 2,3-dihydrophthalazinediones, *e.g.*, luminol. For a review of various labeling or signal producing systems that may be used, see U.S. Patent No. 4,391,904.

Methods for detecting labels are well known. Thus, for example, where the label is a radioactive label, it may be detected using a scintillation counter or with photographic film as in autoradiography. Where the label is a fluorescent label, it may be detected by exciting the fluoro-chrome with the appropriate wavelength of light and detecting the resulting fluorescence. The fluorescence may be detected visually, with photographic film, or using electronic detectors such as charge coupled devices (CCDs) or photomultipliers. Similarly, enzymatic labels may be detected by providing the appropriate substrates for the enzyme and detecting the resulting reaction product. Finally, simple colorimetric labels may be detected simply by observing the color associated with the label. Thus, in various dipstick assays, conjugated gold often appears pink, while various conjugated beads appear the color of the bead.

Some assay formats do not require the use of labeled components. For instance, aggluti-nation assays can be used to detect the presence of the target antibodies. In this case, antigen-coated particles are agglutinated by samples comprising the target antibodies. In this format, none of the components need be labeled and the presence of the target antibody is detected by simple visual inspection.

#### E. Detection of Olfactory Modulators

Methods and compositions for determining whether a test compound specifically binds to a mammalian sensory, and more particularly, olfactory receptor of the invention, both *in vitro* and *in vivo* are described below, as are methods and compositions for determining whether a test compound is neurotoxic to an olfactory neuron expressing an olfactory transmembrane receptor polypeptide. Any aspect of cell physiology can be monitored to assess the effect of sensant-binding to a naturally-occurring or chimeric olfactory receptor. These assays may be performed on intact cells expressing an olfactory receptor, on permeabilized cells or on membrane fractions produced by standard methods.

Olfactory receptors are normally located on the specialized cilia of olfactory neurons. These receptors bind odorants and initiate the transduction of chemical

stimuli into electrical signals. An activated or inhibited G-protein will in turn alter the properties of target enzymes, channels, and other effector proteins. The classic examples are the activation of cGMP phosphodiesterase by transducin in the visual system, adenylate cyclase by the stimulatory G-protein, phospholipase C by Gq and other cognate G-proteins, and modulation of diverse channels by Gi and other G-proteins. Downstream consequences can also be examined such as generation of diacyl glycerol and IP3 by phospholipase C, and in turn, for calcium mobilization by IP3.

The sensory receptor protein of the assay will typically be selected from a natural poly-peptide or conservatively modified variant thereof. Generally, the amino acid sequence identity will be at least 75%, 85%, 90%, 95%, or 99%. Optionally, the polypeptide of the assays can comprise a domain of a sensory receptor protein, such as an extracellular domain, transmembrane region, transmembrane domain, cytoplasmic domain, ligand binding domain, subunit association domain, active site, and the like. Either the sensory receptor protein or a domain thereof can be covalently linked to a heterologous protein to create a chimeric protein used in the assays described herein.

Modulators of sensory receptor activity can be tested using sensory receptor polypeptides as described above, either recombinant or naturally occurring. Protein can be isolated, expressed in a cell, expressed in a membrane derived from a cell, expressed in tissue or in an animal, either recombinant or naturally occurring. Modulation can be tested using one of the *in vitro* or *in vivo* assays described herein.

#### 1. In vitro binding assays

Sensory perception can also be examined *in vitro* with soluble or solid state reactions, using a full-length sensory receptor-GPCR or a chimeric molecule such as an extracellular domain or transmembrane region, or combination thereof, of a sensory receptor covalently linked to a heterologous signal transduction domain, or a heterologous extracellular domain and/or transmembrane region covalently linked to the transmembrane and/or cytoplasmic domain of a sensory receptor. Furthermore, ligand-binding domains of the protein of interest can be used *in vitro* in soluble or solid state reactions to assay for ligand binding. In numerous embodiments, a chimeric receptor will be made that comprises all or part of a sensory receptor polypeptide, as well an additional sequence that facilitates the localization of the

sensory receptor to the membrane, such as a rhodopsin, *e.g.*, an N-terminal fragment of a rhodopsin protein.

Ligand binding to a sensory receptor protein, a domain, or chimeric protein can be tested in solution, in a bilayer membrane, attached to a solid phase, in a lipid  
5 monolayer, or in vesicles. Binding of a modulator can be tested using, *e.g.*, changes in spectroscopic characteristics (*e.g.*, fluorescence, absorbance, refractive index) hydrodynamic (*e.g.*, shape), chromatographic, or solubility properties. Sensory receptors with large (*e.g.*, approximately 600 amino acid residues) extracellular N-terminal segments. These N-terminal segments are thought to form ligand-binding  
10 domains, and are therefore useful in biochemical assays to identify sensory receptor agonists and antagonists. Similar assays have been used with other GPCRs, such as the metabo-tropic glutamate receptors (*e.g.*, Han & Hampson, *J. Biol. Chem.* 274:10008, 1999). These assays might involve displacing a radioactively or fluorescently labeled ligand, and measuring changes in intrinsic fluorescence or  
15 changes in proteolytic susceptibility, *etc.*

Receptor-G-protein interactions can also be examined. For example, binding of the G-protein to the receptor or its release from the receptor can be examined. For example, in the absence of GTP, an activator will lead to the formation of a tight complex of a G protein (all three subunits) with the receptor. This complex can be  
20 detected in a variety of ways, as noted above. Such an assay can be modified to search for inhibitors, *e.g.*, by adding an activator to the receptor and G protein in the absence of GTP, which form a tight complex, and then screen for inhibitors by looking at dissociation of the receptor-G protein complex. In the presence of GTP, release of the alpha subunit of the G protein from the other two G protein subunits  
25 serves as a criterion of activation.

An activated or inhibited G-protein will in turn alter the properties of target enzymes, channels, and other effector proteins. The classic examples are the activation of cGMP phosphodiesterase by transducin in the visual system, adenylate cyclase by the stimulatory G-protein, phospholipase C by Gq and other cognate G  
30 proteins, and modulation of diverse channels by Gi and other G proteins. Downstream consequences can also be examined such as generation of diacyl glycerol and IP3 by phospholipase C, and in turn, for calcium mobilization by IP3.

## 2. Fluorescence Polarization Assays

In another embodiment, Fluorescence Polarization ("FP") based assays may be used to detect and monitor sensant binding. Fluorescence polarization is a versatile laboratory technique for measuring equilibrium binding, nucleic acid hybridization, and enzymatic activity. Fluorescence polarization assays are homogeneous in that they do not require a separation step such as centrifugation, filtration, chromatography, precipitation, or electrophoresis. These assays are done in real time, directly in solution and do not require an immobilized phase. Polarization values can be measured repeatedly and after the addition of reagents since measuring the polarization is rapid and does not destroy the sample. Generally, this technique can be used to measure polarization values of fluorophores from low picomolar to micromolar levels. This section describes how fluorescence polarization can be used in a simple and quantitative way to measure the binding of odorants to the sensory receptors of the invention.

When a fluorescently labeled molecule is excited with plane polarized light, it emits light that has a degree of polarization that is inversely proportional to its molecular rotation. Large fluorescently labeled molecules remain relatively stationary during the excited state (4 nano-seconds in the case of fluorescein) and the polarization of the light remains relatively constant between excitation and emission. Small fluorescently labeled molecules rotate rapidly during the excited state and the polarization changes significantly between excitation and emission. Therefore, small molecules have low polarization values and large molecules have high polarization values. For example, a single-stranded fluorescein-labeled oligonucleotide has a relatively low polarization value but when it is hybridized to a complementary strand, it has a higher polarization value. When using FP to detect and monitor odorant binding which may activate or inhibit the sensory receptors of the invention, fluorescence-labeled sensants or auto-fluorescent sensants may be used. Fluorescence polarization (P) is defined as:

$$P = \frac{Int_{\parallel} - Int_{\perp}}{Int_{\parallel} + Int_{\perp}}$$

Where  $\parallel$  is the intensity of the emission light parallel to the excitation light plane and  $\perp$  is the intensity of the emission light perpendicular to the excitation light plane. P, being a ratio of light intensities, is a dimensionless number. For

example, the Beacon® and Beacon 2000™ System may be used in connection with these assays. Such systems typically express polarization in millipolarization units (1 Polarization Unit = 1000 mP Units).

The relationship between molecular rotation and size is described by the Perrin equation and the reader is referred to Jolley *J. Anal. Toxicol.* 5, 236, 1981 which gives a thorough explanation of this equation. Summarily, the Perrin equation states that polarization is directly proportional to the rotational relaxation time, the time that it takes a molecule to rotate through an angle of approximately 68.5°. Rotational relaxation time is related to viscosity ( $\eta$ ), absolute temperature (T), molecular volume (V), and the gas constant (R) by the following equation:

$$\text{Rotational Relaxation Time} = \frac{3\eta V}{RT}$$

The rotational relaxation time is small ( $\approx 1$  nanosecond) for small molecules (e.g., fluorescein) and large ( $\approx 100$  nanoseconds) for large molecules (e.g., immunoglobulins). If viscosity and temperature are held constant, rotational relaxation time, and therefore polarization, is directly related to the molecular volume. Changes in molecular volume may be due to interactions with other molecules, dissociation, polymerization, degradation, hybridization, or conformational changes of the fluorescently labeled molecule. For example, fluorescence polarization has been used to measure enzymatic cleavage of large fluorescein labeled polymers by proteases, DNases, and RNases. It also has been used to measure equilibrium binding for protein/protein interactions, antibody/antigen binding, and protein/DNA binding.

### 3. Soluble and solid state high throughput assays

In yet another embodiment, the invention provides soluble assays using molecules such as a domain such as ligand binding domain, an extracellular domain, a transmembrane domain (e.g., one comprising seven transmembrane regions and cytosolic loops), the transmembrane domain and a cytoplasmic domain, an active site, a subunit association region, etc.; a domain that is covalently linked to a heterologous protein to create a chimeric molecule; a sensory receptor protein; or a cell or tissue expressing a sensory receptor protein, either naturally occurring or recombinant. In another embodiment, the invention provides solid phase based *in vitro* assays in a high throughput format, where the domain, chimeric molecule, sensory receptor protein, or cell or tissue expressing the sensory receptor is attached to a solid phase substrate.

In the high throughput assays of the invention, it is possible to screen up to several thousand different modulators or ligands in a single day. In particular, each well of a microtiter plate can be used to run a separate assay against a selected potential modulator, or, if concentration or incubation time effects are to be observed, every 5-10 wells can test a single modulator. Thus, a single standard microtiter plate can assay about 100 (*e.g.*, 96) modulators. If 1536 well plates are used, then a single plate can easily assay from about 1000 to about 1500 different compounds. It is possible to assay several different plates per day; assay screens for up to about 6,000-20,000 different compounds is possible using the integrated systems of the invention. More recently, microfluidic approaches to reagent manipulation have been developed.

The molecule of interest can be bound to the solid state component, directly or indirectly, via covalent or non covalent linkage, *e.g.*, via a tag. The tag can be any of a variety of components. In general, a molecule which binds the tag (a tag binder) is fixed to a solid support, and the tagged molecule of interest (*e.g.*, the taste transduction molecule of interest) is attached to the solid support by interaction of the tag and the tag binder.

A number of tags and tag binders can be used, based upon known molecular interactions well described in the literature. For example, where a tag has a natural binder, for example, biotin, protein A, or protein G, it can be used in conjunction with appropriate tag binders (avidin, streptavidin, neutravidin, the Fc region of an immunoglobulin, *etc.*). Antibodies to molecules with natural binders such as biotin are also widely available and appropriate tag binders (*see*, SIGMA Immunochemicals 1998 catalogue SIGMA, St. Louis MO).

Similarly, any haptenic or antigenic compound can be used in combination with an appropriate antibody to form a tag/tag binder pair. Thousands of specific antibodies are commercially available and many additional antibodies are described in the literature. For example, in one common configuration, the tag is a first antibody and the tag binder is a second antibody which recognizes the first antibody. In addition to antibody-antigen interactions, receptor-ligand interactions are also appropriate as tag and tag-binder pairs. For example, agonists and antagonists of cell membrane receptors (*e.g.*, cell receptor-ligand interactions such as transferrin, c-kit, viral receptor ligands, cytokine receptors, chemokine receptors, interleukin receptors,



describing arrays of biopolymers fixed to solid substrates). Non-chemical approaches for fixing tag binders to substrates include other common methods, such as heat, cross-linking by UV radiation, and the like.

#### 4. Computer-based assays

5 Yet another assay for compounds that modulate sensory receptor protein activity involves computer assisted drug design, in which a digital or analog processing system is used to generate a three-dimensional structure of a sensory receptor protein based on the structural information encoded by its amino acid sequence. The input amino acid sequence interacts directly and actively with a  
10 preestablished algorithm in a computer program to yield secondary, tertiary, and quaternary structural models of the protein. The models of the protein structure are then examined to identify regions of the structure that have the ability to bind, *e.g.*, ligands. These regions are then used to identify ligands that bind to the protein.

The three-dimensional structural model of the protein is generated by entering  
15 protein amino acid sequences of at least 10 amino acid residues or corresponding nucleic acid sequences encoding a sensory receptor polypeptide into the computer system. The nucleotide sequence encoding the polypeptide, or the amino acid sequence thereof, can be any of those described herein, or fragments or variants thereof.

20 The amino acid sequence represents the primary sequence or subsequence of the protein, which encodes the structural information of the protein. At least 10 residues of the amino acid sequence (or a nucleotide sequence encoding 10 amino acids) are entered into the computer system from computer keyboards, computer readable substrates that include, but are not limited to, electronic storage media (*e.g.*,  
25 magnetic diskettes, tapes, cartridges, and chips), optical media (*e.g.*, CD ROM), information distributed by internet sites, and by RAM. The three-dimensional structural model of the protein is then generated by the interaction of the amino acid sequence and the computer system, using software known to those of skill in the art.

The amino acid sequence represents a primary structure that encodes the  
30 information necessary to form the secondary, tertiary and quaternary structure of the protein of interest. The software looks at certain parameters encoded by the primary sequence to generate the structural model. These parameters are referred to as "energy terms," and primarily include electrostatic potentials, hydrophobic potentials, solvent

accessible surfaces, and hydrogen bonding. Secondary energy terms include van der Waals potentials. Biological molecules form the structures that minimize the energy terms in a cumulative fashion. The computer program is therefore using these terms encoded by the primary structure or amino acid sequence to create the secondary structural model.

The tertiary structure of the protein encoded by the secondary structure is then formed on the basis of the energy terms of the secondary structure. The user at this point can enter additional variables such as whether the protein is membrane bound or soluble, its location in the body, and its cellular location, *e.g.*, cytoplasmic, surface, or nuclear. These variables along with the energy terms of the secondary structure are used to form the model of the tertiary structure. In modeling the tertiary structure, the computer program matches hydrophobic faces of secondary structure with like, and hydrophilic faces of secondary structure with like.

Once the structure has been generated, potential ligand binding regions are identified by the computer system. Three-dimensional structures for potential ligands are generated by entering amino acid or nucleotide sequences or chemical formulas of compounds, as described above. The three-dimensional structure of the potential ligand is then compared to that of the sensory receptor protein to identify ligands that bind to the protein. Binding affinity between the protein and ligands is determined using energy terms to determine which ligands have an enhanced probability of binding to the protein.

Computer systems are also used to screen for mutations, polymorphic variants, alleles and interspecies homologs of sensory receptor genes. Such mutations can be associated with disease states or genetic traits. As described above, GeneChip™ and related technology can also be used to screen for mutations, polymorphic variants, alleles and interspecies homologs. Once the variants are identified, diagnostic assays can be used to identify patients having such mutated genes. Identification of the mutated sensory receptor genes involves receiving input of a first nucleic acid or amino acid sequence of a sensory receptor gene, or conservatively modified versions thereof. The sequence is entered into the computer system as described above. The first nucleic acid or amino acid sequence is then compared to a second nucleic acid or amino acid sequence that has substantial identity to the first sequence. The second sequence is entered into the computer system in the manner described above. Once

odorant dependent activation monitored. Control samples (untreated with activators or inhibitors) are assigned a relative sensory receptor activity value of 100. Inhibition of a sensory receptor protein is achieved when the sensory receptor activity value relative to the control is about 90%, optionally 50%, optionally 25-0%. Activation of a sensory receptor protein is achieved when the sensory receptor activity value relative to the control is 110%, optionally 150%, 200-500%, or 1000-2000%.

Changes in ion flux may be assessed by determining changes in polarization (*i.e.*, electrical potential) of the cell or membrane expressing a sensory receptor protein. One means to determine changes in cellular polarization is by measuring changes in current, and thereby measuring changes in polarization, with voltage-clamp and patch-clamp techniques, *e.g.*, the "cell-attached" mode, the "inside-out" mode, and the "whole cell" mode (*see, e.g.*, Ackerman *et al.*, *New Engl. J Med.*, 336:1575, 1997). Whole cell currents are conveniently determined using the standard. Other known assays include: assays to measure ion flux using radiolabeled or fluorescent probes such as voltage-sensitive dyes (*see, e.g.*, Vestergaard-Bogind *et al.*, *J. Membrane Biol.*, 88:67, 1988; Gonzales & Tsien, *Chem. Biol.*, 4:269, 1997; Daniel *et al.*, *J. Pharmacol. Meth.*, 25:185, 1991; Holevinsky *et al.*, *J. Membrane Biology*, 137:59, 1994). Generally, the compounds to be tested are present in the range from 1 pM to 100 mM.

The effects of the test compounds upon the function of the polypeptides can be measured by examining any of the parameters described above. Any suitable physiological change that affects GPCR activity can be used to assess the influence of a test compound on the polypeptides of this invention. When the functional consequences are determined using intact cells or animals, one can also measure a variety of effects such as transmitter release, hormone release, transcriptional changes to both known and uncharacterized genetic markers (*e.g.*, Northern blots), changes in cell metabolism such as cell growth or pH changes, and changes in intracellular second messengers such as  $\text{Ca}^{2+}$ , IP3, cGMP, or cAMP.

Preferred assays for G-protein coupled receptors include cells that are loaded with ion or voltage sensitive dyes to report receptor activity. Assays for determining activity of such receptors can also use known agonists and antagonists for other G-protein coupled receptors as negative or positive controls to assess activity of tested compounds. In assays for identifying modulatory compounds (*e.g.*, agonists,

antagonists), changes in the level of ions in the cytoplasm or membrane voltage will be monitored using an ion sensitive or membrane voltage fluorescent indicator, respectively. Among the ion-sensitive indicators and voltage probes that may be employed are those disclosed in the Molecular Probes 1997 Catalog. For G-protein coupled receptors, promiscuous G-proteins such as Gα15 and Gα16 can be used in the assay of choice (Wilkie *et al.*, *Proc. Natl. Acad. Sci.*, 88:10049, 1991). Such promiscuous G-proteins allow coupling of a wide range of receptors.

Receptor activation typically initiates subsequent intracellular events, *e.g.*, increases in second messengers such as IP3, which releases intracellular stores of calcium ions. Activation of some G-protein coupled receptors stimulates the formation of inositol triphosphate (IP3) through phospholipase C-mediated hydrolysis of phosphatidylinositol (Berridge & Irvine, *Nature* 312:315, 1984). IP3 in turn stimulates the release of intracellular calcium ion stores. Thus, a change in cytoplasmic calcium ion levels, or a change in second messenger levels such as IP3 can be used to assess G-protein coupled receptor function. Cells expressing such G-protein coupled receptors may exhibit increased cytoplasmic calcium levels as a result of contribution from both intracellular stores and via activation of ion channels, in which case it may be desirable although not necessary to conduct such assays in calcium-free buffer, optionally supplemented with a chelating agent such as EGTA, to distinguish fluorescence response resulting from calcium release from internal stores.

Other assays can involve determining the activity of receptors which, when activated, result in a change in the level of intracellular cyclic nucleotides, *e.g.*, cAMP or cGMP, by activating or inhibiting enzymes such as adenylate cyclase. There are cyclic nucleotide-gated ion channels, *e.g.*, rod photoreceptor cell channels and olfactory neuron channels that are permeable to cations upon activation by binding of cAMP or cGMP (see, *e.g.*, Altenhofen *et al.*, *Proc. Natl. Acad. Sci.*, 88:9868, 1991 and Dhallan *et al.*, *Nature* 347:184, 1990). In cases where activation of the receptor results in a decrease in cyclic nucleotide levels, it may be preferable to expose the cells to agents that increase intracellular cyclic nucleotide levels, *e.g.*, forskolin, prior to adding a receptor-activating compound to the cells in the assay. Cells for this type of assay can be made by co-transfection of a host cell with DNA encoding a cyclic nucleotide-gated ion channel, GPCR phosphatase and DNA encoding a receptor (*e.g.*, certain glutamate receptors, muscarinic acetylcholine receptors, dopamine receptors,

serotonin receptors, and the like), which, when activated, causes a change in cyclic nucleotide levels in the cytoplasm.

In a preferred embodiment, sensory receptor protein activity is measured by expressing a sensory receptor gene in a heterologous cell with a promiscuous  
5 G-protein that links the receptor to a phospholipase C signal transduction pathway (see Offermanns & Simon, *J. Biol. Chem.*, 270:15175, 1995). Optionally the cell line is HEK-293 (which does not naturally express sensory receptor genes) and the promiscuous G-protein is Gal 5 (Offermanns & Simon, *supra*). Modulation of olfactory transduction is assayed by measuring changes in intracellular  $\text{Ca}^{2+}$  levels,  
10 which change in response to modulation of the sensory receptor signal transduction pathway via administration of a molecule that associates with a sensory receptor protein. Changes in  $\text{Ca}^{2+}$  levels are optionally measured using fluorescent  $\text{Ca}^{2+}$  indicator dyes and fluorometric imaging.

In one embodiment, the changes in intracellular cAMP or cGMP can be  
15 measured using immunoassays. The method described in Offermanns & Simon, *J. Biol. Chem.*, 270:15175, 1995, may be used to determine the level of cAMP. Also, the method described in Felley-Bosco *et al.*, *Am. J. Resp. Cell and Mol. Biol.*, 11:159, 1994, may be used to determine the level of cGMP. Further, an assay kit for measuring cAMP and/or cGMP is described in U.S. Patent No. 4,115,538, herein  
20 incorporated by reference.

In another embodiment, phosphatidyl inositol (PI) hydrolysis can be analyzed according to U.S. Patent No. 5,436,128, herein incorporated by reference. Briefly, the assay involves labeling of cells with 3H-myoinositol for 48 or more hrs. The labeled cells are treated with a test compound for one hour. The treated cells are lysed and  
25 extracted in chloroform-methanol-water after which the inositol phosphates were separated by ion exchange chromatography and quantified by scintillation counting. Fold stimulation is determined by calculating the ratio of cpm in the presence of agonist, to cpm in the presence of buffer control. Likewise, fold inhibition is determined by calculating the ratio of cpm in the presence of antagonist, to cpm in the  
30 presence of buffer control (which may or may not contain an agonist).

In another embodiment, transcription levels can be measured to assess the effects of a test compound on signal transduction. A host cell containing a sensory receptor protein of interest is contacted with a test compound for a sufficient time to

effect any interactions, and then the level of gene expression is measured. The amount of time to effect such interactions may be empirically determined, such as by running a time course and measuring the level of transcription as a function of time. The amount of transcription may be measured by using any method known to those of skill in the art to be suitable. For example, mRNA expression of the protein of interest may be detected using northern blots or their polypeptide products may be identified using immunoassays. Alternatively, transcription based assays using reporter gene may be used as described in U.S. Patent No. 5,436,128, herein incorporated by reference. The reporter genes can be, e.g., chloramphenicol acetyltransferase, luciferase, '3-galactosidase and alkaline phosphatase. Furthermore, the protein of interest can be used as an indirect reporter via attachment to a second reporter such as green fluorescent protein (see, e.g., Mistili & Spector, *Nature Biotech.* 15:961, 1997).

The amount of transcription is then compared to the amount of transcription in either the same cell in the absence of the test compound, or it may be compared with the amount of transcription in a substantially identical cell that lacks the sensory receptor protein of interest. A substantially identical cell may be derived from the same cells from which the recombinant cell was prepared but which had not been modified by introduction of heterologous DNA. Any difference in the amount of transcription indicates that the test compound has in some manner altered the activity of the sensory receptor protein of interest.

#### 6. Transgenic non-human animals expressing sensory receptors

Non-human animals expressing one or more sensory receptor sequences of the invention, particularly human olfactory receptor sequences, can also be used for receptor assays. Such expression can be used to determine whether a test compound specifically binds to a mammalian olfactory transmembrane receptor polypeptide *in vivo* by contacting a non-human animal stably or transiently transfected with a nucleic acid encoding an olfactory receptor or ligand binding region thereof with a test compound and determining whether the animal reacts to the test compound by specifically binding to the receptor polypeptide.

Use of translocation domains in the fusion polypeptides generates a cell expressing high levels of olfactory receptor. Animals transfected or infected with the vectors of the invention are particularly useful for assays to identify and characterize

odorants/ligands that can bind to a specific or sets of receptors. Such vector-infected animals expressing libraries of human olfactory sequences can be used for *in vivo* screening of odorants and their effect on, *e.g.*, cell physiology (*e.g.*, on olfactory neurons), on the CNS (*e.g.*, olfactory bulb activity), or behavior.

- 5           Means to infect/express the nucleic acids and vectors, either individually or as libraries, are well known in the art. A variety of individual cell, organ or whole animal parameters can be measured by a variety of means. For example, recording of stimulant-induced waves (bulbar responses) from the main olfactory bulb or accessory olfactory bulb is a useful tool for measuring quantitative stable olfactory responses.
- 10       When electrodes are located on the olfactory bulb surface it is possible to record stable responses over a period of several days (*see, e.g.*, Kashiwayanagi, *Brain Res. Protoc.* 1:287, 1997). In this study, electroolfactogram recordings were made with a four-electrode assembly from the olfactory epithelium overlying the endoturbinates facing the nasal septum. Four electrodes were fixed along the dorsal-to-ventral axis of
- 15       one turbinate bone or were placed in corresponding positions on four turbinate bones and moved together up toward the top of the bone. *See also*, Scott, *J. Neurophysiol.* 77:1950, 1997; Scott, *J. Neuro-physiol.* 75:2036, 1996; Ezeh, *J. Neurophysiol.* 73:2207, 1995. In other systems, fluorescence changes in nasal epithelium can be measured using the dye di-4-ANEPPS, which is applied on the rat's nasal septum and
- 20       medial surface of the turbinates (*see, e.g.*, Youngentob, *J. Neuro-physiol.* 73:387, 1995). Extracellular potassium activity (aK) measurements can also be carried out in *in vivo*. An increase in aK can be measured in the mucus and the proximal part of the nasal epithelium (*see, e.g.*, Khayari, *Brain Res.* 539:1, 1991).

- The sensory receptor sequences of the invention can be for example expressed
- 25       in animal nasal epithelium by delivery with an infecting agent, *e.g.*, adenovirus expression vector. Recombinant adenovirus-mediated expression of a recombinant gene in olfactory epithelium using green fluorescent protein as a marker is described by, *e.g.*, Touhara, *Proc. Natl. Acad. Sci. USA* 96:4040, 1999.

- The endogenous olfactory receptor genes can remain functional and wild-type
- 30       (native) activity can still be present. In other situations, where it is desirable that all olfactory receptor activity is by the introduced exogenous hybrid receptor, use of a knockout line is preferred. Methods for the construction of non-human transgenic

animals, particularly transgenic mice, and the selection and preparation of recombinant constructs for generating transformed cells are well known in the art.

- Construction of a "knockout" cell and animal is based on the premise that the level of expression of a particular gene in a mammalian cell can be decreased or completely abrogated by introducing into the genome a new DNA sequence that serves to interrupt some portion of the DNA sequence of the gene to be suppressed. Also, "gene trap insertion" can be used to disrupt a host gene, and mouse embryonic stem (ES) cells can be used to produce knockout transgenic animals (*see, e.g.,* Holzschu, *Transgenic Res* 6:97, 1997). The insertion of the exogenous is typically by homologous recombination between complementary nucleic acid sequences. The exogenous sequence is some portion of the target gene to be modified, such as exonic, intronic or transcriptional regulatory sequences, or any genomic sequence which is able to affect the level of the target gene's expression; or a combination thereof. Gene targeting via homologous recombination in pluripotent embryonic stem (ES) cells allows one to modify precisely the genomic sequence of interest. Any technique can be used to create, screen for, propagate, a knockout animal, *e.g., see* Bijvoet, *Hum. Mol. Genet.* 7:53, 1998); Moreadith, *J. Mol. Med.* 75:208, 1997; Tojo, *Cytotechnology* 19:161, 1995; Mudgett, *Methods Mol. Biol.* 48:167, 1995; Longo, *Transgenic Res.* 6:321, 1997; U.S. Patents Nos. 5,616,491; 5,464,764; 5,631,153; 5,487,992; 5,627,059; 5,272,071; WO 91/09955; WO93/09222; WO 96/29411; WO 95/31560; WO 91/12650.

The nucleic acid libraries can also be used as reagents to produce "knockout" human cells and their progeny.

#### F. Modulators

- The compounds tested as modulators of a sensory receptor family member can be any small chemical compound, or a biological entity, such as a protein, sugar, nucleic acid or lipid. Alternatively, modulators can be genetically altered versions of a sensory receptor gene. Typically, test compounds will be small chemical molecules and peptides. Essentially any chemical compound can be used as a potential modulator or ligand in the assays of the invention, although most often compounds can be dissolved in aqueous or organic (especially DMSO-based) solutions are used. The assays are designed to screen large chemical libraries by



automating the assay steps and providing compounds from any convenient source to assays, which are typically run in parallel (*e.g.*, in microtiter formats on microtiter plates in robotic assays). It will be appreciated that there are many suppliers of chemical compounds, including Sigma (St. Louis, MO), Aldrich (St. Louis, MO),  
5 Sigma-Aldrich (St. Louis, MO), Fluka Chemika-Biochemica Analytika (Buchs, Switzerland) and the like.

In one preferred embodiment, high throughput screening methods involve providing a combinatorial chemical or peptide library containing a large number of potential therapeutic compounds (potential modulator or ligand compounds). Such  
10 "combinatorial chemical libraries" or "ligand libraries" are then screened in one or more assays, as described herein, to identify those library members (particular chemical species or subclasses) that display a desired characteristic activity. The compounds thus identified can serve as conventional "lead compounds" or can themselves be used as potential or actual therapeutics.

15 A combinatorial chemical library is a collection of diverse chemical compounds generated by either chemical synthesis or biological synthesis, by combining a number of chemical "building blocks" such as reagents. For example, a linear combinatorial chemical library such as a polypeptide library is formed by combining a set of chemical building blocks (amino acids) in every possible way for a  
20 given compound length (*i.e.*, the number of amino acids in a polypeptide compound). Millions of chemical compounds can be synthesized through such combinatorial mixing of chemical building blocks.

Preparation and screening of combinatorial chemical libraries is well known to those of skill in the art. Such combinatorial chemical libraries include, but are not  
25 limited to, peptide libraries (see, *e.g.*, U.S. Patent No. 5,010,175; Furka, *Int. J. Pept. Prot. Res.* 37:487, 1991; and Houghton *et al.*, *Nature* 354:84, 1991). Other chemistries for generating chemical diversity libraries can also be used. Such chemistries include, but are not limited to: peptoids (*e.g.*, WO 91/19735), encoded peptides (*e.g.*, WO 93/20242), random bio-oligomers (*e.g.*, WO 92/00091),  
30 benzodiazepines (*e.g.*, U.S. Patent No. 5,288,514), diversomers such as hydantoins, benzodiazepines and dipeptides (Hobbs *et al.*, *Proc. Nat. Acad. Sci.* 90:6909, 1993), vinylogous polypeptides (Hagihara *et al.*, *J. Amer. Chem. Soc.* 114:6568, 1992), nonpeptidal peptidomimetics with glucose scaffolding (Hirschmann *et al.*, *J. Amer.*

Moreover, a method is provided for simulating a fragrance or flavor sensed by a mammal (*e.g.*, human), comprising: for each of a plurality of sensory receptors, or fragments or variants thereof, ascertaining the extent to which the sensory receptor interacts with the fragrance and/or flavor; and combining a plurality of compounds, each having a previously-determined interaction with one or more of the sensory receptors, in amounts that together provide a stimulation profile that mimics the profile for the fragrance and/or flavor. Interaction of a fragrance and/or flavor with a sensory receptor can be determined using any of the binding or reporter assays described herein. The interactions can be aggregated or a profile generated using known signal processing techniques (*e.g.*, a neural network) as described below. The sensory receptor, or fragments or variants thereof (*e.g.*, fusion proteins with reporters, chimeric proteins) may be expressed in cells; otherwise, ligand-binding domain(s) may be fixed to a substrate (*e.g.*, planar, bead, or fiber) that is solid or porous. The plurality of compounds may then be combined to form a mixture. If desired, one or more of the plurality of the compounds can be combined covalently. The combined compounds substantially stimulate at least 50%, 60%, 70%, 75%, 80%, 90%, 95%, 99% or all of the receptors that are substantially stimulated by the fragrance or flavor.

In yet another aspect of the invention, a method is provided in which a plurality of standard compounds are tested against a plurality of sensory receptors, or fragments or variants thereof, to ascertain the extent to which the sensory receptors each interact with each standard compound, thereby generating a receptor stimulation profile for each standard compound. These receptor stimulation profiles may then be stored in a relational database on data storage medium. The method may further comprise providing a desired receptor-stimulation profile for an odor and/or taste; comparing the desired receptor stimulation profile to the relational database; and ascertaining one or more combinations of standard compounds that most closely match the desired receptor-stimulation profile. The method may further comprise combining standard compounds in one or more of the ascertained combinations to simulate the odor and/or taste.

A further aspect of the invention is to provide a method for representing sensory perception of a particular odor and/or taste in a mammal (*e.g.*, human), comprising: providing values  $X_1$  to  $X_n$  representative of the quantitative stimulation of each of  $n$  sensory receptors of the mammal; where  $n$  is greater than or equal to 5,  $n$  is

greater than or equal to 10,  $n$  is greater than or equal to 20,  $n$  is greater than or equal to 50,  $n$  is greater than or equal to 75,  $n$  is greater than or equal to 100,  $n$  is greater than or equal to 125,  $n$  is greater than or equal to 150,  $n$  is greater than or equal to 175,  $n$  is greater than or equal to 200,  $n$  is greater than or equal to 225,  $n$  is greater than or equal to 250,  $n$  is greater than or equal to 275,  $n$  is greater than or equal to 300,  $n$  is greater than or equal to 325, or  $n$  is greater than or equal to 350; and generating from the values a quantitative representation of sensory perception. The sensory receptors may be a receptor disclosed herein, or fragments or variants thereof. The representation may constitute a point or a volume in  $n$ -dimensional space, may constitute a graph or a spectrum, or may constitutes a matrix of quantitative representations. Also, the providing step may comprise contacting a plurality of recombinantly-produced sensory receptors, or fragments or variants thereof, with a composition and quantitatively measuring the interaction of the composition with the receptors. The maximum number of taste receptors that are needed to mimic the native repertoire (e.g., about 50) may be less than the maximum number of olfactory receptors that are needed (e.g., about 350). But the number of sensory receptors that need to be represented in an assay to provide useful results may be much less.

It is yet another aspect of the invention to provide a method for predicting the sensory perception in a mammal (e.g., human) generated by one or more molecules or combinations of molecules yielding unknown olfactory perception in the mammal, comprising: providing values  $X_1$  to  $X_n$  representative of the quantitative stimulation of each of  $n$  sensory receptors of the mammal; where  $n$  is greater than or equal to 5,  $n$  is greater than or equal to 10,  $n$  is greater than or equal to 20,  $n$  is greater than or equal to 50,  $n$  is greater than or equal to 75,  $n$  is greater than or equal to 100,  $n$  is greater than or equal to 125,  $n$  is greater than or equal to 150,  $n$  is greater than or equal to 175,  $n$  is greater than or equal to 200,  $n$  is greater than or equal to 225,  $n$  is greater than or equal to 250,  $n$  is greater than or equal to 275,  $n$  is greater than or equal to 300,  $n$  is greater than or equal to 325, or  $n$  is greater than or equal to 350; for one or more molecules or combinations of molecules yielding known sensory perception in a mammal; and generating from the values a quantitative representation of sensory perception in a mammal for the one or more molecules or combinations of molecules yielding known sensory perception in a mammal, providing values  $X_1$  to  $X_n$  representative of the quantitative stimulation of each of  $n$  sensory receptors of the mammal; where  $n$  is

greater than or equal to 5,  $n$  is greater than or equal to 10,  $n$  is greater than or equal to 20,  $n$  is greater than or equal to 50,  $n$  is greater than or equal to 75,  $n$  is greater than or equal to 100,  $n$  is greater than or equal to 125,  $n$  is greater than or equal to 150,  $n$  is greater than or equal to 175,  $n$  is greater than or equal to 200,  $n$  is greater than or equal to 225,  $n$  is greater than or equal to 250,  $n$  is greater than or equal to 275,  $n$  is greater than or equal to 300,  $n$  is greater than or equal to 325, or  $n$  is greater than or equal to 350; for one or more molecules or combinations of molecules yielding unknown sensory perception in a mammal; and generating from the values a quantitative representation of sensory perception in a mammal for the one or more molecules or combinations of molecules yielding unknown sensory perception in a mammal, and predicting the olfactory perception in a mammal generated by one or more molecules or combinations of molecules yielding unknown sensory perception in a mammal by comparing the quantitative representation of sensory perception in a mammal for the one or more molecules or combinations of molecules yielding unknown sensory perception in a mammal to the quantitative representation of sensory perception in a mammal for the one or more molecules or combinations of molecules yielding known sensory perception in a mammal. The sensory receptors used in this method may include a receptor disclosed herein, or fragment or variant thereof. The maximum number of taste receptors that are needed to mimic the native repertoire (e.g., about 50) may be less than the maximum number of olfactory receptors that are needed (e.g., about 350). But the number of sensory receptors that need to be represented in an assay to provide useful results may be much less.

Assaying for ligand-receptor binding in a large set of sensory receptors is envisioned to mimic the function of the nose or tongue in sensory perception of chemical sensants. For a set of sensory receptors with a redundancy of ligand-binding domains, the resultant signal is a summation of the interactions of all sensory receptors in the set: none, one, or a few of which have ligand-binding domains that are a perfect fit for the sensant; some of which have ligand-binding domains that are only an imperfect fit for the sensant; and most of which do not significantly bind to the sensant. The individual sensory receptor's binding affinity for sensant varies accordingly. Thus, a suitably large set of ligand-binding domains from sensory receptors will be analogous to any ability of the native repertoire of olfactory or taste receptors to tolerate varying degrees of mismatch between ligand and ligand-binding domain.

The complication of desensitization of sensory receptor signaling will also be avoided by using the invention instead of preparations of nasal or tongue epithelium containing native sensory receptors. For example, the event of binding between ligand and receptor can be separated from more complicated downstream signaling events in the epithelial cells. But the latter events can be reconstituted in the invention by transferring the sensory receptor of interest into appropriate host cells containing an intact and functional signaling pathway.

#### H. Administration of Novel Sensant Compositions

Sensory modulators can be administered directly to a mammal (*e.g.*, human) for modulation of sensory perception *in vivo*. Administration is by any of the routes normally used for introducing a modulator compound into ultimate contact with the tissue to be treated (*e.g.*, nose or tongue). The olfactory modulators are administered in any suitable manner, optionally with acceptable carriers. Suitable methods of administering such modulators are available and well known to those of skill in the art, and, although more than one route can be used to administer a particular composition, a particular route can often provide a more immediate and more effective reaction than another route. Acceptable carriers are determined at least in part by the particular components of the composition to be administered (*e.g.*, stabilizing the sensants), as well as by the particular method used to administer the composition. Accordingly, there is a wide variety of suitable formulations of pharmaceutical compositions of the present invention (*see, e.g., Remington's Pharmaceutical Sciences*, 17th ed. 1985).

The sensory modulators, alone or in combination with other suitable components, can be made into aerosol formulations (*i.e.*, they can be "nebulized") to be administered via inhalation. Aerosol formulations can be placed into pressurized acceptable propellants, such as dichloro-difluoromethane, propane, nitrogen, and the like that may or may not contribute to sensory perception. Other possible formulation include dry or liquid forms, powders or tablets, solutions of polar (*e.g.*, water) or nonpolar (*e.g.*, alcohol) solvents, emulsions or suspensions, creams, gels, lotions, and syrups.

Formulations suitable for administration include aqueous and non-aqueous solutions, isotonic sterile solutions, which can contain antioxidants; buffers,

bacteriostats, and solutes that render the formulation isotonic, and aqueous and non-aqueous sterile suspensions that can include suspending agents, solubilizers, thickening agents, stabilizers, and preservatives. In the practice of this invention, compositions can be administered, for example, by orally, topically, intravenously, 5 intraperitoneally, intravesically, or intrathecally. Optionally, the compositions are administered orally or nasally. The formulations of compounds can be presented in unit-dose or multi-dose sealed containers, such as ampules and vials. Solutions and suspensions can be prepared from sterile powders, granules, and tablets of the kind previously described. The modulators can also be administered as part of prepared 10 drug, food, or cosmetic. In particular, an un-pleasant odor or taste (e.g., sulfur or bitter, respectively) may not be perceived as such and/or its effects reduced by blocking the binding between sensant ligand and sensory receptor by adding a competitor ligand that blocks binding between cognate ligand and receptor, or inhibiting or reducing signal transduction. In contrast, a pleasant odor or taste can be 15 mimicked or enhanced. Primary sensants are preferred because the subset of activated cells is kept small and the effects limited to projection into a specific region of the brain. But novel olfactants or combinations thereof that bind only a few olfactory receptors (e.g., having less than five different ligand-binding domains) would also be useful.

20 The dose administered to a mammal (e.g., human) should be sufficient to effect a beneficial response in the subject over time. The dose will be determined by the efficacy of the particular sensory modulators employed and the condition of the subject, as well as the body weight or surface area of the area to be treated. The size of the dose also will be determined by the existence, nature, and extent of any adverse 25 side-effects that accompany the administration of a particular compound or vector in a particular subject. In determining the effective amount of the modulator to be administered in a physician may evaluate circulating plasma levels of the sensory modulator, modulator toxicities, and the production of anti-modulator antibodies. In general, the dose equivalent of a modulator is from about 1 ng/kg to 10 mg/kg for the 30 typical mammal. For administration, sensory modulators can be administered at a rate determined by the ED<sub>50</sub> of the modulator, and the side-effects of the inhibitor at various concentrations, as applied to the mass and overall health of the mammal. Administration can be accomplished via single or divided doses.

## I. Kits

Sensory receptor genes, or fragments or variants thereof are useful tools for identifying cells expressing sensory receptors, for forensics and paternity determinations, and for examining signal transduction in isolated cells. Sensory  
5 receptor family member-specific reagents that specifically hybridize to sensory receptor nucleic acids, such as AOFLF1 probes and primers, and sensory receptor specific reagents that specifically bind to a sensory receptor protein, *e.g.*, anti-sensory receptor antibodies are used to examine expression in cells and regulation of signal trans-duction. For example, one or more family member-specific reagents may be  
10 used to detect poly-morphisms that are linked to genetic anosmia or to detect allelic exclusion.

Nucleic acid assays for the presence of DNA and RNA for a sensory receptor family member in a sample include numerous techniques are known to those skilled in the art, such as Southern analysis, Northern analysis, dot blots, RNase protection, S1  
15 analysis, amplification techniques such as PCR, and *in situ* hybridization. In *in situ* hybridization, for example, the target nucleic acid is liberated from its cellular surroundings in such as to be available for hybrid-ization within the cell while preserving the cellular morphology for subsequent interpretation and analysis. The following articles provide an overview of the art of *in situ* hybridization: Singer *et al.*,  
20 *Biotechniques*, 4:230-250 (1986); Haase *et al.*, *Methods in Virology*, vol. VII, pp. 189-226 (1984); and *Nucleic Acid Hybridization: A Practical Approach* (Names *et al.*, eds. 1987). In addition, a sensory receptor protein can be detected with the various immunoassay techniques described above. The test sample is typically compared to both a positive control (*e.g.*, a sample expressing a recombinant sensory  
25 receptor protein) and a negative control.

The present invention also provides for kits for screening for novel modulators of sensory receptor family members. Such kits can be prepared from readily available materials and reagents, as well as any of the aforementioned products. For example, such kits can comprise any one or more of the following materials: sensory receptor  
30 nucleic acids or proteins, reaction tubes, and instructions for testing sensory receptor activity. Optionally, the kit contains a biologically active sensory receptor. A wide variety of kits and components can be prepared according to the present invention, depending upon the intended user of the kit and the particular needs of the user.

## Examples

## AOLFR1 sequences:

5 MKTFSSFLQIGRNMHQGNQTTITEFILLGFFKQDEHQNLLFVFLGMYLVTVIGNGLIIV AISLD  
 TYLHTP MYLFLANLSFADISSISNSVPKMLVNIQTKSQSISYESCITQMYFSIVFVIDNLLGTM  
 AYDHFVAICHPLNYTILMRPRFGILLTVISWFLSNIIALHTLLLIQLLFCNHNTLPHFCDLAPLL  
 KLSCSDTLINELVLFIVGLSVIHPFTLSFFSYVCHRAVLRVSSTQGWKAFSTCGSHLTVVLLFY  
 GTIVGVYFFPSSTHPEDTDKIGAVLFTVVTMPINPFYSLRNKDMKGALRKLINRKISSL (SEQ ID  
 NO: 1)

10 ATGAAGACTTTTAGTTCTTTCTTCAGATCGGCAGAAATATGCATCAAGGAAACCAAACCA  
 CCATCACTGAATTCATTCTCCTGGGATTTTCAAGCAGGATGAGCATCAAAACCTCCTCTTT  
 GTGCTTTTCTTGGGTATGTACCTGGTCACTGTGATTGGGAACGGGCTCATCATTGTGGCTA  
 TCAGCTTGGATACGTACCTTCATACCCCCATGTATCTTCTTCCCTGCCAATCTATCCTTTGCT  
 GATATTTCTCCATTTCCTCACTCAGTCCCCAAATGCTGGTGAATATTCAAACCAAGAGTC  
 15 AATCCATCTCTTATGAGAGCTGCATCACACAGATGTACTTTTCTATTGTGTTTGTCTGTCATT  
 GACAATTTGCTCTTGGGGACCATGGCCTATGACCACTTTGTGGCGATCTGCCACCTCTGA  
 ATTATACAATTCTCATGCGGCCAGGTTTCGGCATTTTGTCTCACAGTCATCTCATGGTTCTCT  
 AGTAATATTATTGCTCTGACACACACCTTCTGTCTCATTCAATTGCTCTTCTGTAACCACAA  
 CACTCTCCACACTTCTTCTGTGACTTGGCCCCCTGTCTCAAACCTGTCTGTTCAGATACAT  
 20 TGATCAATGAGCTTGTGTTGTTTATTGTGGGTTTATCAGTTATCATCTTCCCTTTTACACTC  
 AGCTTCTTTTCTATGTCTGCATCATCAGAGCTGTCTGAGAGTATCTCCACACAGGGAA  
 AGTGGAAAGCCTTCTCCACTTGTGGCTCTCACTGACAGTTGTATTACTGTTCTACGGAAC  
 CATTGTAGGCGTGTACTTTTCCCTCTCCACTCACCCTGAGGACACTGATAAGATTGGT  
 GCTGTCCTATTCACTGTGGTGACCCCATGATAAACCCCTTCATCTACAGCTTGAGGAATA  
 25 AGGATATGAAAGGTGCCCTGAGAAAGCTCATCAATAGAAAAATTCTTCCCTTTGA (SEQ  
 ID NO: 2)

## AOLFR2 sequences:

30 MMMVLRNLSMEPTFALLGFTDYPKLQIPLFLVFLLMYVITVVGNLGMIIIIKINPKFHTPMYFFL  
 SHLSFVDFCYSSIVTPKLEENLVMDKSIFYFSCMMQYFLSCTAVVTESFLLAVMAYDRFVAIC  
 NPLLYTVAMSQRLLCALLVAGSYLVGMFGPLVLLCYALRLNFGSPNVINHFFCEYALISVSGS  
 DILPHLLLFSFATFNEMCTLLILTSYVFIVTVLKIRSVSGRHKAFSTWASHLTAITIFHGTLFL  
 YCVPSKNSRQTVKVASVFYTVVNPMLNPPIYSLRNKDVKDAFWKLIHTQVPFH (SEQ ID NO:  
 3)

35 ATGATGATGGTTTTAAGGAATCTGAGCATGGAGCCCACCTTTGCCCTTTTAGGTTTCACAG  
 ATTACCCAAAGCTTCAGATTCCTCTCTTCTGTGTTTCTGCTCATGTATGTTATCACAGTG  
 GTAGGAAACCTTGGGATGATCATAATAATCAAGATTAACCCCAAATTCACACTCCTATGT  
 40 ACTTTTCTTAGTCACTCTCTTTTGTGATTTTGTACTCTTCCATTGTCACTCCCAAGC  
 TGCTTGAGAACTTGGTAATGGCAGATAAAAGCATCTTCTACTTTAGCTGCATGATGCAGTA  
 CTTCTGTCTGCACTGCTGTGGTGACAGAGTCTTCTTGTGCTGGCAGTGACAGAGGCTCTGTG  
 CGCTTTGTGGCCATCTGCAATCCTCTGCTTTATACAGTGGCCATGTACAGAGGCTCTGTG  
 CCCTGCTGGTGGCTGGGTCATATCTCTGGGGCATGTTTGGCCCCCTTGGTACTCCTTTGTTAT  
 GCTCTCCGGTTAAACTTCTCTGGACCTAATGTAATCAACCACTTCTTTGTGAGTATACTGC  
 45 CCTTCAATGAGATGTGTACACTACTGATCATCTCACTTCTATGTTTTCATTTTGTGACT  
 GTACTAAAAATCCGTTCTGTAGTGGGCGCCACAAAGCCTTCTCCACTGGGCTCCCAAC  
 TGACTGCTATCACCATCTTCCATGGGACCATCTTTCTTTACTGTGTACCAACTCCAA  
 AACTCTCGGCAACAGTCAAAGTGGCCTCTGTATTTACACAGTTGTCAACCCCATGCTGA  
 50 ACCCTCCGATCTACAGCCTAAGGAATAAAGACGTGAAGGATGCTTTCTGGAAGTTAATACA  
 TACACAAGTTCCATTCTCACTGA (SEQ ID NO: 4)

## AOLFR3 sequences:

55 MLLTDRNTSGTTFLLGFS DYPELQVPLFLVFLAIYNVTVLGNIGLIVIIKINPKLHTPMYFFLSQ  
 LSFVDFCYSSIIAPKMLVNLVVKDRITISFLGCVVQFFFFCTFVVTESFLLAVMAYDRFVAICNPL  
 LYTVDM SQKLCVLLVVGSYAWGVSCSLELTCSALKLCFHGFNTINHFFCEFSLLSLSCSDTYI



NQWLLFFLATFNEISTLLIVLTSYAFIVVTILKMRSVSGRRKAFSTCASHLTAITIFHGTLFLYCV  
PNSKNSRHTVKVASVFYTVVIPMLNPLIYSLRNKDVKDTVTEILDTKVFSY (SEQ ID NO: 5)

5 ATGCTGCTGACAGATAGAAATACAAGTGGGACCACGTTACCCCTCTTGGGCTTCTCAGATT  
ACCCAGAACTGCAAGTCCCACTCTTCCTGGTTTTCTGGCCATCTACAATGTCACTGTGCTA  
GGGAATATTGGGTTGATTGTGATCATCAAAATCAACCCCAAACCTGCATACCCCATGTACT  
TTTTCTCAGCCAACTCTCCTTTGTGGATTTCTGCTATTCTCCATCATTGCTCCCAAGATG  
TTGGTGAACCTTGTGTCAAAGACAGAACCATTTCATTTTTAGGATGCGTAGTACAATTCT  
TTTTCTTCTGTACCTTTGTGGTCACTGAATCCTTTTTATTAGCTGTGATGGCCTATGACCGC  
10 TTCGTGGCCATTTGCAACCCTCTGCTCTACACAGTTGACATGTCCAGAACTCTGCGTGC  
TGCTGGTTGTGGGATCCTATGCCTGGGGAGTCTCATGTTCTTGAACTGACGTGCTCTGC  
TTTAAAGTTATGTTTTCATGGTTTCAACACAATCAATCACTTCTTCTGTGAGTTCTCCTCAC  
TACTCTCCCTTTCTTGTCTGTGATACTTACATCAACCAGTGGCTGCTATTCTTTCTTGCCACC  
TTTAATGAAATCAGCACACTACTCATCGTTCTCACATCTTATGCGTTCATTGTTGTAACCAT  
15 CCTCAAGATGCGTTCAGTCAGTGGGCGCCGCAAAGCCTTCTCCACCTGTGCCTCCACCTG  
ACTGCCATCACCATCTTCCATGGCACCATCCTCTTCTTACTGTGTGCCCAACTCCAAAAA  
CTCCAGGCACACAGTCAAAGTGGCCTCTGTGTTTTACACCGTGGTGATCCCCATGTTGAAT  
CCCCTGATCTACAGTCTGAGAAATAAAGATGTCAAGGATACAGTCACCGAGATACTGGAC  
ACCAAAGTCTTCTCTTACTGA (SEQ ID NO: 6)

20

**AOLFR4 sequences:**

MENQNNVTEFILLGLTENLELWKIFSAVFLVMYVATVLENLLIVVTIITSQSLRSPMYFFLTFLS  
LLDVMFSSVVPKVVIVDTLSKSTTISLKGCLTQLFVEHFFGGVGIILLTVMAYDRYVAICKPLHY  
TIIMSPRVCCLMVGGAWVGGFMHAMIQLLFMYQIPFCGPNIIDHFICDLFQLLTACTDTHILGL  
25 LVTLSNGMMCVAFILIASYTVILCSLSYSSKGRHKALSTCSSHLTVVVLFFVPCIFLYMRPV  
VTHPIDKAMAVSDSIITPMLNPLIYTLRNAEVKSAMKKLWMKWEALAGK (SEQ ID NO: 7)

ATGGAAAATCAAAACAATGTGACTGAATTCATTCTTCTGGGTCTCACAGAGAACCTGGAGC  
TGTGGAAAATATTTTCTGCTGTGTTTCTTGTGATGTATGTAGCCACAGTGTGGAAAATCT  
30 ACTTATTGTGGTAACTATTATCACAAGTCAGAGTCTGAGGTCACCTATGTATTTTTTCTTA  
CCTTCTTGTCCCTTTTGGATGTCATGTTCTCATCTGTGCTTGCCCCAAGGTGATTGTAGAC  
ACCCTCTCCAAGAGCACTACCATCTCTCTCAAAGGCTGCCTCACCCAGCTGTTTGTGGAGC  
ATTTCTTTGGTGGTGTGGGGATCATCCTCCTCACTGTGATGGCCTATGACCGCTACGTGGC  
CATCTGTAAGCCCCCTGCACTACACGATCATCATGAGTCCACGGGTGTGCTGCCTAATGGTA  
35 GGAGGGGCTTGGGTGGGGGGATTTATGCACGCAATGATACAACTTCTCTCATGTATCAAA  
TACCTTCTGTGGTCCTAATATCATAGATCACTTTATATGTGATTTGTTTCAGTTGTTGACA  
CTTGCCTGACAGGACACCCACATCCTGGGCCTCTTAGTTACCTCAACAGTGGGATGATGT  
GTGTGGCCATCTTTCTTATCTTAATTGCGTCCTACACGGTCATCCTATGCTCCCTGAAGTCT  
TACAGCTCTAAAGGGCGGCACAAAGCCCTCTCTACCTGCAGCTCCACCTCACGGTGGTTG  
40 TATTGTTCTTTGTCCCCTGTATTTTCTTGTACATGAGGCCTGTGGTCACTACCCCATAGAC  
AAGGCAATGGCTGTGTGCACTCAATCATCACACCCATGTTAAATCCCTTGATCTATACAC  
TGAGGAATGCAGAGGTGAAAAGTGCCATGAAGAACTCTGGATGAAATGGGAGGCTTTGG  
CTGGGAAATAA (SEQ ID NO: 8)

**AOLFR5 sequences:**

MGKENCTTVAEFILLGLSDVPELRVCLFLLFLLIYGVTLLANLGMIALIQVSSRLHTPMYFFLSH  
LSSVDFCYSSIIVPKMLANIFNKDKAISFLGCMVQFYLFCTCVVTEVFLLAVMAYDRFVAICNPL  
LYTVTMSWKVRVELASCCYFCGTVCSLIHLCLALRIPFYRSNVINHFCDLPVLSLACSDITVN  
ETLLFLVATL NESVTIMILTSYLLILTILKMGSAGRHKAFSTCASHLTAITVFHGTVLSIYCRP  
50 SSGNSGDADKVATVFYTVVIPMLNSVIYSLRNKDVKEALRKVMGSKIHS (SEQ ID NO: 9)

ATGGGCAAGGAAAACCTGCACCACTGTGGCTGAGTTCATTCTCCTTGGACTATCAGATGTCC  
CTGAGTTGAGAGTCTGCCTCTTCTGCTGTTCTTCTCATCTATGGAGTCACGTTGTTAGCC  
AACCTGGGCATGATTGCACTGATTAGGTGAGTCTCGGCTCCACACCCCATGTACTTTT  
55 TCCTCAGCCACTTGTCTCTGTAGATTTCTGCTACTCCTCAATAATTGTGCCAAAAATGTTG  
GCTAATATCTTTAACAAGGACAAAGCCATCTCCTTCTAGGGTGCATGGTGCAATTCTACT

TGT TTTGCACTTGTGTGGTCACTGAGGTCTTCTGCTGGCCGTGATGGCCTATGACCGCTTT  
 GTGGCCATCTGTAACCCCTTTGCTATACACAGTCAACATGTCTTGAAGGTGCGTGTGGAGC  
 TGGCTTCTTGCTGCTACTTCTGTGGGACGGTGTGTCTCTGATTCATTGTGCTTAGCTCTT  
 AGGATCCCCCTTCTATAGATCTAATGTGATTAACCACTTTTCTGTGATCTACCTCCTGTCTT  
 5 AAGTCTTGCTTGCTCTGATATCACTGTGAATGAGACACTGCTGTTCTGGTGGCCACTTGT  
 AATGAGAGTGTACCATCATGATCATCTCCTCACCTCCTACCTGCTAATTCTCACCACCATCCT  
 GAAGATGGGCTCTGCAGAGGGCAGGCACAAAGCCTTCTCCACCTGTGCTTCCACCTCACA  
 GCTACTACTGTCTTCCATGGAACAGTCCTTTCCATTTATTGCAGGCCAGTTCAGGCAATA  
 GTGGAGATGCTGACAAAGTGGCCACCGTGTCTACACAGTCGTGATTCTATGCTGAACCTC  
 10 TGTGATCTACAGCCTGAGAAATAAAGATGTGAAAGAAGCTCTCAGAAAAGTGATGGGCTC  
 CAAAATTCACCTCTAG (SEQ ID NO: 10)

# **AOLFR6 sequences:**

15 MMASERNQSSPTFILLGFSEYPEIQVPLFLVFLFVYTVTVVGNLGMIIIRLNSKLHTIMYFFLS  
 HSLTDFCFSTVTPKLENLVVEYRTISFSGCIMQFCACIFGVTETFMLAAMAYDRFVAVCK  
 PLLYTTIMSQKLCALLVAGSYTWGIVCSLILTYFLDLFSCESTFINNFICDHSVIVSASYSOPYIS  
 QRLCFIIAIFNEVSSLIILTSYMLIFTTIMKMRSASGRQKTFSTCASHLTAITIFHGHTILFLYCVPNP  
 KTSSLIVTVASVFYTVAPMLNPLIYSLRNKDINMFEKLVVTKLIYH (SEQ ID NO: 11)

20 ATGATGGCATCTGAAAGAAATCAAAGCAGCACACCCACTTTTATTCTCTTGGGTTTTTCAG  
 AATACCCAGAAATCCAGGTCCACTCTTTCTGGTTTTCTTGTTCGTCTACACAGTCACTGTA  
 GTGGGGAACCTGGGCATGATAATAATCATCAGACTCAATTCAAACTCCATACAATCATGT  
 ACTTTTCTTCTAGTCACTTGTCTTGTGAGACTTCTGTTTTTCCACTGTAGTTACACCTAAA  
 CTGTTGGAGAACTTGGTGTGGAATACAGAACCTTCTTCTCTGTTGTCATCATGCAAT  
 25 TTTGTTTTGCTTGCATTTTTGGAGTGACAGAACTTTCATGTTAGCAGCGATGGCTTATGAC  
 CGTTTTGTGGCAGTTGTAAACCCTTGTGTATACCACTATTATGTCTCAGAAGCTCTGTGC  
 TCTTCTGGTGGCTGGTCTCTATACATGGGGGATAGTGTGCTCCCTGATACTCACATTTTT  
 CTTCTTGACTTATCGTTTTGTGAATCTACCTTCATAAATAATTTATCTGTGACCACTCTGT  
 AATTGTTTCTGCCTCTACTCAGACCCCTATATCAGCCAGAGGCTATGCTTTATTTATGCCA  
 30 ATTATGAAGATGCGATCTGCAAGTGGGCGCCAGAAACTTTCTCCACCTGTGCCTCCCACC  
 TGACAGCCATCACTATCTCCATGGAACATCTTTTCTTTACTGTGTTCTCTAATCTCTAAA  
 ACTTCTAGCCTCATAGTTACAGTGGCTTCTGTGTTTTACACAGTGGCGATTCCAATGCTGA  
 ACCCATGATCTACAGCCTTAGGAACAAAGATATCAATAACATGTTTGAAAAATTAGTTGT  
 35 CACCAAATTGATTTACCACTGA (SEQ ID NO: 12)

# **AOLFR7 sequences:**

40 MSYFYRLKLMKEAVLVKLPFTSLPLLQTLRKSRLDMEIKNYSSSTSGFILLGLSSNPQLQKPLF  
 AIFLIMYLLAAVGNVLIIPIYSDPRLHTPMYFFLSNLSFMDICFTTVIVPKMLVNFLSETKVISY  
 VGCLAQMYFFMAFGNTDSYLLASMAIDRLVAICNPLHYDVVMKPRHCLMLLGSCSISHLSL  
 FRVLLMSRLSFCASHIHKHFFCDTQPVLKLSGSDTSSSQMVMTETLAIVITPFLCIIFSILRIMV  
 TVLRIPSAAGKWKAFSTCGSHLTAVALFYGSIIYVYFRPLSMYSVVRDRVATVMYTVVTPMLN  
 PFIYSLRNKDMKRLKLLQDRIYR (SEQ ID NO: 13)

45 ATGAGCTATTTTTACAGGCTTAAGCTTATGAAAGAAGCTGTCTTGGTCAAACCTGCCCTTTA  
 CATCTCTCCCACTGCTTCTCAAACCTATCCAGGAAGTCCAGAGACATGGAGATAAAGAA  
 CTACAGCAGCAGCAGCAGGCTTCATCTCTGGGCTCTCTTCAAACCTCAGCTGCAG  
 AAACCTCTCTTGGCATCTTCTCATCATGTACCTGCTCGCTGCGGTGGGAATGTGCTCAT  
 CATCCCGGCCATCTACTCTGACCCAGGCTCCACACCCCTATGTACTTTTTCTCAGCAACT  
 50 TGTCTTTCATGGATATCTGCTTCAACAGTCATAGTGCCTAAGATGCTGGTGAATTTCTA  
 TCAGAGACAAAGGTTATCTCCTATGTGGGCTGCCTGGCCAGATGTACTTCTTATGGCAT  
 TTGGGAACACTGACAGCTACCTGCTGGCCTCTATGGCCATCGACCGGCTGGTGGCCATCTG  
 CAACCCCTTACACTATGATGTGGTTATGAAACCAGGCATTGCCTGCTCATGCTATTGGGT  
 TCTTGCAGCATCTCCACCTACATTCCTGTTCGCGTGTACTTATGTCTCGCTTGTCTTT  
 55 CTGTGCCTCTCACATCATTAAAGCACTTTTCTGTGACACCCAGCCTGTGCTAAAGCTCTCCT  
 GCTCTGACACATCTCCAGCCAGATGGTGGTGATGACTGAGACCTTAGCTGTCAATGTGAC

CCCCTTCCTGTGTATCATCTTCTCCTACCTGCGAATCATGGTCACTGTGCTCAGAATCCCCT  
 CTGCAGCCGGGAAGTGGAAGGCCTTCTCTACCTGTGGCTCCCACCTCACTGCAGTAGCCCT  
 TTTCTATGGGAGTATTATTTATGTCTATTTTAGGCCCTGTCCATGTACTCAGTGGTTAGGG  
 ACCGGGTAGCCACAGTTATGTACACAGTAGTGACACCCATGCTGAACCCCTTCATCTACAG  
 5 CCTGAGGAACAAAGATATGAAGAGGGGTTTGAAGAAATTACAGGACAGAATTTACCGGTA  
 A (SEQ ID NO: 14)

#### AOLFR8 sequences:

MATSNHSSGAEFILAGLTQRPELQLPLFLLFLGIYVTVVGNLGMIFLIALSSQLYPPVYYFLSH  
 10 LSFIDLCYSSVITPKMLNVFVPEENIISFLECITQLYFFLIFVIAEGYLLTAMEYDRYVAICRPLLY  
 NIVMSHRVCSIMMAVVYSLGFLWATVHTTRMSVLSFCRSHTVSHYFCDILPLLTSCSSTHINEI  
 LLFIIGGVNTLATTALVLISYAFIFSSILGIHSTEGQSKAFGTCSSHLLAVGIFFGSITFMYFKPPSS  
 TTMEKEKVSSVFYITIPMLNPLIYSLRNKDVKNALKKMTRGRQSS (SEQ ID NO: 15)

15 ATGGCTACTTCAAACCATTCTTCAGGGGCTGAGTTTATCCTGGCAGGCTTGACACAACGCC  
 CAGAACTTCAACTGCCACTCTTCCTCCTGTTCTTGAATATATGTGGTCACAGTGGTGGG  
 GAACCTGGGCATGATCTTCTTAATTGCTCTCAGTTCTCAACTTTACCCTCCAGTGTATTATT  
 TTCTCAGTCATTTGTCTTTCATTGATCTCTGCTACTCCTCTGTCTATTACCCCTAAGATGCTG  
 GTGAACTTTGTTCCAGAGGAGAACATTATCTCCTTTCTGGAATGCATTACTCAACTTTATTT  
 20 CTTCTTATTTTTGTAAATGCAGAAGGCTACCTTCTGACAGCCATGGAATATGACCGTTAT  
 GTTGCTATCTGTGCGCCCACTGCTTTACAATATTGTCTATGTCCACAGGGTCTGTTCCATAAT  
 GATGGCTGTGGTATACTCACTGGGTTTTCTGTGGGCCACAGTCCATACTACCCGCATGTCA  
 GTGTTGTCATTCTGTAGGTCTCATACGGTCAGTCATTATTTTTGTGATATTCTCCCCTTATT  
 GACTCTGTCTTGCTCCAGCACCCACATCAATGAGATTCTGCTGTTTATTATTGGAGGAGTT  
 25 AATACCTTAGCAACTACACTGGCGGTCTTATCTCTTATGCTTTCATTTTCTCTAGTATCCT  
 TGGTATTCAATCCACTGAGGGGCAATCCAAAGCCTTTGGCACTTGCTAGCTCCCATCTCTTG  
 GCTGTGGGCATCTTTTTTGGGTCTATAACATTGATGATTTCAAGCCCCCTTCCAGCACTAC  
 TATGGAAAAAGAGAAGGTGTCTTCTGTGTTCTACATCACAATAATCCCCATGCTGAATCCT  
 CTAATCTATAGCCTGAGGAACAAGGATGTGAAAAATGCACTGAAGAAGATGACTAGGGGA  
 30 AGGCAGTCATCCTGA (SEQ ID NO: 16)

#### AOLFR9 sequences:

MLARNNSLVTEFILAGLTDRPEFWQPFFFLFLVIYIVTMVGNLGLITLFLGLNSHLHTPMYYFLFN  
 LSFIDLCYSSVFTPKMLMNFVSKKNISNVGCMTRLFFFLFFVISECYMLTSMAYDRYVAICNPL  
 35 LYKVTMSHQVCSMLTFAAYIMGLAGATAHTGCMFRLTFCSANIINHLYLCDILPLLQLSCTSTYV  
 NEVVVLIVVGTNITVPSCITILISYVFIVTSILHIKSTQGRSKAFSTCSSHVIALSLFFGSAAFMYIKY  
 SSGSMEQGVFSVFYTNVPMNLPLIYSLRNKDVKVALRKALIKIQRRNIF (SEQ ID NO: 17)

40 ATGCTGGCTAGAAACAACCTCCTTAGTGACTGAATTTATTCTTGCTGGATTAACAGATCGTC  
 CAGAGTTCTGGCAACCCTTCTTTTTCTGTTCTAGTGATCTACATTGTACCATGGTAGGC  
 AACCTTGGCTTGATCACTCTTTTCGGTCTAAATTTCTCACCTCCACACACCAATGTACTATTT  
 CCTCTTCAATCTCTCCTTCATTGATCTCTGTTACTCCTCTGTTTTCACTCCCAAATGCTAAT  
 GAACTTTGTGTCAAAAAAGAATATTATCTCCAATGTTGGGTGCATGACTCGGCTGTTTTTC  
 TTTCTCTTTTCGTCTATCTCTGAATGTTACATGTTGACCTCAATGGCATATGATCGCTATGT  
 45 GGCCATCTGTAATCCATTGCTGTATAAGGTCACCATGTCCCATCAGGTCTGTTCTATGCTCA  
 CTTTTGCTGCTTACATAATGGGATTGGCTGGAGCCACGGCCACACCGGGTGCATGTTTAG  
 ACTCACCTTCTGCAGTGCTAATATCATTAACCATTACTTGTGTGACATACTCCCCCTCCTCC  
 AGCTTTCCTGCACCAGCACCTATGTCAACGAGGTGGTTGTTCTCATTGTTGTGGGTACTAA  
 TATCACGGTACCCAGTTGTACCATCCTCATTCTTATGTTTTTATTGTCTACTAGCATTCTTC  
 50 ATATCAAATCCACTCAAGGAAGATCAAAAGCCTTCAGTACTTGCTAGCTCTCATGTCTATTGC  
 TCTGTCTCTGTTTTTTGGGTGAGCGGCATTGATGATATTAATAATTTCTTCTGGATCTATGG  
 AGCAGGGAAAAGTTTTTCTGTTTTCTACACTAATGTGGTGCCCATGCTCAATCCCCCTCATC  
 TACAGTTTGAGGAACAAGGATGTCAAAGTTGCACTGAGGAAAGCTCTGATTAAAATTCAG  
 AGGAGAAATATATTCTAA (SEQ ID NO: 18)

55

## AOLFR10 sequences:

5 MLARNNSLVTEFILAGLTDRPEFRQPLFFLFLVIYIVTMVGNLGLILFGLNSHLHTPMYYFLFNL  
SFIDLCYSSVFTPKMLMNFVSKKNISYVGCMTQLFFLFFVISECYILTSMA YDRYVAICNPLLY  
KVTMSHQVCSMLTFAAYIMGLAGATAHTGCMRLRTFCSANIINHLYCDILPLLQLSCTSTYVN  
EVVVLIVVGINIMVPSTILISYVFIVTSLHIKSTQGRSKAFSTCSSHVIALSLFFGSAAFM YIKYS  
SGSMEQGVSSVFYTNVVPMLNPLIYSLRNKDV KVALRKALIKIQRNIF (SEQ ID NO: 19)

10 ATGCTGGCTAGAAACAACTCCTTAGTGACTGAATTTATTCTTGCTGGATTAACAGATCGTC  
CAGAGTTCGGGCAACCCCTCTTTTCCTGTTTCTAGTGATCTACATTGTCACCATGGTAGGC  
AACCTTGGCTTGATCATTCTTTTCGGTCTAAATCTCACCTCCACACACCAATGTACTATT  
CCTCTTCAATCTCTCCTTCATTGATCTCTGTTACTCTCTGTTTCACTCCCAAAATGCTAAT  
GAACTTTGTATCAAAAAGAATATTATCTCCTATGTTGGGTGCATGACTCAGCTGTTTTCT  
TTCTCTTTTTGTCTCTCTGAATGCTACATATTGACCTCAATGGCATATGATCGCTATGTG  
15 GCCATCTGTAATCCATTGCTGTATAAGGTCAACCATGTCCCATCAGGTCTGTTCTATGCTCAC  
TTTTGCTGCTTACATAATGGGATTGGCTGGAGCCACGGCCACACCGGTGCATGCTTAGA  
CTCACCTTCTGCAGTGCTAATATCATCAACCACTTGTGTGACATACTCCCCCTCCTCCA  
GCTTTCCTGCACCAGCACCTATGTCAACGAGGTGGTGTCTCATTGTTGTGGGTATTAAT  
ATCATGGTACCCAGTTGTACCATCCTCATTCTTATGTTTTCATTGTCACTAGCATTCTCA  
20 TATCAAATCCACTCAAGGAAGATCAAAAGCCTTCAGTACTTGTAGCTCTCATGTATTGCT  
CTGTCTCTGTTTTTGGGTGAGCGGCATTCTATGATATTAATATTCTTCTGGATCTATGGA  
GCAGGGAAAAGTTTCTTCTGTTTCTACATAATGTGGTGCCCATGCTCAATCCTCTCATCT  
ACAGTTTGAGGAACAAGGATGTCAAAGTGCAGTGAGGAAAGCTCTGATTAATAATTCAGA  
GAAGAAATATATTCTAA (SEQ ID NO: 20)

## 25 AOLFR11 sequences:

MTLRNSSSVTEFILVGLSEPELQLPLFLFLGIYVFTVVGNLGLITLIGINPSLHTPMYYFLFNL  
FIDLCYSCVFTPKMLNDFVSEIISYVGCMTQLFFFCFFVNSECYVLVSMAYDRYVAICNPLLY  
MVTMSPRVCFLLMFGSYVVGAGAMAHTGSMRLRTFCDNSVIDHYLCDVLPPLLQLSCTSTHV  
30 SELVFFIVGVITMLSSISIVISYALILSNILCIPSAEGRSKAFSTWGSIIAVALFFGSGTFTYLTTS  
FPGSMNHGRFASVFYTNVVPMLNPSIYSLRNKDDKLALGKTLKRVLF (SEQ ID NO: 21)

35 ATGACTCTGAGAAACAGCTCCTCAGTGACTGAGTTTATCCTTGTTGGGATTATCAGAACAGC  
CAGAGCTCCAGCTCCCTCTTTTCCTTCTATTCTTAGGGATCTATGTGTTCACTGTGGTGGGC  
AACTTGGGCTTGATCACCTTAATTGGGATAAATCCTAGCCTTCACACCCCATGTACTTTT  
CCTCTTCAACTTGTCTTTATAGATCTCTGTTATTCCTGTGTGTTACCCCAAAATGCTGA  
ATGACTTTGTTTCAGAAAGTATCATCTCTTATGTGGGATGTATGACTCAGCTATTTTCTTC  
TGTTTCTTTGTCAATTCTGAGTGCTATGTGTTGGTATCAATGGCCTATGATCGCTATGTGGC  
CATCTGCAACCCCTGCTCTACATGGTCACCATGTCCCAAGGGTCTGCTTTCTGCTGATGT  
40 TTGGTTCCTATGTGGTAGGGTTTGCTGGGGCCATGGCCACACTGGAAGCATGCTGCGACT  
GACCTTCTGTGATTCCAACGTCATTGACCATTATCTGTGTGACGTTCTCCCCCTCTTGCAGC  
TCTCCTGCACCAGCACCCATGTCAAGTACGCTTTGATACTCTCCAACATCCTCTGTAT  
ATGCTATCCAGCATAAGCATCGTCATCTCTTACGCTTTGATACTCTCCAACATAATTGCTGTT  
TCCTTCTGCAGAGGGCAGATCCAAAGCCTTAGCACATGGGGTCCCACATAATTGCTGTT  
GCTCTGTTTTTGGGTGAGGACATTACCTACTTAACAACATCTTTTCTGGCTCTATGAA  
45 CCATGGCAGATTTGCCTCAGTCTTTACACCAATGTGGTTCCTGCTTAACCTTCGATCT  
ACAGTTTGAGGAATAAGGATGATAAAGTGCCTGGGCAAAACCTGAAGAGAGTGCTCT  
TCTAA (SEQ ID NO: 22)

## AOLFR12 sequences:

50 MERNHNPDNCNVLNFFADKKNRRNFGQIVSDVGRICYSVLSLGEPTTMGRNNLTRPSEFIL  
LGLSSRPEDQKPLFAVFLPIYLITVIGNLLILAIRSDTRLQTPMYFFLSILSFVDICYVTVIIPKMLV  
NFLSETKTISYGECLTQMYFFLAFGNTDSYLLAAMADRYVAICNPFHYITIMSHRCCVLLVLS  
FCIPHFHSLHILLTNQLIFCASNVIIHFFCDDQPVLKLSSSHVFKEITVMTEGLAVIMTFPSCIII  
SYLRILITVLKIPSAAGKRKAFSTCGSHLTVVTLFYGSISYVYFQPLSNYTVKDQIATIIYTVLTP  
55 MLNPFYSLRNKDMKQGLAKLMHRMKCQ (SEQ ID NO: 23)

ATGGAAAGAAACCACAATCCAGATAATTGTAATGTTTTAAATTTTTCTTTGCTGATAAGA  
 AGAATAAAAGGAGAAATTTTGGACAGATTGTATCAGATGTTGGAAGAATCTGTTACAGTG  
 TTAGTTTATCTTTAGGTGAACCCACAACCTATGGGAAGAAATAACCTAACAGACCCCTCTGA  
 ATTCATCCTCCTTGGACTCTCCTCTCGACCTGAGGATCAGAAGCCGCTCTTTGCTGTGTTCC  
 5 TCCCCATCTACCTTATCACAGTGATAGGAAACCTGCTTATCATCCTGGCCATCCGCTCAGA  
 CACTCGTCTCCAGACGCCCATGTACTTCTTTCTAAGCATCCTGTCTTTTGTGACATTGCT  
 ATGTGACAGTCATTATCCCTAAGATGCTGGTGAACCTTCTTATCAGAGACAAAGACCATCTC  
 TTACGGTGAGTGTCTGACCCAGATGTACTTTTCTTAGCCTTTGGAAACACAGACAGTTAC  
 CTGCTAGCAGCCATGGCCATTGACCGCTATGTGGCCATATGTAATCCCTTCCACTACATCA  
 10 CCATTATGAGTCACAGATGCTGTGCTGCTTCTGGTCTCTCCTTCTGCATTCCACATTTT  
 CACTCCCTCCTGCACATTCTTCTGACTAATCAGCTCATCTTCTGTGCCTCCAATGTCATCCA  
 TCACTTTTTCTGCGATGATCAACCAGTGCTAAAATTGTCCTGTTCCCTCCCATTTTGTCAAAG  
 AAATCACAGTAATGACAGAAGGCTTGGCTGTCTAATGACCCCGTTTTTCATGCATCATCAT  
 CTCTTATTTAAGAATCCTCATCACTGTTCTGAAGATTCCTTCAGCTGCTGGAAAGCGTAAA  
 15 GCATTTTCTACCTGTGGCTCTCATCTCACAGTGGTGACCCTGTTTATGGAAGCATTAGCTA  
 TGTCTATTTTACGCCCCCTGTCCAATACTGTCAAGGATCAAATAGCAACAATTATCTAC  
 ACCGTACTGACTCCTATGCTAAATCCATTTATCTATAGTCTGAGGAACAAAGACATGAAGC  
 AGGTTTGGCAAAGTTGATGCACAGGATGAAATGTCAGTAA (SEQ ID NO: 24)

20 **AOLFR13 sequences:**

MDQKNGSSFTGFILLGFSDRPQLELVLFVLLIFYIFTLLGNKTIIVLSHLDPHLHNP MYFFFSNL  
 SFLDLCYTTGIVPQLLVNLRGADKSISYGGCVVQLYISLGLSTECVLLGVMAFDRYAAVCRPL  
 HYTVVMHPCLYVLMASWSWVIGFANSLLQTVLILLTL CGRNKLEHFLCEVPPLLKLACVDTT  
 MNESELFVSVIILLVPVALIIFSYSQIVRAVVRKISATGQRKVFGTCGSHLTVVSLFYGTAIYAY  
 25 LQPGNNYSQDQGXISLFYTIITPMINPLIYTLRNKDVKGALKKVLWKNYDSR (SEQ ID NO:  
 25)

ATGGATCAGAAAAATGGAAGTTCTTTCACTGGATTATCCTACTGGGTTTCTCTGACAGGC  
 CTCAGCTGGAGCTAGTCCTCTTTGTGGTTCTTTGATCTTCTATATCTTCACTTTGCTGGGG  
 30 AACAAAACCATCATTGTATTATCTCACTTGGACCCACATCTTCACAATCCTATGTATTTTTT  
 CTTCTCCAACCTAAGCTTTTTGGATCTGTGTTACACAACCGGCATTGTTCCACAGCTCCTGG  
 TTAATCTCAGGGGAGCAGACAAATCAATCTCCTATGGTGGTTGTGTAGTTCACTGTACAT  
 CTCTCTAGGCTTGGGATCTACAGAATGCGTTCTCTTAGGAGTGATGGCATTGACCGCTAT  
 GCAGCTGTTTGCAGGCCCCCTCCACTACACAGTAGTCATGCACCCTTGTCTGTATGTGCTGA  
 35 TGGCTTCTACTTCATGGGTCATTGGTTTTGCCAACTCCCTATTGCAGACGGTGCTCATCTTG  
 CTTTTAACACTTTGTGGAAGAAATAAATTAGAACACTTTCTTTGTGAGGTTCTCCATTGCT  
 CAAGCTTGCCTGTGTTGACACTACTATGAATGAATCTGAACCTTCTTTGTGAGTGTCATTA  
 TTCTTCTTGTACCTGTTGCATTAATCATATTCTCCTATAGTCAGATTGTCAGGGCAGTCGTG  
 AGGATAAAGTCAGCAACAGGGCAGAGAAAAGTGTTTGGGACATGTGGCTCCACCTCACA  
 40 GTGGTTTCCCTGTTCTACGGCACAGCTATCTATGCTTACCCTCCAGCCCGGCAACAATACTC  
 TCAGGATCAGGGCAAGKTCATCTCTCTTCTACACCATCATTACCCCATGATCAACCCC  
 CTCATATATACTGAGGAACAAGGATGTGAAAGGAGCACTTAAGAAGGTGCTCTGGAAG  
 AACTACGACTCCAGATGA (SEQ ID NO: 26)

45 **AOLFR14 sequences:**

MALPLLLSPSCFASSQSLSSRMNSENLTAAVAPAEFVLLGITNRWDLRVALFLTCLPVYLVSL  
 LGNMGMALLIRMDARLHTPMYFFLANLSLLDACYSSAIGPKMLVDLLPRATIPYTACALQMF  
 VFAGLADTECCLLAAMAYDRYVAIRNPLLYTTAMSQRCLALLGASGLGGAVSAFVHTTLTF  
 RLSFCRSRKINSFFCDIPPLLAISCDTSLNELLFAICGFIQTATVLAITVSYGFIAGAVIHMRSVE  
 50 GSRRAASTGGSHLTAVAMMYGTLIFMYLRPSSSYALDTDKMASVFYTLVIPSLNPLIYSLRNKE  
 VKEALRQTWSRFHCPGQGSQ (SEQ ID NO: 27)

ATGGCCTTGCCATTGCTCTTATCTCCCTCCTGCTTTGCCTCTTCTCAGTCTCTGTCCAGTAG  
 GATGAACTCAGAGAACCTCACCCGGGCGCGGTTGCCCTGCTGAATTGCTCCTCCTGGGC  
 55 ATCACAAATCGCTGGGACCTGCGTGTGGCCCTCTTCTGACCTGCCTGCCTGTCTACCTGG  
 TGAGCCTGCTGGGAAACATGGGCATGGCGCTGCTGATCCGCATGGATGCCCGGCTCCACA

WO 01/98526

CACCTATGTACTTCTTCTGGCCAACTCTCCCTGCTGGATGCCTGCTATTCTCCGCCATC  
 GGCCCCAAGATGCTAGTGGACCTGCTGCTGCCCCGAGCCACCATCCCTTACACAGCCTGTG  
 CCCTCCAGATGTTTGTCTTTGAGGTCTGGCTGATACTGAGTGTGCTTGGCAGCCAT  
 GGCCTATGACCGCTACGTGGCCATCAGAAACCCACTTCTCTATACAACAGCTATGTGCGAG  
 5 CGTCTATGCCTGGCCTTGTGCTGGGAGCATCAGGCCTGGGTGGGGCAGTGAGTGCCTTTGTTC  
 ACACAACCCTCACCTTCCGCCTGAGCTTCTGCCGCTCCCGGAAGATCAATGACTTCTTCTG  
 CGATATCCCTCCACTGCTGGCCATCTCGTGACGTGACACCAGTCTCAATGAACTCCTTCTCT  
 TCGCCATCTGTGGCTTCATCCAGACAGCCACGGTGTTAGCTATCACGGTGTCTTATGGCTT  
 CATCGCTGGGGCTGTGATCCACATGCGCTCGGTGAGGGCAGTCGGCGAGCAGCCTCCAC  
 10 CGGTGGTTCCACCTCACAGCCGTGGCCATGATGTACGGGACACTCATTTTCATGTACCTG  
 CGCCCCAGCTCCAGCTATGCCCTGGACACTGACAAGATGGCCTCTGTGTTCTATACCCTGG  
 TCATCCCGTCTCTCAACCCACTCATCTACAGCCTCCGCAATAAGGAGGTCAAGGAGGCCCT  
 CAGGCAGACCTGGAGCCGATTCCACTGTCCAGGGCAGGGTCCAGTGA (SEQ ID NO: 28)

15 **AOLFR15 sequences:**  
 MRENNQSSTLEFILLGVTGQQEQEDFFYLFLFIYPITLIGNLLIVLAICSDVRLHNP MYFLLANLS  
 LVDIFFSSVTIPKMLANHLGSKSISFGGCLTQMYFMIALGNTDSYILAAMAYDRAVAISHPLH  
 YTTIMSPRSCIWLIAGSWVIGNANALPHTLLTASLSFCGNQEVANFYCDITPLKLSCSDIHFHV  
 KMMYLGVGIFSVPLLCIIVSYIRVFTVFPSTKGVLKAFSTCGSHLTVVSLYGYTVMGTYFR  
 20 PLTNYSLKDAVITVMTAVTPMLNPFYISLRNRMKAALRKLFNKRISS (SEQ ID NO: 29)

ATGAGGGAAAATAACCAGTCCTCTACACTGGAATTCATCCTCCTGGGAGTTACTGGTCAGC  
 AGGAACAGGAAGATTCTTCTACATCCTCTTCTGTTTACCTTACCCCATCACATTGATTGGA  
 AACCTGCTCATTGTCCTAGCCATTTGCTCTGATGTTGCTTCAACCCCATGTATTTCT  
 25 CCTTGCCAACTCTCCTTGGTTGACATCTTCTTCTCATCGGTAACCATCCCTAAGATGCTGG  
 CCAACCATCTCTTGGGCAGCAAATCCATCTCTTTTGGGGGATGCCTAACGCAGATGATTT  
 CATGATAGCCTTGGGTAAACACAGACAGCTATATTTGGCTGCAATGGCATATGATCGAGCT  
 GTGGCCATCAGCCACCCACTTCACTACACAATAATTATGAGTCCACGGTCTTGTATCTGGC  
 TTATTGCTGGGTCTTGGGTGATTGGAAATGCCAATGCCCTCCCCACACTCTGCTCACAGC  
 30 TAGTCTGTCTTCTGTGGCAACCAGGAAGTGGCCAACCTTCTACTGTGACATTACCCCTTG  
 CTGAAGTTATCCTGTTCTGACATCCACTTTCATGTGAAGATGATGTACCTAGGGGTTGGCA  
 TTTTCTCTGTGCCATTACTATGCATCATTGTCTCCTATATTGAGTCTTCTCCACAGTCTTCC  
 AGGTTCTTCCACCAAGGGCGTGCTCAAGGCCTTCTCCACCTGTGGTTCCACCTCACGGT  
 TGTCTCTTTGTATTATGGTACAGTCATGGGCACGTATTTCCGCCCTTTGACCAATTATAGCC  
 35 TAAAAGACGCAGTGATCACTGTAATGTACACGGCAGTGACCCCAATGTAAATCCTTTTCAT  
 CTACAGTCTGAGAAATCGGGACATGAAGGCTGCCCTGCGGAAACTCTTCAACAAGAGAAT  
 CTCTCGTAA (SEQ ID NO: 30)

40 **AOLFR16 sequences:**  
 MRRNCTLVTEFILLGLTSRRELQILLFTLFLAIYMTVAVGNLGMIVLIQANAWLHMP MYFFLSH  
 LSFVDLCFSSNVTIPKMLEIFLSEKKSISYACLVCYLFIALVHVEIYILAVMAFD RYMAICNPLL  
 YGSRMSKSVCSFLITVPYVYGALTGLMETMWTYNLAFCGPNEINH FYCADPPLIKLACSDTYN  
 KELSMFIVAGWNLSFSLFIICISYLYIFPAILKIRSTEGRQKAFSTCGSHLTA VTIFYATLFFMYLR  
 PPSKESVEQGMVAVFYTTVIPMLNLIYSLRNKNVKEALIKELSMKIYFS (SEQ ID NO: 31)

45 ATGAGAAGAACTGCACGTTGGTGACTGAGTTCATTCTCCTGGGACTGACCACTGCGCCGG  
 GAATTACAAATTCTCCTCTTACGCTGTTTCTGGCCATTTACATGGTCACGGTGGCAGGGA  
 ACCTTGGCATGATTGTCCTCATCCAGGCCAACGCCTGGCTCCACATGCCCATGTACTTTTCT  
 CTGAGCCACTTATCCTTCGTGGATCTGTGCTTCTTCCAATGTGACTCCAAAGATGCTGG  
 50 AGATTTTCTTTTTCAGAGAAGAAAAGCATTTCTATCCTGCCTGTCTTGTGAGTGTACCTT  
 TTTATCGCCTTGGTCCATGTTGAGATCTACATCCTGGCTGTGATGGCCTTTGACCGGTACAT  
 GGCCATCTGCAACCCTCTGCTTTATGGCAGCAGAATGTCCAAGAGTGTGTGCTCCTTCTC  
 ATCACGGTGCCTTATGTGTATGGAGCGCTCACTGGCCTGATGGAGACCATGTGGACCTACA  
 ACCTAGCCTTCTGTGGCCCCAATGAAATTAATCACTTCTACTGTGCGGACCCACCTGAT  
 55 TAAGCTGGCTTGTCTGACACCTACAACAAGAGTGTCAATGTTTATTGTGGCTGGCTGG  
 AACCTTTCTTTTCTCTTTCATCATATGTAATTCCTACCTTACATTTTCCCTGCTATTTTA



AAGATTCGCTCTACAGAGGGCAGGCAAAAAGCTTTTTCTACCTGTGGCTCCCATCTGACAG  
CTGTCACTATATTCTATGCAACCCTTTTCTTCATGTATCTCAGACCCCCCTCAAAGGAATCT  
GTTGAACAGGGTAAAATGGTAGCTGTATTTTATACCACAGTAATCCCTATGCTGAACCTTA  
TAATTTATAGCCITAGAAAATAAAAATGTAAAAGAAGCATTAAATCAAAGAGCTGTCAATGA  
5 AGATATACTTTTCTTAA (SEQ ID NO: 32)

**AOLFR17 sequences:**

MLNFTDVTEFILLGLTSRREWQVLFHIFLVVYIITMVGNI GMMVLKIVSPQLNNPMYFFLSHLS  
FVDVWFSSNVTPKMLENLFSDKKTITYAGCLVQCFFIALVHVEIFILAAMAFDRYMAIGNPLL  
10 YGSKMSRVVCIRLITFPYIYGFLTSLAATLWTYGLYFCGKIEINH FYCADPPLIKMACAGTFVKE  
YTMILLAGINFTYSLTVIISYLFILAILRMRS AEGROKAFSTCGSHLTAVIIFYGTLIFMYLRRPTE  
ESVEQGMVAVFYTTVIPMLNPMIYSLRNKDVKKAMMKVISRSC (SEQ ID NO: 33)

ATGCTCAATTTACCGATGTGACAGAGTTCATTCTTTTGGGGCTAACGAGCCGTCGAGAAT  
15 GGCAAGTTCTCTTCTTCATCATCTTTCTTGTGGTCTACATCATCACCATGGTGGGCAATATC  
GGCATGATGGTGTTAATCAAGGTCAGTCCTCAGCTTAACAACCCCATGTACTTTTTCTCA  
GTCACCTGTCAATTTGTTGATGTGTGGTTTTCTTCCAATGTCACCCCTAAAATGTTGGAAAAC  
CTGTTTTTCAGATAAAAAACAATTACTTATGCTGGTTGTTTAGTACAGTGTCTTCTTCTCAT  
TGCTCTTGTCCATGTGGAAATTTTATTCTTGTGCGATGGCCTTTGATAGATACATGGCAA  
20 TTGGGAATCCTCTGCTTATGGCAGTAAAATGTCAAGGGTGTCTGTATTGACTGATTAC  
TTTCCCTTACATTTATGGTTTTCTGACGAGTCTGGCAGCAACATTATGGACTTACGGCTTGT  
ACTTCTGTGAAAAATTGAGATCAACCATTTCTACTGTGCAGATCCACCTCTCATCAAAAT  
GGCCTGTGCCGGGACCTTTGTAAAAGAATATACAATGATCATACTTGCCGGCATTAACTTC  
ACATATTCCTGACTGTAATTATCATCTCTTACTTATTATCCTCATTGCCATTCTGCGAAT  
25 GCGCTCAGCAGAAGGAAGGCAGAAGGCCTTTCCACATGTGGGTCCCATCTGACAGCTGT  
CATTATATTCTATGGTACTCTGATCTTCATGTATCTCAGACGTCCACAGAGGAGTCTGTG  
GAGCAGGGGAAGATGGTGGCTGTGTTCTATACCACAGTGATCCCCATGTTGAATCCCATGA  
TCTACAGTCTGAGGAACAAGGATGTGAAAAAGGCCATGATGAAAGTGATCAGCAGATCAT  
GTAA (SEQ ID NO: 34)

30

**AOLFR18 sequences:**

MSNTNGSAITEFILLGLTDCPELQSLFLVFLVVYLVTLLGNLGMIMLMRLDSRLHTPMYFFLT  
NLA FVDLCYTSNATPQMS TNIVSEKTISFAGCFTQCYIFIALLLTEFYMLAAMAYDRYVAIYDP  
LRYSVKTSRRVCICLATFPYVYGFSDGLFQAILTFRLTFCRSNVINHFYCADPPLIKLSCSDTYVK  
35 EHAMFISAGFNLSSSLTTVLVSYAFILAAILRIKSAEGRHKAFSTCGSHMMAVTLFYGTLFCMYI  
RPPTDKTVEESKIIAVFYTFVSPVLNPLIYSLRNKDV KQALKNVLR (SEQ ID NO: 35)

ATGTCCAACACAAATGGCAGTGCAATCACAGAATTCATTTTACTTGGGCTCACAGATTGCC  
CGGAACTCCAGTCTCTGCTTTTTGTGCTGTTTCTGGTTGTTTACCTCGTACCCTGCTAGGC  
40 AACCTGGGCATGATAATGTTAATGAGACTGGACTCTCGCCTTCACACGCCCATGTACTTCT  
TCCTCACTAACTTAGCCTTTGTGGATTTGTGCTATACATCAAATGCAACCCCGCAGATGTC  
GACTAATATCGTATCTGAGAAGACCATTTCTTTGCTGGTTGCTTTACACAGTGCTACATTT  
TCATTGCCCTTCTACTCACTGAGTTTTACATGCTGGCAGCAATGGCCTATGACCGCTATGT  
GGCCATATATGACCCTCTGCGCTACAGTGTGAAAACGTCCAGGAGAGTTTGCATCTGCTTG  
45 GCCACATTTCCCTATGTCTATGGCTTCTCAGATGGACTCTTCCAGGCCATCCTGACCTTCCG  
CCTGACCTTCTGTAGATCCAATGTCATCAACCACTTCTACTGTGCTGACCCGCCGCTCATT  
AGCTTTCTTGTTCTGATACTTATGTCAAAGAGCATGCCATGTTTCATATCTGCTGGCTTCAAC  
CTCTCCAGCTCCCTCACCATCGTCTTGGTGTCTATGCCTTCATTCTTGCTGCCATCCTCCG  
GATCAAATCAGCAGAGGGAAGGCACAAGGCATTCTCCACCTGTGGTTCCCATATGATGGC  
50 TGTCACCCTGTTTTATGGGACTCTTTTTGCATGTATATAAGACCACCAACAGATAAGACT  
GTTGAGGAATCTAAAATAATAGCTGTCTTTACACCTTTGTGAGTCCGGTACTTAATCCAT  
TGATCTACAGTCTGAGGAATAAAGATGTGAAGCAGGCCTTGAAGAATGTCCTGAGATGA  
(SEQ ID NO: 36)

55

## AOLFR19 sequences:

5 METKNYSSSTSGFILLGLSSNPQLQKPLFAIFLIMYLLTAVGNVLIILAIYSDPRLHTPMYFFLSNL  
 SFMDICFTTVIVPKMLVNFLSETKIISYVVGCLIQMYFFMAFGNTDSYLLASMAIDRLVAICNPLH  
 YDVVMKPWHCLLMLLGSCSISHLHSLFRVLLMSRSLFCASHIHKHFFCDTQPVLKLSGSDTSSSQ  
 MVVMTETLA VIVTPFLCTIFS YLQIIVTVLRIPSAAGKWKAFTSCGSHLTVVLFYGSVIYVYFR  
 PLSMYSVMKGRVATVMYTVVTPMLNPFYSLRNKDMKRGLKCLRHRIS (SEQ ID NO: 37)

10 ATGGAGACAAAGAATTATAGCAGCAGCACCTCAGGCTTCATCCTCCTGGGCCTCTCTTCCA  
 ACCCTAAGCTGCAGAAACCTCTCTTTGCCATCTTCCTCATCATGTACCTACTACTGCGGTG  
 GGGAAATGTGCTCATCCTGGCCATCTACTCTGACCCAGGCTCCACACCCCTATGTACT  
 TTTTCTCAGCAACTTGTCTTTCATGGATATCTGCTTCACAACAGTCATAGTGCCTAAGATG  
 CTGGTGAATTTTCTATCAGAGACAAAGATTATCTCTTATGTGGGCTGCCTGATCCAGATGT  
 ACTTCTTCATGGCATTGGGAACACTGACAGCTACCTGCTGGCCTCTATGGCCATCGACCG  
 GCTGGTGGCCATCTGCAACCCCTTACACTATGATGTGGTTATGAAACCATGGCATTGCCA  
 15 CTCATGCTATTGGGTCTTGCAGCATCTCCCACCTACATTCCCTGTTCCGCGTGCTACTTAT  
 GTCTCGCTTGTCTTCTGTGCCTCTCACATCATTAAAGCACTTTTCTGTGACACCCAGCCTG  
 TGCTAAAGCTCTCCTGCTCTGACACATCCTCCAGCCAGATGGTGGTGATGACTGAGACCTT  
 AGCTGTGCTATTGACCCCTTCTGTGTACCATCTTCTCCTACCTGCAAATCATCGTCACTG  
 TGCTCAGAATCCCCTCTGCAGCCGGGAAGTGAAGGCCTTCTTACCTGTGGCTCCACCT  
 20 CACTGTAGTGGTCTGTTCTATGGGAGTGTCTATGTCTATTTAGGCCTGTGCCATGT  
 ACTCAGTGATGAAGGGCCGGTAGCCACAGTTATGTACACAGTAGTGACACCCATGTCTGA  
 ACCCTTTCATCTACAGCCTGAGGAACAAAGATATGAAAAGGGGTTGAAGAAATTAAGAC  
 ACAGAATTTACTCATAG (SEQ ID NO: 38)

## 25 AOLFR20 sequences:

MVEENHTMKNEFILTGFTDHPKLTLLFVVFVFAIYLITVVGNSLVALIFTHCRLHTPMYIFLGN  
 LALVDSGCCAATPKMLENFFSEGKRISLYECAVQFYFLCTVETADCFLAAVAYDRYVAICNP  
 LQYHIMMSKKLCIQMTTGAFIAGNLHSMIHVGLVFRLVFCGLNHNHFYCDTLPYRLSCVDPF  
 30 INELVLFIFSGSVQVFTIGSVLISYLYILLTIFRMKSKEGRAKAFSTCASHFSSVSLFYGSIFLYIRP  
 NLLEEGNDIPAAILFTIVVPLNPFYSLRNKEVISVLRKILLIKISQGSVNK (SEQ ID NO: 39)

35 ATGGTTGAAGAAAATCATACCATGAAAAATGAGTTTATCCTCACAGGATTTACAGATCACC  
 CTGAGCTGAAGACTCTGCTGTTTGTGGTGTCTTTGCCATCTATCTGATCACCGTGGTGGG  
 GAATATTAGTTTGGTGGCACTGATATTTACACACTGTGCGCTTACACACCAATGTACATC  
 TTTCTGGGAAATCTGGCTCTTGTGGATTCTTGTGCTGTGCTATTACCCCCAAAATGTT  
 AGAGAACTTCTTTCTGAGGGCAAAGGATTTCCCTCTATGAATGTGCAGTACAGTTTTAT  
 TTTCTTGTCACTGTGAAACTGCAGACTGCTTTCTTCTGGCAGCAGTGGCCTATGACCGCT  
 ATGTGGCCATCTGCAACCCACTGCAGTACCACATCATGATGTCCAAGAACTCTGCATTGA  
 40 GATGACCACAGGCGCTTCATAGCTGGAAATCTGCATTCCATGATTCTGTAGGGCTTGTA  
 TTTAGGTTAGTTTCTGTGGATTGAATCACATCAACCACTTTTACTGTGATACTCTTCCCTT  
 GTATAGACTCTCCTGTGTTGACCCTTTCATCAATGAACCTGTTCTATTCTTCTTACTATT  
 CAGTTCAAGTCTTTACCATAGGTAGTGTCTTAATATCTTATCTCTATATTCTTCTTACTATT  
 TTCAGAATGAAATCCAAGGAGGGAAGGGCCAAAGCCTTTTCTACTTGTGCATCCCACTTTT  
 CATCAGTTTCATTATTCTATGGATCTATTTTCTTATACATTAGACCAAATTTGCTTGAA  
 45 GAAGGAGGTAATGATATACCAGCTGCTATTTTCTTATACAAATAGTAGTTCCTTACTAAATC  
 CTTTCATTTATAGTCTGAGAAACAAGGAAGTAATAAGTGTCTTAAGAAAAATTCTGCTGAA  
 AATAAAATCTCAAGGAAGTGTGAACAAATGA (SEQ ID NO: 40)

## AOLFR21 sequences:

50 MEPRKNVTDVLLGFTQNPKEQKVLVFMFLFYILTMVGNLLIVTVTVSETLGSPMSFFLAGL  
 TFIDIIYSSSISRLISDLFFGNNSISFQSFMAQLFIEHLFGGSEVFLLLVMAYDRYVAICKPLHYLV  
 IMRQWVCVLLLVVSWVGGFLQSVFQLSIHYGLPFCGPNVIDHFFCDMYPLLKLACTDTHVIGLL  
 VVANGGLSCTIAFLLLISYGVILHSLKKLSQKGRQKAHSTCSSHITVVVFFVPCIFMCARPAR  
 TFSIDKSVSVFYTVITPMLNPLIYTLRNSEMTSAMKKL (SEQ ID NO: 41)



TCACCCTCTCCTTCTGTAAGGACAATCAAATAAACTTCTTCTTCTGTGACCTCCCACCCCTG  
 CTGAAGCTTGCCTGCAGTGACACAGCAAACATCGAGATTGTATCATCTTCTTTGGCAATT  
 TTGTGATTTTGGCCAATGCCTCCGTCATCCTGATTTCTATCTGCTCATCATCAAGACCATT  
 TTGAAAGTGAAGTCTTCAGGTGGCAGGGCCAAGACTTTCTCCACATGTGCCTCTCACATCA  
 5 CTGCTGTGGCCCTTTTCTTTGGAGCCCTTATCTTCATGTATCTGCAAAGTGGCTCAGGCAAA  
 TCTCTGGAGGAAGACAAAGTCGTGTCTGTCTTCTATACAGTGGTCATCCCCATGCTGAACC  
 CTCTGATCTACAGCTTAAGAAACAAAGATGTAAAAGACGCCTTCAGAAAGGTCGCTAGGA  
 GACTCCAGGTGTCCCTGAGCATGTAG (SEQ ID NO: 46)

10 **AOLFR25 sequences:**

METGNLTWVSDFVFLGLSQTRELQRFLFLMFLFVYITVMGNILIIITVTSDSLHTPMYFLLRN  
 LAVLDLCFSSVTAPKMLVDLLSEKKTISYQCGMGQIFFFHFLGGAMVFFLSVMAFDRLIAISRPL  
 RYVTVMNTQLWVGLVVATWVGGFVHSIVQLALMLPLPFCGPNILDNFYCDVPQVRLACTDT  
 SLLEFLKISNSGLLDVWVFFLLMSYLFILVMLRSHPGARRKAASTCTTHIIVSMIFVPSIYLY  
 15 ARPFTPFMDKLV SIGHTVMTPLNPMIYTLRNQDMQAAVRRLGRHRLV (SEQ ID NO: 47)

ATGGAAACAGGGAACCTCACGTGGGTATCAGACTTTGTCTTCTGTTGGGCTCTCGCAGACTC  
 GGGAGCTCCAGCGTTTCTGTTTCTAATGTTCTGTTTGTCTACATCACCCTGTTATGGGA  
 AACATCCTTATCATCATCACAGTGACCTCTGATTTCCAGCTCCACACACCCATGTACTTTCT  
 20 GCTCCGAAACCTGGCTGTCTAGACCTCTGTTTCTTTCAGTCACTGCTCCCAAAATGCTAG  
 TGGACCTCCTCTCTGAGAAGAAAACCATCTCTTACCAGGGCTGCATGGGTGAGATCTTCTT  
 CTTCCACTTTTGGGAGGTGCCATGGTCTTCTTCTCTCAGTGATGGCCTTTGACCGCTCA  
 TTGCCATCTCCCGGCCCTCCGCTATGTACCGTCATGAACACTCAGCTCTGGGTGGGGCT  
 GGTGGTAGCCACCTGGGTGGGAGGCTTTGTCCACTCTATTGTCCAGCTGGCTCTGATGCTC  
 25 CCACTGCCCTTCTGTGGCCCCAACATTTTGATAACTTCTACTGTGATGTTCCCCAAGTACT  
 GAGACTTGCCTGCACTGACACCTCACTGCTGGAGTTCTCAAGATCTCCAACAGTGGGCTG  
 CTGGATGTCGTCTGGTCTTCTCCTCCTGATGTCTACTTATTATCCTGGTGTGCTGAG  
 GTCACATCCAGGGAGGCAAGAAGGAAGGCAGCTTCCACCTGCACCAACCCACATCATCGT  
 GGTTTCCATGATCTTCGTTCCAAGCATTTACCTCTATGCCCGGCCCTTCACTCCATTCCCTA  
 30 TGGACAAGCTTGTGTCCATCGGCCACACAGTCATGACCCCATGCTCAACCCCATGATCTA  
 TACCTGAGGAACCAGGACATGCAGGCAGCAGTGAGAAGATTAGGGAGACACCGGCTGGT  
 TTGA (SEQ ID NO: 48)

**AOLFR26 sequences:**

35 MAAKNSSVTEFILEGLTHQPLRIPLFFLFLGFYTVTVVGNLGLITLIGLNSHLHTPMYFFLFNLS  
 LIDFCFSTTITPKMLMSFVSRKNHSFTGCMTQLFFCFVVSSEFILLSAMAYDRYVAICNPLLYT  
 VTMSCQVCLLLLLGAYGMGFAGAMAHTGSIMNLTFCADNLVNHFMCIDLPLELSCNSSYMN  
 ELVVFIVVAVDVGMPIVTVFISYALILSSILHNSSTEGRSKAFSTCSSHIIVVSLFFGSGAFMYLKP  
 LSILPLEQGVSSLFYTHIVPVLNPLIYSLRNKDVKVALRRTLGRKIFS (SEQ ID NO: 49)

40 ATGGCAGCCAAAACTCTTCTGTGACAGAGTTTATCCTCGAAGGCTTAACCCACCAGCCGG  
 GACTGCGGATCCCCCTCTTCTTCTGTTTCTGGGTTTCTACACGGTCACCGTGGTGGGGAA  
 CCTGGGCTTGATAACCCTGATTGGGCTGAACCTCTCACCTGCACACTCCCATGTACTTCTTCC  
 TTTTAACTCTCTTTAATAGATTTCTGTTTCTCCACTACCATCACTCCCAAATGCTGATG  
 45 AGTTTGTCTCAAGGAAGAACATCATTTCTTCACAGGGTGTATGACTCAGCTCTTCTTCTT  
 CTGCTTCTTTGTCTCTCTGAGTCCTTCATCCTGTGAGCGATGGCGTATGACCGCTACGTGG  
 CCATCTGTAACCCACTGTTGTACACAGTCACCATGTCTTGCCAGGTGTGTTTGCTCCTTTTG  
 TTGGGTGCCTATGGGATGGGGTTTGTGGGGCCATGGCCACACAGGAAGCATAATGAAC  
 CTGACCTTCTGTGCTGACAACCTTGTCATCATTTTCATGTGTGACATCCTTCTCCTTGA  
 50 GCTCTCCTGCAACAGCTCTTACATGAATGAGCTGGTGGTCTTTATTGTGGTGGCTGTGAC  
 GTTGGAAATGCCCATTTGCACTGTCTTTATTTCTTATGCCCTCATCCTCTCCAGCATTCTACA  
 CAACAGTTCTACAGAAGGCAGGTCCAAAGCCTTTAGTACTTGCAAGTCCACATAATTGTA  
 GTTTCTCTTTTCTTTGGTTCTGGTGTCTTTCATGTATCTCAAACCCCTTTCCATCCTGCCCTC  
 GAGCAAGGGAAAGTGTCTCCTGTTCTATACCATAATAGTCCCCGTGTTAAACCCATTAA  
 55 TCTATAGCTTGAGGAACAAGGATGTCAAAGTTGCCCTGAGGAGAACTTTGGGCAGAAAAA  
 TCTTTTCTTAA (SEQ ID NO: 50)

## AOLFR27 sequences:

- MPSQNYSIIEFNLFQFSAFPQHLLPILFLLYLLMFLFTLLGNLLIMATIWIHRLHTPMYFLCTL  
SVSEILFTVAITPRMLADLLSTHHSITFVACANQMFFSFMFGFTHSFLLLVMGYDRYVAICHPLR  
5 YNVLMSPRDCAHLVACTWAGGSVMGMMVTTIVFHLTFCGSNVIHHFFCHVLSLLKLACENKT  
SSVIMGVMLVCVTALIGCLFLIILSYVFIVAAILRIPSAEGRHKTFSTCVSHLTVVVTHYSFASFIY  
LKPGLHSMYSDALMATTYTVFTPLSPIIFSLRNKELKNAINKNFYRKFCPPSS (SEQ ID NO:  
51)
- 10 ATGCCTAGTCAGAACTATAGCATCATATCTGAATTTAACCTCTTTGGCTTCTCAGCCTCC  
CCAGCACCTCCTGCCCATCTTGTTCTGCTGTACCTCCTGATGTTCTGTTACATTGCTGG  
GCAACCTTCTCATCATGGCCACAATCTGGATTGAACACAGACTCCACACACCCATGTACCT  
CTTCTTGTCACCCCTCTCCGTCTCTGAGATTCTGTTCACTGTTGCCATCACCCCTCGCATGC  
TGGCTGATCTGCTTTCCACCCATCATTCCATCACCTTTGTGGCTTGTGCCAACCATGTTT  
15 TTCTCCTTCATGTTTGGCTTCACTCACTCCTTCTCCTGGTCATGGGCTATGATCGCTA  
TGTGGCCATCTGCCACCACTGCGTTACAATGTGCTCATGAGCCCCGTGACTGTGCCCAT  
CTTGTTGGCCTGTACCTGGGCTGGTGGCTCAGTCATGGGGATGATGGTGACAACGATAGTTT  
TCCACCTCACTTTCTGTGGGTCTAATGTGATCCACCATTCTTCTGTGCTGTTTCCCTCT  
TGAAGTTGGCCTGTGAAAACAAGACATCATCTGTGTCATCATGGGTGTGATGCTGGTGTGT  
20 CACAGCCCTGATAGGCTGTTTATTCTCATCATCTCTCTCTATGTCTTCACTGTGGCTGCCA  
TCTTGAGGATTCCCTCTGCCGAAGGCCGACACAGACATTTTCTACGTGTGTATCCACCT  
CACTGTGGTGGTCACGCACTATAGTTTGCCTCCTTTATCTACCTCAAGCCCAAGGGCTCC  
ATTCTATGTACAGTGACGCTTGATGGCCACCACCTATACTGTCTTACCCCTTCTTACG  
CCAATCATTTTCAGCCTAAGGAACAAGGAGCTGAAGAATGCCATAAATAAAAACTTTTACA  
25 GAAAATTCTGTCTCCAAGTTCCTGA (SEQ ID NO: 52)

## AOLFR28 sequences:

- MPNFTDVTEFTLLGLTCRQELQVLFVFLAVYMITLLGNIGMIILISISPQLQSPMYFFLSHLSF  
ADVCFSSNVTPKMLENLLSETKTISYVGCLVQCYFFIAVVHVEVYILAVMAFDYRMAGCXPLL  
30 YGSKMSRSTVCVRLISVXYXYGFSVSLICLWYGLYFCGNFEINHFYCADPPLIQIACGRVHIKE  
ITMIVIAGINFTYSLSVLISYTLIVVAVLRMRADGRRKAFSTCGSHLTAVSMFYGTPIFMYLR  
RPTEESVEQGMVAVFYTTVIPMLNPMIYSLRNKDVKEAVNKAITKTYVRQ (SEQ ID NO: 53)
- 35 ATGCCTAATTTACGGATGTGACAGAATTTACTCTCCTGGGGCTGACCTGTGCTCAGGAGC  
TACAGGTCTCTTTTTTGTGGTGTTCCTAGCGTTTACATGATCACTCTGTTGGGAAATATT  
GGTATGATCATTTTGATTAGCATCAGTCCTCAGCTTCAGAGTCCCATGTACTTTTCTGAG  
TCATCTGTCTTTTGGGACGTGTGCTTCTCCTCCAACGTTACCCCCAAATGCTGGAAAAT  
TATTATCAGAGACAAAAACCATTCCTATGTGGGATGCTTGGTGCAGTGCTACTTTTCAT  
TGCCGTTGTCCACGTGGAGGTCTATATCCTGGCTGTGATGGCCTTTGACAGGTACATGGCC  
40 GGCTGCAANCCTCTGCTTTATGGCAGTAAAATGTCTAGGACTGTGTGTGTTGGCTCATCT  
CTGTGNNTATGNNTATGGATTCTCTGTGACGCTAATATGCACACTATGGACTATGGCTT  
ATACTTCTGTGGAACTTTGAAATCAATCACTTCTATTGTGCAGATCCCCCTCTCATCCAGA  
TTGCCTGTGGGAGAGTGACATCAAAGAAATCACAATGATTGTTATTGCTGGAATTAACCT  
CACATATCCCTCTCGGTGGTCTCTCTCCTACACTCTCATTGTAGTAGCTGTGCTACGCA  
45 TGCGCTCTGCCGATGGCAGGAGGAAGGCGTTCTCCACCTGTGGGTCCCCTTGACGGCTGT  
TTCTATGTTTTATGGACCCCCATCTTCATGTATCTCAGGAGACCCACTGAGGAATCCGTA  
GAGCAGGGCAAAATGGTGGCTGTGTTTTACACCACAGTAATTCCTATGTTGAATCCCATGA  
TCTACAGTCTGAGAAATAAGGATGTAAAAGAAGCAGTCAACAAAGCAATCACCAAGACAT  
ATGTGAGGCAGTAA (SEQ ID NO: 54)

50

## AOLFR29 sequences:

- MMSFAPNASHSPVFLLLGFSRANISYTLFFLFLAIYLTTLGNVTLVLLISWDSRLHSPMYLLR  
GLSVIDMGLSTVTLPLQLLAHLVSHYPTIPAARCLAQFFFFYAFGVTDTLVIAVMALDRYVAICD  
PLHYALVMNHQRCACLLALSWSVILHTMLRVGLVPLCWTGDAGGNVNLPHFFCDHRPLLR  
55 ASCSDIHSNELAIFEGGFLMLGPCALIVLSYVRIGAILRLPSAAGRRRAVSTCGSHLTMVGFL

TCCTCTGCCATTTGGCCTTTGTAGACATTGGGTACTCCTCATCAGTCACACCTGTCATGCTC  
 ATGAGCTTCCTAAGGAAAGAAACCTCTCTCCCTGTTGCTGGTTGTGTGGCCAGCTCTGTT  
 CTGTAGTGACGTTTGGTACGGCCGAGTGCTTCCTGCTGGCTGCCATGGCCTATGATCGCTA  
 TGTGGCCATCTGCTCACCCCTGCTCTACTCTACCTGCATGTCCCTGGAGTCTGCATCATCT  
 5 TAGTGGGCATGTCTACCTGGGTGGATGTGTGAATGCTTGGACATTCAATTGGCTGCTTATT  
 AAGACTGTCCTTCTGTGGGCCAAATAAAGTCAATCACTTTTTCTGTGACTATTCAACCTTT  
 TGAAGCTTGCTTGTCCCATGATTTTACTTTTGAAATAATTCCAGCTATCTCTTCTGGATCT  
 ATCATTGTGGCCACTGTGTGTGTCATAGCCATATCCTACATCTATATCCTCATCACCATCCT  
 GAAGATGCACTCCACCAAGGGCCGCCACAAGGCCTTCTCCACCTGCACCTCCCACCTCACT  
 10 GCAGTCACTCTGTTCTATGGGACCATTACCTTCATTTATGTGATGCCCAAGTCCAGCTACTC  
 AACTGACCAGAACAAAGGTGGTGTCTGTGTTCTACACCGTGGTGATTCCCATGTTGAACCCC  
 CTGATCTACAGCCTCAGGAACAAGGAGATTAAGGGGGCTCTGAAGAGAGAGCTTAGAATA  
 AAAATATTTTCTTGA (SEQ ID NO: 60)

15 **AOLFR32 sequences:**

MNSLKDGNHTALTGFILLGLTDDPILRVILFMIILSGNLSIIILIRISSQLHHPMYFFLSHLAFADM  
 AYSSSVTPNMLVNFLVERNVSYLGCALQLSAAFFATVECVLLAAMAYDRFVAICSPLLYSTK  
 MSTQVSVQLLL VVYIAGFLIAVSYTTSFYLLFCGPNQVNHFFCDFAPLLELSCSDISVSTVLSF  
 SSGSIHVTVCVIAVCYIYILITILKMRSTEGHHKAFSTCTSHLT VVTLFYGTITFIYVMPNFSYST  
 20 DQNKVSVLYTVVIPMLNPLIYSLRNKEIKGALKRELVRKILSHDACYFSRTSNNDIT (SEQ ID  
 NO: 61)

ATGAATTCCCTGAAGGACGGGAATCACACCGCTCTGACGGGGTTCATCCTATTGGGCTTAA  
 CAGATGATCCAATCCTTCGAGTCATCCTCTTCATGATCATCCTATCTGGTAATCTCAGCATA  
 25 ATTATTCTTATCAGAATTCTTCTCAGCTCCATCATCCTATGTATTTCTTTCTGAGCCACTT  
 GGCTTTTGCTGACATGGCCTATTTCATCTTCTGTACACCCCAACATGCTTGAAACTTCCTGG  
 TGGAGAGAAATACAGTCTCCTACCTTGGATGTGCCATCCAGCTTGGTTCAGCGGCTTTCTT  
 TGCAACAGTCGAATGCGTCCTTCTGGCTGCCATGGCCTATGACCGCTTTGTGGCAATTTGC  
 AGTCCACTGCTTTATTCAACCAAAAATGTCCACACAAGTCAGTGTCCAGCTACTCTTAGTAG  
 30 TTTACATAGCTGGTTTTCTCATTGCTGTCTCCTATACTACTTCTTCTATTTTTTACTCTTCT  
 GTGGACCAATCAAGTCAATCAATTTTTCTGTGATTTGCTCCCTTACTTGAACCTCTCCTGT  
 TCTGATATCAGTGTCTCCACAGTTGTTCTCTCATTTTCTTCTGGATCCATCATTGTGGTCAC  
 TGTGTGTGTCATAGCCGTCTGCTACATCTATATCCTCATCACCATCCTGAAGATGCGCTCCA  
 CTGAGGGGACCAACAAGGCCTTCTCCACCTGCACCTCCCACCTCACTGTGGTTACCTGTT  
 35 CTATGGGACCATTACCTTCATTTATGTGATGCCCAATTTTAGCTACTCAACTGACCAGAAC  
 AAGGTGGTGTCTGTGTTGTACACAGTGGTGATTCCCATGTTGAACCCCTGATCTACAGCC  
 TCAGGAACAAGGAGATTAAGGGGGCTCTGAAGAGAGAGCTTGTTAGAAAAATACTTTCTC  
 ATGATGCTTGTTATTTTAGTAGAACTTCAAATAATGATATTACATAG (SEQ ID NO: 62)

40 **AOLFR34 sequences:**

MLEGVEHLLLLLLLDVNSKELQSGNQTSVSHFILVGLHHPQLGAPLFLAFLVITYLLTVSGNG  
 LIILTVLVDIRLHRPMCLFLCHLSFLDMTISCAIVPKMLAGFLLGSRIISFGGCVIQLFSFHLGCT  
 ECFLYTLMA YDRFLAICKPLHYATIMTHRVCNSLALGTWLGGTIHSLFQTSFVFRLPFCGPNRV  
 DYIFCDIPAMRLACADTA INELVTFADIGFLALTCFMLILTSYGYIVAAILRIPSADGRRNAFST  
 45 CAAHLTVVIVYVPCTFIYLRPCSQEPLDGVVAVFYTVITPLLNSIYTLCKNEMKAALQRLGG  
 HKEVQPH (SEQ ID NO: 63)

ATGTTAGAGGGTGTGAGCATCTCCTTCTGCTACTTCTTTTGACAGATGTGAACAGCAAGG  
 AACTGCAAAGTGGAACCAAGACTTCTGTGTCTCACTTCATTTTGGTGGGCCTGCACCAACC  
 50 ACCACAGCTGGGAGCGCCACTCTTCTTAGCTTTCTTGTCTATCTCCTCACTGTTTCTG  
 GAAATGGGCTCATCATCCTCACTGTCTTAGTGGACATCCGGCTCCATCGTCCCATGTGCTT  
 GTTCTGTGTACCTCTCCTTCTTGGACATGACCAATTTCTTGTGCTATTGTCCCAAGATGC  
 TGGCTGGCTTTCTTGGGTAGTAGGATTATCTCCTTTGGGGGCTGTGTAATCCAACATTTT  
 TCTTTCCATTTCTGGGCTGTACTGAGTGCTTCTTTACACACTCATGGCTTATGACCGTTT  
 55 CTTTGCCATTTGTAAGCCCTTACACTATGCTACCATCATGACCCACAGAGTCTGTAACCTCCC  
 TGGCTTTAGGCACCTGGCTGGGAGGGACTATCCATTCACTTTTCCAAACAAGTTTTGTATT

WO 01/98526

CCGGCTGCCCTTCTGTGGCCCCAATCGGGTCGACTACATCTTCTGTGACATTCTGCCATGC  
 TCGCTCTAGCCTGCGCCGATACGGCCATCAACGAGCTGGTCACCTTTGCAGACATTGGCTT  
 CCTGGCCCTCACCTGCTTCATGCTCATCTCACTTCTATGGCTATATTGTAGCTGCCATCC  
 TGCGAATTCGTCAGCAGATGGGCGCCGAATGCCTTCTCCACTTGTGCTGCCACCTCAC  
 5 TGTGTGATTGTTTACTATGTGCCCTGCACCTTCATTTACCTGCGGCCTTGTTCACAGGAGC  
 CCCTGGATGGGGTGGTAGCTGTCTTTTACACTGTACACTCCCTTGTCTAACTCCATCATC  
 TACACACTGTGCAACAAAGAAATGAAGGCAGCATTACAGAGGCTAGGGGGCCACAAGGAA  
 GTGCAGCCTCACTGA (SEQ ID NO: 64)

10 **AOLFR35 sequences:**  
 MEPLNRTEVSEFFLKGFSGYPALHLLFPLCSAMYLVTLGNTAIMAVSVLDIHLHTPVYFFLG  
 NLSTLDICYTPTFVPLMLVHLLSSRKTFISFVCAIQMCLSLSTGSTECLLAITAYDRYLAICPL  
 RYHVLMSHRLCVLLMGAAWVLCCLKSVTEMVISMRLPFCGHHVVSHTCKILAVLKLACGNT  
 SVSEDFLLAGSILLPVPLAFICLSYLLILATILRVPSAARCCAFSTCLAHLAVVLLFYGTIIFMY  
 15 LKPKSKEAHISDEVFTVLYAMVTTMLNPTIYSLRNKEVKEAARKVWGRSRASR (SEQ ID NO:  
 65)

20 ATGGAGCCGCTCAACAGAACAGAGGTGTCCGAGTTCTTTCTGAAAGGATTTTCTGGCTACC  
 CAGCCCTGGAGCATCTGCTCTTCCCTCTGTGCTCAGCCATGTACCTGGTGACCCCTCTGGG  
 GAACACAGCCATCATGGCGGTGAGCGTGCTAGATATCCACCTGCACACGCCCGTGACTTC  
 TTCCTGGGCAACCTCTCTACCCTGGACATCTGCTACACGCCACCTTTGTGCCTCTGATGCT  
 GGTCCACCTCCTGTATCCCGGAAGACCATCTCCTTTGCTGTCTGTGCCATCCAGATGTGTC  
 TGAGCCTGTCCACGGGCTCCACGGAGTGCCTGCTACTGGCCATCACGGCCTATGACCGCTA  
 CCTGGCCATCTGCCAGCCACTCAGGTACCACGTGCTCATGAGCCACGGGCTCTGCGTGCTG  
 25 CTGATGGGAGCTGCCTGGGTCTCTGCCTCCTCAAGTCGGTGACTGAGATGGTCATCTCCA  
 TGAGGCTGCCCTTCTGTGGCCACCACGTGGTCAGTCACTTCACCTGCAAGATCCTGGCAGT  
 GCTGAAGCTGGCATGCGGCAACACGTGGTCAGCGAAGACTTCTGCTGCGGGCTCCAT  
 CCTGCTGCTGCCTGTACCCCTGGCATTCTATGCTGCTCTACTTGTCTATCCTGGCCACCA  
 TCCTGAGGGGTGCCCTCGGCCGCCAGGTGCTGCAAGCCTTCTCCACCTGCTTGGCACACCT  
 30 GGCTGTAGTGCTGCTTTTCTACGGCACCATCATCTTCATGTACTTGAAGCCCAAGAGTAAG  
 GAAGCCACATCTCTGATGAGGTCTTCAAGTCTCTATGCCATGGTCACGACCATGCTGA  
 ACCCCACCATCTACAGCCTGAGGAACAAGGAGGTGAAGGAGGCCGAGGAAGGTGTGGG  
 GCAGGAGTCGGGCCTCCAGGTGA (SEQ ID NO: 66)

35 **AOLFR36 sequences:**  
 MYLVTVLRNLLSILAVSSDSHPHTPMYFFLSNLCWADIGFTLATVPKMIVDMGSHSKVISYGG  
 CLTQMSFLVLFACIVDMFLTVMAYDCFVAICRPLHYVIVNPHLCVFFVLVSFFLSLLDSQLHS  
 WIVLQFTFFKNVEISNFVCEPSQLKLASYDSVINSIFIYDNTMFGFLPISGILLSYKIVPSILRIS  
 SSDGKYKAFSACGCHLAVVCLFYGTGIGVYLTSAVAPPLRNGMVASVMYAVVTPMLNPFYIS  
 40 LRNRDIQSALWRVCNKTVESHDLFHPFSCVVEKGQPHSIPTSANPAP (SEQ ID NO: 67)

45 ATGTATCTGGTCACGGTGCTGAGGAACCTGCTCAGCATCCTGGCTGTGACTCTGACTCCC  
 ACCCCACACACCCATGTACTTCTCCTCTCCAACCTGTGCTGGGCTGACATCGGTTTCACC  
 TTGGCCACGGTTCCCAAAATGATTGTGGACATGGGGTCGCATAGCAAAGTCATCTTATG  
 GGGGCTGCCTGACACAGATGTCTTTCTTGGTACTTTTGCATGTATAGTAGACATGTTCTT  
 GACTGTGATGGCTTATGACTGCTTTGTAGCCATCTGTGCGCCTCTGCACTACCCAGTCATC  
 GTGAATCCTCACCTCTGTGCTTCTTCGTTTTGGTGTCCTTTTCTTAGCCTGTTGGATTCC  
 CAGCTGCACAGTTGGATTGTGTTACAATTACCTTCTCAAGAATGTGGAAATCTCTAATT  
 TTGCTGTGAGCCATCTCAACTTCTCAAGCTTGCCCTTATGACAGCGTCATCAATAGCATA  
 50 TATATAATTTGATAATACTATGTTTGGTTTTCTTCCCATTTACAGGATCCTTTTGTCTTAC  
 CAGCCTGTGGCTGTACCTGGCAGTGTGTTGCTTATTTATGGAACAGGCATTGGCGTGTA  
 CCTGACTTCAGCTGTGGCACCACCCCTCAGGAATGGTATGGTGGCGTCAGTGATGTACGCT  
 GTGGTCACCCCATGCTGAACCCTTTCATCTACAGCCTGAGAAACAGGGACATTCAAAGTG  
 55 CCCTGTGGAGGGTGTGCAACAAAACAGTCGAATCTCATGATCTGTTCCATCCTTTTCTTG

TGTGGTTGAGAAAGGGCAACCACATTCAATCCCTACATCTGCAAATCCTGCCCCCTTAG  
(SEQ ID NO: 68)

**AOLFR37 sequences:**

5 MEKANETSPVMGFVLLRLSAHPELEKTFVLLMYLVILLGNGVLILVTILDSRLHTPMYFFLG  
NLSFLDICFTTSSVPLVLDSTLTPQETISFSACAVQMAISFAMAGTECLLSMMAFDYVAICNP  
LRYSVIMSKAA YMPMAASSWAIGGAASVVHTSLAIQLPFCGDNVINHFTCEILAVLKLACADIS  
INVISMEVTNVIFLGVPLFISFSYVFIITILRIPSAEGRKKVFSTCSAHLTVVIVFYGTLFFMYG  
KPKSKDSMGADKEDLSDKLIPLFYGVVTPMLNPIIYSLRNKDVKA AVRLLRPKGFTQ (SEQ ID  
10 NO: 69)

ATGGAAAAAGCCAATGAGACCTCCCCTGTGATGGGGTTCGTTCTCCTGAGGCTCTCTGCCC  
ACCCAGAGCTGGAAAAGACATTCTTCGTGCTCATCCTGCTGATGTACCTCGTGATCCTGCT  
GGGCAATGGGGTCCCTCATCCTGGTGACCATCCTTGACTCCCGCCTGCACACGCCCATGTAC  
15 TTCTTCCTAGGGAACCTCTCCTTCCTGGACATCTGCTTCACTACCTCCTCAGTCCCCTGGT  
CCTGGACAGCTTTTTGACTCCCCAGGAAACCATCTCCTTCTCAGCCTGTGCTGTGCAGATG  
GCACTCTCCTTTGCCATGGCAGGAACAGAGTGCTTGCTCCTGAGCATGATGGCATTGTATC  
GCTATGTGGCCATCTGCAACCCCTTAGGTACTCCGTGATCATGAGCAAGGCTGCCTACAT  
GCCCATGGCTGCCAGCTCCTGGGCTATTGGTGGTGCTGCTTCCGTGGTACACACATCCTTG  
20 GCAATTCAGCTGCCCTTCTGTGGAGACAATGTCATCAACCACTTCACCTGTGAGATTCTGG  
CTGTTCTAAAGTTGGCCTGTGCTGACATTTCCATCAATGTGATCAGCATGGAGGTGACGAA  
TGTGATCTTCCTAGGAGTCCCGGTTCTGTTTCATCTCTTCTCCTATGTCTTCATCATACCA  
CCATCCTGAGGATCCCCTCAGCTGAGGGGAGGAAAAAGGTCTTCTCCACCTGCTCTGCCCA  
CCTCACCGTGGTGATCGTCTTCTACGGGACCTTATTCTTCATGTATGGGAAGCCTAAGTCT  
25 AAGGACTCCATGGGAGCAGACAAAGAGGATCTTTCAGACAAACTCATCCCCCTTTTCTATG  
GGGTGGTGACCCCGATGCTCAACCCCATCATCTATAGCCTGAGGAACAAGGATGTGAAGG  
CTGCTGTGAGGAGACTGCTGAGACCAAAAGGCTTCACTCAGTGA (SEQ ID NO: 70)

**AOLFR38 sequences:**

30 MYLVTVLRLNLLIILAVSSDHLHTPMCFFLSNLCWADIGFTSAMVPKMIVDMQSHSRVISYAGC  
LTQMSFFVLFACIEDMLLTVMAYDRFVAICHPLHYPVIMNPHLGVLVLVSFFLSLLDSQLHSW  
IVLQFTFFKNVEISNFVCDPSQLNLACSDSVINSIFYLDSIMFGFLPISGILLSYANNVPSILRISS  
SDRKSKAFTSCGSHLAVVCLFYGTGIGVYLTSAVSPPRNGVVASVMAVAVTPMLNPFYSLR  
NRDIQSALWRLRSRTVESHDLLSQDLLHPFSCVGEKGQPH (SEQ ID NO: 71)

35 ATGTACCTGGTCACGGTGCTGAGGAACCTGCTCATCATCCTGGCTGTCAGCTCTGACTCCC  
ACCTCCACACCCCCATGTGCTTCTCCTCTCCAACCTGTGCTGGGCTGACATCGGTTTCACC  
TCGGCCATGGTTCCCAAGATGATTGTGGACATGCAGTCGCATAGCAGAGTCATCTCTTATG  
CGGGCTGCCTGACACAGATGTCTTTCTTTGTCCTTTTTGTCATGTATAGAAGACATGCTCCTG  
40 ACAGTGATGGCCTATGACCGATTTGTGGCCATCTGTCACCCCTGCACTACCCAGTCATCA  
TGAATCCTCACCTTGGTGCTTCTTAGTTTTGGTGCTTTTTCTCAGCCTGTTGGATTCC  
CAGCTGCACAGTTGGATTGTGTTACAATTCACCTTCTCAAGAATGTGGAAATCTCCAATT  
TTGTCTGTGACCCATCTCAACTTCTCAACCTTGCCTGTTCTGACAGTGTCATCAATAGCATA  
TTCATATAITTAGATAGTATTATGTTTGGTTTTCTTCCCATTTCAGGGATCCTTTTGTCTTAC  
45 GCTAACAATGTCCCCTCCATTCTAAGAATTCATCATCAGATAGGAAGTCTAAAGCCTTCT  
CCACCTGTGGCTCTCACCTGGCAGTTGTTTGTCTATTTTATGGAACAGGCATTGGCGTGTA  
CCTGACTTCAGCTGTGTACCAACCCCCCAGGAATGGTGTGGTGGCATCAGTGATGTACGCT  
GTGGTCACCCCATGCTGAACCTTTTCATCTACAGCCTGAGAAATAGGGACATTCAAAGTG  
CCCTGTGGAGGCTGCGCAGCAGAACAGTGAATCTCATGATCTGTTATCTCAAGATCTGCT  
50 CCATCCTTTTTCTTGTGTGGGTGAGAAAGGTCAACCACATTAA (SEQ ID NO: 72)

**AOLFR39 sequences:**

MGVKNHSTVTEFLSLTEQAELQLPLFLFLGIYTVTVVGNLSMISIIRLNRLHTPMYYFLSS  
LSFLDFCYSSVITPKMLSGFLCRDRSISYSGCMIQLFFFCVVCVISECYMLAAMACDRYVAICSP  
55 LYRVIMSPRVCSLLVA AVFSVGFTDAVIHGGCILRLSFCGSNIUKHYFCDIVPLIKLSCSSTYIDEL

ATGGGTGTAAAAAACCATTCACAGTGACTGAGTTTCTTCTTTCAGGATTAACCTGAACAAG  
5 CAGAGCTTCAGCTGCCCCTCTTCTGCCTCTTCTTAGGAATTTACACAGTTACTGTGGTGGG  
AAACCTCAGCATGATCTCAATTATTAGGCTGAATCGTCAACTTCATACCCCCATGTACTAT  
TTCCTGAGTAGTTTGTCTTTTTTAGATTCTGCTATTCTTCTGTCAATACCCCTAAAATGCT  
ATCAGGGTTTTATGCAGAGATAGATCCATCTCCTATTCTGGATGCATGATTCAGCTGTTTT  
TTTTCTGTGTTTGTGTTATTTCTGAATGCTACATGCTGGCAGCCATGGCCTGCGATCGCTAC  
10 GTGGCCATCTGCAGCCCACTGCTCTACAGGGTCATCATGTCCCCTAGGGTCTGTTCTCTGC  
TGGTGGCTGCTGTCTTCTCAGTAGGTTTCACTGATGCTGTGATCCATGGAGGTTGTATACT  
CAGGTTGTCTTTCTGTGGATCAAACATCATTAAACATTATTTCTGTGACATTGTCCCTCTTA  
TTAAACTCTCCTGCTCCAGCACTTATATTGATGAGCTTTTGATTTTTGTCAATTGGTGGATTT  
AACATGGTGGCCACAAGCCTAACAAATCATTATTTTCATATGCTTTTATCCTCACCAGCATCCT  
15 GCGCATCCACTCTAAAAAGGGCAGGTGCAAAGCGTTAGCACCTGTAGCTCCCACTGACA  
GCTGTTCTTATGTTTTATGGGTCTCTGATGTCCATGTATCTCAAACCTGCTTCTAGCAGTTC  
ACTACCCAGGAGAAAGTATCCTCAGTATTTTATACCACTGTGATTCTCATGTTGAATCCC  
TTGATATATAGTCTGAGGAACAATGAAGTAAGAAATGCTCTGATGAAACTTTTAAGAAGA  
AAAATATCTTTATCTCCAGGATAA (SEQ ID NO: 74)

20 AOLFR40 sequences:  
MSNATLLTAFILTGPHAPGLDAPLFGIFLVVYVLTVLGNLLILLVIRVDSHLHTPMYYFLTNSL  
FIDMWFSTVTVPKMLMTLVSPSGRTISFHSCVAQLYFFHFLGSTECFLYTVMSYDRYLAI SYPL  
RYTNMMTGRSCALLATGTWLSGSLHSAVQTILTFHLPYCGPNQIQHYFCDAPPILKLACADTS  
25 ANEMVIFVNI GLVASGCFVLIVLSYVSIVCSILRIRTSEGRHRAFQTCASHCIVLVCFFGPGFLFIYL  
RPGSRDALHGVVAVFYTTLTPLFNPVVYTLRNKEVKKALLKLKNGSVFAQGE (SEQ ID NO:  
75)

75)

ATGTCCAACGCCACCCTACTGACAGCGTTCATCCTCACGGGCCTTCCCCATGCCCCAGGGC  
TGGACGCCCCCTCTTTGGAATCTTCTGGTGGTTACGTGCTCACTGTGCTGGGGAACCT  
CCTCATCCTGCTGGTGATCAGGGTGGATTCTACCTCCACACCCCCATGTACTACTTCCTCA  
CCAACTGTCTTCATTGACATGTGGTTCTCCACTGTCACGGTGCCAAAATGCTGATGAC  
CTTGGTGTCCCCAAGCGGCAGGACTATCTCTCCACAGCTGCGTGGCTCAGCTCTATTTTT  
TCCACTTCCTGGGGAGCACCGAGTGTTTCTCTACACAGTCATGTCCTATGATCGCTACCT  
GGCCATCAGTTACCCGCTCAGGTACACCAACATGATGACTGGGCGCTCGTGTGCCCTCCTG  
GCCACGGCACTTGGCTCAGTGGCTCTCTGCACTCTGCTGTCCAGACCATATTGACTTCC  
ATTTGCCCTACTGTGGACCCAACCATCCAGCACTACTTCTGTGACGCACCGCCCATCCT  
GAAACTGGCCTGTGCAGACACCTCAGCCAACGAGATGGTCATCTTTGTGAATATTGGGCTA  
GTGGCCTCGGGCTGCTTTGTCTGATAGTGCTGTCTATGTGTCCATCGTCTGTTCCATCCT  
GCGGATCCGCACCTCAGAGGGGAGGCACAGAGCCTTTCAGACCTGTGCCTCCCACTGTATC  
GTGGTCTCTTGCTCTTTGGCCCTGGTCTTTTCATTACCTGAGGCCAGGCTCCAGGGACGC  
CTTGCATGGGGTTGTGGCCGTTTTCTACACCACGCTGACTCCTCTTTTCAACCCTGTTGTGT  
ACACCCTGAGAAACAAGGAGGTAAAGAAAGCTCTGTTGAAGCTGAAAAATGGGTGAGTAT  
TTGCTCAGGGTGAATAG(SEQ ID NO: 76)

45 AOLFR41 sequences:  
MNPENWTQVTSFVLLGFPSSHLIQFLVFLGLMVTYIVTATGKLLIIVLSWIDQRLHIQMYFFLRN  
FSFLELLLVTVVVPKMLVVILTGDHTISFVSCIIQSYYFLGTTDDFLLAVMSLDRYLAICRPLR  
YETLMNGHVCSQLVLASWLAGFLVWLCPTVLMASLPFCGPNGIDHFFRDSWPLLRLSCGDTH  
50 LLKLVAFMLSTLVLLGSLALTSVSYACILATVLRAPTA AERRKAFSTCASHLVVVVIIYGSSIFLY  
IRMSEAQSKLLNK GASVLSCIITPLNPFIFTLRNDKVQQALREALGWPRLTAVMKLRVTSQRK  
(SEQ ID NO: 77)

(SEQ ID NO: 77)

55 ATGAACCTGAAAACCTGGACTCAGGTAACAAGCTTTGTCCTTCTGGGTTTCCCCAGTAGCC  
ACCTCATACAGTTCCTGGTGTTCCTGGGGTTAATGGTGACCTACATTGTAACAGCCACAGG  
CAAGCTGCTAATTATTGTGCTCAGCTGGATAGACCAACGCCTGCACATACAGATGTACTTC



TTCCTGCGGAATTTCTCCTTCCTGGAGCTGTTGCTGGTAACTGTTGTGGTTCCCAAGATGCT  
 TGTCGTCATCCTCACGGGGGATCACACCATCTCATTTGTGAGCTGCATCATCCAGTCCTACC  
 TCTACTTCTTTCTAGGCACCACTGACTTCTTCTCTTGGCCGTCATGTCTCTGGATCGTTAC  
 CTGGCAATCTGCCGACCACTCCGCTATGAGACCTGATGAATGGCCATGTCTGTTCCCAAC  
 5 TAGTGCTGGCCTCCTGGCTAGCTGGATTCTCTGGGTCCTTTGCCCACTGTCCTCATGGCC  
 AGCCTGCCTTTCTGTGGCCCCAATGGTATTGACCACTTCTTTCTGTGACAGTTGGCCCTTGCT  
 CAGGCTTTCTGTGGGGACACCCACCTGCTGAAACTGGTGGCTTTTATGCTCTCTACGTTG  
 GTGTTACTGGGCTCACTGGCTCTGACCTCAGTTTCTATGCCTGCATTCTTGCCACTGTTCT  
 CAGGGCCCCCTACAGCTGCTGAGCGAAGGAAAGCGTTTCCACTTGCGCCTCGCATCTTACA  
 10 GTGGTGGTCATCATCTATGGCAGTTCATCTTTCTCTACATTGCTATGTCAGAGGCTCAGTC  
 CAAACTGCTCAACAAAGGTGCCTCCGTCCTGAGCTGCATCATCACACCCCTCTTGAACCCA  
 TTCATCTTCACTCTCCGCAATGACAAGGTGCAGCAAGCACTGAGAGAAGCCTTGGGGTGGC  
 CCAGGCTCACTGCTGTGATGAAACTGAGGGTCACAAGTCAAAGGAAATGA (SEQ ID NO:

78)

#### AOLFR42 sequences:

MNPANHSQVAGFVLLGLSQVWELRFVFFTVFSVYFMTVVGNLLIVVIVTSDPHLHTTMYFLL  
 GNLSFLDFCYSSITAPRMLVDLLSGNPTISFGGCLTQLFFHFIGGIKIFLLTMAYDRYIAISQPL  
 HYTLIMNQTVCALLMAASWVGFIHSIVQIALTIQLPFCGPKLDNFYCDVPQLIKLACTDTFV  
 20 LELLMVSNNGLVTLMCFLVLLGSYALLVMLRSHSREGRSKALSTCASHIAVVTILFVPCIYVY  
 TRPFRTPMDKAVSVLYTIVTPMLNPAIYTLRNKEVIMAMKKLWRRKKDPIGLEHRPLH  
 (SEQ ID NO: 79)

ATGAATCCAGCAAATCATTCCAGGTGGCAGGATTTGTTCTACTGGGGCTCTCTCAGGTTT  
 25 GGGAGCTTCGGTTTGTCTTCTTCACTGTTTCTCTGCTGTGTATTTTATGACTGTAGTGGGA  
 AACCTTCTTATTGTGGTCATAGTGACCTCCGACCCACACCTGCACACAACCATGTATTTTCT  
 CTTGGGCAATCTTTCTTCTGGAATTTTGTACTCTTCCATCACAGCACCTAGGATGCTGG  
 TTGACTTGCTCTCAGGCAACCCTACCATTTCCTTTGGTGGATGCCTGACTCAACTCTTCTTC  
 TTCCACTTCATTGGAGGCATCAAGATCTTCTGCTGACTGTCATGGCGTATGACCGCTACA  
 30 TTGCCATTTCCAGCCCTGCACTACACGCTCATTATGAATCAGACTGTCTGTGCACTCCTT  
 ATGGCAGCCTCCTGGGTGGGGGGCTTCATCCACTCCATAGTACAGATTGCATTGACTATCC  
 AGCTGCCATTCTGTGGGCCTGACAAGCTGGACAACCTTTTATTGTGATGTGCCTCAGCTGAT  
 CAAATTGGCCTGCACAGATACCTTTGTCTTAGAGCTTTTAATGGTGTCTAACAATGGCCTG  
 GTGACCCTGATGTGTTTTCTGGTGCTTCTGGGATCGTACACAGCACTGCTAGTCATGCTCC  
 35 GAAGCCACTCACGGGAGGGCCGAGCAAGGCCCTGTCTACCTGTGCCTCTCACATTGCTGT  
 GGTGACCTTAATCTTTGTGCCTTGATCTACGTCTATACAAGGCCTTTTCGGACATTCCCCA  
 TGGACAAGGCCGTCTCTGTGCTATACACAATTGTACCCCCATGCTGAATCCTGCCATCTA  
 TACCCTGAGAAACAAGGAAGTGATCATGGCCATGAAGAAGCTGTGGAGGAGGAAAAAGG  
 ACCCTATTGGTCCCCTGGAGCACAGACCCTTACATTAG (SEQ ID NO: 80)

40

#### AOLFR43 sequences:

MQKPQLLVPIIATSNNGNLVHAAYFLLVGIPGLGPTIHFWLAFPLCFMYALATLGNLTIVLIIRVE  
 RRLHEPMYLFLAMLSTIDLVLSSITMPKMASLFLMGIQEIEFNICLAQMFLIHLSAVESAVLLA  
 MAFDRFVAICHPLRHASVLTGCTVAKIGLSALTRGFVFFPLPFILKWLSYQCQHTVTHSFCLHQ  
 45 DIMKLSCTDTRVNVVYGLFIILSVMGVDSLFIGFSYLILWAVLELSSRAALKAFNTCISHLCAV  
 LVFYVPLIGLSVVHRLGGPTSLHVVMAANTYLLPPVVNPLVYGAKTKEICSRVLCMFSSQGGK  
 (SEQ ID NO: 81)

ATGCAGAAGCCCCAGCTCTTGGTCCCTATCATAGCCACTTCAAATGGAAATCTGGTCCACG  
 50 CAGCATACTTCCTTTTGGTGGGTATCCCTGGCCTGGGGCCTACCATACACTTTTGGCTGGCT  
 TTCCCACTGTGTTTTATGTATGCCTTGGCCACCCTGGGTAACCTGACCATTGTCCTCATCAT  
 TCGTGTGGAGAGGCGACTGCATGAGCCCATGTACCTCTTCTGGCCATGCTTTCCACTATT  
 GACCTAGTCCTCTCCTCTATCACCATGCCCAAGATGGCCAGTCTTTTCTGATGGGCATCCA  
 GGAGATCGAGTTCAACATTTGCCTGGCCAGATGTTTCTTATCCATGCTCTGTGAGCCGTG  
 55 GAGTCAGCTGTCTGCTGGCCATGGCTTTTGACCGCTTTGTGGCCATTTGCCACCCATTGC  
 GCCATGCTTCTGTGCTGACAGGGTGTACTGTGGCCAAGATTGGACTATCTGCCCTGACCAG

WO 01/98526

GGGGTTTGTATTCTTCTTCCCACTGCCCTTCATCCTCAAGTGGTGTCTACTGCCAAACAC  
 ATACTGTCACACACTCCTTCTGTCTGCACCAAGATATTATGAAGCTGTCTGTACTGACAC  
 CAGGGTCAATGTGGTTTATGGACTCTTCATCCTCTCAGTCATGGGTGTGGACTCTCTCT  
 TCATTGGCTTCTCATATATCCTCATCCTGTGGGCTGTTTTGGAGCTGTCTCTCGGAGGGCA  
 5 GCACTCAAGGCTTCAACACCTGCATCTCCACCTCTGTGCTGTTCTGGTCTTCTATGTACC  
 CCTCATTGGGCTCTCGGTGGTGCATAGGCTGGGTGGTCCCACCTCCCTCCATGTGGTT  
 ATGGCTAATACCTACTTGGCTGCTACCACCTGTAGTCAACCCCTGTCTATGGAGCCAAGA  
 CCAAAGAGATCTGTTCAAGGGTCTCTGTATGTTCTACAAGGTGGCAAGTGA (SEQ ID  
 NO: 82)

10

**AOLFR44 sequences:**

MSSCNFTHATFVLIGIPGLEKAHFWVGFPLLSMYVVMFNGCIVVFIVRTERS LHAPMYLFLC  
 MLAIDLALSTSTMPKILALFWFDSREISFEACLTQMFFIHALSAIESTILLAMAFDRYVAICHL  
 RHA AVLNNVTVAQIGIVAVVRGSLFFFLPLLIKRLAFCHSNVLSHSYCVHQDVMKLAYADTL  
 15 NVVYGLTAILVMGVDVMFISLSYFLIIRTVLQLPSKSERAKAFGTCVSHIGVVLAFYVPLIGLS  
 VVHRFGNSLHPIVRVVMGDIYLLPPVINPIHYGAKTKQIRTRVLAMFKISCDKDLQAVGGK  
 (SEQ ID NO: 83)

ATGAGTTCCTGCAACTTCACACATGCCACCTTTGTGCTTATTGGTATCCCAGGATTAGAGA  
 20 AAGCCCATTTCTGGGTGGCTTCCCCCTCCTTCCATGTATGTAGTGGCAATGTTTGGAAAC  
 TGCATCGTGGTCTTCATCGTAAGGACGGAACGCAGCCTGCACGCTCCGATGTACCTCTTC  
 TCTGCATGCTTGCAGCCATTGACCTGGCCTATCCACATCCACCATGCCTAAGATCCTTGCC  
 CTTTTCTGGTTTGATTCCCGAGAGATTAGCTTTGAGGCCTGTCTTACCCAGATGTTCTTTAT  
 TCATGCCCTCTCAGCCATTGAATCCACCATCCTGCTGGCCATGGCCTTTGACCGTTATGTGG  
 25 CCATCTGCCACCCACTGCGCCATGCTGCAGTGTCTCAACAATACAGTAACAGCCAGATTGG  
 CATCGTGGCTGTGGTCCGCGGATCCCTCTTTTTTCCCACTGCCTCTGCTGATCAAGCGGC  
 TGGCCTTCTGCCACTCCAATGTCCTCTCGCACTCCTATTGTGTCCACCAGGATGTAATGAA  
 GTTGGCCTATGCAGACACTTTGCCAATGTGGTATATGGTCTTACTGCCATTCTGCTGGTC  
 ATGGGCGTGGACGTAATGTTTCATCTCCTTGTCTATTTTCTGATAATACGAACGGTCTGC  
 30 AACTGCCTTCCAAGTCAGAGCGGGCCAAAGCCTTTGGAACCTGTGTGTACACATTGGTGT  
 GGTACTCGCCTTCTATGTGCCACTTATGGCCTCTCAGTGGTACACCGCTTTGGAAACAGC  
 TTTCATCCCATTTGTGCGTGTGTGATGACATCTACCTGCTGCTGCCTCTGTGATCA  
 TCCCATCATCTATGGTGCCAAACAGATCAGAACACGGGTGCTGGCTATGTTCAAG  
 ATCAGCTGTGACAAGGACTTGCAGGCTGTGGGAGGCAAGTGA (SEQ ID NO: 84)

35

**AOLFR45 sequences:**

MLPSNITSTHPAVFLLVGIPGLEHLHAWISIPFCFAYTLALLGNCTLLFIQADAALHEPMYLFLA  
 MLATIDLVLSTTLPKMLAIFWFRDQENFFACLVMFFLHSFSIMESA VLLAMAFDRYVAICKP  
 LHYYTVLTGSLITKIGMAAVARAVTLMTPLPFLRRFHYCRGPVIAHCYCEHMAVVRACGDT  
 40 SFNNIYGIAVAMFSVLDLLFVLSYVFILQAVLQLASQEARYKAFGTCVSHIGAILSTYTPVVIS  
 SVMHRVARHAAPRVHILLAIFYLLFPPMVNPIHYGVKTKQIREYVLSLFQRKNM (SEQ ID NO:  
 85)

TGGAAACAAGAGGTAATCTTTGCAGGTGGGATAGCACAGGTTGAACTCTAATCATATATA  
 45 CTGTAGAAGGTATATAGAAGGTGAAGAAGCCCTGTAAAAATTGACAAGGAGATTTC  
 GGAGCCATGCTTCCCTCTAATATCACCTCAACACATCCAGCTGTCTTTTGTGGTAGGAAT  
 TCCTGGTTTGGAAACACCTGCATGCCTGGATCTCCATCCCCCTTCTGCTTGTCTTACTCTGG  
 CCTGCTAGGCAACTGTACCTTCTCTTATTATCCAGGCTGATGCAGCCCTCCATGAACCC  
 ATGTACCTCTTTCTGGCCATGTTGGCAACCATGACTTGGTCTTTCTTCTACAACGCTGCC  
 50 CAAAATGCTTGCCATATTCTGGTTCAGGGATCAGGAGATCAACTCTTTGCTGTCTGGTC  
 CAGATGTTCTTCTTCACTCCTTCTCCATCATGGAGTCAGCAGTGTGCTGGCCATGGCCT  
 TGACCGCTATGTGGCCATCTGCAAGCCATTGCACTACACGACGGTCTGACTGGGTCCCTC  
 ATCACCAGATTGGCATGGCTGCTGTGGCCCGGGCTGTGACACTAATGACTCCACTCCCTC  
 TCCTGCTCAGACGCTTCCACTACTGCCGAGGCCAGTGATTGCCCATGCTACTGTGAACA  
 55 CATGGCTGTGGTAAGGCTGGCGTGTGGGGACACTAGCTTCAACAATATCTATGGCATTGCT  
 GTGGCCATGTTTAGTGTGGTGTGGACCTGCTCTTGTATCCTGTCTTATGCTTCTATCCT



TCAGGCAGTTCTCCAGCTTGCCTCTCAGGAGGCCCGCTACAAAGCATTGTTGGGACATGTGTG  
 TCTACATAGGTGCCATCCTGTCCACCTACACTCCAGTAGTCATCTCTTCAGTCATGCACCG  
 TGAGCCCGCCATGCTGCCCCCTCGTGTCCACATACTCCTTGCTATTTTCTATCTCCTTTTCC  
 CACCCATGGTCAATCCTATCATATATGGAGTCAAGACCAAGCAGATTTCGTGAGTATGTGCT  
 5 CAGTCTATTCCAGAGAAAGAACATGTAGATGGATAGTTCTCTTTTTTATCCCACTTGCCA  
 AGTAATGAGAATGCTGGATTGGGGTTGAGGGGAAAAATCTAAATAGGAAAATTGCAGAGT  
 ATCTTTGACAAATTCTTAGTATGATAAGGAAAAATGAGGTTTCATTCTCACAGATCTACGA  
 GTCAGGTCAAACCAGGAGTGCACCTATAGTCTGGTCTGATAGTAGAGGTTTGACCTTCCCA  
 TTGTCATAGACTCATCACATGGCTAAGGAAGACAAACCTCTCAAAGTGGTATTGTAATCTG  
 10 GGTGAAAGACAGTAGGACCTTTATTGGCTGAGATTGGCCCAAACAGCTGAGTC (SEQ ID  
 NO: 86)

#### AOLFR46 sequences:

MNIKHCGWHMIHTWLNIREDDSDDFKNFIGQIQGLSGNPHSTTSRMYFLCFCTSLLGFKVHWV  
 15 SRLIXKLYMASPNDSTAPVSEFLICFPNFQSWQHWLSLPLSLLFLLAMGANTLLITIQLEAS  
 LHQPLYLLSLLSLLDIVLCLTVIPKVLAIWFDFLRISFPACFLQMFIMNSFLTMESCTFMVMA  
 YDRYVAICHPLRYPSTIDQFVARAVFVIARNAFVSLPVPMLSARLRYCAGNIKNCICSNLSVS  
 KLSCDDITFNQLYQFVAGWTLLGSDLILIVISYFILKVVLRIKAEGAVAKALSTCGSHFILILFFS  
 TVLLVLVITNLARKRIPDPVILLNHLHIPPALNPVYGVRTKEIKQGIQNLLKRL (SEQ ID NO:  
 20 87)

ATGAATATAAAACATTGTGGCTGGCATATGATACATACTTGGTTAAATATAAGGGAGGAT  
 GATGACAGTGATTTTAAAACTTTATTGGACAGATACAGGGCCTCAGTGAAACCCACACT  
 CTACTACGTCTAGAATGTACTTTTTATGTTTCTGTACTTCTCTACTAGGTTTTAAGGTACAC  
 25 TGGGTCTCCAGATTGATCANGAACTTTACATGGCATCTCCCAACAATGACTCCACTGCCC  
 CAGTCTCTGAATTCCTCCTCATCTGCTTCCCCAACTTCCAGAGCTGGCAGCACTGGTTGTCT  
 CTGCCCCCAGCCTTCTCTTCTCCTGGCCATGGGAGCTAACACCACCCTCCTGATCACCAT  
 CCAGCTGGAGGCCTCTCTGCACCAGCCCCTGTACTACCTGCTCAGCCTCCTCTCCCTGCTGG  
 ACATCGTGCTCTGCCTCACCGTCATCCCCAAGGTCCTGGCCATCTTCTGGTTTGACCTCAGG  
 30 TCGATCAGCTTCCCAGCCTGCTTCTCCAGATGTTTCATCATGAACAGTTTTTTGACCATGGA  
 GTCCTGCACGTTTCATGGTCATGGCCTATGACCGTTATGTGGCCATCTGCCATCCATTGAGA  
 TACCCGTCTATCATCACTGACCAGTTTGTGGCTAGGGCCGTGGTCTTTGTTATAGCCCGGA  
 ATGCCCTTGTCTCTTCTCCTGTTCCCATGCTTTCTGCCAGGCTCAGATACTGTGCAGGAAAC  
 ATAATCAAGAACTGCATCTGCAGTAACCTGTCTGTGTCCAACTCTCTTGTGATGACATCA  
 35 CTTTCAATCAGCTCTACCAGTTTGTGGCAGGCTGGACTCTGTTGGGCTCTGATCTTATCCTT  
 ATTGTTATCTCCTATTCTTTTATATTGAAAGTTGTGCTTAGGATCAAGGCCGAGGGTGCTGT  
 GGCCAAGGCCTTGAGCACGTGTGGTTCCCACTTCATCCTCATCCTCTTCTTTCAGCACAGTCC  
 TGCTGGTTCTGGTCATCACTAACCTGGCCAGGAAGAGAATTCCTCCAGATGTCCCCATCCT  
 40 GCTCAACATCCTGCACCACCTCATTCCCCCAGCTCTGAACCCCATTTGTTTATGGTGTGAGA  
 ACCAAGGAGATCAAGCAGGGAATCCAAAACCTGCTGAAGAGGTTGTAA (SEQ ID NO: 88)

#### AOLFR47 sequences:

MSASNITLTHPTAFLLVGIPGLEHLHIWISIPFCLAYTLALLGNCTLLLIQADAALHEPMYLFLA  
 MLAAIDLVLSSALPKMLAIFWFRDREINFFACLAQMFFLHSFSIMESAVLLAMAFDRYVAICK  
 45 PLHYTKVLTGSLITKIGMAAVARAVTLMTPLPFLLRFCFHYCRGPVIAHCYCEHMAVVRACGD  
 TSFNNIYGIAMFIVVLDLLLVLISYIFILQAVLLLASQEARYKAFGTCVSHIGAILAFYTTVVIS  
 SVMHRVARHAAPHVHILLANFYLLFPPMVNPIIYGVKTKQIRESILGVFPRKDM (SEQ ID NO:  
 89)

50 ATGTCAGCCTCCAATATCACCTTAACACATCCAACTGCCTTCTTGTGGTGGGGATTCCAG  
 GCCTGGAACACCTGCACATCTGGATCTCCATCCCTTTCTGCTTAGCATATACACTGGCCCTG  
 CTTGGAACTGCACTCTCCTTCTCATCATCCAGGCTGATGCAGCCCTCCATGAACCCATGT  
 ACCTCTTTCTGGCCATGTTGGCAGCCATCGACCTGGTCTTCTCCTCCTCAGCACTGCCAAA  
 55 ATGCTTGCCATATTCTGGTTTCAGGGATCGGGAGATAAACTTCTTTGCTGTCTGGCCAGA  
 TGTTCTTCTTCACTCCTTCTCCATCATGGAGTCAGCAGTGCTGCTGGCCATGGCCTTTGAC  
 CGCTATGTGGCTATCTGCAAGCCACTGCACTACACCAAGGTCTGACTGGGTCCCTCATCA

WO 01/98526

CCAAGATTGGCATGGCTGCTGTGGCCCCGGGCTGTGACACTAATGACTCCACTCCCCTTCCT  
 GCTGAGATGTTTCCACTACTGCCGAGGCCAGTGATCGCTCACTGCTACTGTGAACACATG  
 GCTGTGGTGAGGCTGGCGTGTGGGGACACTAGCTTCAACAATATCTATGGCATCGCTGTGG  
 CCATGTTTATTGTGGTGTGGACCTGCTCCTTGTATCCTGTCTTATATCTTTATTCTTCAG  
 5 GCAGTTCTACTGCTTGCCCTCAGGAGGCCCGCTACAAGGCATTTGGGACATGTGTCTCTC  
 ATATAGGTGCCATCTTAGCCTTCTACACAAGTGTGGTCACTCTTCAGTCATGCACCGTGT  
 GCGCGCATGCTGCCCCCTCATGTCCACATCCTCCTTGCCAAATTTCTATCTGCTCTCCCACC  
 CATGGTCAATCCCATAATCTATGGTGTCAAGACCAAGCAAATCCGTGAGAGCATCTTGGA  
 GTATCCCAAGAAAGGATATGTAG (SEQ ID NO: 90)

10

**AOLFR48 sequences:**

MMVDPNGNESSATYFILIGLPGLEEAQFWLAFPLCSLYLIAVLGNLTIIYVTRTEHSLHEPMYIFL  
 CMLSGIDILISTSSMPKMLAIFWFNSTTIQFDACLLQMFHLSLGMESTVLLAMAFDRYVAICH  
 PLRHATVLTLPRTKIGVAAVVRGAALMAPLPVFIKQLPFCRSNLSHSYCLHQDVMKLACDDI  
 15 RVNVVYGLVHSAIGLDSLLISFSYLLIKTVLGLTREAQAKAFGTCVSHVCAVFIFYVPFIGLSM  
 VHRFSKRDSPLPVILANIYLLVPPVLNPVYGVKTKAIRQLRLRFHVATHASEP (SEQ ID NO:  
 91)

ATGATGGTGGATCCCAATGGCAATGAATCCAGTGCTACATACTTCATCCTAATAGGCCTCC  
 CTGGTTTAGAAGAGGCTCAGTTCTGGTTGGCCTTCCCATTTGTGCTCCCTCTACCTTATTGCT  
 20 GTGCTAGGTAACCTTGACAATCATCTACATTGTGCGGACTGAGCACAGCCTGCATGAGCCCA  
 TGTATATATTTCTTTCATGCTTTTCAAGCATTGACATCCTCATCTCCACCTCATCCATGCC  
 AAAATGCTGGCCATCTTCTGGTTCAATTCCTACTACCATCCAGTTTGTGCTGTCTGCTACA  
 GATGTTTGGCCATCCACTCCTTATCTGGCATGGAATCCACAGTGCTGCTGGCCATGGCTTTT  
 25 GACCGCTATGTGGCCATCTGTACCCACTGCGCCATGCCACAGTACTTACGTTGCCTCGTG  
 TCACCAAAATTGGTGTGGCTGCTGTGGTGCGGGGGCTGCACTGATGGCACCCTTCCCTGT  
 CTTTCATCAAGCAGCTGCCCTTCTGCCGCTCCAATATCCTTTCCCATTCCTACTGCCTACACC  
 AAGATGTCATGAAGCTGGCCTGTGATGATATCCGGGTCAATGTGCTATGGCCTTATCGT  
 CATCATCTCCGCCATTGGCCTGGACTCACTTCTCATCTCCTTCTCATATCTGCTTATTCTTA  
 30 AGACTGTGTTGGGCTTGACACGTGAAGCCAGGCCAAGGCATTTGGCACTTGGCTCTCTCA  
 TGTGTGTGCTGTGTTTCAATTTCTATGTACCTTTCATTGGATTGTCCATGGTGCATCGCTTA  
 GCAAGCGGCGTGACTCTCCGCTGCGCGTCACTTGGCCAATATCTATCTGCTGTTTCCCTCT  
 GTGCTCAACCAATTGTCTATGGAGTGAAGACAAAGGAGATTCGACAGCGCATCCTTCGA  
 CTTTTCATGTGGCCACACACGCTTCAGAGCCCTAG (SEQ ID NO: 92)

35

**AOLFR49 sequences:**

MLTFHNVCSVPSSFVLTGIPGLES�HVWLSIPFGSMYLVAVVGNVTILAVVKIERSLHQPMYFF  
 LCMLAAIDLVLSTSTIPKLLGIFWFGACDIGLDACLGQMFILHCFATVESGIFLAMAFDRYVAIC  
 NPLRHSMLVLTYTTVGRLGLVSLLRGVLYIGPLPLMIRLRLPLYKTHVISHSYCEHMAVVALTC  
 40 GDSRVNNVYGLSIGFLVLILDSVAIAASYVMIFRAVMGLATPEARLKTGTGASHLCAILIFYVP  
 IAVSSLIHRFGQCVPPPVTLLANFYLLIPPILNPVYAVRTKQIRESLLQIPRIEMKIR (SEQ ID  
 NO: 93)

ATGCTCACTTTTCATAATGTCTGCTCAGTACCCAGCTCCTTCTGGCTCACTGGCATCCCAGG  
 45 GCTGGAGTCCCTACACGTCTGGCTCTCCATCCCCTTGGCTCCATGTACCTGGTGGCTGTG  
 GTGGGGAATGTGACCATCTGGCTGTGGTAAAGATAGAACGCAGCCTGCACCAGCCCATG  
 TACTTTTCTTGTGCATGTTGGCTGCCATTGACCTGGTTCTGTCTACTTCCACTATACCCAA  
 ACTTCTGGGAATCTTCTGGTTCGGTGCTTGTGACATTGGCCTGGACGCTGCTTGGGCCAA  
 ATGTTCTTATCCACTGCTTTGCCACTGTTGAGTCAGGCATCTTCTTGGCATGGCTTTTGA  
 50 TCGCTACGTGGCCATCTGCAACCCACTACGTCATAGCATGGTGTCACTTATACAGTGGTG  
 GGTGCTTTGGGGCTGTTTCTCTCCTCCGGGGTGTCTCTACATTGGACCTTGCCTCTGAT  
 GATCCGCTGCGGCTGCCCTTTATAAAACCATGTTATCTCCACTCCTACTGTGAGCAC  
 ATGGCTGTAGTTGCCTTGACATGTGGCGACAGCAGGGTCAATAATGTCTATGGGCTGAGC  
 ATCGGCTTTCTGGTGTGATCCTGGACTCAGTGGCTATTGCTGCATCCTATGTGATGATTTT  
 55 CAGGGCCGTGATGGGGTTAGCCACTCCTGAGGCTAAGGCTTAAACCTGGGGACATGCGC  
 TTCTCACCTCTGTGCCATCCTGATCTTTTATGTTCCCATGCTGTTTCTTCCCTGATTCACCG

ATTTGGTCAGTGTGTGCCTCCTCCAGTCCACACTCTGCTGGCCAACTTCTATCTCCTCATTC  
CTCCAATCCTCAATCCCATTGTCTATGCTGTTTCGCACCAAGCAGATCCGAGAGAGCCTTCT  
CCAAATACCAAGGATAGAAATGAAGATTAGATGA (SEQ ID NO: 94)

5 **AOLFR50 sequences:**

MNLDSSFFSFLKSLIMALSNSSWRLPQPSFVLVGIPLGLESQHWIALPLGILYLLALVGNVTILFII  
WMDPSLHQSMYFLSMLAAIDLVASSTAPKALAVLLVRAQEIGYTVCLIQMFTHAFSSMES  
GVLVAMALDRYVAICHPHLLHSTILHPGVIGHIGMVVLVRGLLLIPFLILLRKLIFCQATIIGHAY  
CEHMAVVKLACSETTVNRAYGLTVALLVVGDLVLAIGVSYAHILQAVLKVPNEARLKAFST  
10 CGSHVCVILVFYIPGMFSFLTHRFGHHVPHHVHVLAILYRLVPPALNPLVYRVKTQKIHQ  
(SEQ ID NO: 95)

ATGAATTTGGATTCTTTTTTCTCTTTCTCCTCAAGTCATTGATAATGGCACTTAGCAATTC  
CAGCTGGAGGCTACCCAGCCTTCTTTTTTCTGCTAGGAATCCGGGTTTAGAGGAAAGC  
15 CAGCACTGGATCGCACTGCCCCCTGGGCATCCTTTACCTCCTTGCTCTAGTGGGCAATGTTA  
CCATTCTCTTCATCATCTGGATGGACCCATCCTTGACCAATCTATGTACCTCTTCTCTGTCC  
ATGCTAGCTGCCATCGACCTGGTTGTGGCCTCCTCCACTGCACCCAAAGCCCTTGCAGTGC  
TCCTGGTTCGTGCCCAAGAGATTGGTTACACTGTCTGCCTGATCCAGATGTTCTTACCCAT  
GCATTCTCCTCCATGGAGTCAGGGGTACTTGTGGCCATGGCTCTGGATCGCTATGTAGCCA  
20 TTTGTACCCCTTGCACCATTCCACAATCCTGCATCCAGGGGTCATAGGGCACATCGGAAT  
GGTGGTGTCTGGTGCGGGGATTACTACTCCTCATCCCCTTCTCATTCTGTTGCGAAAACCTT  
ATCTTCTGCCAAGCCACCATCATAGGCCATGCCTATTGTGAACATATGGCTGTTGTGAAAC  
TTGCCTGCTCAGAAACCACAGTCAATCGAGCTTATGGGCTGACTGTGGCCTTGTCTGTGGT  
TGGGCTGGATGTCTGGCCATTGGTGTTCCTATGCCACATTCTCCAGGCAGTGTCTGAAG  
25 GTACCAGGAAATGAGGCCCGACTTAAGGCCTTTAGCACATGTGGCTCTCATGTTTGTGTCA  
TCCTGGTCTTCTATATCCCGGAATGTTCTCCTTCTCACTCACCGCTTGGTTCATCATGTA  
CCCCATCACGTCCATGTTCTTCTGGCCATACTGTATCGCCTTGTGCCACCTGCACTCAATCC  
TCTTGTCTATAGGGTGAAGACCCAGAAGATCCACCAGTGA (SEQ ID NO: 96)

30 **AOLFR51 sequences:**

MCQQILRDCILLIHLHCINRKKVSLVMLGPAYNHTMETPASFLLVGIPLQSSHLWLAIISLSAM  
YIALLGNTHIVTAIWMDSTRHEPMYCFCLVLAADVIMASSVVPKMVSIFCSGDSISFSACFTQ  
MFFVHLATAVETGLLLTMAFDYVAICKPLHYKRILTPQVMLGMSMAITIRAIITPLSWMVS  
HLPFCGSNVVHSYCEHIALARLACADVPSSLYSLIGSSLMVGSVDVAFIAASYILKAVFGLSS  
35 KTAQLKALSTCGSHVGMALYLPGMASIYAAWLGQDVVPLHTQVLLADLYVIIPATLNPIY  
GMRTKQLRERIWSYLMHVLFHDHNLGS (SEQ ID NO: 97)

ATGTGTCAACAAATCTTACGGGATTGCATTCTTCTCATACATCATTGTGCAATTAACAGGA  
AAAAAGTCTCACTTGTGATGCTGGGTCCAGCTTATAACCACACAATGGAAACCCCTGCCTC  
40 CTTCCTCCTTGTGGGTATCCCAGGACTGCAATCTTCACATCTTTGGCTGGCTATCTCACTGA  
GTGCCATGTACATCATAGCCCTGTAGGAAACACCATCATCGTGAATCTGGATGGA  
TTCCACTCGGCATGAGCCCATGTATTGCTTTCTGTGTGTTCTGGCTGCTGTGGACATTGTTA  
TGGCCTCCTCGGTGGTACCCAAGATGGTGAGCATCTTCTGCTCAGGAGACAGCTCAATCAG  
CTTTAGTGCTTGTTCCTCACTCAGATGTTTTTGTCCACTTAGCCACAGCTGTGGAGACGGGG  
45 CTGCTGCTGACCATGGCTTTTGACCGCTATGTAGCCATCTGCAAGCCTCTACACTACAAGA  
GAATTCTCACGCCTCAAGTGATGCTGGGAATGAGTATGGCCATCACCATCAGAGCTATCAT  
AGCCATAACTCCACTGAGTTGGATGGTGAGTCATCTACCTTTCTGTGGCTCCAATGTGGTT  
GTCCACTCCTACTGTGAGCACATAGCTTTGGCCAGGTTAGCATGTGCTGACCCCGTGCCCA  
GCAGTCTCTACAGTCTGATTGGTCTCTCTTATGGTGGGCTCTGATGTGGCCTTCATTGCT  
50 GCCTCCTATATCTTAATTCTCAAGGCAGTATTTGGTCTCTCCTCAAAGACTGCTCAGTTGAA  
AGCATTAAGCACATGTGGCTCCCATGTGGGGGTTATGGCTTTGTACTATCTACCTGGGATG  
GCATCCATCTATGCGGCCTGGTTGGGGCAGGATGTAGTGCCCTTGACACCCCAAGTCCTGC  
TAGCTGACCTGTACGTGATCATCCAGCCACCTTAAATCCCATCATCTATGGCATGAGGAC  
CAAACAACCTGCGGGAGAGAATATGGAGTTATCTGATGCATGTCCTCTTTGACCATCCAAC  
55 CTGGGTTTCATGA (SEQ ID NO: 98)

**AOLFR52 sequences:**

MLGPAYNHTMETPASFLLVGIPGLQSSHLWLAISSLAMYITALLGNTLIVTAIWMDSTRHEPMY  
 CFLCVLAAVDIVMASSVVPKMVSIFCSGSSISFSACFTQMFFVHLATAVETGLLLTMAFDYV  
 AICKPLHYKRILTPQVMLGMSMAVTIRAVTFMTPLSWMMNHLPCGSNVVHSYCKHIALAR  
 5 LACADVPVSSLYSLIGSSLMVGSDFVAFIAASYILILRAVFDLSSKTAQLKALSTCGSHVGVMA  
 YLPGMASIYAAWLQDIVPLHTQVLLADLYVIIPATLNPITYGMRTKQLLEGIWSYLMHFDFH  
 SNLGS (SEQ ID NO: 99)

10 ATGCTGGGTCCAGCTTACAACCACACAATGGAAACCCCTGCCTCCTTCCTCCTGTGGGTA  
 TCCCAGGACTGCAATCTTCACATCTTTGGCTGGCTATCTCACTGAGTGCCATGTACATCAC  
 AGCCCTGTTAGGAAACACCCTCATCGTGACTGCAATCTGGATGGATTCCACTCGGCATGAG  
 CCCATGTATTGCTTTCTGTGTGTCTGGCTGCTGTGGACATTGTTATGGCCTCCTCCGTGGT  
 ACCCAAGATGGTGAGCATCTTCTGCTCGGGAGACAGCTCCATCAGCTTTAGTGCTTGTTC  
 15 ACTCAGATGTTTTTGTCCACTTAGCCACAGCTGTGGAGACGGGGCTGCTGCTGACCATG  
 CTTTGGACCGCTATGTAGCCATCTGCAAGCCTCTACACTACAAGAGAATTCTCAGCCTCA  
 AGTGATGCTGGGAATGAGTATGGCCGTCAACATCAGAGCTGTCACATTTCATGACTCCACTG  
 AGTTGGATGATGAATCATCTACCTTTCTGTGGCTCCAATGTGGTTGTCCACTCCTACTGTAA  
 GCACATAGCTTTGGCCAGGTTAGCATGTGCTGACCCGTGCCAGCAGTCTCTACAGTCTG  
 ATTGGTTCCTCTCTTATGGTGGGCTCTGATGTGGCCTTCATTGCTGCCTCCTATATCTTAAT  
 20 TCTCAGGGCAGTATTTGATCTCTCCTCAAAGACTGCTCAGTTGAAAGCATTAAAGCACATGT  
 GGCTCCCATGTGGGGGTTATGGCTTTGTACTATCTACCTGGGATGGCATCCATCTATGCGG  
 CCTGGTTGGGGCAGGATATAGTGCCCTTGACACCCAAGTGCTGCTAGCTGACCTGTACGT  
 GATCATCCCAGCCACTTTAAATCCCATCATCTATGGCATGAGGACCAACAATTGCTGGAG  
 GGAATATGGAGTTATCTGATGCACTTCCTCTTTGACCACTCCAACCTGGGTTTCATGA (SEQ  
 25 ID NO: 100)

**AOLFR54 sequences:**

MSDSNLSDNHLDPDTFFLTGIPGLEAAHFWIAIPFCAMYLVALVGNAALILVIAMDNALHAPMY  
 LFLCLSLTDLALSSTTVPKMLAILWLHAGEISFGGCLAQMFCVHSIYALESSILLAMAFDRYVA  
 30 ICNPLRYTTILNHAVIGRIGFVGLFRSVAIVSPFILLRRLPYCGHRVMTHTYCEHMGARLACA  
 NITVNIVYGLTVALLAMGLDSILIAISYGFIHAFVHLP SHDAQHKALSTCGSHIGILVFYIPAFF  
 SFLTHRFHHEVPKHVHIFLANLYVLVPPVLPILYGARTKEIRSRLKLLHLGKTSI (SEQ ID  
 NO: 101)

35 ATGTCAGATTCCAACCTCAGTGATAACCATCTTCCAGACACCTTCTTCTTAACAGGGATCC  
 CAGGGCTGGAGGCTGCCACTTCTGGATTGCCATCCCTTTCTGTGCCATGTATCTTGTAGC  
 ACTGGTTGGAATGCTGCCCTCATCTGGTCATTGCCATGGACAATGCTCTTCATGCACCT  
 ATGTACCTCTTCTCTGCTTCTCTCACTCACAGACCTGGCTCTCAGTTCTACCACTGTGCC  
 CAAGATGCTGGCCATTTTGTGGCTCCATGCTGGTGAGATTTCCTTTGGTGGATGCCTGGCC  
 40 CAGATGTTTTGTGTCCATTCTATCTATGCTCTGGAGTCTCGATTCTACTTGCCATGGCCTT  
 TGATAGGTATGTGGCTATCTGTAACCCATTAAGGTATAACAACATTCTCAACCATGCTGTC  
 ATAGGCAGAATTGGCTTTGTTGGGCTATTCCGTAGTGTGGCTATTGTCTCCCCCTTCATCTT  
 CTTGCTGAGGCGACTCCCCTACTGTGGTCACCGTGTGATGACACACATACTGTGAGCAT  
 ATGGGCATCGCCGACTGGCCTGTGCCAATCACTGTCAATATTGTCTATGGGCTAACTG  
 45 TGGCTCTGCTGGCCATGGGACTGGATTCCATTCTCATTGCCATTCTCTATGGCTTTATCCTC  
 CATGCAGTCTTTCACCTCCATCTCATGATGCCAGCACAAGCTCTGAGTACCTGTGGCT  
 CCCACATTGGCATCATCCTGGTTTTCTACATCCCTGCCTTCTTCTCCTCCTCACCACCGC  
 TTTGGTCACCACGAAGTCCCCAAGCATGTGCACATCTTCTGGCTAATCTCTATGTGCTGG  
 TGCTCCTGTACTCAATCCTATTCTCTATGGAGCTAGAACCAAGGAGATTGCGAGTCGACT  
 50 TCTAAACTGCTTCACCTGGGGAAGACTTCAATATGA (SEQ ID NO: 102)

**AOLFR57 sequences:**

MSFQVTYMFYLHWTMEKSNNSTLFILLGFSQNKNEI VLCFVLFYIAIWMGNLLIMISITCTQ  
 LIHQPMYFFLNYSLSLDCYTSTVTPKLMVDLLAERKTISYNNCMIQLFTTHFFGGIEFILTGM  
 55 AYDRYVAICKPLHYTIIMSRQKCNTHVCCCTGGFIHSASQFLLTIFVPCGPNEDHYFCDVYPL  
 KLACSNHIMIGLLVIANSGLIALVTFVLLSYVFILYTIRAYSAERRSKALATCSSHVIVVLF

APALFIYIRPVTTFSEDKVFALFYTHIAPMFNPLIYTLRNTMKNAMRKVWCCQILLKRNQLF  
(SEQ ID NO: 103)

5 ATGTCATTTTCAGGTGACTTATATGTTCTATCTACACTGGACCATGGAAAAAGCAATAATA  
GCACTTTGTTTATTCTCTTGGGGTTTTCCCAAATAAGAACATTGAAGTCCTCTGCTTTGTA  
TTATTTTTGTTTTGCTACATTGCTATTTGGATGGGAACTTACTCATAATGATTTCTATCAC  
GTGCACCCAGCTCATTACCAACCCATGTATTTCTTCCTCAATTACCTCTCACTCTCCGACC  
TTTGCTACACATCCACAGTGACCCCCAAATTAATGGTTGACTTACTGGCAGAAAGAAAGAC  
10 CATTTCCTATAATAACTGTATGATACAACTCTTTACCACCCATTTTTTTGGAGGCATAGAGA  
TCTTCATTCTCACAGGGATGGCCTATGACCGCTATGTGGCCATTGCAAGCCCCTGCACTA  
CACCATTATTATGAGCAGGCAAAAGTGTAACACAATCATCATAGTTTGTGTACTGGGGGA  
TTTATACATTCTGCCAGTCAGTTTCTCTCACCATCTTTGTACCATTTTGTGGCCCAAATGA  
GATAGATCACTACTTCTGTGATGTGTATCCTTTGCTGAAATTGGCCTGTTCTAATATACACA  
TGATAGGTCTCTTAGTCATTGCTAATTCAGGCTTAATTGCTTTGGTGACATTTGTTGTCTTG  
15 TTGTTGTCTTATGTTTTTATATTGTATACCATCAGAGCATACTCTGCAGAGAGACGCAGCA  
AAGCTCTTGCCACTTGTAGTTCTCATGTAATTGTTGTGGTCCTGTTTTTGTCTCTGCATTG  
TTCATTTACATTAGACCGGTCACAACATTCTCAGAAGATAAAGTGTTTGGCCTTTTTTATAC  
CATCATTGCTCCCATGTTCAACCCTCTCATATACACGCTGAGAAACACAGAGATGAAGAAC  
GCCATGAGGAAAGTGTGGTGTGTCAAATACTCCTGAAAAGAAATCAACTTTTCTGA (SEQ  
20 ID NO: 104)

**AOLFR58 sequences:**

MFSTTEALNNFALGCTNLLMTMIPQIDLKQIFLCPNCRLYMIPVGAFIFSLGNMQNQSFVTEF  
VLLGLSQNPVQEIFVVFVFLFVYIATVGGNMLIVVTILSSPALLVSPMYFFLGFLSFLDACFSSVI  
25 TPKMIVDSLTVTKTISFEGCMMQLFAEHFFAGVEVIVLTAMAYDRYVAICKPLHYSSIMNRRL  
CGILMGVAWTGGLLHSMIQLFTFQLPFCGPNVINHFMCIDLPLLELACTDTHIFGLMVVINS  
FICIINFSLLLVSAYAVILLSLRTHSSEGRWKALSTCGSHLAVVILFFVPCIFVYTRPPSAFSLDKMA  
AIFYIILNPLNPLIYTFRNKEVKQAMRRIWNRLMVVSEKENIKL (SEQ ID NO: 105)

30 ATGTTCTCAATGACAACAGAAGCACTCAATAATTTTGCACCTGGATGTACCAACTTGTTAA  
TGACTATGATACCACAAATTGATCTGAAGCAAATTTTCCTTTGTCCTAATTGCAGACTATA  
CATGATCCCTGTTGGAGCTTTTCATCTTTTCCTTGGGAAACATGCAAAACCAAAGCTTTGTA  
ACTGAGTTTGTCTCCTGCGGACTTTACAGAAATCCAAATGTTTCAGGAAATAGTATTTGTTG  
TATTTTTGTTTGTCTACATTGCAACTGTTGGGGGCAACATGCTAATTGTAGTAACCAATTCTC  
35 AGCAGCCCTGCTCTTCTGGTGTCTCCTATGTACTTCTTCTTGGGCTTCTGTCTTCTGGA  
TGCGTGCTTCTCATCTGTATCACCACAAAGATGATTGTAGACTCCCTCTATGTGACAAAA  
ACCATCTCTTTTGAAGGCTGCATGATGCAGCTCTTTGCTGAACACTTCTTTGCTGGGGTGG  
AGGTGATTGTCTCACAGCCATGGCCTATGATCGTTATGTGGCCATTGCAAGCCCTTGCA  
TTACTCTTCTATCATGAACAGGAGGCTCTGTGGCATTCTGATGGGGTAGCCTGGACAGGG  
40 GGCTCTTGCATTCCATGATACAAATCTTTTTACTTTCCAGCTTCCCTTTTGTGGCCCCAA  
TGTCATCAATCACTTTATGTGTGACTTGTACCCGTTACTGGAGCTTGCCTGCACTGATACTC  
ACATCTTTGGCCTCATGGTGGTCATCAACAGTGGGTTTATCTGCATCATAAACTTCTCCTTG  
TTGCTTGTCTCCTATGCTGTCTCTCTCTGAGAACACACAGTTCTGAAGGGCGCTG  
GAAAGCTCTCTCCACCTGTGGATCTCACATTGCTGTTGTGATTTTGTCTTTGTCCCATGCA  
45 TATTTGTATATACACGACCTCCATCTGCTTTTTCCCTTGACAAAATGGCGGCAATATTTTAT  
ATCATCTTAAATCCCTTGCTCAATCCTTTGATTACACTTTCAGGAATAAGGAAGTAAAC  
AGGCCATGAGGAGAATATGGAACAGACTGATGGTGGTTTCTGATGAGAAAGAAAATATTA  
AACTTTAA (SEQ ID NO: 106)

**AOLFR59 sequences:**

MGDWNNSDAVEPIFILRGFPGLLEYVHWSLSILFCLAYLVAFMGNVTILSVIWISSLHQPMYYFI  
SILAVNDLGMSTLPTMLAVLWDAPEIQASACYAQLFFIHTFTFLESSVLLAMAFDRFVAICH  
PLHYPTILTNSVIGKIGLACLLRSLGVVLPPLLLRHYHYCHGNALSHAFCLHQDVLRSLCTDA  
RTNSIYGLCVVIATLGVDISIFILLSYVLIILNTVLDIASREEQLKALNTCVSHICVVLFFVPVIGVS  
55 MVHFRFGKHLSPIVHILMADIYLLPVLNPIVYSVRTKQIRLGILHKFVLRRLF (SEQ ID NO:  
107)

WO 01/98526

5 ATGGGAGACTGGAATAACAGTGATGCTGTGGAGCCCATATTTATCCTGAGGGGTTTCTCTG  
 GACTGGAGTATGTTCACTTCTGGCTCTCCATCCTCTTCTGTCTTGCATATTTGGTAGCATT  
 ATGGGTAATGTTACCATCCTGTCTGTCAATTTGGATAGAATCCTCTCTCCATCAGCCCATGTA  
 TTACTTTATTTCCATCTTAGCAGTGAATGACCTGGGGATGTCCCTGTCTACACTTCCCACCA  
 TGCTTGCTGTGTTATGGTTGGATGCTCCAGAGATCCAGGCAAGTGCTTGCTATGCTCAGCT  
 GTTCTTCATCCACACATTCACATTCCTGGAGTCCCTCAGTGTTGCTGGCCATGGCCTTTGACC  
 GTTTTGTGCTATCTGCCATCCACTGCACTACCCACCATCCTACCAACAGTGTAATTGGC  
 10 AAAATTGGTTTGGCCTGTTTGTACGAAGCTTGGGAGTTGTACTTCCCACACCTTTGCTACT  
 GAGACACTATCACTACTGCCATGGCAATGCCCTCTCTCACGCCTTCTGTTTGCACCAGGAT  
 GTTCTAAGATTATCCTGTACAGATGCCAGGACCAACAGTATTTATGGGCTTTGTGTAGTCA  
 TTGCCACACTAGGTGTGGATTCAATCTTCTACTTCTTTCTTATGTTCTGATTCTTAATACT  
 GTGCTGGATATTGCATCTCGTGAAGAGCAGCTAAAGGCACTCAACACATGTGTATCCCAT  
 TCTGTGTGGTGCTTATCTTCTTTGTGCCAGTTATTGGGGTGTCAATGGTCCATCGCTTTGGG  
 15 AAGCATCTGTCTCCCATAGTCCACATCCTCATGGCAGACATCTACCTTCTTCTCCCCCAGT  
 CCTTAACCCTATTGTCTATAGTGTGAGAACAAGCAGATTCTAGGAATTCTCCACAAG  
 TTTGTCCTAAGGAGGAGGTTTAA (SEQ ID NO: 108)

**AOLFR60 sequences:**

20 MFLPNDTQFHPSSFLLLGIPGLETLHIWIGFPFCVYMLALIGNFTILLVIKTDSSLHQPmfYFLA  
 MLATTDVGLSTATIPKMLGIFWINLRGIIEAQLTQMFFIHNFTLMESAVLVAMAYDSYVAICN  
 PLQYSAILTNKVVSIGLVFVRALFVIPSILLILRLPFCGNHVPHTYCEHMGHLASCAIKINI  
 IYGLCAICNLVFDITVIALSYVHILCAVFRLPHEPRLKSLSTCGSHVCVILAFYTPALFSFMTHC  
 25 FGRNVPRYIHILLANLYVVVPPMLNPVIYGVRTKQIYKCVKKILLQEQGMEKEEYLIHTRF  
 (SEQ ID NO: 109)

30 ATGTTCTTCCCAATGACACCCAGTTTCACCCCTCCTCCTTCTGTTGCTGGGGATCCCAGG  
 ACTAGAAACACTTCACATCTGGATCGGCTTTCCTTCTGTGCTGTACATGATCGCACTC  
 ATAGGGAACTTCACTATTCTACTTGTGATCAAGACTGACAGCAGCTACACCAGCCCATGT  
 TCTACTTCTGGCCATGTTGGCCACCACTGATGTGGGTCTCTCAACAGCTACCATCCCTAA  
 GATGCTTGGAACTTCTGGAATCAACCTCAGAGGGATCATCTTGAAGCCTGCCTCACCCAG  
 ATGTTTTTTATCCACAACCTCACACTTATGGAGTCAGCAGTCCTTGTGGCAATGGCTTATG  
 ACAGCTATGTGGCCATCTGCAATCCAATATAAGCCATCCTACCAACAAGGTTGT  
 35 TTCTGTGATTGGTCTTGGTGTGTTTGTGAGGGCTTTAATTTTCGTCATTCCCTCTATACTC  
 GGGTCTTGCTCATCTATCTTGTGCCAGCATCAAAATCAATATTATTTATGGTTTATGTGCCA  
 TTTGTAATCTGGTGTGTTGACATCACAGTCATTGCCCTCTCTTATGTGCATATTCTTTGTGCT  
 GTTTTCCGTCCTTCTACTCATGAGCCCCGACTCAAGTCCCTCAGCACATGTGGTTACATGT  
 GTGTGTAATCCTTGCTTCTATACACCAGCCCTCTTTCTTTATGACTCATTGCTTTGGCC  
 40 GAAATGTGCCCCGCTATATCCATATACTCCTAGCCAATCTCTATGTTGTGGTGCCACCAAT  
 GCTCAATCCTGTCATATATGGAGTCAGAACAAGCAGATCTATAAATGTGTAAAGAAAAT  
 ATTATTGCAGGAACAAGGAATGGAAAAGGAAGAGTACCTAATACATACGAGGTTCTGA  
 (SEQ ID NO: 110)

**AOLFR61 sequences:**

45 MSIINTSYVEITTFVLVGMPLGLEYAHIWISIPICSMYLIAILNGTILFIKTEPSLHGPMYYFLSML  
 AMSDLGLSLSSLPTVLSIFLNPETSSSACFAQEFFIHGFSVLESSVLLMSFDRFLAIHNPLRYT  
 SILTTVRVAQIGIVFSFKSMMLVLPFPFTLRSLRYCKKNQLSHSYCLHQDVMKLACSDNRIDVIY  
 50 GFFGALCLMVDFILIAVSYTLILKTVPGIASKKEELKALNTCVSHICAVIIFYPILINLAVVHRFAG  
 HVSPLINVLMANVLLLVPPLMKPIVYCVKTKQIRVRVAKLCQWKI (SEQ ID NO: 111)

55 ATGTCCATTATCAACACATCATATGTTGAAATCACCACCTTCTTCTGTTGGGATGCCAG  
 GGCTAGAAATATGCACACATCTGGATCTCTATCCCCATCTGCAGCATGTATCTTATTGCTATT  
 CTAGGAAATGGCACCATTCTTTTATCATCAAGACAGAGCCCTCCTTGCATGGGCCCCATGT  
 ACTATTTTCTTTCCATGTTGGCTATGTCAGACTTGGGTTTGTCTTTATCATCTCTGCCCCACT  
 GTGTTAAGCATCTTCTGTTCAATGCCCTGAACTTCTTCTAGTGCCTGCTTTGCCAGGA



ATTCTTCATTCATGGATTCTCAGTACTGGAGTCCTCAGTCCTCCTGATCATGTCATTTGATA  
 GATTCTAGCCATCCACAATCCTCTGAGATACACCTCAATCCTGACAACTGTCAGAGTTGC  
 CCAAATAGGGATAGTATTCTCCTTTAAGAGCATGCTCCTGGTTCTTCCCTTCCCTTTCACTT  
 TAAGAAAGCTTGAGATATTGCAAGAAAAACCAATTATCCCATTCTACTGTCTCCACCAGGA  
 5 TGTCATGAAGTTGGCCTGTTCTGACAACAGAATTGATGTTATCTATGGCTTTTTTGGAGCA  
 CTCTGCCTTATGGTAGACTTTATTCTCATTGCTGTGTCTTACACCCTGATCCTCAAGACTGT  
 ACCGGGAATTGCATCCAAAAAGGAGGAGCTTAAGGCTCTCAATACTTGTGTTTCACACATC  
 TGTGCAGTGATCATCTTCTACCTGCCCATCATCAACCTGGCCGTTGTCCACCGCTTTGCCGG  
 GCATGTCTCTCCCCTCATTAAATGTTCTCATGGCAAATGTTCTCCTACTTGTACCTCCGCTGA  
 10 TGAAACCAATTGTTTATTGTGTAATAAATAACAGATTAGAGTGAGAGTTGTAGCAAAATT  
 GTGTCAATGGAAGATTTAA (SEQ ID NO: 112)

#### AOLFR62 sequences:

MFYHNKSIFHPVTFFLIGIPGLEDFHFWISGPFCSVYLVALLGNAITILLVIKVEQTLREPMFYFL  
 15 AILSTIDLALSATSVPRMLGIFWFDAHEINYGACVAQMFLIHAFTGMEAEVLLAMAFDRYVAIC  
 APLHYATILTSVLVGISMCIIVRPVLLTLPVYLIYRLPFCQAHIIAHSYCEHMGIAKLSCGNIRI  
 NGIYGLFVVSFFVLNLVLIGISYVYILRAVFRLPASHDAQLKALSTCGAHVGVICVFYIPSVFSFLT  
 HRFGHQIPGYIHILVANLYLIIPPSLNPIHYGVRTKQIRERVLYVFTKK (SEQ ID NO: 113)

20 ATGTTTTATCACAACAAGAGCATATTTACCCAGTCACATTTTTCTCATTGGAATCCCAGG  
 TCTGGAAGACTTCCACATGTGGATCTCCGGGCCCTTCTGCTCTGTTTACCTTGTGGCTTTGC  
 TGGGCAATGCCACCATCTGCTAGTCATCAAGGTAGAACAGACTCTCCGGGAGCCCATGTT  
 CTACTTCTGGCCATTCTTTCCACTATTGATTTGGCCCTTCTGCAACCTCTGTGCCTCGCA  
 TGCTGGGTATCTTCTGGTTGATGCTCACGAGATTAAGTATGGAGCTTGTGTGGCCAGAT  
 25 GTTCTGATCCATGCCTTCACTGGCATGGAGGCTGAGGTCTTACTGGCTATGGCTTTTGAC  
 CGTTATGTGGCCATCTGTGCTCCACTACATTACGCAACCATCTTGACATCCCTAGTGTTGGT  
 GGGCATTAGCATGTGCATTGTAATTCGTCCCGTTTTACTTACACTTCCCATGGTCTATCTTA  
 TCTACCGCTACCCTTTTGTGAGGCTCACATAATAGCCCATTCCTACTGTGAGCACATGGG  
 CATTGCAAAATTGTCTGTGGAAACATTCGTATCAATGGTATCTATGGGCTTTTTGTAGTTT  
 30 CTTCTTTGTTCTGAACCTGGTGCTCATTGGCATCTCGTATGTTTACATTCTCCGTGCTGTC  
 TTCCGCCTCCCATCACATGATGCTCAGCTAAAAGCCCTAAGCACGTGTGGCGCTCATGTTG  
 GAGTCATCTGTGTTTTCTATATCCCTTCACTCTTCTCTTTCTTACTCATCGATTTGGACAC  
 CAAATACCAGGTTACATTCACATTCTTGTGCAATCTCTATTTGATTATCCCACCTCTCT  
 CAACCCCATCATTTATGGGGTGAGGACCAACAGATTTCGAGAGCGAGTGCTCTATGTTTTT  
 35 ACTAAAAATAA (SEQ ID NO: 114)

#### AOLFR63 sequences:

MSIINTSYVEITFFLVGMPGLEAYAHWISIPICSMYLIAILGNGTILFIKTEPSLHEPMYYFLSML  
 AMSDLGLSLSSLPTVLSIFLNAPEISSNACFAQEFFIHGFSVLESSVLLIMSFDRFLAIHNPLRYTS  
 40 ILTTVRVAQIGIVFSFKSMMLVLPFPFTLRNLRYCKKNQLSHSYCLHQDVMKLACSDNRIDVIY  
 GFFGALCLMVDFILIAVSYTLILKTVLGIASKKEQLKALNTCVSHICAVIIFYLPINLAVVHRFAR  
 HVSPLINVLMANVLLLVPPLTNPIVYCVKTKQIRVRVVAKLCQRKI (SEQ ID NO: 115)

45 ATGTCCATTATCAACACATCATATGTTGAAATCACCACCTTCTTCTTGGTTGGGATGCCAG  
 GGCTAGAATATGCACACATCTGGATCTCTATCCCCATCTGCAGCATGTATCTTATTGCTATT  
 CTAGGAAATGGCACCATTTCTTTTATCATCAAGACAGAGCCCTCCTTGCATGAGCCCATGT  
 ACTATTTTCTTTCCATGTTGGCTATGTCAGACTTGGGTTTGTCTTTATCATCTCTGCCCACT  
 GTGTTAAGCATCTTCTGTTCAATGCTCCTGAAATTTATCCAATGCCTGCTTTGCCAGGA  
 50 ATTCTTCATTCATGGATTCTCAGTACTGGAGTCCTCAGTCCTCCTGATCATGTCATTTGATA  
 GATTCTAGCCATCCACAACCCTCTGAGATACACCTCAATCCTGACAACTGTCAGAGTTGC  
 CCAAATAGGGATAGTATTCTCCTTTAAGAGCATGCTCCTGGTTCTTCCCTTCCCTTTCACTT  
 TAAGAACTTGAGATATTGCAAGAAAAACCAATTATCCCATTCTACTGTCTCCACCAGGA  
 TGTCATGAAGTTGGCCTGTTCTGACAACAGAATTGATGTTATCTATGGCTTTTTTGGAGCA  
 CTCTGCCTTATGGTAGACTTTATTCTCATTGCTGTGTCTTACACCCTGATCCTCAAGACTGT  
 55 ACTGGGAATTGCATCCAAAAAGGAGCAGCTTAAGGCTCTCAATACTTGTGTTTCACACATC  
 TGTGCAGTGATCATCTTCTACCTGCCCATCATCAACCTGGCCGTTGTCCACCGCTTTGCCCG

GCATGTCTCTCCCCTCATTAATGTTCTCATGGCAAATGTTCTCCTACTTGTACCTCCACTGA  
CGAACCCAATTGTTTATTGTGTAAAACTAAACAGATTAGAGTGAGAGTTGTAGCAAAAT  
GTGTCAACGGAAGATTAA (SEQ ID NO: 116)

5 AOLFR64 sequences:

MTILLNSSLQRATFFLTGFQGLEGLHGWISIPFCFIYLTVILGNLTILHVICTDATLHGPMYYFLG  
MLAVTDLGLCLSTLPTVLGFWFDTREIGIPACFTQLFFIHTLSSMESSVLLSMSIDRSVAVCNPL  
HDSTVLTACIVKMGSSVLRSAALLPLPFLLRKFQYCHSHVLAHAYCLHLEIMKLACSSHVN  
HIYGLFVVACTVGVDSLIFLSYALILRTVLSIASHQERLRALNTCVSHICAVLLFYIPMIGLSLV  
10 HRFGEHLPRVHFLFMSYVYLLVPPLMNPPIYSIKTKQIRQRIKKFQFIKSLRCFWKD (SEQ ID  
NO: 117)

ATGACAATTCTTCTTAATAGCAGCCTCCAAAGAGCCACTTTCTTCTGACGGGCTTCCAAG  
GTCTAGAAGGTCTCCATGGCTGGATCTCTATTCCCTTCTGCTTCATCTACCTGACAGTTATC  
15 TTGGGGAACCTCACCATTCTCCACGTCATTTGACTGATGCCACTCTCCATGGACCCATGT  
ACTATTTCTTGGGCATGCTAGCTGTACAGACTTAGGCCTTTGCCTTTCCACACTGCCACT  
GTGCTGGGCATTTTCTGGTTTGATACAGAGAGATTGGCATCCCTGCCTGTTTCACTCAGC  
TCTTCTTCATCCACACCTTGTCTTCAATGGAGTCATCAGTTCTGTTATCCATGTCCATTGAC  
CGCTCCGTGGCCGTCTGCAACCCACTGCATGACTCCACCGTCTGACACCTGCATGTATTG  
20 TCAAGATGGGGCTAAGCTCAGTGCTTAGAAGTGCTCTCTCATCCTCCCTTGGCATTCTC  
CTGAAGCGCTTCCAATACTGCCACTCCCATGTGCTGGCTCATGCTTATTGTCTTCACTGGA  
GATCATGAAGCTGGCCTGCTCTAGCATCATTGTCAATCACATCTATGGGCTCTTTGTGTG  
GCCTGCACCGTGGGTGTGGACTCCCTGCTCATCTTTCTCTACAGCCCTCATCCTTCGCAC  
CGTGCTCAGCATTGCCTCCCACAGGAGCGACTCCGAGCCCTCAACACCTGTGTCTCTCAT  
25 ATCTGTGCTGACTGCTCTTCTACATCCCCATGATTGGCTGTCTTGTGCATCGCTTTGG  
TGAACATCTGCCCCGCTGTGTACACCTCTTCATGTCCTATGTGTATCTGCTGGTACCACCC  
TTATGAACCCCATCATCTACAGCATCAAGACCAAGCAAATTCGCCAGCGCATCATTAAAGAA  
GTTTCAGTTTATAAAGTCACTTAGGTGTTTTTGAAGGATTAA (SEQ ID NO: 118)

30 AOLFR65 sequences:

MAGRMSTSNHTQFHPSSFLLLGPGLDVIHWIGVPFFVYLVALLGNTALLFVIQTEQSLHEPM  
YYFLAMLDSIDLGLSTATIPKMLGIFWFNTKEISFGGCLSHMFFIHFFTAMESIVLVAMAFDRI  
AICKPLRYTMILTSKISLAGIAVLRSLYMVVPLVFLLLRPLFCGHRIIPHTYCEHMGARLACAS  
IKVNIRFGLGNISLLLDVILIISYVRILYAVFCLPSWEARLKALNTCGSHIGVILAFFTPAFFSFL  
35 THREGHNIPQYIHILANLYVVVPPALNPVIYGVRTKQIRERVLRIFLKTNH (SEQ ID NO: 119)

ATGGCAGGAAGAATGTCTACGTCTAATCACACCCAGTTCCATCCTTCTTCATTCTACTGCT  
GGGTATCCCAGGGCTAGAAGATGTGCACATTTGGATTGGAGTCCCTTTTCTTTGTGTAT  
CTTGTTGCACTCCTGGGAAACACTGCTCTCTGTTTGTGATCCAGACTGAGCAGAGTCTCC  
40 ATGAGCCTATGTACTACTTCTGGCCATGTTGGATTCCATTGACCTGGGCTGTCTACAGC  
CACCATCCCCAAAATGTTGGGCATCTTCTGTTCAATACCAAAGAAATATCTTTGGAGGC  
TGCCCTTCTCACATGTTCTTCAATCTTCACTGCTATGGAGAGCATTGTGTTGGTGGC  
CATGGCCTTTGACCGCTACATTGCCATTGCAAACCTCTTCGGTACACCATGATCCTCACCA  
GCAAATCATCAGCCTCATTGCAGGCATTGCTGTCTGAGGAGCCTGTACATGGTTGTTC  
45 ACTGGTGTCTCTCTGAGGCTGCCCTTCTGTGGGCATCGTATCATCCCTCATACTATT  
GTGAGCATGGGCATTGCCCCTGTGGCAGCATCAAAGTCAACATTAGGTTTGG  
CCTTGGCAACATATCTCTTGTACTGGATGTTATCCTTATTCTCTCTATGTGAGGA  
TCCTGTATGCTGTCTTCTGCTGCCCTCCTGGGAAGCTCGACTCAAAGCTCTCAACACCTGT  
GGTTCTCATATTGGTGTATCTTAGCCTTTTTACACCAGCATTCTTCTGACACA  
50 TCGTTTTGGCCATAATATCCACAGTATATACATATTATAGCCAACCTGTATGTGGTTG  
TCCACACGCTCAATCCTGTAATCTATGGAGTCAGGACAAAGCAGATTTCGAGAGAGAG  
TGCTGAGGATTTTTCTCAAGACCAATCACTAA (SEQ ID NO: 120)

AOLFR66 sequences:

55 MSFLNGTSLTPASFILNGIPLEDVHLWISFPLCTMYSIAITGNFGLMYLIYCDEALHRPMYVFL  
ALLSFTDVLMCTSTLPNTLFILWFNLKEIDFKACLAQMFFVHTFTGMESGVMLMLMALDHCVAI



CFPLRYATILTNSVIAKAGFLTFLRGVMLVIPSTFLTKRLPYCKGNVIPHTYCDHMSVAKISCGN  
VRVNAIYGLIVALLIGGFILCITISYTMILQAVVSLSSADARQKAFSTCTAHFCAIVLTYVPAFF  
TFFTHHFGGHTIPLHIHIMANLYLLMPPTMNPVYGVKTRQVRESVIRFFLKGDNSHNF (SEQ  
ID NO: 121)

5

ATGTCATTCTCTAAATGGCACCAGCCTAACTCCAGCTTCATTCATCCTAAATGGCATCCCTG  
GTTTGGAAGATGTGCATTGTGGATCTCCTTCCCACTGTGTACCATGTACAGCATTGCTATT  
ACAGGGAACCTTCGGCCTTATGTACCTCATCTACTGTGATGAGGCCTTACACAGACCTATGT  
ATGCTCTCCTTGCCCTTCTTTCTTCACAGATGTGCTCATGTGCACCAGCACCTTCCCAAC  
10 ACTCTCTTCATATTGTGGTTAATCTCAAGGAGATTGATTTTAAAGCCTGCCTCGCCCAGAT  
GTTCTTTGTGCACACCTTCACAGGGATGGAGTCTGGGGTGCTCATGCTCATGGCCCTGGAC  
CACTGTGTGGCCATCTGCTTCCCTCTGCGTTATGCCACCATCCTCACTAATTCAGTCATTGC  
TAAAGCTGGGTTCTCACTTTTCTTAGGGGTGTGATGCTTGTTATCCCTTCCACTTTCTCA  
CCAAGCGCCTTCCATACTGCAAGGGCAACGTCATACCCACACCTACTGTGACCACATGTC  
15 TGTGGCCAAGATATCTTGTGGTAATGTGAGGGTTAACGCCATCTATGGTTTGATAGTTGCC  
CTGCTGATTGGGGGCTTTGATATCCTGTGCATTACAATCTCCTACACTATGATTCTTCAAGC  
AGTTGTGAGTCTATCATCAGCAGATGCTCGACAGAAGGCCTTCAGCACCTGCACTGCCCAC  
TTCTGTGCCATAGTCTCACCTATGTTCCAGCCTTCTTTACCTTCTTTACACACCATTTTGG  
GGGACACACCATTCCTCTACACATACATATTATTATGGCTAATCTCTACCTACTAATGCCTC  
20 CCACAATGAACCCTATTGTGTATGGGGTGAACCAGGCAGGTACGAGAAAGTGTCTATTA  
GGTTCTTTCTTAAGGGAAAGGACAATTCTCATAACTTTTAA (SEQ ID NO: 122)

#### AOLFR67 sequences:

MSGDNSSSLTPGFFILNGVPGLEATHIWISLPFCFMYIIAVVGNCGLICLSHEEALHRPMYYFLA  
25 LLSFTDVTLCCTMVPMMLCWFNLKEIDFNACLAQMFFVHMLTGMESGVMLMLALDRYVAI  
CYPLRYATILTNPVIAKAGLATFLRNVMLIIPFTLLTKRLPYCRGNFIPHTYCDHMSVAKVSCGN  
FKVNAIYGLMVALLIGVFDICISVSYTMILQAVMSLSSADARHKAFTSTSHMCSIVITYVAAF  
FTFFTHRFVGHNPNIHIIIVANLYLLPPTMNPVYGVKTKQIQEGVIKFLGDKVVSFTYDK  
(SEQ ID NO: 123)

30

ATGTCTGGGGACAACAGCTCCAGCCTGACCCAGGATTCTTTATCTTGAATGGCGTTCCTG  
GGCTGGAAGCCACACACATCTGGATCTCCCTGCCATTCTGCTTTATGTACATCATTGCTGTC  
GTGGGGAACCTGTGGGCTCATCTGCCTCATCAGCCATGAGGAGGCCCTGCACCGGCCCATGT  
ACTACTTCCCTGGCCCTGCTCTCCTTCACTGATGTACCTTGTGCACCACCATGGTACCTAAT  
35 ATGCTGTGCATATTCTGGTTCAACCTCAAGGAGATTGACTTTAACGCCTGCCTGGCCCAGA  
TGTTTTTTGTCCATATGCTGACAGGGATGGAGTCTGGGGTGCTCATGCTCATGGCCCTGGA  
CCGCTATGTGGCCATCTGCTACCCCTTACGCTATGCCACCATCCTTACCAACCCTGTCATCG  
CCAAGGCTGGTCTTGCCACCTTCTTGAGGAATGTGATGCTCATCATCCCATTCCTCTCCTC  
ACCAAGCGCCTGCCCTATTGCCGGGGGAACCTTCATCCCCACACCTACTGTGACCATATGT  
40 CTGTGGCCAAGGTATCCTGTGGCAATTTCAAGGTCAATGCTATTTATGGTCTGATGGTTGC  
TCTCCTGATTGGTGTGTTTGATATCTGCTGTATCTCTGTATCTTACACTATGATTTTGCAGG  
CTGTTATGAGCCTGTCATCAGCAGATGCTCGTCACAAAGCCTTCAGCACCTGCACATCTCA  
CATGTGTTCCATTGTGATCACCTATGTTGCTGCTTTTTTCACTTTTTTCACTCATCGTTTTGT  
AGGACACAATATCCCAAACCATACACATCATCGTGGCCAACCTTTATCTGCTACTGCCT  
45 CCTACCATGAACCCAATTGTTTATGGAGTCAAGACCAAGCAGATTACAGGAAGGTGTAATTA  
AATTTTACTTGGAGACAAGGTTAGTTTTACCTATGACAAATGA (SEQ ID NO: 124)

#### AOLFR68 sequences:

MTTHRNDTLSTEASDFLLNCFVRSPSWQHWLSLPLSLFLAVGANTLLMTTWLEASLHQPL  
50 YYLLSLLSLDIVLCLTVIPKVLTFWFDLRPISFPACFLQMYIMNCFAMESCTFMVMA YDRY  
VAICHPLRYPSIITDHFVVKAAAMFILTRNVLMTLPIPLSAQLRYCGRNVIENCICANMSVRLSC  
DDVTINHL YQFAGGWTLGSDLILFLSYFILRAVLRKAEGAVAKALSTCGSHFMLILFFSTIL  
LVFVLTHVAKKVS PDVPVLLNVLHHVIPAALNPIHYGVRTQEIKQGMQRLLKKGK (SEQ ID  
NO: 125)

55

5 ATGACAACACACCGAAATGACACCCTCTCCACTGAAGCTTCAGACTTCTCTTGAATTGTT  
 TTGTCAGATCCCCAGCTGGCAGCACTGGCTGTCCCTGCCCCCAGCCTCCTTTCTCTTG  
 GCCGTAGGGGCCAACACCACCTCTGATGACCATCTGGCTGGAGGCCTCTCTGCACCAGC  
 CCCTGTACTACCTGCTCAGCCTCCTCTCCCTGCTGGACATCGTGCTCTGCCTCACTGTCATC  
 10 CCCAAGGTCCTGACCATCTTCTGGTTTGACCTCAGGCCCATCAGCTTCCCTGCCTGCTTCT  
 CCAGATGTACATCATGAATTGTTCTAGCCATGGAGTCTTGCACATTCATGGTCATGGCC  
 TATGATCGTTATGTAGCCATCTGCCACCACTGAGATATCCATCAATCATCACTGATCACTT  
 TGATGCAAGGCTGCCATGTTTATTTTGACCAGAAATGTGCTTATGACTCTGCCCATCCCC  
 ATCCTTTCAGCACAACTCCGTTATTGTGGAAGAAATGTCATTGAGAAGTGCATCTGTGCCA  
 15 ATATGTCTGTTTCCAGACTCTCCTGCGATGATGTCACCATCAATCACCTTTACCAATTTGCT  
 GGAGGCTGGACTCTGCTAGGATCTGACCTCATCCTTATCTTCTCTCTACACCTTCATTCT  
 GCGAGCTGTGCTGAGACTCAAGGCAGAGGGTGCCGTGGCAAAGGCCCTAAGCACATGTGG  
 CTCCCACTTCATGCTCATCCTCTTCTCAGCACCATCCTTCTGGTTTTTGTCTCACACATGT  
 GGCTAAGAAGAAAGTCTCCCTGATGTGCCAGTCTTGCTCAATGTTCTCCACCATGTCATT  
 20 CCTGCAGCCCTTAACCCCATCATTTACGGGTGAGAACCAAGAAATTAAGCAGGGAATG  
 CAGAGGTTGTTGAAGAAAGGGTGCTAA (SEQ ID NO: 126)

# **AOLFR69 sequences:**

20 MSYSIYKSTVNIPLSHGTVHSFCHNMNCNFMHIFKVLDFNMKNVTEVTLFVLKGFTDNLELQ  
 TIFFFLFLAIYLFITLMGNLGLILVVIRDSQLHKPMYYFLSMLSSVDACYSSVITPNMLVDFTTKN  
 KVISFLGCVAVFLACSFGTTECFLLAAMAYDRYVAIYNPLLYSVMSPRVYVPLINASYVAGI  
 LHATHTVATFSLFCGANEIRRVFCPIPLLAISYSDHTNQLLLFYFVGSIELVTILVLISYGLIL  
 LAILKMYSAEGRRKVFTSCGAHLTGVSIIYGTILFMYVRPSSSYASDHDIMVIFYTIVIPLLNPV  
 25 IYSLRNKDVKDSMKMFGKNQVINKVYFHTTK (SEQ ID NO: 127)

30 ATGTCGTACAGTATATACAAGAGCACAGTTAACATCCCCTTGAGTCATGGTGTTGTTTCATT  
 CTTTTGTGCATAATATGAACTGTAACCTTATGCATATCTTCAAGTTTGTCTAGATTTCAAC  
 ATGAAGAATGTCAGTGAAGTTACCTTATTTGTACTGAAGGGCTTCACAGACAATCTTGAAC  
 TGCAGACTATCTTCTTCTCCTGTTTCTAGCAATCTACCTCTTCACTCTCATGGGAAATTA  
 35 GGACTGATTTTAGTGGTCAATTAGGGATCCCAGCTCCACAAACCATGTAATTTTCTGA  
 GTATGTTGTCTTCTGTGGATGCCTGCTATTCTCAGTATTACCCCAAATATGTTAGTAGAT  
 TTTACGACAAAGAATAAAGTCATTTCACTTCTGATGTGTAGCACAGGTGTTTCTTGCTT  
 GTAGTTTTGGAACACAGAATGCTTCTTCTTGGCTGCAATGGCTTATGATCGCTATGTAGC  
 CATCTACAACCTCTCCTGTATTGAGTGCATGTCACCCAGAGTCTACATGCCACTCATC  
 40 AATGCTTCTATGTTGCTGGCATTATACATGCTACTATACATACAGTGGCTACATTAGCCT  
 ATCCTTCTGTGGAGCCAATGAAATTAGGCGTGTCTTTGTGATATCCCTCCTCTCCTTGCTA  
 TTTCTTATTCTGACACTCACACAAACAGCTTCTACTCTTCTACTTTGTGGGCTCTATCGAG  
 CTGGTCACTATCCTGATTGTTCTGATCTCCTATGGTTTGATTCTGTTGGCCATTCTGAAGAT  
 GTATTCTGCTGAAGGGAGGAGAAAGTCTTCTCCACATGTGGAGCTCACCTAAGTGGAGT  
 45 GTCAATTTATTATGGGACAATCCTCTTATGTATGTGAGACCAAGTCCAGCTATGCTTCG  
 GACCATGACATGATAGTGTCAATTTTACACCATGTGATTCCCTTGCTGAATCCCGTCAT  
 CTACAGTTTGAGGAACAAAGATGTAAAGACTCAATGAAAAAATGTTTGGGAAAAATCA  
 GGTATCAATAAAGTATATTTTCACTAAAAAATAA (SEQ ID NO: 128)

# **AOLFR70 sequences:**

50 MDSTFTGYNLNLQVKTEMDKLSSGLDIYRNPLKNKTEVTMFILTGFTDDFELQVFLFLFFAI  
 YLFTLIGNLGLVVLVIEDSWLHNPMMYYFLSVLSFLDACYSTVVTPKMLVNFLAKNKSISFIGCA  
 TQMLLFVTFGTTECFLLAAMAYDHYVAIYNPLLYSVMSPRVYVPLITASVYAGILHATHIVA  
 TFSLSFCGSNEIRHVFCMPPLAISCSHTNQLLLFYFVGSIEIVTILVLISCFILLSILKMHS  
 55 KGRQKAFSTCGSHLTGVTHGTLVSYMRPSSSYASDHDIIVSIFYTIVIPKLNPIIYSLRNKEVK  
 KAVKKMLKLVYK (SEQ ID NO: 129)

55 ATGGACTCCACTTTCACAGGCTATAACCTTTATAACCTGCAAGTAAAACTGAAATGGACA  
 AGTTGTGTCAGGTTTGGATATATACAGGAATCCACTGAAGAACAAGACTGAAGTCACCA  
 TGTATATATTGACAGGCTTCACAGATGATTTTGTGCTGCAAGTCTTCTATTTTACTATTT  
 TTTGCAATCTATCTTTACCTTGATAGGCAATTTAGGGCTGGTTGTGTTGGTCATTGAGG

ATTCCTGGCTCCACAACCCCATGTATTATTTTCTTAGTGTTTTATCATTCTTGGATGCTTGC  
 TATTCTACAGTTGTCACTCCAAAAATGTTGGTCAATTTCTGGCAAAAAATAAATCCATTT  
 CATTTATCGGATGTGCAACACAGATGCTTCTTTTTGTTACTTTTGGAACACAGAATGTTTT  
 CTCTTGGCTGCAATGGCTTATGATCACTATGTAGCCATCTACAACCTCTCCTGTATTCACT  
 5 GAGCATGTCAACCCAGAGTCTATGTGCCACTCATCACTGCTTCCTACGTTGCTGGCATTTTAC  
 ATGCTACTATACATATAGTGGCTACATTTAGCCTGTCTTCTGTGGATCCAATGAAATTAG  
 GCATGCTTTTTGTGATATGCCTCCTCTCCTTGCTATTTCTTGTCTGACACTCACACAAACC  
 AGCTTCTACTCTTCTACTTTGTGGGTTCTATTGAGATAGTCACTATCCTGATTGTCCTCATT  
 TCCTGTGATTTTCACTTCTGTTGTCCATTCTGAAGATGCATTCTGCTAAGGGAAGGCAAAAGG  
 10 CCTTCTCTACATGTGGCTCTCACCTAACTGGAGTGACAATTTATCATGGAACAATTCTCGTC  
 AGTTATATGAGACCAAGTTCAGCTATGCTTCAGACCATGACATCATAGTGTCAATATTTT  
 ACACAATTGTGATTCCCAAGTTGAATCCCATCATCTATAGTTTGAGGAACAAAGAAGTAAA  
 AAAGGCAGTGAAGAAAATGTTGAAATTGGTTTACAAATGA (SEQ ID NO: 130)

15 **AOLFR71 sequences:**

MGRNNTNVPDFILTGLSDSEEVQMALFILLLIYLITMLGNVGMILHRLDLQLHTPMYFFLTH  
 LSFIDLSYSTVITPKTLANLLTSNYISFMGCFQMFVFLGAAECFLSSMAYDRYVAICSPRLY  
 PVIMSKRLCCALVTGPYVISFINSFVNVMWSRLHFCDSNVVRHFFCDTSPILALSCMDTYDIEI  
 MIHILAGSTLMVSLITISASYVSILSTILKINSTSGKQKALSTCASHLLGVTFYGTMIFTYLPKPK  
 20 SYSLGRDQVASVFYTIVIPMLNPLIYSLRNKEVKNALIRVMQRRQDSR (SEQ ID NO: 131)

ATGGGTAGAAGAAATAACACAAATGTGCCTGACTTCATCCTTACGGGACTGTCAGATTCTG  
 AAGAGGTCCAGATGGCCCTCTTTATACTATTTCTCCTGATATACCTAATTACTATGCTGGGC  
 AATGTGGGGATGATATTGATAATCCGCCTGGACCTCCAGCTTCACACTCCCATTGATTTTT  
 25 TCCTTACTCACTTGTCACTTTATTGACCTCAGTTACTCAACTGTCATCACACCTAAAACCTTA  
 GCGAAGTTACTGACTTCCAATACTATTTCTTCTGCTGGGCTGCTTTGCCAGATGTTCTTTTT  
 TGTCTTCTTGGGAGCTGCTGAATGTTTTCTTCTCTCATCAATGGCCTATGATGCTACGTAG  
 CTATCTGCAGTCTCTACGTTACCCAGTTATTATGTCCAAAAGGCTGTGTTGCGCTCTTGTC  
 ACTGGGCCCCTATGTGATTAGCTTTATCAACTCCTTTGTCAATGTGGTTTGGATGAGCAGAC  
 30 TGCATTTCTGCGACTCAAATGTAGTTCGTCACCTTTTCTGCGACACGTCTCCAATTTTAGCT  
 CTGTCTGTCATGGACACATACGACATTGAAATCATGATACACATTTTAGCTGGTTCCACCC  
 TGATGGTGTCCCTTATCACAATATCTGCATCCTATGTGTCCATTCTCTTACCATCTGAAA  
 ATTAATTCACCTTCAGGAAAGCAGAAAGCTTTGTCTACTTGTGCCTCTCATCTCTTGGGAG  
 TCACCATCTTTTATGGAAGTATGATTTTTACTTATTTAAAACCAAGAAAGTCTTATTCTTTG  
 35 GGAAGGGATCAAGTGGCTTCTGTTTTTATACTATTGTGATTCCCATGCTGAATCCACTCAT  
 TTATAGTCTTAGAAACAAAGAAGTTAAAAATGCTCTCATTAGAGTCATGCAGAGAAGACA  
 GGACTCCAGGTAA (SEQ ID NO: 132)

**AOLFR72 sequences:**

40 MAPENFTRVTEFILTVSSPELQIPLFLVFLVLYGLTMAGNLGIITLTSVDSRLQTPMYFFLQHL  
 ALINLGNSTVIAPKMLINFLVKKKTSFYECATQLGGFLFFIVSEVIMLALMACDRYVAICNPLL  
 YMVVSRRLCLLLVSLTYLYGFSTAIVVSSYVFSVSYCSSNIINHFCNDVPLLALSCSDTYLPE  
 TVVFISAATNVVGSLLIIVLSYFNIVLSILKICSSEGRKKAFTSCASHMMAVTIFYGTLLFMYVQP  
 RSNHSLDTDDKMASVFYTLVIPMLNPLIYSLRNKDVKTALQRFMTNLCYSFKTM (SEQ ID NO:  
 45 133)

ATGGCTCCTGAAAATTTACACAGGGTCACTGAGTTTATTCTTACAGGTGTCTCTAGCTGTC  
 CAGAGCTCCAGATCCCCCTCTTCTGGTCTTTCTGGTGCTCTATGGGCTGACCATGGCAGG  
 GAACCTGGGCATCATCACCTCACCAGTGTTGACTCTCGACTTCAAACCCCATGTACTTTT  
 50 TCCTGCAACATCTGGCTCTCATTAATCTTGGTAACTCTACTGTCAATGCCCTAAAATGCTG  
 ATTAACTTTTAGTAAAGAAGAAAACCTCATTCTATGAATGTGCCACCAACTGGGAG  
 GGTCTTGTCTTTATTGTATCGGAGGTAATCATGCTGGCTTTGATGGCCTGTGACCGCTAT  
 GTGGCTATTTGTAACCTCTGCTGTACATGGTGGTGGTGTCTCGGCGGCTCTGCCTCCTGCT  
 GGTCTCCCTCACATACCTCTATGGCTTTTCTACAGCTATTGTGGTTTCATCTTATGTATTCT  
 55 CTGTGTCTTATTGCTCTTCTAATATAATCAATCATTTTTACTGTGATAATGTTCTCTGTTA  
 GCATTATCTTGCTCTGATACTTACTTACCAGAAACAGTTGTCTTTATATCTGCAGCAACAA

WO 01/98526

ATGTGGTTGGTTCCTTGATTATAGTTCTAGTATCTTATTTCAATATTGTTTTGTCTATTTTA  
 AAAATATGTTTCATCAGAAGGAAGGAAAAAGCCTTTTCTACCTGTGCTTCACATATGATGG  
 CAGTCACAAATTTTTATGGGACATTGCTATTCATGTATGTGCAGCCCCGAAGTAACCATC  
 ATTGGATACTGATGATAAGATGGCTTCTGTGTTTTACACGTTGGTAATTCCTATGCTGAAT  
 5 CCCTTGATCTACAGCCTGAGGAATAAGGATGTGAAGACTGCTCTACAGAGATTCATGACA  
 AATCTGTGCTATTCCTTTAAACAATGTAA (SEQ ID NO: 134)

**AOLFR73 sequences:**

MNHVVKHNHTAVTKVTEFILMGITDNPGLQAPLFGFLIILYLVTVIGNLGMVILTYLDSKLHTP  
 10 MYFFLRHLSITDLGYSTVIAPKMLVNFIVHKNTISYNWYATQLAFFEIFIHSELFILSAMAYDRYV  
 AICKPLLYVHMAEKVLWVLVVPYLYSTFVSLFTIKLFLKSFCGSNIISYFYCDCIPLMSILCSDT  
 NELELILIFSGCNLLFSLIVLISYMFILVAILRMNSRKGRYKAFSTCSSHLTVVIMFYGTLLFIYL  
 QPKSSHTLAIDKMASVFYTLIPMLNPLIYSLRNKEVKDALKRTLNRFKIPI (SEQ ID NO: 135)

15 ATGAATCATGTGGTAAAAACACAATCACACGGCAGTGACCAAGGTGACTGAATTTATTCTCA  
 TGGGGATTACAGACAACCCTGGGCTGCAGGCTCCACTGTTGGACTCTTCCTCATCATATA  
 TCTGGTCACAGTGATAGGCAATCTGGGCATGGTTATCTTGACCTACTTGGACTCCAAGCTA  
 CACACCCCATGTACTTTTCTTAGACATTGTCAATCACTGATCTTGGTACTCCACTGT  
 CATTGCCCCGAAGATGTTAGTAACTTCATAGTGCACAAAAACACAATTTCTTACAATTGG  
 20 TATGCCACTCAGCTAGCAATCTTGGAGATTTTCATCATCTCTGAGCTCTTATTCTATCAGC  
 AATGGCCTATGATCGCTACGTAGCCATCTGTAAACCTCTTCTGTACGTGATCATCATGGCA  
 GAGAAAGTACTTTGGGTGCTGGTAATTGTTCCCTATCTCTATAGCAGTTTGTGTCACTATT  
 TCTCACAATTAAGTTATTTAACTGTCCTTCTGTGGCTCAAACATAATCAGCTATTTTACT  
 GTGACTGTATCCCTCTGATGTCCATACTCTGTTCTGACACAAATGAATAGAATTAATAAT  
 25 TTTGATCTTCTCAGGCTGTAATTTGCTCTTCTCCCTCTCAATTGTTCTCATATCCTACATGTT  
 TATTCTAGTGGCCATTCTCAGAATGAATCAAGGAAAGGGAGGTACAAAGCCTTCTCCACC  
 TGTAAGTCTCATCTGACAGTGGTGATCATGTTCTATGGGACATTGTTATTTATTTACTTGCA  
 ACCCAAGTCCAGTCATACTTTGGCTATTGATAAAATGGCCTCAGTGTTTTATACCCTGTG  
 ATTCCTATGCTGAATCCGTTGATCTACAGCCTAAGGAACAAAGAAGTAAAGATGCTCTAA  
 30 AGAGAACTTTAACCAATCGATTCAAAATTCCCATTTAA (SEQ ID NO: 136)

**AOLFR74 sequences:**

MEQHNLTTVNEFILTGITDIAELQAPLFAFLMIYVISVMGNLGMIVLTKLDSRLQTPMYFFLRH  
 35 LAFMDLGYSTTVGPKMLVNFVVDKNIISYFCAATQLAFFLVFIGSELFILSAMSYDLYVAICNPL  
 LYTVIMSRRCQVLVAIPYLYCTFISLLVTIKIFTLSFCGYNVISHFYCDLPLPLLCNTHIELI  
 ILIFAAIDLISLLIVLLSYLLILVAILRMNSAGRQKAFSTCGAHLTVVIVFYGTLLFMVYQPKSSH  
 SFDTDKVASIFYTLVIPMLNPLIYSLRNKDVKYALRRTWNNLCNIFV (SEQ ID NO: 137)

40 ATGGAACAACACAATCTAACAACGGTGAATGAATTCATTCTTACGGGAATCACAGATATC  
 GCTGAGCTGCAGGCACCATTTATTTGCATTGTTCCCTCATGATCTATGTGATCTCAGTGATGG  
 GCAATTTGGGCATGATTGTCCTCACCAAGTTGGACTCCAGGTGCAAACCCCTATGTACTT  
 TTTTCTCAGACATCTGGCTTTCATGGATCTTGGTTATTCAACAACGTGGGACCCCAAAATG  
 TTAGTAAATTTGTTGTGGATAAGAATATAATTTCTTATTATTTTGTGCAACACAGCTAGC  
 45 TTTCTTTCTTGTGTTCAATTGGTAGTGAATTTTATTCTCTCAGCCATGTCCTACGACCTCT  
 ATGTGGCCATCTGTAACCTCTGCTATACACAGTAATCATGTGCACGAAGGGTATGTCAGGT  
 GCTGGTAGCAATCCCTTACCTCTATTGCACATTCATTTCTTCTAGTCACCATAAAGATT  
 TTACTTTATCCCTTCTGTGGCTACAACGTCATTAGTCATTTCTACTGTGACAGTCTCCCTTG  
 TGATTTGATTTTCTCTCTGATAGTTCTTTTATCTTACCTGCTCATCCTGTAGCCATTCT  
 50 CAGGATGAATTTCTGCTGGCAGACAAAAGGCTTTTCTACCTGTGGAGCCCAAGTCCAGTCATTCTT  
 GTCATAGTGTCTATGGGACTTTGCTTTTTCATGTACGTGCAGCCCAAGTCCAGTCATTCTT  
 TGACACTGATAAAGTGGCTTCCATATTTACACCTGGTTATCCCCATGTTGAATCCCTTGA  
 TCTATAGTTTACGAAACAAAGATGTAAATATGCCCTACGAAGGACATGGAATAACTTATG  
 55 TAATATTTTGTTTAA (SEQ ID NO: 138)

**AOLFR75 sequences:**

MEGKNQTNISEFLLLGFSWQQQVLLFALFLCLYLTLGLFGNLLILLAIGSDHCLHTPMYFFLA  
 NLSLVDLCLPSATVPKMLLNIQTQTISYPGCLAQMYFCMMFANMDNFLLTVMAYDRYVAI  
 CHPLHYSTIMALRLCASLVAAPWVIAILNPLHLTMMAHLHFCSDNVIIHFFCDINSLPLSCSD  
 5 TSLNQLSVLATVGLIFVVPVCILVSYLIVSAVMKVPSAQGKLKAFSTCGSHLALVILFYGANT  
 GVYMSPLSNHSTEKDSAASVIFMVVAPVLNPFIFYSLRNNELKGTLLKTLSPRGAVAHACNPSTL  
 GGRGGWIMRSGDRDHPG (SEQ ID NO: 139)

ATGGAAGGGAAAAATCAAACCAATATCTCTGAATTTCTCCTCCTGGGCTTCTCAAGTTGGC  
 10 AACACAGCAGGTGCTACTCTTTGCACTTTTCTGTGTCTCTATTAAACAGGGCTGTTTGGA  
 AACTTACTCATCTTGTGGCCATTGGCTCGGATCACTGCCTTCACACACCCATGTATTTCTT  
 CCTTGCCAATCTGTCTTGGTAGACCTCTGCCTTCCCTCAGCCACAGTCCCCAAGATGCTAC  
 TGAACATCCAAACCCAAACCCAAACCATCTCCTATCCCGGCTGCCTGGCTCAGATGTATTT  
 CTGTATGATGTTTGCCAATATGGACAATTTTCTTCTCACAGTGATGGCATTGACCGTTAC  
 15 GTGGCCATCTGTCAACCCTTTACATTACTCCACATTATGGCCCTGCGCCTCTGTGCCTCTCT  
 GGTAGCTGCACCTTGGGTCATTGCCATTTTGAACCCTCTCTTGCACACTCTTATGATGGCCC  
 ATCTGCACTTCTGCTCTGATAATGTTATCCACCATTCTTCTGTGATATCAACTCTCTCCTC  
 CCTCTGTCTGTTCGACACCAGTCTTAATCAGTTGAGTGTTCTGGCTACGGTGGGGCTGA  
 TCTTTGTGGTACCTTCAGTGTGTATCCTGGTATCCTATATCCTCATTGTTTCTGCTGTGATG  
 20 AAAGTCCCTTCTGCCAAGGAAAACTCAAGGCTTTCTCTACCTGTGGATCTCACCTTGCCCT  
 GGTCACTCTTTTCTATGGAGCAAACACAGGGGTCTATATGAGCCCCCTTATCCAATCACTCT  
 ACTGAAAAAGACTCAGCCGCATCAGTCATTTTATGGTTGTAGCACCTGTGTTGAATCCAT  
 TCATTTACAGTTTAAGAAACAATGAAGTGAAGGGGACTTTAAAAAAGACCCTAAGCCGGC  
 CGGGCGCGGTGGCTCACGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGCGGTGGATCA  
 25 TGAGGTCAGGAGATCGAGACCATCCTGGCTAA (SEQ ID NO: 140)

**AOLFR76 sequences:**

MENNTEVSEFILLGLTNAPELQVPLFIMFTLIYLITLTGNLGMILILLDSHLHTPMYFFLSNLSLA  
 GIGYSSAVTPKVLTLIEDKAISYSACAAQMFFCAVFATVENYLLSSMAYDRYAAVCNPLHY  
 30 TTTMTTRVCACLAIGCYVIGFLNASIQIGDTFRLSFCMSNVIIHFFCDKPAVITLTCSEKHISELIL  
 VLISSFNVFFALLVTLISYLFILITILKRHTGKGYQKPLSTCGSHLIAIFLYITVIIMYIRPSSSHSM  
 DTDKIASVFYTMIPMLSPIVYTLRNKDVKNAFMKVVEKAKYSLDSVF (SEQ ID NO: 141)

ATGGAGAATAATACAGAGGTGAGTGAATTCATCCTGCTTGGTCTAACCAATGCCCCAGAA  
 35 CTACAGGTTCCTCTTTATCATGTTTACCCTCATCTACCTCATCACTCTGACTGGGAACCT  
 GGGGATGATCATATTAATCCTGCTGGACTCTCATCTCCACACTCCCATGTACTTTTTTCTCA  
 GTAACCTGTCTCTTGCAGGCATTGGTTACTCCTCAGCTGTCACTCCAAAGGTTTTAACTGG  
 GTTGCTTATAGAAGACAAAGCCATCTCCTACAGTGCCTGTGCTGCTCAGATGTTCTTTTGT  
 GCAGTCTTTGCCACTGTGGAAAATTACCTCTTGTCTCAATGGCCTATGACCGCTACGCAG  
 40 CAGTGTGTAACCCCTACATTATACCACCACCATGACAACACGTGTGTGTGCTTGTCTGGC  
 TATAGGCTGTTATGTCATTGGTTTTCTGAATGCTTCTATCCAAATTGGAGATACATTTCCGC  
 TCTCTTTCTGCATGTCCAATGTGATTCACTTTTTCTGTGACAAACCAGCAGTCATTACT  
 CTGACCTGCTCTGAGAAACACATTAGTGAGTTGATTCTTGTCTTATATCAAGTTTTAATGT  
 CTTTTTGCACCTCTTGTACCTTGATTTCTATCTGTTTCATATTGATCACCATTCTTAAGAG  
 45 GCACACAGGTAAGGGATACCAGAAGCCTTTATCTACCTGTGGTTCTCACCTCATTGCCATT  
 TTCTTATTTTATATAACTGTCATCATCATGTACATACGACCAAGTCCAGTCATTCCATGGA  
 CACAGACAAAATTGCATCTGTGTTCTACACTATGATCATCCCCATGCTCAGTCCTATAGTCT  
 ATACCCTGAGGAACAAAGACGTGAAGAATGCATTTCATGAAGGTTGTTGAGAAGGCAAAAT  
 ATTCTCTAGATTCACTCTTTTAA (SEQ ID NO: 142)

50

**AOLFR77 sequences:**

MGDVNQSVASDFILVGLFSHSGSRQLLFSLVAVMFVIGLLGNTVLLFLIRVDSRLHTPMYFLLS  
 QLSLFDIGCPMVTIPKMASDFLRGEGATSYGGGAAQIFFLTMGVAEVLLVLMSYDRYVAVC  
 QPLQYPVLMRRQVCLLMGSSWVVGVLNASIQTSITLHFPYCASRVDHFFCEVPALLKLSCA  
 55 DTCAYEMALSTSGVLILMLPLSLIATSYGHVLQAVLSMRSEEARHKAVTTCSSHITVVGLFYGA





CTATGCCATAACAGTGGTGGGCAACTTGGGAATGATGGCACTCATCTTCACAGACTCCCAT  
 CTCCAAAGCCCAATGTATTTCTTCCTCAATGTCCTCTCGTTTCTTGATATTTGTTACTCTTCT  
 GTGGTCACACCTAAGCTCTTGGTCAACTTCTGGTCTCTGACAAGTCCATCTCTTTTGAGG  
 GCTGTGTGGTCCAGCTCGCCTTCTTTGTAGTGCATGTGACAGCTGAGAGCTTCCTGCTGGC  
 5 CTCCATGGCCTATGACCGCTTCCTAGCCATCTGTCAACCCCTCCATTATGGTTCTATCATGA  
 CCAGGGGGACCTGTCTCCAGCTGGTAGCTGTGTCTATGCATTTGGTGGAGCCAACTCCGC  
 TATCCAGACTGGAAATGTCTTTGCCCTGCCTTTCTGTGGGCCCCAACAGCTAACACACTAC  
 TACTGTGACATAACACCCCTTCTCCACCTGGCTTGTGCCAACACAGCCACAGCAAGAGTGG  
 TCCTCTATGTCTTTCTGCTCTGGTCACCTTCTGCCTGCTGCAGTCATTCTCACCTCCTACT  
 10 GCTTGGTCTTGGTGGCCATTGGGAGGATGCGCTCAGTAGCAGGGAGGGAGAAGGACCTCT  
 CCACTTGTGCCTCCCCTTTCTGGCCATTGCCATTTTCTATGGCACTGTGGTTTTCACCTAT  
 GTTCAGCCCCATGGATCTACTAACAAATACCAATGGCCAAGTAGTGCCGTCTTCTACACCA  
 TCATAATTCCCATGCTCAATCCCTTCATCTATAGCCTCCGCAACAAGGAGGTGAAGGGCGC  
 TCTGCAGAGGAAGCTTCAGGTCAACATCTTTCCCGGCTGA (SEQ ID NO: 148)

15

**AOLFR80 sequences:**

MEGINKTAKMQFFRPFSPDPEVQMLIFVFLMMYLTSLGGNATIAVIVQINHSLHTPMYFFLA  
 NLAVLEIFYTSSITPLALANLLSMGKTPVSITGCGTQMFFFVFLGGADCVLLVVMAYDRFIAICH  
 PLRYRLMSWSLCVELLVGSLVLGFLLSLPLTILIFHLPFCHNDEIYHFYCDMPAVMRLACADTR  
 20 VHKTALYIISFIVLSIPLSLISISYVFIVVAILRIRSAEGRQAYSTCSSHLVLLQYGCTSFYILSPS  
 SSYSPEMGRVVSVA YTFITPILNPLIYSLRNKELKDALRKALRK (SEQ ID NO: 149)

ATGGAAGGAATAAATAAACTGCAAAGATGCAGTTTTTCTTTCGTCCATTCTCACCTGACC  
 CTGAGGTCCAGATGCTGATTTTTGTGGTCTTCTGATGATGTATCTGACCAGCCTCGGTGG  
 25 AAATGCTACAATTGCAGTCATTGTTGATGATCAATCATTCCCTCCACACCCCCATGTACTTTT  
 TCCTGGCTAATCTGGCAGTTCTAGAAATCTTCTATACATCTTCCATCACCCCATGGCCTTG  
 GCAAACCTCCTTTCAATGGGCAAACTCCTGTTTCCATCACGGGATGTGGCACCCAGATGT  
 TTTCTTTGTCTTCTGGGTGGGGCTGATTGTGTCTGCTGGTAGTCATGGCTTATGACCGG  
 TTTATAGCATCTGTACCCCTCTGCGATACAGGCTCATCATGAGCTGGTCTTGTGTGTGG  
 30 AGCTGCTGGTAGGCTCCTTGGTGTGGGGTCTGTTGTCACTGCCACTCACCATTTTAATC  
 TTCCATCTCCCATTTCTGCCACAATGATGAGATCTACCCTTCTACTGTGACATGCCTGCAGT  
 CATGCGCTGGCTTGTGCAGACACACGCGTTCACAAGACTGCTCTGTATATCATCAGCTTC  
 ATCGTCCTTAGCATCCCCCTCTCATTGATCTCCATCTCCTATGTCTTCATCGTGGTAGCCAT  
 TTTACGGATCCGGTCAGCAGAAGGGCGCCAGCAAGCCTACTCTACCTGCTCTTCTCACATC  
 35 TTAGTGGTCTCCTGCAATATGGCTGCACAGCTTTATATACTTGTCCCCCAGTCCAGCTA  
 CTCTCCTGAGATGGGCGGGTGGTATCTGTGGCCTACACATTTATCACTCCCATTTTAAAC  
 CCCTTGATCTATAGTTTGAGGAACAAGGAAGTAAAGATGCCCTAAGGAAAGCATTGAGA  
 AAATTCTAG (SEQ ID NO: 150)

40 **AOLFR81 sequences:**

MGVKNHSTVTEFLLSGLTEQAEQLPLFCLFLGIYTVTVVGNLSMISIIRLNRLHTPMYYFLSS  
 LSFLDFCYSSVITPKMMKLWMESHLPETRPSRMMNSQTLVTEFILQGFSEHPEYRVFLSCF  
 LFLYSGALTGNVLITLITFNPGLHAPMYFFLLNLATMDICTSSIMPKALASLVSEESSISYGGC  
 MAQLYFLTWAASSELLLLTVMAYDRYAAICHPLHYSSMMSKVFCGLATAVWLLCAVNTAIH  
 45 TGLMLRLDFCGPNVIIHFFCEVPPLLLSCSSTYVNGVMIVLADAFYGINFLMTIASYGFIVSSI  
 LKVKTAWGRQKAFSTCSSHLTVVCMYYTAVFYAYISPVSGYSAGSKLAGLLYTVLSPTLNPL  
 IYTLRNKEVKAAALRKLPFFRN (SEQ ID NO: 151)

ATGAAGCTGTGGATGGAGAGTCACCTGATAGTCCCAGAAACCCGTCCCAGCCCAAGGATG  
 50 ATGAGTAACCAGACGTTGGTAACCGAGTTCATCCTGCAGGGCTTTTCGGAGCACCCAGAAT  
 ACCGGGTGTTCTTATTACAGCTGTTTCTCTCTACTCTGGGGCCCTCACAGGTAATGTC  
 CTCATACCTTGGCCATCACGTTCAACCCTGGGCTCCACGCTCCTATGTACTTTTTCTTACT  
 CAACTTGGCTACTATGGACATTATCTGCACCTCTTCCATCATGCCCAAGGCGCTGGCCAGT  
 CTGGTGTGGAAGAGAGCTCCATCTCCTACGGGGGCTGCATGGCCAGCTCTATTTCTCA  
 55 CGTGGGCTGCATCCTCAGAGCTGCTGCTCCTCACGGTCATGGCCTATGACCGGTACGCAGC  
 CATCTGCCACCCGCTGCATTACAGCAGCATGATGAGCAAGGTGTTCTGCAGCGGGCTGGCC

WO 01/98526

ACAGCCGTGTGGCTGCTCTGCGCCGTCAACACGGCCATCCACACGGGGCTGATGCTGCGCT  
 TGGATTTCTGTGGCCCAATGTCATTATCCATTCTTCTGCGAGGTCCCTCCCCTGCTGCTT  
 CTCTCCTGCAGCTCCACCTACGTCAACGGTGTCTATGATTGTCTGCGGATGCTTTCTACG  
 GCATAGTGAACCTTCTGATGACCATCGCGTCTATGGCTTCATCGTCTCCAGCATCCTGAA  
 5 GGTGAAGACTGCCTGGGGGAGGCAGAAAGCCTTCTCCACCTGCTCTTCCCACCTACCGTG  
 GTGTGCATGTATTACACCGCTGTCTTCTACGCCTACATAAGCCCGGTCTCTGGCTACAGCG  
 CAGGGAAGAGCAAGTTGGCTGGCCTGCTGTACACTGTGCTGAGTCTACCTCAACCCCTT  
 CATCTATACTTTGAGAAACAAGGAGGTCAAAGCAGCCCTCAGGAAGCTTTCCCTTTCTTC  
 AGAAATTAA (SEQ ID NO: 152)

10

**AOLFR82 sequences:**

MQLNNNVTEFILLGLTQDPFWKKIVFVIFLRLYLGTLLGNLLIISVKASQALKNPMFFFLFYLSL  
 SDTCLSTSIAPRMIVDALLKKTTSFSECMQVFSHVFGLEIFILITAVDRYVDICKPLHYMTII  
 SQWVCGVLMMAVAVWGSCVHSLVQIFLALSFPFCGPNVINHCFLDQLPLKQACSETYVNNLL  
 15 VNSGAICAVSYVMLIFSIVIFLHSLRNHSAEVIKKALSTCVSHIIVILFFGPCIFMYTTPATVFP  
 MDKMIAVFYTVGTSFLNPVIYTLKNTEVKSAMRKLWSKLLITDDKR (SEQ ID NO: 153)

20

ATGCAACTGAATAATAATGTGACTGAGTTCATTCTGCTTGGATTGACACAGGATCCTTTTT  
 GGAAGAAAATAGTGTGTTGTTATTTTTTTCGCTCTCTACTTGGGAACACTGTTGGGTAATTT  
 GCTAATCATTATTAGTGTCAAGGCCAGCCAGGCACTTAAGAACCCAATGTTCTTCTTCCTT  
 TTCTACTTATCTTATCTGATACTTGCCTCTCTACTTCCATAGCCCTAGAATGATTGTGGA  
 TGCCCTTTTGAAGAAGACAACTATCTCCTTCAGCGAGTGCATGATCCAAGTCTTTTCATCC  
 CATGTCTTTGGCTGCCTGGAGATCTTCATCCTCATCCTCACGGCTGTTGACCGCTATGTGGA  
 CATCTGTAAAGCCCTGCACTACATGACCATCATAAGCCAGTGGGTCTGTGGTGTGTTGATG  
 25 GCTGTGGCCTGGGTGGGATCCTGTGTGCATTCTTTAGTTGAGATTTTCTTGCCTGAGTTT  
 GCCATTCTGTGGCCCAATGTGATCAATCACTGTTTCTGTGACTTGCAGCCCTTGTGAAA  
 CAAGCCTGTTTCAGAAACCTATGTGGTTAACTACTCCTGTTTCCAATAGTGGGGCCATTT  
 GTGCAGTGAGTTATGTGCTAATATTCTCTATGTCTCTTCTGCACTCTCTGAGAAAC  
 CACAGTGCTGAAGTGATAAAGAAAGCACTTTCCACATGTGTCTCCACATCATTGTGGTCA  
 30 TCTTGTCTTTGGACCTTGCATATTTATGTACACATGCCCTGCAACCGTATTCCCCATGGAT  
 AAGATGATAGCTGTATTTTATACAGTTGGAACATCTTTTCTCAACCCTGTGATTTACACGCT  
 GAAGAATACAGAAGTGAAGAGTCCATGAGGAAGCTTTGGAGCAAGAAATTGATCACAGA  
 TGACAAAAGATAA (SEQ ID NO: 154)

35 **AOLFR83 sequences:**

MGNWTAAVTEFVLLGFSLSREVELLLLVLPTFLLTLLGNLLIISTVLSCSRHTPMYFFLCNL  
 SILDILFTSVISPKVLANLGSRDKTISFAGCITQCYFYFFLGTVEFLLTVMYSYDRYATICPLRYT  
 TIMRPSVCIGTVVFSWVGFLSVLFPTILISQLPFCGSNIINHFFCDSGPLLALACADTTAIELMDF  
 MLSSMVLCCIVLVAYSYTYIILTIVRIPSASGRKKAFNTCASHLTIVIPSGITVFIYVTPSQKEYL  
 40 EINKIPLVLSSVTPFLNPFIYTLRNDTVQGVLRDVWVRVGVFEKRMRAVLRSRLSSNKDHQ  
 GRACSSPPCVYSVKLQC (SEQ ID NO: 155)

45

ATGGGTAACTGGACTGCAGCGGTGACTGAGTTTGTCTGCTGGGGTTTTCCCTGAGCAGGG  
 AGGTGGAGCTGCTGCTCCTGGTCTCTGCTGCCCACGTTCTGCTGACTCTTCTGGGGAA  
 CCTGCTCATCATCTCCACTGTGCTGCTGCTCCCGCTCCACACCCCATGACTTCTTCT  
 TGTGCAACCTCTCTATCCTGGACATCCTCTTCACTCAGTCATCTCTCCAAAAGTGTGGCC  
 AACTTAGGATCTAGGGATAAAACCATCTCCTTTGCCGGATGTATCACCAGTGCTATTCTT  
 ACTTTTTCTTGGGCACAGTTGAGTTCTCCTGCTGACGGTCATGTCCTATGACCGTTATGCC  
 ACCATCTGCTGCCCCCTGCGGTACACCACCATCATGAGACCTTCTGTCTGCATTGGGACCG  
 50 TTGTATTCTCTTGGGTGGGAGGCTTCTGTCTGTGCTCTTTCCAACCATCCTCATCTCCAG  
 CTGCCCTTCTGTGGCTCCAATATCATTAAACCACTTCTTCTGTGACAGTGGACCTTGTGGC  
 CCTGGCCTGTGCAGACACCACTGCCATCGAGCTGATGGATTTTATGCTTTCTTCCATGGTC  
 ATCCTCTGCTGCATAGTCTCGTGGCCTATTCTATACGTACATCATCTTGACCATAGTGCG  
 CATTCCTTCTGCAAGTGAAGGAAGAAGGCCTTTAATACCTGTGCTTCCACCTGACCATA  
 55 GTCATCATTCTAGTGGCATCACTGTGTTTATCTATGTGACTCCCTCCAGAAAGAATATCT  
 GGAGATCAACAAGATCCCTTTGGTTCTGAGCAGTGTGGTGAAGTCCATTCCTCAACCCCTT



ATATATACTCTGAGGAATGACACAGTGCAGGGAGTCCTCAGGGATGTGTGGGTCAGGGTT  
CGAGGAGTTTTTGAAGAGGATGAGGGCAGTGCTGAGAAGCAGATTATCCTCCAACAAA  
GACCACCAAGGAAGGGCTTGCTCTTCTCCACCATGTGTCTATTCTGTAAAGCTCCAGTGT  
AG (SEQ ID NO: 156)

5

**AOLFR85 sequences:**

MGAKNNVTEFVLFGLFESREMQHTCFVFFLFHVLTVLGNLLVIITINARKTLKSPMYFFLSQL  
SFADICYPSTTIPKMIADTFVEHKIISFNGCMTQLFSAHFFGGTEIFLLTAMAYDRYVAICRPLHY  
TAIMDCRKCGLLAGASWLAGFLHSILQTLTVQLPFCGPNEIDNFFCDVHPLLKLACADTYMV  
10 GLIVVANSGLASFFILIISYVILLNLRSSQSEDRRKAVSTCGSHVITVLLVLMPPMFMYIRPS  
TTLAADKLIILFNIVMPPLNPLIYTLRNNDVKAMRKLFRVKRSLGEK (SEQ ID NO: 157)

ATGGGTGCCAAGAACAATGTGACTGAGTTTGTATTTGGCCTTTTTGAGAGCAGAGAGA  
TGCAGCATACATGCTTTGTGGTATTCTTCCTCTTTCATGTGCTCACTGTCCTGGGGAACCTT  
15 CTGGTCATCATCACCATCAATGCTAGAAAGACCCTGAAGTCTCCCATGTATTTCTTCCTGA  
GCCAGTTGTCTTTGCTGACATATGTTATCCATCCACTACCATAACCAAGATGATTGCTGAC  
ACTTTTGTGGAGCATAAGATCATCTCCTTCAATGGCTGCATGACCCAGCTCTTTTCTGCCCA  
CTTCTTTGGTGGCACTGAGATCTTCCTCCTTACAGCCATGGCCTATGACCGCTATGTGGCC  
ATCTGTAGGCCCCCTGCACTACACAGCCATCATGGATTGCCGGAAGTGTGGCCTGCTAGCGG  
20 GGGCCTCCTGGTTAGCTGGCTTCTGCAATCCATCCTGCAGACCCTCCTCACGGTTCAGCTG  
CCTTTTTGTGGGCCCAATGAGATAGACAACTTCTTCTGTGATGTTTCATCCCCTGCTCAAGTT  
GGCCTGTGCAGACACCTACATGGTAGGTCTCATCGTGGTGGCCAACAGCGGTATGATTTCT  
TTAGCATCCTTTTTATCCTTATCATTTCCTATGTTATCATCTTACTGAACCTAAGAAGCCA  
GTCATCTGAGGACCGGCGTAAGGCTGTCTCCACATGTGGCTCACACGTAATCACTGTCCTT  
25 TTGGTTCTCATGCCCCCATGTTTCATGTACATTTCCTCCCTCCACCACCTGGCTGCTGACAA  
ACTTATCATCCTCTTTAACATTGTGATGCCACCTTTGCTGAACCCTTTGATCTATACACTAA  
GGAACAACGATGTGAAAAATGCCATGAGGAAGCTGTTTAGGGTCAAGAGGAGCTTAGGGG  
AGAAGTGA (SEQ ID NO: 158)

30 **AOLFR86 sequences:**

MQLVLLLMFLLVFIGNTAPAFSVTLESMDIPQNITEFFMLGLSQNSEVQRVLFVVFLLIYVVTVC  
GNMLIVVTITSSPTLASPVYFFLANLSFIDTFYSSSMAPKLIADSLYEGRTISYECCMAQLFGAHF  
LGGVEIILLTVMAYDRYVAICKPLHNTTIMTRHLCAMLVGVAVLGGFLHSLVQLLLVLWLPFC  
GPNVINHFACDLYPLLEVACTNTYVIGLLVVANSGLICLLNFLMLAASYTVILYSLRSHSADGRC  
35 KALSTCGAHFIVVALFFVPCIFTYVHPFSTLPIDKNMALFYGILTPMLNPLIYTLRNEEVKNAMR  
KLFTW (SEQ ID NO: 159)

ATGCAATTAGTTCTATTACTTATGTTTCTCCTTGTCTTTATAGGCAATACTGCACCTGCATT  
CTCAGTGACCTTGGGAATCTATGGACATACCACAAAATATCACAGAATTTTTTCATGCTGGGG  
40 CTCTCACAGAACTCAGAGGTACAGAGAGTTCTCTTTGTGGTCTTTTGTGATCTATGTGG  
TCACGGTTTGTGGCAACATGCTCATTGTGGTCACTATCACCTCCAGCCCCACGCTGGCTTC  
CCCTGTGTATTTTTCTGGCCAACCTATCCTTTATTGACACCTTTTATTCTTCTTCTATGGC  
TCCTAAACTCATTGCTGACTCATTGTATGAGGGGAGAACCATCTCTTATGAGTGCTGCATG  
GCTCAGCTCTTTGGAGCTCATTTTTTGGGAGGTGTTGAGATCATTCTGCTCACAGTGATGG  
45 CTTATGACCGCTATGTGGCCATCTGTAAGCCCCTGCACAATACTACCATCATGACCAGGCA  
TCTCTGTGCCATGCTTGTAGGGGTGGCTTGGCTTGGGGGCTTCTGCAATTCATTGGTTCAG  
CTCCTCCTGGTCTTTGGTTGCCCTTCTGTGGGCCCAATGTGATCAATCACTTTGCCTGTGA  
CTTGTAACCTTTGCTGGAAGTTGCCTGCACCAATACGTATGTCATTGGTCTGCTGGTGGTT  
GCCAACAGTGGTTAATCTGCCTGTTGAACCTCCTCATGCTGGCTGCCTCCTACATTGTCAT  
50 CCTGTACTCCTTGAGGTCCCACAGTGCAGATGGGAGATGCAAAGCCCTCTCCACCTGTGGA  
GCCCACTTCATTGTTGTTGCCCTGTTCTTTGTGCCCTGTATTTTACTTATGTGCATCCATTT  
TCTACTTTACCTATAGACAAAAATATGGCATTATTTTATGGTATTCTGACACCTATGTTGAA  
TCCACTCATTTATACCCTGAGAAATGAAGAGGTAAAAAATGCCATGAGAAAGCTCTTTACA  
TGGTAA (SEQ ID NO: 160)

55

WO 01/98526

## AOLFR87 sequences:

MNNIAQLSLGFIDLGPSVLQKIILTKIILLFKMYVSNCPCAIHRKINYPNTKLDFEQVNNITEFI  
 LLGLTQNAEAQKLLFAVFTLIYFLTMVDNLHVTTITSPALDSPVYFFLSFFSFIDGCSSTMAP  
 KMIFDLLTEKKTISFSGCMTQLFVEHFFGGVEIILLVVMAYDCYVAICKPLYLITMNRQVCGL  
 5 LVAMAWVGGFLHALIQMLLIVWLPFCGPNVIDHFICDLFLLKLSCTDTHVFGLFVAANSGLM  
 CMLIFSILITSYVLILCSQRKALSTCAFHITVVVLFVPCILVYLRPMITFPIDKAVSVFYTVVTPM  
 LNPLIYTLRNTVEKNAMKQLWSQIHWGNLDC (SEQ ID NO: 161)

10 ATGAATAACATAGCTCAACTTAGTCTTGGGTTTATAGATTTAGGGATTCCATCAGTGTTAC  
 AGAAAATAATCCTGACCAAAATTATTTTATTGTTCAAAATGTATGTGTCAAATTGCAATCC  
 TTGTGCTATTACAGAAAAATCAATTATCCAAATACCAAACTGGATTCGAGCAAGTGAAC  
 AACATAACGGAATTCATCTTGCTTGGCCTGACACAGAACGCAGAGGCACAGAACTCTTGT  
 TTGCTGTGTTTACACTCATCTACTTTCTCACCATGGTAGACAACCTAATCATTGTGGTGACA  
 15 ATCACCACCAGCCCAGCCCTGGACTCCCCCGTGATTTTTTCTGTCTTTCTTTCTCTCAT  
 AGATGGCTGCTCCTCTTCTACCATGGCCCCCAAAATGATATTTGACTTACTCACTGAAAAG  
 AAAACTATTTCTTTCAGTGGGTGCATGACCCAGCTCTTTGTAGAATTTCTTTGGGGAG  
 TTGAGATCATTCTGCTCGTGGTGATGGCCTATGACTGCTATGTGGCCATCTGCAAGCCCCT  
 GTACTACCTGATCACAATGAACAGGCAGGTATGTGGCCTCCTGGTGGCCATGGCATGGGTG  
 GGGGATTTCTTACGCTCTGATTCAAATGCTTTTAATAGTCTGGCTGCCCTCTGTGGCCC  
 20 CAATGTCAATTGACCATTTTCATCTGTGACCTTTTCCCTCTGCTAAAACTCTCCTGCACTGACA  
 CTCACGTCTTTGGACTCTTTGTTGCCGCAACAGTGGGCTGATGTGTATGCTCATTTTTTCT  
 ATTCTTATTACCTCTTACGTCCTAATCCTCTGCTCACAGCGGAAGGCTCTCTACCTGCGC  
 CTTCCATATCACTGTAGTCGTCCTATTCTTTGTTCCCTGTATATTGGTGTACCTTCGACCCA  
 TGATCACCTCCCTATTGATAAAGCTGTGTCTGTGTTTTATACTGTGGTAACCCCATGTGA  
 25 AACCCTTTAATCTACACCCTCAGAAACACAGAGGTGAAAAATGCCATGAAGCAGCTCTGG  
 AGCCAAATAATCTGGGGTAACAATTTGTGTGATTAG (SEQ ID NO: 162)

## AOLFR88 sequences:

30 MWQKNQTSADFILEGLFDDSLTHLFLSLTMVVFLIAVSGNTLTILLICIDPQLHTPMYFLLSQ  
 LSLMDLMHVSTILKMATNYLSGKKSISFVGCATQHFLYLCLGGAECFLAVMSYDRYVAICH  
 PLRYAVLMNKKVGLMMAVMSWLGASVNSLIHMAILMHFPFCGPRKVYHFYCEFAVVKLVC  
 GDITVYETTVYISSILLLLPIFLISTSYVFILQSVIQMRSSGSKRNAFATCGSHLTVVSLWFGACIFS  
 YMRPRSQCTLLQNKVGSVFYSIITPTLNSLIYTLRNDVAKALRRVLRRDVITQCIQRLQLWLP  
 RV (SEQ ID NO: 163)

35 ATGTGGCAGAAGAATCAGACCTCTCTGGCAGACTTCATCCTTGAGGGGCTCTTCGATGACT  
 CCCTTACCCACCTTTTCTCTCTTGGACCATGGTGGTCTTCTTATTGCGGTGAGTGGC  
 AACACCCCTACCAATTCTCCTCATCTGCATTGATCCCCAGCTTCATACACCAATGTATTTCT  
 40 GCTCAGCCAGCTCTCCCTCATGGATCTGATGCATGTCTCCACAATCATCCTGAAGATGGCT  
 ACCAACTACCTATCTGGCAAGAAATCTATCTCCTTTGTGGGCTGTGCAACCCAGCACTTC  
 TCTATTTGTGTCTAGGTGGTGTGAATGTTTTCTCTTAGCTGTCTATGACCGCTAT  
 GTTGCCATCTGTCTCATCCACTGCGCTATGCTGTGCTCATGAACAAGAAGGTGGGACTGATGA  
 TGGCTGTCTGTCTATGGTTGGGGGCATCCGTGAACCTCCCTAATTCACATGGCGATCTTGAT  
 GCACTTCCCTTTCTGTGGGCTCGGAAAGTCTACCACTTCTACTGTGAGTTCCCAGCTGTTG  
 45 TGAAGTTGGTATGTGGCGACATCACTGTGTATGAGACCACAGTGTACATCAGCAGCATTCT  
 CCTCCTCCTCCCCATCTTCTGATTTCTACATCCTATGTCTTCTCCTTCAAAGTGTCTATTCA  
 GATGCGCTCATCTGGGAGCAAGAGAAATGCCTTTGCCACTGTGGCTCCCACCTCAGGTG  
 GTTCTCTTTGGTTTGGTGCCTGCATCTTCTCCTACATGAGACCCAGGTCCCAGTGCATCT  
 ATTGCAGAACAAAGTGGTTCTGTGTTCTACAGCATCATTACGCCACATTGAATTCTCTG  
 50 ATTTATACTCTCCGGAATAAAGATGTAGCTAAGGCTCTGAGAAGAGTGTGAGGAGAGAT  
 GTTATACCCAGTGCAATCAACGACTGCAATTGTGGTTGCCCCGAGTGTAG (SEQ ID NO:  
 164)

## AOLFR89 sequences:

55 MLDPSISSHTLYLHSLFPQGLRKGTMWQKNQTSADFILEGLFDDSLTHLFLSLTMVVFLIAVS  
 GNTLTILLICIDPQLHTPMYFLLSQLSLMDLMHVSTILKMATNYLSGKKSISFVGCATQHFLYL

CLGGAECFLLAVMSYDRYVAICHPLRYAVLMNKKVGLMMAVMSWLGASVNSLIHMAILMHF  
PFCGRKVVYHFYCEFPVVKLVCGDITVYETTVYISSILLLLPIFLISTSYVFILQSVIQMRSSGSK  
RNAFATCGSHLTVVSLWFGACIFSYMRPRSQCTLLQNKVGSVFYSIITPTLNSLIYTLRNKDVA  
KALRRVLRDVTQCIQRLQLWLPRV (SEQ ID NO: 165)

5

ATGCTGGACCCAGTATTTCCAGTCACACTCTTTATCTCCACTCTCTGTTTCCTCAGGGATT  
GAGAAAGGGGACAATGTGGCAGAAGAATCAGACCTCTCTGGCAGACTTCATCCTTGAGGG  
GCTCTTCGATGACTCCCTTACCCACCTTTTCCTTTTCTCCTTGACCATGGTGGTCTTCCTTAT  
TGCGGTGAGTGGCAACACCCCTCACCATTCTCCTCATCTGCATTGATCCCCAGCTTCATACA  
10 CCAATGTATTTCTGCTCAGCCAGCTCTCCCTCATGGATCTGATGCATGTCTCCACAACCAT  
CCTGAAGATGGCTACCAACTACCTATCTGGCAAGAAATCTATCTCCTTTGTGGGCTGTGCA  
ACCCAGCACTTCCTCTATTTGTGTCTAGGTGGTGTGAATGTTTTCTCTTAGCTGTCATGTC  
CTATGACCGCTATGTTGCCATCTGTCATCCACTGCGCTATGCTGTGCTCATGAACAAGAAG  
GTGGGACTGATGATGGCTGTCATGTCATGGTTGGGGGCATCCGTGAACCTCCCTAATTCACA  
15 TGGCGATCTTGATGCACTTCCCTTTCTGTGGGCCTCGGAAAGTCTACCATTCTACTGTGA  
GTTCCCAGCTGTTGTGAAGTTGGTATGTGGCGACATCACTGTGTATGAGACCACAGTGTAC  
ATCAGCAGCATTCTCCTCCTCCTCCCCATCTCCTGATTCTACATCCTATGTCTTCATCCTT  
CAAAGTGTCAATCAGATGCGCTCATCTGGGAGCAAGAGAAATGCCTTTGCCACTTGTGGCT  
CCCACCTCACGGTGGTTTCTCTTTGGTTTGGTGCCTGCATCTTCTCCTACATGAGACCCAGG  
20 TCCCAGTGCACCTCTATTGCAGAACAAAGTTGGTTCTGTGTTCTACAGCATCATTACGCCCA  
CATTGAATTCTCTGATTTATACTCTCCGGAATAAAGATGTAGCTAAGGCTCTGAGAAGAGT  
GCTGAGGAGAGATGTTATCACCCAGTGCATTCAACGACTGCAATTGTGGTTGCCCCGAGTG  
TAG (SEQ ID NO: 166)

#### 25 AOLFR90 sequences:

MFSMTTEALNNFALGCTNLLMTMPIDLKQIFLCPNCRLYMIPVGAFIFSLGNMQNQSFVTEF  
VLLGLSQPNPVQEIVFVFLFVYIATVGGNMLIVVTILSSPALLVSPMYFFLGFLSFLDACFSSVI  
TPKMIVDLSLYVTKTISFEGCMMQLFAEHFFAGVEVIVLTAMAYDRYVAICKPLHYSSIMNRRL  
CGILMGVAWTGGLLHSMIQLFTFQLPFCGPNVNHFMCDLYPLLELACTDTHIFGLMVVINS  
30 FICIINFSLLLVSAYAVILLSLRTHSSEGRWKALSTCGSHIAVVILFFVPCIFVYTRPPSAFSLDKMA  
AIFYIILNPLLNPLIYTFRNKEVKQAMRRIWNRLMVVSDEKENIKL (SEQ ID NO: 167)

ATGTTCTCAATGACAACAGAAGCACTCAATAATTTTGCACCTGGATGTACCAACTTGTTAA  
TGACTATGATACCACAAATTGATCTGAAGCAAATTTTCCTTTGCTCTAATTGCAGACTATA  
35 CATGATCCCTGTTGGAGCTTTTCATCTTTTCCTTGGGAAACATGCAAAACCAAAGCTTTGTA  
ACTGAGTTTGTCTCCTGCTGGGACTTTCACAGAATCCAAATGTTTCAGGAAATAGTATTTGTTG  
TATTTTGTGTTGTCTACATTGCAACTGTTGGGGGCAACATGCTAATTGTAGTAACCAATTCTC  
AGCAGCCCTGCTCTTCTGGTGTCTCCTATGTACTTCTTCTTGGGCTTCTGTCTTCTCTGGA  
TGCCTGCTTCTCATCTGTCATCACCCCAAAGATGATTGTAGACTCCCTCTATGTGACAAAA  
40 ACCATCTCTTTTGAAGGCTGCATGATGACGCTCTTTGCTGAACACTTCTTTGCTGGGGTGG  
AGGTGATTGTCTCAGCCATGGCCTATGATCGTTATGTGGCCATTGCAAGCCCTTGCA  
TTACTCTTCTATCATGAACAGGAGGCTCTGTGGCATTCTGATGGGGGTAGCCTGGACAGGG  
GGCCTCTTGCAATCCATGATACAAATTCTTTTACTTTCCAGCTTCCCTTTTGTGGCCCCAA  
TGTCATCAATCACTTTATGTGTGACTTGTACCCGTTACTGGAGCTTGCCTGCACTGATACTC  
45 ACATCTTTGGCCTCATGGTGGTCATCAACAGTGGGTTTATCTGCATCATAAACTTCTCCTTG  
TTGCTTGTCTCCTATGCTGTCTCTTCTCTCTGAGAACACACAGTTCTGAAGGGCGCTG  
GAAAGCTCTCTCCACCTGTGGATCTCACATTGCTGTTGTGATTTTGTCTTTGTCCCATGCA  
TATTTGTATATACACGACCTCCATCTGCTTTTTCCTTGACAAAATGGCGGCAATATTTTAT  
ATCATCTTAAATCCCTTGCTCAATCCTTTGATTTACACTTTCAGGAATAAGGAAGTAAAC  
50 AGGCCATGAGGAGAATATGGAACAGACTGATGGTGGTTTCTGATGAGAAAGAAAATATTA  
AACTTTAA (SEQ ID NO: 168)

#### AOLFR91 sequences:

MGNWSTVTEITLIAFPALLEIRISLFVVLVVTYTLTATGNITIISLIWIDHRLQTPMYFFLSNLSFL  
55 DILYTTVITPKLLACLLGEEKTISFAGCMIQTYFYFFLGTVEFILLAVMSFDRYMAICDPLHYTVI  
MNSRACLLLVLCWVGAFSLVLFPTIVVTRLPCYRKEINHFFCDIAPLLQVACINTHLIEKINFL

SALVILSSLAFTTGSYVYIISTILRIPSTQGRQKAFSTCASHITVVSIAHGSNIFVYVRPNQNSSLD  
YDKVA AVLITVVTPLNPFYISLRNEKVQEVLRQETVNRIMTLIQRKT (SEQ ID NO: 169)

5 ATGGGAAACTGGAGCACTGTGACTGAAATCACCTAATTGCCTTCCCAGCTCTCCTGGAGA  
TTCGAATATCTCTCTTCGTGGTTCTTGTGGTAACTTACACATTAACAGCAACAGGAAACAT  
CACCATCATCTCCCTGATATGGATTGATCATCGCTGCAAACTCCAATGTACTTCTCCTCA  
GTAATTTGTCTTTCTGGATATCTTATACCACTGTCTATTACCCCAAAGTTGTTGGCCTGC  
CTCCTAGGAGAAGAGAAAACCATATCTTTGTCTGGTGCATGATCCAAACATATTTCTACT  
TCTTTCTGGGGACGGTGGAGTTTATCCTCTTGGCGGTGATGTCCTTTGACCGCTACATGGC  
10 TATCTGCGACCCACTGCACTACCGGTGATCATGAACAGCAGGGCCTGCCTTCTGCTGGT  
CTGGGATGCTGGGTGGGAGCCTTCTGTCTGTGTTGTTTCCAACCATTGTAGTGACAAGGC  
TACCTTACTGTAGGAAAGAAATTAATCATTCTTCTGTGACATTGCCCTCTTCTTCAGGTG  
GCCTGTATAAATACTCACCTCATTGAGAAGATAAACTTTCTCCTCTCTGCCCTGTCTCCT  
GAGCTCCTGGCATTCACTACTGGGTCTACGTGTACATAATTTCTACCCTCGGTATCC  
15 CCTCCACCCAGGGCCGTCAGAAAGCTTTTTCTACCTGTGCTTCTCACATCACTGTTGTCTCC  
ATTGCCACGGGAGCAACATCTTTGTGTATGTGAGACCCAATCAGAACTCCTCACTGGATT  
ATGACAAGGTGGCCGCTGTCTCATCAGTGGTGACCCCTCTCCTGAACCTTTTATCTA  
CAGCTTGAGGAATGAGAAGGTACAGGAAGTGTGAGAGAGACAGTGAACAGAATCATGAC  
CTGATACAAAGGAAAACCTGA (SEQ ID NO: 170)

20

**AOLFR92 sequences:**

MRNGTVITEFILLGFPVIQGLQTPLFIAIFLYILTLAGNGLIATVWAEPLQIPMYFFLCNLSFLE  
IWYTTTVPKLLGTFVARTVICMSCCLLQAFHFFVGTTEFLILTIMSFDRLTICNPLHPTIM  
TSKLCLQALSSWVVGFTIVFCQTMILLIQLPCGNNVISHFYCDVGPSLKAACIDTSILELLGVIA  
25 TILVIPGSLLFNMISYIYILSAILRIPSATGHQKTFSTCASHLTVVSLLYGAVLFMYLRPTAHSSFK  
INKVSVLNTILTPLLNPFIYTIRNKEVKALRKAMTCPKTGHAH (SEQ ID NO: 171)

30 ATGAGAAATGGCACAGTAATCACAGAATTCATCCTGCTAGGCTTTCTGTTATCCAAGGCC  
TACAAACACCTCTCTTTATTGCAATCTTTCTCACCTACATATTAACCCTTGAGGCAATGGG  
CTTATTATTGCCACTGTGTGGGCTGAGCCAGGCTACAAATCCAATGTACTTCTCCTTTG  
TAACTTGTCTTTCTAGAAATCTGGTACACCACCACAGTCATCCCCAACTGCTAGGAACC  
TTTGTAGTGGCAAGAACAGTAATCTGCATGTCCTGCTGCCTGCTGAGGCCCTCTTCCACT  
TCTTCGTGGGCACCCAGGTCTTGATCCTCACTATCATGTCTTTTGACCGCTACCTCACC  
ATCTGCAATCCCCCTTACCACCCCACTCATGACCAGCAAACTCTGCCTGCAGCTGGCCC  
35 TGAGCTCCTGGGTGGGCTTACCATTGTCTTTGTGACGATGCTGCTCATCCAGTT  
GCCATTCTGTGGCAATAATGTTATCAGTCATTTCTACTGTGATGTTGGGCCCAGTTTGAAA  
GCCGCTGCATAGACACCAGCATTTTGGAACTCCTGGGCGTCATAGCAACCCTCTGTGA  
TCCAGGGTCACTTCTCTTTAATATGATTTCTTATCTACATTCTGTCCGCAATCCTACGA  
ATTCCTTCAGCCACTGGCCACCAAAAGACTTTCTACCTGTGCCTCGCACCTGACAGTTGT  
40 CTCCTGTCTACGGGGCTGTTCTGTTTATGTACCTAAGACCCACAGCACTCCTCCTTTA  
AGATTAATAAGGTGGTGTCTGTGCTAAATACTATCCTCACCCCTTCTGAATCCCTTTAT  
TATACTATTAGAAACAAGGAGGTGAAGGGAGCCTTAAGAAAGGCAATGACTTGCCCAAAG  
ACTGGTCATGCAAAGTAA (SEQ ID NO: 172)

45 **AOLFR93 sequences:**

MLMNYSSATEFYLLGFPGSEELHHILFAIFFFFYLVTLMGNTVIIMIVCVDKRLQSPMYFFLGH  
SALEILVTIIVPVMLWGLLPQMOTIYLSACVVQLFLYLAVGTTTEFALLGAMAVDRYVAVCN  
PLRYNIIMNRHTCNFVVLVSUVGFQIWPVYVMFQLTYSKSNVNNFFCDRGQLKLSCN  
NTLFTEFILFLMAVFVLFGLIPTIVSNAYIISTILKIPSSSGRRKSFSTCASHFTCVVIGYGSCLFLY  
50 VKPKQTQAADYNWVSLMVSVVTPLNPFIFLTRNDKVIEALRDGVKRCCLFRN (SEQ ID  
NO: 173)

55 ATGTTGATGAATTACTCTAGTGCCACTGAATTTTATCTCCTTGGCTTCCCTGGCTCTGAAGA  
ACTACATCATATCCTTTTTGCTATATTCTTTTCTACTTGGTGACATTAATGGGAAACA  
CAGTCATCATCATGATTGTCTGTGTGATAAACGTCTGCAGTCCCCCATGATTTCTTCTCCT  
GGCCACCTCTCTGCCCTGGAGATCCTGGTCACAACCATAATCGTCCCCGTGATGCTTTGGG

GATTGCTGCTCCCTGGGATGCAGACAATATATTGTCTGCCTGTGTTGTCCAGCTCTTCTTG  
 TACCTTGCTGTGGGGACAACAGAGTTCGCATTACTTGGAGCAATGGCTGTGGACCGTTATG  
 TGGCTGTCTGTAACCCCTCTGAGGTACAACATCATTATGAACAGACACCTGCAACTTTGT  
 5 GGTTCTTGTGTCATGGGTGTTTGGGTTCTTTTCAAATCTGGCCGGTCTATGTCATGTTTC  
 AGCTTACTTACTGCAAATCAAATGTGGTGAACAATTTTTTTGTGACCGAGGGCAATTGCT  
 CAAACTATCCTGCAATAATACTCTTTTCACGGAGTTATCCTCTTCTTAATGGCTGTTTTG  
 TTCTCTTGGTCTTTGATCCCTACAATTGTCTCCAACGCCTACATCATCTCCACCATCTC  
 AAGATCCCGTCATCCTCTGGCCGAGGAAATCCTTCTCCACTTGTGCCTCCCACTTCACCTG  
 10 TGTGTGATTGGCTACGGCAGCTGCTTGTCTTCTACGTGAAACCCAAAGCAACGCAGGCA  
 GCTGATTACAATTGGGTAGTTTCCCTGATGGTTTCAGTAGTAACTCCTTCTCAATCCTTT  
 CATCTTACCCTCCGGAATGATAAAGTCATAGAGGCCCTTCGGGATGGGGTGAAACGCTGC  
 TGTCAACTATTCAGGAATTAG (SEQ ID NO: 174)

**AOLFR94 sequences:**

15 METWVNQSYTDGFFLLGIFSHSTADLVLFSSVMAVFTVALCGNVLLIFLIYMDPHLHTPMYFF  
 LSQSLMDLMLVCTNVPKMAANFLSGRKSISFVCGIQIGLVCLVGSEGLLLGLMAYDRYVA  
 ISHPLHYPILMNQRVCLQITGSSWAFGHIIDGLIQMVVMNFPYCGLRKVNHFCEMLSLLKLAC  
 VDTSLFEKVIFACCVFMLLPFSIIVASYAHILGTVLQMHSAQAWKKALATCSSHLTAVTLFYG  
 20 AAMFIYLRPRHYRAPHSHDKVASIFYTVLTPMLNPLIYSLRNREVMGALRKGLDRCRIGSQH  
 (SEQ ID NO: 175)

ATGGAGACGTGGGTGAACCAGTCTACACAGATGGCTTCTTCTCTTAGGCATCTTCTCCC  
 ACAGTACTGCTGACCTTGTCTCTTCTCCGTGGTTATGGCGGTCTTCACAGTGGCCCTCTGT  
 25 GGAATGTCTCTCATCTTCTCATCTACATGGACCCTCACCTTCACACCCCATGTACTT  
 CTCTCTCAGCCAGCTCTCCCTCATGGACCTCATGTTGGTCTGTACCAATGTGCCAAAGATG  
 GCAGCCAACTTCTGTCTGGCAGGAAGTCCATCTCCTTTGTGGGCTGTGGCATACAAATTG  
 GCCTCTTGTCTGTCTTGTGGGATCTGAGGGGCTTGTCTGGGACTCATGGCTTATGACCG  
 CTATGTGGCCATTAGCCACCACTTCACTATCCCATCCTCATGAATCAGAGGGTCTGTCTCC  
 AGATTACTGGGAGCTCCTGGGCCTTTGGGATAATCGATGGCTTGATCCAGATGGTGGTAGT  
 30 AATGAATTTCCTACTGTGGCTTGAGGAAGGTGAACCAATTTCTTCTGTGAGATGCTATCC  
 TTGTTGAAGCTGGCCTGTGTAGACACATCCCTGTTTGAGAAGGTGATATTTGCTTGGTGTG  
 TCTTCATGCTTCTTCCCATCTCCATCATCGTGGCCTCCTATGCTCACATTTAGGGACT  
 GTGCTGCAAAATGCACTCTGCTCAGGCCTGGAAAAAGGCCCTGGCCACCTGCTCTCCACC  
 TGACAGCTGTCAACCCTCTTCTATGGGGCAGCCATGTTTCTACCTGAGGCCTAGGCACTA  
 35 CCGGGCCCCCAGCCATGACAAGGTGGCCTCTATCTTCTACACGGTCTTACTCCCATGCTC  
 AACCCCTCATTTACAGCTTGAGGAACAGGGAGGTGATGGGGGCACTGAGGAAGGGGCTG  
 GACCGCTGCAGGATCGGCAGCCAGCACTGA (SEQ ID NO: 176)

**AOLFR95 sequences:**

40 MLGSKPRVHLYILPCASQQVSTMGDRGTSNHSEMTDFILAGFRVRPELHILLFLLFLFVYAMILL  
 GNVGMMTHMTDPRLNTPMYFFLGNLSFIDLFYSSVIEPKAMINFWSENKSISFAGCVAQLFLFA  
 LLIVTEGFLLAAMAYDRFLAICNPLLYSVQMSTRCTQLVAGSYFCGCISSVIQTSMTFTLSFCAS  
 RAVDHFYCDSPQLRLSCSDLFIHRMISFSLSCIILPTHVIIVSVMYIVSTVLKIHSTEGHKKAFST  
 45 CSSHLGVVSVLYGAVFFMYLTPDRFPELSKVASLCYSLVTPMLNPLIYSLRNKDVQEALKKFLE  
 KKNIL (SEQ ID NO: 177)

ATGCTAGGATCCAAACCAAGAGTTCAATTTGTATATTTTGCCCTGTGCCTCTCAACAGGTTTC  
 TACCATGGGTGACAGGGGAACAAGCAATCACTCAGAAATGACTGACTTCACTTCTGCAGG  
 50 CTTCAGGGTACGCCAGAGCTCCACATTTCTCTCTCTCTGCTATTTTGTGTTTATGCCA  
 TGATCCTTCTAGGGAATGTTGGGATGATGACCAATTATTGACTGATCCTCGGCTGAACAC  
 ACCAATGATTTTTCTAGGCAATCTCTCTTCAATTGATCTTTTCTATTCTGTTATTGA  
 ACCCAAGGCTATGATCAACTTCTGGTCTGAAAAACAAGTCTATCTCTTTGCAAGGCTGTGTG  
 GCCCAGCTCTTCTCTTTGCCCTCCTCATTTGACTGAGGGATTTCTCTGCGGCCATGGC  
 TTATGACCGCTTATTGCCATCTGCAACCCTCTGCTCTACTCTGTTCAAATGTCCACAGTC  
 55 TGTGTACTCAGTTGGTGGCTGGTTCCTATTTTGTGGCTGCATTAGCTCAGTTATTCAGACT  
 AGCATGACATTTACTTTATCTTTTTCGCTTCTCGGGCTGTTGACCACTTTTACTGTGATTC

WO 01/98526

TCGCCCCACTTCAGAGACTGTCTTGTTCTGATCTCTTTATCCATAGAATGATATCTTTTTCCT  
 TATCATGTATTATTATCTTGCCTACTATCATAGTCATTATAGTATCTTACATGTATATTGTG  
 TCCACAGTTCTAAAGATACATTCTACTGAGGGACATAAGAAGGCCTTCTCCACCTGCAGCT  
 CTCACCTGGGAGTTGTGAGTGTGCTGTATGGTGTCTTTTTTATGTATCTCACTCCTGAC  
 5 AGATTTCTGAGCTGAGTAAAGTGGCATCCTTATGTTACTCCCTAGTCACTCCCATGTTGA  
 ATCCTTTGATTACTCTCTGAGGAACAAAGATGTCCAAGAGGCTCTAAAAAATTTCTAGA  
 GAAGAAAAATATTATTCTTTGA (SEQ ID NO: 178)

**AOLFR96 sequences:**

10 MICENHTRVTEFILLGFTNNPEMQVSLFIFFLAIYTVTLLGNFLIVTVTSVDLALQTPMYFFLQN  
 LSLLEVCFILVMVPKMLVDLVSPRKIISFVCGTQMYFFFFFGSSECFLLSMMAYDRFVAICNP  
 LHYSVIMNRSCLLWMAIGSWMSGVPVSMQLQAWMMALPFCGPNAVDFHFFCDGPPVLKLVTV  
 DTTMYEMQALASTLLFIMFPFCLILVSYTRIHTILRMSSATGRQKAFSTCSSHLIVVSLFYGTASL  
 TYLRPKSNQSPESKKLVLSYTVITPMLNPIIYGLRNNEVKGAVKRTITQKVLQKLDVF (SEQ  
 15 ID NO: 179)

ATGATCTGTGAAAATCACACCAGAGTCACTGAATTTATTCTTCTTGTTTTACAAACAACC  
 CCGAGATGCAAGTTTCCCTCTTATTTTTTCTGGCCATTTATACAGTCACTTGTGTTGGC  
 AACTTTCTTATTGTACAGTTACCAGTGTGGATCTCGCACTTCAAACACCCATGTACTTCTT  
 20 TCTTCAAAATCTGTCACTTCTTGAAGTATGTTTACCTTGGTTATGGTGCCAAAAATGCTTG  
 TAGATCTAGTGTCCCAAGGAAATATCTCTTTTGTGGGCTGTGGTACCCAGATGTACTT  
 CTTCTTCTTCTTGGCAGTTCTGAATGTTTCTTCTCTCCATGATGGCTTATGATCGCTTGT  
 GGCCATCTGTAAACCTCTCCATTATTCAGTCATAATGAACAGGTCCCTATGCTTGTGGATG  
 GCCATAGGCTCTTGGATGTCCGGTGTCTGTGTCTATGCTACAGACAGCTTGGATGATGG  
 25 CCTTCTCTTCTGTGGACAAATGCCGTGGACCACTTTTCTGTGATGGTCCCCAGTGTTA  
 AAACAGTACAGTGGATAACAACCATGTATGAAATGCAAGCACTTGCCTCCACACTCCTGT  
 TTATCATGTTTCCCTTTTGTCTCATTTTGGTTTCTACACCGCATTATCATAACAATTCTG  
 AGGATGTCCTCTGCCACTGGCCGCCAGAAGGCATTCTTCTACTTGTCTCACACCTCATGT  
 GGTGTCCCTCTTCTACGGAACAGCCAGTCTGACCTACCTGCGGCCAAATCAAACCACTCC  
 30 CCTGAGAGCAAGAAGCTAGTGTCTTGTCTTCTACACTGTCATCACACCTATGCTAAACCCCA  
 TCATCTACGGCCTGAGGAACAATGAAGTGAAAGGGGCTGTCAAGAGGACAATCACTCAAA  
 AAGTCTTACAGAAGTTAGATGTGTTTTGA (SEQ ID NO: 180)

**AOLFR97 sequences:**

35 MTEFHLQSQMPSIRLIFRRLSLGRIKPSQSPRCSTSFMVVPSFSIAEHWRRMKGANLSQGMFEL  
 LGLTTDPQLQRLLFVFLGMYTATLLGNLVMFLLIHVSATLHTPMYSLKLSLDFCYSSSTVV  
 PQLVNFLAKRKVISYFGCMTQMFFYAGFATSECYLIAAMAYDRYAAICNPPLYSTIMSPEVC  
 ASLIVGSYSAGFLNSLIHTGCIFSLKFCGAHVVTTHFFCDGPPILSLSCVDTSLCEILLFIFAGFNLS  
 CTLTILISYFLILNTILKMSSAQGRFKAFSTCASHLTAICLFFGTTLFMYLRPRSSYSLTQDRTVA  
 40 VIYTVVIPVLNPLMYSRLNKDVKKALIKVWGRKTME (SEQ ID NO: 181)

ATGACAGAGTTTCATCTGCAAAGCCAAATGCCCTCAATAAGACTCATCTTCAGAAGGCTGT  
 CCTTAGGCAGAATTAACCCAGTCAGAGCCCCAGGTGTTCAACCTCATTTATGGTGGTGCC  
 TTCTTTCTCCATCGCAGAGCACTGGAGAAGGATGAAAGGGGCAAACCTGAGCCAAGGGAT  
 45 GGAGTTTGAGCTCTTGGGCCTCACCCTGACCCCCAGCTCCAGAGGCTGCTTCTCGTGGTG  
 TTCCTGGGCATGTACACAGCCACTCTGCTGGGGAACCTGGTCATGTTCTCTCTGATCCATG  
 TGAGTGCCACCCTGCACACCCCATGTACTCCCTCCTGAAGAGCCTCTCTTCTTGGATTC  
 TGCTACTCTCCACGGTGTGCCCCAGACCCTGGTGAACCTCTTGGCCAAGAGGAAAGTGA  
 TCTCTTATTTGGCTGCATGACTCAGATGTTCTTCTATGCGGGTTTTGCCACCACTGATGC  
 50 TATCTCATCGCTGCCATGGCCTATGACCGCTATGCGCTATTTGTAACCCCTGCTCTACTC  
 AACCATCATGTCTCCTGAGGTCTGTGCTCGCTGATTGTGGGCTCCTACAGTGCAGGATTC  
 CACTCACTTCTTCTGTGATGGGCCACCCATCCTGCTTGTCTGTGTAGACACCTCACTGT  
 GTGAGATCCTGCTCTTCAATTTTGTGTTTCAACCTTTTGTAGCTGCACCCCTACCATCTTG  
 55 ATCTCTACTTCTTAATTTCTCAACACCATCCTGAAATGAGCTCGGCCAGGGCAGGTTTA  
 AGGCATTTTCCACCTGTGCATCCACCTCACTGCCATCTGCTCTTCTTGGCACAACACTT



TTTATGTACCTGCGCCCCAGGTCCAGCTACTCCTTGACCCAGGACCGCACAGTTGCTGTCA  
TCTACACAGTGGTGATCCAGTGCTGAACCCCTCATGTACTCTTTGAGAAACAAGGATGT  
GAAGAAAGCTTTAATAAAGGTTTGGGGTAGGAAAACAATGGAATGA (SEQ ID NO: 182)

5 **AOLFR98 sequences:**

MRGFNKTTVVVTQFILVGFSSLGELQLLLFVIFLLLYLTILVANVTIMAVIRFSWTLHTPMYGFLEI  
LSFSESCYTFVIIPQLLVHLLSDTKTISFMACATQLFFFLGFACTNCLLIAMGYDRYVAICHPLR  
YTLIINKRLGLELISLSGATGFFIALVATNLICDMRFCGPNRVNHYFCDMAPVIKLACTDTHVKE  
LALFSLILVIMVPFLILISYGFIVNTILKIPSAEGKKAFTVCASHLTVFVHYGCASIIYLRPKSK  
10 SASDKDQLVAVTYTVVTPLLNPLVYSLRNKEVKTALKRVLGMPVATKMS (SEQ ID NO: 183)

ATGCGAGGTTTCAACAAAACCACTGTGGTTACACAGTTCATCCTGGTGGGTTTCTCCAGCC  
TGGGGGAGCTCCAGCTGCTGCTTTTGTGTCATCTTCTCTCCTATACTTGACAATCCTGGTG  
GCCAATGTGACCATCATGGCCGTTATTCGCTTCAGCTGGACTCTCCACACTCCCATGTATG  
15 GCTTTCTATTTCATCCTTTTCACTTTCTGAGTCCTGCTACACTTTTGTGTCATCATCCCTCAGCTGC  
TGGTCCACCTGCTCTCAGACACCAAGACCATCTCCTTCATGGCCTGTGCCACCCAGCTGTT  
CTTTTCTCTGGCTTTGCTTGCACCAACTGCCTCCTCATTGCTGTGATGGGATATGATCGCT  
ATGTAGCAATTTGTGACCCCTCTGAGGTACACACTCATCATAAACAAGGCTGGGGTTGGA  
GTTGATTTCTCTCTCAGGAGCCACAGGTTTCTTTATTGCTTTGGTGGCCACCAACCTCATT  
20 GTGACATGCGTTTTTGTGGCCCCAACAGGGTTAACCCTATTTCTGTGACATGGCACCTGT  
TATCAAGTTAGCCTGCACTGACACCCATGTGAAAGAGCTGGCTTTATTAGCCTCAGCATC  
CTGGTAATTATGGTGCTTTTCTGTAAATTCTCATATCCTATGGCTTCATAGTTAACACCAT  
CCTGAAGATCCCCTCAGCTGAGGGCAAGAAGGCCTTTGTCACTGTGCCTCACATCTCACT  
GTGGTCTTTGTCCACTATGGCTGTGCCTCTATCATCTATCTGCGGCCCAAGTCCAAGTCTGC  
25 CTCAGACAAGGATCAGTTGGTGGCAGTGACCTACACAGTGGTACTCCCTTACTTAATCCT  
CTTGTCTACAGTCTGAGGAACAAAGAGGTAAAACTGCATTGAAAAGAGTTCTTGGAATG  
CCTGTGGCAACCAAGATGAGCTAA (SEQ ID NO: 184)

**AOLFR99 sequences:**

30 MERVNETVVREVIPLGFSSLARLQQLFVIFLLLYLFTLGTNAIISTIVLDRALHIPMYFFLAILSC  
SEICYTFIIVPKMLVDLLSQKKTISFLGCAIQMFSFLFLGCSHSFLLAVMGYDRYIAICNPLRYSV  
LMGHGVCMLGVAAACACGFTVAQIITSLVFHLPFYSSNQLHHFFCDIAPVLKLASHHNHFSQIV  
IFMLCTLVLAIPLLLILVSYVHLSAILQFPSTLGRCKAFSTCVSHLIIVTVHYGCASFIYLRPQSNY  
SSSQDALISVSYTIITPLFNPMIYSLRNKEFKSALCKIVRRTISLL (SEQ ID NO: 185)

35 ATGGAGCGGGTCAATGAGACTGTGGTGAGAGAGGTCATCTTCTCGGCTTCTCATCCCTGG  
CCAGGCTGCAGCAGCTGCTCTTTGTTATCTTCTGCTCCTCTACCTGTTCACTCTGGGCACC  
AATGCAATCATCATTTCCACCATTGCTCTGGACAGGGCCCTTCATATCCCCATGTACTTCTT  
CCTTGCCATCCTCTCTTGCTCTGAGATTTGCTACACCTTCATCATTGTACCCAAGATGCTGG  
40 TTGACCTGCTGTCCCAGAAGAAGACCATTTCTTCTGCTGGGCTGTGCCATCCAAATGTTTTCC  
TTCCTCTTCTTGGCTGCTCTCACTCCTTTCTGCTGGCAGTCATGGGTTATGATCGTTACAT  
AGCCATCTGTAACCCACTGCGCTACTCAGTGCTAATGGGACATGGGGTGTGTATGGGACTA  
GTGGCTGCTGCCTGTGCCTGTGGCTTCACTGTTGCACAGATCATCACATCCTTGGTATTTCA  
CCTGCCTTTTTATTCTCCAATCAACTACATCACTTCTTCTGTGACATTGCTCCTGCTCTCA  
45 AGCTGGCATCTCACCATAACCACTTTAGTCAGATTGTCATCTTCATGCTCTGTACATTGGTC  
CTGGCTATCCCCTTATTGTTGATCTTGGTGTCTATGTTACATCCTCTCTGCCATACTTCA  
GTTTCCTTCCACACTGGGTAGGTGCAAAGCTTTTCTACCTGTGTATCTCACCTCATTATTG  
TCACTGTCCACTATGGCTGTGCCTCCTTTATCTACTTAAGGCCTCAGTCCAATACTCTCTCA  
AGCCAGGATGCTCTAATATCAGTATCCTACACTATTATAACTCCATTGTTCAACCCAATGA  
50 TTTATAGCTTGAGAAATAAAGAGTTCAAATCAGCTCTTTGTAAAATTGTGAGAAGAACAAT  
TTCCTGTTGTAA (SEQ ID NO: 186)

**AOLFR101 sequences:**

MDTGNWSQVAEFILGFPHLQGVQIYLFLLLLLIYLMTVLGNLLIFLVCLDSRLHTPMYHFVSI  
55 LSFSELGYTAATIPKMLANLLSEKKTISFSGCLLQIYFFHSLGATECYLLTAMAYDRYLAICRPL  
HYPTLMTPTLCAEIAIGCWLGGLAGPVVEISLISRLPFCGPNRIQHVFCDFPVLACTDTSINV





**AOLFR105 sequences:**

ATGCAGGGGCTAAACCCACACCTCCGTGCTGAATTCATCCTCGTTGGCTTCTCTGCCTTCCC  
CCACCTCCAGCTGATGCTCTTCTGCTGTTCTGCTGATGTACCTGTTACGCTGCTGGGCA  
ACCTGCTCATCATGGCCACTGTCTGGAGCGAGCGCAGCCTCCACATGCCCATGTACCTCTT  
25 CCTGTGTGCCCTCTCCATCACCGAGATCCTCTACACCGTGGCCATCATCCCGCGCATGCTG  
GCCGACCTGCTGTCCACCCAGCGCTCCATCGCCTTCTGTCCTGTGCCAGTCAGATGTTCTT  
CTCCTTCAGCTTCGGCTTCACCCACTCCTTCTGCTCACTGTCTATGGGCTACGACCGCTACG  
TGGCCATCTGCCACCCCTGCGTTACAACGTGCTCATGAGCCTGCGGGGCTGCACCTGCCG  
GGTGGGCTGCTCCTGGGCTGGTGGCTTGGTCATGGGGATGGTGGTGACCTCGGCCATTTTC  
30 CACCTCGCCTTCTGTGGACACAAGGAGATCCACCATTCTTCTGCCACGTGCCACCTCTGTT  
GAAGTTGGCCTGTGGAGATGATGTGCTGGTGGTGGCCAAAGGCGTGGGCTTGGTGTGTAT  
CACGGCCCTGCTGGGCTGTTTTCTCCTCATCCTCCTCTCCTATGCCTTCATCGTGGCCGCCA  
TCTTGAAGATCCCTTCTGCTGAAGGTCGGAACAAGGCCTTCTCCACCTGTGCCTCTCACCT  
CACTGTGGTGGTTCGTGCACTATGGCTTTGCCTCCGTCATTTACCTGAAGCCCAAAGGTCCC  
35 CAGTCTCCGGAAGGAGACACCTTGATGGGCATCACCTACACGGTCTCACACCCTTCCTCA  
GCCCCATCATCTTCAGCCTCAGGAACAAGGAGCTGAAGGTCGCCATGAAGAAGACTTGCTT  
CACCAAACCTCTTCCACAGAACTGCTGA (SEQ ID NO: 194)

40 METANYTKVTEFVLTGLSQTPEVQLVLFVIFLSFYLFILPGNIICTISLDPHLTSPMYFLLANLA  
FLDIWYSSITAPEMLIDFFVERKIIISFDGCIQLFFLHFAGASEMFLLTVMAFDLYTAICRPLHYA  
TIMNQRLCCILVALSWRGGFIHSIIQVALIVRLPFCGPNELDSYFCDITQVVRIACANTFPEELVM  
ICSSGLISVVCLIALMSYAFLLALFKKLSGSGENTNRAMSTCYSHITIVLMFGPSIYIYARPF  
SFSLDKVVSVFNTLIFPLRNPIIYTLRNKEVKAAAMRKLVTKYILCKEK (SEQ ID NO: 195)

100

WO 01/98526

5 GAAACTTTCAGGCTCAGGTGAGAATACCAACAGGGCCATGTCCACCTGCTATTTCCACATT  
 ACCATTGTGGTGCTAATGTTTGGGCCATCCATCTACATTTATGCTCGCCCATTTGACTCGTT  
 TTCCCTAGATAAAGTGGTGTCTGTGTTCAATACTTTAATATCCCTTTACGTAATCCCATT  
 TTTACACATTGAGAAACAAGGAAGTAAAGGCAGCCATGAGGAAGTTGGTCACCAATATA  
 TTTTGTGTAAAGAGAAGTGA (SEQ ID NO: 196)

## AOLFR107 sequences:

10 MELWNFTLGSFILVGILNDSGSPPELLCATITILYLLALISNGLLLLAITMEARLHMPMYLLLGQ  
 LSLMDLLFTSVVTPKALADFLRRENTISFGGALQMFLALTMGGAEDLLAFMAYDRYVAICH  
 PLTYMTLMSSRACWLMVATSWILASLSALIYTVYTMHYPCRAQEIRHLLCEIPHLKLVACAD  
 TSTRYELMVYVMGVTFILPSLAAILASYTQILLTVLHMPSNEGRKKALVTCSSHLTVMFYGA  
 ATFMVLPSSFHSTRQDNISVFYITVTPALNPLIYSLRNKEVMRALRRVLGKMYLPAHSTL  
 (SEQ ID NO: 197)

15 ATGGAGCTCTGGAACCTCACCTTGGGAAGTGGCTTCATTTTGGTGGGGATTCTGAATGACA  
 GTGGGTCTCCTGAACTGCTCTGTGCTACAATTACAATCCTATACTTGTGGCCCTGATCAG  
 CAATGGCCTACTGCTCCTGGCTATCACCATGGAAGCCCGGCTCCACATGCCCATGTACCTC  
 CTGCTTGGGCAGCTCTCTCATGGACCTCCTGTTACATCTGTTGTAATCCCAAGGCCCT  
 TGCGGACTTTCTGCGCAGAGAAAACACCATCTCCTTTGGAGGCTGTGCCCTTCAGATGTTT  
 20 CTGGCACTGACAATGGGTGGTGGTGGAGACCTCCTACTGGCCTTCATGGCCTATGACAGGT  
 ATGTGGCCATTTGTATCCTCTGACATACATGACCCCTCATGAGCTCAAGAGCCTGCTGGCT  
 CATGGTGGCCACGTCTGATCCTGGCATCCCTAAGTGCCCTAATATATACCGTGTATACC  
 ATGCACTATCCCTTCTGCAGGGCCCAGGAGATCAGGCATCTTCTGTGAGATCCCACT  
 TGCTGAAGGTGGCCTGTGCTGATACCTCCAGATATGAGCTCATGGTATATGTGATGGGTGT  
 25 GACCTTCTGATTCCTCTCTTGTGCTATACTGGCCTCCTATACACAAATTCTACTACTG  
 TGCTCCATATGCCATCAAATGAGGGGAGGAAGAAAGCCCTGTACCTGCTCTTCCACCT  
 GACTGTGGTTGGGATGTTCTATGGAGCTGCCACATTCATGTATGTCTTGGCCAGTTCCTTC  
 ACAGCACCAGACAAGACAACATCATCTCTGTTTCTACACAATTGTCACTCCAGCCCTGAA  
 TCCACTCATCTACAGCCTGAGGAATAAGGAGGTCTGCGGGCCTTGAGGAGGGTCTGGG  
 30 AAAATACATGCTGCCAGCACACTCCACGCTCTAG (SEQ ID NO: 198)

## AOLFR108 sequences:

35 MCSFFLCQTKQAKISMGEENQTFVSKFIFLGLSQDLQTLILLFILHLYLLTVLGNQLIHLFLD  
 SRLHTPMYFFLRNLSFADLCFSTSIQVVLVHFLVKKRTISFYGCMTQIIVFLLVGTECALLAV  
 MSYDRYVAVCKPLYSTIMTQRVCLWLSFRSWASGALVSLVDTSTFHLPHYWGQNIINHYFCE  
 PPALLKLASIDTYSTEMAIFSMGVVILLAPVSLILGSYWNIISTVIQMQSGEGRKAFSTCGSHLI  
 VVVLFGSGIFTYMRPNSKTTKELDKMISVFYTAFTPMLNPIIYSLRNKDVKGALRKLVRGRC  
 FSHRQ (SEQ ID NO: 199)

40 ATGTGTTCTTTTTCTTGTGCCAAACAGGTAAACAGGCCAAAAATATCAATGGGAGAAGAAA  
 ACCAAACCTTTGTGTCCAAGTTTATCTTCTGGGTCTTTCACAGGACTTGCAGACCCAGAT  
 CCTGCTATTTATCCTTTTCTCATCTTTATCTGCTGACCGTGCTTGGAAACCAGCTCATCA  
 TCATTCTCATCTTCTGGATTCTCGCCTTCACTCCCATGTATTTTTTCTTAGAAATCTCT  
 CCTTGCAGATCTCTGTTTCTCTACTAGCATTGTCCCTCAAGTGTTGGTTCACTTCTTGGTA  
 45 AAGAGGAAAACCATTTCTTTTTATGGGTGTATGACACAGATAATTGTCTTCTTCTGTTG  
 GGTGTACAGAGTGTGCGCTGCTGGCAGTGATGTCCTATGACCGGTATGTGGCTGTCTGCAA  
 GCCCCTGTACTACTCTACCATCATGACACAACGGGTGTGTCTCTGGCTGTCTCAGGTCTT  
 GGGCCAGTGGGGCACTAGTGTCTTTAGTAGATAACAGCTTTACTTTCCATCTTCCCTACTG  
 GGGACAGAATATAATCAATCACTACTTTTGTGAACCTCCTGCCCTCCTGAAGCTGGCTTCC  
 50 ATAGACACTTACAGCACAGAAATGGCCATCTTTTCAATGGGCGTGGTAATCCTCCTGGCCC  
 CTGTCTCCCTGATTCTTGGTTCTTATTGGAATATTATCTCCACTGTTATCCAGATGCAGTCT  
 GGGGAAGGGAGACTCAAGGCTTTTTCCACCTGTGGCTCCCATCTTATTGTTGTTGTCTCTT  
 CTATGGGTCAGGAATATTCACCTACATGCGACCAAACTCCAAGACTACAAAAGAACTGGA  
 TAAAATGATATCTGTGTTCTATACAGCGGTGACTCCAATGTTGAACCCATAATTTATAGC  
 55 TTGAGGAACAAAGATGTCAAAGGGCTCTCAGGAACTAGTTGGGAGAAAGTGCTTCTCT  
 CATAGGCAGTGA (SEQ ID NO: 200)

**AOLFR109 sequences:**

- MLRNGSIVTEFILVGFQSSSTRALLFALFLALYSLTMAMNGLIIFITSWTDPKLNSPMYFFLG  
 5 HSLSLDVCFITTTIPQMLIHLVVRDHIVSFVCCMTQMYFVFCVGVAECILLAFMAYDRYVAICY  
 PLNYVPIISQKVCVRLVGTAWFFGLINGIFLEYISFREPFRRDNHIESFFCEAPIVIGLSCGDPQFSL  
 WAIFADAIVVILSPMVLTVTSYVHILATILSKASSSGRGKTFSTCASHLTVVIFLYTSAMFSYMN  
 PHSTHGPDKDKPFSLLYTIITPMCNPIIYSFRNKEIKEAMVRALGRTRLAQPSV (SEQ ID NO:  
 201)
- 10 ATGCTAAGGAATGGCAGCATAGTGACGGAATTTATCCTCGTGGGCTTTCAGCAGAGCTCCA  
 CTTCCACACGAGCATTGCTCTTTGCCCTCTTCTTGGCCCTCTACAGCCTCACCATTGGCCATG  
 AATGGCCTCATCATCTTTATCACCTCCTGGACAGACCCCAAGCTCAACAGCCCCATGTACT  
 TCTTCTCGGCCATCTGTCTCTCCTGGATGTCTGCTTCATCACCATTACCATCCACAGATG  
 TTGATCCACCTCGTGGTCAGGGACCACATTGTCTCCTTTGTATGTTGCATGACCCAGATGT  
 15 ACTTTGTCTTCTGTGTTGGTGTGGCCGAGTGCATCCTCTTGGCTTTCATGGCCTATGACCGT  
 TATGTTGCTATCTGCTACCCACTTAAGTATGTCCCGATCATAAGCCAGAAGGTCTGTGTCA  
 GGCTTGTGGGAAGTGCCTGGTCTTTGGGCTGATCAATGGCATCTTTCTCGAGTATATTTT  
 ATTCCGAGAGCCCTTCCGAGAGACAACCACATAGAAAGCTTCTTCTGTGAGGCCCCCAT  
 GTGATTGGCCTCTCTTGTGGGGACCCCTCAGTTTAGTCTGTGGGCAATCTTTGCCGATGCCA  
 20 TCGTGGTAATTCTCAGCCCCATGGTGCTCACTGTCACTTCCTATGTGCACATCCTGGCCACC  
 ATCCTCAGCAAAGCCTCCTCCTCAGGTGCGGGGAAGACTTTCTCTACTTGTGCCTCTCACC  
 TGACTGTGGTCATCTTTCTCTACACTTCAGCTATGTTCTCTTACATGAACCCCCACAGCACA  
 CATGGGCCTGACAAAGACAAACCTTTCTCCCTCCTGTACACCATCATTACCCCATGTGCA  
 ACCCATCATTTATAGTTTCCGCAACAAGGAAATTAAGGAGGCCATGGTGAGGGCACTTG  
 25 GAAGAACCAGGCTGGCCCAGCCACAGTCTGTCTAG (SEQ ID NO: 202)

**AOLFR110 sequences:**

- MKIANNTVVTEFILLGLTQSQDIQLLVFVLILIFYLILPGNFIIFTIRSDPGLTAPLYLFLGNLAFL  
 30 DASYSFIVAPRMLVDFLSEKKVISYRGCTQLFFLHFLGGEGLLLVMFAFDRIAICRPLHCST  
 VMNPRACYAMMLALWLGGFVHSIIQVVLRLPFCGPNQLDNFFCDVRQVIKLA CTDMFVVEL  
 LMVFNSGLMTLLCFLGLLASYAVILCHVRRASEGKNKAMSTCTTRVIIIILMFGPAIFIYMCPP  
 RALPADKMVSLFHTVIFPLMNPMIYTLRNQEVKTSMKRLLSRHVVCQVDFIIRN (SEQ ID NO:  
 203)
- 35 ATGAAGATAGCAAACAACACAGTAGTGACAGAATTTATCCTCCTTGGTCTGACTCAGTCTC  
 AAGATATTCAGCTCTTGGTCTTTGTGCTGATCTTAATTTCTACCTTATCATCCTCCCTGGA  
 AATTTTCTCATTATTTTACCATAAAGGTGAGCCCTGGGCTCACAGCCCCCTCTATTTATT  
 TCTGGGCAACTTGGCCTTCTGATGCATCCTACTCCTTCAATTGTGGCTCCCAGGATGTTGG  
 TGGACTTCTCTCTGAGAAAAAGGTAATCTCCTACAGAGGCTGCATCACTCAGCTCTTTT  
 40 CTTGCACTTCTTGGAGGAGGGGAGGGATTACTCCTTGTGTTGTGATGGCCTTTGACCGCTAC  
 ATCGCCATCTGCCGGCCTCTGCACTGTTCAACTGTCTATGAACCCTAGAGCCCTGCTATGCAA  
 TGATGTTGGCTCTGTGGCTTGGGGGTTTTGTCCACTCCATTATCCAGGTGGTCTCATCCTC  
 CGCTTGCTTTTTGTGGCCCAAACCAGCTGGACAACTTCTTCTGTGATGTCCGACAGGTCA  
 TCAAGCTGGCTTGACCGACATGTTTGTGGTGGAGCTTCTAATGGTCTTCAACAGTGGCCT  
 45 GATGACACTCCTGTGCTTTCTGGGGCTTCTGGCTTCTATGCAGTCATCCTCTGCCATGTTT  
 GTAGGGCAGCTTCTGAAGGGAAGAAACAAGGCCATGTCCACGTGCACCACTCGTGTCATTA  
 TTATACTTCTTATGTTTGGACCTGCTATCTTCATCTACATGTGCCCTTTCAGGGCCTTACCA  
 GCTGACAAGATGGTTTCTCTCTTTACACAGTGATCTTTCCATTGATGAATCCTATGATTTA  
 TACCCTTCGCAACCAGGAAGTGAAAACCTCCATGAAGAGGTTATTGAGTCGACATGTAGTC  
 50 TGTCAAGTGGATTTTATAATAAGAACTGA (SEQ ID NO: 204)

**AOLFR111 sequences:**

- MCYIYLIFKEWTLIFYFSLLLFLQITPAIMANLTIVTEFILMGFSTNKNMCILHSILFLLIYLCALM  
 55 GNVLIIMITLTDHHLHTPVYFLKNLSFLDLCLISVTAPKSIANSIHNNSISFLGCVSQVFLLSS  
 ASAELLLLTVMSFDRYTAICHPLHYDVIMDRSTCVQRATVSWLYGGGLIIVMHTAGTFSLSYCG  
 SNMVHQFFCDIPQLLAISCSSENIREIALILINVVLDFCCFIVIIITYVHVSTVKKIPSTEGQSKAY

WO 01/98526

SICLPHLLVVFLSTGFIAYLKPASESPSILDAVISVFYTMPLPTFNPIIYSLRNKAIKVALGMLIKG  
KLTKK (SEQ ID NO: 205)

5 ATGTGTTATATATATTTAATATTTAAAGAGTGGACATTGATATTTTACTTCAGTCTTCTCT  
TTTCCTGCAGATTACTCCTGCAATAATGGCAAATCTCACAATCGTGACTGAATTTATCCTTA  
TGGGGTTTTCTACCAATAAAAAATATGTGCATTTTGCATTGCTCTTCTTGTGATTAT  
TTGTGTGCCCTGATGGGGAATGTCTCATTATCATGATCACAACCTTGGACCATCATCTCC  
ACACCCCGTGTATTTCTTCTTGAAGAATCTATCTTTCTTGGATCTCTGCCTTATTTAGTC  
ACGGCTCCCAAATCTATCGCCAATTTTGTGATACACAACAACCTCCATTTTCTTGGCTG  
10 TGTTCCTCCAGGTCTTTTGTGCTTTCTCAGCATCTGCAGAGCTGCTCCTCCTCACGGTGA  
TGTCTTTGACCGCTATACTGCTATATGTACCCCTGCACTATGATGTATCATGGACAGG  
AGCACCTGTGTCCAAAGAGCCACTGTGTCTTGGCTGTATGGGGTCTGATTGCTGTGATGC  
ACACAGCTGGCACCTTCTCCTTATCCTACTGTGGGTCCAACATGGTCCATCAGTTCTTCTGT  
GACATCCCCAGTTATTAGCTATTTCTGCTCAGAAAATTTAATAAGAAATTGCACTCA  
15 TCCTTATTAATGTAGTTTGGATTCTGCTGTTTTATTGTATCATCATCATTACCTATGTCCAC  
GTCTTCTCTACAGTCAAGAAGATCCCTCCACAGAAGGCCAGTCAAAAGCCTACTCTATT  
GCCTCCACACTTGTGGTTGTGTTATTTCTTCCACTGGATTGATTGCTTATCTGAAGCCA  
GCTTCAGAGTCTCCTTCTATTTGGATGCTGTAATTTCTGTGTTCTACACTATGCTGCCCC  
AACCTTTAATCCCATTATATACAGTTTGAGAAACAAGGCCATAAAGGTGGCTCTGGGGATG  
20 TTGATAAAGGGAAAGCTACCAAAAAGTAA (SEQ ID NO: 206)

## AOLFR113 sequences:

MKFWHGFSSHLNPMFSSFLLYSLPWINTTIQAWLNLCSLALPVWAMSGAGFLSCCYWHTCSP  
SVVTCSSSQSSDWMQLCTHLCTTSLVFFPSWSCGIQLPLSLRCLIFSRRKPFLLQDASFRPTSS  
25 TPWGACECYLLTAMAYDRYLAICRPLHYPIIMTTTLCAKMAAACWTCGFLCPISEVILASQLPF  
CAYNEIQHIFCDFPPLSLACKDTSANILVDFAINAFILITFFIMISYARIIGA VLKIKTASGRKK  
AFSTCASHLAVVLIFFGSIIFMYVRLKKSYSLTLDRTLAIVSVLTPMVNPIIYSLRNKEIKAIR  
TIFQGDKASLAHL (SEQ ID NO: 207)

30 ATGTGTCAACAAATCTTACGGGATTGCATTCTTCTCATACATCATTGTGCATTAACAGGA  
AAAAAGTCTCATTGTGATGCTGGGTCCAGCTTATAACCACACAATGGAAACCCCTGCCTC  
CTTCTCCTTGTGGGTATCCCAGGACTGCAATCTTCACATCTTGGCTGGCTATCTCACTGA  
GTGCCATGTACATCATAGCCCTGTAGGAAACACCATCATCGTGACTGCAATCTGGATGGA  
TTCCACTCGGCATGAGCCCATGTATTGCTTTCTGTGTTCTGGCTGCTGTGGACATTGTA  
35 TGGCCTCCTCGGTGGTACCCAAGATGGTGAGCATCTTCTGCTCAGGAGACAGCTCAATCAG  
CTTTAGTGCTTGTTCCTCAGATGTTTTGTGCTTACTAGCCATCTGCAAGCCTCTACACTACAAGA  
CTGCTGCTGACCATGGCTTTGACCGCTATGTAGCCATCTGCAAGCCTCTACACTACAAGA  
GAATTCTCACGCCTCAAGTGATGCTGGGAATGAGTATGGCCATCACCATCAGAGCTATCAT  
AGCCATAACTCCACTGAGTTGGATGGTGAGTCATCTACCTTTCTGTGGCTCCAATGTGGTT  
40 GTCCACTCCTACTGTGAGCACATAGCTTTGGCCAGGTTAGCATGTGCTGACCCCTTCAATTGCT  
GCAGTCTCTACAGTCTGATTGGTTCTCTTATGGTGGGCTCTGATGTGGCCTTCAATTGCT  
GCCTCTATATCTTAATTCTCAAGGCAGTATTTGGTCTCTCCTCAAAGACTGCTCAGTTGAA  
AGCATTAAAGCATGTGGCTCCCATGTGGGGGTTATGGCTTTGTACTATCTACCTGGGATG  
GCATCCATCTATGCGGCCTGGTTGGGGCAGGATGTAGTGCCCTTGACACCCCAAGTCCTGC  
45 TAGCTGACCTGTACGTGATCATCCAGCCACCTTAAATCCCATCATCTATGGCATGAGGAC  
CAACAACCTGCGGGAGAGAATATGGAGTTATCTGATGCATGCTCTTTGACCATTCCAAC  
CTGGGTTCTATGA (SEQ ID NO: 208)

## AOLFR114 sequences:

50 MERINHNTSSVSEFILLGLSSRPEDQKTLFVLFLIVYLVTITGNLLILAIRFNPHLQTPMYFFLSFLS  
LTDICFTTSVVPKMLMNFLSEKKTISYAGCLTQMYFLYALGNSDSCLLAVMAFDYVAVCDPF  
HYVTTMSHHHCVLLVAFSCSFPHLSLLHTLLNRLTFCDNSNVIHFLCDLSPVLKSCSSIFVN  
EIVQMTEAPIVLVTRFLCIAFSYIRILTTVLKIPSTSGKRKAFSTCGFYLTVVTLFYGSIFCVYLQ  
PSTYAVKDHVATIVYTVLSSMLNPFYSLRNKDLKQGLRKLMSKRS (SEQ ID NO: 209)

55

ATGGAAAGAATCAACCACACCAGCAGTGTCTCCGAGTTTATCCTCCTGGGACTCTCCTCCC  
 GGCCTGAGGACCAAAAGACACTCTTTGTTCTCTTCCTCATCGTGTACCTGGTCACCATAAC  
 AGGGAACCTGCTCATCATCTGGCCATTTCGCTTCAACCCCCATCTTCAGACCCCTATGTATT  
 TCTTCTTGAGTTTTCTGTCTCTCACTGATATTTGCTTTACAACAAGCGTTGTCCCCAAGATG  
 5 CTGATGAACCTTCTGTGAGAAAAGAAGACCATCTCCTATGCTGGGTGTCTGACACAGATGT  
 ATTTTCTCTATGCCTTGGGCAACAGTGACAGCTGCCTTCTGGCAGTCATGGCCTTTGACCG  
 CTATGTGGCCGTCTGTGACCCCTTTCCACTATGTCAACCACCATGAGCCACCACCACTGTGTCC  
 TGCTGGTGGCCTTCTCCTGCTCATTTCTCACCTCCACTCACTCCTGCACACACTTCTGCTG  
 AATCGTCTCACCTTCTGTGACTCCAATGTTATCCACCACCTTTCTCTGTGACCTCAGCCCTGT  
 10 GCTGAAATTGTCTGCTCTTCCATATTTGTCAATGAAATTGTGCAGATGACAGAAGCACCT  
 ATTGTTTTGGTGACTCGTTTTCTCTGCATTGCTTTCTCTTATATACGAATCCTCACTACAGT  
 TCTCAAGATTCCCTCTACTTCTGGGAAACGCAAAGCCTTCTCCACCTGTGGTTTTTACCTCA  
 CCGTGGTGACGCTCTTTTATGGAAGCATCTTCTGTGTCTATTTACAGCCCCCATCCACCTAC  
 GCTGTCAAAGGACCACGTGGCAACAATTGTTTACACAGTTTTGTTCATCCATGCTCAATCCTT  
 15 TTATCTACAGCCTGAGAAACAAAGACCTGAAACAGGGCCTGAGGAAGCTTATGAGCAAGA  
 GATCCTAG (SEQ ID NO: 210)

**AOLFR115 sequences:**

MEGFYLRRSHELQGMGKPGRVNQTTVSDFLLLGLSEWPPEQPLLFGIFLGMVLTVMVGNLLII  
 20 LAISSDPHLHTPMYFFLANLSLTDACFTSASIPKMLANIHTQSQIISYSGCLAQLYFLLMFGLD  
 NCLLAVMAYDRYVAICQLHYSTSMSPQLCALMLGVCWVLTNCPALMHITLLTRVAFCAQK  
 AIPHFYCDPSALLKLACSDTHVNELMIITMGLLFLTVPLLLIVFSYVRIFWAVFVISSPGGRWKA  
 FSTCGSHLTVVLLFYGSLMGVYLLPPSTYSTERESRAAVLYMVIPTLNPFIYSLNRNDRMKEALG  
 KLFVSGKTFFL (SEQ ID NO: 211)

25 ATGGAAGGTTTTATCTGCGCAGATCACACGAACTACAAGGGATGGGAAAACCAGGCAGA  
 GTGAACCAAACCACTGTTTCAGACTTCCTCCTTCTAGGACTCTCTGAGTGGCCAGAGGAGC  
 AGCCTCTTCTGTTTGGCATCTTCCTTGGCATGTACCTGGTCACCATGGTGGGGAACCTGCTC  
 ATTATCCTGGCCATCAGCTCTGACCCACACCTCCATACTCCCATGTACTTCTTTCTGGCCAA  
 30 CCTGTCAATTAACCTGATGCCTGTTTCACTTCTGCCTCCATCCCCAAAATGCTGGCCAAACATTC  
 ATACCCAGAGTCAGATCATCTCGTATTCTGGGTGTCTTGCACAGCTATATTTCTCCTTATG  
 TTTGGTGGCCTTGACAACTGCCTGCTGGCTGTGATGGCATATGACCGCTATGTGGCCATCT  
 GCCAACCCTCCATTACAGCACATCTATGAGTCCCCAGCTCTGTGCTACTAATGCTGGGTGT  
 GTGCTGGGTGCTAACCAACTGCTCCTGCCCTGATGCACACACTGTTGCTGACCCGCTGGCT  
 35 TTCTGTGCCCAGAAAGCCATCCCTCATTTCTATTGTGATCCTAGTGCTCTCCTGAAGCTTGC  
 CTGCTCAGATACCCATGTAAACGAGCTGATGATCATCACCATGGGCTGCTGTTCTCCTACT  
 GTTCCCCTCCTGCTGATCGTCTTCTCCTATGTCCGCATTTTCTGGGCTGTGTTTGTCTCTC  
 ATCTCCTGGAGGGAGATGGAAGGCCTTCTCTACCTGTGGTTCTCATCTCACGGTGGTTCTG  
 CTCTTCTATGGGTCTCTTATGGGTGTGATTTACTTCTCCATCAACTTACTCTACAGAGAG  
 40 GGAAAGTAGGGCTGCTGTTCTCTATATGGTGATTATTCCCACGCTAAACCCATTCAATTAT  
 AGCTTGAGGAACAGAGACATGAAGGAGGCTTTGGGTAAACTTTTTGTCAAGTGGAAAAACA  
 TTCTTTTTATGA (SEQ ID NO: 212)

**AOLFR116 sequences:**

45 MDEANHSVVFSEFVFLGLSDSRKIQLLLFLFFSVFYVSSLMGNLLIVLTVTSDPRLQSPMYFLLAN  
 LSIINLVFCSSTAPKMIYDLFRKHTISFGGCVVQIFFIHAVGGTEMVLLIAMAFDRYVAICKPLH  
 YLTIMNPQRCLFLVISWIIHISVIQLAFVVDLLFCGPNELDSFFCDLPRFIKLACIETYTLGFMV  
 TANSFISLASFLILISYIFLVTVQKSSGGIFKAFLMLSAHVIVVVLVFGPLIFFYIFPPTSHLD  
 KFLAIFDAVITPVLNPVIYTFRNKEMMVAMRRRCSQFVNYSKIF (SEQ ID NO: 213)

50 ATGGATGAAGCCAATCACTCTGTGGTCTCTGAGTTTGTGTTCTCCTGGGACTCTCTGACTCGC  
 GGAAGATCCAGCTCCTCCTCTTCTCTTTTTCTCAGTGTTCTATGTATCAAGCCTGATGGGA  
 AATCTCCTCATTGTGCTAACTGTGACCTCTGACCCTCGTTTACAGTCCCCCATGTACTTCTC  
 GCTGGCCAACCTTTCCATCATCAATTTGGTATTTTGTTCCTCCACAGCTCCCAAGATGATTT  
 55 ATGACCTTTTTCAGGAAGCACAAGACCATCTCTTTTGGGGGCTGTGTAGTTCAGATCTTCTT  
 TATCCATGCAGTTGGGGGAACTGAGATGGTGCTGCTCATAGCCATGGCTTTTGACCGATAT

GTGGCCATATGTAAGCCTCTCCACTACCTGACCATCATGAACCCACAAAGGTGCATTTTGT  
TTTTAGTCATTTTCTGGATTATAGGTATTATTCACTCAGTGATTGAGTTGGCTTTTGTGTA  
GACCTGCTGTTCTGTGGCCCTAATGAATTAGATAGTTTCTTTTGTGATCTTCTCGATTAT  
5 CAAACTGGCTTGCATAGAGACCTACACATTGGGATTCATGGTTACTGCCAATAGTGGATT  
ATTCTCTGGCTTCTTTTAAATTCTCATAATCTCTTACATCTTATTTTGGTGACTGTTTCTG  
AAAAAATCTTCAGGTGGTATATTCAAGGCTTCTCTATGCTGTCAGCTCATGTCATTGTGG  
TGGTTTTGGTCTTTGGGCCATTAATCTTTTCTATATTTTCCATTCCCACATCATCTTG  
ATAAATTCCTTGGCATCTTTGATGCAGTTATCACTCCCCTTTTGAATCCAGTCATCTATACT  
10 TTTAGAAATAAAGAGATGATGGTGGCAATGAGAAGACGATGCTCTCAGTTTGTGAATTAC  
AGTAAAATCTTTTAA (SEQ ID NO: 214)

**AOLFR117 sequences:**

MNNTIVFVIKIQIEKSDLKYRAISLQEISKISLLFWVLLVISRLLAMTLGNSTEVTEFYLLGFGA  
QHEFWCILFIVFLLIYVTSIMGNSGILLINTDSRFQTLTYFFLQHLAFVDICYTSAITPKMLQSFT  
15 EEKNLILFQGCVIQFLVYATFATSDCYLLAMMAVDYVAICKPLHYTVIMSRTVCIRLVAGSYI  
MGSINASVQTGFTCSLSFCKSNSINHFFCDVPILALSCSNVDINIMLLVVFVGSNLIFTGLVVIFS  
YIYIMATILKMSSSAGRKKSFSTCASHLTAVTIFYGTLASYMYLQSHSNNSQENMKVAFIFYGTVI  
PMLNPLIYSLRNKEVKEALKVIGKKLF (SEQ ID NO: 215)

20 ATGAATAACACTATTGTATTTGTCATAAAAAATACAAATAGAAAAAAGTGACTTGAAATATA  
GAGCCATTTTCATTGCAAGAAATCTCAAAGATTTCCCTTCTTTTCTGGGTCCTTCTCTTGGTC  
ATTTCTAGACTTTTACTAGCCATGACACTAGGAAACAGCACTGAAGTCACTGAATTCTATC  
TTCTGGGATTTGGTGCCAGCATGAGTTTTGGTGTATCCTCTTCATTGTATCCTTCTCATC  
TATGTGACCTCCATAATGGGTAATAGTGAATAATCTTACTCATCAACACAGATTCCAGAT  
25 TTCAAACACTCACGTACTTTTTTCTACAACATTTGGCTTTTGTGATATCTGTTACACTTCT  
GCTATCACTCCCAAGATGCTCCAAAGCTTCACAGAAGAAAAGAATTTGATATTATTTTCTCAGG  
GCTGTGTGATACAATTCTTAGTTTATGCAACATTTGCAACCAGTGACTGTTATCTCTCTGGCT  
ATGATGGCAGTGGATCCTTATGTTGCCATCTGTAAGCCCTTCACTATACTGTAATCATGT  
CCCGAACAGTCTGCATCCGTTTGGTAGCTGGTTCATACATCATGGGCTCAATAAATGCCTC  
30 TGTACAAACAGGTTTACATGTTCACTGTCTTCTGCAAGTCCAATAGCATCAATCACTTTT  
TCTGTGATGTTCCCCCTATTCTTGCTCTTTTCTGCAAGTCCAATAGCATCAATCATGCTA  
CTTGTGTCTTTGTGGGATCTAACTGATATTCAGTGGGTTGGTCGTCATCTTTCTCTACAT  
CTACATCATGGCCACCCTGAAAATGTCTTCTAGTGCAGGAAGGAAAAATCCTTCTCA  
ACATGTGCTTCCCACCTGACCGCAGTACCATTTTCTATGGGACACTCTTACATGTATTT  
35 GCAGTCTCATTCTAATAATCCCAGGAAAAATAGAAAGTGGCCTTTATATTTATGGCACA  
GTTATTCCTATGTTAAATCCTTTAATCTATAGCTTGAGAAATAAGGAAGTAAAAGAAGCTT  
TAAAAGTGATAGGAAAAAGTTATTTTAA (SEQ ID NO: 216)

**AOLFR118 sequences:**

40 MNHMSASLKISNSSKFQVSEFILLGFPPIHSWQHWLSLPLALLYLSALAANTLILIIHWQNPSLQQ  
PMYIFLGILCMVDMGLATTIIPKILAFWFDKVISLPECFAQIYAIHFFVGMESGILLCMFDRY  
VAICHPLRYPSTVSSILKATLFMVLRLNGLFVTPVLAQRDYCSKNEIEHCLCSNLGVTSIA  
CDDRRPNSICQLVLAWLGMGSDLSLILSYLILYVLRNLNSAEAAKALSTCSSHLTLILFFYTIV  
45 VVISVTHLTEMKATLIPVLLNVLHNIIPPSLNPTVYALQTKELRAAFQKVLFALTKERS (SEQ ID  
NO: 217)

ATGAATCATATGTCTGCATCTCTCAAAATCTCCAATAGCTCCAAATCCAGGTCTCTGAGTT  
CATCCTGCTGGGATTCCCGGGCATTACAGCTGGCAACACTGGCTATCTCTGCCCCTGGCA  
CTACTGTATCTCTCAGCACTTGCTGCAAAACACCTCATCTCATCATCTGGCAGAACCC  
50 TTCTTTACAGCAGCCCATGTATATTTTCTTGGCATCCTCTGTATGGTAGACATGGGTCTGG  
CCACTACTATCATCCCTAAGATCCTGGCCATCTTCTGGTTTGTGCAAGGTTATTAGCCTC  
CCTGAGTGCTTTGCTCAGATTTATGCCATTCACTTCTTGTGGGCATGGAGTCTGGTATCCT  
ACTCTGCATGGCTTTTGTAGATATGTGGCTATTTGTCAACCTCTTCGCTATCCATCAATTG  
TCACCAGTTCCTTAATCTTAAAAGCTACCCTGTTTGTGCTGAGAAATGGCTTATTTGTG  
55 ACTCCAGTGCCTGTGCTTGAGCACAGCGTGATTATTGCTCCAAGAATGAAATTGAACACT  
GCCTGTGCTCTAACCTTGGGGTCACAAGCCTGGCTTGTGATGACAGGAGGCCAAACAGCAT



TTGCCAGTTGGTTCTGGCATGGCTTGAATGGGGAGTGATCTAAGTCTTATTATACTGTCA  
 TATATTTTGATTCTGTACTCTGTACTTAGACTGAACTCAGCTGAAGCTGCAGCCAAGGCC  
 TGAGCACTTGTAGTTCACATCTCACCCCTCATCTTTCTTTTACACTATTGTTGTAGTGATT  
 TCAGTGACTCATCTGACAGAGATGAAGGCTACTTTGATTCCAGTTCTACTTAATGTGTTGC  
 5 ACAACATCATCCCCCTTCCCTCAACCCTACAGTTTATGCACTTCAGACCAAAGAAGCTTAG  
 GGCAGCCTTCCAAAAGGTGCTGTTTGCCCTTACAAAAGAAATAAGATCTTAG (SEQ ID NO:  
 218)

**AOLFR119 sequences:**

10 MPLFNSLCWFPTIHVTPPSFILNGIPGLERVHVWISLPLCTMYIIFLVGNLGLVYLIYYEESLHHP  
 MYFFFGHALSLIDLLTCTTTLPNALCIFWFSLEINFNACLAQMFFVHGFTGVESGVMLMALD  
 RYIAICYPLRYATTLTNPIIAKELATFLRGVLLMIPFPFLVKRLPFCQSNISHTYCDHMSVVKL  
 SCASIKVNVIYGLMVALLIGVFDICCSLSYTLILKAAISLSSSDARQKAFSTCTAHISAIITYVPA  
 FFTFFAHRFGGHTIPPSLHIIVANLYLLPPTLNPIVYGVKTKQIRKSVIKFFQGDKGAG (SEQ ID  
 15 NO: 219)

ATGCCTCTATTTAATTCATTATGCTGGTTTCCAACAATTCATGTGACTCCTCCATCTTTTAT  
 TCTTAATGGAATACCTGGTCTGGAAAGAGTACATGTATGGATCTCCCTCCCACTCTGCACA  
 ATGTACATCATCTTCTTGTGGGGAATCTTGGTCTTGTGTACCTCATTATTATGAGGAGTC  
 20 CTTACATCATCCGATGTATTTTTTTTTTGGCCATGCTCTCTCCCTCATTGACCTCCTTACCTG  
 CACCACCACTCTACCCAATGCACTCTGCATCTTCTGGTTCAGTCTCAAAGAAATTAACCTCA  
 ATGCTTGCTTGGCCCAGATGTTCTTTGTTCATGGGTTACAGGTGTGGAGTCTGGGGTGCT  
 CATGCTCATGGCTCTAGACCGCTATATAGCCATTTGCTACCCTTTGCGTTATGCTACCACAC  
 TCACCAACCCTATCATTGCCAAGGCTGAGCTTGCCACCTTCTGAGGGGTGTATTGCTGAT  
 25 GATTCTTTCCCATTTCTTGTTAAGCGTTTGCCTTTCTGCCAAAGCAATATTATCTCCCAT  
 CGTACTGCGACCACATGTCTGTAGTAAAGCTATCTTGTGCCAGCATCAAGGTCAATGTAAT  
 CTATGGTCTAATGGTTGCTCTCCTGATTGGAGTGTTTGACATTTGTGTATATCTTGTCTT  
 ACACTTTGATCCTCAAGGCAGCGATCAGCCTCTCTTCATCAGATGCTCGGCAGAAGGCTTT  
 CAGCACCTGCACTGCCATATATCTGCCATCATCATCACCTATGTTCCAGCATTCTTCACTT  
 30 TCTTTGCCACCGTTTTTGGGGGACACACAATTCCCCCTTCTCTTACATCATTGTGGCTAAT  
 CTTTATCTTCTTCTCCCCCAACTCTAAACCCTATTGTTTATGGAGTAAAGACAAAACAGAT  
 ACGCAAGAGTGTCTATAAAGTTCTTCCAGGGTGATAAGGGTGCAGGTTGA (SEQ ID NO: 220)

**AOLFR120 sequences:**

35 MQPYTKNWTQVTEFVMMGFAGIHEAHLFFILFLTMYLFTLVENLAAILVVGDLHRLRRPMYF  
 FLTHLSCLEIYWYTSVTPKMLAGFIGVDGKNISYAGCLSQLFIFTFLGATECFLLAAMAYDRY  
 VAICMPLHYGAFVSWGTCIRLAAACWLVGFLTPIPIYLLSQLTFCGPNVIDHFSCDASPLLALS  
 CSDVTWKETVDFLVSLAVLLASSMVIASVYGNIVWTLHIRSAAERWKAFSTCAAHLTVVSLF  
 YGTLFFMYVQTKVTSSINFNKVVSFYSVTPMLNPLIYSLRNKEVKGALGRVFSLNFWKQG  
 40 (SEQ ID NO: 221)

ATGCAACCATATACCAAAAACTGGACCCAGGTAAGTGAATTTGTCATGATGGGCTTTGCTG  
 GCATCCATGAAGCACACCTCCTCTTCTCATACTCTTCTCACCATGTACCTGTTACCTTG  
 GTGGAGAATTTGGCCATCATTTTAGTGGTGGGTTTGGACCACCGACTACGGAGACCCATGT  
 45 ATTTCTTCTGACACACTTGTCTGCCTTGAAATCTGGTACACTTCTGTTACAGTGCCCAAG  
 ATGCTGGCTGGTTTTATTGGGGTGGATGGTGGCAAGAATATCTCTTATGCTGGTTGCCTAT  
 CCCAGCTCTTCATCTTACCTTTCTTGGGGCAACTGAGTGTTTCTACTGGCTGCCATGGCC  
 TATGATCGTTATGTGGCCATTTGTATGCCTCTCCACTATGGGGCTTTTGTGTCTGGGGCAC  
 CTGCATCCGCTCTGGCAGCTGCCTGTTGGCTGGTAGGTTTCTCACACCCATCTTGCCAATCT  
 50 ACCTCTTGTCTCAGCTAACATTTTGTGGCCCAAATGTCATTGACCATTCTCCTGTGATGCC  
 TCACCTTGTAGCCTTGTCTGTCTCAGATGTCACTTGGAAGGAGACTGTGGATTTCTGG  
 TGTCTCTGGCTGTGCTACTGGCCTCCTCTATGGTCAATTGCTGTGTCTATGGCAACATCGTC  
 TGGACACTGCTGCACATCCGCTCAGCTGCTGAGCGCTGGAAGGCCTTCTCTACCTGTGCAG  
 CTCACCTGACTGTGGTGAGCCTCTTCTATGGCACTCTTTCTTTATGTATGTCCAGACCAAG  
 55 GTGACCTCCTCCATCAACTTCAACAAGGTGGTATCTGTCTTCTACTCTGTTGTACGCCCAT

GCTCAATCCTCTCATCTACAGTCTTAGGAACAAGGAAGTGAAGGGAGCTCTGGGTGAGTC  
TTTTCTCTCAACTTTTGAAGGGACAGTGA (SEQ ID NO: 222)

**AOLFR121 sequences:**

5 MKRKNFTEVSEFIFLGFSSFGKHQITLFFVFLTVYILTLVANIIVTICIDHHLHTPMYFFLSMLA  
SSETVYTLVIVPRMLLSLIFHNQPISLAGCATQMFFFVILATNNCFLLTAMGYDRYVAICRPLRY  
TVIMSKGLCAQLVCGSFGIGLTMAVLHVTAMFNLPCGTVDHFFCDIYPVMKLSCIDTTINEII  
NYGVSSFVIFVPIGLIFISYVLVISSILQIASAEGRKKTFATCVSHLTVVIVHCGCASIAYLKPKSES  
SIEKDLVLSVTYTIITPLNPPVYSLRNKEVDALCRVVGRNIS (SEQ ID NO: 223)

10 ATGAAGAGAAAGAACTTCACAGAAGTGTCAGAATTCATTTTCTGGGATTTTCTAGCTTTG  
GAAAGCATCAGATAACCCTCTTTGTGGTTTTCTTAAGTGTCTACATTTTAACTCTGGTTGCT  
AACATCATCATTGTGACTATCATCTGCATTGACCATCATCTCCACACTCCCATGTATTTCTT  
CCTAAGCATGCTGGCTAGTTCAGAGACGGTGTACACACTGGTCATTGTGCCACGAATGCTT  
15 TTGAGCCTCATTITTCATAACCAACCTATCTCCTTGGCAGGCTGTGCTACACAAATGTTCTT  
TTTTGTTATCTTGGCCACTAATAATTGCTTCTGCTTACTGCAATGGGGTATGACCGCTATG  
TGGCCATCTGCAGACCCCTGAGATACACTGTCATCATGAGCAAGGGACTATGTGCCACGCT  
GGTGTGTGGGTCTTTGGCATTGGTCTGACTATGGCAGTTCTCCATGTGACAGCCATGTTT  
AATTTGCCGTTCTGTGGCACAGTGGTAGACCATTCTTTTGTGACATTTACCCAGTCATGA  
20 AACTTTCTTGCATTGATAACCACTATCAATGAGATAATAAATTATGGTGTAAGTTCATTTGT  
GATTTTGTGCCCATAGGCCTGATATTTATCTCCTATGTCCTTGTCTCTTCCATCCTTC  
AAATTGCCTCAGCTGAGGGCCGGAAGAAGACCTTTGCCACCTGTGTCTCCACCTCACTGT  
GGTTATTGTCCACTGTGGCTGTGCCTCCATTGCCTACCTCAAGCCGAAGTCAGAAAGTTCA  
ATAGAAAAAGACCTTGTCTCTCAGTGACGTACACCATCATCACTCCCTGTGAACCCGT  
25 TTGTTTACAGTCTGAGAAACAAGGAGGTAAAGGATGCCCTATGCAGAGTTGTGGGCAGAA  
ATATTTCTTAA (SEQ ID NO: 224)

**AOLFR122 sequences:**

30 MEWENQTILVEFFLKGHVHPRELLFFVLIFIMYVVILLGNGTLILISILDPHLHTPMYFFLGNL  
SFLDICYTTSIPSTLVSLSERKTISFSGCAVQMFLGLAMGTTECVLLGMMAFDYVAICNPLR  
YPIIMSKNA YVPMAGVSWFAGIVNSAVQTTFFVQLPFCRKNVINHFSCEILAVMKLACADISGN  
EFLMLVATILFTLMPLLIVISYSLIISILKHSSEGRSKAFSTCSAHLTVIIFYGTILFMYMKPKS  
KETLNSDDLDATDKIISMFGVMTMMPNPLIYSLRNKDVKEAVKHLNRRFFSK (SEQ ID NO:  
225)

35 ATGGAATGGGAAAACCAACCAATTCTGGTGAATTTTTTCTGAAGGGACATTCTGTTCAAC  
CAAGGCTTGAGTACTCTTTTTGTGCTAATCTTCATAATGTATGTGGTCATCCTTCTGGGG  
AATGGTACTCTCATTTAATCAGCATCTTGGACCCTCACCTTCACACCCTATGTACTCTT  
TCTGGGGAACCTCTCCTTCTTGGACATCTGCTACACCACCACCTCTATCCCTCCACACTAG  
40 TGAGCTTCCTTTCAGAAAGAAAGACCATTTCTTTTTCTGGCTGTGCAAGTGCAGATGTTCTT  
GGCTTGGCCATGGGGACAACAGAGTGTGTGCTTCTGGGCATGATGGCCTTTGACCGCTATG  
TGGCTATCTGCAACCCTCTGAGATATCCCATCATCATGAGCAAGAATGCCTATGTACCCAT  
GGCTGTTGGGTCTGGTTTGCAGGGATTGTCAACTCTGCAGTACAACTACATTTGTAGTA  
CAATTGCCTTTCTGCAGGAAGAATGTCATCAATCATTTCTCATGTGAAATTCTAGCTGTCT  
45 TTCACATTGATGCCACTGCTCTTGATAGTATCTTACTCATTAAATCATTTCCAGCATCCT  
CAAGATTCACTCCTCTGAGGGGAGAAGCAAAGCTTTCTTACCTGCTCAGCCCATCTGACT  
GTGGTCATAATATTCTATGGGACCATCCTTCTCATGTATATGAAGCCCAAGTCTAAAGAGA  
CACTTAATTGAGATGACTGGATGCTACCGACAAAATTATCCATGTTCTATGGGGTGAT  
50 GACTCCCATGATGAATCCTTTAATCTACAGTCTTAGAAACAAGGATGTGAAAGAGGCAGT  
AAAACACCTACCGAACAGAAGGTTCTTTAGCAAGTGA (SEQ ID NO: 226)

**AOLFR123 sequences:**

55 MYRFTDFDVSNISYLNHVLFFYTTQAGDLEHMETRNYSAMTEFFLVGLSQYPELQLFLFLCL  
IMYMILLGNSLLIITILDSRLHTPMYFFLGNSFLDICYTSSSIPPLIIFMSERKSISFIGCALQM  
VVSGLGSTECVLLAVMAYDHYVAICNPLRYSIIMNGVLYVQMAAWSWIIGCLTSLQTVLT



MMLPFCGNNVIDHITCEILALLKLVCSDITINVLIMTVTNIVSLVILLLLIFISYVFILSSILRINCAE  
GRKKAFTCSAHSIVILFYGSALFMYMKPSKNTNTSDEIIGLSYGVVSPMLNPIIYSLRNKEV  
KEAVKKVLSRHLHLLKM (SEQ ID NO: 227)

- 5 ATGTACAGATTTACAGATTTTGATGTATCAAACATTTCAATTTACCTGAATCATGTCCTTTT  
CTATACTACCCAGCAGGCAGGTGACCTAGAACACATGGAGACAAGAAATTACTCTGCCAT  
GACTGAATTCTTTCTGGTGGGGCTTTCCCAATATCCAGAGCTCCAGCTTTTCTGTTCTCTGC  
TCTGCCTCATCATGTACATGATAATCCTCCTGGGAAATAGCCTCCTCATTATCATCACCATC  
10 TTGGATTCTCGCCTCCATACTCCCATGTATTTCTTTCTTGAAACCTCTCATTCTTGACAT  
CTGTTACACATCCTCATCCATTCCTCCAATGCTTATTATTTATGTCTGAGAGAAAATCCA  
TCTCCTTCATTGGCTGTGCTCTGCAGATGGTTGTGTCCTTGCTTGGGCTCCACTGAGTGT  
GTCCTCCTGGCTGTGATGGCCTATGACCACTATGTGGCCATCTGCAACCCACTGAGGTACT  
CCATCATCATGAACGGAGTGCTGTATGTGCAAATGGCTGCATGGTCTGGATCATAGGCTG  
TCTGACCTCCCTATTGCAAACAGTTCTGACAATGATGTTGCCCTTCTGTGGGAATAATGTC  
15 ATTGATCATATTACCTGTGAAATTTTGGCCCTTCTAAAACCTTGTTTGTTCAGATATCACCAT  
CAATGTGCTTATCATGACAGTGACAAATATTGTTTCACTGGTGATTCTTCTACTGTTAATTT  
TCATCTCCTATGTGTTTATTCTCTCTTCCATCCTGAGAATTAATTGTGCTGAGGGAAGAAAG  
AAAGCCTTCTCTACCTGTTTACGCGCACTCGATTGTGGTCATCTTATTCTACGGTTCAGCCCT  
TTTATGTACATGAAACCCAAGTCAAAGAACACTAATACATCTGATGAGATTATTGGGCTG  
20 TCTTATGGAGTGGTAAGCCCAATGTTAAATCCCATCATCTATAGCCTCAGGAATAAAGAGG  
TCAAAGAGGCTGTAAAGAAAGTCCTGAGCAGACATCTGCATTATTGAAAATGTGA (SEQ  
ID NO: 228)

**AOLFR124 sequences:**

- 25 MNHSVVTEFIILGLTKKPELQGIIFLFLIVYLVAFLGNMLIIAKIYNNTLHTPMYVFLTLAVV  
DICTTSIIPKMLGTMILTSENTISYAGVMSQLFLFTWSLGAEMVLFITMAYDRYVAICFPLHYST  
VMNHMCMVALLSMVMAIAVTNSWHTALIMRLTFCGPNTIDHFFCEIPPLALSCSPVRINEV  
MVYVADITLAIQDILTCISYGFIIIVAILRIRTVGKRAKAFSTCSSHLTVVTLYYSPVIYTYIRPASS  
YTFERDKVVAALYTLVPTLNPMVYSFQNRMQAGIRKVFAFLKH (SEQ ID NO: 229)
- 30 ATGAATCACAGCGTTGTAAGTGAAGTTCATTATTCTGGGCCTCACCAAAAAGCCTGAACTCC  
AGGGAATTATCTTCTCTTTTCTCATTGTCTATCTTGTGGCTTTTCTCGGCAACATGCTC  
ATCATCATTGCCAAAATCTATAACAACACCTTGACATACGCCCATGTATGTTTCTTCTGAC  
ACTGGCTGTTGTGGACATCATCTGCACAACAAGCATCATACCGAAGATGCTGGGGACCAT  
35 GCTAACATCAGAAAAATACCATTTTCATATGCAGGCTGCATGTCCCAGCTCTTCTTGTTTACA  
TGGTCTCTGGGAGCTGAGATGGTTCTCTTACCACCATGGCCTATGACCGCTATGTGGCCA  
TTTGTTCCTCTTCTTACAGTACTGTTATGAACCACCATATGTGTGTAGCCTTGCTCAGC  
ATGGTCAATGGCTATTGCAGTCACCAATTCCTGGGTGCACACAGCTCTTATCATGAGGTTGA  
CTTCTGTGGGCCAAACACCATTTGACCACTTCTTCTGTGAGATACCCCATTTGCTGGCTTTG  
40 TCCTGTAGCCCTGTAAGAATCAATGAGGTGATGGTGTATGTTGCTGATATTACCCTGGCCA  
TAGGGGACTTTATTCTTACCTGCATCTCCTATGGTTTTATCATTGTTGCTATTCTCCGTATC  
CGCACAGTAGAAGGCAAGAGGAAGGCCTTCTCAACATGCTCATCTCATCTCACAGTGGTG  
ACCCTTTACTATTCTCCTGTAATCTACACCTATATCCGCCCTGCTTCCAGCTATACATTTGA  
AAGAGACAAGGTGGTAGCTGCACTCTATACTCTTGTGACTCCCACATTAAACCCGATGGTG  
45 TACAGCTTCCAGAATAGGGAGATGCAGGCAGGAATTAGGAAGGTGTTTGCATTTCTGAAA  
CACTAG (SEQ ID NO: 230)

**AOLFR125 sequences:**

- 50 MTNQTQMMFEFLVRFTENWVLLRLHALLFSLIYLTAVLMNLVILLMILDHRLHMAMYFFLRH  
LSFLDLCLISATVPKSILNSVASTDSISFLGCVLQLFLVLLAGSEIGILTAMSVDYAAICCPHLC  
EAVMSRGLCVQLMALSWLNRGALGLLYTAGTFSLNFYGSDELHQFFCDVPALLKLTCSKEHAI  
ISVSVAIGVCYAFSCLVCIVVSYYIFSAVLRISQRQROSKAFSNCVPHLIVVTVFLVTGAVAYL  
KPGSDAPSILDLLVSFYSVAPPTLNPVITYCLKNKDIKSALS KVLWNVRSSGVMKDD (SEQ ID  
NO: 231)

55

WO 01/98526

5 ATGACCAATCAGACACAGATGATGGAATTCTTGCTTGTGAGATTTACTGAGAATTGGGTGC  
 TCCTGAGGCTGCATGCTTTGCTCTTCTCACTGATCTACCTCACGGCTGTGCTGATGAATTA  
 GTCATCATTCTCCTCATGATTCTGGACCATCGTCTCCACATGGCAATGTACTTTTTCTCCG  
 ACATTTGTCCTTCTTAGACCTGTGTCTCATTTCTGCCACAGTCCCAAATCCATCCTCAACT  
 10 CTGTGCGCTCCACTGACTCCATCTCCTTCCTGGGTGTGTGTGCAGCTCTTCTTGGTGGA  
 CTGTGCGCTGGATCAGAGATTGGCATCCTTACTGCCATGTCTATGACCGCTATGTGATGGA  
 TCTGCTGCCCCCTACACTGTGAGGCTGTCTGATGAGCAGAGGGCTCTGTGTCCAGTTGATGGC  
 AATTTTATGGCTCTGATGAGCTACATCAGTTCTTCTGCGATGTCCCTGCCCTACTAAAGCT  
 15 CACTGTCTCTAAAGAACATGCCATCATTAGTGTGAGTGTGGCCATTGGGGTCTGTTATGCA  
 TTTTCATGTTTAGTTTGCATTGTAGTTTCTATGTGTACATTTTCTCTGTGTGTTAAGGAT  
 ATCAGAGACAGAGACAATCCAAAGCCTTTTCCAAGTGTGTGCTCACCTCATGTGTGTC  
 ACTGTGTTTCTTGTAAAGGTGCTGTGTTATTTAAAGCCAGGGTCTGATGCACCTTCTAT  
 TCTAGACTTGCTGGTGTCTGTGTTCTATTCTGTGCGACCTCCAACCTGAACCTGTTATCT  
 20 ACTGTCTGAAGAACAAGGACATTAATCCGCTCTGAGTAAAGTCTGTGGAATGTTAGAA  
 GCAGTGGGGTAATGAAAGATGACTAA (SEQ ID NO: 232)

**AOLFR126 sequences:**

20 MFLYLCFIFQRTCSEEMEEENATLLTEFVLTGFLHQPDCIPLFLAFLVIYLITMGNLGLVLIW  
 KDPHLHIPMYLFLGSLAFVDASLSTVTPKMLINFLAKSKMISLSECMVQFFSLVTTVTTECFLL  
 ATMAYDRYVAICKALLYPVMITNELCIQLLVLSFIGLLHALIHEAFSRLTFCNSNIQHIFYCDII  
 PLLKISCTDSSINFLMVIFAGSVQVFTIGTILISYTHILFTILEKKSIRKAVSTCGAHLVSLSLY  
 YGPLTFKYLGSASPQADDQDMMESLFYTVIVPLLNPMIYSLRNKQVIASFTKMFKSNV (SEQ ID  
 NO: 233)

25 ATGTTCTTTACCTTTGCTTCATTTTTTCAGAGGACATGCAGTGAGGAGATGGAAGAGGAAA  
 ATGCAACATTGCTGACAGAGTTTGTCTCACAGGATTTTACATCAACCTGACTGTAAAT  
 ACCGCTCTTCTGGCATTCTTGGTAATATATCTCATCACCATCATGGGAATCTTGGTCTAA  
 TTGTTCTCATCTGGAAGACCCTCACCTTCATATCCCAATGTACTTATCCTTGGGAGTTA  
 30 GCCTTTGTGGATGCTTCGTTATCATCCACAGTGACTCCGAAGATGCTGATCAACTTCTAG  
 CTAAGAGTAAGATGATATCTCTCTGAATGCATGGTACAATTTTTTCCCTGTAAACCAT  
 GTAACCACAGAAATGTTTTCTTGGCAACAATGACATATGATCGCTATGTAGCCATTGCA  
 AAGCTTTACTTTATCCAGTCATTATGACCAATGAAGCTTTTTCATTGAGTTAACCTTCTG  
 TTTATAGGTGGCCTTCTCATGCTTTAATCCATGAAGCTTTTTCATTGAGTTAACCTTCTG  
 35 TAATCCAAACATAATAACAACCTTTACTGTGACATTATCCCATGTTAAAGATTCTGTGTA  
 CTGATTCCTCTATTAACCTTTCTAATGGTTTTATTTTCGAGGTTCTGTTCAAGTTTACCA  
 TTGGAATAATTCTTATATCTTATAACAATTATCTCTTTACAATCTTAGAAAAGAGTCTATC  
 AAAGGGATACGAAAAGCTGTCTCCACCTGTGGGGCTCATCTCTATCTGTATCTTTATCT  
 ATGGCCCCCTCACCTTCAAAATCTGGGGCTCTGCATCTCCGCAAGCAGATGACCAAGATAT  
 40 GATGGAGTCTCTATTTTACACTGTCTAGTTCTTTTATTAATCCCATGATCTACAGCCTGA  
 GAAACAAGCAAGTAATAGCTTCATTCACAAAAATGTTCAAAAGCAATGTTTAG (SEQ ID  
 NO: 234)

**AOLFR127 sequences:**

45 MSNEDMEQDNTLLTEFVLTGLTYQPEWKMPFLVFLVIYLITVWNLGLIALIWNDPQLHIPM  
 YFFLGSLAFVDAWISSTVTPKMLVNFLAKNRMISLSECMIQFFSFAFGGTTECFLLATMAYDRY  
 VAICKPLLYPVMNNSLCIRLLAFSFLGGFLHALIHEVLIFRLTFCNSNIHHIFYCDIPLFMISCTD  
 PSINFLMVFILSGSIQVFTIVTVLNSYTFALFTILKKKSVRGVRKAFSTCGAHLVSLSLYGPLIF  
 MYLRPASQADDQDMIDSVFYTHIPLLNPIIYSLRNKQVIDSFTKMVKRNV (SEQ ID NO: 235)

50 ATGTGCAATGAGGACATGGAACAGGATAATAACAATTGCTGACAGAGTTTGTCTCACA  
 GGAATTACATATCAGCCAGAGTGGAATAATGCCCTGTCTTGGTGTCTTGGTGATCTATC  
 TCATCACTATTGTGTGGAACCTTGGTCTGATTGCTCTTATCTGGAATGACCCACAACCTCAC  
 ATCCCATGTACTTTTTCTTGGGAGTTTAGCCTTTGTGATGCTTGGATATCTTCCACAGT  
 55 AACTCCCAAAATGTTGGTTAATTTCTTGGCAAAAAACAGGATGATATCTGTCTGAATGC  
 ATGATTCAATTTTTTCTTTGCATTGGTGGAACTACAGAATGTTTCTTGGCAACAAT

GGCATATGATCGCTATGTAGCCATATGCAAACCTTTACTATATCCAGTGATTATGAACAAT  
 TCACTATGCATACGGCTGTTAGCCTTCTCATTTTATAGGTGGCTTCCTCCATGCCTTAATTCA  
 TGAAGTCCTTATATTCAGATTAACTTCTGCAATTCTAACATAATACATCATTTTTACTGTG  
 ATATTATACCACTGTTTATGATTTCTGTACTGACCCTTCTATTAATTTTCTAATGGTTTTTA  
 5 TTTTGTCTGGCTCAATTCAGGTATTCACCATTGTGACAGTTCTTAATTCTTACACATTTGCT  
 CTTTTCACAATCCTAAAAAGAAGTCTGTTAGAGGCGTAAGGAAAGCCTTTTCCACCTGTG  
 GAGCCCATCTCTTATCTGTCTTTTATATTATGGCCCACTTATCTTCATGTATTTGCGCCCT  
 GCATCTCCACAAGCAGATGACCAAGATATGATAGACTCTGTCTTTTATACAATCATAATTC  
 CTTTGCTAAATCCCATTATCTACAGTCTGAGAAATAACAAGTAATAGATTCAATCACAAA  
 10 AATGGTAAAAAGAAATGTTTAG (SEQ ID NO: 236)

**AOLFR128 sequences:**

METQNLTVVTEFILLGLTQSQDAQLLVFVLVLFYLIILPGNFLIIFTIKSDPGLTAPLYFFLGNLA  
 LLDASYSFIVVPRMLVDLSEKKVISYRSCITQLFFLHFLGAGEMFLLVVMFAFDRIAICRPLHY  
 15 STIMNPRACYALSLVLWLGGFHSIVQVALILHLPFCGPNQLDNFFCDVPQVIKLACTNTFVVEL  
 LMVSNGLLSLLCFLGLLASYAVILCRIEHSSEGKSKAISTCTTHIIIFLMFGPAIFIYTCPFQAFP  
 ADKVVSLFHTVIFPLMNPVIYTLRNQEVKASMRKLLSQHMF (SEQ ID NO: 237)

ATGGAAACACAGAACCTCACAGTGGTGACAGAATTCATTCTTCTTGGTCTGACCCAGTCTC  
 20 AAGATGCTCAACTTCTGGTCTTTGTGCTAGTCTTAATTTTCTACCTTATCATCCTCCCTGGA  
 AATTTCTCATCATTTTCACCATAAAGTCAGACCTGGGCTCACAGCCCCCTCTATTTCTT  
 TCTGGGCAACTTGGCCTTACTGGATGCATCCTACTCCTTATTGTGGTTCACAGGATGTTG  
 GTGGACTTCCTCTCTGAGAAGAAGGTAATCTCCTATAGAAGCTGCATCACTCAGCTCTTTT  
 TCTTGCATTTTCTTGGAGCGGGAGAGATGTTCTCCTCGTTGTGATGGCCTTTGACCGCTAC  
 25 ATCGCCATCTGCCGGCCTTTACACTATTCAACCATCATGAACCCTAGAGCCTGCTATGCAT  
 TATCGTTGGTTCTGTGGCTTGGGGGCTTTATCCATTCCATTGTACAAGTAGCCCTTATCCTG  
 CACTTGCCTTTCTGTGGCCAAACCAGCTCGATAACTTCTTCTGTGATGTTCCACAGGTCAT  
 CAAGCTGGCCTGCACCAATACCTTTGTGGTGGAGCTTCTGATGGTCTCCAACAGTGGCCTG  
 CTCAGCCTCCTGTGCTTCTGGCCTTCTGGCCTCCTATGCAGTCATCCTCTGTGCTATAAG  
 30 GGAGCACTCCTCTGAAGGAAAGAGCAAGGCTATTTCCACATGCACCACCCATATTATCATT  
 ATATTTCTCATGTTTGGACCTGCTATTTTCATCTACACTTGCCCTTCCAGGCTTTCCCAGC  
 TGACAAGGTAGTTTCTCTTTTCCATACTGTATCTTTCTTTGATGAACCCTGTTATTTATA  
 CGCTTCGCAACCAGGAGGTGAAAGCTTCCATGAGGAAGTTGTTAAGTCAACATATGTTTTG  
 CTGA (SEQ ID NO: 238)

35

**AOLFR129 sequences:**

MALYFSLILHGMSDLFFLSTGHPRASCRMEAMKLLNQSQVSEFILLGLTSSQDVEFLFALFSVI  
 YVVTVLGNLLIIVTVFNTPNLNTPMYFLLGNLSFVDMTLASFATPKVILNLLKKQKVISFAGCFT  
 QIFLLHLLGGVEMVLLVSMFAFDRYVAICKPLHYMTIMNKKVCVLLVVTSWLLGLLHSGFQIPF  
 40 AVNLPFCGPNVVDISIFCDLPLVTKLACIDIYFVQVIVANSGLSLSCFIILLISYLLITIKNHSPT  
 GQSKARSTLTAHITVILFFGPCIFIYWPFGNHSVDKFLAVFYTIITPILNPIIYTLRNKEMKISMK  
 KLWRAFVNSREDT (SEQ ID NO: 239)

ATGGCTCTTTATTTTTCACTCATACTCCATGGTATGAGTGATCTTTTCTTCTCTCTACAGG  
 45 TCATCCAAGAGCGAGCTGTAGGATGGAGGCCATGAACTATTAAATCAATCTCAAGTGTC  
 AGAATTCATTTTGTGGGACTGACCAGCTCCCAGGATGTAGAGTTTCTTCTCTTTGCCCTCT  
 TCTCGGTTATCTATGTGGTCACAGTTTGGGTAACCTTCTATTATAGTCACAGTGTTTAAC  
 ACCCTAACCTGAATACTCCCATGTATTTCTCCTTGGTAATCTCTCTTTGTAGATATGAC  
 CCTTGCTTCTTTGCCACCCCTAAGGTGATTCTGAACTTGTTAAAAAAGCAGAAGGTAATT  
 50 TCTTTTGTGGGTGCTTCACTCAGATATTTCTCCTTCACTTACTGGGTGGGGTTGAAATGGT  
 ACTGTTGGTCTCCATGGCTTTTGACAGATATGTGGCCATTTGTAAGCCCTACACTACATG  
 ACCATCATGAACAAGAAGGTATGTGTTTGTGTTAGTGACCTCATGGCTCTTGGGTCTCC  
 TTCACTCAGGGTTTCAGATACCATTGTGCTGTGAACCTTGCCCTTTGTGGTCCCAATGTGGTA  
 GACAGCATTTTTTGTGACCTCCCTTTGGTTACTAAGCTTGCCCTGTATAGACATATTTTTGT  
 55 ACAGGTAGTCATTGTTGCCAACAGTGGCATAATCTCCCTGAGCTGTTTCATTATTTGCTTA  
 TCTCCTACAGTCTGATCCTCATAACCATTAAAGAACCTCTCCTACTGGGCAATCTAAAGC

WO 01/98526

CCGTTCCACTTTGACTGCTCACATCACAGTGGTGATTCTCTCTTTGGCCCATGCATCTTTA  
TCTACATTTGGCCCTTCGGCAACCACTCTGTAGATAAGTTCCTTGCTGTGTTTTATACCATC  
ATCACTCCTATCTTGAATCCAATTATCTATACTCTGAGAAACAAAGAAATGAAGATATCCA  
TGAAAAAACTCTGGAGAGCTTTTGTGAATTCTAGAGAAGATACTTAG (SEQ ID NO: 240)

5

**AOLFR131 sequences:**

MASTSNVTELIIFTGLFQDPAVQSVCFVFLPVYLATVVGNGLIVLTVSISKSLDSPMYFFLSCLS  
LVEISYSSTIAPKFIIDLLAKIKTISLEGCLTQIFFHFFGVAEILLIVVMAYDCYVAICKPLHYMNI  
ISRQLCHLLVAGSWLGGFCHSIIQLVIIQLPFCGPNVIDHYFCDLQPLFLACTDTFMEGVIVLA  
10 NSGLFSVFSFLILVSSYIVILVNLNRNLSAEGRHKALSTCASHITVVILFFGPAIFLYMRPSSTFTED  
KLAVFYTVITPMLNPIIYTLRNAEVKIAIRRLWSKKNPGRE (SEQ ID NO: 241)

15

ATGGCCAGTACAAGTAATGTGACTGAGTTGATTTTCACTGGCCTTTTCCAGGATCCAGCTG  
TGCAGAGTGATGCTTTGTGGTGTCTCTCCCGTGACCTTGCCACGGTGGTGGGCAATGG  
CCTCATCGTTCTGACGGTCAGTATCAGCAAGAGTCTGGATTCTCCCATGTACTTCTCCTTA  
GCTGCCTGTCTTGGTGGAGATCAGTTATTCTCCACTATCGCCCCATAAATTCATCATAGAC  
TTACTTGCCAAGATTAACCAATCTCTCTGGAAGGCTGTCTGACTCAGATATTCTTCTTCCA  
CTTCTTTGGGGTTGTGAGATCCTTTTGATTGTGGTGATGGCCTATGATTGCTACGTGGCC  
20 ATTTGCAAGCCTCTTCATTATATGAACATTATCAGTCGTCAACTGTGTACCTTCTGGTGGC  
TGGTTCCTGGCTGGGGGGCTTTTGTACTCCATAATTAGATTCTCGTTATCATCCAATTGC  
CCTCTGTGGTCCCAATGTGATTGACCACTATTTCTGTGACCTCCAGCCTTTATTCAAGCTT  
GCCTGCACTGACACCTTCATGGAGGGGGTTATTGTGTGGCCAACAGTGGATTATTCTCTG  
TCTTCTCCTTCCTCATCTTGGTGTCTCTTATATTGTCACTTCTGGTCAACTGAGGAACCAT  
TCTGCAGAGGGGAGGCACAAAGCCCTCTCCACCTGTGCTTCTCACATCACAGTGGTCATCT  
25 TGTTTTTTGGACCTGCTATCTTCTCTACATGCGACCTTCTTCCACTTTCACTGAAGATAAA  
CTTGTGGCTGATTCTACACGGTCATACCCCCATGCTGAACCCCATCATTTACACACTCAG  
GAATGCAGAGGTGAAAATCGCCATAAGAAGATTGTGGAGCAAAAAGGAGAATCCAGGGA  
GGGAGTGA (SEQ ID NO: 242)

30

**AOLFR132 sequences:**

MVATNNVTEIIFVGFSSQNWSEQRVISVMFLMYTAVVLGNGLIVVTILASKVLTSPMYFFLSYL  
SFVEICYCSVMAPKLIFDSFIKRVISLKGCLTQMFSLHFFGGTEAFLMVMAYDRYVAICKPL  
HYMAINQRMCGLLVRIA WGGGLLHVSQGTFILFQLPFCGPNIMDHVFCDVHPVLELACADT  
FFISLLITNGGSISVVSFFVLMASYLILHLRSHNLEGQHKALSTCASHVTVVDLFFIPCSLVYR  
35 PCVTLPADKIVAVFYTVVTPLLNPVIYSFRNAEVKNAMRRFIGGKVI (SEQ ID NO: 243)

40

ATGGTTGCTACAAACAATGTGACTGAAATAATTTTCGTGGGATTTTCCCAGAATTGGAGTG  
AGCAGAGGGTCATTTCTGTGATGTTTCTCCTCATGTACACAGCTGTTGTGCTGGGCAATGG  
CCTCATTGTGGTGACCATCCTGGCCAGCAAGAGTGTACCTCCCCCATGTATTTCTTCTCA  
GCTACTTATCCTTTGTGGAGATCTGCTACTGTTCTGTCTATGGCCCCAAGCTTATCTTTGAC  
TCCTTTATCAAGAGGAAAGTCATTTCTCTCAAGGGCTGCCTCACACAGATGTTTTCCCTCC  
ATTTCTTTGGTGGCACTGAGGCCTTTCTCCTGATGGTGATGGCCTATGACCGCTATGTGGC  
CATCTGCAAGCCCTTGCACTACATGGCCATCATGAACCAGCGAATGTGTGGTCTCCTCGTG  
AGGATAGCATGGGGCGGGGGCTGTGCTGATTCTGTTGGGCAAACCTTCTGATTTTCCAGC  
45 TCCCGTTCTGTGGCCCCAACATCATGGACCACTACTTCTGTGATGTCCACCCAGTGTGGA  
GCTGGCCTGCGCAGACACCTTCTTATTAGCCTGCTGATCATCAACCAATGGCGGCTCCATC  
TCCGTAGTCAGTTTCTTCTGTGCTGATGGCTTCTACCTGATCATCTGCATTCTCTGAGAAG  
CCACAACCTGGAGGGGCGAGCAAGGCCCTCTCCACCTGTGCTCTCATGTACAGTTGTC  
GACCTGTTCTTACATCTTGGTCTATATTAGGCCCTGTGTACCCCTCCCTGCAGA  
50 CAAGATAGTTGCTGATTTTATACAGTGGTCACACCTCTCTTAAACCTGTGATTTACTCCT  
TCAGGAATGCTGAAGTGAAAAATGCCATGAGGAGATTTATTGGGGGAAAAGTAATTTGA  
(SEQ ID NO: 244)

**AOLFR133 sequences:**

55 MTEFIFLVSPNQEVQRVCFVIFLYTAIVLGNFLIVLTVMTSRSLGSPMYFFLSYLSFMEICYS  
SATAPKLISDLLAERKVISWWGCMALFLLHFFGGTEIFLLTVMAYDHYVAICKPLSYTTIMN

WQVCTVLVGIAWVGGFMHSFAQILLIFHLLFCGPNVINHYFCDLVPLLKLACSDTFLIGLLIVAN  
GGTLSVISFGVLLASYMVILLHLRTWSSEGWCKALSTCGSHFAVVILFFGPCVFNSLRPSTTLPI  
DKMVAVFYTVITAILNPVIYSLRNAEMRKAMKRLWIRTLRLNEK (SEQ ID NO: 245)

- 5 ATGACTGAATTCATTTTTCTGGTACTTTCTCCCAACCAGGAGGTGCAGAGGGTTTGCTTTG  
TGATATTTCTGTTCTTGTACACAGCAATTGTGCTGGGGAATTCCTCATTGTGCTCACTGTC  
ATGACCAGCAGAAGCCTTGGTTCCCCCATGTACTTCTTCTCAGCTACCTCTCCTTCATGGA  
GATCTGCTACTCCTCCGCTACAGCCCCCAAACCTCATCTCAGATCTGCTGGCTGAAAGGAAA  
GTCATATCTTGGTGGGGCTGCATGGCACAGCTTTTCTTCTTGCACTTCTTTGGTGGCACTGA  
10 GATTTTCTGCTCACTGTGATGGCCTATGACCACTATGTGGCCATCTGCAAGCCCCCTCAGC  
TACACCACCATCATGAACCTGGCAGGTGTGTACTGTCTTGTAGGAATAGCATGGGTGGGA  
GGCTTCATGCATTCTTTGCACAAATCCTTCTCATCTTCCACCTGCTCTTCTGTGGCCCCAA  
TGTGATCAATCACTATTTCTGTGACCTAGTTCCCTTCTCAAACCTGCCTGCTCTGACACCT  
TCCTCATTGGTCTGCTGATTGTTGCCAATGGAGGCACCCTGTCTGTGATCAGTTTTGGGGT  
15 CCTCTTAGCATCCTATATGGTCATCTTGCTCCATCTGAGAACCTGGAGCTCTGAAGGGTGG  
TGCAAAGCCCTCTCCACCTGTGGGTCCCATTTTCGCTGTGGTTATCTTGTTCTTTGGGCCCTG  
CGTCTTCAACTCTCTGAGGCCTTCTACCACTCTGCCCATAGACAAGATGGTGGCTGTGTTCT  
ACACAGTGATAACCGCGATCCTGAACCCTGTCATCTACTCTCTGAGAAATGCTGAAATGAG  
GAAGGCCATGAAGAGGCTGTGGATTAGGACATTGAGACTAAATGAGAAATAG (SEQ ID  
20 NO: 246)

**AOLFR134 sequences:**

- MTTILEVDNHTVTTRFILLGFPTRPAFQLLFFSIFLATYLLTLENLLIILAIHSDGQLHKPMYFFL  
SHLSFLEMWYVTVISPKMLVDFLSHDKSISFNGCMTQLYFFVTFVCTEYILLAIMAFDRYVAIC  
25 NPLRYPVIMTNQLCGTLAGGCWFCGLMTAMIKMVFLAQLHYCGMPQINHYFCDISPLNVSCE  
DASQAEMVDFFLALMVIAIPLCVVASYAAILATILRIPSAQGRQKAFSTCASHLTVVILFYSM  
LFTYARPKLMYAYNSNKVVSVLYTVIVPLLNPIIYCLRNHEVKAALRKTIHCRGSGPQGN  
S (SEQ ID NO: 247)

- 30 ATGACCACCATAATTCTGGAAGTAGATAATCATACAGTGACAACACGTTTCATTCTTCTGG  
GGTTTCCAACACGACCAGCCTTCCAGCTTCTCTTTTCTCCATTTTCTGGCAACCTATCTG  
CTGACACTGCTGGAGAATCTTCTTATCATCTTAGCTATCCACAGTGATGGGCAGCTGCATA  
AGCCCATGTACTTCTTCTTGAGCCACCTCTCCTTCTGGAGATGTGGTATGTCACAGTCATC  
AGCCCCAAGATGCTTGTGACTTCTCAGTCATGACAAGAGTATTTCTTCAATGGCTGCA  
35 TGACTCAACTTTACTTTTTGTGACCTTTGTCTGCACTGAGTACATCCTTCTTGCTATCATG  
GCCTTTGACCGCTATGTAGCCATTTGTAATCCACTACGCTACCCAGTCATCATGACCAACC  
AGCTCTGTGGCACACTGGCTGGAGGATGCTGGTTCTGTGGACTCATGACTGCCATGATTAA  
GATGGTTTTATAGCACAACCTCACTACTGTGGCATGCCTCAGATCAATCACTACTTTTGTG  
ATATCTCTCCACTCCTTAACGTCTCCTGTGAGGATGCCTCACAGGCTGAGATGGTGGACTT  
40 CTCTTGCCCTCATGGTCATTGCTATTCTCTTTGTGTTGTGGTGGCATCCTACGCTGCTA  
TCCTTGCCACCATCCTCAGGATCCCTTCTGCTCAGGGCCGCCAAAAGGCATTCTCCACCTG  
TGCCCTCCACCTGACCGTCGTAATTCTCTTATTCCATGACACTTTTCACCTATGCCCGTC  
CCAAACTCATGTATGCCTACAATTCCAACAAAGTGGTATCTGTTCTCTACACTGTCATTGTT  
CCACTCCTCAACCCCATCATTTACTGTCTGAGGAACCATGAAGTAAAGGCAGCCCTCAGAA  
45 AGACCATACATTGCAGAGGAAGTGGGCCCCAGGGAAATGGGGCTTTCAGTAGTTAA (SEQ  
ID NO: 248)

**AOLFR135 sequences:**

- MIFPSHDSQAFTSVDMEVGNCTILTEFILLGFSADSQWQPILFGVFLMLYLITLSGNMTLVILIRT  
50 DSHLHTPMYFFIGNLSFLDFWYTSVYTPKILASCVSEDKRISLAGCGAQLFFSCVVAYTECYLL  
AAMAYDRHAAICNPLLYSGTMSTALCTGLVAGSYIGGFLNAIAHTANTFRLHFCGKNIDHFFC  
DAPPLVKMSCTNTRVYEKVLGTVGFTVLSSILAILISYVNILLAILRIHSASGRHKAFSTCASHL  
ISVMLFYGSLLFMYSRPSSTYSLERDKVAALFYTVINPLLNPLIYSLRNKDIKEAFRKATQTIQPO  
T (SEQ ID NO: 249)

55

WO 01/98526

5 ATGATTTTCCCTTCTCATGATAGTCAGGCTTTACCTCCGTGGACATGGAAGTGGGAAATT  
 GCACCATCTGACTGAATTCATCTTGTTGGGTTTCTCAGCAGATTCCCAGTGGCAGCCGAT  
 TCTATTTGGAGTGTCTGATGCTCTATTTGATAACCTTGTGAGGAAACATGACCTTGGTTA  
 10 TCTTAATCCGAAGTATTCCCACTTGCATACACCTATGTACTTTTTTATTGGCAATCTGTCT  
 TTTTGGATTCTGGTATACCTCTGTGTATACCCCAAAATCCTGGCCAGTTGTGTCTCAGA  
 AGATAAGCGCATTTCCCTGGCTGGATGTGGGCTCAGCTGTTTTTCTGTGTGTAGCCT  
 AACTGAATGCTATCTCCTGGCAGCCATGGCATATGACCGCCATGCAGCAATTTGTAACCC  
 ATTGCTTTATTCAGGTACCATGTCCACCGCCCTCTGTACTGGGCTTGTGTGCTGCTTACA  
 TAGGAGGATTTTTGAATGCCATAGCCATACTGCCAATACATTCCGCTGCAATTTTGTGG  
 15 TAAAAATATCATTGACCACTTTTTCTGTGATGCACCACTTGGTAAAAATGTCTGTACA  
 AACACCAGGGTCTACGAAAAAGTCTGCTTGGTGTGGTGGGCTTACAGTACTCTCCAGCA  
 TTCTTGCTATCCTGATTTCTATGTCAACATCCTCCTGGCTATCCTGAGAATCCACTCAGCT  
 TCAGGAAGACACAAGGCATTCTCCACTGTGCTTCCCACCTCATCTCAGTCATGCTCTTCTA  
 TGGATCATTGTTGTTTATGTATTCAAGGCCTAGTTCCACCTACTCCCTAGAGAGGGACAAA  
 GTAGCTGCTCTGTTCTACACCGTGATCAACCCACTGCTCAACCCCTCTCATCTATAGCCTGAG  
 20 AAACAAAGATATCAAAGAGGCCTTCAGGAAAGCAACACAGACTATACAACCACAAACATG  
 A (SEQ ID NO: 250)

## AOLFR136 sequences:

20 MTMENYSMAAQFVLDGLTQQAELQLPLFLLFLGIYVTVVGNLGMILLIAVSPLLHTPMYYFL  
 SLSFVDFCYSSVITPKMLVNFLGKNTILYSECMVQLFFVVFVVAEGYLLTAMAYDRYVAIC  
 SPLLYNAIMSSWVCSLLVLAFFLGFSLALHTSMMKLSFCKSHIINHFCVDLPLNLSCSNT  
 HLNELLLFIAGFNTLVPTLAVAVSYAFILYSLHRSSEGRSKAFGTCSHLMVVFIFGGSITFMY  
 FKPPSSNSLDQEKVSSVFYTTVIPMLNPLIYSLRNKDVKKALRKVLVGK (SEQ ID NO: 251)

25 ATGACCATGGAAAATTATTCTATGGCAGCTCAGTTTGTCTTAGATGGTTAAACACAGCAAG  
 CAGAGCTCCAGCTGCCCCTCTTCTCCTGTTCCCTGGGAATCTATGTGGTCACAGTAGTGGG  
 CAACCTGGGCATGATTCTCCTGATTGCAGTCAGCCCTCTACTTCACACCCCCATGTACTATT  
 TCCTCAGCAGCTTGTCTTCGTCGATTTCTGCTATTCCTCTGTCATTACTCCCAAAATGCTG  
 30 GTGAACCTCCTAGGAAAGAAGAATAACAATCCTTACTCTGAGTGCATGGTCCAGCTTTTT  
 TCTTTGTGGTCTTTGTGGTGGCTGAGGGTTACCTCCTGACTGCCATGGCATATGATCGCTA  
 TGTGGCCATCTGTAGCCCACTGCTTTATAATGCGATCATGTCTCATGGGTCTGCTCACTGC  
 TAGTGTGGCTGCCTTCTTCTGGGCTTCTCTGCTTGAATGCTCATAAAGTGGCATGATG  
 AAACCTGTCCTTTTGCAAATCCCACATTATCAACCATTACTTCTGTGATGTTCTTCCCTCCT  
 35 CAATCTCTCCTGCTCCAACACACACCTCAATGAGCTTCTACTTTTTATCATTGCGGGGTTA  
 ACACCTTGGTGCCCACTAGCTGTTGCTGCTCCTATGCCTTCATCCTTACAGCATCCTT  
 CACATCCGCTCCTCAGAGGGCCGTCCAAAGCTTTTGAACATGCAGCTCTCATCTCATGG  
 CTGTGGTGATCTTTTGGGTCCATTACCTTCATGTATTTCAAGCCCCCTTCAAGTAACTCC  
 CTGGACCAGGAGAAGGTGTCCTCTGTGTTCTACACCAGGTGATCCCCATGCTGAACCTT  
 40 TAATATACAGTCTGAGGAATAAGGATGTGAAGAAAGCATTAAAGGAAGGTCTTAGTAGGAA  
 AATGA (SEQ ID NO: 252)

## AOLFR137 sequences:

45 MSPENQSSVSEFLLGLPIRPEQQA VFFALFLGMYLTTVLGNLLIMLLIQLDShLHTPMYFFLSH  
 LALTDISFSSVTPKMLMNMQTQHLAVFYKGCISQTYFFIFFADLDSFLITSMAYDRYVAICPL  
 HYATIMTQSQCVMLVAGSWVIACALLHTLLAQLSFCADHIIPHYFCDLGA LLKLSCSDTSL  
 NQLAIFTAALTAIMLPFLCILVSYGHIGVTILQIPSTKGICKALSTCGSHLSVVTIYRTIIGLYFLP  
 PSSNTNDKNIIASVIYTA VTPMLNPFYISLRNKDIKGALRKLLSRGAVAHACNLSTLGG (SEQ  
 ID NO: 253)

50 ATGAGCCCTGAGAACCAGAGCAGCGTGTCCGAGTTCCTCCTCCTGGGCTCCCCATCCGGC  
 CAGAGCAGCAGGCCGTGTTCTTCGCCCTGTTCCCTGGGCATGTACCTGACCACGGTGCTGGG  
 GAACCTGCTCATCATGCTGCTCATCCAGCTAGACTCTCACCTTCACACCCCCATGTACTTCT  
 TCCTTAGCCACTTGGCCCTCACTGACATCTCCTTTTCATCTGTCACTGTCCCTAAGATGCTG  
 55 ATGAACATGCAGACTCAGACCTAGCCGTCTTTTACAAGGGATGCATTTACAGACATATT  
 TTTTCATATTTTGTGCTGACTTAGACAGTTTCTTATCACTTCAATGGCATATGACAGGTAT



GTGGCCATCTGTCATCCTCTACATTATGCCACCATCATGACTCAGAGCCAGTGTGTCATGC  
 TGGTGGCTGGGTCCTGGGTCATCGCTTGTGCGTGTGCTCTTTTGCATACCCCTCCTGGCC  
 CAGCTTTCCCTTCTGTGCTGACCACATCATCCCTCACTACTTCTGTGACCTTGGTGCCCTGCT  
 CAAGTTGTCCTGCTCAGACACCTCCCTCAATCAGTTAGCAATCTTTACAGCAGCATTGACA  
 5 GCCATTATGCTTCCATTCTGTGCATCCTGGTTTCTTATGGTCACATTGGGGTCACCATCCT  
 CCAGATTCCCTCTACCAAGGGCATATGCAAAGCCTTGTCCACTTGTGGATCCACCTCTCA  
 GTGGTGACTATCTATTATCGGACAATTATTGGTCTCTATTTTCTTCCCCCATCCAGCAACAC  
 CAATGACAAGAACATAATTGCTTCAGTGATATACACAGCAGTCACTCCCATGTTGAACCCA  
 TTCATTTACAGTCTGAGAAATAAAGACATTAAGGGAGCCCTAAGAAAACCTCTGAGTAGG  
 10 TCAGGCGCAGTGGCTCATGCCTGTAATCTCAGCACTTTGGGAGGCTGA (SEQ ID NO: 254)

**AOLFR138 sequences:**

MLNFTDVTEFILLGLTSRREWQVLFFIVFLVVYIITVVGNIQMMLLIKVSPQLNSPMYFFLSHLS  
 FVDVWFSSNVTPKMLENLFSDKKTISYADCLAQCFFIALVHVEIFILAAIAFDRTVIGNPLLY  
 15 GSKMSRGCIRLITFPYIYGFLTSLTATLWTYGLYFCGKIEINHFCADPPLIKMACAGTFVKEY  
 TMLILAGINFTYSLTVIISYLFILAILMRSAEGRQKAFSTCGSHPTAVIIFYGTLIFMYLRRPTE  
 ESVEQGMVAVFYTTVIPMLNPMIYSLRNKDVKKAMMKVISRSC (SEQ ID NO: 255)

ATGCTCAATTTACCGATGTGACAGAGTTCAATCTTTTGGGGCTAACGAGCCGTCGGGAAT  
 20 GGCAAGTTCTCTTCTTCATCGTTTTTCTTGTGGTCTACATTATCACCGTGGTGGGCAATATC  
 GGCATGATGTTGTTAATCAAGGTCAGTCCTCAGCTTAACAGCCCCATGTACTTTTCTCTCA  
 GTCACCTGTCAATTTGTTGATGTGTGGTTTTCTTCCAATGTCACCCCTAAAATGTTGGAAAT  
 CTGTTATCAGATAAAAAACAATTTCTTATGCTGGCTGTTAGCACAGTGTCTTCTTCTCAT  
 TGCTCTTGTCCATGTGGAAATTTTATCTTGTGCTGCGATTGCCTTTGATAGATACACAGTGA  
 25 TTGGAAATCCTTTGCTTTATGGCAGCAAAATGTCAAGGGATGTCTGTATTGACTGATTAC  
 TTTCCCTTACATTTATGGTTTTCTGACGAGTCTGACAGCAACATTATGGACTTATGGCTTGT  
 ACTTCTGTGGAAAAATTGAGATCAACCATTTCTACTGTGCAGATCCACCTCTCATCAAAAT  
 GGCCTGTGCCGGGACCTTTGTAAAAGAATATACAATGCTCATACTTGCCGGCATCAAACTC  
 ACATATTCCCTGACTGTAATTATCATCTCTTACTTATTATCCTCATTTGCCATTCTGCGAAT  
 30 GCGCTCAGCAGAAGGAAGGCAGAAAGGCCTTTTCCACATGTGGGTCCCATCTGACAGCTGT  
 CATCATATTCTATGGTACTCTGATCTTCATGTATCTCAGACGTCCACAGAGGAGTCTGTG  
 GAGCAGGGGAAGATGGTGGCTGTGTTCTATACCACAGTGATCCCCATGTTGAATCCCATGA  
 TCTACAGTCTGAGGAACAAGGATGTGAAAAAGGCCATGATGAAAGTGATCAGCAGATCAT  
 GTTAA (SEQ ID NO: 256)

35

**AOLFR139 sequences:**

MGFPGIHSWQHWSLPLALLYLLALSANILILIIINKEAALHQPMMYYFLGILAMADIGLATTIMP  
 KILAILWFNAKTISLLECFAMQYAIHCFVAMESSTFVCMADRYVAICRPLRYPYIITESFVFKAN  
 GFMALRNSLCLISVPLLAQRHYCSQNQIEHCLCSNLGVTSLSDDRRINSINQVLLAWTLMGS  
 40 DLGLIILSYALILYSVLKLNSPEAASKALSTCTSHLILILFFYTVIIVISITRSTGMRVPLIPVLLNL  
 HNVIPPALNPMVYALKNKELRQGLYKVLRLGVKGT (SEQ ID NO: 257)

ATGGGATTCCCTGGCATTACAGTTGGCAGCACTGGCTCTCCCTGCCCCTGGCTCTGCTCT  
 ACCTCTTAGCTCTCAGTGCCAACATCCTTATCCTGATCATCATCAACAAAGAGGCAGCACT  
 45 GCACCAGCCTATGTACTATTTCTGGGCATCTTGGCTATGGCAGACATAGGCCTGGCTACC  
 ACCATCATGCCTAAGATTTTGGCCATCTTATGGTTCAATGCTAAGACCATCAGTCTCCTGG  
 AGTGCTTTGCTCAGATGTATGCCATACATTGCTTTGTGGCCATGGAATCAAGTACCTTTGT  
 CTGCATGGCTATTGATAGATATGTAGCCATTTGTGACCGCTACGATATCCATCAATCATC  
 ACTGAATCTTTTGTCTTCAAAGCAAATGGGTTTATGGCACTGAGAAACAGCCTGTGTCTCA  
 50 TCTCAGTGCTCTGTTGGCTGCCAGAGGCATTACTGCTCCCAGAAATCAAATTGAGCACTG  
 TCTTTGTTCTAACCTTGGAGTCACTAGCCTATCTTGTGATGATCGAAGAATCAATAGCATT  
 AACCAGGTCCTTTTGGCTTGGACACTCATGGGAAGTGACCTGGGTTTGATTATTTTATCAT  
 ATGCTCTAATACTTTACTCTGTCTGAAGCTGAAGTCTCCAGAAGCTGCATCCAAGGCCTT  
 AAGTACCTGCACCTCCACCTCATCTTAATCCTTTTCTTCTACACAGTCATCATTGTGATTT  
 55 CCATTACTCGTAGTACAGGAATGAGAGTTCCCTTATTCCAGTTCTACTTAATGTGCTACA

CAATGTCATTCCCCCTGCCCTGAACCCCATGGTATATGCACTCAAGAACAAGGAACCTCAGG  
CAAGGCTTATACAAGGTACTTAGACTGGGAGTGAAGGGCACCTGA (SEQ ID NO: 258)

**AOLFR140 sequences:**

5 MLTLNKTDLIPASFILNGVPGLEDQLWISFPFCSMYVVMVGNCGLLYLIHYEDALHKPMYY  
FLAMLSFTDLVMCSSTIPKALCIFWFHLKDIGFDECLVQMFFIHTFTGMESGVLMLMALDRYV  
AICYPLRYSTILTNPVIAKVGATFLRGVLLIIPFTFLTKRLPYCRGNILPHTYCDHMSVAKLSCG  
NVKVNAIYGLMVALLIGGFDILCITISYTMILRAVVSLSADARQKAFNTCTAHICAIVFSYTPAF  
10 FSFFSHRFGHEHPPSCHIIIVANIYLLLPPTMNPVYGVKTKQIRDCVIRLSGSKDTKSYSM (SEQ  
ID NO: 259)

ATGCTAACACTGAATAAAACAGACCTAATACCAGCTTCATTTATTCTGAATGGAGTCCCAG  
GACTGGAAGACACAACTCTGGATTTCCTTCCCATTCTGCTCTATGTATGTTGTGGCTAT  
GGTAGGGAATTGTGGACTCCTCTACCTCATTCACTATGAGGATGCCCTGCACAAACCCATG  
15 TACTACTTCTTGGCCATGCTTTCCTTACTGACCTGTTATGTGCTCTAGTACAATCCCTAA  
AGCCCTCTGCATCTTCTGGTTTCATCTCAAGGACATTGGATTGATGAATGCCTTGTCCAG  
ATGTTCTTCATCCACACCTTCACAGGGATGGAGTCTGGGGTGCTTATGCTTATGGCCCTGG  
ATCGCTATGTGGCCATCTGCTACCCCTTACGCTATTCAACTATCCTCACCATCCTGTAATT  
20 GCAAAGGTTGGGACTGCCACCTTCCTGAGAGGGGTATTACTCATTATTCCCTTACTTTCT  
CACCAAGCGCCTGCCCTACTGCAGAGGCAATATACTCCCCATACCTACTGTGACCACATG  
TCTGTAGCCAAATTGTCCTGTGGTAATGTCAAGGTCAATGCCATCTATGGTCTGATGGTTG  
CCCTCCTGATTGGGGGCTTTGACATACTGTGTATCACCATCTCCTATACCATGATTCTCCGG  
GCAGTGGTCAGCCTCTCCTCAGCAGATGCTCGGCAGAAGGCCTTTAATACCTGCACTGCCC  
ACATTTGTGCCATTGTTTTCTCCTATACTCCAGCTTTCTTCTCCTTTTCCACCGCTTTG  
25 GGGAAACACATAATCCCCCTTCTTGCCACATCATTGTAGCCAATATTTATCTGCTCCTACCA  
CCCACTATGAACCCCTATTGTCTATGGGGTGAAAACCAAACAGATACGAGACTGTGTCTATA  
GGATCCTTTCAGGTTCTAAGGATACCAATCCTACAGCATGTGA (SEQ ID NO: 260)

**AOLFR141 sequences:**

30 MSSTLGHNMESPNHTDVPDSVFFLLGIPGLEQFHLWLSLPVCGLTATIVGNITLVVATEPVL  
HKPVYLFCLMLSTIDLAASVSTVPKLLAIFWCGAGHISASACLAQMFFIHAFMMESTVLLAM  
AFDRYVAICHPLRYATILDTIAHIGVAAVVRGSLMLPCPFLIGRLNFCQSHVILHTYCEHMA  
VVKLACGDTRPNRVYGLTAALLVIGVDLFCIGLSYALSAQAVLRLSSHEARSKALGTGCGSHVC  
VILISYTPALFSFFTHRFGHHVPVHIHILLANVYLLLPALNPVVYGVKTKQIRKRVVRVFQSGQ  
35 GMGIKASE (SEQ ID NO: 261)

ATGTCCAGCACTCTTGGCCACAACATGGAATCTCCTAATCACACTGATGTTGACCCTTCTG  
TCTTCTTCTCCTGCGGCATCCCAGGTCTGGAACAATTCATTTGTGGCTCTCACTCCCTGTG  
TGTGGCTTAGGCACAGCCACAATTGTGGGCAATATAACTATTCTGGTTGTTGTGGCACTG  
40 AACCAGTCTTGACACAAGCCTGTGTACCTTTTTCTGTGCATGCTCTCAACCATCGACTTGGCT  
GCCTCTGTCTCCACAGTTCCCAAGCTACTGGCTATCTTCTGGTGTGGAGCCGGACATATAT  
CTGCCTCTGCCTGCCTGGCACAGATGTTCTTCATTATGCCTTCTGCATGATGGAGTCCACT  
GTGCTACTGGCCATGGCCTTTGATCGCTACGTGGCCATCTGCCACCCACTCCGCTATGCCA  
CAATCCTCACTGACACCATCATTGCCACATAGGGGTGGCAGCTGTAGTGCGAGGCTCCCT  
45 GCTCATGCTCCCATGTCCCTTCTTATTGGGCGTTTGAACCTTCTGCCAAAGCCATGTGATCC  
TACACACGTACTGTGAGCACATGGCTGTGGTGAAGCTGGCCTGTGGAGACACCAGGCCTA  
ACCGTGTGTATGGGCTGACAGCTGCACTGTTGGTCATTGGGTTGACTTGTTTTGCAATTGG  
TCTCTCCTATGCCCTAAGTGACAAGCTGTCCTTCGCCTCTCATCCCATGAAGCTCGGTCCA  
AGGCCCTAGGGACCTGTGGTTCCCATGTCTGTGTCATCCTCATCTTATACACCAGCCCTC  
50 TTCTCCTTTTTTACACACCGCTTTGGCCATCACGTTCCAGTCCATATTCACATTCTTTTGGC  
CAATGTTTATCTGCTTTTGCCACCTGCTCTAATCCTGTGGTATATGGAGTTAAGACCAAAC  
AGATCCGTAAAAGAGTTGTCAGGGTGTTCAAAGTGGCAGGGAATGGGCATCAAGGCAT  
CTGAGTGA (SEQ ID NO: 262)



**AOLFR143 sequences:**

MLGLNGTPFQPATLQLTGIPGIQTGLTWVALIFCILYMISIVGNLSILTLVFWEPALHQPMYYFL  
 SMLALNDLGVSFSTLPTVISTFCFNYNHVAFNACLVMFFIHTFSFMESGILLAMSLDRFVAICY  
 PLRYVTVLTHNRILAMGLGILTKSFTTLFPFPFVVKRLPFCKGNVLHHSYCLHPDLMKVACGDI  
 5 HVNNIYGLLVIIIFTYGMDSFTILLSYALILRAMLVISQEQRLKALNTCMSHICAVLAFYVPIIAVS  
 MIHRFWKSAPPVVHVMMNSNVYLFVPPMLNPIIYSVKTKAIRKILKFFHKSQA (SEQ ID NO:  
 263)

ATGCTGGGTCTCAATGGCACCCCTTCCAGCCAGCAACACTCCAGCTGACAGGCATTCCTG  
 10 GGATACAAACAGGCCTCACCTGGGTTGCCCTGATTTTCTGCATCCTCTACATGATCTCCATT  
 GTAGGTAACCTCAGCATTCTCACTCTGGTGTTTTGGGAGCCTGCTCTGCATCAGCCCATGT  
 ACTACTTCCTCTCTATGCTCGCTCTCAATGATCTGGGAGTGTCTTTTCTACACTTCCCACT  
 GTGATTTCTACTTTCTGCTTCAACTACAACCATGTTGCGTTAATGCTTGCCTGGTCCAGAT  
 GTTCTTCATCCACACTTTCTCCTTCATGGAGTCAGGCATACTGCTGGCCATGAGCTTGGATC  
 15 GCTTTGTGGCTATTTGTTATCCATTACGCTATGTCACTGTGCTCACTCACAACCGTATATTG  
 GCTATGGGTCTGGGCATCCTTACCAAGAGTTTCACCACTCTCTCCCTTTCCCTTTTGTGGT  
 GAAACGACTGCCCTTCTGCAAAGGCAATGTTTTGCATCACTCCTACTGTCTCCATCCAGAT  
 CTCATGAAAGTAGCATGTGGAGACATCCATGTTAACAACATTTATGGGCTCTTGGTGATCA  
 TTTTACCTATGGTATGGACTCAACTTTCATCCTGCTTTCCTACGCATTGATCCTGAGAGCC  
 20 ATGCTGGTCATCATATCCCAGGAACAGCGGCTCAAGGCACTCAACACCTGCATGTCACACA  
 TCTGTGCAGTGCTGGCCTTTTATGTGCCATAATTGCTGTCTCCATGATTCACCGCTTCTGG  
 AAAAGTGCTCCACCTGTTGTTTCATGTCATGATGTCCAATGTCTACCTGTTTGTACCACCCAT  
 GCTCAACCCTATCATCTACAGTGTGAAAACCAAGGAGATCCGCAAAGGGATTCTCAAGTTC  
 TTCCATAAATCCCAGGCCTGA (SEQ ID NO: 264)

25

**AOLFR144 sequences:**

MGLFNVTHPAFFLLTGIPGLESSHWSLGPCLVEMYAVALGGNTVILQAVRVEPSLHEPMYYFL  
 SMLSFSDDVAISMATLPTVLRITFCLNARNITFDACLIQMFLIHFFSMMESGILLAMSFDRYVAICD  
 PLRYATVLTTEVIAAMGLGAAARSFTTLFPLPFLIKRLPICRSNVLSHSYCLHPDMMRLACADISI  
 30 NSIYGLFVLVSTFGMDLFFIFLSYVLILRSVMATASREERLKALNTCVSHILAVLAFYVPMIGVS  
 TVHRFGKHVPCYIHVLMNSNVYLFVPPVLNPLIYSAKTKEIRRAIFRMFHHIKI (SEQ ID NO: 265)

ATGGGGTTGTTCAATGTCACTCACCTGCATTCTTCTCCTGACTGGTATCCCTGGTCTGGA  
 GAGCTCTCACTCCTGGCTGTCAGGGCCCCCTCTGCGTGATGTATGCTGTGGCCCTTGGGGGA  
 35 AATACAGTGATCCTGCAGGCTGTGCGAGTGAGGCCAGCCTCCATGAGCCCATGTACTACT  
 TCCTGTCCATGTTGTCCTTCAGTGATGTGGCCATATCCATGGCCACACTGCCCACTGTACTC  
 CGAACCTTCTGCCTCAATGCCCGCAACATCACTTTTGATGCCTGTCTAATTCAGATGTTTCT  
 TATTCACCTTCTTCTCCATGATGGAATCAGGTATTCTGCTGGCCATGAGTTTTGACCGCTATG  
 TGGCCATTTGTGACCCCTTGCCTATGCAACTGTGCTCACCCTGAAGTCATTGCTGCAAT  
 40 GGGTTTAGGTGCAGCTGCTCGAAGCTTCATCACCTTTTCCCTCTTCCCTTTCTTATTAAGA  
 GGCTGCCTATCTGCAGATCCAATGTTCTTCTCACTCCTACTGCCTGCACCCAGACATGATG  
 AGGCTTGCCTGTGCTGATATCAGTATCAACAGCATCTATGGACTCTTTGTTCTTGATCCAC  
 CTTTGGCATGGACCTGTTTTTATCTTCTCTCCTATGTGCTCATTCTGCGTTCTGTGATGG  
 CCACTGCTTCCCGTGAGGAACGCCTCAAAGCTCTCAACACATGTGTGTACATATCCTGGC  
 45 TGTACTTGCATTTTATGTGCCAATGATTGGGGTCTCCACAGTGCACCGCTTTGGGAAGCAT  
 GTCCCATGCTACATACATGTCCTCATGTCAAATGTGTACCTATTTGTGCCTCCTGTGCTCAA  
 CCCTCTCATTTATAGCGCCAAGACAAAGGAAATCCGCCGAGCCATTTCCGCATGTTTCAC  
 CACATCAAAATATGA (SEQ ID NO: 266)

## AOLFR145 sequences:

MSVQYSLSPQFMLSNTQFSPIFYLTSPFGLGKHWIFIPFFMYMVAISGNCFILIIKTNPRH  
 TPMYYLLSLLALDGLCVSTLPTTMGIFWFNSQSIYFGACQIQMFCIHSFSMESSVLLMMSFD  
 RFVAICHPLRYSVIITGQQVVRAGLIVFRGPVATIPVLLLKAFPYCGSVVLSHSFCLHQEVIQLA  
 5 CTDITFNLYGLMVVFTVMLDLVLIALSGLIHTVAGLASQEEQRRAFQCTAHLCAVLVF  
 FVPMGLSLVHRFGKHAPPAIHLMLANVYLFVPPMLNPIIYSIKTKEIHRANKLLGLKKASK  
 (SEQ ID NO: 267)

10 ATGTCAGTCCAATATTCGCTCAGTCCTCAATTCATGCTGCTATCCAACATTACTCAGTTTAG  
 CCCCATATTCTATCTACCAGCTTTCCTGGATTGGAAGGCATCAAACACTGGATTTCATCC  
 CCTTTTTCTTTATGTACATGGTTGCCATCTCAGGCAATTGTTTCATTCTGATCATTATTAAG  
 ACCAACCCTCGTCTGCACACACCCATGTACTATCTACTATCCTTGCTGGCCCTCACTGACCT  
 GGGGCTGTGTGTGCCACGTTGCCACCACTATGGGGATCTTCTGGTTTAACTCCCAGAGT  
 ATCTACTTTGGAGCGTGTCAAATCCAGATGTTCTGCATCCACTCTTTTCTTCATGGAGTC  
 15 CTCAGTGCTCCTCATGATGTCCTTTGACCGCTTTGTGGCCATCTGCCACCCTCTGAGGTATT  
 CGGTCAATTATCACTGGCCAGCAAGTGGTCAGAGCAGGCCTAATTGTCATCTTCCGGGGACC  
 TGTGGCCACTATCCCTATTGTCCTCCTCTGAAGGCTTTCCCTACTGTGGATCTGTGGTCC  
 TCTCCCACTCATTTTGCCTGCACCAGGAAGTGATACAGCTGGCCTGCACAGATACCACCTT  
 CAATAATCTGTATGGACTGATGGTGGTAGTTTTCACTGTGATGCTGGACCTGGTGTCTCATC  
 20 GCACTGTCCTATGGACTCATCTGCACACAGTAGCAGGCCTGGCCTCCCAAGAGGAGCAGC  
 GCCGTGCCTTTCAGACATGCACCGCTCATCTCTGTGCTGTGCTAGTATTCTTTGTGCCATG  
 ATGGGGCTGTCCCTGGTGCACCGTTTTGGGAAGCATGCCCCACCTGCTATTCATCTTCTAT  
 GGCCAATGTCTACCTTTTGTGCCTCCCATGCTTAACCCAATCATATACAGCATTAAAGACC  
 AAGGAGATCCACCGTGCCATTATCAAACCTCTAGGTCTTAAAAAGGCCAGTAAATGA (SEQ  
 25 ID NO: 268)

## AOLFR146 sequences:

MSQVTNTTQEGIFYLTDIPGFEASHIWISIPVCCLYTISIMGNTTILTVIRTEPSVHQRMVFLSM  
 LALDGLTLTTLPTVMQLLWFNVRISSEACFAQFFFLHGFMSMESSVLLAMSVDCYVAICCP  
 30 LHYASILTNEVIGRTGLAIICCVLAVLPSLFLKRLPFCHSHLLRSYCLHQDMIRLVACDIRLN  
 SWYGFALALLIIVDPLLVISYTLILKNILGTATWAERLRALNNCLSHILAVLVLYPMVGVSM  
 HRFKASPLVHVIMANIYLLAPPVMNPIIYSVKNKQIQWGMNLSLKNMHSR (SEQ ID NO:  
 269)

35 ATGTCCCAGGTGACTAACACCACACAAGAAGGCATCTACTTCATCCTCACGGACATCCCTG  
 GATTTGAGGCCTCCACATCTGGATCTCCATCCCCGTCTGCTGTCTCTACACCATCTCCATC  
 ATGGGCAATACCACCATCCTCACTGTCATTGCGACAGAGCCATCTGTCCACAGCGCATGT  
 ATCTGTTTCTCTCCATGCTGGCCCTGACGGACCTGGGTCTCACCCCTACCACCTACCCACA  
 GTCATGCAGCTTCTCTGGTTCAACGTTCTAGAAATCAGCTCTGAGGCCTGTTTGTCTGAGT  
 40 TTTCTTCTTCATGGATTCTCCTTATGGAGTCTTCTGTCTCCTCCTGGCTATGTCCGTGACT  
 GCTATGTGGCCATCTGCTGTCCCTCCATTATGCCTCCATCCTCACCAATGAAGTCATTGGT  
 AGAACTGGGTAGCCATCATTGCTGCTGTGTTCTGGCGGTTCTTCCCTCCCTTTTCTTACT  
 CAAGCGACTGCCTTTCTGCCACTCCACCTTCTCTCTCGCTCCTATTGCCTCCACCAGGATA  
 TGATCCGCTGGTCTGTGCTGACATCAGGCTCAACAGCTGGTATGGATTGCTCTTGCTT  
 45 GCTCATTATTATCGTGGATCCTCTGCTCATTGTGATCTCCTATACACTATTCTGAAAAATA  
 TCTTGGGCACAGCCACTGGGCTGAGCGACTCCGTGCCCTCAATAACTGCCTGTCCACAT  
 TCTAGCTGTCTGCTCTACATTCCCATGGTGGTGTATCTACTGCTGGCAGCCCCGGT  
 AGCATGCCTCTCCACTGGTCCATGTTATCATGGCCAATATCTACCTGCTGGCAGCCCCGGT  
 GATGAACCCCATCATTTACAGTGTAAGAACAAGCAGATCCAATGGGGAATGTAAATTC  
 50 CTTTCCCTCAAAAATATGCATTCAAGATGA (SEQ ID NO: 270)

## AOLFR147 sequences:

MPSASAMIIFNLSSYNPGPFILVGIPGLEQFHVWIGIPFCIIYIVAVVGNCLLYLIVVEHSLHEPMF  
 FFLSMLAMTDLILSTAGVPKALSIFWLGAIREITFPGLTQMFFLHYNFVLDLSAILMAMAFDHYV  
 55 AICSPRYTTILTPKTIKSAMGISFRSFCILPDVFLLTCLPFCRTRIPTYCEHIGVAQLACADISI  
 NFWYGFCVPIMTVISDVILIAVSYAHILCAVFLPSQDACQKALGTCGSHVCVILMFYTPAFFSI

LAHREFGHNVSRTFHIMFANLYIVIPPALNPMVYGVKTKQIRDKVILLFSKGTG (SEQ ID NO: 271)

5 ATGCCATCTGCCTCTGCCATGATCATTTTCAACCTGAGCAGTTACAATCCAGGACCCCTTCAT  
TCTGGTAGGGATCCCAGGCCTGGAGCAATTCATGTGTGGATTGGAATTCCTTCTGTATC  
ATCTACATTGTAGCTGTTGTGGGAACTGCATCCTTCTCTACCTCATTGTGGTGGAGCATA  
GTCTTCATGAACCCATGTTCTTCTTCTCTCCATGCTGGCCATGACTGACCTCATCTTGTCC  
ACAGCTGGTGTGCCTAAAGCACTCAGTATCTTTTGGCTAGGGGCTCGCGAAATCACATTCC  
CAGGATGCCTTACACAAATGTTCTTCCCTTCACTATAACTTTGTCCTGGATTGAGCCATTCTG  
10 ATGGCCATGGCATTGTGATCACTATGTAGCTATCTGTTCTCCCTTGAGATATAACCACCATCTT  
GACTCCCAAGACCATCATCAAGAGTGCTATGGGCATCTCCTTTCGAAGCTTCTGCATCATC  
CTGCCAGATGTATTCTTGCTGACATGCCTGCCTTTCTGCAGGACACGCATCATACCCACACA  
CATACTGTGAGCATATAGGTGTTGCCAGCTCGCCTGTGCTGATATCTCCATCAACTTCTG  
GTATGGCTTTTGTGTTCCCATCATGACGGTCACTCAGATGTGATTCTCATTGCTGTTTCTCCT  
15 ACGCACACATCCTCTGTGCTGTCTTGGCCTTCCCTCCCAAGATGCCTGCCAGAAAGCCCT  
CGGCACITGTGGTTCTCATGTCTGTGTCATCCTCATGTTTTATACACCTGCCTTTTCTCCA  
TCCTCGCCCATCGCTTGGACACAATGTCTCTCGCACCTTCCACATCATGTTTGCCAATCTC  
TACATTGTTATCCACCTGCACTCAACCCCATGGTTTACGGAGTGAAGACCAAGCAGATCA  
GAGATAAGGTTATACTTTTGTCTTCTAAGGGTACAGGATGA (SEQ ID NO: 272)

20

**AOLFR148 sequences:**

MPTVNHSGTSHTVFHLGIPGLQDQHMWISIPFFISYVTALLGNSLLIFIILTKRSLHEPMYLFLC  
MLAGADIVLSTCTIPQALAIWFWRAGDISLDRCTQLFFIHSTFISESGILLVMAFDHYIAICYPLR  
YTTILTALIKKICVTVSLRSYGTIFPIIFLLKRLTFCQNNIPHTFCEHIGLAKYACNDIRINIWYG  
25 FSILMSTVVLDDVVLIFISYMLILHAVFHMPSPDACHKALNTFGSHVCIILFYGSGIFTILTQRFGR  
HIPPCIHIPLANVCILAPPMNLPIIYGIKTKQIQEQVVQFLFIKQKITLV (SEQ ID NO: 273)

ATGCCTACTGTAAACCACAGTGGCACTAGCCACACAGTCTTCCACTTGCTGGGCATCCCTG  
GCCTACAGGACCAGCACATGTGGATTTCTATCCCATTCTTCATTCCCTATGTCACCGCCCTT  
30 CTTGGGAACAGCCTGCTCATCTTCATTATCCTCACAAAGCGCAGCCTCCATGAACCCATGT  
ACCTCTTCCCTCTGCATGCTGGCTGGAGCAGACATTGTCCTCTCCACGTGCACCATTCCTCAG  
GCCTTAGCTATCTTCTGGTTCCGTGCTGGGGACATCTCCCTGGATCGTTGCATCACTCAGCT  
CTTCTTCATCCATTCCACCTTCATCTCTGAGTCAGGGATCTTGCTGGTGATGGCCTTTGACC  
ACTATATTGCCATATGCTACCCACTGAGGTACACCACCATTCCTTACAAATGCTCTGATCAA  
35 GAAAATTTGTGTGACTGTCTCTCTGAGAAGTTATGGTACAATTTTCCCTATCATATTTCTTT  
TAAAAAGATTGACTTTCTGCCAGAATAATATTATCCACACACCTTTTGTGAACACATTGG  
CCTAGCCAAATATGCATGTAATGACATTGCAATAAACATTTGGTATGGGTTTTCCATTCTA  
ATGTCGACGGTGGTCTTAGATGTTGTACTAATTTTTATTTCCCTATATGCTGATTCTCCATGC  
TGTCTTCCACATGCCTTCTCCAGATGCTTGCCACAAAGCTCTCAACACATTGGCTCCCATG  
40 TCTGCATCATCATCCTCTTTTATGGGTCTGGCATCTTCAACAATCCTTACCCAGAGGTTTGGA  
CGCCACATTCACCTTGATCCACATCCCGTTGGCTAATGTCTGCATTCTGGCTCCACCTAT  
GCTGAATCCCATTATTTATGGGATCAAACCAAGCAAATCCAGGAACAGGTGGTTCAGTTT  
TTGTTTATAAAACAGAAAATAACTTTGGTTTAA (SEQ ID NO: 274)

**AOLFR149 sequences:**

MSNASLLTAFILMGLPHAPALDAPLFGVFLVYVLTVLGNLLILLVIRVDSHLHTTMYFLTNL  
SFIDMWFSVTVPKLLMTLVFPSGRAISFHSMAQLYFFHFLGGTECFLYRVMSCDRYLAISSYP  
LRYTSMMTGRSCTLLATSTWLSGSLHSAVQAILTFHLPYCGPNWIQHYLCDAPPILKLACADTS  
AIETVIFVTVGIVASGCFVLIVLSYVSIVCSILRIRTSEKHFRAFQTCASHCIVVLCFFGPGLFIYLR  
50 PGSRKAVDGVVAVFYTVLTPLLNPVVYTLRNKEVKKALLKLKDKVAHSQSK (SEQ ID NO:  
275)

ATGTCCAACGCCAGCCTACTGACAGCGTTCATCCTCATGGGCCTTCCCCATGCCCCAGCGC  
TGGACGCCCCCTCTTTGGAGTCTTCTGGTGGTTTACGTGCTCACTGTGCTGGGGAACCT  
55 CCTCATCCTGCTGGTGATCAGGGTGGATTCTCACCTCCACACCACCATGTACTACTTCTCA  
CCAACCTGTCGTTCAATTGACATGTGGTTCTCCACTGTCACGGTGCCCAAATTGCTGATGAC

TTTGGTGTTCCTCAAGTGGCAGGGCTATCTCCTTCCACAGCTGCATGGCTCAGCTCTATTCT  
 TTCCTTCTAGGGGGCACCAGTGTTCCTCTACAGGGTCATGCTGTGATCGCTACCT  
 GGCCATCAGTTACCCGCTCAGGTACACCAGCATGATGACTGGGCGCTCGTGTACTCTTCTG  
 GCCACCAGCACTTGGCTCAGTGGCTCTCTGCACTCTGCTGTCCAGGCCATATTGACTTTCC  
 5 ATTTGCCCTACTGTGGACCAACTGGATCCAGCACTATTTGTGTGATGCACCGCCATCCT  
 GAAACTGGCCTGTGCAGACACCTCAGCCATAGAGACTGTCATTTTTGTGACTGTTGGAATA  
 GTGGCCTCGGGCTGCTTTGTCCTGATAGTGTCTGTCTATGTGTCCATCGTCTGTTCATCCT  
 GCGGATCCGCACCTCAGAGGGGAAGCACAGACCTTTCAGACCTGTGCCCTCCACTGTATC  
 GTGGTCTTTGCTTCTTTGGCCCTGGTCTTTTCAATTTACCTGAGGCCAGGCTCCAGGAAAGC  
 10 TGTGGATGGAGTTGTGGCCGTTTTCTACACTGTGCTGACGCCCTTCTCAACCCTGTTGTGT  
 ACACCCTGAGGAACAAGGAGGTGAAGAAAGCTCTGTTGAAGCTGAAAGACAAAGTAGCAC  
 ATTCTCAGAGCAAATAG (SEQ ID NO: 276)

## AOLFR150 sequences:

15 MELGNVTRVKEFIFLGLTQSQDQSLVLFLLCLVYMTLLGNLLIMVTVTCESSLHTPMYFLLR  
 NLAILDICFSSTAPKVLDDLLSKKKTISYTSMTQIFLHLLGGADIFSLSVMAFDCYMAISKPL  
 HYVTIMSRGQCTALISASWMGGFVHSIVQISLLLPLFCGPNVLDTFYCDVPQVILKTCTDTFA  
 LEFLMISNGLVITLWFIFLLVSYTVILMTLSQAGGRRKAISTCTSPHHCGDPAFCALHLCLC  
 PALHCPPHRKGHLLHCHLPSAEPFDLHSEEPGNEVSHEKTEEKTRAF (SEQ ID NO: 277)

20 ATGGAGTTGGGAAATGTCACCAGAGTAAAAGAATTTATATTTCTGGGACTTACTCAATCCC  
 AAGACCAGAGTTTGGTCTTGTCTTTTATATGCTTGTGTACATGACGACTCTGCTGGGA  
 AACCTCCTCATCATGGTCACCGTGACCTGTGAGTCTCGCCTTACACCCCCATGTACTTCT  
 GCTCCGCAATCTAGCCATCCTTGACATCTGCTTCTCCTCCACAAGCTGCATGACACAGATATTTCT  
 25 TGGACCTTCTGTCAAAGAAAAAGACCATATCCTATACAAGCTGCATGACACAGATATTTCT  
 CTTCCACCTCCTTGGTGGGGCAGACATTTTTTCTCTCTGTGATGGCGTTTACTGTCTACA  
 TGGCCATCTCCAAGCCCCTGCACTATGTGACCATCATGAGTAGAGGGCAATGCACTGCCCT  
 CATCTCTGCCTCTTGGATGGGGGGCTTTGTCCACTCCATCGTGCAGATCTCCCTGTTGCTGC  
 CTCTCCCTTCTGTGGACCCAATGTTCTTGACACTTTCTACTGCGATGTCCCCAGGTCTCT  
 30 AAACCTCACTTGCACTGACACTTTTGTCTTGTGAGTTCTTGATGATTCCAACAATGGCCTGGT  
 CACTACCCTGTGGTTTATCTTCTGCTTGTGTCTTACACAGTCATCTAATGACGCTGAGGT  
 CTCAGGCAGGAGGGGGCAGGAGGAAAGCCATCTCCACTTGCACCTCCCCACATCACTGTG  
 GTGACCTGCAATTTGTGCCCTGCATCTATGTCTATGCCCGGCCCTTCACTGCCCTCCCCAC  
 AGAAAAGGCCATCTCTGTACCTTCACTGTCTCTCCCTCTGCTGAACCTTTGATCTACA  
 35 CTCTGAGGAACCAGGAAATGAAGTCAGCCATGAGAAGACTGAAGAGAAGACTCGTGCCTT  
 CTGA (SEQ ID NO: 278)

## AOLFR151 sequences:

40 MFSPNHTIVTEFILLGLTDDPVLEKILFGVFLAIYLITLAGNLCMILLRTNSHLQTPMYFFLGHL  
 FVDICYSSNVTNMLNHLSEQKTISYAGCFTQCLLFIALVITEFYILASMAIDRYVAICSPHYS  
 SRMSKNICVCLVTIPYMYGFLSGFSQSLTFLHLSFCGSLEINHFYCADPPLIMLACSDTRVKKMA  
 MFVVAGFNLSSSLFIILLSYLFAAIFRIRSAEGRHKAFTSCASHLTIVTLFYGTFLFCMYVRPPE  
 KSVEESKJITAVFYTFILSPMLNPLIYSLRNTDVLAMQMQMIRGKSFHKIAV (SEQ ID NO: 279)

45 ATGTTCTCCCCAAACCACACCATAGTGACAGAATTCATTCTCTTGGGACTGACAGACGACC  
 CAGTGCTAGAGAAGATCCTGTTTGGGGTATTCTTGGGATCTACCTAATCACACTGGCAGG  
 CAACCTGTGCATGATCCTGCTGATCAGGACCAATCCCACCTGCAAAACCCCATGTATTTC  
 TTCTTGGCCACCTCTCCTTTGTAGACATTTGCTATTCTTCCAATGTTACTCCAAATATGCT  
 GCACAATTTCTCTCAGAACAGAAGACCATCTCTACGCTGGATGCTTACACAGTGTCTT  
 50 CTCTCATCGCCCTGGTGATCACTGAGTTTTACATCCTTGCTTCAATGGCATTGGATCGCTA  
 TGTAGCCATTTGCAGCCCTTTGCATTACAGTTCCAGGATGTCCAAGACATCTGTGTCTGT  
 CTGGTCACTATCCCTTACATGTATGGGTTTCTTAGTGGGTTCTCTCAGTCACTGCTAACCTT  
 TCACTTATCCTTCTGTGGTCCCTTGAATCAATCATTTCTACTGCGCTGATCCTCCTCTTA  
 TCATGCTGGCCTGCTCTGACACCCGTGTCAAAAAGATGGCAATGTTGTAGTTGCAGGCTT  
 55 TAATCTCTCAAGCTCTCTTTCATCATTCTTGTCTCTATCTTTTCAATTTTGCAGCGATCTT  
 CAGGATCCGTTCTGCTGAAGGCAGGCACAAAGCCTTTTCTACGTGTGCTTCCACCTGACA

ATAGTCACTTTGTTTTATGGAACCCTCTTCTGCATGTACGTAAGGCCTCCATCAGAGAAGT  
CTGTAGAGGAGTCCAAAATAACTGCAGTCTTTTATACTTTTTTGAGCCCAATGCTGAACCC  
ATTGATCTATAGCCTACGGAACACAGATGTAATCCTTGCCATGCAACAAATGATTAGGGGA  
AAATCCTTTCATAAAATTGCAGTTTAG (SEQ ID NO: 280)

5

**AOLFR152 sequences:**

MDQINHTNVKEFFLELTRSRELEFFLVVFFAVYVATVLGNALIVVTITCESRLHTPMYFLLRN  
KSVLDIVFSSITVPKFLVDLLSDRK TISYND CMAQIFFFH FAGGADIFFLSVMAYDRYLAIAKPL  
HYVTMMRKEVWVALVVASWVSGGLHSIIQVILMLPFPFCGPNTLDAFYCYVLQVVKLACTDT  
10 FALELFMISNGLVTLLWFLLLLGSYTVILVMLRSHSGEGRNKALSTCTSHMLVVTLHFVPCV  
YIYCRPFMTLPMDDTISINNTVITPMLNPIIYSLRNQEMKSAMQRLQRRLLGPSES RKWG (SEQ ID  
NO: 281)

ATGGACCAGATCAACCACACTAATGTGAAGGAGTTTTTCTTCTGGAACCTTACACGTTCCC  
15 GAGAGCTGGAGTTTTTCTTGTTGTGGTCTTCTTGTCTGTGTATGTAGCAACAGTCCTGGG  
AAATGCACTCATTGTGGTCACTATTACCTGTGAGTCCCGCCTACACACTCCTATGTACTTTC  
TCCTGCGGAACAAATCAGTCCTGGACATCGTTTTTTCATCTATCACCGTCCCCAAGTTCCTG  
GTGGATCTTTTATCAGACAGGAAAACCATCTCCTACAATGACTGCATGGCACAGATCTTTT  
TCTTCCACTTTGCTGGTGGGGCAGATATTTTTTCTCTCTGTGATGGCCTATGACAGATAC  
20 CTTGCAATCGCCAAGCCCTGCACTATGTGACCATGATGAGGAAAGAGGTGTGGGTGGCC  
TTGGTGGTGGCTTCTTGGGTGAGTGGTGGTTTGCATTCAATCATCCAGGTAATTCTGATGC  
TTCCATTCCCCTTCTGTGGCCCCAACACACTGGATGCCTTCTACTGTTATGTGCTCCAGGTG  
GTAAACTGGCCTGCACTGACACCTTTGCTTTGGAGCTTTTCATGATCTCTAACAAACGGAC  
TGGTGACCCTGCTCTGGTTCTCTGCTCCTGGGCTCCTACACTGTCATTCTGGTGATGCTG  
25 AGATCCCACTCTGGGGAGGGGCGGAACAAGGCCCTCTCCACGTGCACGTCCCACATGCTG  
GTGGTGACTCTTCACTTCGTGCTTGTGTTTACATCTACTGCCGGCCCTTCATGACGCTGCC  
CATGGACACAACCATATCCATTAAATAACACGGTCATTACCCCCATGCTGAACCCCATCATC  
TATTCCCTGAGAAATCAAGAGATGAAGTCAGCCATGCAGAGGCTGCAGAGGAGACTTGGG  
CCTTCCGAGAGCAGAAAATGGGGGTGA (SEQ ID NO: 282)

30

**AOLFR153 sequences:**

MSKTSLVTA FILTGLPHAPGLDAPLFGIFLVVYVLTVLGNLLILLVIRVDSHLHTPMYYFLTNLS  
FIDMWFSTVTVPKMLMTLVSPSGRAISFHS CVAQLYFFHFLGSTECFLYTVMSYDRYLAI SYPL  
RYTSMMSGSRCALLATSTWLSGSLHSAVQ TILTFHLPYCGPNQIQHYLCDAPPILKLACADTSA  
35 NEMVIFVDIGLVASGCFL LIVLSYVSIVCSILRIHTSEGRHRAFQTCASHCIVVL CFFVXCVFIYLR  
PGSRDVVDGVVAIFYTVLTPLLNPVYVTLRNKEVKKAVLKL RDKVAHSQGE (SEQ ID NO:  
283)

ATGTCCAAGACCAGCCTCGTGACAGCGTTCATCCTCACGGGCCTTCCCCATGCCCCAGGGC  
40 TGGACGCCCCACTCTTTGGAATCTTCTGGTGGTTTACGTGCTCACTGTGCTGGGGAACCT  
CCTCATCCTGCTGGTGATCAGGGTGGATTCTCACCTCCACACCCCCATGTACTACTTCCTCA  
CCAACCTGTCCTTCATTGACATGTGGTTCTCCACTGTCACGGTGCCCCAAAATGCTGATGAC  
CTTGGTGTCCCCAAGCGGCAGGGCTATCTCCTTCCACAGCTGCGTGGCTCAGCTCTATTTTT  
TCCACTTCTGGGGAGCACCGAGTGTTTCTCTACACAGTCATGTCCTATGATCGCTACTTG  
45 GCCATCAGTTACCCGCTCAGGTACACCAGCATGATGAGTGGGAGCAGATGTGCCCTCCTGG  
CCACCAGCACTTGGCTCAGTGGCTCTCTGCACTCTGCTGTCCAGACCATAATTGACTTTCCAT  
TTGCCCTACTGTGGACCCAACCAGATCCAGCACTATTTGTGTGATGCACCGCCCATCCTGA  
AACTGGCCTGTGCAGACACCTCAGCCAACGAGATGGTCATCTTTGTGGACATTGGGCTAGT  
GGCCTCGGGCTGCTTCTCCTGATAGTGCTGTCTTATGTGTCCATCGTCTGTTCCATCCTGC  
50 GGATCCACACCTCAGAGGGGAGGCACAGAGCCTTTCAGACCTGTGCCTCCCACTGCATCGT  
GGTCTTTTGCTTTTTTGTNNCCTGTGTTTTCATTTACCTGAGACCAGGCTCCAGGGACGTCG  
TGGATGGAGTTGTGGCCATTTTCTACACTGTGCTGACACCCCTTCTCAACCTGTTGTGTAC  
ACCCTGAGAAACAAGGAGGTGAAGAAAGCTGTGTTGAAACTGAGAGACAAAGTAGCACAT  
TCTCAGGGAGAATAA (SEQ ID NO: 284)

55

## AOLFR156 sequences:

MCWAMPSPFTGSSTRNMESRNQSTVTEFIFTGFPQLQDGSLLYFFPLLFIYTFIHDNLLIFS AVR  
 DTHLGNPMYNFISFLEIWYTTATIPKMLSNLISEKKAISMTGCILQMYFFHSLNSEGILLTT  
 MAIDRYVAICNPLRYQMIMTPRLCAHLSAGSCLFGFLILLPEIVMISTLPFCGPNQIHQIFCDLVP  
 5 VLSLACTDTSMLIEDVIHAVTHITFLIALSYVRIVTVILRIPSSEGRQKAXSTCAGHLMVFLIFFG  
 SVSLMYLRFSTNTYPPVLDTAIALMFTVLAPFFNPIHYSRLNKDMNNAIKKLFCLQKVLNKP GG  
 (SEQ ID NO: 285)

10 ATGTGCTGGGCTATGCCCTCTCCATTTACAGGTAGCTCTACTAGAAATATGGAGAGCAGAA  
 ACCAATCAACAGTGAATTTATCTTCACTGGATTCCCTCAGCTTCAGGATGGTAGTCT  
 CCTGTACTTCTTTCCTTTACTTTTCTATCTATACTTTTATTATCATTGATAACTTATTAATCTT  
 CTCTGCTGTAAGGCTGGACACCCATCTGGGCAACCCCATGTATAATTTTATCAGTATATTTT  
 CCTTCTGGAGATCTGGTACACCACAGCCACCATCCCAAGATGCTCTCCAACCTCATCAG  
 TGAAAAGAAGGCCATCTCAATGACTGGCTGCATCTTGCAGATGTATTCTTCCACTCACTT  
 15 GAAACTCAGAGGGGATCTTGCTGACCACCATGGCCATTGACAGATACGTTGCCATCTGCA  
 ACCCTCTTCGCTATCAAATGATCATGACCCCCCGGCTCTGTGCTCACCTCTCTGCAGGTTCC  
 TGCCTCTTCGGTTTCCTTATCCTGCTTCCCGAGATTGTGATGATTTCCACACTGCCTTTCTG  
 TGGGCCAACCAATCCATCAGATCTTCTGTGACTTGGTCCCTGTGCTAAGCCTGGCCTGT  
 ACAGACACGTCCATGATTCTGATTGAGGATGTGATTGCTGTGACCATCATCATTACCT  
 20 TCCTAATCATTGCCCTGTCTATGTAAGAATTGTCACTGTGATAATTGAGGATTCCTCTTCT  
 GAAGGGAGGCAAAAGGCTNTTCTACCTGTGCAGGCCACCTCATGGTCTTCTGTATTTGACAC  
 TTGGCAGTGTATCACTCATGTACTTGGCTTTCAGCAACACTTATCCACCAGTTTGGACAC  
 AGCCATTGCACTGATGTTTACTGTACTTGGCTTCTCAATCCCATCATTTATAGCCTGA  
 GAAACAAGGACATGAACAATGAATTAATAAACTGTTCTGTCTTCAAAAAGTGTGAACA  
 25 AGCCTGGAGGTAA (SEQ ID NO: 286)

## AOLFR157 sequences:

MAMDNVTA VFQFLLIGISNYPQWRDTFFTLVLIYLSLTLGNGFMIFLIHFDPNLHTPIYFFLSNL  
 SFLDLCYGTASMPQALVHCFSTHPYLSYPRCLAQTSVSLALATAECLLLAAMAYDRVVAISNP  
 30 LRYSVVMNGPVCVCLVATSWGTSVLTLAMLILSLRLHFCGANVINHFACILSLIKLTCSDTSL  
 NEFMILITSIFTLLLPGFVLLSYIRIAMAIIRSLQRLKAFTTCGSHLTVVTIFYGSAISM MYMKT  
 QSKSSPDQDKFISVFY GALTPMLNPLIYSLRKKDVKRAIRKVMLKRT (SEQ ID NO: 287)

35 ATGGCCATGGACAATGTACAGCAGTGTTCAGTTTCTCCTTATTGGCATTCTTA ACTATCC  
 TCAATGGAGAGACAGTTTTTACATTAGTGCTGATAATTTACCTCAGCACATTGTTGGGG  
 AATGGATTTATGATCTTTCTTACTTTGACCCCAACCTCCACACTCCAATCTACTTCTT  
 CCTTAGTAACCTGTCTTTCTTAGACCTTTGTTATGGAACAGCTTCCATGCCCCAGGCTTTGG  
 TGCATTGTTTCTCTACCCATCCCTACCTCTCTTATCCCCGATGTTTGGCTCAAACGAGTGTG  
 TCCTTGGCTTTGGCCACAGCAGAGTGCCTCTACTGGCTGCCATGGCCTATGACCGTGTGG  
 40 TTGCTATCAGCAATCCCCTGCGTTATTCAGTGGTTATGAATGGCCAGTGTGTGTCTGCTT  
 GGTGCTACCTCATGGGGACATCACTTGTGCTCACTGCCATGCTCATCCTATCCCTGAGG  
 CTTCACTTCTGTGGGGCTAATGTCATCAACCATTTTGCCTGTGAGATTCTCTCCCTCATTA  
 GCTGACCTGTTCTGATACCAGCCTCAATGAATTTATGATCCTCATCACCAGTATCTTCACCC  
 TGCTGCTACCATTTGGGTTTGTCTCCTCTCCTACATACGAATTGCTATGGCTATCATAAGG  
 45 ATTCGCTCACTCCAGGGCAGGCTCAAGGCCTTTACCACATGTGGCTCTCACCTGACCGTGG  
 TGACAATCTTCTATGGGTCAGCCATCTCCATGTATGAAAACCTCAGTCCAAGTCTCCCC  
 TGACCAGGACAAGTTTATCTCAGTGTTTTATGGAGCTTTGACACCCATGTTGAACCCCTG  
 ATATATAGCCTGAGAAAAAAGATGTTAAACGGGCAATAAGGAAAGTTATGTTGAAAAGG  
 ACATGA (SEQ ID NO: 288)

50

## AOLFR158 sequences:

MKAGNFSDTPEFFLLGLSGDPELQPIFLFMSMYLATMLGNLLIILAVNSDSLHTPMYFLLSI  
 LSLVDICFTSTTMPKMLVNIQAQAQSINYTGCLTQICFVLVFGLENGILVMMAYDRFVAICHP  
 LRYNVIMNPKLCGLLLLLSFIVSVLDALLHTLMVLQLTFCIDLEPHFFCELAHILKLACSDVLIN  
 55 NILVYLVTSLGVPVLSGHIIFS YTRIVSSVMKIPSAGGKYKAFSICGSHLIVVSLFYGTGFGVYLS  
 GATHSSRKGAIASVMTVVTMLNPLIYSLRNKDMKLALRKLISRPSFH (SEQ ID NO: 289)



ATGAAAGCAGGAACTTCTCAGACACTCCAGAATTCTTTCTCTTGGGATTGTCAGGGGATC  
 CGGAGCTGCAGCCCATCCTCTTCATGCTGTTCTGTCCATGTACCTGGCCACAATGCTGGG  
 GAACCTGCTCATCATCCTGGCCGTCAACTCTGACTCCCACCTCCACACCCCCATGTACTTCC  
 5 TCCTCTCTATCCTGTCTTGGTCGACATCTGTTTACCTCCACCACGATGCCCAAGATGCTG  
 GTGAACATCCAGGCACAGGCTCAATCCATCAATTACACAGGCTGCCTCACCCAAATCTGCT  
 TTGTCTGGTTTTTGTGGATTGGAAAATGGAATTCTGGTCATGATGGCCTATGATCGATT  
 TGTGGCCATCTGTCACCCACTGAGGTACAATGTCATCATGAACCCCAAATCTGTGGGCTG  
 CTGCTTCTGCTGTCCTTCATCGTTAGTGTCTGCTGGATGCTCTGCTGCACACGTTGATGGTGCT  
 10 ACAGCTGACCTTCTGCATAGACCTGGAAATTCCTTCTGTGAACTAGCTCATATTC  
 TCAAGCTCGCCTGTTCTGATGTCCTCATCAATAACATCCTGGTGTATTTGGTGACCAGCCT  
 GTTAGGTGTTGTTCTCTCTCTGGGATCATTTTCTCTTACACACGAATTGTCTCTCTGTCA  
 TGAATAATCCATCAGCTGGTGGAAAGTATAAAGCTTTTCCATCTGCGGGTACACATTTAAT  
 CGTTGTTTCTTGTGTTTATGGAACAGGGTTTGGGGTGTACCTTAGTTCTGGGGCTACCCACT  
 15 CCTCCAGGAAGGGTGCAATAGCATCAGTGATGTATACCGTGGTCACCCCATGCTGAACCC  
 ACTCATTTACAGCCTGAGAAACAAGGACATGTTGAAGGCTTTGAGGAACTAATATCTAG  
 GATACCATCTTTCCATTGA (SEQ ID NO: 290)

**AOLFR159 sequences:**

20 MGPRNQTA VSEFLMKVTEDPELKLIPFSLFLSMYLVITLGNLLILLAVISDSHLHTPMYFLLFN  
 LSFTDICLTTTTVPKILVNIQAQNSITYTGCLTQICLVLFAGLESCFLAVMAYDRYVAICHPL  
 RYTVLMNVHFVGLLILLSMFMSTMDALVQSLMVLQLSFCKNVEIPLFFCEVVQVIKLACSDTL  
 INNILIYFASSVFGAIPLSGIIFSYSQIVTSVLRMPARGKYKAFSTCGCHLSVFSLFYGTAFGVYIS  
 SAVAESSRITAVASVMYTVVPQMMNPFYSLRNKEMKKALKLIGRLPF (SEQ ID NO: 291)

25 ATGGGACCCAGAAACCAAACAGCTGTTTCAGAATTTCTTCTCATGAAAGTGACAGAGGAC  
 CCAGAACTGAAGTTAATCCCTTTCAGCCTGTTCTGTCCATGTACCTGGTCACCATCCTGG  
 GGAACCTGCTCATTCTCCTGGCTGTCATCTCTGACTCCCACCTCCACACCCCCATGTACTTC  
 CTTCTCTTTAATCTCTCCTTTACTGACATCTGTTTAAACACAACCACAGTCCCAAAGATCCT  
 30 AGTGAACATCCAAGCTCAGAATCAGAGTACTACTTACACAGGCTGCCTCACCCAGATCTGT  
 CTTGTCTTGGTTTTTGTCTGGCTTGAAAGTTGCTTTCTTGCAGTCATGGCCTACGACCGCTA  
 TGTGGCCATTTGCCACCCACTGAGGTACACAGTCCTCATGAATGTCCATTTCTGGGGCTTG  
 CTGATTCTTCTCTCCATGTTTCATGAGCACTATGGATGCCCTGGTTTCAGAGTCTGATGGTATT  
 GCAGCTGTCCTTCTGCAAAAACGTTGAAATCCCTTTGTTCTTCTGTGAAGTCGTTACAGGTC  
 35 ATCAAGCTCGCCTGTTCTGACACCCTCATCAACAACATCCTCATATATTTTGCAAGTAGTGT  
 ATTTGGTGCAATTCCTCTCTCTGGAATAATTTTCTCTTATTCTCAAATAGTCACCTCTGTTT  
 TGAGAATGCCATCAGCAAGAGGAAAGTATAAAGCGTTTTCCACCTGTGGCTGTCACCTCTC  
 TGTTTTTCTTGTCTATGGGACAGCTTTTGGGGTGTACATTAGTTCTGCTGTTGCTGAGT  
 CTTCCCGAATTACTGCTGTGGCTTCAGTGATGTACACTGTGGTCCCTCAAATGATGAACCC  
 40 CTTTCATCTACAGCCTGAGAAATAAGGAGATGAAGAAAGCTTTGAGGAACTTATTGGTAG  
 GCTGTTTCCTTTTAG (SEQ ID NO: 292)

**AOLFR160 sequences:**

45 MPMQLLLTDFIIFSIRFIINSMEARNQTAISKFLLGLIEDPELQPVLFSLFLSMYLVITLGNLLILL  
 AVISDSHLHTPMYFFLSNLSFLDICLSTTTIPKMLVNIQAQNSITYSGCLTQICFVLFAGLENC  
 LLAAMAYDRYVAICHPLRYTVIMNPRLCGLLILLSLLTSVNNALLLSLMVLRSLFCTDLEIPLFF  
 CELAQVIQLTCSDTLINNILIYFAACIFGGVPLSGIILSYTQITSCVLRMPASGKHKA VSTCGSHL  
 SIVLLFYGAGLGVYISSVVTDSPRKTA VASVMYSVFPQMVNPFYSLRNKDMKGTLRKFIGRIP  
 SLLWCAICFGFRFLE (SEQ ID NO: 293)

50 ATGCCGATGCAGCTGCTGCTTACAGATTTTATTATCTTTTCCATCAGATTCATCATCAACAG  
 CATGGAAGCGAGAAACCAAACAGCTATTTCAAAATTCCTTCTCCTGGGACTGATAGAGGAT  
 CCGGAACCTGCAGCCCGTCTTTTTAGCCTGTTCTGTCCATGTACTTGGTACCATCCTGGG  
 GAACCTGCTCATCCTCTTGGCTGTCATCTCTGACTCTCACCTCCACACCCCCATGTACTTCT  
 55 TCCTCTCCAATCTCTCCTTTTTGGACATTTGTTTAAAGCAACACGATCCCAAAGATGCTG  
 GTGAACATCCAAGCTCAGAATCGGAGCATCACGTACTCAGGCTGCCTCACCCAGATCTGCT



WO 01/98526

TTGTCTTGT TTTTGTGCTGGCTTGGAAAATTGTCTCCTTGCAGCAATGGCCTATGACCGCTAT  
 GTGGCCATTTGTACCCCTTAGATACACAGTCATGAACCCCGCCTCTGTGGCCTGC  
 TGATTCTTCTCTCTGTGACTAGTGTGTGAATGCCCTTCTTCTCAGCCTGATGGTGTG  
 AGGCTGTCTTCTGCACAGACCTGGAAATCCCGCTCTTCTTCTGTGAAGTGGCTCAGGTCA  
 5 TCCAACTCACCTGTTCAGACACCTCATCAATAACATCCTGATATATTTTGCAGCTTGCTA  
 TTTGGTGGTGTCTCTGTCTGGAATCATTTTGTCTTACACTCAGATCACCTCCTGTGTTT  
 GAGAATGCCATCAGCAAGTGGAAAGCACAAGCAGTTCCACCTGTGGGTCTCACCTCTCC  
 ATTGTCTCTTGTCTATGGGGCAGGTTTGGGGGTGTACATTAGTTCTGTGGTTACTGACTC  
 ACCTAGGAAGACTGCAGTGGCTTCAGTGATGTATTCTGTGTTCCTCAAATGGTGAACCCC  
 10 TTTATCTATAGTCTGAGGAATAAGGACATGAAAGGAACCTTGAGGAAGTTCATAGGGAGG  
 ATACCTTCTCTTCTGTGGTGTGCCATTGCTTTGGATTGAGGTTTCTAGAGTAA (SEQ ID  
 NO: 294)

## AOLFR161 sequences:

15 MEPRNQTSASQFILLGLSEKPEQETLLFSLFFCMYLVMMVGNLLILAISIDSHLHTPMYFFLANL  
 SLVDFCLATNTIPKMLVSLQTGSKAISYPCLIQMYFFHFFGIVDSVIHAMMAYDRFVAICHPLH  
 YAKIMSLRLCRLVGALWAFSCFISLTHILLMARLVFCGSHEVPHYFCDLTPILRLSCTDTSVNR  
 IFILIVAGMVIATPFVCILASYARILVAIMKVPSAGGRKKAFSTCSSHLSVVALFYGTIGVYLCP  
 SSVLTTVKEKASAVMYTAVTPMLNPFYSLNRDLKGALRKL VNRKITSSS (SEQ ID NO: 295)

20 ATGGAACCAAGAAACCAACCAAGTGCATCTCAATTCATCCTCCTGGGACTCTCAGAAAAGC  
 CAGAGCAGGAGACGCTTCTCTTTCCCTGTTCTTCTGCATGTACCTGGTCACTGGTCTGGG  
 GAACCTGCTCATCATCCTGGCCATCAGCATAGACTCCACCTCCACACCCCATGTACTTCT  
 TCCTGGCCAACCTGTCCCTGGTTGATTTCTGTCTGGCCACCAACACCATCCCTAAGATGCT  
 25 GGTGAGCCTTCAAACCGGGAGCAAGGCCATCTCTTATCCCTGCTGCCTGATCCAGATGTAC  
 TTCTTCCATTTCTTTGGCATCGTGGACAGCGTCATAATCGCCATGATGGCTTATGACCGGT  
 CGTGGCCATCTGCCACCCATTGCACTACGCCAAGATCATGAGCCTACGCCTCTGTGCGCTG  
 CTGGTCGGCGCCCTCTGGGCGTTTTCTGCTTCACTCACTCACTCACTCCTCTGATGGC  
 CCGTCTCGTTTTCTGCGGAGCCATGAGGTGCCTCACTACTTCTGCGACCTCACTCCCATCC  
 30 TCCGACTTTCGTGCACGGACACCTCTGTGAATAGGATCTTCACTCCTCATTGTGGCAGGGAT  
 GGTGATAGCCACGCCCTTTGTCTGCATCCTGGCCTCCTATGCTCGCATCCTGTGGCCATCA  
 TGAAGGTCCCTCTGCAAGCGGCAGGAAGAAAGCCTTCCACCTGCAGTCCACCTGTC  
 TGTGGTTGCTCTTCTATGGGACCACCTTGGCGTCTATCTGTGTCCCTCCTCGGTCTCA  
 CCACTGTGAAGGAGAAAGCTTCTGCGGTGATGTACACAGCAGTCACCCCATGCTGAATCC  
 35 CTTCACTACAGCTTGAGGAACAGAGACCTGAAAGGGCTCTCAGGAAGCTGGTCAACAG  
 AAAGATCACCTCATCTTCTGA (SEQ ID NO: 296)

## AOLFR162 sequences:

40 MMRLMKEVRGRNQTEVTEFLLGLSDNPDQGVLFALFLIYMANMVGNLGMIVLIKIDLCLH  
 TPMYFFLSSLSFVDASYSSSVTPKMLVNLMAENKAISFHGCAAQFYFGSFLGTECFLLAMMA  
 YDRAAIWNPLLYPVLVSGRICFLIATSFLAGCGNAIHTGMTFRLSFCGSNRINHFYCDTPPL  
 LKLSGSDTHFNGIVIMAFSSFIVISCMIVLISYLCIFIAVLKMPSEGRHKAFSTCASYLMAVTIF  
 FGTILFMYLRPTSSYSMEQDKVVSFYTIVIPVLNPLIYSLKNKDVKKALKKILWKHIL (SEQ ID  
 NO: 297)

45 ATGATGAGACTTATGAAAGAGGTTGAGGCAGAAATCAAACAGAAAGTAACAGAATTTCTC  
 CTCTTAGGACTTTCCGACAATCCAGATCTACAAGGAGTCTCTTTCATTTGTTTCTGTTGAT  
 CTATATGGCAAACATGGTGGGCAATTTGGGGATGATTGTATTGATTAGATTGATCTCTGT  
 CTCCACACCCCATGTATTTCTTCTCAGTAGCCTCTCTTTGTAGATGCCTCTTACTCTCT  
 50 TCCGTCACTCCCAAGATGCTGGTGAACCTCATGGCTGAGAATAAGGCCATTTCTTTTCATG  
 GATGTGCTGCCCAGTTCTACTTCTTTGGCTCCTTCTGGGGACTGAGTGCTTCTCTGCTGT  
 ATGATGGCATATGACCGCTATGCAGCCATTGGAACCCCTGCTCTACCCAGTTCTCGTGT  
 CTGGGAGAATTTGCTTTTGTCTAATAGCTACCTCCTTCTAGCAGTTGTGGAAATGCAGC  
 CATAACACAGGGATGACTTTTAGGTTGTCTTTTGTGGTTCTAATAGGATCAACCAATTCT  
 55 ACTGTGACACCCCGCCACTGCTCAAACCTCTTGTCTGTATACCCACTTCAATGGCATTGTG  
 ATCATGGCATTCTCAAGTTTATTGTATCAGCTGTGTTATGATTGTCTCATTCTCTACCT

GTGTATCTTCATTGCCGTCTTGAAGATGCCTTCGTTAGAGGGCAGGCACAAAGCCTTCTCC  
 ACCTGTGCCTCTTACCTCATGGCTGTCACCATATTCTTTGGAACAATCCTCTTCATGTACTT  
 GCGCCCTACATCTAGCTACTCAATGGAGCAAGACAAGGTTGTCTCTGTCTTTTATACAGTA  
 ATAATCCCTGTGCTAAATCCCTCATCTATAGTTTAAAAAATAAGGATGTAAAAAAGGCC  
 5 TAAAGAAGATCTTATGGAAACACATCTTGTAG (SEQ ID NO: 298)

**AOLFR163 sequences:**

MQRSNHTVTEFILLGFTTDPGMQLGLFVFLGVYSLTVVGNSTLIVLICNDSLHTPMYFFTGN  
 10 LSFDLWYSSVYTPKILVTCISEDKSISFAGCLCQFFFSAGLAYSECYLLAAVAYDRYVAISKPL  
 LYAQAMSIKLCALLVAVSYCGGFINSIHKTFNFNFCRENIIDDFCDLLPLVELACGEKGGYK  
 IMMYFLLASNVCPAVLILASYLFIITSVLRISSSKGYLKAFTSCSSHLTSVTLYYGSILYIYALPRS  
 SYSFDMDKIVSTFYTVVFPMLNLMYSLRNKDVKEALKKLLP (SEQ ID NO: 299)

ATGCAGAGGAGCAATCATACAGTGACTGAGTTTATACTGCTGGGCTTCACCACAGACCCA  
 15 GGAATGCAGCTGGGCCTCTTCGTGGTGTTCCTGGGCGTGTACTCTCTCACTGTGGTAGGAA  
 ATAGACCCTCATCGTGTGATCTGTAATGACTCCTGCCTCCACACACCCATGTATTTTTTC  
 ACTGGAAATCTGTCGTTTCTGGATCTCTGGTATTCTTCTGTCTACACCCCAAAGATCCTAGT  
 GACCTGCATCTCTGAAGACAAAAGCATCTCCTTTGCTGGCTGCCTGTGTCACTTCTTCTTCT  
 CTGCAGGGCTGGCCTATAGTGAGTGCTACCTGCTGGCTGCCGTGGCTTATGACCGCTACGT  
 20 GGCCATCTCCAAGCCCCTGCTTTATGCCAGGCCATGTCCATAAAGCTGTGTGCATTGCTG  
 GTAGCAGTCTCATATTGTGGTGGCTTTATTAACCTCTTCAATCATCACCAGAAAACGTTTTC  
 CTTTAACTTCTGCCGTGAAAACATCATTGATGACTTTTTCTGTGATTTGCTTCCCTTGGTGG  
 AGCTGGCCTGTGGCGAGAAGGGCGGCTATAAAATTATGATGTACTTCTGCTGGCCTCCAA  
 TGTCATCTGCCCCGCAGTGCTCATCTGGCCTCCTACCTCTTATCATCACCAGTGTCTTGA  
 25 GGATCTCCTCCTCCAAGGGCTACCTCAAAGCCTTCTCCACATGCTCCTCCCACCTGACCTCT  
 GTCACTTTATACTATGGCTCCATTCTCTACATCTACGCTCTCCCAGATCTAGCTATTCTTT  
 TGATATGGACAAAATAGTTTCTACATTTTACACTGTGGTATCCCCATGTTGAATCTCATG  
 ATCTACAGCCTAAGGAATAAGGATGTGAAAGAGGCTCTGAAAAAATTCTCCCATAA (SEQ  
 ID NO: 300)

30

**AOLFR164 sequences:**

MFLTERNTTSEATFTLLGFSDYLELQIPLFFVFLAVYGFSVVGNLGMIVIIKINPKLHTPMYFFLN  
 HLSFVDFCYSSIIAPMMLVNLVVEDRTISFSGCLVQFFFFCTFVVTELILFAVMAYDHFVAICNP  
 35 LLYTVAISQKLCAMLVVVLYAWGVACSLTLACSALKLSFHGFNTINHHFCELSLISLSYPDSYL  
 SQLLFTVATFNEISTLLIILTSYAFIIVTTLKMPSASGHRKVFSTCASHLTAITIFHGTLFLYCV  
 NSKNRHTVKVASVFYTVVIPLNPLIYSLRNKDVKDAIRKIINTKYFHIKHRHWYPNFVIEQ  
 (SEQ ID NO: 301)

ATGTTTCTGACAGAGAGAAATACGACATCTGAGGCCACATTCACTCTCTTGGGCTTCTCAG  
 40 ATTACCTGGAAGTCAAATTCCTCTCTTTGTATTTCTGGCAGTCTACGGCTTCAGTGTG  
 GTAGGGAATCTTGGGATGATAGTGATCATCAAATTAACCCAAAATTGCATACCCCATGT  
 ATTTTTCTCCTCAACCACCTCTCCTTTGTGGATTTCTGCTATTCTCCATCATTGCTCCCATGA  
 TGCTGGTGAACCTGGTTGTAGAAGATAGAACCATTTCATTCTCAGGATGTTTGGTGCAATT  
 CTTTTCTTTTGCACCTTTGTAGTGACTGAATTAATTCTATTGCGGTGATGGCCTATGACC  
 45 ACTTTGTGGCCATTTGCAATCCTCTGCTCTACACAGTTGCCATCTCCCAGAACTCTGTGCC  
 ATGCTGGTGGTTGTATTGTATGCATGGGGAGTCGCATGTTCCCTGACACTCGCGTGCTCTG  
 CTTTAAAGTTATCTTTTCATGGTTTCAACACAATCAATCATTTCTTCTGTGAGTTATCCTCC  
 CTGATATCACTCTCTTACCCTGACTCTTATCTCAGCCAGTTGCTTCTTTCACTGTTGCCAC  
 TTTAATGAGATAAGCACACTACTCATCTTCTGACATCTTATGCATTTCATCATTTGTCACCA  
 50 CCTGAAGATGCCTTCAGCCAGTGGGCACCGCAAAGTCTTCTCCACCTGTGCCTCCACCT  
 GACTGCCATCACCATCTTCCATGGCACCATCCTCTTCTCTACTGTGTACCCAACTCCAAAA  
 ACTCCAGGCACACAGTCAAAGTGGCCTCTGTGTTTTACACCGTGGTGATCCCCTTGTGAA  
 TCCCCTGATCTACAGTCTGAGAAATAAAGATGTTAAGGATGCAATCCGAAAAATAATCAAT  
 ACAAATATTTTCATATTAAACATAGGCATTGGTATCCATTTAATTTGTTATTGAACAATA  
 55 A (SEQ ID NO: 302)

WO 01/98526

## AOLFR165 sequences:

MAVGRNNTIVTKFILLGLSDHPQMKIFLMLFLGLYLLTLAWNLSLIALIKMDSHLHMPMYFFL  
 SNLSFLDICYVSSAPKMLSDITEQKTISFVGCATQYFVFCGMGLTECFLLAAMAYDRYAAICN  
 PLYTVLISHTLCLKMVVGAYVGGFLSSFIETYSVYQHDFCGPYMINHFFCDLPPVLALSCSDTF  
 5 TSEVVTFIVSVVVGIVSVLVVLISYGYIVA AVVKISSATGRTKAFSTCASHLTAVTLFYGSGFFM  
 YMRPSSSYSLNRDKVVSIFYALVIPVNPPIYSFRNKEIKNAMRKAMERDPGISHGGPFIFMTLG  
 (SEQ ID NO: 303)

10 ATGGCTGTAGGAAGGAACAACACAATTGTGACAAAATTCATTCTCCTGGGACTTTCAGACC  
 ATCCTCAAATGAAGATTTTCCTTTTCATGTTATTTCTGGGGCTCTACCTCCTGACGTTGGCC  
 TGGAACTTAAGCCTCATTGCCCTCATTAGATGGACTCTCACCTGCACATGCCCATGTACT  
 TCTTCTCAGTAACCTGTCCTTCCTGGACATCTGCTATGTGTCTCCACCGCCCTAAGATG  
 CTGTCTGACATCATCACAGAGCAGAAAACCATTTCTCTTGTGGCTGTGCCACTCAGTACT  
 TTGTCTTCTGTGGGATGGGGCTGACTGAATGCTTTCTCCTGGCAGCTATGGCCTATGACCG  
 15 GTATGCTGCAATCTGCAACCCCTTGCTTTACACAGTCCTCATATCCCATACACTTTGTTAA  
 AGATGGTGGTTGGCGCCTATGTGGGTGGATTCTTAGTTCTTTCTGTAACATACTCTGT  
 CTATCAGCATGATTTCTGTGGGCCCTATATGATCAACCACTTTTTCTGTGACCTCCCTCCAG  
 TCCTGGCTCTGTCTGCTCTGATACCTTACCAGCGAGGTGGTGACCTTCATAGTCAGTGT  
 GTCGTGGGAATAGTGTCTGTGCTAGTGGTCTCATCTCTTATGGTTACATTGTTGCTGCTGT  
 20 TGTGAAGATCAGCTCAGCTACAGGTAGGACAAAGGCCTTCAGCACTTGTGCCTCTCACCTG  
 ACTGCTGTGACCCTCTTCTATGGTTCTGGATTCTTCATGTACATGCGACCCAGTTCAGCTA  
 CTCCTAAACAGGGACAAGGTGGTGTCCATATTCTATGCCTGGTGATCCCCGTGGTGAAT  
 CCCATCATCTACAGTTTATAGGAATAAGGAGATTAAAAATGCCATGAGGAAAGCCATGGAA  
 AGGGACCCCGGATTTCTCACGGTGGACCATTCTTTTATGACCTTGGGCTAA (SEQ ID  
 25 NO: 304)

## AOLFR166 sequences:

MEMENCTRVKEFIFLGLTQNVSLVLFLLLVYVTTLLGNLLIMVTVTCESRLHTPMYFLLH  
 NLSIADICFSSITVPKVLVDLLSERKTISFNHCFQMFLFHLIGGVDVFSLSVMALDRYVAISKPL  
 30 HYATIMSRDHCIGLTVA AWLGGFVHSIVQISLLPLPFCGPNVLDTFYCDVHRVLKLAHTDIFIL  
 ELLMISNGLLTTLWFFLLVSYIVILSLPKSQAGEGRRKAISTCTSHITVTVLHFVPCIVYVARP  
 FTALPMDKAISVTFTVISPLNPLIYTLRNHEMKSAMRRLKRRLVPSDRK (SEQ ID NO: 305)

35 ATGGAGATGGAAAAGTGCACCAGGGTAAAAGAATTTATTTCTTGGCCTGACCCAGAATC  
 GGGAAAGTGAGCTTAGTCTTATTTCTTCTACTCTTGGTGTATGTGACAACTTTGCTGGGA  
 AACCTCCTCATCATGGTCACTGTTACCTGTGAATCTCGCCTTCACACGCCCATGTATTTTT  
 GCTCCATAATTTATCTATTGCCGATATCTGCTTCTTCCATCACAGTGCCCAAGGTTCTGG  
 TGGACCTTCTGTCTGAAAGAAAGACCATCTCCTTCAATCATTGCTTCACTCAGATGTTTCTA  
 TTCCACCTTATTGGAGGGGTGGATGTATTTCTCTTTCGGTGATGGCATTGGATCGATATG  
 40 TGGCCATCTCCAAGCCCCTGCACTATGCGACTATCATGAGTAGAGACCATTGCATTGGGCT  
 CACAGTGGCTGCCTGGTTGGGGGGCTTTGTCCACTCCATCGTGACATTTCTACTGTGATGTCCACCGGGTCT  
 CCACTCCCTTTCTGCGGACCCAATGTTCTTGACACTTTCTACTGTGATGTCCACCGGGTCT  
 CAAACTGGCCCATACAGACATTTTCATACTTGAACCTACTAATGATTTCCAACAATGGACTG  
 CTCACCACACTGTGGTTTTCTGCTCCTGGTGTCTTACATAGTCATATTATCATTACCCAA  
 45 GTCTCAGGCAGGAGAGGGCAGGAGGAAAGCCATCTCCACCTGCACCTCCCATCACTGT  
 GGTGACCTGCATTTCTGTGCCCTGCATCTATGTCTATGCCCCGGCCCTTCACTGCCCTCCCA  
 TGGATAAGGCCATCTCTGTACCTTCACTGTCTCTCCCTCTGCTCAACCCCTTGATCTAC  
 ACTCTGAGGAACCATGAGATGAAGTCAGCCATGAGGAGACTGAAGAGAAGACTTGTGCCT  
 TCTGATAGAAAATAG \*SEQ ID NO: 306)

50

## AOLFR167 sequences:

MSITKAWNSSSVTMFILLGFTDHPQLQALLFVTFGLGIYLLTLAWNLAFLIRGDTHLHTPMYFF  
 LSNLSFIDICYSSAVAPNMLTDFWEQKTISFVGCAAQFFFFVGMGLSECLLLTAMAYDRYAAI  
 SSPLLYPTIMTQGLCTRMVVGAYVGGFLSSLIQASSIFRLHFCGPNINHFFCDLPPVLALSCSDT  
 55 FLSQVVNFLVVVTVGGTSFLQLLISYGYIVSAVLKIPSAEGRWKACNTCASHLMVVTLLFGTAL

FVYLRPSSSYLLGRDKVVSFVYSLVIPMLNPLIYSLRNKEIKDALWKVLERKKVFS (SEQ ID NO: 307)

5 ATGTCCATAACCAAAGCCTGGAACAGCTCATCAGTGACCATGTTTCATCCTCCTGGGATTCA  
CAGACCATCCAGAACTCCAGGCCCTCCTCTTTGTGACCTTCCTGGGCATCTATCTTACCACC  
CTGGCCTGGAACCTGGCCCTCATTTTTCTGATCAGAGGTGACACCCATCTGCACACACCCA  
TGTACTTCTTCCTAAGCAACTTATCTTTTCATTGACATCTGCTACTCTTCTGCTGTGGCTCCC  
AATATGCTCACTGACTTCTTCTGGGAGCAGAAGACCATATCATTTGTGGGCTGTGCTGCTC  
10 AGTTTTTTTTCTTTGTCGGCATGGGTCTGTCTGAGTGCCTCCTCCTGACTGCTATGGCATA  
GACCGATATGCAGCCATCTCCAGCCCCCTTCTACCCCACTATCATGACCCAGGGCCTCT  
GTACACGCATGGTGGTTGGGGCATATGTTGGTGGCTTCCTGAGCTCCCTGATCCAGGCCAG  
CTCCATATTTAGGCTTCACTTTTGCGGACCCAACATCATCAACCACTTCTTCTGCGACCTCC  
CACCAGTCTGGCTCTGTCTTGCTCTGACACCTTCCTCAGTCAAGTGGTGAATTTCTCGTG  
15 GTGGTCACTGTCGGAGGAACATCGTTCTCCAACCTCCTTATCTCCTATGGTTACATAGTGT  
CTGCGGTCCTGAAGATCCCTTCAGCAGAGGGCCGATGGAAAGCCTGCAACACGTGTGCCT  
CGCATCTGATGGTGGTGAATCTGTCTGTTTGGGACAGCCCTTTTCGTGTAATTTGCGACCCAG  
CTCCAGCTACTTGCTAGGCAGGGACAAGGTGGTGTCTGTTTTCTATTGATTGGTGTATCCCC  
ATGCTGAACCTCTCATTTACAGTTTGAGGAACAAAGAGATCAAGGATGCCCTGTGGAAG  
20 GTGTTGGAAGGAAGAAAGTGTTCCTTAG (SEQ ID NO: 308)

**AOLFR168 sequences:**

MEKINNVTETIFWGLSQSPEIEKVCFVVSFFYIIILLGNLLIMLTVCLSNLFKSPMYFFLSFLSFV  
DICYSSVTAPKMIVDLLAKDKTISYVGCMLQLLGVHFFGCTEIFILTVMAYDRYVAICKPLHYM  
TIMNRETCKNMLLGTWVGGFLHSIIQVALVQLPFCGPNEIDHYFCDVHPVLKLACTETIYIG  
25 VVVVTANSGTIALGSFVILLISYSIILVSLRKQSAEGRRKALSTCGSHIAMVVIFFGPCTFMYMRPD  
TTFSEDKMVAVFYTIITPMLNPLIYTLRNAEVKNAMKKLWGRNVFLEAKGK (SEQ ID NO:  
309)

30 ATGGAAAAAATAACAACGTAACCTGAATTCATTTTCTGGGGTCTTTCTCAGAGCCCAGAGA  
TTGAGAAAGTTTGTGGTGTTCCTTCTTCTACATAATCATTCTTCTGGGAAATCTC  
CTCATCATGCTGACAGTTTGCTGAGCAACCTGTTTAAGTCACCCATGTATTTCTTTCTCAG  
CTTCTTGTCTTTGTGGACATTTGTTACTCTTCAGTCACAGCTCCCAAGATGATTGTTGACC  
TGTTAGCAAAGGACAAAACCATCTCCTIATGTGGGGTGCATGTTGCAACTGCTTGGAGTAC  
35 ATTTCTTTGGTTGCACTGAGATCTTCATCCTTACTGTAATGGCCTATGATCGTTATGTGGCT  
ATCTGTAAACCCCTACATTATATGACCATCATGAACCGGGAGACATGCAATAAAATGTTAT  
TAGGGACGTGGGTAGGTGGGTCTTACACTCCATTATCCAAGTGGCTCTGGTAGTCCAACCT  
ACCCTTTTGTGGACCCAATGAGATAGATCACTACTTTTGTGATGTTACCCCTGTGTTGAAA  
CTTGCCCTGCACAGAAACATAACATTGTTGGTGTGTTGTGACAGCCAACAGTGGTACCATTG  
40 CTCTGGGGAGTTTTGTTATCTTGCTAATCTCCTACAGCATCATCCTAGTTTCCCTGAGAAAG  
CAGTCAGCAGAAAGGCAGGCGCAAGGCCCTCTCCACCTGTGGCTCCACATTGCCATGGTTCG  
TTATCTTTTTTCGGCCCTGTACTTTTATGTACATGCGCCCTGATACGACCTTTTCAGAGGAT  
AAGATGGTGGCTGTATTTTACACCATTATCACTCCCATGTTAAATCCTCTGATTTATACACT  
GAGAAATGCAGAAGTAAAGAATGCAATGAAGAACTGTGGGGCAGAAATGTTTTCTTGGA  
45 GGCTAAAGGGAAATAG (SEQ ID NO: 310)

**AOLFR169 sequences:**

MMDNHSSATEFHLLGFGSQGLHHILFAIFFFFYLVTLMGNTVIIVIVCVDKRLQSPMYFFLSHL  
STLEILVTTHVPMMLWGLLFLGCRQYLSLHVSINFSCGTMEFALLGVMAVDYVAVCNPLRY  
NIIMNSSTCIWVIVSWVFGFLSEIWPIYATFQTFRKNSLDHFYCDRGQLLKSCDNTLLTEFI  
50 LFLMAVFILIGSLIPTIVSYTYIISTILKIPSASGRRKAFSTFASHFTCVVIGYGSCLFLYVKPKQTQ  
GVEYNKIVSLLVSVLTPFLNPFIITLRNDKVKEALRDGMKRCCQLLKD (SEQ ID NO: 311)

55 ATGATGGACAACCACTCTAGTGCCACTGAATTCACCTTCTAGGCTTCCCTGGGTCCCAAG  
GACTACACCACATTCTTTTGTCTATATTCTTTTCTTCTATTAGTGACATTAATGGGAAAC  
ACGGTCATCATTGTGATTGTCTGTGTGGATAAACGTCTGCAGTCCCCCATGTATTTCTTCCT  
CAGCCACCTCTCTACCCTGGAGATCCTGGTCACAACCATAATTGTCCCCATGATGCTTTGG

WO 01/98526

5 GGATTGCTCTTCTGGGATGCAGACAGTATCTTTCTCTACATGTATCGCTCAACTTTTCCTG  
 TGGGACCATGGAGTTTGCATTACTTGGAGTGATGGCTGTGGACCGTTATGTGGCTGTGTG  
 AACCTTTGAGGTACAACATCATTATGAACAGCAGTACCTGTATTTGGGTGGTAATAGTGT  
 CATGGGTGTTTGGATTCTTTCTGAAATCTGGCCCATCTATGCCACATTTACGTTTACCTTC  
 10 CGCAAATCAAATTCATTAGACCAATTTTACTGTGACCGAGGGCAATTGCTCAAACGTGCTC  
 GCGATAACACTCTTCTCACAGAGTTTATCCTTTTCTTAATGGCTGTTTTATTCTCATTGGT  
 TCTTTGATCCCTACGATTGTCTCCTACACCTACATTATCTCCACCATCCTCAAGATCCCGTC  
 AGCCTCTGGCCGGAGGAAAGCCTTCTCCACTTTTGCCTCCCACTTCACCTGTGTGTGATTG  
 GCTATGGCAGCTGCTTGTCTCTACGTGAAACCAAGCAAACACAGGGAGTGTAGTACAA  
 15 TAAGATAGTTTCCCTGTTGGTTTCTGTGTTAACCCCTTCTGAATCCTTTCATCTTTACTCT  
 TCGGAATGACAAAGTCAAAGAGGCCCTCCGAGATGGGATGAAACGCTGCTGTCAACTCCT  
 GAAAGATTAG (SEQ ID NO: 312)

## AOLFR170 sequences:

15 MSFTSLIPSLCFSLTLPFLFCYLSLLPFLSAFLFITRWLLAFLSLFSVSVVPVSSVSSSMVLCYLSV  
 ASPSVFCFSCMQGPILWIMANLSQPSEFVLLGFSSFGELQALLYGPFLMLYLLAFMGNTIIHVMVI  
 ADTHLHTPMYFFLGNFSLLEILVTMTAVPRMLSDLLVPHKVITFTGCMVQFYHFHSLGSTSFLIL  
 TDMALDRFVAICHPLRYGTLMSRAMCVQLAGAAWAAPFLAMVPTVLSRAHLDYCHGDVINH  
 20 FFCDNEPLLQLSCSDTRLLEFWDFLMALTFVLSSFLVTLISYGYVTTVLRIPSASSCQKAFSTCG  
 SHLTLVFIGYSSTIFLYVRPGKAHSVQVRKVVALVTSVLTLPFLNPFILTFCNQTVKTVLQGMQ  
 RLKGLCKAQ (SEQ ID NO: 313)

25 ATGTCTTTCACTTCTCTCATACCCTCACTCTGTTTCTCCTTGACTCTCCCATTCCTGTTTGT  
 TATCTTTCTTTATTGCCGTTTCTTTCTGCTTTTCTGTTTATCACTCGCTGGCTACTGCTTT  
 CTCTCTCTATTCTCTGTCTGTCCCTGTTTCTTCTGTTTCAAGTTCAATGGTCTCTGTCTC  
 TATCTCTCTGTTTCTGCTCTCCGTCTGTCTTTGTTTCTCTTGCATGCAGGGCCCCATACTG  
 TGGATCATGGCAAATCTGAGCCAGCCCTCCGAATTTGTCCTCTTGGGCTTCTCCTCTTTGG  
 TGAGCTGCAGGCCCTTCTGTATGGCCCTTCTCATGCTTTATCTTCTCGCCTTCATGGGAA  
 ACACCATCATCATAGTTATGGTCATAGCTGACACCCACCTACATACACCCATGTACTTCTTC  
 30 CTGGGCAATTTTCCCTGCTGGAGATCTTGGTAACCATGACTGCAGTGCCAGGTCTACTTC  
 CAGACCTGTTGGTCCCCCAAAAGTCATTACCTTCACTGGCTGCATGGTCCAGTTCTACTTC  
 CACTTTTCCCTGGGGTCCACCTCCTTCTCATCTGATGAGCCGGGCTATGTGTGTCCAGCTG  
 GGCCATCTGCCACCACTGCGCTATGGCACTCTGATGAGCCGGGCTATGTGTGTCCAGCTG  
 GCTGGGGCTGCCTGGGCAGCTCCTTTCCTAGCCATGGTACCACTGTCTCTCCCGAGCTC  
 35 ATCTTGATTACTGCCATGGCGACGTCATCAACCACTTCTTCTGTGACAATGAACCTTCCCTG  
 CAGTTGTCTGCTCTGACACTCGCCTGTTGGAATTCTGGGACTTTCTGATGGCCTTGACCTT  
 TGCTCTCAGCTCCTTCTGGTGACCCTCATCTCCTATGGCTACATAGTGACCACTGTGCTGC  
 GGATCCCTCTGCCAGCAGCTGCCAGAAAGCTTTCTCCACTTGGCGGTCTCACCTCACACT  
 40 GGTCTTCATCGGCTACAGTAGTACCATTTCTGTATGTCAGGCCTGGCAAAGCTCACTCT  
 GTGCAAGTCAGGAAGGTCGTGGCCTTGGTGACTTCAGTTCTACCCCTTCTCAATCCCT  
 TTATCCTTACCTTCTGCAATCAGACAGTTAAAACAGTGCTACAGGGGCAGATGCAGAGGCT  
 GAAAGGCCTTGTCAAGGCACAATGA (SEQ ID NO: 314)

## AOLFR171 sequences:

45 MVGNLLIWVTTIGSPSLGSLMYFFLAYLSLMDAIYSTAMSPKLMIDLLCDKIAISLSACMGQLFI  
 EHLLGGAEVFLVVMAYDRYVAISKPLHYLNIMNRLVCILLVVMAMIGGFVHSVQIVFLYSLP  
 ICGPNVIDHSVCDMYLLELLCLDIFYGLTVVANGGIICMVFTFLLISCGVILNFLKTYSQEER  
 HKALPTCISHIIVVALVFPCIFMYVRPVSNFPFDKLMTVFYSHITLMNPLIYSLRQSEMKNAM  
 50 KNLWCEKLSIVRKRVSPTLNIFIPSSKATNRR (SEQ ID NO: 315)

55 ATGGTGGGAAACCTCCTCATTGTTGGGTGACTACTATTGGCAGCCCTCCTTGGGCTCCCTAA  
 TGTACTTCTTCTTGCCTACTTGTACATTATGGATGCCATATATCCACTGCCATGTCAACC  
 AAATTGATGATAGACTTACTCTGTGATAAAATCGCTATTTCTTGTGAGCTTGCATGGGTC  
 AGCTCTTCATAGAACACTTACTTGGTGGTGCAGAGGTCTTCTTTGGTGGTGATGGCCTA  
 TGATCGCTATGTGGCTATCTTAAGCCGCTGCACTATTTGAACATCATGAATCGACTGGTT  
 TGCATCCTTCTGTTGGTGGCCATGATTGGAGGTTTGTGCACTCTGTGTTCAAATGTG

CTTTCTGTACAGTCTACCAATCTGTGGCCCCAATGTTATTGACCACTCTGTCTGTGACATGT  
 ACCCATTGTTGGAAGTGTGTGCCTTGACACCTACTTTATAGGACTCACTGTGGTTGCCAA  
 TGGTGGAATAATTTGTATGGTCATCTTTACCTTTCTGCTAATCTCCTGTGGAGTCATCCTAA  
 ACTTCCTTAAAACTTACAGTCAGGAAGAGAGGCATAAAGCCCTGCCTACCTGCATCTCCCA  
 5 CATCATTGTGGTTGCCCTCGTTTTTGTTCCTGTATTTTTATGTATGTTAGACCCGTTTCCA  
 ACTTTCCCTTTGATAAAATTAATGACTGTGTTTTATTCAATTATCACACTCATGTTGAATCCT  
 TTAATATACTCGTTGAGACAATCAGAGATGAAAAATGCTATGAAAAATCTCTGGTGTGAA  
 AAGTTAAGTATAGTTAGAAAAAGAGTATCTCCACACTGAACATATTTATTCCTAGTTCTA  
 AGGCAACAAATAGGCGGTAA (SEQ ID NO: 316)

10

**AOLFR172 sequences:**

MAETLQLNSTFLHPNFFILTGFPLGSAQTWLTTLVFGPIYLLALLGNGALPAVVWIDSTLHQPM  
 FLLAILAATDLGLATSIAPGLLAVLWLGPRSVPYAVCLVQMMFFVHALTAMESGVLLAMACDR  
 AAAIGRPLHYPVLVTKACVGYAALALALKAVAIVVPFLLVAKFEHFQAKTIGHTYCAHMAV  
 15 VELVVGNTQATNLYGLALSLAISGMDILGITGSYGLIAHAVLQLPTREAHAKAFGTCSHICVIL  
 AFYIPGLFSYLAHRFGHHTVPKPVHILLSNIYLLLPPALNPLIYGARTKQIRDRLLETFTFRKSPL  
 (SEQ ID NO: 317)

ATGGCAGAACTCTACAACCTCAATTCCACCTTCCTACACCCAACTTCTTCATACTGACTG  
 20 GCTTTCCAGGGCTAGGAAGTGCCGAGCTTGGCTGACACTGGTCTTTGGGCCCATTTATCT  
 GCTGGCCCTGCTGGGCAATGGAGCACTGCCGGCAGTGGTGTGGATAGACTCCACACTGCA  
 CCAGCCCATGTTTCTACTGTTGGCCATCCTGGCAGCCACAGACCTGGGCTTAGCCACATCT  
 ATAGCCCCAGGGTTGCTGGCTGTGCTGTGGCTTGGGCCCGATCTGTGCCATATGCTGTGT  
 GCCTGGTCCAGATGTTCTTTGTACATGCACTGACTGCCATGGAATCAGGTGTGCTTTTGGC  
 25 CATGGCCTGTGATCGTGCTGCGGCAATAGGGCGTCCACTGCACTACCCTGTCTGGTCACC  
 AAAGCCTGTGTGGGTTATGCAGCCTTGGCCCTGGCACTGAAAGCTGTGGCTATTGTTGTAC  
 CTTTCCCACTGCTGGTGGCAAAGTTTGAGCACTTCCAAGCCAAGACCATAGGCCATACCTA  
 TTGTGCACACATGGCAGTGGTAGAACTGGTGGTGGGTAACACACAGGCCACCAACTTATA  
 TGGTCTGGCACTTTCACTGGCCATCTCAGGTATGGATATTCTGGGTATCACTGGCTCCTAT  
 30 GGACTCATTGCCCATGCTGTGCTGCAGCTACCTACCCGGGAGGCCCATGCCAAGGCCTTTG  
 GTACATGTAGTTCTCACATCTGTGTCACTTCTGGCCTTCTACATACCTGGTCTCTTCTCCTAC  
 CTCGCACACCGCTTTGGTCATCACACTGTCCCAAAGCCTGTGCACATCCTTCTCTCCAAAT  
 CTACTTGCTGCTGCCACCTGCCCTCAACCCCTCATCTATGGGGCCCGCACCAAGCAGATC  
 AGAGACCGACTCCTGGAAACCTTCACATTCAGAAAAAGCCCGTTGTAA (SEQ ID NO: 318)

35

**AOLFR173 sequences:**

MSHTNVITIFHPAVFVLPGIPGLEAYHIWLSIPLCLIIYITAVLGNSILIVVIVMERNLHVPMYFFLS  
 MLAVMDILLSTTTVPKALAIFWLQAHNIAFDACVTQGGFFVHMMFVGESAILLAMAFDRFVAIC  
 APLRYTTVLTWPVVGRIALAVITRSFCIIFPVIFLLKRLPFCLTNIVPHSYCEHIGVARLACADITV  
 40 NIWYGFSVPVIMVILDVILIAVSYSILRAVFRPLPSQDARHKALSTCGSHLCVILMFYVPSFFTLL  
 THHFGRNIPQHVHILLANLYVAVPPMLNPIVYGVKTKQIREGVAHRFFDIKTWCCTSPGLS  
 (SEQ ID NO: 319)

ATGAGTCACACCAATGTTACCATCTTCCATCCTGCAGTTTTTGTCTTCCTGGCATCCCTGG  
 45 GTTGGAGGCTTATCACATTTGGCTGTCAATACCTCTTGCCTCATTACATCACTGCAGTCC  
 TGGGAAACAGCATCCTGATAGTGGTTATTGTCATGGAACGTAACCTTCATGTGCCCATGTA  
 TTTCTTCCTCTCAATGCTGGCCGTCATGGACATCCTGCTGTCTACCACCACTGTGCCCAAGG  
 CCTAGCCATCTTTTGGCTTCAAGCACATAACATTGCTTTTGATGCCTGTGTACCCCAAGGC  
 TTCTTTGTCCATATGATGTTTGTGGGGGAGTCAGCTATCCTGTTAGCCATGGCCTTTGATCG  
 50 CTTTGTGGCCATTTGTGCCCCACTGAGATATACAACAGTGCTAACATGGCCTGTTGTGGGG  
 AGGATTGCTCTGGCCGTCATACCCGAAGCTTCTGCATCATCTTCCCAGTCATATTCTTGCT  
 GAAGCGGCTGCCCTTCTGCCTAACCAACATTGTTCCCTCACTCCTACTGTGAGCATATTGGA  
 GTGGCTCGTTAGCCTGTGCTGACATCACTGTAAACATTTGGTATGGCTTCTCAGTGCCCAT  
 TGTGATGGTCATCTTGGATGTTATCCTCATCGCTGTGCTTACTCACTGATCCTCCGAGCAG  
 55 TGTTTCGTTTGGCCTCCAGGATGCTCGGCACAAGGCCCTCAGCACTTGTGGCTCCCACT  
 CTGTGTCATCCTTATGTTTTATGTTCCATCCTTCTTACCTTATTGACCCATCATTTTGGGCG



TAATATTCCTCAACATGTCCATATCTTGCTGGCCAATCTTTATGTGGCAGTGCCACCAATGC  
TGAACCCCATTTGTCTATGGTGTGAAGACTAAGCAGATACGTGAGGGTGTAGCCCACCGGT  
CTTTGACATCAAGACTTGGTGTCTGTACCTCCCCTCTGGGCTCATGA (SEQ ID NO: 320)

- 5 AOLFR175 sequences:  
MHFLSQNDLNINLPHLCLHRHSVIAGAFTIHRHMKIFNSPNSSTFTGFILLGFPCPREGQILLFV  
LFTVVYLLTLMGNGSIIICAVHWDQRLHAPMYILLANFSFLEICYVTSTVPSMLANFLSDTKIISF  
SGCFLQFYFFFSLGSTECFFLAVMAFDRLAICRPLRYPTIMTRRLCTNLVNCWVLGFIWFLPI  
VNISQMSFCGSRIDHFLCDPAPLLTLTCKKGPVIELVFSVLSPLPVFMLFLFIVGSYALVVRVAVL  
10 RVPSAAGRRKAFSTCGSHLAVVSLFYGSVLVVMYGSPSKNEAGKQKTVTLFYSVVTPLLNPI  
YSLRNKDMRKALKKFWGT (SEQ ID NO: 321)

- 15 ATGCATTTTCTTTCCCAAAATGATTTAAATATAAATCTGATTCCCCATCTATGTTTGCACCG  
TCATTACAGTAATTGCTGGTGTCTTTACAATTCACAGGCACATGAAAATCTTCAACAGCCCC  
AGCAACTCCAGCACCTTCACTGGCTTCATCCTCCTGGGCTTCCCTTGCCCCAGGGAGGGGC  
AGATCCTCCTCTTTGTGCTCTTCACTGTTGTTACCTCCTGACCCTCATGGGCAATGGTTCC  
ATCATCTGTGCTGTGCACTGGGATCAGAGACTCCACGCCCCCATGTACATCCTGCTCGCCA  
ACTTCTCCTTCTTGGAGATATGTTATGTACCTCCACAGTCCCCAGCATGCTGGCCAATTCC  
CTCTCTGACACCAAGATCATCTCGTCTCTGGCTGCTTCCCTCCAGTTCTACTTTTCTTCTCC  
20 TTGGGCTCTACAGAATGCTTTTTCTGGCAGTTATGGCATTGATCGATACTTGGCATCTG  
TCGGCCTCTACGCTATCCAACATTATGACCAGACGTCTCTGTACCAATCTTGTGGTCAATT  
GCTGGGTACTTGGTTTCATCTGGTTCTTGATTCTATCGTCAACATCTCCAAATGTCCTTC  
TGTGGATCTAGGATTATTGACCACTTCTATGTGACCCAGCTCCTCTCTAACTCTCACTTG  
CAAAAAAGGCCCTGTGATAGAGCTTGTCTTTCTGTCTTAAGTCTCTGCCTGTCTTTATGC  
25 TCTTTCTCTTCAATTGTGGGGTCTATGCTCTGGTCTGAGAGCTGTGTTGAGGGTCCCTTCA  
GCAGCTGGGAGAAGAAAGGCTTTCTCCACCTGTGGGTCTCACCTGGTGTGGTTTCACTGT  
TCTACGGCTCAGTACTGGTCATGTATGGGAGCCCACTCTAAGAATGAAGCTGGAAAGC  
AGAAGACTGTGACTCTGTTTTATTCTGTTGTTACCCCACTGCTTAACCCTGTGATATATAGT  
CTTAGGAACAAAGATATGAGAAAAGCTCTGAAGAAATTTGGGGAACATAA (SEQ ID NO:  
30 322)

- AOLFR176 sequences:  
MFFIIHSLVTSVFLTALGPQNRMTMHFVTEFVLLGFHGQREMQSCFFSFILVLYLLTLLGNGAIVC  
35 AVKLDRLHTPMYILLGNFAFLEIWIYSTVPMNLVNLSEIKTISFSGCFLQFYFFFSLGTTECF  
LSVMAYDRYLAICRPLHYPSIMTGKFCIILVCVCWVGGLCYVPVIVLISQLPFCGPNIDHLVCD  
PGPLFALACISAPSTELICYTFNSMIIFGPPLSILGSYTLVIRAVLCIPSGAGRTKAFSTCGSHLMV  
VSLFYGTLMVMYVSPSTSGNPAGMQKIITLVYAMTPFLNPLIYSLRNKMDKALKRVLGLTVS  
Q (SEQ ID NO: 323)

- 40 ATGTTCTTTATTATTCACTTTTGGTTACTTCTGTTTTCTAACAGCTTTGGGACCCAGAA  
CAGAACAATGCATTTTGTGACTGAGTTTGTCTCCTGCTGGTTCATGGTCAAAGGGAGATG  
CAGAGCTGCTTCTTCTCATTATCCTGGTTCTCTATCTCCTGACACTGCTAGGGAATGGAGC  
TATTGTCTGTGCAAGTAAATGGACAGGCGCTCCACACCCCATGTACATCCTTCTGGGA  
AACTTTGCCCTTCTAGAGATCTGCTGTTTCTCTGGTTGCTTCTGCAATTCTATTCTTTTTTC  
45 CCTCTCTGAGATTAACCATCTCCTTCTCTGGTTGCTTCTGCAATTCTATTCTTTTTTC  
ACTGGGTACAACAGAGTGTCTTTTATCAGTTATGGCTTATGATCGGTACCTGGCCATC  
TGTCTGCCATTACACTACCCCTCCATCATGACTGGGAAGTTCTGTATAATTCTGGTCTGTGT  
ATGCTGGGTAGGCGGATTTCTCTGCTATCCAGTCCCTATTGTTCTTATCTCCCAACTCCCT  
TCTGTGGGCCCAACATCATTGACCACTTGGTGTGTGACCCAGGCCATTGTTTGCAGTGGC  
50 CTGCATCTCTGCTCCTTCCACTGAGCTTATCTGTTACACCTTCAACTCGATGATTATCTTTG  
GGCCCTTCTCTCCATCTTGGGATCTTACACTCTGGTTCATCAGAGCTGTGCTTGTATTCCC  
TCTGGTGTGCTGGTGAAGCTTTCTCCACATGTGGGTCCCACTAATGGTGGTGTCTC  
TATTCTATGGAACCTTATGGTGTATGTGTGAGCCCAACATCAGGGAACCCAGCAGGAAT  
GCAGAAGATCATCACTCTGGTATACACAGCAATGACTCCATTCTTAAATCCCTTATCTAT  
55 AGTCTTCGAAACAAAGACATGAAAGATGCTCTAAAGAGAGTCTGGGGTTAACAGTTAGC  
CAAACTGA (SEQ ID NO: 324)



**AOLFR177 sequences:**

MSFFFVDLRPMNRSATHIVTEFILLGFPWCWKIQIFLFLVYVLTLLGNGAIYAVRCNPLLH  
 TPMYFLLGNFAFLIWIYVSSSTIPNMLVNILSKTKAISFSGCFLQFYFFSLGTTECLFLAVMAYD  
 5 RYLAICHPLQYPAIMTVRFCGKLVSCWLIGFLGYPIPIFYISQLPFCGPNIIDHFLCDMDPLMAL  
 SCAPAPITECIFYTQSSLVLFSTSMYILRSYILLLTAVFQVPSAAGRRAKAFSTCGSHLVVVSIFYG  
 TVMVMYVSPTYGIPTLLQKILTLVYSVTTPLFNPLIYTLRNKDMKLALRNVLFGMJRJRQNS  
 (SEQ ID NO: 325)

10 ATGTCTTTCTTCTTTGTAGACTTAAGACCCATGAACAGGTCAGCAACACACATCGTGACAG  
 AGTTTATTCTCCTGGGATTCCCTGGTTGCTGGAAGATTGAGATTTTCTCTTCTCATTGTTT  
 TTGGTGATTTATGTCTTGACCTTGCTGGGAAATGGAGCCATCATCTATGCAGTGAGATGCA  
 ACCCACTACTACACACCCCCATGTACTTTCTGCTGGGAAATTTGCCTTCTTGAGATCTGG  
 TATGTGTCCTCCACTATTCCTAACATGCTAGTCAACATTCTCTCCAAGACCAAGGCCATCTC  
 15 ATTTTCTGGGTGCTTCTCTCCAGTTCTATTTCTTCTTTTCACTGGGAACAACCTGAATGTCTCT  
 TTCTGGCAGTAATGGCTTATGATCGATACCTGGCCATCTGCCACCCACTGCAGTACCCTGC  
 CATCATGACTGTAAGGTTCTGTGGTAAGCTGGTGTCTTTCTGTTGGCTTATTGGATTCTTG  
 GATACCCAATTCCCATTTTCTACATCTCCCAACTCCCCTTCTGTGGTCCTAATATCATTGAT  
 CACTTCTGTGTGACATGGACCCATTGATGGCTCTATCCTGTGCCCCAGCTCCCATAACTG  
 20 AATGTATTTTCTATACTCAGAGCTCCCTTGCTCTTTTCACTAGTATGTACATTCTTCGA  
 TCCTATCTCTGTTACTAACAGCTCTTTTTCAGGTCCTTCTGCAGCTGGTCGGAGAAAAAG  
 CTTTCTCTACCTGTGGTTCTCATTTGGTTGTGGTATCTCTTTTCTATGGGACAGTCATGGTA  
 ATGTATGTAAGTCCTACATATGGGATCCCAACTTTATTGCAGAAGATCCTCACACTGGTAT  
 ATTCAGTAACGACTCCTCTTTTAAATCCTCTGATCTATACTCTTCGTAATAAGGACATGAAA  
 25 CTCGCTCTGAGAAATGTCCTGTTTGAATGAGAATTCGTCAAAATTCGTGA (SEQ ID NO:  
 326)

**AOLFR178 sequences:**

MVGANHSVVSEFVFLGLTNSWEIRLLLLVFSSMFYMASMMGNSLILLTVTSDPHLHSPMYFLL  
 30 ANLSFIDLGVSSVTSPKMIYDLFRKHEVISFGGCIQIFFIHVIGGVEMVLLIAMAFDRYVAICKP  
 LQYLTIMSPRMCMFFLVAAWVTGLIHSVVLVFNLPFCGPNVSDSFYCDLPRFIKLACTDSY  
 RLEFMVTANSFISLGSFFILIISYVVIITVLKHSSAGLSKALSTLSAHVSVVVLFFGPLIFVYTW  
 PSPSTHLDKFLAIFDAVLTPVLNPIIYTFRN (SEQ ID NO: 327)

35 ATGGTTGGGGCAAATCACTCCGTGGTGTGAGAGTTTGTGTTCTCTGGGACTCACCAATTCCT  
 GGGAGATCCGACTTCTCCTCCTTGTTTCTCCTCCATGTTTTACATGGCCAGTATGATGGGA  
 AACTCTCTCATTTTGCTCACTGTGACTTCTGACCCTCACTTGCACTCCCCCATGTATTTCT  
 GTTAGCCAACCTCTCCTTCATTGACCTGGGTGTTTCTCTGTCACTTCTCCCAAAATGATTT  
 ATGACCTGTTGAGAAAGCACGAAGTCATCTCCTTTGGAGGCTGCATCGCTCAAAATCTTCTT  
 40 CATCCACGTCATTGGCGGTGTGGAGATGGTGCTGCTCATAGCCATGGCCTTTGACAGATAT  
 GTGGCCATATGTAAGCCCCTCCAGTACCTGACCATTATGAGCCCAAGAATGTGCATGTTCT  
 TCTTAGTGGCTGCCTGGGTGACCGGCCTTATCCACTCTGTAGTTCAATTGGTTTTTGTAGTA  
 AACTTGCCCTTCTGTGGTCCTAATGTATCGGACAGCTTTTACTGTGACCTTCTCGGTTTCAT  
 CAAACTTGCCTGCACAGACAGCTACCGACTGGAGTTCATGGTTACAGCCAACAGTGGATTC  
 45 ATCTCTCTGGGCTCCTTCTTCATACTGATCATTTTCTATGTGGTCATCATTTCTCACTGTTCT  
 GAAACACTCTTCAGCTGGTTTATCCAAGGCTCTGTCCACCCCTTTCAGCTCACGTCAGTGTG  
 GTAGTTTTGTTCTTTGGTCCTTTGATTTTTGTCTATACGTGGCCATCTCCCTCCACACACCT  
 GGATAAGTTTCTGGCCATCTTTGATGCAGTTCTCACTCCTGTTTTAAATCCTATCATCTACA  
 CATTGAGGAATTGA (SEQ ID NO: 328)

50

**AOLFR179 sequences:**

MNGMNHSVVSEFVFMGLTNSREIQLLLVFSLLFYFASMMGNLVIVFTVTMDAHLHSPMYFLL  
 ANLSIIDMAFCSITAPKMICDIFKKHKAISFRGCITQIFFSHALGGTEMVLLIAMAFDRYMAICKP  
 LHYLTIMSPRMCLYFLATSSIIHLIHSVLVLFVVDLPFCGPNIFDSFYCDLPRLLRLACTNTQEL  
 55 EFMVTVNSGLISVGSFVLLVISYIFLFTVWKHSSGGLAKALSTLSAHVTVVILFFGPLMFFYTW  
 PSPTSHLDKYLAIFDAFITPFLNPVIYTFRNKDMKVAMRRLCSRLAHFTKIL (SEQ ID NO: 329)

5 ATGAATGGAATGAATCACTCTGTGGTATCAGAATTTGTATTCATGGGACTCACCAACTCAC  
 GGGAGATTGAGCTTCTACTTTTTGTTTTCTCTTTGTTGTTCTACTTTGCGAGCATGATGGGA  
 AACCTTGTCAATTGATTCAGTGAACCATGGATGCTCATCTGCACTCCCCCATGTATTTCT  
 CCTGGCTAACCTCTCAATCATTGATATGGCATTGCTCAATTACAGCCCCAAGATGATTT  
 GTGATATTTTCAAGAAGCACAAGGCCATCTCCTTTGCGGGATGTATTACTCAGATCTTCT  
 TAGCCATGCTCTTGGGGGCACTGAGATGGTGCTGCTCATAGCCATGGCCTTTGACAGATA  
 10 ATGGCCATATGTAAACCTCTCCACTACCTGACCATCATGAGCCCAAGAATGTGTCTATACT  
 TTTAGCCACTTCTCTATCATTGGCCTTATCCACTCATTGGTCCAATTAGTTTTGTGGTA  
 GATTTACCTTTTTGTGGTCTTAATATCTTTGACAGTTTTTACTGTGATCTCCCTCGGCTCCT  
 CAGACTTGCTGTACCAACACCCAAGAACTGGAGTTCATGGTCACTGTCAATAGTGGACT  
 ATTTCTGTGGGCTCCTTTGTCTGTGTAATTTCTTACATCTTCACTGTTTGT  
 GAAACATTCTTCTGGTGGTCTAGCCAAGGCCCTCTTACCCTGTCAGCTCATGTCACTGTG  
 15 GTCATCTTGTCTTTGGGCCACTGATGTTTTCTACACATGGCCTTCTCCACATCACACCT  
 GGATAAATATCTTGCTATTTTGTGATGATTTATTACTCCTTTTCTGAATCCAGTTATCTACA  
 CATTGAGGAACAAAGACATGAAAGTGGCAATGAGGAGACTGTGCAGTCTGCGCATT  
 TTACAAAGATTTTGTA (SEQ ID NO: 330)

# AOLFR180 sequences:

20 MTNKMAYIYIKNLNYFSFLIVQCLQPTMAIFNNTSSSSNFLTAFPGLECAHVWISIPVCCLYTI  
 ALLGNSMIFLVIITKRLHKPMYYFLSMLAAVDLCLTITLPTVLGVLWFHAREISFKACFIQMF  
 FVHAFSLLESSVLVAMAFDRFVAICNPLNYATILTDRMVLVIGLVICIRPAVFLPLLVAINTVSF  
 HGGHELHPFCYHPEVIKYTYSKPWISSFWGLFLQLYLNGTDVLFILFSYVLILRTVLGIVARKK  
 25 QQKALSTCVCHICAVTIFYVPLISLSLAHRLFHSTPRVLCSTLANIYLLPVLNPIIYSLKTKTIR  
 QAMFQLQSKGSWGFNVRGLRGRWD (SEQ ID NO: 331)

30 ATGACTAATAAAATGTATGCTATATATATAAAGAATCTTAATTATTTTCTTCTCCTCATAGT  
 TCAGTGCTTCAACCAACCATGGCAATATCAATAACACCACTTCGTCTTCTCAAACCTTCC  
 TCCTCACTGCATTCCCTGGGCTGGAATGTGCTCATGTCTGGATCTCCATTCCAGTCTGCTGT  
 CTCTACACCATGGCCCTCTTGGGAAACAGTATGATCTTTCTTGTCTCATTACTAAGCGGA  
 GACTCCACAAACCCATGTATTATTTCTCTCCATGCTGGCAGCTGTTGATCTATGTCTGACC  
 ATTACGACCTTCCCACTGTGCTTGGTGTCTCTGGTTTCATGCCCCGGGAGATCAGCTTTAA  
 AGCTTGCTTCATTCAAATGTTCTTTGTGTCATGCTTCTCCTTGCTGGAGTCTCGGTGCTGG  
 35 TAGCCATGGCCTTTGACCGCTTCGTGGCTATCTGTAACCACTGAACTATGCTACTATCCTC  
 ACAGACAGGATGGTCTGCTGATAGGGCTGGTTCATGTTTTCATGGGGGTCACGAGCTTTCCCATCCA  
 TTCCCCTTCTGTAGCCATAAACAATGTGCTTTTCTGTAACCACTGAACTATGCTACTATCCTC  
 TTTTGCTACCAACCCAGAAGTGATCAAATACACATATCCAAACCTTGGATCAGCAGTTTTT  
 GGGGACTGTTTCTTCACTCTACCTGAATGGCACTGACGTATTGTTATTCTTTCTCCTAT  
 GTCCTGATCCTCCGTACTGTTCTGGGCATTGTGGCCGAAAGAAGCAACAAAAGCTCTCA  
 40 GCATTGTGTCTGTACATCTGTGCACTCAATTTTCTATGTGCCACTGATCAGCCTCTCT  
 TTGGCACACCGCCTCTTCACTCCACCCCAAGGGTGTCTGTAGCACTTTGGCCAATATTTA  
 TCTGCTCTTACCACCTGTGCTGAACCCTATCTTACAGCTTGAAGACCAAGACAATCCGC  
 CAGGCTATGTTCCAGCTGCTCCAATCCAAGGTTCATGGGGTTTTAATGTGAGGGGTCTTA  
 GGGGAAGATGGGATTGA (SEQ ID NO: 332)

45

# AOLFR181 sequences:

MSVLNNSEVKLFLLIGIPGLEHAHIWFSIPICLMYLLAIMGNCTILFIKTEPSLHEPMYYFLAML  
 AVSDMGLSLSSLPTMLRVFLFNAMGISPNACFAQEFFIHGFTVMESSVLLIMSLDRFLAHNPLR  
 YSSILTSNRVAKMGLILAIRSILLVIPFPTLRLKYCQKNLLSHSYCLHQDTMKLACSDNKTNV  
 50 IYGFIALCTMLDLALIVLSYVLILKTILSIASLAERLKALNTCVSHICAVLTFYVPIITLAAMHHF  
 AKHKSPLVILIADMFLVPLMNPVYCVKTRQIWEKILGKLLNVCGR (SEQ ID NO: 333)

55 ATGTCTGTTCTCAATAACTCCGAAGTCAAGCTTTTCTTCTGATTGGGATCCCAGGACTGG  
 AACATGCCCCACATTTGGTTCTCCATCCCCATTTGCCTCATGTACCTGCTTGCCATCATGGGC  
 AACTGCACCATTTCTTTATTATAAAGACAGAGCCCTCGCTTCATGAGCCCATGTATTATTT  
 CCTTGCCATGTTGGCTGTCTCTGACATGGGCTGTCCCTCTCCTCCCTTCTACCATGTGTA

GGGTCTTCTTGTTC AATGCCATGGGAATTTACCTAATGCCTGCTTTGCTCAAGAATTCTTC  
 ATTCATGGATTCACTGTCATGGAATCCTCAGTACTTCTAATTATGTCTTTGGACCGCTTTCT  
 TGCCATTACAAATCCCTTAAGATACAGTTCTATCCTCACTAGCAACAGGGTTGCTAAAATG  
 GGACTTATTTTAGCCATTAGGAGCATTCTCTTAGTGATTCCATTTCCCTCACCITAAGGAG  
 5 ATAAAAATATTGTCAAAAAGAATCTTCTTTCTCACTCATACTGTCTTCATCAGGATACCATGA  
 AGCTGGCCTGCTCTGACAACAAGACCAATGTCATCTATGGCTTCTTCATTGCTCTCTGTACT  
 ATGCTGGACTTGGCACTGATTGTTTTGTCTTATGTGCTGATCTTGAAGACTATACTCAGCAT  
 TGCATCTTTGGCAGAGAGGCTTAAGGCCCTAAATACCTGTGTCTCCCACATCTGTGCTGTG  
 CTCACCTTCTATGTGCCCATCATCACCTGGCTGCCATGCATCACTTTGCCAAGCACAAAA  
 10 GCCCTCTTGTGTGATCCTTATTGCAGATATGTTCTTGTGTTGGTGCCGCCCTTATGAACCCC  
 ATTGTGTA CTGTGTAAAGACTCGACAAATCTGGGAGAAGATCTTGGGGAAGTTGCTTAAT  
 GTATGTGGGAGATAA (SEQ ID NO: 334)

#### AOLFR182 sequences:

15 MTLGSLGNSSSSVSATFLLSGIPGLERMHIWISIPLCFMYLVSIPGNCTILFIKTERSLHEPMYLFL  
 SMLALIDLGLSLCTLPTVLGIFWVGAREISHDACFAQLFFIHCFSFLESSVLLSMAFDRFVAICHP  
 LHYVSILTNTVIGRIGLVSLGRSVLIFPLPFMLKRFPYCGSPVLSHSYCLHQEVMKLACADMK  
 ANSIYGMFVIVSTVGIDSLILFSYALILRTVLSIASRAERFKALNTCVSHICAVLLFYTPMIGLSV  
 IHRFGKQAPHLVQVVMGFMVLLFPPVMNPVYSVKTKQIRDRVTHAFY (SEQ ID NO: 335)

20 ATGACCCTGGGATCCCTGGGAAACAGCAGCAGCAGCGTTTCTGCTACCTTCCTGCTGAGTG  
 GCATCCCTGGGCTGGAGCGCATGCACATCTGGATCTCCATCCCCTGTGCTTCATGTATCT  
 GGTTTCCATCCCGGGCAACTGCACAATTCTTTTATCATTAAAAACAGAGCGCTCACTTCAT  
 GAACCTATGTATCTCTTCTGTCCATGCTGGCTCTGATTGACCTGGGTCTCTCCCTTTGCAC  
 25 TCTCCCTACAGTCCTGGGCATCTTTTGGGTTGGAGCACGAGAAATTAGCCATGATGCCTGC  
 TTTGCTCAGCTCTTTTTCATTCACTGCTTCTCCTTCCTCGAGTCCTCTGTGCTACTGTCTATG  
 GCCTTTGACCGCTTTGTGGCTATCTGCCACCCCTTGCACTATGTTTCCATTCTCACCAACAC  
 AGTCATTGGCAGGATTGGCCTGGTCTCTCTGGGTCGTAGTGTAGCACTCATTTTTCCATTA  
 CCTTTTATGCTCAAAAAGATTCCCCTATTGTGGCTCCCCAGTTCTCTCACATTCTTATTGTCT  
 30 CCACCAAGAAAGTGATGAAATTGGCCTGTGCCGACATGAAGGCCAACAGCATCTACGGCAT  
 GTTTGTATCGTCTCTACAGTGGGTATAGACTCACTGCTCATCCTCTTCTCTTATGCTCTGA  
 TCCTGCGCACCGTGCTGTCCATCGCCTCCAGGGCTGAGAGATTCAAGGCCCTTAACACCTG  
 TGTTTCCCACATCTGTGCTGTGCTGCTCTTCTACACTCCCATGATTGGCCTCTCTGTATCC  
 ATCGCTTTGGAAAGCAGGCACCCACCTGGTCCAGGTGGTCATGGGTTTCATGTATCTTCT  
 35 CTTTCTCCTGTGATGAATCCCATTGTCTACAGTGTGAAGACCAAACAGATCCGGGATCGA  
 GTGACGCATGCCTTTTGTACTAA (SEQ ID NO: 336)

#### AOLFR183 sequences:

40 MTNLNASQANHRNFILTGPITPDKNPWLAFLPLGFLYTLTLGNGTILAVIKVEPSLHEPTYFYFL  
 SILALTDVSLSMSTLPSMLSIYWFNAPQIVFDACIMQMFFIHVFGIVESGLVLSMAFDRFVAIRN  
 PLHYVSILTHDVIRKTGISVLTRA VCVFVPVFLIKCLPFCHSNVLSHSYCLHQNMMLRACASTR  
 INSLYGLIVVIFTLGLDVLLTLLSYVLTLKTVLGIVSRGERLKTLSLCLSHMSTVLLFYVPFMGA  
 ASMIHRFWEHLSPVVMVMADIYLLPVLNPVYSVKTKQI (SEQ ID NO: 337)

45 ATGACGAACCTGAATGCATCACAGGCCAACACCGTAACTTCATTCTGACAGGTATCCCAG  
 GAACGCCAGACAAGAACCCTATGGTTGGCCTTTCCCTGGGATTTCTCTACACACTCACACT  
 CCTGGGAAATGGTACCATCCTAGCTGTCATCAAGGTGGAGCCAAGTCTCCATGAGCCACG  
 TATTACTTCTTTCTATCTTGGCTCTCACTGACGTTAGTCTCTCCATGTCCACCTTGCCCTCC  
 ATGCTCAGCATCTACTGGTTTAATGCCCTCAGATTGTTTTTGTGATGCATGCATCATGCAGAT  
 50 GTTCTTCATCCATGTATTTGGAATAGTAGAATCAGGAGTCCTAGTGTCCATGGCCTTTGAC  
 AGATTTGTGGCCATCCGAAACCCATTACACTATGTTTCCATCCTCACTCACGATGTTATTG  
 AAAGACTGGAATATCTGTCTCACCCGGGAGTCTGTGTGGTATTCCTGTGCCCTTCCTT  
 ATAAAGTGCCTACCTTCTGCCATTCCAATGTCTTGTCTCATTCACTGTCTTACCAAAA  
 CATGATGCGGCTAGCTTGTGCCAGCACCCGCATCAACAGCCTCTACGGCCTCATCGTCGTC  
 55 ATCTTCACTGGGGCTCGATGTTCTCCTCACTCTACTGTCTTATGTA CTACCCCTGAAGAC  
 TGTGCTGGGCATTGTCTCCAGAGGTGAAAGGCTGAAAACCTCAGCACATGCCTCTCTCAC

ATGTCTACCGTGCTCCTCTTCTATGTTCTTTTATGGGTGCTGCCTCCATGATCCACAGATT  
TTGGGAGCATTTATCACCAGTAGTGACATGGTCATGGCTGATATATACCTACTGCTCCCG  
CCTGTGCTAAACCCCATTTGTCTACAGTGTGAAGACCAAGCAAATTTGA (SEQ ID NO: 338)

- 5 **AOLFR184 sequences:**  
MSTLPTQIAPNSSTSMAPTFLLVGMPGLSGAPSWWTLPLIAVYLLSALNGNTILWIALQPALHR  
PMHFFLLSVSDIGLVTALMPTLLGIALAGAHTVPASACLLQMVFHVSVMESVLLAMSID  
RALAICRPLHYPALLTNGVISKISLAISFRCLGLHLPLPFLAYMPYCLPQVLTHSYCLHPDVARL  
ACPEAWGAAYSFLVLSAMGLDPLLIFFSYGLIGKVLQGVESREDRWKAGQTCAAHLSAVLLF  
10 YIPMILLALINHPITQHTHTLLSYVHFLPPLINPILYSVKMKEIRKRLNRLQPRKVGAQ  
(SEQ ID NO: 339)

- 15 ATGTCAACATTACCAACTCAGATAGCCCCAATAGCAGCACTTCAATGGCCCCACCTTCT  
TGCTGGTGGGCATGCCAGGCCTATCAGGTGCACCCTCCTGGTGGACATTGCCCTCATTGC  
TGTCTACCTTCTCTGCACTGGGAAATGGCACCATCCTCTGGATCATTGCCCTGCAGCCC  
GCCCTGCACCGCCAATGCACTTCTTCTCTTGTCTAGTGTGTCTGATATTGGATTGGT  
CACTGCCCTGATGCCACACTGCTGGGCATCGCCCTTGCTGGTGTCTCACACTGTCCCTGCC  
TCAGCCTGCCTTCTACAGATGGTTTTATCCATGTCTTTCTGTCTGAGTCTCTGTCTT  
GCTCGCCATGTCCATTGATCGGGCACTGGCCATCTGCCGACCTCTCCACTACCCAGCGCTC  
20 CTCACCAATGGTGTAAATTAGCAAAATCAGCCTGGCCATTTCTTTTCGATGCCTGGGTCTCC  
ATCTGCCCTGCCATTCTCTGCTGGCCTACATGCCCTACTGCCTCCACAGGTCTAACCCAT  
TCTTATTGCTTGCATCCAGATGTGGCTCGTTTGGCCTGCCAGAAGCTTGGGTGCAGCCT  
ACAGCCTATTTGTGGTTCTTTTCAGCCATGGGTTTGGACCCCTGCTTATTTCTTCTCCTAT  
GGCCTGATTGGCAAGGTGTTGCAAGGTGTGGAGTCCAGAGAGGATCGCTGGAAGGCTGGT  
25 CAAACCTGTGCTGCCACCTCTCTGCACTGCTCCTCTTATATCCCTATGATCCTCCTGGC  
ACTGATTAACCATCCTGAGCTGCCAATCACTCAGCATAACCCATACTCTTCTATCCTATGTCC  
ATTTCTTCTTCTCCTCCATTGATAAACCTATTCTCTATAGTGTCAAGATGAAGGAGATTAGA  
AAGAGAATACTCAACAGGTTGCAGCCAGGAAGGTGGGTGGTGTCTAGTGA (SEQ ID NO:  
340)

- 30 **AOLFR185 sequences:**  
MFYPILNDISTKNNSNIMSCCNILFIKTVEIILVYNQTSQSPWYPIVPSKSLVYNNNTCFDCYHLQR  
VDCVPSRDHINQSMVLASGNSSHPVSVFILLGIPGLESFQLWIAFPFCATYA VAVVGNITLLHVIR  
IDHTLHEPMYLFLAMLAITDLVLSSTQPKMLAIFWFHAHEIQYHACLIQVFFHAFSSVESGVL  
35 MAMALDCYVATCFPLRHSSILTPSVVIKLGTIVMLRGLLWVSPFCFMVSRMPFCQHQAIPQSYC  
EHMAVLKLVCA DTSISRGYGLFVAFSVAGFDMIVIGMSYVMILRAVLQLPSGEARLKAFSTRA  
SHICVILALYIPALFSFLTFRGHDVPRVVHILFANLYLLIPMLNPIHYGVRTKQIGDRVIQCCCG  
NIP (SEQ ID NO: 341)

- 40 ATGTTCTACCCCATTTTGAATGACATAAGTACGAAAAACAACAGTAACATCATGTCTGTT  
GTAACATATTATTTATTAACAGTTGAAATTATTCTAGTTTATAATCAAACCCAATCACC  
CTGGTATCCAATAGTCCCATCCAAAAGCCTTGATATAATAAACACTTGTGTTGATTGTT  
ATCATCTGCAGAGAGTAGATTGCGTTCCAGCAGAGACCATATTAACAGTCCATGGTGCT  
GGCTTCAGGGAACAGCTCTTCTCATCCTGTGCTCTCATCCTGCTTGGAAATCCAGGCCTG  
45 GAGAGTTTCCAGTTGTGGATTGCCCTTCCGTTCTGTGCCACGTATGCTGTGGCTGTTGTTGG  
AAATATCACTCTCCTCCATGTAATCAGAATTGACCACACCCTGCATGAGCCCATGTACCTC  
TTTCTGGCCATGCTGGCCATCACTGACCTGGTCTCTCCTCCTCACTCAACCTAAGATGTT  
GGCCATATTCTGGTTTCATGCTCATGAGATTGAGTACCATGCCTGCCTCATCCAGGTGTTCT  
TCATCCATGCCCTTTCTTCTGTGGAGTCTGGGGTGTCTATGGCTATGGCCTGGACTGCTAC  
50 GTGGCTACCTGCTTCCCACTCCGACACTCTAGCATCCTGACCCCATCTGCTTCATGGTGTG  
TGGGGACCATCGTGATGCTGAGAGGGCTGCTGTGGGTGAGCCCTTCTGCTTCATGGTGTG  
CTGAAGTTGGTGTGTGCTGATACAAGCATAAGTCGTGGGTATGGGCTCTTTGTGGCCTTCT  
CTGTGGCTGGCTTTGATATGATTGTCATTGTTATGTCATACGTGATGATTTTGAGAGCTGT  
55 GCTTCAGTTGCCCTCAGGTGAAGCCCGCTCAAAGCTTTTAGCACACGTGCCTCCCATATC  
TGTGTCATCTGGCTCTTTATATCCAGCCCTTTTTCTTCTCCTACCTACCGCTTTGGCCAT

GATGTGCCCCGAGTTGTACACATCCTGTTTGCTAATCTCTATCTACTGATACCTCCCATGCT  
CAACCCCATCATTTATGGAGTTAGAACCAACAGATCGGGGACAGGGTTATCCAAGGATG  
TTGTGGAAACATCCCCTGA (SEQ ID NO: 342)

5 **AOLFR186 sequences:**

MSNASLVTAFLTGLPHAPGLDALLFGIFLVVYVLTVLGNLLILLVIRVDSHLHTPMYYFLTNLS  
FIDMWFSTVTVPKMLMTLVSPSGRAISFHSCVAQLYFFHFLGSTECFLYTVMSYDRYLAISYPL  
RYTSMMSGSRCALLATGTWLSGSLHSAVQTILTFHLPYCGPNQIQHYFCDAPPILKLACADTSA  
NVMVIFVDIGIVASGCFVLIVLSYVSIVCSILRIRTS DGRRAAFQTCASHCIVVLCFFVPCVVIYLR  
10 PGSM DAMDGVVAIFYTVLTPLLNPVYTLRNKEVKKAVLKL RDKVAHPQRK (SEQ ID NO:  
343)

ATGTCCAACGCCAGCCTCGTGACAGCATTCATCCTCACAGGCCTTCCCCATGCCCCAGGGC  
TGGACGCCCTCCTCTTTGGAATCTTCCTGGTGGTTACGTGCTCACTGTGCTGGGGAACCT  
15 CCTCATCCTGCTGGTGATCAGGGTGGATTCTCACCTCCACACCCCCATGTACTACTTCCTCA  
CCAACCTGTCCTTCATTGACATGTGGTTCTCCACTGTCACGGTGCCCAAAATGCTGATGAC  
CTTGGTGTCCCCAAGCGGCAGGGCTATCTCCTTCCACAGCTGCGTGGCTCAGCTCTATTTT  
TCCACTTCCTGGGGAGCACCGAGTGTTTCTCTACACAGTCATGTCCTATGATCGCTACTTG  
GCCATCAGTTACCCGCTCAGGTACACCAGCATGATGAGTGGGAGCAGGTGTGCCCTCCTGG  
20 CCACCGGCACTTGGCTCAGTGGCTCTCTGCACTCTGCTGTCCAGACCATATTGACTTTCCAT  
TTGCCCTACTGTGGACCCAACCAGATCCAGCACTACTTCTGTGACGCACCGCCCATCCTGA  
AACTGGCCTGTGCAGACACCTCAGCCAACGTGATGGTCATCTTTGTGGACATTGGGATAGT  
GGCCTCAGGCTGCTTTGTCTGATAGTGCTGTCTATGTGTCCATCGTCTGTTCCATCCTGC  
GGATCCGCACCTCAGATGGGAGGCGCAGAGCCTTTCAGACCTGTGCCTCCCACTGTATTGT  
25 GGTCTTTGCTTCTTTGTTCCCTGTGTTGTCAATTTATCTGAGGCCAGGCTCCATGGATGCCA  
TGGATGGAGTTGTGGCCATTTTCTACACTGTGCTGACGCCCTTCTCAACCCTGTTGTGTAC  
ACCCTGAGAAACAAGGAGGTGAAGAAAGCTGTGTTGAACTTAGAGACAAAGTAGCACAT  
CCTCAGAGGAAATAA (SEQ ID NO: 344)

30 **AOLFR187 sequences:**

MAQVRALHKIMALFSANSIGAMNNSDTRIAGCFLTGPGLLEQLHIWLSIPFCIMYIAALEGNGILI  
CVILSQAILHEPMYIFLSMLASADVLLSTTTMPKALANLWLGYSHISFDGCLTQKFFIHFIFIHSA  
VLLAMAFDRYVAICSPRYVTILTSKVIGKIVTATLSRSFIIMFPSIFLLEHLHYCQINIIAHTFCEH  
MGIAHLSCSDISINVWYGLAAALLSTGLDIMLITVSYIHILQAVFRLLSQDARSKALSTCGSHICV  
35 ILLFYVPALFSVFAYRFGGRSIPCYVHILLASLYVVIPMLNPVIYGVRTKPILEGAKQMFSNLAK  
GSK (SEQ ID NO: 345)

ATGGCACAGGTGAGGGCGCTGCATAAAATCATGGCCCTTTTTTCTGCTAACAGCATAGGTG  
CTATGAACAACCTCTGACACTCGCATAGCAGGCTGCTTCCTCACTGGCATCCCTGGGCTGGA  
40 GCAACTACATATCTGGCTGTCCATCCCCTTCTGCATCATGTACATCGCTGCCCTGGAAGGC  
AATGGCATCCTAATTTGTGTCACTCTCTCCAGGCAATCCTGCATGAGCCCATGTACATAT  
TCTTATCTATGCTGGCCAGTGCTGATGTCTTGCTCTCTACCACCACCATGCCTAAGGCCCTG  
GCCAATTTGTGGCTAGGTTATAGCCACATTTCTTTGATGGCTGCCTCACTCAAAGTTCTT  
CATTCACTTCCTCTTCATTCACTCTGCTGTCTGCTGGCCATGGCCTTTGACCGCTATGTGG  
45 CCATCTGCTCCCCCTGCGATATGTCACAATCCTCACAAGCAAGGTCAATGGGAAGATCGT  
CACTGCCACCCTGAGCCGCAGCTTCATCATTATGTTTCCATCCATCTTTCTCCTTGAGCACC  
TGCATATTGCCAGATCAACATCATTGCACACACATTTTGTGAGCACATGGGCATTGCCCA  
TCTGTCTGTCTGATATCTCCATCAATGTCTGGTATGGGTTGGCAGCTGCTCTTCTCTCCA  
CAGGCCTGGACATCATGCTTATTACTGTTTCTACATCCACATCCTCCAAGCAGTCTTCCGC  
50 CTCCTTTCTCAAGATGCCCCGCTCCAAGGCCCTGAGTACCTGTGGATCCCATATCTGTGTCA  
CCTACTCTTCTATGTCCCTGCCCTTTTTTCTGTCTTTGCCTACAGGTTTGGTGGGAGAAGCA  
TCCCATGCTATGTCCATATCTCCTGGCCAGCCTCTACGTTGTCAATCCTCCTATGCTCAAT  
CCCGTTATTTATGGAGTGAGGACTAAGCCAATACTGGAAGGGGCTAAGCAGATGTTTTCA  
AATCTTGCCAAAGGATCTAAATAA (SEQ ID NO: 346)

55

WO 01/98526

**AOLFR188 sequences:**

- MFPSLPCPVLLVQLPLMNENMQCFVFCSDSLRMMVSRFIHVFPVKMKRIIVGGYSKHFFSN  
 ELLCVRPWSGKTWSIRHHIFDMELLTNNLKFITDPFVCLRLHLSPTPSEEHMKNKNNVTEFILL  
 GLTQNPEGQKVLVFTLLIYMTIMGNLLIIVTIMASQSLGSPMYFFLASLFSIDTVYSTAFAPK  
 5 MIVDLLSEKKTISFQGCMAQLFMDHLFAGAENVLLVMAYDRYMAICKPLHELITMNRVVCVL  
 MLLAAWIGGFLHSLVQFLFIYQLPFCGPNVIDNFLCDLYPLLKLACTNTYVTGLSMIANGGAIC  
 AVTFTILLSYGVILHSLKTSLEGKRKAFYTCASHVTVVILFFVPCIFLYARPNTSPIDKSMTV  
 VLTFTPLNPLIYTLKNAEMKSAMRKLWSKKVSLAGKWLYHS (SEQ ID NO: 347)
- 10 ATGTTCCCCTCCCTGTGTCCATGTGTTCTCCTTGTTCAACTCCCCTTATGAATGAGAACAT  
 GCAGTGTGTTTGTGTTTCTGTTCTGTGATAGTTGCTGAGAATGATGGTTTCCCGCTTCATCC  
 ATGTCCCATTTGTAAAAATGAAAAGGATAATTGTGGGAGGATATTCTAAACACTTCTTTTC  
 TAATGAGCTGCTCTGTGTGAGGCCCTGGTCAGGGAAAACGTGGTCGATAAGGCATCACAT  
 TTTTGACATGGAGCTTCTGACAAATAATCTCAAATTTATCACTGACCTTTTGTGTTGTAGGC  
 15 TCCGACACCTGAGTCCAACACCTTCAGAAGAACACATGAAAAATAAGAACAATGTGACTG  
 AATTTATCCTCTTAGGGCTCACACAGAACCCTGAGGGGCAAAAGGTTTATTTGTACATT  
 CTTACTAATCTACATGGTGACGATAATGGGCAACCTGCTTATCATAGTGACCATCATGGCC  
 AGCCAGTCCCTGGGTCCCCCATGTACTTTTTCTGGCTCTTTATCATTATAGATACCGT  
 CTATTCTACTGCATTTGCTCCAAAATGATTGTTGACTTGCTCTGAGAAAAAGACCATTT  
 20 CCTTCAGGGTGTATGGCTCAACTTTTTATGGATCATTATTTGCTGGTGTGAAGTCATT  
 CTCTGGTGGTAATGGCCTATGATCGATACATGGCCATCTGTAAGCCTCTTCATGAATTGA  
 TCACCATGAATCGTCGAGTCTGTGTTCTTATGCTGTTGGCGGCTGGATTGGAGGCTTTCT  
 TCACTCATTGGTTCAATTTCTCTTTATTTATCAGCTCCCTTTCTGTGGACCCAATGTCACTG  
 ACAACTTCCTGTGTGATTTGTATCCCTTATTGAACTTGCTTGACCAATACCTATGTCCT  
 25 GGGCTTTCTATGATAGCTAATGGAGGAGCGATTTGTGCTGTACCTTCTTCACTATCCTGC  
 TTTCTATGGGTCATATTACACTCTCTTAAGACTCAGAGTTTGAAGGGAAACGAAAGC  
 TTTCTACACTGTGCATCCACGTCAGTGTGTCATTTTATTCTTTGTCCCTGTATCTTCTT  
 GTATGCAAGGCCCAATTCTACTTTTCCCATGATAAATCCATGACTGTAGTTCTAATTCTT  
 TAACTCCCATGCTGAACCCACTAATCTATACCCTGAAGAATGCAGAAATGAAAAGTGCCAT  
 30 GAGGAACTTTGGAGTAAAAAAGTAAGCTTAGCTGGGAAATGGCTGTATCACTCATGA  
 (SEQ ID NO: 348)

**AOLFR189 sequences:**

- MQQNSVPEFILLGLTQDPLRQKIVFVIFLYMGTVVGNMLIIVTIKSSRTLGSPPMYFFLYLSF  
 35 ADSCFSTSTAPRLIVDALSEKKIITYNECMTQVFAHLHFGCMEIFVLILMAVDYVAICKPLRYP  
 TIMSQVQVCHILIVLAWIGSLIHSTAQILALRLPFCGPYLIDHYCCDLQPLLKACMDTYMINLLL  
 VNSGAICSSFMILIYSIVILHSLRNHSAKGKKKALSACTSHIIVILFFGPCIFIYTRPPTTFPMD  
 KMAVAVFYTIGTPFLNPLIYTSEECRSEKCHEK (SEQ ID NO: 349)
- 40 ATGCAGCAAAATAACAGTGTGCCTGAATTCATACTGTTAGGATTAACACAGGATCCCTTGA  
 GGCAGAAAATAGTGTGTTGTAATCTTCTTAATTTCTATATGGGAAGTGTGGTGGGGAATAT  
 GCTCATTATTGTGACCATCAAGTCCAGCCGACACTAGGAAGCCCCATGTACTTCTTTCTA  
 TTTATTTGTCTTTGCAGATTCTTGCTTTTCAACTCCACAGCCCCATGATTAATTGTGGA  
 TGCTCTCTCTGAAAAGAAAATTATAACCTACAATGAGTGCATGACACAAGTCTTTGCACTA  
 45 CATTTATTTGGCTGCATGGAGATCTTTGCTCTCATTCTCATGGCTGTTGATCGCTATGTGGC  
 CATCTGTAAGCCCTTGCGTTACCCAACCATCATGAGCCAGCAGGTCTGCATCATCCTGATT  
 GTTCTTGCCCTGGATAGGGTCTTAATACACTCTACAGCTCAGATTATCCTGGCCTTAAGATT  
 GCCTTTCTGTGGACCTATTTGATTGATCATTATTGCTGTGATTGTCAGCCCTTGTGAAAC  
 TTGCCTGCATGGACACTTACATGATCAACCTGCTGTTGGTGTCTAACAGTGGGGCAATTTG  
 50 CTCAAGTAGTTTCATGATTTTGATAATTTATATATTGTCATCTTGCACTCACTGAGAAACC  
 ACAGTGCCAAAGGGAAGAAAAAGGCTCTCTCCGCTTGACGCTCACATAATTGTAGTCAT  
 CTTATTCTTTGGCCCATGTATATTCATATATACACGCCCCCGACCACTTTCCCATGGACA  
 AGATGGTGGCAGTATTTTATACTATTGGAACACCCCTTTCTCAATCCACTCATCTACACATCT  
 GAGGAATGCAGAAGTGAAAAATGCCATGAGAAAG (SEQ ID NO: 350)
- 55

**AOLFR190 sequences:**

MQRSNHTVTEFILLGFTTDPGMQLGLFVVFLGVYCLTVVGSSTLIVLICNDSRLHTPMYFVIGN  
LSFLDLWYSSVHTPKILVTCISEDKSISFAGCLCQFFSARLAYSECYLLAAMAYDHYVAISKPLL  
YAQTMPRRLCICLVLYSYTGGFVNAILTSNTFTLDFCGDNVIDDFCDVPPLVKLACSVRESYQ  
5 AVLHFLLASNVISPTVLILASYLSIITLIRIHSTQGRIKVFSTCSSHLISVTLYYGSILYNYSRPSSS  
YSLKRDKMVSTFYTMLFPMLNPMIYSLRSKDMKDALKKFFKSA (SEQ ID NO: 351)

ATGCAGAGGAGCAATCACACAGTGACTGAGTTCATCCTGCTGGGCTTCACCACAGATCCAG  
GGATGCAACTGGGCCTCTTTGTGGTGTTCTGGGTGTGTACTGTCTGACTGTGGTAGGAAG  
10 TAGCACCTCATCGTGTTGATCTGTAATGACTCCCGCTACACACACCCATGTATTTTGTCA  
TTGGAAATCTGTCATTTCTGGATCTCTGGTATTCTTCTGTCCACACCCCAAAGATCCTAGTG  
ACCTGCATCTCTGAAGACAAAAGCATCTCCTTTGCTGGCTGCCTGTGTCAGTTCTTCTCTGC  
CAGGCTGGCCTATAGTGAGTGCTACCTACTGGCTGCCATGGCTTATGACCACTACGTGGCC  
ATCTCCAAGCCCCTGCTTTATGCTCAGACCATGCCAAGGAGATTGTGCATCTGTTTGGTTTT  
15 ATATTCCTATACTGGGGGTTTTGTCAATGCAATAATATTAACCAGCAACACATTCACATTG  
GATTTTTGTGGTGACAATGTCATTGATGACTTTTTCTGTGATGTTCCACCCCTCGTGAAGCT  
GGCATGCAGTGTGAGAGAGAGCTACCAGGCTGTGCTGCACTTCCTTCTGGCCTCCAATGTC  
ATCTCCCCTACTGTGCTCATCCTTGCTCTTACCTCTCCATCATCACCACCATCCTGAGGAT  
CCACTCTACCCAGGGCCGCATCAAAGTCTTCTCCACATGCTCCTCCCACCTGATCTCCGTTA  
20 CCTTATACTATGGCTCCATTCTCTACAATACTCCCGGCCAAGTTCAGCTACTCCCTCAAG  
AGGGACAAAATGGTTTCTACCTTTTATACTATGCTGTTCCCATGTTGAATCCCATGATCTA  
CAGTCTGAGGAGTAAAGACATGAAAGACGCTCTGAAAAAATTCTTCAAGTCAGCATAA  
(SEQ ID NO: 352)



WO 01/98526

**AOLFR191 sequences:**

MTGGGNITEITYFILLGFSDFPRIKVLFTIFLVIYITSLAWNLSLIVLIRMDSHLHTPMYFFLSNLS  
 FIDVCYISSTVPKMLSNLLQEQQTITFVGCIQYFIFSTMGLSECLMTAMAYDRYAAICNPLLYS  
 SIMSPTLCVWMVLGAYMTGLTASLFQIGALLQLHFCGSNVIRHFFCDMPQLLILSCTDTFFVQV  
 5 MTAILTMFFGLASALVIMISYGYIGISIMKITSAGSPKAFNTCASHLTAVSLFYTSIGIFVYLRSSS  
 GGSSSFDRAFASVFYTVVIPMLNPLIYSLRNKEIKDALRLQKRKCC (SEQ ID NO: 353)

ATGACTGGGGGAGGAAATATTACAGAAATCACCTATTTTCATCCTGCTGGGATTCTCAGATT  
 TTCCCAGGATCATAAAAGTGCTCTTCACTATATTCCTGGTGATCTACATTACATCTCTGGCC  
 10 TGGAACTCTCCCTCATTGTTTTAATAAGGATGGATTCCCACCTCCATACACCCATGTATTT  
 CTTCTCAGTAACCTGTCCTTCATAGATGTCTGCTATATCAGCTCCACAGTCCCCAAGATGC  
 TCTCCAACCTCTTACAGGAACAGAACTATCACTTTTGTTGGTTGTATTATTCAGTACTTT  
 ATCTTTTCAACGATGGGACTGAGTGAGTCTTGTCTCATGACAGCCATGGCTTATGATCGTT  
 ATGCTGCCATTTGTAACCCCTGCTCTATTTCATCCATCATGTACCCACCCTCTGTGTTTGG  
 15 ATGGTACTGGGAGCCTACATGACTGGCCTCACTGCTTCTTTATTCCAAATTGGTGCTTTGCT  
 TCAACTCCACTTCTGTGGGTCTAATGTATCAGACATTTCTTCTGTGACATGCCCCAAGTGT  
 TAATCTTGTCTGTACTGACACTTTCTTTGTACAGGTCATGACTGCTATATTAACCATGTTT  
 TTTGGGATAGCAAGTGCCCTAGTTATCATGATATCCTATGGCTATATTGGCATCTCCATCA  
 TGAAGATCACTTCAGCTAAAGGCAGTCCAAAGGCATTCAACACCTGTGCTTCTCATCTAAC  
 20 AGCTGTTTCCCTCTTCTATACATCAGGAATCTTTGTCTATTTGAGGTCCAGCTCTGGAGGT  
 CTTCAAGCTTTGACAGATTTGCATCTGTTTTCTACACTGTGGTCATTCCCATGTTAAATCCC  
 TTGATTTACAGTTTGAGGAACAAAGAAATTAAAGATGCCTTAAAGAGGTTGCAAAAGAGA  
 AAGTGCTGCTGA (SEQ ID NO: 354)

**AOLFR192 sequences:**

25 MENNTEVTEFILVGLTDDPELQIPLFVFLFIYLITLVGNLGMIELLLDSCSLHTPMYFFLSNLSLV  
 DFGYSSAVTPKVMVGF LTGDKFILYNACATQFFFFVAFITAESFLLASMA YDRYAAALCKPLHY  
 TTTMTTNVCACLAIGSYICGFLNASIHTGNTFRLSFCRSNVVEHFFCDAPLLTLSCSDNYISEM  
 VIFFVVGFNDFLSILVILISYLFIFITIMKMRSPGRQKAFSTCASHLTAVSIFYGTGIFMYLRPNSS  
 30 HFMGTDKMASVFYAIVIPMLNPLVYSLRNKEVKSFAFKTVGKAKASIGFIF (SEQ ID NO: 355)

ATGGAGAACAACACAGAGGTGACTGAATTCATCCTTGTGGGGTTAACTGATGACCCAGAA  
 CTGCAGATCCCCTCTTCATAGTCTTCTTTTCATCTACCTCATCACTCTGGTTGGGAACCT  
 35 GGGGATGATTGAATTGATTCTACTGGACTCCTGTCTCCACACCCCCATGTACTTCTTCTCA  
 GTAACCTCTCCCTGGTGGACTTTGGTTATTCCTCAGCTGTCACTCCCAAGGTGATGGTGGG  
 GTTTCTCACAGGAGACAAATTCATATTATATAATGCTTGTGCCACACAATCTTCTTCTTTG  
 TAGCCTTTATCACTGCAGAAAGTTTCTCCTGGCATCAATGGCCTATGACCGCTATGCAGC  
 ATTGTGTAAACCCCTGCATTACACCACCACCATGACAACAAATGTATGTGCTTGCCTGGCC  
 40 ATAGGCTCCTACATCTGTGGTTTCTGAATGCATCCATTCTACTGGGAACACTTTACGGC  
 TCTCCTTCTGTAGATCCAATGTAGTTGAACACTTTTTCTGTGATGCTCCTCCTCTCTTGACT  
 CTCTCATGTTGAGACAACTACATCAGTGAGATGGTTATTTTTTTGTGGTGGGATTCAATG  
 ACCTCTTTTCTATCCTGGTAATCTTGATCTCCTACTTATTTATATTTATCACCATCATGAAG  
 ATGCGCTCACCTGAAGGACGCCAGAAGGCCITTTCTACTTGTGCTTCCCACCTTACTGCAG  
 TTTCCATCTTTTATGGGACAGGAATCTTTATGTACTTACGACCTAACTCCAGCCATTTTCATG  
 45 GGCACAGACAAAATGGCATCTGTGTTCTATGCCATAGTCATTCCCATGTTGAATCCACTGG  
 TCTACAGCCTGAGGAACAAAGAGGTTAAGAGTGCCTTTAAAAAGACTGTAGGGAAGGCAA  
 AGGCCTCTATAGGATTCATATTTTAA (SEQ ID NO: 356)

**AOLFR193 sequences:**

50 MENKTEVTQFILLGLTNDSELQVPLFITFPFIYITLVGNLGIIVLIFWDSCLHNPMYFFLSNLSLV  
 DFCYSSAVTPIVMAGFLIEDKVISYNACAAQMYIFVAFATVENYLLASMA YDRYAAVCKPLHY  
 TTTMTTTCARLAIGSYLGGFLNASIHTGDTFSLSFCKSNEVHHFFCDIPAVMVLSCSDRHISEL  
 VLIYVVSFNIFIALLVILISYTFIFITILKMHSASVYQKPLSTCASHFLAVGIFYGTIFMYLQPSSSH  
 SMDTDKMAPVFYTMVIPMLNPLVYSLRNKEVKSFAFKKVVEKAKLSVGWSV (SEQ ID NO:  
 55 357)

ATGGAAAATAAGACAGAAGTAACACAATTCATTCTTCTAGGACTAACCAATGACTCAGAA  
 CTGCAGGTTCCCCTCTTTATAACGTTCCCCTTCATCTATATTATCACTCTGGTTGGAAACCT  
 GGGAAATTATTGTATTGATATTCTGGGATTCTGTCTCCACAATCCCATGTACTTTTTTCTCA  
 GTAACCTGTCTCTAGTGGACTTTTGTCTACTCTTCAGCTGTCACTCCCATCGTCATGGCTGGA  
 5 TTCCTTATAGAAGACAAGGTCATCTCTTACAATGCATGTGCTGCTCAAAATGTATATCTTTGT  
 AGCTTTTGCCACTGTGGAAAATTACCTCTTGGCCTCAATGGCCTATGACCGCTATGCAGCA  
 GTGTGCAAACCCCTACATTACACCACAACCATGACAACAACTGTGTGTGCTCGTCTGGCCA  
 TAGGCTCCTACCTCTGTGGTTTCTGAATGCCTCCATCCACACTGGGGACACATTTAGTCTC  
 TCTTTCTGTAAGTCCAATGAAGTCCATCACTTTTTCTGTGATATTCCAGCAGTCATGGTTCT  
 10 CTCTTGCTCTGATAGACATATTAGCGAGCTTGTTCCTTATTTATGTTGTGAGCTTCAATATCT  
 TTATAGCTCTCCTGGTTATCTTGATATCCTACACATTCATTTTTATCACCATCCTAAAGATG  
 CACTCAGCTTCAGTATACCAGAAAGCCTTTGTCCACCTGTGCCTCTCATTTTCATTGCAGTCGG  
 CATCTTCTATGGGACTATTATCTTCATGTACTTACAACCCAGCTCCAGTCACTCCATGGACA  
 CAGACAAAATGGCACCTGTGTTCTATACAATGGTCATCCCCATGCTGAACCCTCTGGTCTA  
 15 TAGTCTGAGGAACAAGGAAGTGAAGAGTGCATTCAAGAAAGTTGTTGAGAAGGCAAAATT  
 GTCTGTAGGATGGTCAGTTTAA (SEQ ID NO: 358)

#### AOLFR194 sequences:

20 MERQNSQSCVVEFILLGFSNYPELQGQLFVAFLVIYLVTLIGNAIIIVIVSLDQSLHVPMYLFLNL  
 SVVDLSFSAVIMPEMLVVLSTKTTISFGGCAQMYFILLFGGAECFLLGAMAYDRFAAICHPL  
 NYQMIMNKGVMKLIIFSWALGFMLGTVQTSWSSFPFCGLNEINHISCETPAVLELACADTFL  
 FEIYAFTGTFLIILVPFLLILLSYIRVLFALIKMPSTTGRQKAFSTCAHLTSVTLFYGTASMTYLQ  
 PKSGYPETKKVMSLSYSLTPLLNLIIYSLRNSEMKRALMKLWRRRVVLHTI (SEQ ID NO:  
 359)

25 ATGGAAAGACAAAATCAAAGCTGTGTGGTTGAATTCATCCTCTTGGGCTTTTCTAACTATC  
 CTGAGCTCCAGGGGCAGCTCTTTGTGGCTTTCCTGGTTATTTATCTGGTGACCCTGATAGG  
 AAATGCCATTATTATAGTCATCGTCTCCCTAGACCAGAGCCTCCACGTTCCCATGTACCTGT  
 TTCTCCTGAACTTATCTGTGGTGGACCTGAGTTTCAGTGCAGTTATTATGCCTGAAATGCT  
 30 GGTGGTCTCTCTACTGAAAAAACTACAATTTCTTTTGGGGGCTGTTTTGCACAGATGTAT  
 TTCATCCTTCTTTTGGTGGGGCTGAATGTTTTCTTCTGGGAGCAATGGCTTATGACCGATT  
 TGCTGCAATTTGCCATCCTCTCAACTACCAAATGATTATGAATAAAGGAGTTTTTATGAAA  
 TTAATTATATTTTCATGGGCCTTAGGTTTTATGTTAGGTACTGTTCAAACATCATGGGTATC  
 TAGTTTTCCCTTTTGTGGCCTTAATGAAATTAACCATATATCTTGTGAAACCCAGCAGTGT  
 35 TAGAAGTTGCATGTGCAGACACGTTTTTGTGAAATCTATGCATTACAGGCACCTTTTTG  
 ATTATTTTGGTTCCTTTCTTGTGATACTCTTGTCTTACATTGAGTTCTGTTTGCATCCTG  
 AAGATGCCATCAACCACTGGGAGACAAAAGGCCTTTCCACCTGTGCCGCTCACCTCACAT  
 CTGTGACCCTATTCTATGGCACAGCCAGTATGACTTATTTACAACCCAAATCTGGCTACTC  
 ACCGGAACCAAGAAAGTGATGTCTTACTCACTTCTGACACCACTGCTGAATCTG  
 40 CTTATCTACAGTTTGCAGAAATAGTGAGATGAAGAGGGCTTTGATGAAATTATGGCGAAGG  
 CGAGTGGTTTTACACACAATCTGA (SEQ ID NO: 360)

#### AOLFR195 sequences:

45 MIVQLICTVCFILAVNTFHVRSSFDLKAADDMEINQTLVSEFLLGLSGYPKIEIVYFALILVMY  
 LVILIGNGVLIASIFDSHFHTPMYFFLGNLSFLDICYTSSSVPSLTVSLISKRNISFSGCAVQMFF  
 GFAMGSTECLLLGMMAFDYVAICNPLRYPIHLSKVAYVLMASVSWLSGGINSVQTLAMRL  
 PFCGNNIINHFACEILAVLKLACADISLNIITMVISNMAFLVPLMVIFFSYMFILYTIQMNSTATG  
 RRKAFSTCSAHLTVVIIIFYGTIFFMYAKPKSQDLIGEEKLQALDKLISLFYGVVTPMLNPILYSLR  
 NKDVKAADVLYLLNKKPIH (SEQ ID NO: 361)

50 ATGATTGTTCAAGTTAATTTGTACTGTTTGTTCCTTGGCAGTAAATACATTTTCATGTTAGATC  
 TTCTTTTGATTTCTGAAAGCAGATGACATGGGTGAGATTAACCAGACACTTGTGTCAGAA  
 TTTCTTCTTCTGGGTCTTTCTGGATACCCAAAGATTGAGATTGTTTACTTTGCTCTCATTCT  
 AGTTATGTACCTAGTGATTCTAATTGGCAATGGTGTCTAATCATAGCCAGCATCTTTGATT  
 55 CTCATTTTCACACACCAATGTACTTCTTCTGGGCAACCTCTTTTCTGGATATCTGCTAT  
 ACATCCTCCTCTGTTCCCTCAACATTGGTGAGCTTAATCTCAAAGAAAAGAAACATTTCT

TCTCTGGATGTGCAGTGCAGATGTTCTTTGGGTTTGCAATGGGGTCAACAGAATGTCTGCT  
 TCTTGGCATGATGGCATTGATCGTTATGTGGCCATCTGCAACCCACTGAGATACCCCATC  
 ATCCTGAGCAAGGTGGCGTATGTATTGATGGCTTCTGTGCTGCTGGCTGTCCGGTGAATAA  
 ATTCAGCTGTGCAAACATTACTTGCCATGAGACTGCCTTTCTGTGGGAATAATATTATCAA  
 5 TCATTTTCGCATGTGAAATATTAGCTGTCTCAAGCTGGCCTGTGCTGATATATCCCTCAATA  
 TTATCACCATGGTGATATCAAATATGGCCTTCTGGTTCTTCCACTGATGGTCATTTTTTTC  
 TCCTATATGTTTCATCCTCTACACCATCTTGCAAATGAATTCAGCCACAGGAAGACGCAAGG  
 CATTTTCCACGTGCTCAGCTCACCTGACTGTGGTGATCATATTTTACGGTACCATCTTCTTT  
 ATGTATGCGAAACCGAAGTCTCAAGACCTGATTGGGGAAGAAAAATTGCAAGCATTAGAC  
 10 AAGCTCATTTCTCTGTTTTATGGGGTAGTGACCCCATGCTGAATCCTATACTCTATAGCTT  
 GAGAAATAAGGATGTAAAAGCTGCTGTAAAATATTTGCTGAACAAAAACCAATTCATA  
 A (SEQ ID NO: 362)

# **AOLFR196 sequences:**

15 MLESNYTMPTEFLFVGFTDYLPLRVTLFLVFLLVYTLTMVGNILLIILVNINSSLQIPMYFLSNL  
 SFLDISCSTAITPKMLANFLASRKSISPYGCALQMFFASFADAECILILAAAMAYDRYAAICNPIL  
 YTTLMSSRRVCVCFIVLAYFSGSTTSLVHVCLTFLRSLFCGSNIVNHFFCDIPILLALSCTDTQINQL  
 LLFALCSFIQTSTFVVFISYFCILITVLSIKSSGGRSKTFSTCASHLIAVTLFYGALLFMYLQPTTS  
 20 YSLDIDKVVAVFYTVVFPMPFNPIIYSFRNKDVKNALKKLLERIGYSNEWYLNRLRIVNI (SEQ  
 ID NO: 363)

ATGTTGGAGAGTAATTACACCATGCCAACTGAGTTCCTATTTGTTGGATTACAGATTATC  
 TACCTCTCAGAGTCACACTGTTCTTGGTATTCTTCTGGTATATACATTAACCTATGGTCGGA  
 AATATACTCTTAATAATTCTAGTTAATTAATTCAAGCCTTCAAATCCCATGTATTATTT  
 25 TCTTAGCAACTTATCTTTCTTAGACATCAGCTGTTCTACAGCAATCACTCCTAAAATGCTGG  
 CAAACTTCTTGGCATCCAGGAAAAGCATCTCTCCTTATGGGTGTGCACTACAAATGTTTTT  
 CTTTCGCTTCTTTTGGCTGATGCTGAGTGCCTTATCCTGGCAGCAATGGCTTATGACCGCTATG  
 CAGCCATGTGCAACCCACTGCTCTATACTACACTGATGTCTAGGAGAGTCTGTGTCTGCTT  
 CATTTGTGTTGGCATATTTTCACTGGAAGTACAACATCACTGGTCCATGTGTGCCTCACATTC  
 30 AGGCTGTCTTTTGTGGCTCCAATATCGTCAATCATTTTTTCTGTGATATCCCACCTCTCT  
 GGCTTTATCATGTACAGACACTCAGATCAACCAGCTTCTGCTCTTTGCTTTGTGCAGCTTCA  
 TCCAGACCAGCACTTTTGTGGTAATATTTATTTCTTACTTCTGCATCCTCATCACTGTGTTG  
 AGCATCAAGTCCTCAGGTGGCAGAAAGCAAAACATTCTCCACTTGTGCTTCCCACCTCATAG  
 CAGTCACCTTATTCTATGGAGCGCTCCTGTTTATGTACTTACAGCCCACCTAGCTATTCC  
 35 CTAGACACTGATAAGGTGGTGGCAGTGTTTTATACTGTTGTATTTCCCATGTTTAAATCCAA  
 TAATTTATAGTTTCAGAAACAAGGATGTGAAAAATGCTCTCAAAAAGCTATTAGAAAGAA  
 TTGGATATTCAAATGAATGGTATTTAAATCGTTTAAAGAATAGTCAATATCTAA (SEQ ID NO:  
 364)

40 **AOLFR197 sequences:**  
 MCYLSQLCLSLGEHTLHMGVVRHTNESNLAGFILLGFSDDYPQLQKVLFLILLYLLTILGNTTI  
 ILVSRLEPKLHMPMYFFLSHLSFLYRCFTSSVIPQLLVNLWEPMKTIAYGGCLVHLYNSHALGS  
 TECVLLALMSCDRYVAVCRPLHYTVLMHHILCMALASMAWLSGIATTLVQSTLTLQLPFCGH  
 RQVDHFICEVPVLIKLAACVGTTFNEAEFLVASILFLVPSFILVSSGYIAHAVLRIKSATRRQKAF  
 45 GTCFSLTLVVTIFYGTHIFMYLQPAKSRSDQGKVSFLFYTVVTRMLNPLIYTLRIKEVKGALKK  
 VLAKALGVNIL (SEQ ID NO: 365)

ATGTGTTATCTTTCTCAGCTATGCCTCAGCCTTGGGGAACACACTTTACATATGGGGATGG  
 TGAGACATACCAATGAGAGCAACCTAGCAGGTTTCATCCTTTTAGGGTTTCTGATTATCC  
 50 TCAGTTACAGAAGGTTCTATTTGTGCTCATATTGATTCTGTATTTACTAACTATTTTGGGGA  
 ATACCACCATCATTTCTGGTTTCTCGTCTGGAACCCAAGCTTCATATGCCGATGTATTTCTTC  
 CTTTCTCATCTCTCCTTCTGTACCGCTGCTTACCAGCAGTGTTATTTCCAGCTCCTGGT  
 AAACCTGTGGGAACCCATGAAAACATATCGCCTATGGTGGCTGTTTGGTTCACTTTACAAC  
 TCCCATGCCCTGGGATCCACTGAGTGCCTCTTGGCTCTGATGTCCTGTGACCGCTATGT  
 55 GGCTGTCTGCCGTCCTCTCCATTACACTGTCTTAATGCATATCCATCTCTGCATGGCCTTGG  
 CATCTATGGCATGGCTCAGTGAATAGCCACCACCTGGTACAGTCCACCCTCACCTGCA

GCTGCCCTTCTGTGGGCATCGCCAAGTGGATCATTTTCATCTGCGAGGTCCCTGTGCTCATC  
 AAGCTGGCTTGTGTGGGCACCACGTTTAACGAGGCTGAGCTTTTGTGGCTAGTATCCTTT  
 TCCTTATAGTGCCTGTCTCATTCATCCTGGTCTCCTCTGGCTACATTGCCACGCAGTGTTG  
 5 AGGATTAAGTCAGCTACCAGGAGACAGAAAGCATTTCGGGACCTGCTTCTCCACCTGACA  
 GTGGTCACCATCTTTTATGGAACCATCATCTTCATGTATCTGCAGCCAGCCAAGAGTAGAT  
 CCAGGGACCAGGGCAAGTTTGTCTCTTCTACACTGTGGTAACCCGCATGCTTAACCC  
 TCTTATTTATACCTTGAGGATCAAGGAGGTGAAAGGGGCATTAAAGAAAGTTCTAGCAAA  
 GGCTCTGGGAGTAAATATTTTATGA (SEQ ID NO: 366)

10 **AOLFR198 sequences:**

MENCTEVTKFILLGLTSVPELQIPLFILFTFIYLLTLCGNLGMMLLILMDSCLHTPMYFFLSNLSL  
 VDFGYSSAVTPKVMAGFLRGDKVISYNACAVQMFFVALATVENYLLASMAFYDRYAAVCKP  
 LHYTTTMTASVGACALGSYVCGFLNASFHIGGIFSLSFCKSNLVHHFFCDVPAVMALSCSDKH  
 TSEVILVFMSSFNIFVLLVIFISYLFIFITILKMHSAGHQKALSTCASHFTAVSVFYGTIVIFIYLO  
 15 PSSSHSMDTDKMASVIFYAMIIPMLNPVVYSLRNREVQNAFKKVLRRQKFL (SEQ ID NO: 367)

ATGGAGAATTGTACGGAAGTGACAAAGTTCATTCTTCTAGGACTAACCAGTGTCCCAGAAC  
 TACAGATCCCCCTCTTTATCTTGTTACCTTCATCTACCTCCTCACTCTGTGTGGGAACCTG  
 GGGATGATGTTGCTGATCCTGATGGACTCTTGCTCCACACCCCCATGTACTTTTCTCCTCAG  
 20 TAACCTGTCTCTGGTGGACTTTGGATACTCCTCAGCTGTCACTCCCAAGGTCATGGCTGGG  
 TTCCTTAGAGGAGACAAGGTCATCTCCTACAATGCATGTGCTGTTTCTTCTTTGT  
 AGCCTTGGCCACGGTGGAAAATTACTTGTGGCCTCAATGGCCTATGACCGCTATGCAGCA  
 GTGTGCAAACCCCTACACTACACCACCACCATGACGGCCAGTGTAGGTGCCTGTCTGGCCC  
 TAGGCTCATATGTCTGTGGCTTCCTAAATGCCTCATTCACATTGGGGGCATATTCAGTCTC  
 25 TCTTTCTGTAAATCCAATCTGGTACATCACTTTTTCTGTGATGTTCCAGCAGTCATGGCTCT  
 GTCTTGCTCTGATAAACACACTAGTGAGGTGATTCTGGTTTTATGTCAAGCTTTAATATCT  
 TTTTGTCTCTTAGTTATCTTTATCTCCTACTTGTTTCATATTCATCACCATCTTGAAGATGC  
 ATTCAGCTAAGGGACACCAAAAAGCATTGTCCACCTGTGCCTCTCACTTCACTGCAGTCTC  
 CGTCTTCTATGGGACAGTAATCTTCTACTTGCAGCCCAGCTCCAGCCACTCCATGGAC  
 30 ACAGACAAAATGGCATCTGTGTTCTATGCTATGATCATCCCCATGCTGAACCTGTGGTCT  
 ACAGCCTGAGGAACAGAGAAGTCCAGAATGCATTCAAGAAAGTGTGAGAAGGCAAAAAT  
 TTCTATAA (SEQ ID NO: 368)

**AOLFR199 sequences:**

35 MDTGNKTL PQDFLLGFPGSQTQLQSLFMLFLVMYILTVSGNVAILMLVSTSHQLHTPMYFFLS  
 NLSFLEIWTYTTAAVPKALAILLGRSQTISFTSCLLQMYFVFSLGCTEYFLAAMAYDRCLAICY  
 LHYGAIMSSLLSAQLALGSWVCGFVAIAVPTALISGLSFCGPRAINHHFCDIAPWIALACTNTQA  
 VELVAFVIAVVVILSSCLITFVSYYIISTILRIPSASGRSKAFSTCSSHLTVVLIWYGSTVFLHVR  
 TSIKDALDLIKA VHLNTPVTPVLNPFYTLRNKEVRETLKKWK GK (SEQ ID NO: 369)

40 ATGGACACAGGCAACAAAACCTCTGCCCCAGGACTTTCTCTTACTGGGCTTTCCTGGTTCTC  
 AAACCTTTCAGCTCTCTCTCTTTATGCTTTTTCTGGTGATGTACATCCTCACAGTTAGTGGT  
 AATGTGGCTATCTTGATGTTGGTGAGCACCTCCCATCAGTTGCATACCCCATGTACTTCTT  
 TCTGAGCAACCTCTCCTTCTGGAGATTTGGTATACCACAGCAGCAGTGCCCAAAGCACTG  
 45 GCCATCCTACTGGGGAGAAGTCAGACCATATCATTTACAAGCTGTCTTTTGAGATGTACT  
 TTGTTTTCTCATTAGGCTGCACAGAGTACTTCCTCCTGGCAGCCATGGCTTATGACCGCTGT  
 CTTGCCATCTGCTATCCTTTACACTACGGAGCCATCATGAGTAGCCTGCTCTCAGCGCAGC  
 TGGCCCTGGGCTCCTGGGTGTGTGGTTTCGTGGCCATTGCAGTGCCACAGCCCTCATCAG  
 TGGCCTGTCTTCTGTGGCCCCCGTGCCATCAACCACTTCTTCTGTGACATTGCACCCTGGA  
 50 TTGCCCTGGCCTGCACCAACACACAGGCAGTAGAGCTTGTGGCCTTTGTGATTGCTGTTGT  
 GGTATCCTGAGTTCATGCCTCATCACCTTTGTCTCCTATGTGTACATCATCAGCACCATCC  
 TCAGGATCCCCCTCTGCCAGTGGCCGGAGCAAAGCCTTCTCCACGTGCTCCTCGCATCTCAC  
 CGTGGTGCTCATTTGGTATGGGTCCACAGTTTTCCTTCACGTCCGCACCTCTATCAAAGAT  
 GCCTTGGATCTGATCAAAGCTGTCCACGTCTGAACACTGTGGTGACTCCAGTTTAAACC  
 55 CCTTCATCTATACGCTTCGTAATAAGGAAGTAAGAGAGACTCTGCTGAAGAAATGGAAGG  
 GAAAATAA (SEQ ID NO: 370)

## AOLFR200 sequences:

5 MTRKNYTSLEFVLLGLADTLELQILFLFLVIYTLTVLGNLGMILLIRIDSQ LHTPMYFFLANL  
SFVDVCNSTTITPKMLADLLSEKKTISFAGCFLQMYFFISLATTECILFGLMAYDRYAAICRPLL  
YSLMSRTVYLKMAAGAFAGLLNFMVNTSHVSSLSFCDNSVIHHFFCDSPPLFKLSCSDTILKE  
SISSILAGVNIVGTLLVILSSYSYVLFISFMSHSGEGRHRAFSTCASHLTAILFYATCIYTYLRPSS  
SYSLNQDKVASVFYTVVIPMLNPLIYSLRSKEVKALANVISRKRTSSFL (SEQ ID NO: 371)

10 ATGACCAGAAAAAATTATACCTCACTGACTGAGTTCGTCCTATTGGGATTAGCAGACACGC  
TGGAGCTACAGATTATCCTCTTTTGTCTTTTCTTGATTTATACACTTACAGTACTGGGA  
AATCTCGGGATGATCCTCTTAATCAGGATCGATTCCCAGCTTACACACCCCATGTATTTCTT  
CCTGGCTAACCTGTCTTTGTGGACGTTTGTAACTCACTACCATCACCCCAAAGATGCTG  
GCAGATTTATTATCAGAGAAGAAAACCATCTCTTTGCTGGCTGCTTCTACAGATGTACT  
TCTTTATCTCCCTGGCGACAACCGAATGCATCCTCTTTGGGTAAATGGCCTATGACAGGTA  
15 TGCGGCCATATGTCGCGCTGCTTTACTCCTTGATCATGTCCAGGACCGTCTACCTAAAA  
ATGGCAGCCGGGGCTTTGCTGCAGGGTGTGTAACCTCATGGTCAACACAAGCCATGTCA  
GCAGCTTGTCAATTCTGTGACTCCAATGTCACTCATCTTCTGTGACAGTCCCCACTT  
TTCAAGCTCTCTTGTCTGACACAATCCTGAAAGAAAGCATAAGTTCTATTTTGGCTGGTG  
TGAATATTGTGGGGACTCTGCTTGTATCCTCTCCTCTACTCCTACGTTCTCTTCTCCATT  
20 TTTTCTATGCATTGGGGGAGGGGAGGCACAGAGCTTTCTCCACGTGTGCTCTCACCTGA  
CAGCCATAATTCTGTTCTATGCCACCTGCATCTATACTTACCTGAGACCTAGTTCAGCTAC  
TCCCTGAATCAGGACAAAGTGGCTTCTGTGTTCTACACAGTGGTGATTCCCATGTTGAATC  
CTCTGATCTACAGCCTCAGGAGTAAGGAAGTAAAGAAGGCTTAGCGAATGTAATTAGCA  
GGAAAAGGACCTCTCCTTTCTGTGA (SEQ ID NO: 372)

25

## AOLFR201 sequences:

MEWENHTILVEFFLKGLSGHPRLELLFFVLIFIMYVILLGNGTLILISILDPHLHTPMYFFLGNL  
SFLDICYTTSIPSTLVSFLSERKTISLSCAVQMFLGLAMGTTECVLLGMMAFDYVAICNPLR  
YPIIMSKDAYVPMAAGSWIIGAVNSAVQSVFVQLPFCRNININHTCEILAVMKLACADISDN  
30 EFIMLVATTLFILTPLLLIIVSYTLIIVSIFKISSSEGRSKASSTCSAHLTVVIIFYGTILFMYMKPKS  
KETLNSDDL DATDKIISMFGVMTMPMNPLIYSLRNKDVKAEVKHLLNRRFFSK (SEQ ID NO:  
373)

35 ATGGAATGGGAAAACACACCAATTCTGGTGGAATTTTTCTGAAGGGACTTTCTGGTCACC  
CAAGACTTGAGTTACTCTTTTTGTGCTCATCTTCATAATGTATGTGGTCATCCTTCTGGGG  
AATGGTACTCTCATTTTAATCAGCATCTGGACCCTCACCTTACACCCCTATGTAATCTT  
TCTGGGGAACTCTCCTTCTTGGACATCTGCTACACCACCCTCTATCCCTCCACGCTAG  
TGAGCTTCTTTTCAAGAAAGAACCATTTCCCTTTCTGGCTGTGCAGTGCAGATGTTCTT  
CGGCTTGGCCATGGGGACAACAGAGTGTGTGCTTCTGGGCATGATGGCCTTTGACCGCTAT  
40 GTGGCTATCTGCAACCCTCTGAGATATCCCATCATCATGAGTAAGGATGCCTATGTACCCA  
TGGCAGCTGGGTCCTGGATCATAGGAGCTGTCAATTCTGCAGTACAATCAGTGTGTTGTGGT  
ACAATTGCCTTTCTGCAGGAATAACATCATCAATCATTTACCTGTGAAATTCTGGCTGTC  
ATGAAACTGGCCTGTGCTGACATCTCAGACAATGAGTTCATCATGCTTGTGGCCACAACAT  
TGTTCAATATTGACACCTTTGTTATTAATCATTGTCTCTTACACGTTAATCATTGTGAGCATC  
45 TTCAAAATTAGCTCTTCCGAGGGGAGAAGCAAAGCTTCTCTACCTGTTTACGCCATCTGA  
CTGTGGTCATAATATTCTATGGGACCATCCTCTTATGTACATGAAGCCCAAGTCTAAAGA  
GACACTTAATTCGGATGACTTGGATGCTACCGACAAAATTATATCCATGTTCTATGGGGTG  
ATGACTCCCATGATGAATCCTTTAATCTACAGTCTTAGAAACAAGGATGTGAAAGAGGCA  
GTAAAACACCTACTGAACAGAAGGTTCTTTAGCAAGTGA (SEQ ID NO: 374)

50

## AOLFR202 sequences:

MEWENHTILVEFFLKGLSGHPRLELLFFVLIFIMYVILLGNGTLILISILDPHLHTPMYFFLGNL  
SFLDICYTTSIPSTLVSFLSERKTISLSCAVQMFLSLAMGTTECVLLGVMAFDYVAICNPLR  
YPIIMSKDAYVPMAAGSWIIGAVNSAVQTVFVQLPFCRNININHTCEILAVMKLACADISGN  
55 EFILLVTTTLFLLTPLLLIIVSYTLIILSIFKISSSEGRSKPSSTCSARLTVVITFCGTIFLMYMKPKSQ

ETLNSDDLDATDKLIFIFYRVMTMPMMNPLIYSLRNKDVKEAVKHLRRKNFNK (SEQ ID NO: 375)

5 ATGGAATGGGAAAACACACCATCTGGTGGAATTTTTCTGAAGGGACTTTCTGGTCACC  
CAAGACTTGAGTTACTCTTTTTGTGCTCATCTTCATAATGTATGTGGTCATCCTTCTGGGG  
AATGGTACTCTCATTTTAATCAGCATCTTGGACCCTCACCTTCACACCCCTATGTACTTCTT  
TCTGGGGAACCTCTCCTTCTTGGACATCTGCTACACCACCCTCTATTCCCTCCACGCTAG  
TGAGCTTCCTTTTCAGAAAGAAAGACCATTTCCCTTTCTGGCTGTGCAGTGCAGATGTTCTC  
10 CAGCTTGGCCATGGGGACAACAGAGTGTGTGCTTCTGGGCGTGATGGCCTTTGACCGCTAT  
GTGGCTATCTGCAACCCTCTGAGATATCCCATCATCATGAGTAAGGATGCCTATGTACCCA  
TGGCAGCTGGGTCCTGGATCATAGGAGCTGTCAATTCTGCAGTACAAACAGTGTGTTGTGGT  
ACAATTGCCTTTCTGCAGGAATAACATCATCAATCATTTACCTGTGAAATTCTAGCTGTC  
ATGAAACTGGCCTGTGCTGACATCTCAGGCAATGAGTTCATCCTGCTTGTGACCACAACAT  
TGTTCTATTGACACCTTTGTTATTAATTATTGTCTCTTACACGTTAATCATTTTGAGCATC  
15 TTCAAAATTAGCTCTTCGGAGGGGAGAAGCAAACTTCTCTACCTGCTCAGCTCGTCTGA  
CTGTGGTGATAACATTCTGTGGGACCATCTTCTCATGTACATGAAGCCCAAGTCTCAAGA  
GACACTTAATTCAGATGACTTGGATGCCACTGACAACTTATATTCATATTCTACAGGGTG  
ATGACTCCCATGATGAATCCTTTAATCTACAGTCTTAGAAACAAGGATGTGAAGGAGGCA  
GTAAACACCTACTGAGAAGAAAAAATTTTAAACAAGTAA (SEQ ID NO: 376)

20

**AOLFR203 sequences:**

MKRQNSQCVVEFILLGFSNPELQVQLFGVFLVIYVVTLMGNAITVIISLNQSLHVPMYLFLN  
LSVVEVSFSAVITPEMLVVLSTEKTMISFVGCFAQMYFILLFGGTECFLLGAMAYDRFAAICHPL  
NYPVIMNRGVFMKL VIFSWISGIMVATVQTTWVFSFPFCGPNEINHLFCETPPVLELVCADTFLE  
25 EIYAFTGTILIVMPFLLILLSYIRVLFALIKMPSTTGRQKAFSTCASHLTSVTLFYGTANMTYLQ  
PKSGYSPETKKLISLAYTLLTPLLNPLIYSLRNSEMKRTLKLRWKVILHTF (SEQ ID NO: 377)

ATGAAAAGACAAAATCAAAGCTGTGTGGTTGAATTCATCCTCCTGGGCTTTTCTAACTTTC  
CTGAGCTCCAGGTGCAGCTCTTTGGGGTTTCTAGTTATTTATGTGGTGACCCTGATGGG  
30 AAATGCCATCATTACAGTCATCATCTCCTTAAACCAGAGCCTCCACGTTCCCATGTACCTGT  
TCCTCCTGAACCTATCTGTGGTGGAGGTGAGTTTCAGTGCAGTCATTACGCCTGAAATGCT  
GGTGGTGCTCTCTACTGAGAAAATATGATTTCTTTTGTGGGCTGTTTGCACAGATGTAT  
TTCATCCTTCTTTTGGTGGGACTGAATGTTTTCTCCTGGGAGCGATGGCTTATGACCGATT  
TGCTGCAATTTGCCATCCTCTGAACTACCCAGTGATTATGAACAGAGGGGTTTTATGAAA  
35 TTAGTAATATTCTCATGGATCTCAGGGATCATGGTGGCTACTGTGCAGACCACTGGGTAT  
TTAGTTTTCCATTTTGTGGCCCCAATGAAATTAATCATCTCTTCTGTGAGACTCCCCCGGTA  
CTAGAGCTTGTGTGTGCAGACACCTTCTTATTTGAAATCTATGCCTTCACAGGCACCATTTT  
GATTGTTATGGTTCCTTTCTTGTGATCCTCTTGTCTTACATTCGAGTTCTGTTTGCCATCCT  
GAAGATGCCATCAACTACTGGGAGACAAAAGGCCTTTTCCACCTGTGCCTCTCACCTCACA  
40 TCTGTGACCCTGTTCTATGGCACAGCCAATATGACTTATTTACAACCCAAATCTGGCTACTC  
ACCCGAAACCAAGAACTGATCTCATTGGCTTACACGTTGCTTACCCCTCTGCTCAATCCG  
CTCATCTATAGCTTACGAAACAGTGAGATGAAGAGGACTTTGATAAACTATGGCGAAGA  
AAAGTGATTTTACACACATTCTGA (SEQ ID NO: 378)

45 **AOLFR204 sequences:**

MEKKKNVTEFILIGLTQNPIMEKVTFVFLVLYMITLSGNLLIVVTITTSQALSSPMYFFLTHLSL  
IDTVYSSSSAPKLIVDSFQEKKIISFNGCMAQAYAEHIFGATEIILLTVMACDCYVAICKPLNYTT  
IMSHSLCILLVAVAWVGGFLHATIQILFTVWLPFCGPNVIGHFMCDLYPLLKLVCIDHTLGLFV  
AVNSGFICLLNFLILVVSIVILRSLKNSLEGRCKALSTCISHIIVVLFVPCIFVYLRSVTTLPI  
50 DKAVAVFYTMVVPMLNPVVYTLRNAEVKSAIRKLWRKKVTSND (SEQ ID NO: 379)

ATGGAGAAGAAAAAGAATGTGACTGAATTCATTTTAATAGGTCTTACACAGAACCCCAT  
ATGGAGAAAGTCACGTTTGTAGTATTTTGGTCTTTACATGATAACACTTTCAGGCAACC  
TGCTCATTGTGGTTACCATACCACCAGCCAGGCTCTGAGCTCCCCCATGTACTTCTTCTG  
55 ACCCACCTTTCTTTGATAGACACAGTTTATTCTTCTTCTTACAGCTCCTAAGTTGATTGTGGA  
TTCCTTTCAAGAGAAGAAAATCATCTCCTTTAATGGGTGTATGGCTCAAGCCTATGCAGAA



WO 01/98526

CACATTTTTGGTGCTACTGAGATCATCCTGCTGACAGTGATGGCCTGTGACTGCTATGTGG  
 CCATCTGCAAACCTCTGAACTACACAACCATTATGAGCCACAGCCTGTGCATTCTCCTGGT  
 GGCAGTGGCCTGGGTGGGAGGATTCTTCATGCAACTATTCAGATTCTCTTTACAGTATGG  
 CTGCCCTTCTGTGGCCCAATGTCATAGGCCACTTCATGTGTGACTTGTACCCATTGTTAA  
 5 ACTTGTGTCATAGACACTCATACCCTTGGTCTCTTTGTGCTGTGAACAGTGGGTTTATCT  
 GCTTATTAACCTTCCTTATCTTGGTGGTATCCTATGTGATCATCTTGAGATCTTTAAAGAAC  
 AATAGCTTGGAGGGGAGGTGTAAAGCCCTCTCCACCTGTATTTCTCACATCATAGTAGTTG  
 TCTTATTCTTTGTGCCCTGTATATTGTGTATCTGCGCTCAGTGACCACTCTGCCATTGAT  
 AAAGCTGTTGCTGTATTTTATACTATGGTGGTCCCAATGTTAAATCCCGTGGTCTACACAC  
 10 TCAGAAATGCTGAGGTAAAAAGTGCAATAAGGAAGCTTTGGAGAAAAAAGTGACTTCAG  
 ATAATGATTAA (SEQ ID NO: 380)

## AOLFR205 sequences:

15 MESENRTVIREFILLGLTQSQDIQLLVFVLVLIFYFILPGNFLIFTIKSDPGLTAPLYFFLGNLAF  
 DASYSFTVAPRMLVDFLSAKKIISYRGCTQLFHLHFLGGGEGLLLVMAFDRIAICRPLHYPT  
 VMNPRTCYAMMLALWLGGFVHSIIQVVLRLPFCGPNQLDNFFCDVPQVIKACTDTFVVEL  
 LMVFNGLMTLLCFLGLASYAVILCRIGSSSEAKNKAMSTCITHIIVFFMFGPGIFITRPFRA  
 FPADKVVSLFHTVIFPLNPNVITYTLRNQEVKASMKKVFENKHLA (SEQ ID NO: 381)

20 ATGGAAAGCGAGAACAGACAGTGATAAGAGAATTCACTCCTTGGTCTGACCCAGTCT  
 CAAGATATTCAGCTCCTGGTCTTTGTGCTAGTTTTAATATTCTACTTCATCATCCTCCCTGG  
 AAATTTTCTCATTATTTTACCATAAAGTCAGACCCTGGGCTCACAGCCCCCTCTATTCT  
 TTCTGGGCAACTTGGCCTTCTGGATGCATCCTACTCCTTCACTGTGGCTCCCCGGATGTTG  
 GTGGACTTCTCTGCGAAGAAGATAATCTCTACAGAGGCTGCATCACTCAGCTCTTTT  
 25 TCTTGCACTTCTTGGAGGAGGGGAGGATTACTCCTTGTGTGATGGCCTTGACCGCTA  
 CATCGCCATCTGCCGGCCTCTGCACTATCCTACTGTGATGAACCTAGAACCTGCTATGCA  
 ATGATGTTGGCTCTGTGGCTTGGGGGTTTTGTCCACTCCATTATCCAGGTGGTCTCATCCT  
 CCGCTTGCCTTTTTGTGGCCAAACCAGCTGGACAACTTCTTGTGATGTCCACAGGTC  
 ATCAAGCTGGCCTGCACCGACACATTTGTGGTGGAGCTTCTGATGGTCTTCAACAGTGGCC  
 30 TGATGACACTCCTGTGCTTTCTGGGGCTTCTGGCCTCCTATGCAGTCATTCTTTGTCGATA  
 CGAGGGTCTTCTTCTGAGGCAAAAAACAAGGCCATGTCCACGTGCATACCCATATCATTG  
 TTATATTCTTCATGTTTGGACCTGGCATCTTCATCTACACGCGCCCTTCAGGGCTTCCCA  
 GCTGACAAGGTGGTTTCTCTCTTCCACACAGTGATTTTCTTTGTTGAATCCTGTCTTTA  
 TACCTTCGCAACCAGGAAGTGAAAGCTCCATGAAAAAGGTGTTAATAAGCACATAGC  
 35 CTGA (SEQ ID NO: 382)

## AOLFR206 sequences:

40 MANRNNVTEFILLGLTENPKMQKIIFVVSVIYNAMIGNVLIVVTTTASPSLRSPMYFFLAYLSFI  
 DACYSSVNTPKLITDSLYENKTLFNGCMTQVGEHFRGVEVILLTVMAYDHYVAICKPLHYT  
 TIMKQHVCSLLVGVSWSVGGFLHATIQILFICQLPFCGPNVIDHFMCDLYTLINACTNHTLGLF  
 IAANSFGICLLNCLLLVSCVVLISLKTHSLEARHEALSTCVSHITVILSFIPCFVYMRPPATL  
 PIDKAVAVFYTMITSMLNPLIYTLRNAQMKNARKLCSRKAISSVK (SEQ ID NO: 383)

45 ATGGCGAATAGAAACAATGTGACAGAGTTTATTCTATTGGGGCTTACAGAGAATCCAAAA  
 ATGCAGAAAATCATATTTGTTGTGTTTTCTGTCATCTACATCAACGCCATGATAGGAAATG  
 TGCTCATTGTGGTCACCATCACTGCCAGCCATCACTGAGATCCCCCATGACTTTTCTCTG  
 GCCTATCTCTCCTTATTGATGCCTGCTATTCTCTGTCAATACCCCTAAGCTGATCACAGA  
 TTCCTCTATGAAAACAAGACTATCTTATTCAATGGATGTATGACTCAAGTCTTTGGAGAA  
 CATTTTTTCAAGGTGTTGAGGTATCCTACTTACTGTAATGGCCTATGACCACTATGTGG  
 50 CCATCTGCAAGCCCTTGCATATACCACCATCATGAAGCAGCATGTTTGTAGCCTGCTAGT  
 GGGAGTGTCATGGGTAGGAGGCTTTCTTCATGCAACCATAACAGATCCTCTTCATCTGTCAA  
 TTACCTTTCTGTGGTCCTAATGTGATGATCACTTTATGTGTGATCTCTACACTTTGATCAA  
 TCTTGCCTGCACTAATACCACACTCTAGGACTCTTATTGCTGCCAACAGTGGGTTTATAT  
 GCCTGTAAACTGTCTCTTGTCTCCTGGTCTCCTGCGTGGTGCATGACTGTTAAAGACC  
 55 CACAGCTTAGAGGCAAGGCATGAAGCCCTCTCTACCTGTGTCTCCACATCACAGTTGTCA  
 TCTTATCCTTTATACCCTGCATATTTGTGTACATGAGACCTCCAGCTACTTTACCATTTGAT



AAAGCAGTTGCTGTATTCTACACTATGATAACTTCTATGTTAAACCCCTTAATCTACACCTT  
GAGGAATGCTCAAATGAAAAATGCCATTAGGAAATTGTGTAGTAGGAAAGCTATTTCAAG  
TGTCAAATAA (SEQ ID NO: 384)

5 **AOLFR207 sequences:**

MERTNDSTSTEFFLVGLSAHPKLQTVFFVLILWMYLMILLGNGVLISVIIFDSHLHTPMYFFLCN  
LSFLDVCTSSSVPLILASFLAVKKKVSFSGCMVQMFISFAMGATECMILGTMALDRYVAICYP  
LRYPVIMSKGAYVAMAAGSWVTGLVDSVVQTAFAMQLPFCANNVIKHFVCEILAILKLACADI  
SINVISM TGSNLIVLVIPLLVISISYIFIVATILRIPSTEGKHKAFSTCSAHLTVVIIFYGTIFFMYAKP  
10 ESKASVDSGNEDIIEALISLFYGVMTPLNPLIYSLRNKDVKAAVKNILCRKNFSDGK (SEQ ID  
NO: 385)

ATGGAAAGGACCAACGATTCCACGTCGACAGAATTTTTCTGCTGGTAGGGCTTTCTGCCCACC  
CAAAGCTCCAGACAGTTTTCTTCGTTCTAATTTTGTGGATGTACCTGATGATCCTGCTTGGA  
15 AATGGAGTCCTTATCTCAGTTATCATCTTTGATTCTCACCTGCACACCCCATGTATTTCTT  
CCTCTGTAATCTTTCTTCTCCTCGACGTTTGCTACACAAGTTCTCTGTCCCACTAATTTCTG  
CCAGCTTTCTGGCAGTAAAGAAAAAGGTTTCTTCTCTGGGTGTATGGTGCAAAATGTTTAT  
TTCTTTTGCCATGGGGGCCACGGAGTGCATGATCTTAGGCACGATGGCACTGGACCGCTAT  
GTGGCCATCTGCTACCCACTGAGATAACCTGTCATCATGAGCAAGGGTGCCTATGTGGCCA  
20 TGGCAGCTGGGTCTGGGTCACTGGGCTTGTTGGACTCAGTAGTGCAGACAGCTTTTGCAAT  
GCAGTTACCATTCTGTGCTAATAATGTCATTAAACATTTTGTCTGTGAAATTCTGGCTATCT  
TGAAACTGGCCTGTGCTGATATTTCAATCAATGTGATTAGTATGACAGGGTGAATCTGAT  
TGTTCTGGTTATTCCATTGTTAGTAATTTCCATCTCTTACATATTTATTGTTGCCACTATTCT  
GAGGATTCTTCCACTGAAGGAAAACATAAGGCCTTCTCCACCTGCTCAGCCACCTGACA  
25 GTGGTGATTATATTCTATGGAACCATCTTCTTCATGTACGCAAAGCCTGAGTCTAAAGCCT  
CTGTTGATTACAGGTAATGAAGACATCATTGAGGCCCTCATCTCCCTTTTCTATGGAGTGAT  
GACTCCCATGCTTAATCCTCTCATCTATAGTCTGCGAAACAAGGATGTAAAGGCTGCTGTC  
AAAAACATACTGTGTAGGAAAAACTTTTCTGATGGAAAATGA (SEQ ID NO: 386)

30 **AOLFR208 sequences:**

MFPANWTSVKVFFFLGFFHYPKVQVIIFAVCLLMYLITLLGNIFLISITILDSHLHTPMYFLSLNL  
SFLDIWYSSSALSPMLANFVSGRNTISFSGCATQMYLSLAMGSTECVLLPMMAYDRYVAICNP  
LRYPVIMNRRTCQVIAAGSWMTGCLTAMVEMMSVLP LSLCGNSIINHFTCEILAILKLVCVDTS  
LVQLIMLVISVLLL PMPMLLICISYAFILASILRISSVEGRSKAFSTCTAHLMVVVLFYGTALSMH  
35 LKPSAVDSQEIDKFMALVYAGQTPMLNPIIYSLRNKEVKVALKKLLIRNHFNTAFISILK (SEQ  
ID NO: 387)

ATGTTCCCGGCAAATTGGACATCTGTAAAAGTATTTTTCTTCTGCGGATTTTTTCACTACCC  
CAAAGTTCAGGTCATCATATTTGCGGTGTGCTTGCTGATGTACCTGATCACCTTGCTGGGC  
40 AACATTTTTCTGATCTCCATCACCATTCTAGATTCCCACCTGCACACCCCTATGTACCTCTT  
CCTCAGCAATCTCTCCTTTCTGGACATCTGGTACTCCTCTTCTGCCCTCTCTCCAATGCTGG  
CAAACCTTTGTTTCAGGGAGAAACACTATTTCAATTCTCAGGGTGCGCCACTCAGATGTACCT  
CTCCCTTGCCATGGGCTCCACTGAGTGTGTGCTCCTGCCCATGATGGCATATGACCGGTAT  
GTGGCCATCTGCAACCCCTGAGATAACCTGTCATCATGAATAGGAGAACCTGTGTGCAGA  
45 TTGCAGCTGGCTCCTGGATGACAGGCTGTCTCACTGCCATGGTGGAAATGATGTCTGTGCT  
GCCACTGTCTCTGTGGTAATAGCATCATCAATCATTTCACTTGTGAAATTCTGGCCATCT  
TGAAATTGGTTTGTGTGGACACCTCCCTGGTGCAGTTAATCATGCTGGTGATCAGTGTACT  
TCTTCTCCCCATGCCAATGCTACTCATTTGTATCTCTTATGCATTTATCCTCGCCAGTATCC  
TGAGAATCAGCTCAGTGGAAGGTGGAAGTAAAGCCTTTTCAACGTGCACAGCCACCTGA  
50 TGGTGGTAGTTTTGTCTATGGGACGGCTCTCTCCATGCACCTGAAGCCCTCCGCTGTAGA  
TTCACAGGAAATAGACAAATTTATGGCTTTGGTGTATGCCGGACAAACCCCATGTTGAAT  
CCTATCATCTATAGTCTACGGAACAAAGAGGTGAAAAGTGGCCTTGAAAAAATTGCTGATTA  
GAAATCATTTTAATACTGCCTTCATTCCATCCTCAAATAA (SEQ ID NO: 388)

## AOLFR209 sequences:

MDKINQTFVREFILLGLSGYPKLEIIFALILVMYVVLIGNVLIHASILDSRLHMPMYFFLGNLS  
 5 FLDICYTTSSIPSTLVSLISKRNISFSGCAVQMFFGFAMGSTECLLGMMAFDYVAICNPLRY  
 PIIMNKVVYVLLTSVSWLSGGINSTVQTSLAMRWPF CGNNIINHFLCEILAVLKLACSDISVNIV  
 TLAVSNIAFLVPLLVIFFSYMFILYTLRTNSATGRHKAFTCSAHLTVVIIFYGTIFFMYAKPKS  
 QDLLGKDNLQATEGLVSMFYGVVTPMLNPIIYSLRNKDVKAAIKYLLSRKAINQ (SEQ ID NO:  
 389)

10 ATGGACAAGATAAACCAGACATTTGTGAGAGAATTCATTCTTCTGGGACTCTCTGGTTACC  
 CCAAACCTTGAGATCATTTTCTTGTCTGATTCTAGTTATGTACGTAGTGATTCTAATTGGC  
 AATGGTGTTCTGATCATAGCAAGCATCTTGGATTCTCGTCTTCACATGCCCATGTACTTCTT  
 CCTGGGCAACCTCTCTTCTGGGATATCTGCTATACAACCTCCTCCATCCCTCAACACTGG  
 TGAGCTTAATCTCAAAGAAAAGAAACATTTCTTCTCTGGATGTGCAGTGCAGATGTTCTT  
 15 TGGGTTTGCAATGGGGTCAACAGAATGTTTCTCCTTGGCATGATGGCATTGTATGTCGTTAT  
 GTGGCCATCTGTAACCTCTGAGATACCCCATCATCATGAACAAGTGGTGTATGTACTGC  
 TGACTTCTGTATCATGGCTTTCTGGTGAATCAATTCAACTGTGCAACATCACTTGCCAT  
 GCGATGGCCTTTCTGTGGGAACAATATTATTAATCATTCTTATGCGAGATCTTAGCTGTCC  
 TAAATAGCTTGTCTGATATATCTGTCAATATTGTTACCCTAGCAGTGTCAAATATTGCT  
 20 TTCTAGTTCTTCTCTGCTCGTGATTTTTTCTCCTATATGTTTCATCCTCTACACCATCTTG  
 CGAACGAACTCGGCCACAGGAAGACACAAGGCATTTTCTACATGCTCAGCTCACCTGACTG  
 TGGTGATCATATTTATGGTACCATCTTCTTATGTATGCAAAACCTAAGTCCCAGGACCTC  
 CTTGGGAAAAGACAACTTGCAAGCTACAGAGGGGCTTGTTCATGTTTTATGGGGTGTGA  
 CCCCCATGTTAAACCCATAATCTATAGCTTGAGAAATAAAGATGTAAGCTGCTATAAA  
 25 ATATTTGCTGAGCAGGAAAGCTATTAACAGTAA (SEQ ID NO: 390)

## AOLFR210 sequences:

MMGRRNDTNVADFILTGLSDSEEVQMALFMLFLLIYLITMLGNVGMILLIRLDLQLHTPMYFFL  
 30 THLSFIDLSTVTPKTLANLLTSNYISFTGCFQMFCFVFLGTAECYLLSSMAYDRYAAICSP  
 LHYTVIMPKRLCLALITGPYVIGFMDSFVNVVMSRLHFCDTSPIALSCDTDN  
 TEMLIFILAGSTLMVSLITISASYVSILSTILKINSTSGKQKAFSTCVSHLLGVTIFYGTMIFTYLPK  
 RKSYSGLRDQVAPVFYTTIVPMLNPLIYSLRNREVKNALIRVMQRRQDSR (SEQ ID NO: 391)

35 ATGATGGGTAGAAGGAATGACACAAATGTGGCTGACTTCATCCTTACGGGACTGTCAGAC  
 TCTGAAGAGGTCCAGATGGCTCTGTTTATGCTATTTCTCCTCATATACCTAATTACTATGCT  
 GGGGAATGTGGGGATGCTATTGATAATCCGCTGGACCTCCAGCTTCACACTCCCATGTAT  
 TTTTCTTACTACCTGTCAATTATTGACCTCAGTTACTCAACTGTGTCACACCTAAAC  
 CTTAGCGAACTTACTGACTTCCAATATAATTTCTTACGGGCTGCTTGGCCAGATGTTCT  
 GTTTTGTCTTCTTGGGTACTGCTGAATGTTATCTTCTCCTCAATGGCCTATGATCGCTAT  
 40 GCAGCGATCTGCAGTCTCTACACTACACAGTTATTATGCCAAAAGGCTCTGCCTCGCTC  
 TCATCACTGGGCCTTATGTGATTGGCTTTATGGACTCCTTTGTCAATGTGGTTCCATGAGC  
 AGATTGCATTTCTGTGACTCAAACATAATTCATCACTTTTCTGTGACTTCCCCAATTTT  
 AGCTCTGTCTGCACTGACACAGACAACACTGAAATGCTGATATTCATTATCGCTGGTTCC  
 ACCCTGATGGTGTCCCTTATCACAATATCTGCATCCTATGTGTCCATTCTCTACCATCCT  
 45 GAAAATTAATCCACTTCAGGAAAGCAGAAAGCTTCTCTACTTGGCTCTCTCATCTCTTG  
 GGAGTCACCATCTTCTATGGAATATGATTTTACTTAAAGCCAAGAAAGCTTATT  
 CCTTGGGAAGAGATCAAGTGGCTCCTGTGTTTTATACTATTGTGATCCCATGCTGAATCC  
 ACTCATTTATAGTCTTAGAAACAGAGAAGTGAAAAATGCTCTCATTAGAGTCATGCAGAG  
 AAGACAGGACTCCAGGTAG (SEQ ID NO: 392)

50

## AOLFR211 sequences:

MMGRRNNTNVADFILMGLTLSEEIQMALFMLFLLIYLITMLGNVGMILLIRLDLQLHTPMYFFL  
 THLSFIDLSTVTPKTLANLLTSNYISFTGCFQMFFAFLGTAECYLLSSMAHRYAAICSP  
 LHYTVIMSKRLCLALITGPYVIGFIDSFVNVVMSRLHFYDSNVIIHFFCDTSPIALSCDTYNT  
 55 EILFIIVGSTLMVSLFTISASYVFILFTILKINSTSGKQKAFSTCVSHLLGVTIFYSTLIFTYLPKPK  
 SYSGLRDQVASVFYTTIVPVLNPLIYSLRNKEVKNVIRVMQRRQDSR (SEQ ID NO: 393)

ATGATGGGTAGAAGGAATAACACAAATGTGGCTGACTTCATCCTTATGGGACTGACACTTT  
 CTGAAGAGATCCAGATGGCTCTGTTTATGCTATTTCTCCTGATATACCTAATTACTATGCTG  
 GGAATGTGGGGATGATATTGATAATCCGCCTGGACCTCCAGCTTCACACTCCCATGTATT  
 5 TTTTCCTTACTCACCTGTCAATTTATTGACCTCAGTTACTCAACTGTCGTCACACCTAAAACC  
 TTAGCGAACTTACTGACTTCCAACATATTTCCCTTACGGGCTGCTTTGCCAGATGTTCTT  
 TTTTGCCTTCTTGGGTACTGCTGAATGTTACCTTCTCCTCAATGGCCCATGATCGCTATG  
 CAGCGATCTGCAGTCCTCTACACTACACAGTTATTATGTCCAAAAGGCTCTGCCTCGCTCT  
 CATCACTGGGCCTTATGTGATTGGCTTTATAGACTCCTTTGTCAACGTGGTTTCCATGAGCA  
 10 GATTGCATTTCTACGACTCAAACGTAATTCATCACTTTTTCTGTGACACTTCCCCAATTTTA  
 GCTCTGTCCTGCACTGATACATAACAACCCGAAATCCTGATATTCATTATTGTTGGTTCCAC  
 CCTGATGGTGTCCCTTTTCACAATATCTGCATCCTATGTGTTCACTCTCTTTACCATCCTGA  
 AAATTAATTCACCTTCAGGAAAGCAGAAAGCTTTCTCTACTTGCCTCTCTCATCTCTTGGG  
 AGTCACCATCTTTTATAGCACTCTGATTTTACTTATTTAAACCAAGAAAGTCTTATTCCT  
 15 TGGGAAGAGATCAAGTGGCTTCTGTTTTTATACTATTGTGATTCCCGTGCTGAATCCACT  
 CATTTATAGTCTTAGAAACAAAGAGGTGAAAAATGCTGTCATCAGAGTCATGCAGAGAAG  
 ACAGGACTCCAGGTAA (SEQ ID NO: 394)

#### AOLFR212 sequences:

20 MAGNNFTEVTVFILSGFANHPQLVSLFLMFLFIYLFVLGNLGLITLIRMDSQLHTPMYFFLSN  
 LAFIDIFYSSVTVPKALVNFQSNRRSISFVGCFVQMYFFVGLVCCECFLLGSMAYNRYIAICNPL  
 LYSVMSQKVSNNWLGVMPIYVIGFTSSLISVWVISSLAFCDSINHFCDTTALLALSCVDTFGT  
 EMVSFVLGFTLLSSLLIITVTYIIISAILRIQSAAGRQKAFSTCASHLMAVTIFYGSLIFTYLQPD  
 NTSSLTQAQVASVFYTVIPMLNPLIYSLRNKDVKNALLRVIHRKLFP (SEQ ID NO: 395)

25 ATGGCTGGCAACAATTTCACTGAGGTTACCGTCTTCATCCTCTCTGGATTTGCAAATCACC  
 CTGAATTACAAGTCAGTCTTTTCTTGATGTTTCTCTTCATTTATCTATTCACTGTTTTGGGA  
 AACCTGGGACTGATCACGTTAATCAGAATGGATTCTCAGCTTCACACCCCTATGACTTTT  
 30 TCCTGAGCAATTTAGCATTTATTGACATATTTTACTCCTCTACTGTAACACCTAAGGCATTG  
 GTGAATTTCCAATCCAATCGGAGATCCATCTCCTTTGTTGGCTGCTTTGTTCAATGTACTT  
 TTTTGTGGATTGGTGTGTTGTGAGTGTTTCTTCTGGGATCAATGGCCTACAATCGCTACA  
 TAGCAATCTGCAATCCCTTACTGTATTCAAGTAGTCATGTCCCAAAAAGTGTCCTCACTGGCT  
 GGGAGTAATGCCATATGTGATAGGCTTCACAAGCTCGCTGATATCTGTCTGGGTGATAAGC  
 AGTTTGGCGTTCTGTGATTCCAGCATCAATCATTTTTTTGTGACACCACAGCTCTTTTAGC  
 35 ACTCTCCTGTGTAGATACATTCCGCACAGAAATGGTGAGCTTTGTCTTAGCTGGATTCACT  
 CTTCTTAGCTCTCTCCTTATCATCAGTCACACTTATATCATCATCATCTCAGCCATCCTGAG  
 GATCCAGTCAGCAGCAGGCAGGCAGAAGGCCTTCTCCACCTGCGCATCCCACCTCATGGCT  
 GTAACATCTTTTATGGGTCTCTGATTTTACCTATTTGCAACCTGATAACACATCATCGCT  
 GACCCAGGCGCAGGTGGCATCTGTATTCTATACGATTGTCATTCCCATGCTGAATCCACTC  
 40 ATCTACAGTCTGAGGAACAAAGATGTGAAAAATGCTCTTCTGAGAGTCATACATAGAAAA  
 CTTTTTCCATGA (SEQ ID NO: 396)

#### AOLFR213 sequences:

45 MNSLGLKLVSMILSAHVFCYSKFNCFGCTHSIPALGADPPGGMGLGNESSLMDFILLGFSDHPRL  
 EAVLFVFFVLFYLLTLVGNFTIIISYLDPPPLHTPMYFFLSNLSLLDICFTTSLAPQTLVNLQRPKK  
 TITYGGCVAQLYISLALGSTECILLADMALDRYIAVCKPLHYVVMNPRLCQQLASISWLSGLA  
 SSLIHATFTLQLPLCGNHRDLHFICEVPALLKLACVDTTVNELVLFVVSFLFVVPALISISYGF  
 TQAVLRIKSVEARHKAFSTCSSHLTVVIFYGTHYVYVYLPQSDSYAQDQKGFISLFYTMVPTLNP  
 IYTLRNKDMKEALRKLLSGKL (SEQ ID NO: 397)

50 ATGAATAGTTTGGGAAAGTTGGTCTCCATGATCCTCTCAGCTCATGTGTTCTGTTATTCTAA  
 ATTTAATTGTTTGGATGTACCCATTCCATTCCCTGCCTTAGGTGCGGATCCCCCTGGAGGG  
 ATGGGATTGGGCAATGAGAGTTCCTAATGGATTTATCCTTCTAGGCTTCTCAGACCACC  
 CTCGTCTGGAGGCTGTTCTCTTTGTATTTGTCCCTTTTCTTCTACCTCCTGACCTTGTGGGA  
 55 AACTTCACCATAATCATCATCTCATATCTGGATCCCCCTTTCATACCCCAATGTACTTTTT  
 TCTCAGCAACCTCTCTTACTGGACATCTGCTTCACTACTAGCCTTGCTCCTCAGACCTTAG

WO 01/98526

TTAACTTGCAAAGACCAAAGAAGACGATCACTTACGGTGGTTGTGTGGCGCAACTCTATAT  
 TTCTCTGGCACTGGGCTCCACTGAATGTATCCTCTTGGCTGACATGGCCTTGGATCGGTAC  
 ATTGCTGTCTGCAAACCCCTCCACTATGTAGTCATCATGAACCCACGGCTTTGCCAACAGC  
 TGGCATCTATCTCCTGGCTCAGTGGTTTGGCTAGTTCCTAATCCATGCAACTTTTACCTTG  
 5 CAATTGCCTCTCTGTGGCAACCATAGGCTGGACCATTATTTATTGCGAAGTACCAGCTCTTCT  
 CAAGTTGGCTTGTGTGGACACCACTGTCAATGAATTGGTGGCTTTTGTGTGTAGTGTCTGT  
 TTGTTGTCATTCCACCAGCACTCATCTCCATCTCCTATGGCTTCATAACTCAAGCTGTGCTG  
 AGGATCAAATCAGTAGAGGCAAGGCATAAAGCCTTCAGCACCTGCTCCTCCACCTTACAG  
 TGGTGATTATATTCTATGGCACCATAATCTACGTGTACCTGCAACCTAGTGACAGCTATGC  
 10 CCAGGACCAAGGGAAGTTTATCTCCCTCTTCTACACCATGGTGACCCCACTTTAAATCCT  
 ATCATCTATACTTTAAGGAACAAGGATATGAAAGAGGCTCTGAGGAACTTCTCTCGGGA  
 AAATTGTGA (SEQ ID NO: 398)

**AOLFR214 sequences:**

15 MDKSNSSVVSEFVLLGLCSSQKLQLFYCFFSVLVTIVVLGNLLIILTVTSDTSLHSPMYFLLGN  
 LSFVDICQASFATPKMIADFLSAHETISFSGCIAQIFFIHLFTGGEMVLLVSMAYDRYVAICKPLY  
 YVVMISRRRTCTVLMISWAVSLVHTLSQLSFTVNLPCGPNVDSFFCDLPRVTKLACLDSEYIE  
 ILIVVNSGILSLSTFSLVSSYIHLVTWLVKSSAAMAKAFSTLASHIAVVILFFGPCIFYVWPFTIS  
 20 PLDKFLAIFYTVFTPVLPNIHYTLNRDMKAAVRKIVNHYLRPRRISEMSLVVRTSFH (SEQ ID  
 NO: 399)

ATGGATAAGTCCAATTCTCAGTGGTGTCTGAATTTGTAAGTGTGGGACTCTGTAGTTCTC  
 AAAAATCCAGCTTTTCTATTTTGTCTTCTCTGTGTGTATACAGTCATTGTGCTGGGA  
 AATCTTCTCATTATCCTCACAGTGACTTCTGATACCAGCCTGCACTCCCTATGTACTTCT  
 25 CTTGGGAAACCTTTCTTTGTTGACATTTGTGAGGCTTCTTTGCTACCCCTAAAATGATTG  
 CAGATTTTCTGAGTGCACACGAGACCATATCTTTCAGTGGCTGCATAGCCAAATTTCTTT  
 ATTCACCTTTTACTGGAGGGGAGATGGTGTCTACTTGTTCGATGGCCTATGACAGGTATG  
 TAGCCATATGCAAACCTTATACTATGTGGTGCATCATGAGCCGAAGGACATGCACTGTCTT  
 GGTAATGATCTCCTGGGCTGTGAGCTTGGTGCACACATTAAGCCAGTTATCATTACTGTG  
 30 AACCTGCCTTTTGTGGACCTAATGTAGTAGACAGCTTTTTTGTGATCTTCTCGAGTCAC  
 CAAACTTGCCTGCCTGGACTCTTACATCATTGAAATACTAATTGTGGTCAATAGTGGAATT  
 CTTTCCCTAAGCACTTTCTCTCTTGGTCAGCTCCTACATCATTATTCTTGTACAGTTTG  
 GCTCAAGTCTTCAAGTGCATGGCAAAGGCATTTTCTACGCTGGCTTCCCATATTGCAGTA  
 GTAATATTATTCTTTGGACCTTGCATCTTACATCTATGTGTGGCCCTTACCATCTCTCCTT  
 35 GGATAAATTTCTTGCCATATTTTACACTGTTTACCCCGTCTAAACCCCAATTATTATA  
 CACTAAGGAATAGGATATGAAGGCTGCCGTAAGGAAAATTGTGAACCATACCTGAGGC  
 CAAGGAGAATTTCTGAAATGTCAGTAGTAGTGAAGTCTCCTTTCATTAA (SEQ ID NO:  
 400)

**AOLFR215 sequences:**

40 MAHTNESMVSEFVLLGLSNSWGLQLFFFAIFSIVYVTSVLGNVLIIVISFDSHLNSPMYFLLSNL  
 SFIDICQSNFATPKMLVDFIERKTISFEGCMAQIFVLHSFVGSEMMLLVAMAYDRFIAICKPLH  
 YSTIMNRRLCVIFVSISWAVGVLSVSHLAFTVDLPFCGPNEVDSFFCDLPLVIELACMDTYEM  
 EIMTLTNSGLISLSCFLALIISYTHLIGVRCRSSGSSKALSTLTAHITVVILFFGPCIFYWPF SRL  
 45 PVDKFLSVFYTVCTPLLNPYSLRNEDVKAAMWKLNRHHVNSWKN (SEQ ID NO: 401)

ATGGCTCACACAAATGAATCGATGGTGTCTGAGTTTGTACTTTTGGGACTCTCTAATTCCT  
 GGGGACTCAACTTTTCTTTTCGCCATCTTCTCTATAGTCTATGTGACATCAGTGCTAGGC  
 AATGTCTTAATTATTGTCAATTATTCTTTGACTCCCATTTGAACTCTCCTATGTACTTCTTG  
 50 CTCAGTAATCTTTCTTTCAATTGATATCTGTGAGTCTAACTTTGCCACCCCAAGATGCTTGT  
 AGACTTTTTATTGAGCGCAAGACTATCTCCTTTGAGGGTTGCATGGCCAGATATTCGTT  
 CTTACAGTTTGTGGGAGTGAGATGATGTTGCTTGTAGCTATGGCATATGACAGATTTA  
 TAGCCATATGTAAGCCTCTGCACTACAGTACAATTATGAACCGGAGGCTCTGTGTAATTTT  
 TGTGTCTATTTCTGGGCGGTGGCGTTCTTCAATTCTGTGAGCCACTTGGCTTTTACAGTGG  
 55 ACCTGCCATTCTGTGGTCCCAATGAGGTGGATAGCTTCTTTGTGACCTTCCCTTGGTGATA  
 GAGCTGGCTTGCATGGATACATATGAAATGGAATTATGACCCTAACGAACAGTGGCCTG

ATATCATTGAGCTGTTTCCTGGCTTTAATTATTTCTACACCATCATTTTGATCGGTGTCCG  
 ATGCAGGTCCTCCAGTGGGTCATCTAAGGCTCTTTCTACATTAAGTGGCCACATCACAGTG  
 GTCATTCTTTTCTTCGGGCCTTGCAATTTATTTCTATATATGGCCTTTTAGCAGACTTCCTGT  
 GGACAAATTTCTTTCTGTGTTCTACACTGTTTGTACTCCCTTGTTGAACCCCATCATCTACT  
 5 CTTTGAGGAATGAAGATGTTAAAGCAGCCATGTGGAAGCTGAGAAACCATCATGTGAAC  
 CCTGGAAAACTAG (SEQ ID NO: 402)

**AOLFR216 sequences:**

MDVGNKSTMSEFVLLGLSNSWELQMFFFMVFSLLYVATMVGNSLIVITVIVDPHLHSPMYFLL  
 10 TNLSIIDMSLASFATPKMITDYLTGHKTISFDGCLTQIFFLHLFTGTEILLMAMSFDRYIAICKPL  
 HYASVISQPVCVALVVASWIMGVMHMSQVIFALTLFPCGPYEVDSEFFCDLPVVFQLACVDY  
 VLGLFMISTSGIHALSCFIVLFNSYVIVLVTVKHSSRGSSKALSTCTAHFIVVFLFFGPCIFIYMW  
 PLSSFLTDKILSVFYTIFTPTLNPIYTLRNQEVKIAMRKLKNRFLNFKAMPS (SEQ ID NO: 403)

15 ATGGATGTGGGCAATAAGTCTACCATGTCTGAATTTGTTTTGCTGGGGCTCTCTAATTCCT  
 GGGAACACAGATGTTTTCTTTATGGTGTTTTATTGCTTTATGTGGCAACAATGGTGGG  
 TAACAGCCTCATAGTCATCACAGTTATAGTGGACCCTCACCTACACTCTCCTATGTATTTCC  
 TGCTTACCAATCTTTCAATCATTGATATGTCTCTTGCTTCTTTTCGCCACCCCAAAGATGATT  
 ACAGATTACCTAACAGGTCACAAAACCATCTCTTTTGATGGCTGCCTTACCCAGATATTCT  
 20 TTCTCCACCTTTTCACTGGAAGTGAAGTCATCTTACTCATGGCCATGTCCTTTGATAGGTAT  
 ATTGCAATATGCAAGCCCCTGCACTATGCTTCTGTCAATTAGTCCCCAGGTGTGTGTTGCTCT  
 CGTGGTGGCTTCCTGGATTATGGGAGTTATGCATTCAATGAGTCAGGTCATATTTGCCCTC  
 ACGTTACCATTCGTGGTCCCTATGAGGTAGACAGCTTTTTCTGTGACCTTCCTGTGGTGT  
 CCAGTTGGCTTGTGTGGATACTTATGTTCTGGGCCTCTTTATGATCTCAACAAGTGGCATA  
 25 ATTGCGTTGCTCTGTTTTATTGTTTTATTTAATTCATATGTTATTGCTGGTTACTGTGAA  
 GCATCATTCTCCAGAGGATCATCTAAGGCCCTTTCTACTTGTACAGCTCATTTTATTGTTG  
 TCTTCTTGTCTTTTGGGCCATGCATCTTCTCATCTACATGTGGCCACTAAGCAGCTTTCTACA  
 GACAAGATTCTGTCTGTGTTTTATACCATCTTTACTCCCACTCTGAACCCAAATAATCTATAC  
 TTTGAGGAATCAAGAAGTAAAGATAGCCATGAGGAACTGAAAAATAGGTTTCTAAATTT  
 30 TAATAAGGCAATGCCTTCATAG (SEQ ID NO: 404)

**AOLFR217 sequences:**

MLESFQKSEQMAWSNQSAVTEFILRGLSSSLELQIFYFLFFSIVYAATVLGNLLIVVTIASEPHLH  
 SPTYFLLGNLSFIDMSLASFATPKMIADFLREHKAISFEGCMTQMFFLHLLGGAIEVLLISMSFD  
 35 RYVAICKPLHYLTIMSRRMCVGLVILSWIVGIFHALSQLAFTVNLFPFCGPNEVDSEFFCDLPV  
 LACVDYIILGVFMISTSGMIALVCFILLVISYTHILVTVRQRSSGGSSKALSTCSAHFTVTVLFFGP  
 CTFIYVWPFTNFPIDKVLVSVFYTIYTPLLNPVIYTVRNKDVKYSMRKLSSHIFKSRKTDHTP  
 (SEQ ID NO: 405)

40 ATGCTAGAGTCCTTCCAGAAATCAGAGCAAATGGCCTGGAGCAATCAGTCTGCGGTAACC  
 GAATTCATACTACGGGGTCTGTCCAGTTCTTTAGAAGTCCAGATTTTCTACTTCTGTTTTT  
 CTCCATAGTCTATGCAGCCACTGTGCTGGGGAACCTTCTTATTGTGGTCACCATTCATCA  
 GAGCCACACCTTCATTCCCCTACGTACTTTCTGCTGGGCAATCTCTCCTTCATTGACATGTC  
 CCTGGCCTCATTTGCCACCCCAAAATGATTGCAGACTTCCTTAGAGAACACAAAGCCATC  
 45 TCTTTTGAAGGCTGCATGACCCAGATGTTCTTCTACATCTCTTAGGGGGTGTGAGATTG  
 TACTGCTGATCTCCATGTCCTTTGATAGGTACGTGGCTATCTGTAAGCCTCTACATTACCTA  
 ACAATCATGAGCCGAAGAATGTGTGTTGGGCTTGTGATACTTCTGATTGTGCGGCATCT  
 TCCATGCTCTGAGTCAGTTAGCATTTACAGTGAATCTGCCCTTCTGTGGACCCAATGAAGT  
 AGACAGTTTCTTTTGTGACCTCCCTTTGGTGATTAACTTGCTTGTGTGACACATATATTC  
 50 TGGGGGTGTTTCATGATCTCAACAGTGGCATGATTGCCCTGGTGTGCTTCATCCTCTTGGT  
 GATCTCTTACACTATCATCCTGGTCACCGTTCGGCAGCGTTCCTCTGGTGGATCCTCCAAA  
 GCCCTCTCCACGTGCAGTGCCCACTTTACTGTTGTGACCCTTTTCTTTGGCCCATGCACTTT  
 CATTTATGTGTGGCCTTTCACAAATTTCCCAATAGACAAAGTACTCTCAGTATTTATACCA  
 TATACTCCCTCTTGAATCCAGTGATCTATACCGTTAGGAATAAAGATGTCAAGTATTC  
 55 CATGAGGAACTAAGCAGCCATATCTTTAAATCTAGGAAGACTGATCATACTCCTTAA  
 (SEQ ID NO: 406)

## AOLFR218 sequences:

5 METANYTKVTEFVLTGLSQTREVQLVLFVIFLSFYLFILPGNIICTIRLDPHLTSPMYFLLANLA  
 LLDIYSSITAPKMLIDFFVERKIIISFGGCIQFLHFGVASEMFLIVMAYDRYAAICRPLHYA  
 TIMNRRLCCILVALSWMGGFIHSIIQVALIVRLPFCGPNELDSYFCDITQVVRACANTFPEELVM  
 ICSSGLISVVCFIALLMSYAFLLALLKKHSGSDENTNRAMSTCYSHITIVVLMFGPSIYIYARFPD  
 SFSLDKVVSVFHTVIFPLLNPIIYTLRNKEVKAAMRKVVTKYILCEEK (SEQ ID NO: 407)

10 ATGGAAACTGCAAATTACACCAAGGTGACAGAATTTGTTCTCACTGGCCTATCCCAGACTC  
 GGGAGGTCCAAGTCTATTTGTTATATTTCTATCCTTCTATTTGTTTCATCCTACCAGGA  
 AATATCCTTATCATTGACCATCAGGCTAGACCCTCATCTGACTTCTCCTATGTATTTCTT  
 GTTGCTAATCTGGCCCTCCTTGATATTTGGTACTCTTCCATTACAGCCCCTAAAATGCTCA  
 TAGACTTCTTTGTGGAGAGGAAGATAATTTCTTTGGTGGATGCATTGCACAGCTCTTCTT  
 CTTACACTTTGTTGGGGCTTCGGAGATGTTCTTGCTCATAGTGATGGCCTATGACCGCTAT  
 15 GCTGCTATCTGCCGACCCCTCCACTATGCTACCATCATGAATCGACGTCTCTGCTGTATCCT  
 GGTGGCTCTCTCCTGGATGGGGGGCTTCATTCTTCTATAATACAGGTGGCTCTCATTGTT  
 CGACTTCTTTCTGTGGGCCCAATGAGTTAGACAGTTACTTCTGTGACATCACACAGGTTG  
 TCCGGATTGCCTGTGCCAACACCTTCCCAGAGGAGTTAGTGATGATCTGTAGTAGTGGTCT  
 GATCTCTGTGGTGTGTTTCATTGCTCTGTTAATGTCCTATGCCTTCTTCTGGCCTTGCTCA  
 20 AGAAACATTCAGGCTCAGATGAGAATACCAACAGGGCCATGTCCACCTGCTATTCCCACAT  
 TACCATTGTGGTGCTAATGTTTGGGCCATCCATCTACATTTATGCTCGCCCAATTTGACTCAT  
 TTTCCCTAGATAAAGTGGTGTCTGTGTTTCTACTGTAATATTCCCTTTACTTAATCCCAT  
 ATTTACACATTGAGAAACAAGGAAGTAAAGGCAGCCATGAGGAAGGTGGTCACCAAATAT  
 ATTTTGTGTGAAGAGAAGTGA (SEQ ID NO: 408).

25

## AOLFR219 sequences:

30 MLTSLTDLCSPIQVAEIKSLPKSMNETNHSRVTEFVLLGLSSSRELQPFLLTFSLLYLAILLGNF  
 LIILTVTSDSRLHTPMYFLLANLSFIDVCVASFATPKMIADFLVERKTISFDACLAQIFFVHLFTGS  
 EMVLLVSMAYDRYVAICKPLHYMTVMSRRVCVVLVLISWVFGFIHTTSQLAFTVNLFPFCGN  
 KVDSEFCDLPLVTKLACIDTYVVSLLIVADSGFLSLSSFLLVVSYTVILVTVNRSSASMAKAR  
 STLTAHITVVTLFFGPCIFIYVWPFSSYSVDKVLAVFYTIFTLILNPVIYTLRNKEVKAAMSKLKS  
 RYLKPSQVSVVIRNVLFLETK (SEQ ID NO: 409).

35 ATGCTCACTTCATTAAGTATCTCTGTTTCTCTCCTATTCAGGTAGCTGAAATTAAGTCCCT  
 TCCAAAATCGATGAATGAGACAAATCATTCTCGGGTGACAGAATTTGTGTTGCTGGGACTG  
 TCTAGTTCAAGGGAGCTCCAACCTTTCTTGTCTTACATTTTCACTACTTTATCTAGCAAT  
 TCTGTTGGGCAACTTTCTCATCATCCTCACTGTGACCTCAGATTTCCCGCCTTCACACCCCCA  
 TGTACTTTCTGCTTGCAAACCTGTCAATTTATAGACGTATGTGTTGCCTCTTTGCTACCCCT  
 AAAATGATTGCAGACTTTCTGGTTGAGCGCAAGACTATTTCTTTTGATGCCTGCCTGGCCC  
 40 AGATTTTCTTTGTTTCATCTCTTCACTGGCAGTGAAATGGTGCTCCTAGTTTCCATGGCCTAT  
 GACCGTTATGTTGCTATATGCAAACCTCTCCACTACATGACAGTCATGAGCCGTCGTGTAT  
 GTGTTGTGCTCGTCTCATTTGATGGTTTGTGGGCTTCATCCATACTACCAGCCAGTTGGCA  
 TTCAGTGTTAATCTGCCATTTGTGGTCTAATAAGGTAGACAGTTTCTTGTGACCTTCC  
 TCTAGTGACCAAGTTAGCCTGCATAGACACTTATGTTGTGACGTTACTAATAGTTGCAGAT  
 45 AGTGGCTTTCTTTCTGAGTTCTTTCTCCTCTTGGTTGTCTCCTACACTGTAATACTTGT  
 ACAGTTAGGAATCGCTCCTCTGCAAGCATGGCGAAGGCCCGCTCCACATTGACTGCTACA  
 TCACTGTGGTCACTTTATTCTTTGGACCATGCATTTTCATCTATGTGTGGCCCTTCAGCAGT  
 TACTCAGTTGACAAAGTCCTTGCTGTATTCTACACCATCTTCAGCTTATTTTAAACCCTGT  
 AATCTACACGCTAAGAAACAAAGAAGTGAAGGCAGCTATGTCAAACTGAAGAGTCGGTA  
 50 TCTGAAGCCTAGTCAGGTTTCTGTAGTCATAAGAAATGTTCTTTTCTAGAAACAAAGTAA  
 (SEQ ID NO: 410).

## AOLFR220 sequences:

55 MKQYSVGNQHSNYSLLFPFLCSQMTQLTASGNQTMVTEFLFSMFPAHRRGGLFFIPLLLIYG  
 FILTGNLIMFIVIQVGMALHTPLYFFISVLSFEICYTTTTIPKMLSCLISEQKSISVAGCLLQMYFF  
 HSLGITESCVLTAIDAIDRYAICNPLRYPTIMPKLCLQITVGSFCGFLVLPEIAWISTLPFCGS



NQIHQIFCDFTPVLSLACTDTFLVVIVDAIHAAEIVASFLVIALSYIRIHVILGMHSAEGHHKAFST  
CAAH LAVFLFFGSAVMYLRFSATYSVFWDTAIAVTFVILAPFFNP IISLKNKMDMKEAIGRLF  
HYQKRAGWAGK (SEQ ID NO: 411).

- 5 ATGAAGCAATATTCAGTGGGTAATCAACATTCCAATTATAGGAGTCTCTTGTTTCCITTTCT  
GTGTTACAGATGACACAGTTGACGGCCAGTGGGAATCAGACAATGGTGACTGAGTTCCT  
CTTCTCTATGTTCCCGCATGCGCACAGAGGTGGCCTCTTATTCTTTATCCCTTGCTTCTCA  
TCTACGGATTTATCCTAACTGGAAACCTAATAATGTTTCATTGTCATCCAGGTGGGCATGGC  
CCTGCACACCCCTTTGTATTTCTTTATCAGTGTCTCTCCTTCCTGGAGATCTGCTATACCA  
10 CAACCACCATCCCCAAGATGCTGTCCTGCCTAATCAGTGAGCAGAAGAGCATTTCCTGTC  
TGGCTGCCTCCTGCAGATGTACTTTTCCACTCACTTGGTATCAGAGAAAGCTGTGTCTG  
ACAGCAATGGCCATTGACAGGTACATAGCTATCTGCAATCCACTCCGTTACCCAACCATCA  
TGATTCCCAAACCTTTGTATCCAGCTGACAGTTGGATCCTGCTTTTGTGGCTTCCTCCTGTG  
15 CTTCTGAGATTGCATGGATTTCCACCTTGCTTTCTGTGGCTCCAACCAGATCCACCAGAT  
ATTCTGTGATTTACACCTGTGCTGAGCTTGGCCTGCACAGATACATTCTAGTGGTCATT  
GTGGATGCCATCCATGCAGCGGAAATTGTAGCCTCCTTCCTGGTCATTGCTCTATCCTACA  
TCCGGATTATTATAGTGATTCTGGGAATGCACTCAGCTGAAGGTCATCACAAGGCCTTTTC  
CACCTGTGCTGCTCACCTTGCTGTGTTCTTGCTATTTTTTGGCAGTGTGGCTGTCTGTATT  
20 TGAGATTCTCAGCCACCTACTCAGTGTTTTGGGACACAGCAATTGCTGTCACTTTTGTATC  
CTTGCTCCCTTTTCAACCCCATCATCTATAGCCTGAAAAACAAGGACATGAAAGAGGCTA  
TTGGAAGGCTTTTCCACTATCAGAAGAGGGCTGGTTGGGCTGGGAAATAG (SEQ ID NO:  
412).

**AOLFR221 sequences:**

- 25 MRNLSGGHVEEFVLVGFPTTPPLQLLLFVLFVFFAIYLLTLENALIVFTIWLAPSLHRPMYFFLGH  
LSFLELWYINVITPRLAALFTQDGRVSYVGCMTQLYFFIALACTECVLLAVMAYDRYLAICGP  
LLYPSLMPSSLATRLAAASWGSFFSSMMKLLFISQLSYCGPNIINHFFCDISPLNLTCSDEQA  
ELVDLLALVMILLPLAVVSSYTAIAAILRIPTSRGRHKAFSTCAHLAVVVIYSSITLFTYAR  
PRAMYTFNHNKIISVLYTHVPPFNPAIYCLRNKEVKEAFRKTVMGRCHYPRDVQD (SEQ ID  
30 NO: 413).

- ATGAGAAATTTGAGTGGAGGCCATGTCGAGGAGTTTGTCTTGGTGGGTTTCCCTACCACGC  
CTCCCTCCAGCTGCTCCTCTTTGTCTTTTTTTGCAATTTACCTTCTGACATTGTTGGAGA  
ATGCACTTATTGTCTTCACAATATGGCTTGCTCCAAGCCTTCATCGTCCCATGTACTTTTTT  
35 CTGGCCATCTCTCTTTCTGGAGCTATGGTACATCAATGTCAACCATTCCTCGGCTCTTGGC  
AGCCTTTCTTACCCAGGATGGTAGAGTCTCCTACGTAGGTTGCATGACCCAACTGTACTTC  
TTTATTGCCTTAGCCTGTACTGAATGTGTGCTGTGGCAGTTATGGCCTATGATCGCTACCT  
GGCCATCTGTGGACCCCTCCTTTACCCTAGTCTCATGCTTCCAGTCTGGCCACTCGCCTTG  
TGCTGCTCTTGGGGCAGTGGCTTCTTCACTCCATGATGAAGCTTCTTTTATTTCCCAA  
40 TTGTCTACTGTGGACCCAACATTATCAACCACTTTTCTGTGATATTTCCCACTACTCAA  
CCTCACCTGCTCTGACAAGGAGCAAGCAGAGCTAGTAGACTTCCTTCTGGCCCTGGTGATG  
ATTCTACTCCCTCTATTGGCTGTGGTTTCATCATACACTGCCATCATTGCAGCCATCCTGAG  
GATCCCTACGTCCAGGGGACGCCACAAAGCCTTTTCCACTTGTGCCGCTCATCTGGCAGTG  
GTTGTTATCTACTACTCCTCCACTCTCTTACCTATGCACGGCCCCGGGCCATGTACACCTT  
45 CAACCACAACAAGATTATCTCTGTGCTCTACACTATCATTGTACCATTCTTCAACCCAGCCA  
TCTACTGCCTGAGGAACAAGGAGGTGAAGGAGGCCTTCAGGAAGACAGTGATGGGCAGAT  
GTCATATCCTAGGGATGTTCAAGACTGA (SEQ ID NO: 414).

**AOLFR222 sequences:**

- 50 MGQTNVTSWRDFVFLGFSSSGELQLLLFALFLSLYLVTLSNVFIHAIRLDSHLHTPMYFLSFL  
SFSETCYTLGIIPRMLSGLAGGDQAIYSVGCQAQMFFSASWACTNCFLLAAMGFDRYVAICAPL  
HYASHMNP TLCAQLVITSFLTGYLFGMLTVIFHLSFCSSHEIQHFFCDTPPVLSLACGDTGPS  
ELRIFILSLLVLLVSFFFITISYAYILAAAILRIPSAEGQKKAFTSCASHLTVVIIHYGCASFVYLRPK  
ASYSLERDQLIAMTYTVVTPLLNPVYSLRTRAIQTALRNAFRGRLLGKG (SEQ ID NO: 415).
- 55



WO 01/98526

5 ATGGGGCAGACCAACGTAACCTCCTGGAGGGATTTGTCTTCCTGGGCTTCTCCAGTTCTG  
 GGGAGTTGCAGCTCCTTCTCTTTGCCTTGTTCCTCTCTGTATCTAGTCACTCTGACCAGC  
 AATGTCTTCATTATCATAGCCATCAGGCTGGATAGCCATCTGCACACCCCATGTACCTCTT  
 CCTTTCTCCTATCCTTCTCTGAGACCTGCTACACTTTGGGCATCATCCCTAGAATGCTCT  
 CTGGCCTGGCTGGGGGGGACCAGGCTATCTCCTATGTGGGCTGTGCTGCCAGATGTTCTT  
 10 TTCTGCCTCATGGCCTGTACTAACTGCTTCCTTCTGGCTGCCATGGGCTTTGACAGATATG  
 TGGCCATCTGTGCTCCACTCCACTATGCCAGCCACATGAATCCTACCCTCTGTGCCAGCT  
 GGTCATTACTTCCTTCCTGACTGGATACTCTTTGGACTGGGAATGACACTAGTTATTTTCC  
 ACCTCTCATTCTGCAGCTCCCATGAAATCCAGCACTTTTTTGTGACACGCCACCTGTGCTG  
 15 AGCCTAGCCTGTGGAGATACAGGCCGAGTGAGCTGAGGATCTTATCCTCAGTCTTTTGG  
 TCCTCTTGGTCTCCTTCTTCTCATCACCATCTCCTACGCCTACATCTTGGCAGCAATACTG  
 AGGATCCCCTCTGCTGAGGGGCAGAAGAAGGCCTTCTCCACTTGTGCCTCGCACCTACAG  
 TGGTCATTATTCATTATGGCTGTGCTTCTTCTGTACCTGAGGCCCAAAGCCAGCTACTCT  
 CTTGAGAGAGATCAGCTTATTGCCATGACCTATACTGTAGTGACCCCCCTCTTAATCCCA  
 20 TTGTTTATAGTCTAAGGACTAGGGCTATACAGACAGCTCTGAGGAATGCTTTCAGAGGGAG  
 ATTGCTGGGTAAAGGATGA (SEQ ID NO: 416).

## AOLFR223 sequences:

20 MEAANESSEGISFVLLGLTTSPPGQQRPLFVLLLYVASLLGNGLIVAAIQASPALHAPMYFLLA  
 HLSFADLCFASVTPKMLANLLAHDHSISLAGCLTQMYFFALGVTDSCLLAAMAYDCYVAIR  
 HPLPYATRMSRAMCAALVGMAWLVSHVSLYILLMARLSFCASHQVPHFFCDHQPLRLSC  
 SDTHHIQLLIFTEGAAVVVTPFLLILASYGAIAAAVLQPSASGRLRAVSTCGSHLAVVSLFYGT  
 VIAVYFQATSRREAEGRVATVMYTVVTPMLNPIYSLWNRDVQGAIRALLIGRRISASDS  
 (SEQ ID NO: 417).

25 ATGGAGGCTGCCAATGAGTCTTCAGAGGGAATCTCATTTCGTTTTATTGGGACTGACAACAA  
 GTCCTGGACAGCAGCGGCTCTCTTTGTGCTGTTCTTGCTCTTGTATGTGGCCAGCCTCCTG  
 GGTAATGGACTCATTGTGGCTGCCATCCAGGCCAGTCCAGCCCTTCATGCACCCATGTACT  
 TCCTGCTGGCCACCTGTCTTTGCTGACCTCTGTTTCGCCTCCGTCAGTGTGCCAAGATG  
 30 TTGGCCAACTTGTGGCCCATGACCACTCCATCTCGCTGGCTGGCTGCCTGACCCAAATGT  
 ACTTCTTCTTTGCCCTGGGGGTAAGTATAGCTGTCTTCTGGCGGCCATGGCCTATGACTG  
 CTACGTGGCCATCCGGCACCCCTCCCCTATGCCACGAGGATGTCCCGGGCCATGTGCCGA  
 GCCCTGGTGGGAATGGCATGGCTGGTGTCCACGTCCACTCCCTCCTGTATATCCTGCTCA  
 TGGCTCGCTTGTCTTCTGTGCTTCCACCAAGTGCCCACTTCTTCTGTGACCAAGCCT  
 35 CTCTTAAGGCTCTCGTGCTCTGACACCCACCATCCAGCTGCTCATCTTACCCAGGGCG  
 CCGCAGTGGTGGTCACTCCCTTCTGCTCATCCTCGCCTCCTATGGGGCCATCGCAGCTGC  
 CGTGCTCCAGCTGCCCTCAGCCTCTGGGAGGCTCCGGGCTGTGTCCACCTGTGGCTCCCAC  
 CTGGCTGTGGTGAGCCTCTTCTATGGGACAGTCATTGCAGTCACTTCCAGGCCACATCCC  
 GACGCGAGGCAGAGTGGGGCCGTGTGGCACTGTGATGACACTGTAGTACCCCCATGC  
 40 TGAACCCCATCATCTACAGCCTCTGGAATCGCGATGTACAGGGGCACTCCGAGCCCTCT  
 CATTGGGCGAAGGATCTCAGCTAGTGACTCCTGA (SEQ ID NO: 418).

## AOLFR224 sequences:

45 MGSFNSTFEDGFILVGFSDWPQLEPILFVFIFYSLTFLGNTIIHLSWLDRLHTPMYFFLSHL  
 LDLCFTTSTVPQLINLCGVDRITIRGGCVAQLFIYALGSTECVLLVMAFDRYAAVCRPLHY  
 MAIMHPHLCQTLAIASWGAGFVNSLIQTGLAMAMPLCGHRLNHFFCEMPVFLKLACADTEGT  
 EAKMFVARVIVVAVPAALILGSYVHIAHAVLRVKSTAGRRKAFGTGSHLLVFLFYGSAIYT  
 YLQSIHNYSEREGKFVALFYTIITPILNPLIYTLRNKDVKGALWKVLWRGRDSG (SEQ ID NO:  
 419).

50 ATGGGAAGTTTCAACACCAGTTTTGAAGATGGCTTCATTTGGTGGGATTCTCAGATTGGC  
 CGCAACTGGAGCCCACCTGTTGTCTTTATTTTATTTTCTACTCCCTAACTCTCTTTGGC  
 AACACCATCATCATCGCTCTCTCCTGGCTAGACCTTCGGCTGCACACACCTATGTACTTCTT  
 TCTCTCATCTGTCCCTCCTGGACCTCTGCTTACCACACGACCGTGCCCCAGCTCCTGA  
 55 TCAACCTTTGCGGGGTGGACCGCACCATACCCGTGGAGGGTGTGTGGCTCAGCTCTTCAT  
 CTACCTAGCCCTGGGCTCCACAGAGTGTGTGCTCCTGGTGGTGATGGCCTTTGACCGCTAT

GCTGCTGTCTGTCTGCTCCACTCCACTACATGGCCATCATGCACCCCCATCTCTGCCAGACCCCT  
 GGCTATCGCCTCCTGGGGTGC GG GTTTCGTGA ACTCTCTGATCCAGACAGGTCTCGCAATG  
 GCCATGCCCTCTCTGTGGCCATCGACTGAATCACTTCTTCTGTGAGATGCCTGTATTTCTGAA  
 GTTGGCTTGTGCGGACACAGAAGGAACAGAGGCCAAGATGTTTGTGGCCCCGAGTCATAGT  
 5 CGTGGCTGTTTCCTGCAGCACTTATTCTAGGCTCCTATGTGCACATTGCTCATGCAGTGCTG  
 AGGGTGAAGTCAACGGCTGGGCGCAGAAAAGGCTTTTGGGACTTGTGGGTCCACCTCCTA  
 GTAGTTTTCTTTTTTATGGCTCAGCCATCTACACATATCTCCAATCCATCCACAATTATTC  
 TGAGCGTGAGGGAAAATTTGTTGCCCTTTTTTATACTATAATTACCCCCATTCTCAATCCTC  
 TCATTTATACACTAAGAAACAAGGACGTGAAGGGGGCTCTGTGGAAAGTACTATGGAGGG  
 10 GCAGGGACTCAGGGTAG (SEQ ID NO: 420).

**AOLFR225 sequences:**

MENYNQTSTDFILLGLFPFSIDLFFFILVIFILMALIGNLSMILLIFLDTHLHTPMYFLLSQLSLID  
 LNYISTIVPKMASDFLHGNKSISFTGCGIQSFFFLALGGAEALLASMA YDRYIAICFPLHYLIRM  
 15 SKRVCVLMITGSWIIGSINACAHTVYVLHIPYCRSRAINHFFCDVPAMVTLACMDTWVYEGTV  
 FLSATIFLVFPFIGISCSYGQVLFVYHMKSAEGRKKA YLTCSTHLTVVTFYAPFVYTYLRPRS  
 LRSPTEDKVLAVFYTILTPMLNPIIYSLRNKEVMGALTRVSQRICSVKM (SEQ ID NO: 421).

ATGGAAAATTACAATCAAACATCAACTGATTTTCATCTTATTGGGGCTGTTTCCACCATCAA  
 20 TAATTGACCTTTTCTTCTTCACTTCTCATTTGTTTTCA TTTTCCTGATGGCTCTAATTGGAAACC  
 TGTCATGATTCTTCTCATCTTCTTGGACACCCATCTCCACACACCCATGTATTTCTACTG  
 AGTCAGCTCTCCCTCATTGACCTAAATTACATCTCCACCATTTGTTCTAAGATGGCATCTGA  
 TTTTCTGCATGGAAACAAGTCTATCTCCTTCACTGGGTGTGGGATTGAGAGTTTCTTCTTCT  
 TGGCATTAGGAGGTGCAGAAGCACTACTTTGGCATCTATGGCCTATGATCGTTACATTGC  
 25 TATTGCTTTCTCTCCACTATCTCATCCGCATGAGCAAAAAGAGTGTGTGTGCTGATGATA  
 ACAGGGTCTTGGATCATAGGCTCGATCAATGCTTGTGCTCACACTGTATATGTACTCCATA  
 TTCCTTATTGCCGATCCAGGGCCATCAATCA TTTTCTTCTGTGATGTCCCAGCAATGGTGACT  
 CTGGCCTGCATGGACACCTGGGTCTATGAGGGCACAGTGT TTTTGTAGTGCCACCATCTTTC  
 TCGTGTTTCCCTTCATTGGTATTTTCATGTTCTATGGCCAGGTTCTCTTTGCTGTCTACCAC  
 30 ATGAAATCTGCAGAAGGGAGGAAGAAAGCCTATTTGACCTGCAGCACCCACCTCACTGTA  
 GTAAC TTTCTACTATGCACCTTTTGTCTACACTTATCTACGTCCAAGATCCCTGCGATCTCC  
 AACAGAGGACAAGGTTCTGGCTGTCTTCTACACCATCCTCACCCCAATGCTCAACCCCATC  
 ATCTATAGCCTGAGGAACAAGGAGGTGATGGGGGCCCTGACACGAGTGAGTCAGAGAATC  
 TGCTCTGTGAAAATGTAG (SEQ ID NO: 422).

35

**AOLFR226 sequences:**

MEWRNHSGRVSEFVLLGFPAPAPLQVLLFALLLLAYVLVTENTLIIMAIRNHSTLHKPMYFFL  
 ANMSFLEIWYVTVTIPKMLAGFVGSQD H GQLISFEGCMTQLYFFLGLGCTECVLLAVMAYD  
 RYMAICYPLHYPVIVSGRLCVQMAAGSWAGGFGISMVKVFLISGLSYCGPNINHFFCDVSPLL  
 40 NLCTDMSTAELTDFILAIFILLGPLSVTGASYVAITGAVMHISAAAGRYKAFSTCASHLTVVIIF  
 YAASIFIYARPKALSAFDTNKLVS VLYAVIVPLLNPIIYCLRNQEVKRALCCTLHLYQHQPDP  
 KKASRN (SEQ ID NO: 423).

ATGGAGTGGCGGAACCATAGTGGGAGAGTGAGTGAGTTTGTGTTGCTGGGCTTCCCTGCT  
 45 CCTGCGCCACTACAGGTACTATTGTTTGCCCTTTTGCTGCTGGCCTATGTGTTGGTGCTGAC  
 TGAGAACACACTCATCATTATGGCAATTAGGAACCATCTACCCTCCACAAACCCATGTAC  
 TTTTTTCTAGCTAATATGTCTTTCTGGAGATCTGGTATGTCACTGTCACTATTCCCAAGAT  
 GCTTGCTGGCTTTGTTGGATCCAAACAGGATCATGGACAGCTAATCTCCTTTGAGGGATGC  
 ATGACACAGCTCTACTTTTCTTGGCTTGGGCTGCACTGAGTGTGTCCTTCTCGCTGTTAT  
 50 GGCCTATGATCGCTATATGGCCATCTGCTATCCTCTCCACTACCCAGTCATTGTGAGTGGCC  
 GGCTGTGTGTGAGATGGCTGCTGGCTCTTGGGCTGGAGGTTTTGGCATCTCCATGGTCAA  
 AGTTTTTCTTATTTCTGGCCTCTCTTACTGTGGCCCCAACATCATCAACCACTTTTTCTGTG  
 ATGTCTCTCCATTGCTCAACCTCTCATGCACTGATATGTCCACAGCAGAGCTTACAGATTTT  
 ATCCTGGCCATTTTTATTCTTCTAGGGCCACTCTCTGTCACTGGGGCCTCCTATGTGGCCAT  
 55 TACTGGTGCTGTGATGCACATATCTTCGGCTGCTGGACGCTATAAGGCCTTTTCCACCTGT  
 GCCTCTCATCTCACTGTTGTGATAATCTTCTATGCAGCCAGTATCTTCATCTATGCTCGGCC

AAAGGCACTCTCAGCTTTTGACACCAACAAGTTGGTCTCTGTAAGTGTATGCTGTCATTGTA  
CCATTGCTCAATCCCATCATTTACTGCCTGCGCAATCAAGAGGTCAAGAGAGCCCTATGCT  
GTACTCTGCACCTGTACCAGCACCAGGATCCTGACCCCAAGAAAGCTAGCAGAAATGTATA  
G (SEQ ID NO: 424).

5

**AOLFR227 sequences:**

MEPQNTSTVTNFQLLGFQNLLEWQALLFVIFLLIYCLTIIGNVVIITVVSQGLRLHSPMYMFLQH  
LSFLEVWYTTTVPLLLNLSSWGQAISSACMAQLYFFVFLGATECFLLAFMAYDRYLAICSP  
LRYPLMHRGLCARLVVWSWCTGVSTGFLHSMMSRLDFCGRNQINHHFCDLPLMQLSCSR  
10 YITEVTIFILSIAVLCICFFLTLPYVIVSSILRIPSTSGRRKTFSTCGSHLAVVTLYYGTMISMVY  
CPSPHLLPEINKIISVFYTVVTPLLNPVIYSLRNKDFKEAVRKVMRRKCGILWSTSKRKF  
LY (SEQ ID NO: 425).

15

ATGGAGCCCCAAAATACCTCCACTGTGACTAACTTTCAGCTGTTAGGATTCCAGAACCTTC  
TTGAATGGCAGGCCCTGCTCTTTGTCAATTTCTGCTCATCTACTGCCTGACCATTATAGGG  
AATGTTGTTCATCATACCGTGGTGAGCCAGGCCCTGCGACTGCACTCCCCTATGTACATGT  
TCCTCCAGCATCTCTCCTTTCTGGAGGTCTGGTACACGTCCACCACTGTGCCCTTCTCCTA  
GCCAACCTGCTGTCTGGGGCCAAGCCATCTCCTTCTCTGCCTGCATGGCACAGCTCTACT  
TCTTCGTATTCTCGGCGCCACCGAGTGCTTTCTCCTGGCCTTCATGGCCTATGACCGTTAC  
20 CTGGCCATCTGCAGCCCACTCCGCTACCCCTTTCTCATGCATCGTGGGCTATGTGCCAGGT  
GGTGGTGGTCTCATGGTGACAGGGGTGACACAGGCTTTCTGCATTCCATGATGATTTC  
AGGTTGGACTTCTGTGGGCGCAATCAGATTAACCATTTCTTCTGCGACCTCCCGCCACTCA  
TGCAGCTCTCCTGTTCCAGAGTTTATATACCGAGGTGACCATCTTCATCCTGTCAATTGCC  
GTGCTGTGCATTTGTTTTTCTGACACTGGGGCCCTATGTTTTATTGTGTCTCCATATT  
25 GAGAATCCCTTCCACCTCTGGCCGGAGAAAGACCTTTTCCACATGTGGCTCCACCTGGCT  
GTTGTCACTCTCTACTACGGGACCATGATCTCCATGTATGTGTGTCCCAGTCCCACCTGTT  
GCCTGAAATCAACAAGATCATTTCTGTCTTCTACACTGTGGTACACCACTGCTGAACCA  
GTTATCTACAGCTTGAGGAACAAAGACTTCAAGAAGCTGTTAGAAAGGTCATGAGAAGG  
AAATGTGGTATTCTATGGAGTACAAGTAAAAGGAAGTTCCTTTATTAG (SEQ ID NO: 426).

30

**AOLFR229 sequences:**

MFYVNQIPFQLYHISFVYPTELWSRAIIPCMPTLSFWVCSATPVSPGFFALILLVFVTSIASNVVK  
IILIHDSRLHTPMYFLLSQLSLRDILYISTIVPKMLVDQVMSQRAISFAGCTAQHFLYLTLAGAE  
FFLLGLMSCDRYVAICNPLHYPDLMRSRKICWLIVAAA WLGGSIDGFLTPVTMQFFPCASREIN  
35 HFFCEVPALLKLSCTDTSAYETAMYVCCIMMLLIPFSVISGSYTRILITVYRMSEAEGRRKAVAT  
CSSHMVVVSLFYGAAMYTYVLPHSYHTPEQDKAVSAFYTILTPMLNPLIYSLRNKDVGTALQK  
VVGRCVSSGKVTTT (SEQ ID NO: 427).

40

ATGTTTTATGTAAATCAGATACCTTTCCAACCTTATCATATCTCTTTCGTGTACCCTACAGA  
GCTATGGAGCAGAGCAATTATCCGTGTATGCCGACTTATCCTTCTGGGTTTGTTCAGCA  
ACGCCCCGTTTCCCCTGGCTTCTTGGCCCTATTCTCCTGGTCTTGTGACCTCCATAGCCAG  
CAACGTGGTCAAGATCATTCTCATCCACATAGACTCCCGCCTCCACACCCCATGTACTTC  
CTGCTCAGCCAGCTCTCCCTCAGGGACATCTCTTGTGATATTTCCACCATTTGTGCCAAAATGCT  
GGTCGACCAAGGTGATGAGCCAGAGAGCCATTTCTTGTGATGCACTGCCCAACACTTC  
45 CTCTACTTGACCTTAGCAGGGGCTGAGTCTTCTCCTAGGACTCATGTCTGTGATCGCTA  
CGTAGCCATCTGCAACCCTCTGCACTATCCTGACCTCATGAGCCGCAAGATCTGCTGGTGTG  
ATTGTGGCGGCAGCCTGGCTGGGAGGGTCTATCGATGGTTTCTTGTCTACCCCGTCACCA  
TGCAGTTCCCCTTCTGTGCCTCTCGGGAGATCAACCACTTCTTGTGCGAGGTGCTGCTGTTG  
CTGAAGCTCTCCTGCACGGACACATCAGCCTACGAGACAGCCATGTATGTCTGTGATTATTA  
TGATGCTCCTCATCCCTTTCTGTGATCTCGGGCTTACACAAGAATTCTCATTACTGTT  
50 TATAGGATGAGCGAGGCAGAGGGAGGCGAAAGGCTGTGGCCACCTGCTCCTCACACATG  
GTGGTTGTGACCTCTTCTATGGGGCTGCCATGTACACATACGTGCTGCCTCATTCTTACCA  
CACCCCTGAGCAGGACAAAGCTGTATCTGCCTTCTACACCATCCTCACTCCCATGCTCAAT  
CCACTCATTTACAGCCTTAGGAACAAGGATGTACGGGGGCCCTACAGAAGGTTGTTGGG  
55 AGGTGTGTGCTCAGGAAAGGTAACCACTTTCTAA (SEQ ID NO: 428).

**AOLFR230 sequences:**

MGMEGLLQNSTNFVLTGLITHPAFPGLLFAIVFSIFVVAITANLVMILLIHMDSR LHTPMYFLLS  
 QLSIMDTIYICITVPMKMLQDLLSKDKTISFLGCAVQIFLYLTIGGEFFLLGLMAYDRYVAVCNP  
 LRYPLLMNRRVCLFMVVGSWVGGSLDGFMLTPVTMSFPFCRSREINHFFCEIPAVLKLSCDTDS  
 5 LYETLMYACCVLMLLIPLSVISVSYTHILLTVHRMNSAEGRRKAFATCSSHIMVVSVFYGAIFY  
 TNVLPHSYHTPEKDKVVSIFYTILTPMLNPLIYSLRNKDVAAALRKVLGRCGSSQSIRVATVIR  
 KG (SEQ ID NO: 429).

ATGGGCATGGAGGGTCTTCTCCAGAACTCCACTAACTTCGTCTCACAGGCCTCATCACCC  
 10 ATCTGCCTTCCCCGGGCTTCTCTTTGCAATAGTCTTCTCCATCTTTGTGGTGGCTATAACA  
 GCCAACCTGGTCATGATTCTGCTCATCCACATGGACTCCCGCCTCCACACACCCATGTACTT  
 CTTGCTCAGCCAGCTCTCCATCATGGATACCATCTACATCTGTACTGTCCCCAAGATGC  
 TCCAGGACCTCCTGTCCAAGGACAAGACCATTTCCTTCTGGGTGTGCAGTTCAGATCTT  
 CCTCTACCTGACCCTGATTGGAGGGGAATTCTTCTGCTGGGTCTCATGGCTTACACCGC  
 15 TATGTGGCTGTGTGCAACCCTCTACGGTACCCTCTCCTCATGAACCGCAGGGTTTGCTTATT  
 CATGGTGGTCTGGCTCCTGGGTGGTGGTTCCTTGGATGGGTTCATGCTGACTCCTGTCACT  
 ATGAGTTTCCCCTTCTGTAGATCCCGAGAGATCAATCACTTTTCTGTGAGATCCCAGCCGT  
 GCTGAAGTTGTCTTGACAGACACGTCACTCTATGAGACCCTGATGTATGCCTGCTGCGTG  
 CTGATGCTGCTTATCCCTCTATCTGTCTCTGTCTCTACACGCACATCCTCCTGACTGT  
 20 CCACAGGATGAACTCTGCTGAGGGCCGGCGCAAAGCCTTTGCTACGTGTTCTCCACATT  
 ATGGTGGTGAGCGTTTTCTACGGGGCAGCCTTCTACACCAACGTGCTGCCCCACTCCTACC  
 AACTCCAGAGAAAGATAAAGTGGTGTCTGCCTTCTACACCATCCTCACCCTCATGCTCAA  
 CCCACTCATCTACAGCTTGAGGAATAAAGATGTGGCTGCAGCTCTGAGGAAAGTACTAGG  
 GAGATGTGGTTCCTCCAGAGCATCAGGGTGGCGACTGTGATCAGGAAGGGCTAG (SEQ ID  
 25 NO: 430).

**AOLFR231 sequences:**

MERANHSVVSEFILLGLSKSQNLQILFFLGFSVVFVGIVLGNLLILVTVTFDSLHTPMYFLLSNL  
 SCIDMILASFATPKMIVDFLRERKTISWWGCYSQMFFMHLLGGSEMMLLVAMADRYVAICKP  
 30 LHYMTIMSPRVL TGLLLSSYAVGVHSSQMAFMLTLPFCGPNVIDSFCDLPLVIKLACKDTYI  
 LQLLVIADSGLLSLVCFLLLLVSYGVIFSVRYRAASRSSKAFSTLSAHITVTVLFFAPCVFIYVW  
 PFSRYSDKILSVFYTIFTPLNPIHTLRNQEVAIAIKRLCI (SEQ ID NO: 431).

ATGGAAAGAGCAAACCATTCAGTGGTATCGGAATTTATTTTGTGGGACTTTCCAAATCTC  
 35 AAAATCTTCAGATTTTATTCTTCTTGGGATTCTCTGTGGTCTTCGTGGGGATTGTGTTAGGA  
 AACCTGCTCATCTTGGTGACTGTGACCTTTGATTTCGCTCCTTCACACACCAATGTATTTTCT  
 GCTTAGCAACCTCTCCTGCATTGATATGATCCTGGCTTCTTTTGTACCCCTAAGATGATTG  
 TAGATTTCTCCGAGAACGTAAGACCATCTCATGGTGGGGATGTTATTCCCAGATGTTCTT  
 40 TATGCACCTCCTGGGTGGGAGTGAGATGATGTTGCTTGTAGCCATGGCAATAGACAGGTAT  
 GTTGCCATATGCAAACCCCTCCATTACATGACCATCATGAGCCACGGGTGCTCACTGGGC  
 TACTGTTATCCTCCTATGCAGTTGGATTTGTGCACTCATCTAGTCAAATGGCTTTTATGTTG  
 ACTTTGCCCTTCTGTGGTCCCAATGTTATAGACAGCTTTTCTGTGACCTTCCCCTTGTGAT  
 TAAACTTGCTGCAAGGACACCTACATCCTACAGCTCCTGGTCAATTGCTGACAGTGGGCTC  
 CTGTCACTGGTCTGCTTCTCCTCTTGTCTCCTATGGAGTCATAATATTCTCAGTTAG  
 45 GTACCGTGCTGCTAGTCGATCCTCTAAGGCTTCTCCACTCTCTCAGCTCACATCACAGTTG  
 TGACTCTGTTCTTTGCTCCGTGTGTCTTTATCTACGTCTGGCCCTTCAGCAGATACTCGGTA  
 GATAAAATCTTTCTGTGTTTTACACAATTTTACACCTCTCTTAAATCCTATTATTTATAC  
 ATTAAGAAATCAAGAGGTAAGAGCAGCCATTAAAAAAGACTCTGCATATAA (SEQ ID NO:  
 432).

50

**AOLFR232 sequences:**

MDNITWMASHTGWSDFILMGLFRQSKHPMANITWMANHTGWSDFILLGLFRQSKHPALLCV  
 VIFVVFMLALSGNAVLILLIHCD AHLHTPMYFFISQLSLMDMAYISVTPKMLLDQVMGVNKNIS  
 APEGCMQMFFYVTLAGSEFFLATMAYDRYVAICHPLRYPVLMNHRVCLFLSSGCWFLGSVD  
 55 GFTFTPTITMFPFRGSREIHFFCEVPAVLNLSCSDTSLYEIFMYLCCVLMLLIPVVISSYLLILL

WO 01/98526

TIHGMNSAEGRKKAFATCSSHLTVVILFYGAAIYTYMLPSSYHTPEKDDMMVSVFYTLTPVVPN  
LIYSLRNKDVGMALKMLTVEPAFQKAME (SEQ ID NO: 433).

- 5 ATGGACAACATCACCTGGATGGCCAGCCACACTGGATGGTTCGGATTTTCATCCTGATGGGAC  
TCTTCAGACAATCCAAACATCCAATGGCCAATATCACCTGGATGGCCAACCACACTGGATG  
GTCGGATTTTCATCCTGTTGGGACTCTTCAGACAATCCAAACATCCAGCACTACTTGTGTG  
GTCATTTTTGTGGTTTTCTCTGATGGCGTTGTCTGGAAATGCTGCTGATCCTTCTGATACA  
CTGTGACGCCCACCTCCACACCCCCATGTACTTTTCATCAGTCAATTGTCTCTCATGGACA  
TGGCGTACATTTCTGTCACTGTGCCAAGATGCTCCTGGACCAGGTATGGGTGTGAATAA  
10 GATCTCAGCCCCTGAGTGTGGGATGCAGATGTTCTTCTACGTGACACTAGCAGGTTTCAGAA  
TTTTTCCTTCTAGCCACCATGGCCTATGACCGCTACGTGGCCATCTGCCATCCTCTCCGTTA  
CCCTGTCCTCATGAACCATAGGGTGTGTCTTCTCCTGTCATCAGGCTGCTGGTTCCTGGGCT  
CAGTGGATGGCTTACATTCACTCCCATCACCATGACCTTCCCCTTCCGTGGATCCCGGA  
GATTCATCATTTCTCTGTGAAGTTCCTGCTGTATTGAATCTCTCCTGCTCAGACACCTCAC  
15 TCTATGAGATTTTCATGTACTTGTGCTGTGCTCCTCATGCTCCTCATCCCTGTGGTGATCATT  
TCAAGCTCCTATTTACTCATCCTCCTCACCATCCACGGGATGAACTCAGCAGAGGGCCGGA  
AAAAGGCCTTTGCCACCTGCTCCTCCACCTGACTGTGGTCACTCCTTCTATGGGGCTGCC  
ATCTACACCTACATGCTCCCAGCTCCTACCACCCCCTGAGAAGGACATGATGGTATCTG  
TCTTCTATACCATCCTCACTCCAGTGGTGAACCTTTAATCTATAGTCTTAGGAATAAGGAT  
20 GTCATGGGGGCTCTGAAGAAAATGTAAACAGTGGAACTGCCTTTCAAAAAGCTATGGAG  
TAG (SEQ ID NO: 434).

## AOLFR233 sequences:

- 25 MANITRMANHTGKLDFILMGLFRRSKHPALLSVVIFVFLKALSGNAVILLIHCD AHLHSPMY  
FFISQLSLMDMAYISVTVPKMLLDQVMGVNKVSAPECGMQMFLYLTLAGSEFFLATMAYDR  
YVAICHLRYPVLMNHRVCLFLASGCWFLGSDGFMLTPITMSFPFCRSWEIHFFCEVPAVTI  
LSCSDTSLYETLMLCCVLMMLIPVTIHSYLLILLTVHRMNSAEGRKKAFATCSSHLTVVILFY  
GAAVYTYMLPSSYHTPEKDDMMVSVFYTLTPVLNPLIYSLRNKDVGMALKMLTVRFVL  
(SEQ ID NO: 435).

- 30 ATGGCCAACATCACCAGGATGGCCAACCACACTGGAAAGTTGGATTTTCATCCTCATGGGAC  
TCTTCAGACGATCCAAACATCCAGCTCTACTTAGTGTGGTCACTTTGTGGTTTTCTGAAG  
GCGTTGTCTGGAAATGCTGTCTGATCCTTCTGATACACTGTGACGCCACCTCCACAGCC  
CCATGTACTTTTTTCATCAGTCAATTGTCTCTCATGGACATGGCGTACATTTCTGTCACTGTG  
35 CCAAGATGCTCCTGGACCAGGTCACTGGGTGTGAATAAGGTCTCAGCCCCTGAGTGTGGG  
ATGCAGATGTTCTCTATCTGACACTAGCAGGTTCCGGAATTTTCTTCTAGCCACCATGGC  
CTATGACCGCTACGTGGCCATCTGCCATCCTTCCGTTACCCTGTCCTCATGAACCATAGG  
GTCTGTCTTTTCTGGCATCGGGCTGCTGGTTCCTGGGCTCAGTGGATGGCTTCATGCTCAC  
TCCCATCACCATGAGCTTCCCCTTCTGCAGATCCTGGGAGATTCATCATTCTTCTGTGAAG  
40 TGCTGTGCTCCTCATGCTCCTCATCCCTGTGACGATCATTCAAGCTCCTATTTACTCATCCT  
CCTCACCGTCCACAGGATGAACTCAGCAGAGGGCGGAAAAAGGCCTTTGCCACCTGCTC  
CTCCACCTGACTGTGGTCATCCTTCTATGGGGCTGCCGTCTACACCTACATGCTCCCCA  
GCTCCTACCACACCCCTGAGAAGGACATGATGGTATCTGTCTTCTATACCATCCTCACTCC  
45 GGTGCTGAACCTTTAATCTATAGTCTTAGGAATAAGGATGTCATGGGGGCTCTGAAGAAA  
ATGTTAACTGTGAGATTGCTCCTTTAG (SEQ ID NO: 436).

## AOLFR234 sequences:

- 50 MPNSTTVMEFLMRFSVDVWTLQILHSASFFMLYLVTLMGNILIVTTCDSHLHMPMYFFLRN  
LSILDACYISVTVPTSCVNSLLDSTISKAGCVAQVFLVFFVYVELLFTIMAHDRYVAVCQPL  
HYPVIVNSRICQMTLASLLSGLVYAGMHTGSTFQLPFCRSNVIHQFFCDIPSLKLSCSDTFSNE  
VMIVVSALGVGGGCFIIRSYIHIFSTVLGFPRGADRTKAFSTCIPHILVSVFLSSCSSVYLRPP  
AIPAATQDLILSGFYSIMPLFNPIIYSLRNKQKVAIKKIMKRIFYSENV (SEQ ID NO: 437).
- 55 ATGCCCAATTCAACCACCGTGATGGAATTTCTCCTCATGAGGTTTTCTGATGTGTGGACAC  
TACAGATTTTACATTCTGCATCCTTCTTTATGTTGATTTGGTAACTCTAATGGGAAACATC

CTCATTGTGACCGTCACCACCTGTGACAGCAGCCTTCACATGCCCATGTACTTCTTCCTCAG  
GAATCTGTCTATCTTGGATGCCTGCTACATTTCTGTTACAGTCCCTACCTCATGTGTCAATT  
CCCTACTGGACAGCACCACCATTTCTAAGGCGGGATGTGTAGCTCAGGTCTTCCTCGTGGT  
TTTTTTTGTATATGTGGAGCTTCTGTTTCTCACCATTATGGCTCATGACCGCTATGTGGCTG  
5 TCTGCCAGCCACTTCACTACCCTGTGATCGTGAACCTCTCGAATCTGCATCCAGATGACACT  
GGCCTCCCTACTCAGTGGTCTTGTCTATGCAGGCATGCACACTGGCAGCACATTCCAGCTG  
CCCTTCTGTGCGGTCCAACGTTATTCATCAATTCTTCTGTGACATCCCCTCTCTGCTGAAGCT  
CTCTTGCTCTGACACCTTCAGCAATGAGGTCATGATTGTTGTCTCTGCTCTGGGGGTAGGT  
GGCGGCTGTTTCATCTTTATCATCAGGTCTTACATTCACATCTTTTCGACCGTGCTCGGGTT  
10 TCCAAGAGGAGCAGACAGAAACAAAGGCCTTTTCCACCTGCATCCCTCACATCCTGGTGGTG  
TCAGTCTTCCTCAGTTCATGCTCTTCTGTGTACCTCAGGCCACCTGCGATACCTGCAGCCAC  
CCAGGATCTGATCCTTTCTGGTTTTTATCCATAATGCCTCCCCTCTTTAACCCTATTATTTA  
CAGTCTTAGAAAATAAGCAAATAAAGGTGGCCATCAAGAAAATCATGAAGAGAATTTTTTA  
TTCAGAAAATGTGTAA (SEQ ID NO: 438).

15

**AOLFR235 sequences:**

MDGVNDSSLQGFVLMGISDHPQLEMIFFLAILFSYLLTLLGNSTIILSRLEARLHTPMYFFLSNL  
SSLDLAFATSSVPQMLINLWGPBKTISSYGGCITQLYVFLWLGATECILLVMAFDYVAVCRPL  
RYTAIMNPQLCWLAVIACLGGLGNSVIQSTFTLQLPLCGHRRVEGFLCEVPAMIKLACGDTSL  
20 NQAVLNGVCTFFTAVPLSIIVISYCLIAQAVLKIRSAEGRRKAFNTCLSHLLVFLFYGSASYGY  
LLPAKNSKQDQGKFISLFYSLVTPMVNPLIYTLRNMEVKGALRRLLGKGREVG (SEQ ID NO:  
439).

ATGGACGGGGTGAATGATAGCTCCTTGCAGGGCTTTGTTCTGATGGGCATATCAGACCATC  
25 CCCAGCTGGAGATGATCTTTTTTATAGCCATCCTCTTCTCCTATTTGCTGACCTACTTGGG  
AACTCAACCATCATCTTGCTTTCCCGCTGGAGGCCCGGCTCCATACACCCATGTACTTCTT  
CCTCAGCAACCTCTCCTCCTTGGACCTTGCTTTCGCTACTAGTTCAGTCCCCCAAATGCTGA  
TCAATTTATGGGGACCAGGCAAGACCATCAGCTATGGTGGCTGCATAACCCAGCTCTATGT  
CTTCCTTTGGCTGGGGGCCACCGAGTGCATCCTGCTGGTGGTGTATGGCATTGACCGCTAC  
30 GTGGCAGTGTGCCGGCCCCCTCCGCTACACCGCCATCATGAACCCCCAGCTCTGCTGGCTGC  
TGGCTGTGATTGCCTGCCTGGGTGGCTTGGGCAACTCTGTGATCCAGTCAACATTCACTCT  
GCAGTCCCATTGTGTGGGCACCGGAGGGTGGAGGGATTCTCTGCGAGGTGCCTGCCAT  
GATCAAACCTGGCCTGTGGCGACACAAGTCTCAACCAGGCTGTGCTCAATGGTGTCTGCACC  
TTCTTCACTGCAGTCCCACTAAGCATCATCGTGATCTCCTACTGCCTCATTGCTCAGGCAGT  
35 GCTGAAAATCCGCTCTGCAGAGGGGAGGCGAAAGGCGTTCAATACGTGCCTCTCCCATCT  
GCTGGTGGTGTCTCTCTATGGCTCAGCCAGCTATGGGTATCTGCTTCCGGCCAAGAAC  
AGCAAACAGGACCAGGGCAAGTTCATTTCCCTGTTCTACTCGTTGGTACACCCATGGTGA  
ATCCCCTCATCTACACGCTGCGGAACATGGAAGTGAAGGGCGCACTGAGGAGGTTGCTGG  
GGAAAGGAAGAGAAGTTGGCTGA (SEQ ID NO: 440).

40

**AOLFR236 sequences:**

MTSQERDTAIYSINVSFVAKGMTSRSVCEKMTMTTENPNQTVVSHFFLEGLRYTAKHSSLFFL  
LFLLIYSITVAGNLLILLTVGSDSHLSLPMYHFLGHLISFLDACLSTVTPKVMAGLLTLDGKVIS  
FEGCAVQLYCFHFLASTEFLYTVMAYDRYLAICQPLHYPVAMNRRMCAEMAGITWAIGATH  
45 AAIHTSLTFRLLYCGPCHIAFFCDIPPVLKLACTDTTINELVMLASIGIVAAGCLILIVISYIFIVA  
AVLRIRTAQGRQRAFPCTAQLTGVLVYVPPVCIYLQPRSSEAGAGAPAVFYTIVTPMLNPFYI  
TLRNKEVKHALQRLLCSSFRETAGSPPP (SEQ ID NO: 441).

ATGACATCTCAGGAAAGGGATACAGCTATTTATTCCATTAATGTCAGTTTTGTTGCAAAGG  
50 GGATGACTAGCCGCTCTGTGTGTGAGAAGATGACCATGACAACGGAGAACCCCAACCAGA  
CTGTGGTGAGCCACTTCTTCCTGGAGGGTTTGAGGTACACCGCTAAACATTCTAGCCTCTT  
CTTCCTCCTCTTCCTCCTCATCTACAGCATCACTGTGGCTGGGAATCTCCTCATCCTCCTAA  
CTGTGGGCTCTGACTCTCACCTCAGCTTACCCATGTACCACTTCTGGGGCACCTCTCCTTC  
CTGGATGCCTGTTGTCTACAGTGACAGTGCCCAAGGTCATGGCAGGCCTGCTGACTCTGG  
55 ATGGGAAGGTGATCTCCTTTGAGGGCTGTGCCGTACAGCTTTATTGCTTCCACTTCTGGC  
CAGCACTGAGTGCTTCTGTACACAGTCATGGCCTATGACCGCTATCTGGCTATCTGTCAA



CCCCTGCACTACCCAGTGGCCATGAACAGAAGGATGTGTGCAGAAATGGCTGGAATCACC  
 TGGGCCATAGGTGCCACGCACGCTGCAATCCACACCTCCCTCACCTTCCGCCTGCTCTACT  
 GTGGGCCCTTGCCACATTGCCTACTTCTTCTGCGACATAACCCCTGTCTAAAGCTCGCCTGT  
 ACAGACACCACCATTAATGAGCTAGTCATGCTTGCCAGCATTGGCATCGTGGCTGCAGGCT  
 5 GCCTCATCCTCATCGTTATTTCTACATCTTCATCGTGGCAGCTGTGTTGCGCATCCGCACA  
 GCCCAGGGCCGGCAGCGGGCCTTCTCCCCCTGCACTGCCAGCTCACTGGGGTGCTCCTGT  
 ACTACGTGCCACCTGTCTGTATCTACCTGCAGCCTCGCTCCAGTGAGGCAGGAGCTGGGGC  
 CCCTGCTGTCTTCTACACAATCGTAACTCCAATGCTCAACCCATTCAATTACACTTTGCGGA  
 ACAAGGAGGTGAAGCATGCTCTGCAAAGGCTTTTGTGCAGCAGCTTCCGAGAGTCTACAG  
 10 CAGGCAGCCCACCCCATAG (SEQ ID NO: 442).

#### AOLFR237 sequences:

MDQRNYTRVKEFTFLGITQSRELSQVLFTEFLVYMTTLMGNFLIMVTVTCESHLHTPMYFLL  
 RNLSILDICFSSITAPKVLIDLLSETKTISFSGCVTQMFFHLLGGADVFSLSVMAFDRIYIAISKPL  
 15 HYMTIMSRGRCTGLIVGFLGGGLVHSIAQISLLLLPLVCGPNVLDTFYCDVPQVLKLA CTDTFT  
 LELLMISNNGLVSWFVFFLLISYTVILMMLRSHTGEGRRKAISTCTSHITVTVLHFVPCIYVYA  
 RPFTALPTDTAISVTFTVISPLLNPIIYTLRNQEMKLAMRKLKRRLGQSERILIQ (SEQ ID NO:  
 443).

20 ATGGATCAGAGAAATTACACCAGAGTGAAAGAATTTACCTTCCTGGGAATTACTCAGTCCC  
 GAGAACTGAGCCAGGTCTTATTTACCTTCCTGTTTTTGGTGTACATGACAACTCTAATGGG  
 AAACCTTCCTCATCATGGTTACAGTTACCTGTGAATCTCACCTTCATACGCCCATGTACTTCC  
 TGCTCCGCAACCTGTCTATTCTTGACATCTGCTTTTCTCCATCACAGCTCCTAAGGTCCTG  
 ATAGATCTTCTATCAGAGACAAAAACCATCTCCTTCAGTGGCTGTGTCACTCAAATGTTCT  
 25 TCTTCCACCTTCTGGGGGGAGCAGACGTTTTTCTCTCTGTGATGGCGTTTGACCGCTAT  
 ATAGCCATCTCCAAGCCCCTGCACTATATGACCATCATGAGTAGGGGGCGATGCACAGGCC  
 TCATCGTGGGCTTCCTGGGTGGGGGGCTTGCCACTCCATAGCGCAGATTTCTCTATTGCT  
 CCCACTCCCTGTCTGTGGACCCAATGTTCTTGACACTTTCTACTGCGATGTCCCCCAGGTCC  
 TCAAACCTTGCTGCACTGACACCTTCACTCTGGAGCTCCTGATGATTTCAAATAATGGGTT  
 30 AGTCAGTTGGTTTGTATTCTTCTTCTCCTCATATCTTACACGGTCATCTTGATGATGCTGA  
 GGCTCACACTGGGGAAGGCAGGAGGAAAGCCATCTCCACCTGCACCTCCCACATCACCG  
 TGGTGACCCTGCATTTCTGTGCCCTGCATCTATGTCTATGCCCCGCCCTTCACTGCCCTCCCC  
 ACAGACACTGCCATCTCTGTACCTTCACTGTCTATCTCCCTTTGCTCAATCCTATAATTTA  
 CACGCTGAGGAATCAGGAAATGAAGTTGGCCATGAGGAACTGAAGAGACGGCTAGGAC  
 35 AATCAGAAAGGATTTTAATTCAATAA (SEQ ID NO: 444).

#### AOLFR238 sequences:

MAPENFTRVTEFILTGVSSPELQIPLFLVFLVLYVLTMAGNLGIITLTSVDSRLQTPMYFFLRHL  
 AIINLGNSTVIAPKMLMNFLVKKKTTSFYECATQLGGFLFFIVSEVMMLAVMAYDRYVAICNP  
 40 LLYMVVVSRRCLLLVSLTYLYGFSTAIVVSPCIFSVSYCSSNIINH FYCDIAPLLALSCSDTYPE  
 TIVFISAATNLFFSMITVLVS YFNIVLSILRIRSPEGRKKAFTSCASHMIAVTVFYGTMLFMYLQP  
 QTNHSLD TDKMASVFYTLVIPMLNPLIYSLRNNDVNVALKKF MENPCYSFKSM (SEQ ID NO:  
 445).

45 ATGGCTCCTGAAAATTTACCAGGGTCACTGAGTTTATTCTCACAGGTGTCTCTAGCTGTC  
 CAGAGCTCCAGATTCCCTCTTCCTGGTCTTCCTAGTGCTCTATGTGCTGACCATGGCAGG  
 GAACCTGGGCATCATCACCTCACCAGTGTTGACTCTCGACTTCAAACCCCATGTACTTTT  
 TCCTGAGACATCTAGCTATCATCAATCTTGCAACTCTACTGTCAATTGCCCTAAAATGCTG  
 ATGAACTTTTAGTAAAGAAGAAAACCTCATTCTATGAATGTGCCACCAACTGGGAG  
 50 GGTCTTGTCTTTATTGTATCGGAGGTAATGATGCTGGCTGTGATGGCCTATGACCGCTA  
 TGTGGCCATTTGTAACCTCTGCTCTACATGGTGGTGGTGTCTCGGCGGCTCTGCCTCCTGC  
 TGGTGTCCCTCACGTACCTCTATGGCTTTTCTACAGCTATTGTGGTTTACCTTGTATATTC  
 TCTGTGCTTATTGCTCTTCTAATAATAATCAATCATTTTTTACTGTGATATTGCACCTCTGTT  
 AGCATTATCTTGCTCTGATACTTACATAACCAGAAACAATAGTCTTTATATCTGCAGCAACA  
 55 AATTTGTTTTTTTCCATGATTACAGTTCTAGTATCTTATTTCAATATTGTTTTGTCCATTCTA  
 AGGATACGTTACCAGAAGGAAGGAAAAAAGCCTTTTCCACCTGCGCTTCGCATATGATA



GCAGTCACGGTTTTCTATGGGACAATGCTATTTATGTATTTGCAGCCCCAAACCAACCACT  
 CACTGGATACTGATAAGATGGCTTCTGTGTTTTACACATTGGTGATTCTCTATGCTGAATCC  
 CTTGATCTACAGCCTGAGGAATAATGATGTAAATGTTGCCTTAAAGAAATTCATGGAAAAT  
 CCATGTTACTCCTTTAAATCAATGTAA (SEQ ID NO: 446).

5

**AOLFR239 sequences:**

MDPQNYSLVSEFVLHGLCTSRHLQNFFFIFFGVYVAIMLGNLLILVTVISDPCLHSSPMYFLLG  
 NLAFLDMWLASFATPKMIRDFLSDQKLISFGGCMQAIFLHFTGGAEMVLLVSMAYDRYVAIC  
 KPLHYMTLMSWQTCIRLVLASWVGVFVHSISQVAFVNLPHYCGPNEVDSFFCDLPLVIKLACM  
 10 DTYVLGIHMISDSGLLSLSCFLLLLISYTVILLAIRQRAAGSTSKALSTCSAHIMVVTLFFGPCIFV  
 YVRPFSRFSVDKLLSVFYTIFTPLLNPIYTLRNEEMKAAMKKLQNRRTVFQ (SEQ ID NO: 447).

ATGGACCCACAGAACTATTCCTTGGTGTCAGAAATTTGTGTTGCATGGACTCTGCACTTCAC  
 GACATCTTCAAAATTTTTCTTTATATTTTCTTTGGGGTCTATGTGGCCATTATGCTGGGT  
 15 AACCTTCTCATTTTGGTCACTGTAATTTCTGATCCCTGCCTGCACTCCTCCCCTATGTACTT  
 CCTGCTGGGGAACCTAGCTTTCTGACATGTGGCTGGCCTCATTTGCCACTCCCAAGATG  
 ATCAGGGATTTCTTAGTGATCAAAAACCTCATCTCCTTTGGAGGATGTATGGCTCAAATCT  
 TCTTCTGCACTTTACTGGTGGGGCTGAGATGGTGCTCCTGGTTTCCATGGCCTATGACAG  
 ATATGTGGCCATATGCAAACCTTGCATTACATGACTTTGATGAGTTGGCAGACTTGCATC  
 20 AGGCTGGTGCTGGCTTCATGGGTCGTTGGATTTGTGCACTCCATCAGTCAAGTGGCTTTCA  
 CTGTAAATTTGCCTTACTGTGGCCCCAATGAGGTAGACAGCTTCTTCTGTGACCTCCCTCTG  
 GTGATCAAACCTTGCCTGCATGGACACCTATGTCTTGGGTATAATTATGATCTCAGACAGTG  
 GGTGCTTTCCTTGAGCTGTTTTCTGCTCCTCCTGATCTCCTACACCGTGATCCTCCTCGCT  
 ATCAGACAGCGTGCTGCCGGTAGCACATCCAAAGCACTCTCCACTTGCTCTGCACATATCA  
 25 TGGTAGTGACGCTGTTCTTTGGCCCTTGCATTTTGTATTATGTGCGGCCTTTTCAAGTAGGTTT  
 TCTGTGGACAAGCTGCTGTCTGTGTTTTATACCATTTTACTCCACTCCTGAACCCCATAT  
 CTACACATTGAGAAATGAGGAGATGAAAGCAGCTATGAAGAACTGCAAAACCGACGGGT  
 GACTTTTCAATGA (SEQ ID NO: 448).

30 **AOLFR240 sequences:**

MAGENHTTLPEFLLLGFSDLKALQGPLFWVVLVYLVTLLGNSLIILLTQVSPALHSPMYFFLR  
 QLSVVELFYTTDIVPRTLNLGSPHPQAISFQGCAQMYVFIVLGISECCLLTAMAYDRYVAIC  
 QPLRYSTLLSPRACLAMVGSSWLTGIITATTHASLIFSLPFRSHPIIPHFLCDILPVLRLASAGKHR  
 SEISVMTATIVFIMPFSLIVTSYIRILGAILAMASTQSRKVFSTCSSHLLVSLFFGTASITYIRPQ  
 35 AGSSVTTDRVLSLFYTVITPMLNPIYTLRNDVRRALRHLVKRQRPS (SEQ ID NO: 449).

ATGGCTGGGGAAAACCATACTACACTGCCTGAATTCCTCCTTCTGGGATTCTCTGACCTCA  
 AGGCCCTGCAGGGCCCCCTGTTCTGGGTGGTGCTTCTGGTCTACCTGGTCACCTTGCTGGG  
 40 TAACTCCCTGATCATCCTCCTCACACAGGTGAGCCCTGCCCTGCACTCCCCATGTACTTCT  
 TCCTGCGCCAACTCTCAGTGGTGGAGCTCTTCTACACCACTGACATCGTGCCAGGACCCT  
 GGCCAATCTGGGCTCCCCGCATCCCCAGGCCATCTCTTCCAGGGCTGTGCAGCCCAGATG  
 TACGTCTTCATTGTCCTGGGCATCTCGGAGTGCTGCCTGCTCACGGCCATGGCCTATGACC  
 GATATGTTGCCATCTGCCAGCCCCCTACGCTATTCCACCCTCTTGAGCCACGGGCCTGCTT  
 GGCCATGGTGGGGTCTCCTGGCTCACAGGCATCATCACGGCCACCACCCATGCCTCCCTC  
 45 ATCTTCTCTACCTTTTCGAGCCACCCGATCATCCCGCACTTTCTCTGTGACATCCTGCC  
 AGTACTGAGGCTGGCAAGTGCTGGGAAGCACAGGAGCGAGATCTCCGTGATGACAGCCAC  
 CATAGTCTTCATTATGATCCCCTTCTCTCTGATTGTCACTTCTACATCCGCATCCTGGGTG  
 CCATCCTAGCAATGGCCTCCACCCAGAGCCGCCGAAGGTCTTCTCCACCTGCTCCTCCCA  
 TCTGCTCGTGGTCTCTCTCTTTTGAACAGCCAGCATCACCTACATCCGGCCGCAGGCA  
 50 GGCTCCTCTGTTACCACAGACCGCGTCTCAGTCTCTTCTACACAGTCATCACACCCATGCT  
 CAACCCCATCATCTACACCCTTCGGAACAAGGACGTGAGGAGGGCCCTGCGACACTTGGT  
 GAAGAGGCAGCGCCCCCTCACCTGA (SEQ ID NO: 450).

**AOLFR241 sequences:**

MPQILIFTYLNMFYFFPLQILAENLTMVTEFLLLGFSSLGEIQLALFVVFLFLYLVLSGNVTIIS  
 55 VIHLDKSLHTPMYFFLGILSTSETFYTFVILPKMLNLLSVARTISFNCCALQMFFFLGFAITNCLL

LGVMGYDRYAAICHPLHYPTLMSWQVCGKLAACAIGGFLASLTVVNLVFSLPFCSANKVNH  
YFCDISAVILLACTNTDVNEFVIFICGVLVLVVPFLFICVSYLCILRTILKIPSAEGRRKAFSTCAS  
HLSVVIVHYGCASFIYLRPTANYVSNKDRLVTVTYITVPLNPMVYSLRNKDVQLAIRKVLG  
KKGSLKLYN (SEQ ID NO: 451).

5 ATGCCCCAAATTCTTATATTCACATACCTGAATATGTTTTACTTCTTCCCCCTTTGCAGAT  
CTTGGCAGAAAACCTCACCATGGTCACCGAATTCCTGTTGCTGGGTTTTTCCAGCCTTGGT  
GAAATTCAGCTGGCCCTCTTTGTAGTTTTCTTTTTCTGTATCTAGTCATTCTTAGTGGCAA  
10 TGTACCATATCAGTGTATCCACCTGGATAAAAGCCTCCACACACCAATGTACTTCTTCC  
TTGGCATTCTCTCAACATCTGAGACCTTCTACACCTTTGTCATTCTACCCAAGATGCTCATC  
AATCTACTTTCTGTGGCCAGGACAATCTCCTTCAACTGTTGTGCTCTTCAATGTTCTTCTT  
CCTTGGTTTTTGCATTACCAACTGCCTGCTATTGGGTGTGATGGGTATGATCGCTATGCTG  
CCATTTGTCACCCCTCTGCATTACCCCACTCTTATGAGCTGGCAGGTGTGTGAAAACTGGC  
15 AGCTGCCTGTGCAATTGGTGGCTTCTTGGCCTCTCTTACAGTAGTAAATTTAGTTTTAGCC  
TCCCTTTTTGTAGCGCCAACAAAGTCAATCATTACTTCTGTGACATCTCAGCAGTCATTCTT  
CTGGCTTGTACCAACACAGATGTTAACGAATTTGTGATATTCAATTTGTGGAGTTCTTGTAC  
TTGTGGTTCCCTTTCTGTTTATCTGTGTTTCTTATCTCTGCATTCTGAGGACTATCCTGAAG  
ATCCCTCAGCTGAGGGCAGACGAAAGCGTTTTCCACCTGCGCCTCTCACCTCAGTGTG  
20 TTATTGTTTATTATGGCTGTGCTTCTTCTACCTGAGGCTACAGCAAACTATGTGTCC  
AACAAGACAGGCTGGTGACGGTGACATACAGATTGTCACTCCATTACTAAACCCCATG  
GTTTATAGCCTCAGAAACAAGGATGTCCAATTGCTATCAGAAAAGTGTGGGCAAGAAA  
GGTCTCTAAAACTATATAATTGA (SEQ ID NO: 452).

#### AOLFR242 sequences:

25 MNTTLFHPYSFLLLGIPGLESMHLWVGPFPAVFLTAVLGNITILFVIQTDSSLHHPMFYFLAILS  
SIDPGLSTSTIPKMLGTFWFTLREISFEGCLTQMFFIHLCTGMESAVLVAMAYDCYVAICDPLCY  
TLVLTNKVVSVMALAIPLRPLVFVIFVLFILRLPFCGHQIIPHTYGEHMGRIARLSCASIRVNIY  
LCAISILVFDIIAIVISYVQILCAVFLSSHDARLKAFSTCGSHVCMVMTFYMPAFFSMTHRFGR  
NIPFIIHILLANFYVIPPALNSVIYGVRTKQIRAVLKMFFNK (SEQ ID NO: 453).

30 ATGAATACCACTCTATTTATCCTTACTCTTTCTTCTGGAATTCCTGGGCTGGAAAG  
TATGCATCTCTGGGTGGTTTTCTTTCTTTGCTGTGTTCTGACAGCTGTCTTGGGAATA  
TCACCATCCTTTTTGTGATTGAGACTGACAGTAGTCTCCATCATCCCATGTTCTACTTCTG  
GCCATTCTGTCTATTGACCCGGGCTGTCTACATCCACCATCCCTAAAAATGCTTGGCAG  
35 CTTCTGGTTTACCCTGAGAGAAATCTCCTTTGAAGGATGCCTTACCAGATGTTCTTCTATCC  
ACCTGTGCACTGGCATGGAATCAGCTGTGCTTGTGGCCATGGCCTATGATTGCTATGTGGC  
CATCTGTGACCCTCTTTGCTACACGTTGGTGCTGACAAACAAGGTGGTGTGATGGCA  
CTGGCCATCTTTCTGAGACCTTAGTCTTTGTCATACCTTTGTTCTATTTATCCTAAGGCT  
TCCATTTGTGGACACCAAATTATTCCTCATACTTATGGTGAGCACATGGGCATTGCCCCG  
40 CTGCTTTGTGGCAGCATCAGGTTAATCATCTATGGCTTATGTGCCATCTCTATCCTGGT  
CTTTGACATCATAGCAATTGTCATTTCCTATGTACAGATCCTTTGTGCTGTATTTCTACTCT  
CTTCACATGATGCACGACTCAAGGCATTGACACCTGTGGCTCTCATGTGTGTGTCATGTT  
GACTTTCTATATGCCTGCATTTTCTCATTCATGACCCATAGGTTTGGTCGGAATATACCTC  
ACTTTATCCACATTCTTCTGGCTAATTTCTATGTAGTCATTCCACCTGCTCTCAACTCTGTA  
45 ATTTATGGTGTGAGAACCAACAGATTAGAGCACAAGTGCTGAAAATGTTTTCAATAAAT  
AA (SEQ ID NO: 454).

#### AOLFR243 sequences:

50 MEQVNKTVVREFVVLGFSSLARLQQLFVIFLLLYLFTLGTNAINSTIVLDRALHTPMYFFLAIL  
SCSEICYTFVIVPKMLVDLLSQKKTISFLGCAIQMFSFLFFGSSHSFLLAAMGYDRYMAICNPLR  
YSVLMGHGVCMLMAAACACGFTVSLVTSVLFHLPFHSSNQLHHFFCDISPVKLKASQHSFG  
SQLVIFMLGVFALVPLLLILVSIRIISAILKIPSSVGRYKTFSTCASHLIVTVHYSCASFIYLRPK  
TNYTSSQDTLISVSYITLPLFNPIMYSLRNKEFKSALRRITIGQTFYPLS (SEQ ID NO: 455).

55 ATGGAGCAAGTCAATAAGACTGTGGTGAGAGAGTTCGTCGTCCTCGGCTTCTCATCCCTGG  
CCAGGCTGCAGCAGCTGCTCTTTGTATCTTCTGCTCCTCTACCTGTTCACTCTGGGCACC

AATGCAATCATCATTTCCACCATTGTGCTGGACAGAGCCCTTCATACTCCCATGTACTTCTT  
 CCTTGCCATCCTTTCTTGCTCTGAGATTTGCTATACCTTTGTCATTGTACCCAAGATGCTGG  
 TTGACCTGCTGTCCCAGAAGAAGACCATTTCCTTCCCTGGGCTGTGCCATCCAAATGTTTTCC  
 TTCTCTTCTTTGGCTCCTCTCACTCCTTCCCTGCTGGCAGCCATGGGCTATGATCGCTATAT  
 5 GGCCATCTGTAACCCACTGCGCTACTCAGTGCTCATGGGACATGGGGTGTGTATGGGACTA  
 ATGGCTGCTGCCTGTGCCTGTGGCTTCACTGTCTCCCTGGTCACCACCTCCCTAGTATTTCA  
 TCTGCCCTTCCACTCCTCCAACCAGCTCCATCACTTCTTCTGTGACATCTCCCCTGTCCCTA  
 AACTGGCATCTCAGCACTCCGGCTTCAGTCAGCTGGTCATATTCATGCTTGGTGTATTTGC  
 CTTGGTCAATCCTCTGCTACTTATCCTAGTCTCCTACATCCGCATCATCTCTGCCATTCTAA  
 10 AAATCCCTTCCCTCCGTTGGAAGATAACAAGACCTTCTCCACCTGTGCCTCCCATCTCATTGTG  
 GTAATGTTCACTACAGTTGTGCCTCTTTCATCTACTTAAGGCCCAAGACTAATTACACTTC  
 AAGCCAAGACACCCTAATATCTGTGTACATACCATCCTTACCCCATTTGTTCAATCCAATG  
 ATTTATAGTCTGAGAAATAAGGAATTCAAATCAGCCCTACGAAGAACAATCGGCCAAACT  
 TTCTATCCTCTTAGTTAA (SEQ ID NO: 456).

15

**AOLFR244 sequences:**

MWQEYYFLNVFFPLKVCCLTINSHVILLPWECHYHLIWKILPYIGTTVGSMEEYNTSSTDFTF  
 MGLFNRKETSGLIFAIISIIFFALMANGVMIFLIQTDLRLHTPMYFLLSHLSLIDMMYISTIVPKM  
 LVNYLLDQRTISFVGCTAQHFLYLTIVGAEFFLLGLMAYDRYVAICNPLRYPVLMSSRVCWMI  
 20 IAGSWFGGSLDGFLLTPITMSFPFCNSREINHHFCEAPAVLKLACADTALYETVMYVCCVLMML  
 IPFSVVLASYARILTTVQCMSSVEGRKKAFATCSSHMTVVSIFYGAAMYTYMLPHSYHKPAQ  
 DKVLSVFYITLTPMLNPLIYSLRNKDVGTGALKRALGRFKGPQRVSGGVF (SEQ ID NO: 457).

ATGTGGCAAGAATACTATTTTTTAAATGTTTTCTTCCCACTTTTAAAAGTTTGCTGCCTAAC  
 25 AATTAATTCACATGTTGTTATTTTACTGCCCTGGGAATGCTATCATCTTATTTGGAAGATAT  
 TACCTTATATCGGCACAACGTAGGATCAATGGAAGAGTACAACACATCCTCTACAGACTT  
 CACTTTTCATGGGGCTGTTCAACAGAAAGGAAACCTCAGGTCTTATTTTGGCATCATCTCT  
 ATCATCTTCTTACCAGCACTGATGGCCAATGGGGTTATGATCTTCTGATCCAAACAGATT  
 TGCGCCTTCATACACCCATGTACTTCTCCTCAGCCACCTTTCCTTAATTGACATGATGTAT  
 30 ATTTCCACTATTGTGCCTAAGATGCTGGTTAATTACCTGCTGGATCAAAGGACCATTTCCTT  
 TGTGGGGTGCACAGCTCAACACTTCTCTACCTTACCCTTGTGGGAGCTGAATTCTTCTCTG  
 CTGGGCCTCATGGCCTATGACCGCTATGTGGCCATTTGCAACCCTCTGAGATACCCTGTCC  
 TCATGAGCCGCGGGCTGTGTTGGATGATTATAGCAGGTTCTGCTGTTTGGGGGCTCTTTGGA  
 TGGCTTCCCTCTAACCCCATCACCATGAGCTTTCCCTTCTGCAATTCCCGGGAGATTAAACC  
 35 ACTTCTTCTGTGAGGCACAGCAGTCTGAAGTTGGCATGTGCAGACACAGCCCTTACGA  
 GACAGTGATGTATGTGTGCTGTGTTTTGATGCTGCTGATTCTTCTCTGTAGTCTTGTCT  
 CCTATGCCCCGAATCCTGACTACAGTTCAGTGCATGAGCTCAGTGGAGGGCAGGAAGAAGG  
 CATTGCGCACTTGCTCATCCACATGACTGTGGTGTCTTGTCTACGGGGCTGCCATGTAC  
 ACCTACATGCTGCCACATTCTTACCACAAGCCAGCCAGGACAAAGTCTCTCTGTGTTTT  
 40 ACACCATCTCACACCCATGCTGAACCCCTCATCTACAGCCTTAGAAACAAGGATGTGAC  
 TGGAGCTCTGAAGAGGGCCTTGGGGAGGTTCAAGGGTCTCAAAGGGTGTGAGGAGGTGT  
 CTTTTGA (SEQ ID NO: 458).

**AOLFR245 sequences:**

MDLKNGLSVTEFILLGFFGRWELQIFFVTFSLIYGATVMGNILMVTVTCRSTLHSPYFLLGN  
 45 LSFLDMCLSTATTPKMIDLLTDHKTISVWGCVTQMFFMHFFGGAEMTLLIIMAFDRYVAICKP  
 LHYRTIMSHKLLKGFAILSWIIGFLHSISQIVLTMNLPFCGHNVINNIFCDLPLVIKLACIETYTLE  
 LFVIADSGLLSFTCFILLVSVYIVILVSVPPKSSHGLSKALSTLSAHIIIVTLFFGPCIFIYVWPFSSL  
 ASNKTALVFYTVITPLNPSIYTLRNKKMQEAIKRLRFQYVSSAQNF (SEQ ID NO: 459).

50

ATGGATCTTAAAAATGGATCTCTAGTGACCGAGTTTATTTTACTAGGATTTTTTGGACGAT  
 GGGAACCTCAAATTTTCTTCTTTGTGACATTTTCCCTGATCTACGGTGCTACTGTGATGGGA  
 AACATTCTCATTATGGTCACAGTGACATGTAGGTCAACCCCTCATTCTCCCTTGTACTTTCT  
 CCTTGGAAATCTCTCTTTTTTGGACATGTGTCTCTCCACTGCCACAACACCCAAGATGATCA  
 55 TAGATTTGCTCACTGACCACAAGACCATCTCTGTGTGGGGCTGCGTGACCCAGATGTTCTT  
 CATGCACTTCTTGGGGGTGCTGAGATGACTCTTCTGATAATCATGGCCTTTGACAGGTAT

GTAGCCATATGTAAACCCCTGCACTATAGGACAATCATGAGCCACAAGCTGCTAAAGGGG  
 TTTGCGATACTTTTCATGGATAATTGGTTTTTACACTCCATAAGCCAGATAGTTTAAACAAT  
 GAACTTGCCCTTCTGTGGCCACAATGTCATAAACACATAATTTGTGATCTTCCCTTGTGA  
 TCAAGCTTGCTTGCAATTGAAACATACACCCTGGAATTATTTGTCATTGCTGACAGCGGGCT  
 5 GCTCTCTTTCACCTGTTTCATCCTCTTGCTTGTCTTACATTGTCATCCTGGTCAGTGTACC  
 AAAAAAATCATCACATGGGCTCTCCAAGGCGCTGTCCACATTGTCTGCCACATCATTGTG  
 GTCACCTGTCTTTGGACCTGTATTTTATCTATGTTTGGCCATTAGTAGTTTGGCAAG  
 CAATAAACTCTTGCCGTATTTTATACAGTTATCACACCCTTACTGAATCCGAGTATTTATA  
 CCCTGAGAAATAAGAAAATGCAAGAGGCCATAAGAAAATTACGGTTCCAATATGTTAGTT  
 10 CTGCACAGAATTTCTAG (SEQ ID NO: 460).

# AOLFR246 sequences:

MSPENQSSVSEFLLGLPIRPEQQA VFFTLFLGMYLTTVLGNLLIMLLIQLDLHPTMYFFLSH  
 LALTDISFSSVTVPKMLMDMRKYKSILYEECISQMYFFIFTDLDSFLITSMA YDRYVAICHPL  
 15 HYTVIMREELCVFLVAVSWILSCASSLSHTLLRLSFCAANTIPHVFCDLAALLKLS CSDIFLNE  
 LVMFTVG VVVITL PFMCIL VSYGYIGATILRVPSTKGH KALSTCGSHLSVVS LYYGSIFGQYLF  
 PTVSSSIDKDVIVALMYTVVTPMLNPFYSLRNRDMKEALGKLF SRATFFSW (SEQ ID NO:  
 461).

20 ATGAGCCCTGAGAACCAGAGCAGCGTGTCCGAGTTCCTCCTTCTGGGCCTCCCCATCCGGC  
 CAGAGCAGCAGGCTGTGTTCTTCAACCCTGTTCCCTGGGCATGTACCTGACCACGGTGCTGGG  
 GAACCTGCTCATCATGCTGCTCATCCAGCTGGACTCTCACCTTCACACCCCATGTACTTCT  
 TCCTCAGCCACTTGGCTCTCACTGACATCTCCTTTTCATCTGTCACTGTCCCTAAGATGCTG  
 ATGGACATGCGGACTAAGTACAAATCGATCCTCTATGAGGAATGCATTCTCAGATGTATT  
 25 TTTTATAATTTTACTGACCTGGACAGCTTCCTTATTACATCAATGGCATATGACCGATAT  
 GTTGCCATATGTCACCCCTCTCCACTACACTGTATCATGAGGGAAGAGCTCTGTGCTTCTT  
 AGTGGCTGTATCTTGGATTCTGTCTTGTGCCAGCTCCCTCTCTCACACCCTTCTCCTGACCC  
 GGCTGTCTTTCTGTGCTGCGAACACCATCCCCATGTCTTCTGTGACCTTGTGCCCCTGCTC  
 AAGCTGTCTGCTCAGATATCTTCTCAATGAGCTGGTCATGTTACAGTAGGGGTGGTGG  
 30 TCATTACCCTGCCATTCATGTGTATCCTGGTATCATATGGCTACATTGGGGCCACCATCCTG  
 AGGGTCCCTTCAACCAAAGGGATCCACAAAGCATTGTCCACATGTGGCTCCCATCTCTCTG  
 TGGTGTCTCTTATTATGGGTCAATATTTGGCCAGTACCTTTTCCCGACTGTAAGCAGTTCT  
 ATTGACAAGGATGTCATTGTGGCTCTCATGTACACGGTGGTCACACCCATGTTGAACCCCT  
 TTATCTACAGCCTTAGGAACAGGGACATGAAAGARGCCCTTGGGAACTCTTCAGTAGAG  
 35 CAACATTTTCTCCTTGGTGACATCTGACTTTTTAAAAAATTAG (SEQ ID NO: 462).

# AOLFR247 sequences:

MGQHNLTVLTEFILMELTRRPELQIPFGVFLVIYLTITVVGNLTMILTKLDSHLHPTMYFSIRHL  
 ASVDLGNSTVICPKVLANFVDRNTISYYACAAQLAFFLMFIIEFFILSAMAYDRYVAICNPLL  
 40 YYVIMSQRLCHVLVGIQYLYSTFQALMFTIKIFLTFCGSNVISHFYCDDVPLLPMLCSNAQEIE  
 LLSILFSVFNLISSFLIVLSYMLILLAICQMHS AGRKKAFFSTCGSHLTVVVVFYGSLLFM YMQ  
 PNSTHFFD TDKMASVFYTLVIPMLNPLIYSLRNEEVKN AFYKLFEN (SEQ ID NO: 463).

45 ATGGGCCAACACAATCTAACAGTGCTAACTGAATTCATTCTGATGGAACCTACAAGGCGGC  
 CTGAGCTGCAGATTTCCCTTTTTGGAGTCTTCTCGTCATCTACCTAATCACAGTGGTGGGC  
 AACCTAACTATGATCATTTTGACCAAAGTGGACTCCCACTACATACACCTATGTACTTTT  
 TATCAGACATTTGGCTTCTGTTGATCTTGGTAATTCTACTGTCAATTTGTCCCAAGGTGCTGG  
 CAAATTTTGTGTGGATCGAAATACTATTTCTTATTATGCATGTGCTGCACAGCTGGCATTG  
 50 TTCCTTATGTTTATTATCAGTGAATTTTTCATCCTGTGAGCCATGGCCTATGACCGCTATGT  
 GGCCATTTGTAACCCCTCTGCTCTAATTATGTTAATTATGTCTCAGCGACTGTGTCATGTACTGG  
 TTGACCTTCTGTGGCTCTAATGTCATCAGTCATTTTACTGTGATGATGTTCTTTGCTACC  
 TATGCTTTGCTCAAATGCACAGGAAATAGAATTGTTGAGCATACTATTTTCTGTATTTAATT  
 TGATCTCCTCCTTCTGATAGTCTTAGTGTCTACATGTGATTTTGTAGCTATATGTCAA  
 55 ATGCATTCTGCAGAGGGCAGGAAAAAGGCTTTCTCCACATGTGGTTCCTTTGACAGTGG  
 TGGTGTGTTCTATGGGTCTCTACTCTTCATGTACATGCAGCCCAATCCCACTCACTTCTT

GATACTGATAAAATGGCTTCTGTGTTTTACACTTTAGTAATCCCCATGCTTAACCCCTTTGAT  
TTACAGCTTAAGAAACGAAGAGGTGAAAAATGCCTTCTATAAGCTCTTTGAGAAATTGA  
(SEQ ID NO: 464).

5 **AOLFR248 sequences:**

MPCMPALPTGGLLPHQHTMMEIANVSSPEVFVLLGFSTRPSLETVLFIVVLSFYMVLSILNGNI  
IILVSHTDVHLHTPMYFFLANLPFLDMSFTTSIVPQLLANLWGPQKTISYGGCVVQFYISHWL  
ATECVLLATMSYDRYAAICRPLHYTVIMHPQLCLGLALASWLGLTSMVGSTLTMLPLCG  
NNCIDHFFCEMPLIMQLACVDTSLNEMEMYLASFVFFVPLPLGLILVSYGHIARAVLKIRSAEGR  
10 RKAFTNCSSHVAVVSLFYGSIIFMYLQPAKSTSHEQGKFIALFYTVVTPALNPLIYTLRNTEVKS  
ALRHMVLENC CGSAGKLAQI (SEQ ID NO: 465).

ATGCCCTGTATGCCCTGTGCTCTTCCCACAGGTGGCCTTTTGCCCCACCCCCAGCATACAAT  
GATGGAAATAGCCAATGTGAGTTCTCCAGAAGTCTTTGTCCTCCTGGGCTTCTCCACACGA  
15 CCCTCACTAGAACTGTCCTCTTCATAGTTGTCTTGAGTTTTTACATGGTATCGATCTTGGG  
CAATGGCATCATCATTCTGGTCTCCCATACAGATGTGCACCTCCACACACCTATGTACTTCT  
TTCTTGCCAACTCCCTTCTGGACATGAGCTTACCACGAGCATTGTCCACAGCTCCTG  
GCTAACCTCTGGGGACCACAGAAAACCATAAGCTATGGAGGGTGTGTGGTCCAGTTCTAT  
ATCTCCCATTTGGCTGGGGGCAACCGAGTGTGTCCTGCTGGCCACCATGTCCTATGACCGCT  
20 ACGCTGCCATCTGCAGGCCACTCCATTACACTGTCATTATGCATCCACAGCTTTGCCTTGG  
GCTAGCTTTGGCCTCCTGGCTGGGGGTCTGACCACCAGCATGGTGGGCTCCACGCTCACC  
ATGCTCCTACCGCTGTGTGGGAACAATTGCATCGACCACTTCTTTGCGAGATGCCCCCTCA  
TTATGCAACTGGCTTGTGTGGATACCAGCCTCAATGAGATGGAGATGTACCTGGCCAGCTT  
TGTCTTTGTTGTCCTGCCTCTGGGGCTCATCCTGGTCTCTTACGGCCACATTGCCCGGGCCG  
25 TGTTGAAGATCAGGTCAGCAGAAGGGCGGAGAAAGGCATTCAACACCTGTTCTTCCCACG  
TGGCTGTGGTGTCTCTGTTTTACGGGAGCATCATCTTCATGTATCTCCAGCCAGCCAAGAG  
CACCTCCCATGAGCAGGGCAAGTTCATAGCTCTGTTCTACACCGTAGTCACTCCTGCGCTG  
AACCCACTTATTTACACCCTGAGGAACACGGAGGTGAAGAGCGCCCTCCGGCACATGGTA  
TTAGAGAACTGCTGTGGCTCTGCAGGCAAGCTGGCGCAAATTTAG (SEQ ID NO: 466).

30

**AOLFR249 sequences:**

MKSQIEKSDLKYRAILLQKVTRMFLFWVLLLVLRLVVMGRGNSTEVTEFHLLGFGVQHEF  
QHVLFIVLLLIYVTSIGNIGMILLIKTDSRLQTPMYFFPQHAFVDICYTSAITPKMLQSFTEN  
NLITFRGCVIQLVYATFATSDCYLLAMAMDCYVAICKPLRYPMIMSQT VYIQLVAGSYIIGSI  
35 NASVHTGFTFSLFCKSNKINHFFCDGLPILALSCSNIDINILDVVFVGFDFLMFTELVIIFSYYIM  
VTILKMSSTAGRKKSFSSTCASHLTA VTIFYGTLSYMYLQPQSNNSQENMKVASIFYGTVIPMLN  
PLIYSLRNKEGK (SEQ ID NO: 467).

ATGAAAAGTCAAATTGAAAAAAGTGACTTAAAATATAGAGCCATTTTATTGCAAAAAGTC  
40 ACAAGGATGTTCTGCTTTTCTGGGTCCTTCTCTTGGTCCTTTCTAGACTTTTGGTAGTCAT  
GGGTCGAGGAAACAGCACTGAAGTGACTGAATTCCATCTTCTGGGATTTGGTGTCCAACAC  
GAATTTAGCATGTCTTTTCACTGACTTCTTCTTATCTATGTGACCTCCCTGATAGGAAA  
TATTGGAATGATCTTACTCATCAAGACCGATTCCAGACTTCAAACACCCATGTACTTTTTTC  
45 CACAACATTTGGCTTTTGTGATATCTGTTATACTTCTGCTATCACTCCCAAGATGCTCCAA  
AGCTTCACAGAAGAAAATAATTTGATAACATTTGGGGGCTGTGTGATACAATTCTTAGTTT  
ATGCAACATTTGCAACCAGTGACTGTTACCTCCTAGCTATTATGGCAATGGATTGTTATGT  
TGCCATCTGTAAGCCCCCTTCGCTATCCCATGATCATGTCCCAAACAGTCTACATCCAACCTCG  
TAGCTGGCTCATATATTATAGGCTCAATAAATGCCTCTGTACATACAGGTTTACATTTTCA  
CTGTCCTTCTGCAAGTCTAATAAAATCAATCACTTTTTCTGTGATGGTCTCCCAATTCTTGC  
50 CCTTTCATGCTCCAACATTGACATCAACATCATTCTAGATGTTGTCTTTGTGGGATTTGACT  
TGATGTTCACTGAGTTGGTCATCATCTTTCTTACATCTACATTATGGTCACCATCCTGAAG  
ATGCTTCTACTGCTGGGAGGAAAAAATCCTTCTCCACATGTGCCTCCCACCTGACAGCAG  
TAACCAATTTCTATGGGACACTCTCTTACATGTACTTACAGCCTCAGTCTAATAATTCTCAG  
GAGAATATGAAAGTAGCCTCTATATTTTATGGCACTGTTATCCCATGTTGAATCCTTTAAT  
55 CTATAGCTTGAGAAATAAGGAAGGAAATAA (SEQ ID NO: 468).

**AOLFR250 sequences:**

MENQSSISEFFLRGISAPPEQQQSLFGIFLCMYLVTLTGNLLIILAIGSDLHLHTPMYFFLANLSFV  
 DMGLTSSVTKMLVNIQTRHHTISYTGCLTQMYFFLMFGDLSFFLAAMAYDRYVAICHPLCY  
 STVMRPQVCALMLALCWVLTNIVALHTHFLMARLSFCVTGEIAHFFCDITPVLKLSGSDTHINE  
 5 MMVFLVGGTVLIVPFLCIVTSYIHVPAILRVTRGGVGKAFSTCSSHLCVVCVFGTLFSAYLC  
 PPSIASEEKDIAAAAMYTIVTPMLNPFYSLRNKDMKGALKRFLSHRSIVSS (SEQ ID NO: 469).

ATGGAAAACCAATCCAGCATTTCTGAATTTTCTCCGAGGAATATCAGCGCCTCCAGAGC  
 AACAGCAGTCCCTCTTCGGAATTTTCTGTGTATGTATCTTGTACCTTGACTGGGAACCTG  
 10 CTCATCATCTGGCCATTGGCTCTGACCTGCACCTCCACACCCCATGTACTTTTCTTGGC  
 CAACCTGTCTTTTGTGACATGGGTTTAAACGTCCTCCACAGTTACCAAGATGCTGGTGAAT  
 ATACAGACTCGGCATCACACCATCTCCTATACGGGTTGCCTCACGCAAATGTATTTCTTTCT  
 GATGTTTGGTGATCTAGACAGCTTCTTCTGGCTGCCATGGCGTATGACCGCTATGTGGCC  
 ATTTGCCACCCCTCTGCTACTCCACAGTCATGAGGCCCAAGTCTGTGCCCTAATGCTTGC  
 15 ATTTGTCTGGGTCTCACCATAATCGTTGCCCTGACTCACACGTTCTCATGGCTCGGTTGT  
 CCTTCTGTGTGACTGGGGAAATTGCTCACTTTTCTGTGACATCACTCCTGTCTGAAGCTG  
 TCATGTTCTGACACCCACATCAACGAGATGATGGTTTTTGTCTTGGGAGGCACCGTACTCA  
 TCGTCCCCTTTTATGCATTGTACCTCCTACATCCACATTGTGCCAGCTATCTGAGGGTC  
 CGAACCCGTGGTGGGGTGGGCAAGGCCCTTTCCACCTGCAGTCCCACTCTGCGTTGTT  
 20 GTGTGTTCTATGGGACCCTCTTCAGTGCCTACCTGTGTCTCCCTCCATTGCCTCTGAAGAG  
 AAGGACATTGCAGCAGCTGCAATGTACACCATAGTGAAGTCCCATGTTGAACCCCTTTATCT  
 ATAGCCTAAGGAACAAGGACATGAAGGGGCCCTAAAGAGGCTCTTCAGTCACAGGAGTA  
 TTGTTTCTCTTAG (SEQ ID NO: 470).

**AOLFR251 sequences:**

MEGNKTWITDITLPRFQVGPALAILLCGLSFAFYTLTLLGNVIFGHIICLDCKLHTPMYFFLSHLA  
 IVDISYASNYVPKMLTNLMNQESTISFFPCIMQTFLYLAFHVECLILVMSYDRYADICHPLRY  
 NILMSWRVCTVLAVASWVFSFLLALVPLVLILRPLFCGPHEINHFCILSVLKLACADTWLNQV  
 VIFAACVFILVGPLCLVLVSYLRLAILRIQSGEGRRKAFSTCSSHLCVVGFFGSAIVTYMAPK  
 30 SRHPEEQQKVLVSLFYSLFNPMLNPLIYSLRNAEVKGALRRALRKERLT (SEQ ID NO: 471).

ATGGAAGGCAACAAGACATGGATCACAGACATCACCTTGCCGCGATTCCAGGTTGGTCCA  
 GCACTGGAGATTCTCCTCTGTGGACTTTTCTCTGCCTTCTATACACTCACCTGCTGGGGAA  
 TGGGGTCATCTTTGGGATTATCTGCCTGGACTGTAAGCTTCACACACCCATGTACTTCTTCC  
 35 TCTCACACCTGGCCATTGTTGACATATCCTATGCTTCCAATATGTCCCAAGATGCTGACG  
 AATCTTATGAACCAGGAAAGCACCATCTCCTTTTTTCCATGCATAATGCAGACATTCTTGT  
 ATTTGGCTTTTGTCTACGTAGAGTGTCTGATTTTGGTGGTGATGTCCTATGATCGCTATGCG  
 GACATCTGCCACCCCTTACGTTACAATATCCTCATGAGCTGGAGAGTGTGCACTGTCTCTGG  
 CTGTGGCTTCTGCGGGCCTCATGAAATCAACCACTTCTGTGAAATCCTGTCTGTCTCAAGTT  
 40 CTGCCCTTCTGCGGGCCTCATGAAATCAACCACTTCTGTGAAATCCTGTCTGTCTCAAGTT  
 GGCCTGTGCTGACACCTGGCTCAACCAGGTGGTCATCTTTCAGCCTGCGTGTTCATCCTG  
 GTGGGGCCACTCTGCCTGGTGTCTGCTCCTACTTGCATCCTGGCGCCATCTTGAGGA  
 TCCAGTCTGGGGAGGGCCGAGAAAGGCCTTCTCCACCTGCTCCTCCACCTTTGCGTGGT  
 GGGACTCTTCTTTGGCAGCGCCATTGTACGTACATGGCCCCCAAGTCCCGCCATCCTGAG  
 45 GAGCAGCAGAAAGTTCTTTCCCTGTTTTACAGCCTTTTCAATCCAATGCTGAACCCCTGA  
 TATATAGCCTAAGGAATGCAGAGGTCAAGGGCGCCCTGAGGAGGGCACTGAGGAAGGAG  
 AGGCTGACGTGA (SEQ ID NO: 472).

**AOLFR252 sequences:**

MRLANQTLGGDFLLGIFSQISHPGRLCLLIFSIFLMAVSWNITLILLIHIDSSLHTPMYFFINQLSL  
 50 IDLTYSIVTVPKMLVNQLAKDKTISVLGCGTQMYFYQLGGAECCLLAAMAYDRYVAICHPLR  
 YSVLMSHRVCLLLASGCWFVGSVDGFMPLPIAMSFPFCSHEIQHFCEVPAVLKLSGSDTSLY  
 KIFMYLCCVIMLLIPVTVISVSYYYIILTIHKMNSVEGRKKAFTTCSHITVVSIFYGAAIYNYML  
 PSSYQTPEKDMSSFFYTILTPVLNPIIYSFRNKDVTRALKKMLSVQKPPY (SEQ ID NO: 473).



ATGCGGCTGGCCAACCAGACCCTGGGTGGTGACTTTTTCTCTGTTGGGAATCTTCAGCCAGA  
 TCTCACACCCTGGCCGCCTCTGCTTGCTTATCTTCAGTATATTTTTGATGGCTGTGTCTTGG  
 AATATTACATTGATACTTCTGATCCACATTGACTCCTCTCTGCATACTCCCATGTACTTCTT  
 TATAAACCAGCTCTCACTCATAGACTTGACATATAATTTCTGTCACTGTCCCCAAAATGCTG  
 5 GTGAACCAGCTGGCCAAAGACAAGACCATCTCGGTCCTTGGGTGTGGCACCCAGATGTAC  
 TTCTACCTGCAGTTGGGAGGTGCAGAGTGCTGCCTTCTAGCCGCCATGGCCTATGACCGCT  
 ATGTGGCTATCTGCCATCCTCTCCGTTACTCTGTGCTCATGAGCCATAGGGTATGTCTCCTC  
 CTGGCATCAGGCTGCTGGTTTGTGGGCTCAGTGGATGGCTTCATGCTCACTCCCATCGCCA  
 TGAGCTTCCCCTTCTGCAGATCCCATGAGATTGAGCACTTCTTCTGTGAGGTCCCTGCTGTT  
 10 TTGAAGCTCTCTTGCTCAGACACCTCACTTTACAAGATTTTCATGTACTTGTGCTGTGTCAT  
 CATGCTCCTGATACCTGTGACGGTCATTTCAAGTGTCTTACTACTATATCATCTCACCATCC  
 ATAAGATGAAGTCAAGTTGAGGGTCGGAAAAAGGCCTTCACCACCTGCTCCTCCCACATTAC  
 AGTGGTCAGCCTCTTCTATGGAGCTGCTATTTACAACACTACATGCTCCCCAGCTCCTACCAA  
 ACTCCTGAGAAAGATATGATGTCATCCTTTTTCTACACTATCCTTACACCTGTCTTGAATCC  
 15 TATCATTTACAGTTTCAGGAATAAGGATGTCACAAGGGCTTTGAAAAAATGCTGAGCGT  
 GCAGAAACCTCCATATTAA (SEQ ID NO: 474).

#### AOLFR253 sequences:

MTFFSSGGNCEPVMCSGNQTSQNQTASTDFTLTGLFAESKHAALLYTVTFLLFLMALTGNALL  
 20 ILLIHSEPRLHTPMYFFISQLALMDLMLYLCVTVPKMLVGQVTGDDTISPSGCGIQMFFHLTLAG  
 AEVFLLAAMAYDRYAACVCRPLHYPLLMNQVQCQLLVSACWVLGMVDGLLLTPITMSFPFCQS  
 RKILSFFCETPALLKLSCSDVSLYKMLTYLCCILMLLTPIMVISSYTLILHLIHRMNSAAGRKA  
 LATCSSHMIIIVLLFGASFYTYMLRSSYHTAEQDMMVSAFYTIFTPVLNPLIYSLRNKDVTRAL  
 RSMMQSRMNQEK (SEQ ID NO: 475).

ATGACTTTTTTTCTCTCAGGGGGAAACTGTGAGCCAGTCATGTGCTCAGGGAATCAGACTT  
 CTCAGAATCAAACAGCAAGCACTGATTTACCCCTCACGGGACTCTTTGCTGAGAGCAAGCA  
 TGCTGCCCTCCTCTACACCGTGACCTTCCTTCTTTCTTGATGGCCCTCACTGGGAATGCCC  
 30 TCCTCATCCTCCTCATCCACTCAGAGCCCCGCCTCCACACCCCCATGTACTTCTTCATCAGC  
 CAGCTCGCGCTCATGGATCTCATGTACCTATGCGTGACTGTGCCCAAGATGCTTGTGGGCC  
 AGGTCACTGGAGATGATACCATTTCCCCGTCAGGCTGTGGGATCCAGATGTTCTTCCACCT  
 GACCCTGGCTGGAGCTGAGGTTTTCTCTCCTGGCTGCCATGGCCTATGACCGATATGCTGCT  
 GTTTCAGACCTCTCCATTACCCACTGCTGATGAACCAGAGGGTGTGCCAGCTCCTGGTGT  
 CAGCCTGCTGGGTTTTGGGAATGGTTGATGGTTTGTGCTCACCCCCATTACCATGAGCTT  
 35 CCCCTTTTGCCAGTCTAGGAAAATCCTGAGTTTTTTCTGTGAGACTCCTGCCCTGCTGAAGC  
 TCTCCTGCTCTGACGTCTCCCTCTATAAGATGCTCACGTACCTGTGCTGCATCCTCATGCTT  
 CTCACCCCCATCATGGTCATCTCCAGCTCATACACCTCATCCTGCATCTCATCCACAGGAT  
 GAATTCTGCCGCCGGCCGCAGGAAGGCCTTGGCCACCTGCTCCTCCCACATGATCATAGTG  
 CTGCTGCTCTTCGGTGCTTCTTCTACACCTACATGCTCCGGAGTTCTACCACACAGCTGA  
 40 GCAGGACATGATGGTGTCTGCCTTTTACACCATCTTCACTCCTGTGCTGAACCCCTCATTT  
 ACAGTCTCCGCAACAAAGATGTCACCAGGGCTCTGAGGAGCATGATGCAGTCAAGAATGA  
 ACCAAGAAAAGTAG (SEQ ID NO: 476).

#### AOLFR254 sequences:

MTNTSSDFTLLGLLVNSEAAGIVFTVILAVFLGAVTANLVMIFLIQVDSRLHTPMYFLLSQLSI  
 45 MDTLFICTTVPKLLADMVSKEKHSFVACGIQIFLYLTMIGSEFFLLGLMAYDCYVAVCNPLRYP  
 VLMNRKKCLLLAAGAWFGGSLDGFLLPITMNPVPCGSR SINHFFCEIPAVLKLACADTSLYET  
 LMYICCVLMLLIPISIISTSYSLILLTIHRMPSAEGRKKAFTTCSHLTVVSIFYGAAFYTYVLPQS  
 FHTPEQDKVVSAFYTIVTPMLNPLIYSLRNKDVIGAFKKVFACSSAQKVATSDA (SEQ ID NO:  
 50 477).

ATGACGAACACATCATCCTCTGACTTCACCCTCCTGGGGCTTCTGGTGAACAGTGAGGCTG  
 CCGGGATTGTATTTACAGTGATCCTTGCTGTTTTCTTGGGGGCCGTGACTGCAAAATTTGGT  
 CATGATATTCTTGATTGAGGTGGACTCTCGCCTCCACACCCCCATGTACTTTCTGCTCAGTC  
 55 AGCTGTCCATCATGGACACCCTTTTTATCTGTACCACTGTCCCAAACTCCTGGCAGACAT  
 GGTTTCTAAAGAGAAGATCATTTCTTTGTGGCCTGTGGCATCCAGATCTTCTCTACCTG



ACCATGATTGGTTCTGAGTTCTTCCTCCTGGGCCTCATGGCCTATGACTGCTACGTGGCTGT  
CTGTAACCTCTGAGATACCCAGTCTGATGAACCGCAAGAAGTGTCTTTTGCTGGCTGCT  
GGTGCCTGGTTTGGGGGCTCCCTCGATGGCTTTCTGCTCACTCCCATCACCATGAATGTCC  
CTTACTGTGGCTCCCGAAGTATCAACCATTTTTTCTGTGAGATCCCAGAGTTCTGAAACT  
5 GGCCTGTGCAGACACGTCCTTGTATGAAACTCTGATGTACATCTGCTGTGCCTCATGTTG  
CTCATCCCCATCTCTATCATCTCCACTTCTACTCCCTCATCTTGTTAACCATCCACCGCAT  
GCCCTCTGCTGAAGGTCGAAAAAGGCCTTACCACCTTGTTCCTCCCAGTCTTCCACACCCCG  
AGCATCTTCTATGGGGCTGCCTTCTACACATACGTGCTGCCCCAGTCTTCCACACCCCG  
AGCAGGACAAAGTAGTGTACGCTTCTATACCATTTGTACGCCCCATGCTTAATCCTCTCAT  
10 CTACAGCCTCAGAAACAAGGACGTATAGGGGCATTTAAAAAGGTATTTGCATGTTGCTCA  
TCTGCTCAGAAAGTAGCAACAAGTGATGCTTAG (SEQ ID NO: 478).

**AOLFR255 sequences:**

MEQSNYSVYADFILLGLFSNARFPWLLFALILLVFLTSIASNVVKILIHIDSRHTPMYFLLSQLS  
15 LRDILYISTIVPKMLVDQVMSQRAISFAGCTAQHFLYLTLAGAEFFLLGLMSYDRYVAICNPLH  
YPVLMRSKICWLIVAAAWLGGSIDGFLTPVTMQPFCASREINHFFCEVPALLKLSCTDTSAY  
ETAMYVCCIMMLLIPFSVISGSYTRILITVYRMSEAEGRGKAVATCSSHMVVVSLFYGAAMYT  
YVLPHSYHTPEQDKAVSAFYTLTPMLNPLIYSLRNKDVGTALQKVVGRCVSSGKVTF (SEQ  
ID NO: 479).

20 ATGGAGCAGAGCAATTATTCCGTGTATGCCGACTTTATCCTTCTGGGTTTGTTCAGCAACG  
CCCGTTTCCCTGGCTTCTCTTGGCCCTCATTCTCCTGGTCTTTTGACCTCCATAGCCAGC  
AACGTGGTCAAGATCATTCTCATCCACATAGACTCCCGCCTCCACACCCCATGTACTTCT  
25 GCTCAGCCAGCTCTCCCTCAGGGACATCCTGTATATTTCCACCATGTGCCCCAAATGCTG  
GTCGACCAGGTGATGAGCCAGAGAGCCATTTCTTTGCTGGATGCACTGCCAACACTTCC  
TCTACTTGACCTTAGCAGGGGCTGAGTTCTTCTCCTAGGACTCATGTCCTATGATCGCTAC  
GTAGCCATCTGCAACCTCTGCACTATCCTGTCCTCATGAGCCGCAAGATCTGCTGGTTGA  
TTGTGGCGGCAGCCTGGCTGGGAGGGTCTATCGATGGTTTCTTGCTCACCCCGTCACCAT  
GCAGTTCCCTTCTGTGCCTCTCGGGAGATCAACCACTTCTTCTGCGAGGTGCCTGCCCTT  
30 TGAAGCTCTCCTGCACGGACACATCAGCCTACGAGACAGCCATGTATGTCTGCTGATTAT  
GATGCTCCTCATCCCTTCTCTGTCTATCTCGGGCTCTTACACAAGAATTCTCATTACTGTTT  
ATAGGATGAGCGAGGCAGAGGGGAGGGGAAAGGCTGTGGCCACCTGCTCCTCACACATGG  
TGGTTGTCAGCCTTCTATGGGGCTGCCATGTACACATACGTGCTGCCTCATTCTTACCAC  
ACCCCTGAGCAGGACAAAGCTGTATCTGCCTTCTACACCATCCTTACTCCCATGCTCAATC  
35 CACTCATTTACAGCCTTAGGAACAAGGATGTACAGGGGCCCTACAGAAGGTTGTGGGGA  
GGTGTGTCTCCTCAGGAAAGGTAACCACTTTCTAA (SEQ ID NO: 480).

**AOLFR256 sequences:**

MGGKQPWVTEFILVGFQVGPALAILLGLFSVFYTLTLLGNGVIFGHIICLDSKLHTPMYFFLSHL  
40 AIIDMSYASNVPKMLANLMNQKSTISFVPCIMQTFLYLAFVTECLILVMSYDRYVAICHPF  
QYTVIMSWRVCTILASTCWIISFLMALVHITHILRPPFCGPQKINHFIQIMS VFKLACAGPRLNQ  
VVL YAGSAFIVEGPLCLELVSNLHILSRHLEDPVMGRAADRLTLPAPSHLCMVGLFGSTMVM  
YMAPKSRHPPEEQKVLSLFYSLFNPMLNPLIYSLRNAEVKGALKRVLWKQRSK (SEQ ID NO:  
481).

45 ATGGGAGGCAAGCAGCCCTGGGTACAGAATTCATCCTGGTGGGATTCCAGGTTGGTCCA  
GCACTGGCGATTCTCCTCTGTGGACTCTTCTGTCTTCTATACACTCACCTGCTGGGGAA  
TGGGGTCATCTTTGGGATTATCTGCCTGGACTCTAAGCTTCACACACCCATGTACTTCTCC  
TCTCACACCTGGCCATCATTGACATGTCCTATGCTTCCAACAATGTTCCCAAGATGTTGGC  
50 AAACCTAATGAACCAGAAAAGCACCATCTCCTTTGTTCCATGCATAATGCAGACTTTTTTG  
TATTTGGCTTTTGTGTTACAGAGTGCCTGATTTTGGTGGTGTATGTCCTATGATAGGTATGT  
GGCCATCTGCCACCTTTCCAGTACACTGTCTCATCATGAGCTGGAGAGTGTGCACGATCCTG  
GCCTCAACATGCTGGATAATTAGCTTCTCATGGCTCTGGTCCATATACTCATATTCTGAG  
GCCGCTTTTGTGGCCCAAAAAGATCAACCACTTTATCTGTCAAATCATGTCCGTATTCA  
55 AATTGGCCTGTGCTGGCCCTAGGCTCAACAGGTGGTCTATATGCGGGTCTGCGTTCAT  
CGTAGAGGGGCCGCTCTGCCTGGAGCTGGTCTCCAACCTTGCACATCCTGTGCGCCATCTT

GAGGATCCAGTAATGGGGAGGGCCGCGAGACCGACTTACTCTTCCTGCTCCTTCCCACCTTT  
GCATGGTGGGACTCCTTTTTGGCAGCACCATGGTCATGTACATGGCCCCCAAGTCCCGCCA  
CCCTGAGGAGCAGCAGAAGGTCCTTTCCCTGTTTTACAGCCTTTTCAACCCGATGCTGAAC  
CCCTTGATCTACAGCCTGAGGAACGAGAGGTCAAGGGTGCCCTGAAAAGAGTGTTGTGG  
5 AAACAGAGATCAAAGTGA (SEQ ID NO: 482).

**AOLFR257 sequences:**

MESNQTWITEVILLGFQVDPALELFLFGFLLFYSLTLMGNHILGLIYLDRLHTPMYVFLSHL  
AIVDMSYASSTVPKMLANLVMHKKVISFAPCILQTFLYLAFATECLILVMMCYDRYVAICHPL  
10 QYTLIMNWRVCTVLAISTCWIFSLLALVHITLILRPFQKINHHFFCQIMSVFKLACADTRLN  
QVVLFAGSFILVGPLCLVLVSYLHILVAILRIQSGEGRKAFSTCSSHLCVVGLFFGSAIVMYM  
APKSSHSQERRKILSLFYSLFNPLNPLIYSLRNAEVKGALKRVLWKQRSM (SEQ ID NO: 483).

ATGGAAAGCAATCAGACCTGGATCACAGAAGTCATCCTGTTGGGATTCCAGGTGGACCCA  
15 GCTCTGGAGTTGTTCTCTTTGGGTTTTCTTGCTATTCTACAGCTTAACCCTGATGGGAAA  
TGGGATTATCCTGGGGCTCATCTACTTGGACTCTAGACTGCACACACCCATGTATGTCTTC  
CTGTACACCTGGCCATTGTGGACATGTCCTATGCCTCGAGTACTGTCCCTAAGATGCTAG  
CAAATCTTGATGCACAAAAAGTCATCTCCTTTGCTCCTTGCTACTTCAGACTTTTTTG  
TATTTGGCGTTTGCTATTACAGAGTGTCTGATTTTGGTGATGATGTGCTATGATCGGTATG  
20 TGGCAATCTGTACCCCTTGCAATACACCCTCATTATGAACTGGAGAGTGTGCACTGTCCT  
GGCTCAACTTGCTGGATATTTAGCTTTCTCTTGGCTCTGGTCCATATTACTCTTATTCTGA  
GGCTGCCTTTTTGTGGCCACAAAAGATCAACCACCTTTTTCTGTCAAATCATGTCCGTATTC  
AAATTGGCCTGTGCTGACACTAGGCTCAACCAGGTGGTCCTATTTGCGGGTTCTGCGTTCA  
TCTTAGTGGGGCCGCTCTGCCTGGTGTGCTGCTCCTACTTGACATCCTGGTGGCCATCTTG  
25 AGGATCCAGTCTGGGGAGGGCCGCGAGAAAGGCCTTCTCTACCTGCTCCTCCCACCTCTGCG  
TGGTGGGGCTTTTCTTTGGCAGCGCCATTGTATGTACATGGCCCCCAAGTCAAGCCATTC  
TCAAGAACGGAGGAAGATCCTTTCCCTGTTTTACAGCCTTTTCAACCCGATCCTGAACCCC  
CTCATCTACAGCCTTAGGAATGCAGAGGTGAAAGGGGCTCTAAAGAGAGTCCTTTGGAAA  
CAGAGATCAATGTGA (SEQ ID NO: 484).

30

**AOLFR259 sequences:**

MGDNQSRVTEFILVGFQLSVEMEVLLFWIFSLLYLFSLLANGMILGLICLDPRLRTPMYFFLSHL  
AVIDIYYASSNLLNMLENLVKHKKTISFISCIMQMALYLTFAAAVCMILVMSYDRFVAICHPL  
HYTVIMNWRVCTVLAITSWACGFSALINLILLRPFQKINHHFFGEILSVLKLACADTWIN  
35 EIFVFAGGVFVLVGPLSLMLISYMRILLAILKIQSKEGRKAFSTCSSHLCVVGLYFGMAMVVY  
LVPDNSQRQKQKILTLFYSLFNPLNPLIYSLRNAQVKALYRALQKKRTM (SEQ ID NO:  
485).

ATGGGGGACAACCAATCACGGGTACAGAATTCATCCTGGTTGGATTCCAGCTCAGTGTG  
40 GAGATGGAAGTGCTCCTCTTCTGGATCTTCTCCCTGTTATATCTCTTCAGCCTGCTGGCAAA  
TGGCATGATCTTGGGGCTCATCTGTCTGGATCCCAGACTGCGCACCCCATGTACTTCTTCC  
TGTCACACTTGGCCGTCATTGACATATACTATGCTTCCAGCAATTTGCTCAACATGCTGGA  
AAACCTAGTGAAACACAAAAAACTATCTCGTTTCATCTCTTGCAATTATGCAGATGGCTTTG  
TATTTGACTTTTGCTGCTGCAGTGTGCATGATTTTGGTGGTGATGTCCTATGACAGATTTGT  
45 GGGCATCTGCCATCCCCTGCATTACACTGTCATCATGAACTGGAGAGTGTGCACAGTACTG  
GCTATTACTTCTGGGCATGTGGATTTTCCCTGGCCCTCATAAATCTAATTCTCCTTCTAAG  
GCTGCCCTTCTGTGGGCCCCAGGAGGTGAACCACTTCTTCGGTGAAATTTCTGTCTGTCTC  
AAACTGGCCTGTGCAGACACCTGGATTAATGAAATTTTGTCTTTGCTGGTGGTGTGTTT  
TCTTAGTCGGGGCCCTTTCTTGTATGCTGATCTCCTACATGCGCATCCTCTTGGCCATCCTG  
50 AAGATCCAGTCAAAGGAGGGCCGCAAAAAAGCCTTTTCCACCTGCTCCTCCCACCTCTGTG  
TGGTTGGGCTTTACTTTGGCATGGCCATGGTGGTTTACCTGGTCCCAGACAACAGTCAACG  
ACAGAAGCAGCAGAAAATCTCACCTGTTTTACAGCCTTTTCAACCCATTGCTGAACCCC  
CTCATCTACAGCCTGCGGAATGCTCAAGTGAAGGGTGCCCTATACAGAGCACTGCAGAAA  
AAGAGGACCATGTGA (SEQ ID NO: 486).

55

**AOLFR24B sequences:**

MPSINDTHFYPPFLLGLDGLDTHLWISFPFCIVYLIAIVGNMTILFVIKTEHSLHQPMFYFLAM  
LSMIDLGLSTSTIPKMLGIFWFNLQEISFGGCLLQMFHMFMTGMETVLLVVMAYDRFVAICNP  
LQYTMILTNTISILASVVVGRNLVLTVPFVFLRLPFCGHNVPHPTYCEHRLAGLACAPIKIN  
5 IYGLMVISYIIVDVILASSYVLILRAVFLPSQDVRLKAFNTCGSHVCVMLCFYTPAFFSFMTH  
RFGQNPHYIHILLANLYVVVPPALNPVIYGVRTKQIREQIVKIFVQKE (SEQ ID NO: 487)

ATGCCTTCTATCAATGACACCCACTTCTATCCCCCTTCTTCTCCTGCTAGGAATACCAGG  
ACTGGACACTTTACATATCTGGATTCTTTCCCATTCTGTATTGTGTACCTGATTGCCATTG  
10 TGGGGAATATGACCATTCTCTTTGTGATCAAACTGAACATAGTCTACACCAGCCCATGTT  
CTACTTCTGGCCATGTTGTCTATGATTGATCTGGGTCTGTCCACATCCACTATCCCCAAAA  
TGCTAGGAATCTTCTGGTTCAACCTCCAAGAGATCAGCTTTGGGGGATGCCTTCTTCAGAT  
GTTCTTTATTACATGTTTACAGGCATGGAGACTGTTCTGTTGGTGGTCATGGCTTATGACC  
GCTTTGTTGCCATCTGCAACCTCTCCAGTACACCATGATCCTCACCAATAAAACCATCAG  
15 TATCCTAGCTTCTGTGGTTGTTGGAAGAAATTTAGTTCTTGTAAACCCCATTTGTGTTTCTCA  
TTCTGCGTCTGCCATTCTGTGGGCATAACATCGTACCTCACACATACTGTGAGCACAGGGG  
TCTGGCCGGGTTGGCCTGTGCACCCATTAAGATCAACATAATCTATGGGCTCATGGTGATT  
TCTTATATTATTGTGGATGTGATCTTAATTGCCTCTTCTATGTGCTTATCCTTAGAGCTGT  
TTTTCGCCTTCCCTCTCAAGATGTCCGACTAAAGGCCTTCAATACCTGTGGTTCTCATGTCT  
20 GTGTTATGCTGTGCTTTTACACACCAGCATTTTTCTTTTATGACACATCGTTTTGGCCAA  
AACATTCCCCACTATATCCATATTCTTTTGGCTAACCTGTATGTGGTTGTCCCACCTGCCCT  
TAACCCTGTCATTTATGGAGTCAGGACCAAGCAGATCCGAGAGCAAATTGTGAAAATATTT  
GTACAGAAAGAATAA (SEQ ID NO: 488)

**AOLFR33B sequences:**

MLHTNNTQFHPSTFLVVGVPGLDVHVWIGFPFFAVYLTALLGNHILFVIQTEQSLHQPMFYFL  
AMLAGTDLGLSTATIPKMLGIFWFNLGEIAGACITQMYTHICTGLESVVLTVTGIDRYAICNP  
LRYSMILTNTKVIAILGIVIVRTL VFVTPFTLTLRLPFCGVRIIPHTYCEHMLAKLACASINVIY  
GLIAFSVGYIDISVIGFSYVQILRAVFLPAWDARLKALSTCGSHVCVMLAFYLPALFSFMTHRF  
30 GHNIPHYIHILLANLYVVFPALNSVIYGVKTKQIREQVLRILNPKSFWHFDPKRIFHNNSVRQ  
(SEQ ID NO: 489)

ATGCTTCATACCAACAATACACAGTTTCAACCTTCCACCTTCTCCTAGTGGGGGTCCCAG  
GGCTGGAAGATGTGCATGTATGGATTGGCTTCCCCTTCTTTGCGGTGTATCTAACAGCCCT  
35 TCTAGGGAACATCATTATCCTGTTTGTGATACAGACTGAACAGAGCCTCCACCAACCCATG  
TTTTACTTCTAGCCATGTTGGCCGGCACTGATCTGGGCTTGTCTACAGCAACCATCCCCA  
AGATGCTGGGAATTTTCTGGTTAATCTTGGAGAGATTGCATTGTTGGTGCCTGCATCACACA  
GATGTATACCATTCATATATGCACTGGCCTGGAGTCTGTGGTACTGACAGTCACGGGCATA  
GATCGCTATATTGCCATCTGCAACCCCTGAGATATAGCATGATCCTTACCAACAAGGTAA  
40 TAGCCATTCTGGGCATAGTCATCATTGTGAGGACTTTGGTATTGTGACTCCATTACATTT  
CTCACCTGAGATTGCCTTTCTGTGGTGTCCGGATTATCCCTCATACCTATTGTGAACACAT  
GGGCTTGGCAAAGTTAGCTTGTGCCAGTATTAATGTTATATATGGATTGATTGCCTTCTCA  
GTGGGATACATTGACATTTCTGTGATTGGATTTTCTATGTCCAGATCCTCCGAGCTGTCTT  
CCATCTCCCAGCCTGGGATGCCCGGCTTAAGGCACTCAGCACATGTGGCTCTCACGTCTGT  
45 GTTATGTTGGCTTTCTACCTGCCAGCCCTCTTTTCTTCTATGACACACCGCTTTGGCCCAA  
CATCCCTCATTACATCCACATTTCTTCTGGCCAATCTGTATGTGGTTTTTCCCCTGCTCTTA  
ACTCTGTTATCTATGGGGTCAAAACAAAACAGATACGAGAGCAGGTACTTAGGATACTCA  
ACCCTAAAAGCTTTTGGCATTTTGACCCCAAGAGGATCTTCCACAACAATTACGTTAGACA  
ATAA (SEQ ID NO: 490)

50

**AOLFR112B sequences:**

MKNKTVLTFILLGLTDVPELQVAVFTFLFLAYLLSILGNLTILTLTLLDSHLQTPMYFFLRNFSF  
LEISFTNIFIPRVLSITTNKKSISFAGCFTQYFFAMFLGATEFYLLAAMSVDYVAICKPLHYTTI  
MSSRICQLIFCSWLGLMAIPTITLMSQQDFCASNRLNHYFCDYEPLLELSCSDTSLIEKVFL  
55 VASVTLVTLVLVLSYAFIHKTLKLPSAQQRKAFSTCSSHMIVISLSYGSCMFMYINPSAKEG  
DTFNKGVALLITSVAPLLNPFYTLRNQQVKQPFKDMVKLLNL (SEQ ID NO: 491)

ATGAAAAATAAAACCGTGTTAACTGAGTTTATCCTTCTGGGTCTAACAGATGTCCCTGAAC  
 TCCAGGTGGCAGTTTTACCTTTCTTTTCCTTGCATTTTACTCAGCATCCTTGGAAATCTG  
 ACTATCCTCATCCTCACCTTGCTGGACTCCCACCTCAGACTCCCATGTATTTCTTTCTCCG  
 5 GAACTTCTCCTTCTTGAAATTTCTTCCACAAACATCTTCATTCCAAGGGTCTGATTAGCA  
 TCACAACAGGGAACAAGAGTATCAGCTTTGCTGGCTGCTTCACTCAGTATTTCTTTGCCAT  
 GTTCCTTGGGGCTACAGAGTTTTACCTTCTGGCTGCCATGTCCTATGACCGCTATGTGGCC  
 ATCTGCAAACCTCTGCATTACACCACCATCATGAGCAGCAGAATCTGCATCCAGCTGATTT  
 TCTGCTCTTGGCTGGGTGGGCTAATGGCTATTATACCAACAATCACCTGATGAGTCAGCA  
 10 GGACTTTTGTGCATCCAACAGACTGAATCATTACTTCTGTGACTATGAGCCTCTTCTGGAA  
 CTCTCATGTTTCAGACACAAGCCTCATAGAGAAGGTTGTCTTTCTTGTGGCATCTGTGACCC  
 TGGTGGTCACTCTGGTGTAGTGATTCTCTCCTATGCATTCAATTATCAAGACTATTCTGAAG  
 CTCCCTCTGCCCCAACAAAGGACAAAAGCCTTTTCCACATGTTCTTCCCACATGATTGTCAT  
 CTCCCTCTCTTACGGAAGCTGCATGTTTATGTACATTAATCCCTCTGCAAAAGAAGGGGAT  
 15 ACATTCAACAAGGGAGTAGCTCTACTCATTACTTCAGTTGCTCCTTTGTTGAACCCCTTTAT  
 TTACACCCTAAGGAACCAACAGGTAAAACAACCCCTCAAGGATATGGTCAAAAAGCTTCT  
 GAATCTTTAA (SEQ ID NO: 492)

#### AOLFR130B sequences:

20 MEGKNQTAPSEFIILGFDHLNELQYLLFTIFFLTYICTLGGNVFIHVVTIADSHLHTPMYYFLGNL  
 ALIDICYTTTNVPQMMVHLLSEKKIISYGGCVTQLFAFIFVVGSECLLLAAMAYDRYIAICKPLR  
 YSFIMNKALCSWLAASCWTCGFLNSVLHTVLTFLHPFCGNNQINYFFCDIPPLILSCGDTSLNE  
 LALLSIGILISWTPFLCIILSYLYIISTILRISSEGRHKAFSTCASHLLIVILYYGSAIFTYVRPISYS  
 LEKDRLISVLYSVVTPLNPNVIYTLRNKDIKEAVKAIGRKWQPPVFSSDI (SEQ ID NO: 493)

25 ATGGAAGGAAAGAATCAAACAGCTCCATCTGAATTCATCATCTTGGGGTTCGACCACCTGA  
 ATGAATTGCAGTATTTACTCTTCACCATCTTCTTTCTGACCTACATATGCACCTTAGGAGGC  
 AATGTTTTTATCATTGTGGTGACCATAGCTGATTCCCACCTACACACACCCATGTATTATTT  
 CCTAGGAAATCTTGGCCTTATTGACATCTGCTACACTACTACTAATGTCCCCCAGATGATG  
 30 GTGCATCTTCTGTGAGAGAAGAAAATCATTTCTTATGGAGGCTGTGTGACCCAGCTCTTTG  
 CATTCAATTTCTTTGTTGGCTCAGAGTGTCTCCTCCTGGCAGCAATGGCATATGATCGATAT  
 ATTGCTATCTGTAAGCCGTTAAGGTACTCATTATTTATGAACAAGGCCCTGTGCAGCTGGT  
 TAGCAGCCTCATGCTGGACATGTGGGTTTCTCAACTCAGTGTTGCACACCGTTCTGACCTT  
 CCACCTGCCCTTCTGTGGTAACAATCAGATCAATTATTTCTTCTGTGACATACCTCCCTTGC  
 35 TCATCTTGTCTTGTGGTGATACTTCCCTCAATGAACTGGCTTTGCTGTCCATTGGGATCCTC  
 ATAAGCTGGACTCCTTTCTGTGCATCATCTTTCTTACCTTTACATCATCTCCACCATCCT  
 GAGGATCCGTTCTCTGAGGGGAGGCACAAAGCCTTTTCCACCTGTGCCTCCACCTGCTC  
 ATTGTTATTCTCTATTATGGCAGTGCTATCTTACGTATGTGAGGCCCATCTCATCTTACTC  
 TCTAGAGAAAGATAGATTGATCTCAGTGCTGTATAGTGTGTGACACCCCATGCTGAATCCT  
 40 GTAATTTATACGCTAAGGAATAAGGACATCAAAGAGGCTGTGAAGGCCATAGGGAGAAAG  
 TGGCAGCCACCAGTTTTCTTCTGTATATATAA (SEQ ID NO: 494)

#### AOLFR142B sequences:

45 MARKDMAHINCTQATEFILVGLTDHQELKMPLFVLFLSIYLFVVGNLGLILLIRADTSLNTPM  
 YFFLSNLAFVDFCYSSVITPKMLGNFLYKQNVISFDACATQLGCFLTFMISESLLASMAVDYR  
 VAICNPLLYMVVMTGPGICQLVAVPYSYFLMALFHITLTFRLSYCHSNIVNHFYCDDMPLRL  
 TCSDFRQKQLWIFACAGIMFISSLLIVFVSYMFHISAILRMHSAEGRQKAFSTCGSHMLAVTIFYG  
 TLIFMYLQPSSSHLDTDKMASVFYTVIIPMLNPLIYSLQNKEVKEALKKIIINKN (SEQ ID NO:  
 495)

50 ATGGCCAGAAAAGATATGGCTCACATCAATTGCACCCAGGCGACAGAGTTTATTCTTGTGG  
 GCCTCACAGACCATCAGGAGTTGAAGATGCCCTCTTTGTGCTATTCTTATCCATCTACCTC  
 TTCACAGTGGTAGGCAACTTGGGTTTGATCCTACTCATTAGAGCGGATACAAGTCTCAACA  
 CACCAATGTACTTCTTTCTTAGCAACCTAGCTTTTGTGGATTTCTGTTACTCTTCTGTCAAT  
 55 ACACCCAAAATGCTTGGGAATTTCTTGTACAAACAAAATGTTATATCCTTTGATGCATGTG  
 CTAATCAACTGGGCTGCTTTCTCACCTTCATGATATCAGAATCCTTGCTACTGGCTTCCATG

WO 01/98526

GCCTATGACCGATATGTGGCCATTTGTAACCTCTATTGTATATGGTTGTAATGACTCCAG  
 GAATCTGCATTCAACTTGTAGCAGTTCCTTATAGCTATAGCTTCCTAATGGCACTATTTAC  
 ACCATCCTCACCTTCCGCCTCTCCTATTGCCACTCCAACATTGTCAACCATTCTATTGTGA  
 TGACATGCCTCTCCTCAGGCTAACTTGCTCAGACACTCGCTTCAAACAGCTCTGGATCTTT  
 5 GCCTGTGCTGGTATCATGTTCAATTCCTCCCTTCTGATTGTCTTTGTCTCCTACATGTTTCAT  
 ATTCTGCCATCCTGAGGATGCATTACAGCTGAGGGAAGACAGAAGGCTTTCTCGACGTGTG  
 GCTCTCACATGCTGGCAGTCACCATATTCTATGGGACCCTCATTTTTATGTACTTACAGCCT  
 AGCTCTAGCCATGCCCTGGACACAGACAAGATGGCCTCTGTCTTCTACACAGTGATCATTC  
 CCATGTTGAATCCCTTAATCTATAGCCTCCAGAATAAGGAGGTGAAAGAAGCTCTGAAGA  
 10 AAATCATTATCAATAAAAACTAG (SEQ ID NO: 496)

**AOLFR171C sequences:**

MAEVNIIVTVFILKGITNRPELQAPCFGVFLVIYLVTVLGNLGLITLIKIDTRLHTPMYYFLSHL  
 AFVDLCYSSAITPKMMVNFVVERNTIPFHACATQLGCFLTFMITECFLLASMAFYDCYVAICSP  
 15 HYSTLMSRRVCIQLVAVPYIYSFLVALFHTVITFRLTYCGPNLNFHYCDDLPLFALSCSDTHMK  
 EILIFAFAGFDMISSSIVLTSYIFIIAILRIRSTQGQHKAISTCGSHMVTVTIFYGTLIFMYLPKS  
 NHSLDTDKMASVFYTVVIPMLNPLIYSLRNKEVKDASKKALDKGCENLQILFLKIRKLY (SEQ  
 ID NO: 497)

20 ATGGCTGAAGTTAATATCATTTATGTCACTGTATTCAATCTGAAAGGAATTACCAACCGGC  
 CAGAGCTTCAGGCCCCGTGCTTTGGGGTGTITTTAGTTATCTATCTGGTCACAGTGCTGGG  
 CAATCTTGGGTGATTACTTTAATCAAGATTGATACTCGACTCCACACACCTATGTACTATT  
 TCCTCAGCCACCTGGCCTTTGTTGACCTTTGTTACTCCTCTGCTATTACACCGAAGATGATG  
 GTGAATTTTGTGTGGAACGCAACACCATTCCTTTCCATGCTTGTGCAACCCAACTGGGTT  
 25 GTTTTCTACCTTCATGATCACTGAGTGTTTCTTCTAGCCTCCATGGCCTACGATTGCTAT  
 GTCGCCATCTGTAGTCCCCTGCATTATTCAACACTGATGTCAAGAAGAGTCTGCATTCAAC  
 TGGTGGCAGTTCCATATATATACAGCTTCCTGGTTGCCCTCTTCCACACCGTTATCACTTC  
 CGTCTGACTTACTGTGGCCAACTTAATTAACCATTTCTATTGTGATGACCTCCCCTTCTT  
 AGCTCTGTCTCTGCTCAGACACACATGAAGGAAATTCTGATATTTGCCCTTTGCTGGCTTT  
 30 GATATGATCTCTTCTCTTCCATTGTCTCCTACCTCCTACATCTTTATTATTGCCGCTATCCTA  
 AGGATCCGCTCTACTCAGGGGCAACACAAAGCCATTTCCACCTGTGGCTCCCATATGGTGA  
 CTGTCACTATTTCTATGGCACACTGATCTTTATGTACCTACAGCCCAAATCAATCACTCC  
 TTGGACACAGACAAGATGGCTTCTGTATTTTACACAGTGGTGATCCCCATGTTAAACCCC  
 TAATCTATAGTCTAAGGAACAAAGAGTGAAGATGCCTCAAAGAAAGCCTTGGATAAAG  
 35 GTTGTGAAAACCTACAGATATTAACATTTTAAAAATAAGAAAACCTTATTAA (SEQ ID NO:  
 498)

**AOLFR225B sequences:**

MKNRTMFGEFILLGLTNQPELQVMIFIFLTYMLSILGNLTITLTLDDPHLQTPMYFFLRNFSF  
 40 LEISFTSIFIPRLTSMITGNKVISFAGCLTQYFFAIFLGATEFYLLASMSYDRYVAICKPLHYLTI  
 MSSRVCIQLVFCSWLGGFLAILPPIILMTQVDFCVSNILNHYYCDYGPLVELACSDTSLLELMVI  
 LLAVVTLMTLVLTLSYTYIIRTLRIPSAQQRKAFSTCSSHMIVISLSYGSCMFMYNPSAKE  
 GGA FNKGIAVLITSVTPLNPFYITLRNQVKQAFKDSVKKIVKL (SEQ ID NO: 499)

45 ATGAAAAACAGAACCATGTTTGGTGAGTTTATTCTACTGGGCCTTACAAATCAACCTGAAC  
 TCCAAGTGATGATATTCTTTCTGTTCCCTACCTACATGCTAAGTATCCTAGGAAATCTG  
 ACTATTATCACCTCACCTTACTAGACCCCCACCTCCAGACCCCATGTATTTCTTCTCCTCG  
 GAATTTCTCCTTCTTAGAAATTTCTTCCATCCATTTTTATTCCCAGATTTCTGACCAGCA  
 TGACAACAGGAAATAAAGTTATCAGCTTTGCTGGCTGCTGACTCAGTATTTTTTGTCTAT  
 50 ATTTCTTGGAGCTACCGAGTTTTACCTCCTGGCCTCCATGTCTTATGATCGTTATGTGGCCA  
 TCTGCAAACCTTGCATTACCTGACTATTATGAGCAGCAGAGTCTGCATACAACTAGTGTT  
 CTGCTCCTGGTTGGGGGATTCTAGCAATCTTACCACCAATCATCTGATGACCCAGGTA  
 GATTTCTGTGTCTCCAACATTCTGAATCACTATTACTGTGACTATGGGCCTCTCGTGAGCT  
 TGCCTGCTCAGACACAAGCCTCTTGAAGTATGATGGTCATCCTCTTGGCCGTTGTGAGCT  
 55 ATGGTTACTCTGGTGCTGGTGACACTTTCTTACACATACATTATCAGGACTATTCTGAGGA  
 TCCCTTCTGCCCAGCAAAGGACAAAGGCCTTTTCCACTGTTCCTCCACATGATTGTCATC

TCCCTCTCTTATGGCAGCTGCATGTTTATGTACATTAATCCTTCTGCAAAAGAAGGAGGTG  
CTTTCAACAAAGGAATAGCTGTACTCATTACTTCGGTTACTCCCTTACTGAATCCCTTCATA  
TATACTTTAAGAAATCAGCAAGTGAAACAAGCTTTCAAGGACTCAGTCAAAAAGATTGTG  
AAACTTTAA (SEQ ID NO: 500)

5

**AOLFR274B sequences:**

MEFVFLAYPSCPELHLSFLGVSLVYGLIITGNILIVVSIHTETCLCTSMYYFLGSLSGIEICYTAV  
VVPFILANTLQSEKTITLLGCATQMAFFIALGSADCFLLAAMAYDRYVAICHPLQYPLMLTLTL  
CVHLVVASVISGLFSLQLVAFIFSLPFCQAQGIEHFFCDVPPVMHVCAQSHIHEQSVLVAAIL  
10 AIAVPFLITTSYTFIVAALLKIHSAAGRHRAFSTCSSHLTVVLLQYGCCAFMYLCPSSSYNPKQ  
DRFISLVYTLGTPLLNPLIYALRNSEMKGAVGRVLTRNCLSQNS (SEQ ID NO: 501)

ATGGAATTTGTGTTCTGCGCTATCCCTCCTGCCCAGAACTGCATATTCTGTCCTTCCTTGG  
GGTCAGCCTGGTTTATGGTTTGATCATCACTGGGAACATTCTCATTGTGGTGTCCATTAC  
15 ACAGAAACCTGTCTATGCACATCCATGTACTATTTCTGGGAGCCTTTCTGGGATTGAAA  
TATGCTACACTGCAGTGGTGGTGGCCCATATCCTGGCCAACACCCTACAGTCAGAGAAGAC  
CATCACTCTCCTGGGCTGTGCCACCCAGATGGCTTTCTTCATTGCACTGGGCAGTGTCTGAT  
TGCTTCCTCTTGGCTGCCATGGCCTATGACCGCTATGTGGCCATTGTCACCCGTTGCAGTA  
CCCTCTCCTCATGACATTGACTCTTTGTGTCCACTTGGTTGTGGCATCAGTCATCAGTGGTC  
20 TGTTCCTGTCTTACAACCTGGTGGCCTTCATCTTCTCTGCCATTCTGCCAGGCTCAGGGC  
ATTGAGCACTTCTTTGTGATGTGCCACCAGTCATGCATGTTGTTTGTGCTCAGAGTCACAT  
TCATGAGCAGTCAGTGTGGTGGCAGCCATACTAGCCATTGCTGTGCCTTTCTTCCTCATC  
ACCACCTCCTACACCTTCATAGTGGCTGCTCTGCTCAAGATCCACTCGGCTGCTGGCCGCC  
ACCGGGCCTTCTCCACCTGCTCTTCCACCTCACTGTGGTGTGCTGCAGTATGGCTGCTGT  
25 GCCTTCATGTACCTGTGCCCCAGCTCCAGCTACAACCCCAAGCAAGATCGGTTTCATCTCAC  
TGGTGTACACATTGGGAACCCCACTGCTCAACCCACTTATCTATGCCCTGAGGAACAGTGA  
GATGAAAGGGGCGTAGGGAGAGTTCTTACCAGGAACTGCCTTTCCAGAACAGCTAG  
(SEQ ID NO: 502)

30 **AOLFR276B sequences:**

MGGFGTNISSSTTSFTLTGFPEMKGLEHWLAALLLLLYAISFLGNILILFIIKEEQSLHQPMYYFLS  
LFSVNDLGVSFSTLPTVLAAVCFHAPETTFDACLAQMFFIHFSSWTEFGILLAMSFHDHYVAICNP  
LRYATVLT DVRVAHNGISIVIRSFCMVFLPFLKRLPFCKASVLAHSYCLHADLRLPWGDT  
TINSMYGLFIVISAFGVDSLILLSYVLILHSVLAIASRGERLKTNLNCTVSHIYAVLIFYVPMVSVS  
35 MVHRFRGRHAPEYVHKFMSLCTSNALPNYLFHQD (SEQ ID NO: 503)

ATGGGGGGCTTTGGGACTAACATCTCAAGTACTACCAGCTTCACTCTAACAGGCTTCCCTG  
AGATGAAGGGTCTGGAGCACTGGCTGGCTGCCCTTCTGCTGCTGCTTTATGCTATTTCTT  
CCTGGGCAACATCCTCATCCTCTTTATCATAAAGGAAGAGCAGAGCTTGCAACAGCCAATG  
40 TACTACTTCTGTCTCTTTTTTCTGTAAATGACCTGGGTGTGCTTTTTCTACATTGCCCACT  
GTACTGGCTGCTGTGTGTTTCATGCCCCAGAGACAACCTTTGATGCCTGCCTGGCCCA  
TGTTCTTCATCCACTTTTCTCCTGGACAGAGTTTGGCATCCTACTGGCCATGAGTTTGTGAC  
CACTATGTGGCCATCTGTAACCCGCTGCGCTATGCCACAGTGCTCACTGATGTCCGTGTGG  
CCCACAATGGCATATCCATTGTCATCCGCAGCTTCTGCATGGTATTCCCACTTCCCTTCTC  
45 CTGAAGAGACTGCCTTTCTGTAAGGCCAGTGTGGTACTGGCCATTCTACTGTCTGCATG  
CAGACCTGATTGCGCTGCCCTGGGGAGACACTACCATCAACAGCATGTATGGCCTGTTTAT  
TGTCATCTCTGCCTTTGGTGTAGATTCACTGCTCATCCTCCTCTCCTATGTGCTCATTCTAC  
ATTCTGTGCTGGCCATTGCCTCCAGGGGTGAGAGGCTTAAGACACTCAACACATGTGTGTC  
ACATATCTATGCAGTGTGATCTTCTATGTGCCTATGGTTAGTGTGCCATGGTTTCATCGAT  
50 TTGGGAGGCATGCTCCTGAATATGTGCACAAGTTCATGTCTCTTTGTACCTCCAATGCTCT  
ACCCAATTATCTATTCCATCAAGACTAA (SEQ ID NO: 504)

**AOLFR311B sequences:**

MDWENCSSLTDFLLGITNNPEMKVTLFAVFLAVYIINFANLGMIVLIRMDYQLHTPMYFFLS  
55 HLSFCDLCYSTATGPKMLVDLLAKNKSIPFYGCALQFLVFCIFADSECLLSVMAFDYKAIJNP  
LLYTVNMSSRVCYLLLTGVYLVGIADALHMTLAFRLCFCGSNEINHFFCDIPPLLLLSRSDTQV



WO 01/98526

NELVLFTVFGFIELSTISGVFISYCYIILSVLEIHS AEGRFKALSTCTSHLSAVAIFQGTLLFMYFRP  
SSSYSLDQDKMTSLFYTLVVPMLNPLIYSLRNKDVKEALKLKNKILF (SEQ ID NO: 505)

5 ATGGACTGGGAAAATTGCTCCTCATTAAGTATTTTCTCTTGGGAATTACCAATAACCC  
AGAGATGAAAGTGACCCTATTTGCTGTATTCTTGGCTGTTATATCATTAATTTCTCAGCAA  
ATCTTGGAATGATAGTTTAAATCAGAATGGATTACCAACTTCACACACCAATGTATTTCTT  
CCTCAGTCATCTGTCTTTCTGTGATCTCTGCTATTCTACTGCAACTGGGCCAAGATGCTGG  
TAGATCTACTTGCCAAGAACAAGTCAATACCCTTCTATGGCTGTGCTCTGCAATTCTTGGT  
CTTCTGTATCTTTGCAGATTCTGAGTGTCTACTGCTGTCAAGTGTGCTATCTACT  
10 AGGCCATCATCAACCCCTGCTCTATACAGTCAACATGTCTAGCAGAGTGTGCTATCTACT  
CTTGGACTGGGGTTTATCTGGTGGGAATAGCAGATGCTTTGATACATATGACACTGGCCTTC  
CGCCTATGCTTCTGTGGGTCTAATGAGATTAATCATTCTTCTGTGATATCCCTCCTCTCTT  
ATTACTCTCTCGCTCAGATACACAGGTCAATGAGTTAGTGTATTACCGTCTTTGGTTTAA  
TTGAACTGAGTACCATTTCAGGAGTTTTCATTCTTATTTGTTATATCATCCTATCAGTCTTG  
15 GAGATACACTCTGCTGAGGGGAGGTTCAAAGCTCTCTACATGCACCTCCCACTTATCTG  
CGGTTGCAATTTTCCAGGGAAGTCTGCTCTTATGTATTTCCGGCCAAGTCTTCTCCTATTCT  
CTAGATCAAGATAAAATGACCTCATTGTTTACACCCTGTGGTCCCATGTTGAACCCCT  
GATTTATAGCCTGAGGAACAAGGATGTGAAAGAGGCCCTGAAAAAAGTAAAAATAAAAT  
TTTATTTTAA (SEQ ID NO: 506)

20

**AOLFR314 sequences:**

MEVKNCCMVTEFILLGIPHTGLEMTLFLVFLPFYACTLLGNVSILVAVMSSARLHTPMYFFLG  
NLSVDFDMGFSSVTCPKMLLYLMGLSRLISYKDCVCQLFFHFLGSIECFLFTVMAYDRFTAICY  
PLRYTVIMNPRICVALAVGTWLLGCIHSSILTSITFTLPYCGPNEVDHFFCDIPALLPLACADTSL  
25 AQRVSFTNVGLISLVCFLILLSYTRITISILSIRTTEGRRRAFSTCSAHLIALCAYGPIITVYLQPT  
PNPMLGTVVQILMNLVGPMLNPLIYTLRNKEVKLTALKTILHRTGHVPES (SEQ ID NO: 507)

30 ATGGAGGTGAAGAACTGCTGCATGGTGACAGAGTTCATCCTTTTGGGAATCCACACACA  
GAGGGGCTGGAGATGACACTTTTGTCTTATTCTTGCCCTTCTATGCCTGCACTCTACTGGG  
AAATGTGTCTATCCTTGTGCTGTTATGTCTTCTGCTCGCCTTCACACACCTATGTATTTCT  
TCCTGGGAAACTTGTCTGTGTTTGACATGGGTTTCTCCTCAGTGACTGTGCTGCAAGTCTTCT  
GCTCTACCTTATGGGGCTGAGCCGACTCATCTCCTACAAAGACTGTGTCTGCCAGCTTTTCT  
TCTTCCATTTCTCGGGAGCATTGAGTGTCTTGTGTTACGGTGATGGCCTATGACCGCTTC  
ACTGCCATCTGTTATCCTCTGCGATACACAGTCATCATGAACCCAAGGATCTGTGTGGCCC  
35 TGGCTGTGGGCACATGGCTGTTAGGGTGCAATTCATTCCAGTATCTTGACCTCCCTCACCTTC  
ACCTTGCCATACTGTGGTCCCAATGAAGTGATCACTTCTTCTGTGACATTCCAGCACTGTT  
GCCCTTGGCCTGTGCTGACACATCCTTAGCCCAGAGGGTGAGCTTCACCAACGTTGGCCTC  
ATATCTCTGTCTGCTTTCTGCTAATCTTTATCCTACACTAGAAATCACAATATCTATCTT  
AAGCATTTCGTACAACTGAGGGCCGTCGCCGTGCCTTCTCCACCTGCAGTGTCACTCATT  
40 GCCATCCTCTGTGCCTATGGGCCCATCATCACTGTCTACCTGCAGCCACACCCAACCCA  
TGCTGGGAACCGTGGTACAAATTCTCATGAATCTGGTAGGACCAATGCTGAACCTTTGAT  
CTATACCTTGAGGAATAAGGAAGTAAAAACAGCCCTGAAAACAATATTGCACAGGACAGG  
CCATGTTCTGAGAGTTAG (SEQ ID NO: 508)

45 **AOLFR324B sequences:**

MPIANDTQFHTSSFLLLGIPGLEDVHIWIGPFFSVYLIALLGNAAIFFVIQTEQSLHEPMYYCLA  
MLDSIDLSTATIPKMLGIFWFNIKEISFGGYLSQMFFHFFTVMESIVLVAMAFDRYIAICKPL  
WYTMILTSKIISLIAGIIVLRSLYMVPLVFLLLRPLFCGHRIPHTYCEHMGIA RLACASIKVNM  
FGLGSISL LLLDVLLIHLSHIRLYAVFCLPSWEARLKALNTCGSHIGVILAFSTPAFFSFFTHCFGH  
50 DIPQYIHIFLANLYVVPPTLNPVIYGVRTKHIRETVLRFFKTDH (SEQ ID NO: 509)

ATGCCTATAGCTAACGACACCCAGTTCATCTTCTCATTCTCTGCTGGGTATCCCAGG  
GCTAGAAGATGTGCACATCTGGATTGGATTCCCTTTTTTCTCTGTGTATCTTATTGCACTCC  
TGGGAAATGCTGCTATCTTCTTTGTGATCCAAACTGAGCAGAGTCTCCATGAGCCCATGTA  
CTACTGCCTGGCCATGTTGGATTCCATTGACCTGAGCTTGTCTACGGCCACCATCCCAA  
55 ATGCTGGGCATCTTCTGGTTCAATATCAAGGAAATATCTTTGGAGGCTACCTTTCTCAGA



TGTTCTTCATCCATTTCTTCACTGTCATGGAGAGCATCGTATTGGTGGCCATGGCCTTTGAC  
CGCTACATTGCCATTTGCAAACCTCTTTGGTACACCATGATCCTCACCAGCAAAATCATCA  
GCCTCATTCAGGCATTGCTGTCTTGAGGAGCTTGTACATGGTCATTCCACTGGTGTTTCT  
5 CCTCTTAAGGTTGCCCTTCTGTGGACATCGTATCATCCCTCATACTTACTGTGAGCACATGG  
GCATTGCCCCGTCTGGCCTGTGCCAGCATCAAAGTCAACATTATGTTTGGTCTTGGCAGTAT  
TTCTCTCTTGTTATTGGATGTGCTCCTTATTATTCTCTCCCATATCAGGATCCTCTATGCTGT  
CTTCTGCCTGCCCTCCTGGGAAGCTCGACTCAAAGCTCTCAACACCTGTGGCTCTCACATT  
GGTGTTATCTTAGCCTTTTCTACACCAGCATTTTTCTCTTTCTTTACACACTGCTTTGGCCAT  
10 GATATCCCAATATATCCACATTTTCTTGGCTAATCTATATGTGGTTGTTCTCCACCCT  
CAATCCTGTAATCTATGGGGTCAGAACCAACATATTAGGGAGACAGTGCTGAGGATTTTC  
TTCAAGACAGATCACTAA (SEQ ID NO: 510)

**AOLFR328 sequences:**

15 MALGNHSTITEFLLGLSADPNIRALLFVLFLGIYLLTIMENLMLLLVIRADSCLHKPMYFFLSH  
LSFVDLCFSSVIVPKMLENLLSQRKTISVEGCLAQVFFVFTAGTEACLLSGMAYDRHAAIRRP  
LLYGQIMGKQLYMHLVWGSWGLGFLDALINVLLAVNMVFCEAKIIHHYSYEMPSLLPLSCSDI  
SRLIVLLCSTLLHGLGNFLLVFLSYTRIISTILSISSTSGRSKAFSTCSAHLTAVTLYYGSGLLRHL  
MPNSGSPIELIFSVQYTVVTPMLNSLIYSLKNKEVKVALKRTLEKYLQYTRR (SEQ ID NO: 511)

20 ATGGCCTTGGGGAATCACAGCACCATCACCGAGTTCCTCCTCCTTGGGCTGTCTGCCGACC  
CCAACATCCGGGCTCTGCTCTTTGTGCTGTTCTTGGGGATTTACCTCCTGACCATAATGGA  
AAACCTGATGCTGCTGCTCGTGATCAGGGCTGATTCTTGTCTCCATAAGCCCATGTATTTCT  
TCCTGAGTCACCTCTCTTTTGTGATCTCTGCTTCTCTTCAGTCATTGTGCCCAAGATGCTG  
25 GAGAACCTCCTGTCACAGAGGAAAACCATTTAGTAGAGGGCTGCCTGGCTCAGGTCTTCT  
TTGTGTTTGTCACTGCAGGGACTGAAGCCTGCCTTCTCTCAGGGATGGCCTATGACCGCCA  
TGCTGCCATCCGCCGCCCACTACTTTATGGACAGATCATGGGTAAACAGCTGTATATGCAC  
CTTGTGTGGGGCTCATGGGGACTGGGCTTTCTGGACGCACTCATCAATGTCCTCCTAGCTG  
TAAACATGGTCTTTTGTGAAGCCAAAATCATTACCACTACAGCTATGAGATGCCATCCCT  
CCTCCCTCTGTCTGCTCTGATATCTCCAGAAGCCTCATCGTTTTGCTCTGCTCCACTCTCC  
30 TACATGGGCTGGGAACTTCCTTTTGGTCTTCTTATCCTACACCCGTATAATCTCTACCATC  
CTAAGCATCAGCTCTACCTCGGGCAGAAGCAAGGCCTTCTCCACCTGCTCTGCCCACCTCA  
CTGCAGTGACACTTTACTATGGCTCAGGTTTGCTCCGCCATCTCATGCCAACTCAGGTTC  
CCCCATAGAGTTGATCTTCTCTGTGCAGTATACTGTAGTCACTCCCATGCTGAATTCCTCA  
TCTATAGCCTGAAAAATAAGGAAGTGAAGGTAGCTCTGAAAAGAACTTTGGAAAAATATT  
35 TGCAATATACCAGACGTTGA (SEQ ID NO: 512)

Claims:

1. A method for representing sensory perception of one or more odorants comprising:
  - 5 (a) providing a representative class of  $n$  olfactory receptors or ligand-binding domains thereof;
  - (b) measuring values  $X_1$  to  $X_n$  representative of at least one activity of the one or more odorants selected from the group consisting of binding of the one or more odorants to the ligand-binding domain of at least one of the  $n$  olfactory receptors, activating at least one of the  $n$  olfactory receptors with the one or more odorants, and blocking at least one of the  $n$  olfactory receptors with the one or more odorants; and
  - 10 (c) generating a representation of sensory perception from the values  $X_1$  to  $X_n$ ;
- 15 wherein at least one of the  $n$  olfactory receptors has an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 25, SEQ ID NO: 27, SEQ ID NO: 29, SEQ ID NO: 31, SEQ ID NO: 33, SEQ ID NO: 35, SEQ ID NO: 37, SEQ ID NO: 39, SEQ ID NO: 41, SEQ ID NO: 43, SEQ ID NO: 45, SEQ ID NO: 47, SEQ ID NO: 49, SEQ ID NO: 51, SEQ ID NO: 53, SEQ ID NO: 55, SEQ ID NO: 57, SEQ ID NO: 59, SEQ ID NO: 61, SEQ ID NO: 63, SEQ ID NO: 65, SEQ ID NO: 67, SEQ ID NO: 69, SEQ ID NO: 71, SEQ ID NO: 73, SEQ ID NO: 75, SEQ ID NO: 77, SEQ ID NO: 79, SEQ ID NO: 81, SEQ ID NO: 83, SEQ ID NO: 85, SEQ ID NO: 87, SEQ ID NO: 89, SEQ ID NO: 91, SEQ ID NO: 93, SEQ ID NO: 95, SEQ ID NO: 97, SEQ ID NO: 99, SEQ ID NO: 101, SEQ ID NO: 103, SEQ ID NO: 105, SEQ ID NO: 107, SEQ ID NO: 109, SEQ ID NO: 111, SEQ ID NO: 113, SEQ ID NO: 115, SEQ ID NO: 117, SEQ ID NO: 119, SEQ ID NO: 121, SEQ ID NO: 123, SEQ ID NO: 125, SEQ ID NO: 127, SEQ ID NO: 129, SEQ ID NO: 131, SEQ ID NO: 133, SEQ ID NO: 135, SEQ ID NO: 137, SEQ ID NO: 139, SEQ ID NO: 141, SEQ ID NO: 143, SEQ ID NO: 145, SEQ ID NO: 147, SEQ ID NO: 149, SEQ ID NO: 151, SEQ ID NO: 153, SEQ ID NO: 155, SEQ ID NO: 157, SEQ ID NO: 159, SEQ ID NO: 161, SEQ ID NO: 163, SEQ ID NO: 165, SEQ ID NO: 167, SEQ ID NO: 169,
- 20
- 25
- 30

SEQ ID NO: 171, SEQ ID NO: 173, SEQ ID NO: 175, SEQ ID NO: 177, SEQ ID  
NO: 179, SEQ ID NO: 181, SEQ ID NO: 183, SEQ ID NO: 185, SEQ ID NO: 187,  
SEQ ID NO: 189, SEQ ID NO: 191, SEQ ID NO: 193, SEQ ID NO: 195, SEQ ID  
NO: 197, SEQ ID NO: 199, SEQ ID NO: 201, SEQ ID NO: 203, SEQ ID NO: 205,  
5 SEQ ID NO: 207, SEQ ID NO: 209, SEQ ID NO: 211, SEQ ID NO: 213, SEQ ID  
NO: 215, SEQ ID NO: 217, SEQ ID NO: 219, SEQ ID NO: 221, SEQ ID NO: 223,  
SEQ ID NO: 225, SEQ ID NO: 227, SEQ ID NO: 229, SEQ ID NO: 231, SEQ ID  
NO: 233, SEQ ID NO: 235, SEQ ID NO: 237, SEQ ID NO: 239, SEQ ID NO: 241,  
SEQ ID NO: 243, SEQ ID NO: 245, SEQ ID NO: 247, SEQ ID NO: 249, SEQ ID  
10 NO: 251, SEQ ID NO: 253, SEQ ID NO: 255, SEQ ID NO: 257, SEQ ID NO: 259,  
SEQ ID NO: 261, SEQ ID NO: 263, SEQ ID NO: 265, SEQ ID NO: 267, SEQ ID  
NO: 269, SEQ ID NO: 271, SEQ ID NO: 273, SEQ ID NO: 275, SEQ ID NO: 277,  
SEQ ID NO: 279, SEQ ID NO: 281, SEQ ID NO: 283, SEQ ID NO: 285, SEQ ID  
NO: 287, SEQ ID NO: 289, SEQ ID NO: 291, SEQ ID NO: 293, SEQ ID NO: 295,  
15 SEQ ID NO: 297, SEQ ID NO: 299, SEQ ID NO: 301, SEQ ID NO: 303, SEQ ID  
NO: 305, SEQ ID NO: 307, SEQ ID NO: 309, SEQ ID NO: 311, SEQ ID NO: 313,  
SEQ ID NO: 315, SEQ ID NO: 317, SEQ ID NO: 319, SEQ ID NO: 321, SEQ ID  
NO: 323, SEQ ID NO: 325, SEQ ID NO: 327, SEQ ID NO: 329, SEQ ID NO: 331,  
SEQ ID NO: 333, SEQ ID NO: 335, SEQ ID NO: 337, SEQ ID NO: 339, SEQ ID  
20 NO: 341, SEQ ID NO: 343, SEQ ID NO: 345, SEQ ID NO: 347, SEQ ID NO: 349,  
SEQ ID NO: 351, SEQ ID NO: 353, SEQ ID NO: 355, SEQ ID NO: 357, SEQ ID  
NO: 359, SEQ ID NO: 361, SEQ ID NO: 363, SEQ ID NO: 365, SEQ ID NO: 367,  
SEQ ID NO: 369, SEQ ID NO: 371, SEQ ID NO: 373, SEQ ID NO: 375, SEQ ID  
NO: 377, SEQ ID NO: 379, SEQ ID NO: 381, SEQ ID NO: 383, SEQ ID NO: 385,  
25 SEQ ID NO: 387, SEQ ID NO: 389, SEQ ID NO: 391, SEQ ID NO: 393, SEQ ID  
NO: 395, SEQ ID NO: 397, SEQ ID NO: 399, SEQ ID NO: 401, SEQ ID NO: 403,  
SEQ ID NO: 405, SEQ ID NO: 407, SEQ ID NO: 409, SEQ ID NO: 411, SEQ ID  
NO: 413, SEQ ID NO: 415, SEQ ID NO: 417, SEQ ID NO: 419, SEQ ID NO: 421,  
SEQ ID NO: 423, SEQ ID NO: 425, SEQ ID NO: 427, SEQ ID NO: 429, SEQ ID  
30 NO: 431, SEQ ID NO: 433, SEQ ID NO: 435, SEQ ID NO: 437, SEQ ID NO: 439,  
SEQ ID NO: 441, SEQ ID NO: 443, SEQ ID NO: 445, SEQ ID NO: 447, SEQ ID  
NO: 449, SEQ ID NO: 451, SEQ ID NO: 453, SEQ ID NO: 455, SEQ ID NO: 457,  
SEQ ID NO: 459, SEQ ID NO: 461, SEQ ID NO: 463, SEQ ID NO: 465, SEQ ID

NO: 467, SEQ ID NO: 469, SEQ ID NO: 471, SEQ ID NO: 473, SEQ ID NO: 475,  
SEQ ID NO: 477, SEQ ID NO: 479, SEQ ID NO: 481, SEQ ID NO: 483, SEQ ID  
NO: 485, SEQ ID NO: 487, SEQ ID NO: 489, SEQ ID NO: 491, SEQ ID NO: 493,  
SEQ ID NO: 495, SEQ ID NO: 497, SEQ ID NO: 499, SEQ ID NO: 501, SEQ ID  
5 NO: 503, SEQ ID NO: 505, SEQ ID NO: 507, SEQ ID NO: 509 and SEQ ID NO:  
511.

2. The method of Claim 1, wherein at least one of the olfactory receptors  
specifically recognizes the odorant, and there are between 5 and 350 of the n olfactory  
10 receptors selected from the listed amino acid sequences.

3. The method of Claim 1, wherein at least two different activities are measured  
to provide the values  $X_1$  to  $X_n$ .

15 4. The method of Claim 1, wherein each odorant receptor is expressed in cells,  
and the cells expressing each odorant receptor are located at an identifiable position.

5. The method of Claim 1, wherein at least one olfactory receptor is soluble, and  
binding of odorant to a ligand-binding domain of the soluble olfactory receptor is  
20 measured in solution.

6. The method of Claim 1, wherein at least one olfactory receptor is in solid state,  
and binding of odorant to a ligand-binding domain of the solid-state olfactory receptor  
is measured on a substrate.

25 7. The method of Claim 1, wherein the value measured for binding is above a  
preset limit for specific binding to olfactory receptors.

8. The method of Claim 1, wherein the value measured for activating an olfactory  
30 receptor is derived from a signal selected from the group consisting of intracellular  
 $\text{Ca}^{2+}$ , cAMP, cGMP and IP3.

9. The method of Claim 1, wherein the value measured for activating an olfactory receptor is above a preset limit for specific activation.
10. The method of Claim 1, wherein the value measured for blocking an olfactory  
5 receptor is at least a reduction in binding of the odorant or activation by the odorant.
11. The method of Claim 1, wherein the representation of sensory perception is generated with a neural network.
- 10 12. A biosensor comprised of the  $n$  ligand-binding domains or olfactory receptors of Claim 1.
13. A method for producing a database of odorant representations comprising:  
(a) providing one or more known odorants and  
15 (b) generating a representation of the one or more known odorants in accordance with the method of Claim 1 to produce the database.
14. A database produced by Claim 13.
- 20 15. A method of identifying an unknown odorant comprising:  
(a) measuring values  $X_1$  to  $X_n$  representative of at least one activity selected from the group consisting of binding the unknown odorant to a ligand-binding domain of at least one of  $n$  olfactory receptors, activating at least one of  $n$  olfactory receptors with the unknown odorant, and blocking at  
25 least one of  $n$  olfactory receptors with the unknown odorant;  
(b) generating a representation of the unknown odorant from the values  $X_1$  to  $X_n$ ; and  
(c) comparing the unknown odorant's representation to the database of Claim 14 to identify the known odorant which is most similar in  
30 representation.
16. A method of producing an artificial odorant comprising:

- 5 (a) measuring values  $X_1$  to  $X_n$  representative of at least one activity selected from the group consisting of binding a desirable odorant to a ligand-binding domain of at least one of  $n$  olfactory receptors, activating at least one of  $n$  olfactory receptors with a desirable odorant, and blocking at least one of  $n$  olfactory receptors with a desirable odorant;
- (b) generating a representation of the desirable odorant from the values  $X_1$  to  $X_n$ ;
- 10 (c) decomposing the desirable odorant's representation into representations of known odorants from the database of Claim 14 or superposing known odorants' representations from the database to reproduce the desirable odorant; and
- (d) formulating the known odorants to reproduce sensory perception of the desirable odorant and thereby produce the artificial odorant.

15 17. An artificial odorant produced by Claim 16.

18. A method of identifying a primary odorant related to sensory perception comprising:

- 20 (a) providing a representative class of  $n$  olfactory receptors or ligand-binding domains thereof,
- (b) measuring at least one activity of a odorant selected from the group consisting of binding of the candidate odorant to the ligand-binding domain of at least one of the  $n$  olfactory receptors and activating with the candidate odorant at least one of the  $n$  olfactory receptors, and
- 25 (c) identifying the candidate odorant as a primary odorant if only one or less than 10% of the representative class of  $n$  olfactory receptors is bound or activated;

wherein at least one of the  $n$  olfactory receptors has an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 25, SEQ ID NO: 27, SEQ ID NO: 29, SEQ ID NO: 31, SEQ ID NO: 33, SEQ ID NO: 35, SEQ ID NO: 37, SEQ ID NO: 39, SEQ ID NO: 41, SEQ ID NO: 43, SEQ ID NO: 45, SEQ ID

NO: 47, SEQ ID NO: 49, SEQ ID NO: 51, SEQ ID NO: 53, SEQ ID NO: 55, SEQ ID  
NO: 57, SEQ ID NO: 59, SEQ ID NO: 61, SEQ ID NO: 63, SEQ ID NO: 65, SEQ ID  
NO: 67, SEQ ID NO: 69, SEQ ID NO: 71, SEQ ID NO: 73, SEQ ID NO: 75, SEQ ID  
NO: 77, SEQ ID NO: 79, SEQ ID NO: 81, SEQ ID NO: 83, SEQ ID NO: 85, SEQ ID  
5 NO: 87, SEQ ID NO: 89, SEQ ID NO: 91, SEQ ID NO: 93, SEQ ID NO: 95, SEQ ID  
NO: 97, SEQ ID NO: 99, SEQ ID NO: 101, SEQ ID NO: 103, SEQ ID NO: 105, SEQ  
ID NO: 107, SEQ ID NO: 109, SEQ ID NO: 111, SEQ ID NO: 113, SEQ ID NO: 115,  
SEQ ID NO: 117, SEQ ID NO: 119, SEQ ID NO: 121, SEQ ID NO: 123, SEQ ID  
NO: 125, SEQ ID NO: 127, SEQ ID NO: 129, SEQ ID NO: 131, SEQ ID NO: 133,  
10 SEQ ID NO: 135, SEQ ID NO: 137, SEQ ID NO: 139, SEQ ID NO: 141, SEQ ID  
NO: 143, SEQ ID NO: 145, SEQ ID NO: 147, SEQ ID NO: 149, SEQ ID NO: 151,  
SEQ ID NO: 153, SEQ ID NO: 155, SEQ ID NO: 157, SEQ ID NO: 159, SEQ ID  
NO: 161, SEQ ID NO: 163, SEQ ID NO: 165, SEQ ID NO: 167, SEQ ID NO: 169,  
SEQ ID NO: 171, SEQ ID NO: 173, SEQ ID NO: 175, SEQ ID NO: 177, SEQ ID  
15 NO: 179, SEQ ID NO: 181, SEQ ID NO: 183, SEQ ID NO: 185, SEQ ID NO: 187,  
SEQ ID NO: 189, SEQ ID NO: 191, SEQ ID NO: 193, SEQ ID NO: 195, SEQ ID  
NO: 197, SEQ ID NO: 199, SEQ ID NO: 201, SEQ ID NO: 203, SEQ ID NO: 205,  
SEQ ID NO: 207, SEQ ID NO: 209, SEQ ID NO: 211, SEQ ID NO: 213, SEQ ID  
NO: 215, SEQ ID NO: 217, SEQ ID NO: 219, SEQ ID NO: 221, SEQ ID NO: 223,  
20 SEQ ID NO: 225, SEQ ID NO: 227, SEQ ID NO: 229, SEQ ID NO: 231, SEQ ID  
NO: 233, SEQ ID NO: 235, SEQ ID NO: 237, SEQ ID NO: 239, SEQ ID NO: 241,  
SEQ ID NO: 243, SEQ ID NO: 245, SEQ ID NO: 247, SEQ ID NO: 249, SEQ ID  
NO: 251, SEQ ID NO: 253, SEQ ID NO: 255, SEQ ID NO: 257, SEQ ID NO: 259,  
SEQ ID NO: 261, SEQ ID NO: 263, SEQ ID NO: 265, SEQ ID NO: 267, SEQ ID  
25 NO: 269, SEQ ID NO: 271, SEQ ID NO: 273, SEQ ID NO: 275, SEQ ID NO: 277,  
SEQ ID NO: 279, SEQ ID NO: 281, SEQ ID NO: 283, SEQ ID NO: 285, SEQ ID  
NO: 287, SEQ ID NO: 289, SEQ ID NO: 291, SEQ ID NO: 293, SEQ ID NO: 295,  
SEQ ID NO: 297, SEQ ID NO: 299, SEQ ID NO: 301, SEQ ID NO: 303, SEQ ID  
NO: 305, SEQ ID NO: 307, SEQ ID NO: 309, SEQ ID NO: 311, SEQ ID NO: 313,  
30 SEQ ID NO: 315, SEQ ID NO: 317, SEQ ID NO: 319, SEQ ID NO: 321, SEQ ID  
NO: 323, SEQ ID NO: 325, SEQ ID NO: 327, SEQ ID NO: 329, SEQ ID NO: 331,  
SEQ ID NO: 333, SEQ ID NO: 335, SEQ ID NO: 337, SEQ ID NO: 339, SEQ ID  
NO: 341, SEQ ID NO: 343, SEQ ID NO: 345, SEQ ID NO: 347, SEQ ID NO: 349,



SEQ ID NO: 351, SEQ ID NO: 353, SEQ ID NO: 355, SEQ ID NO: 357, SEQ ID NO: 359, SEQ ID NO: 361, SEQ ID NO: 363, SEQ ID NO: 365, SEQ ID NO: 367, SEQ ID NO: 369, SEQ ID NO: 371, SEQ ID NO: 373, SEQ ID NO: 375, SEQ ID NO: 377, SEQ ID NO: 379, SEQ ID NO: 381, SEQ ID NO: 383, SEQ ID NO: 385, SEQ ID NO: 387, SEQ ID NO: 389, SEQ ID NO: 391, SEQ ID NO: 393, SEQ ID NO: 395, SEQ ID NO: 397, SEQ ID NO: 399, SEQ ID NO: 401, SEQ ID NO: 403, SEQ ID NO: 405, SEQ ID NO: 407, SEQ ID NO: 409, SEQ ID NO: 411, SEQ ID NO: 413, SEQ ID NO: 415, SEQ ID NO: 417, SEQ ID NO: 419, SEQ ID NO: 421, SEQ ID NO: 423, SEQ ID NO: 425, SEQ ID NO: 427, SEQ ID NO: 429, SEQ ID NO: 431, SEQ ID NO: 433, SEQ ID NO: 435, SEQ ID NO: 437, SEQ ID NO: 439, SEQ ID NO: 441, SEQ ID NO: 443, SEQ ID NO: 445, SEQ ID NO: 447, SEQ ID NO: 449, SEQ ID NO: 451, SEQ ID NO: 453, SEQ ID NO: 455, SEQ ID NO: 457, SEQ ID NO: 459, SEQ ID NO: 461, SEQ ID NO: 463, SEQ ID NO: 465, SEQ ID NO: 467, SEQ ID NO: 469, SEQ ID NO: 471, SEQ ID NO: 473, SEQ ID NO: 475, SEQ ID NO: 477, SEQ ID NO: 479, SEQ ID NO: 481, SEQ ID NO: 483, SEQ ID NO: 485, SEQ ID NO: 487, SEQ ID NO: 489, SEQ ID NO: 491, SEQ ID NO: 493, SEQ ID NO: 495, SEQ ID NO: 497, SEQ ID NO: 499, SEQ ID NO: 501, SEQ ID NO: 503, SEQ ID NO: 505, SEQ ID NO: 507, SEQ ID NO: 509 and SEQ ID NO: 511.

20

19. A primary odorant identified by Claim 18.

20. A method of identifying a compound which blocks activation by a odorant of at least one olfactory receptor comprising:

- 25 (a) producing a structurally-related candidate compound from a ligand of the at least one olfactory receptor,
- (b) measuring activation by the odorant of the at least one olfactory receptor with the candidate compound, and
- (c) identifying the candidate compound as a compound which blocks activation if activation of the at least one olfactory receptor is reduced or
- 30 inhibited;

wherein at least one of the olfactory receptors has an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID

NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID  
NO: 17, SEQ ID NO: 19, SEQ ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 25, SEQ ID  
NO: 27, SEQ ID NO: 29, SEQ ID NO: 31, SEQ ID NO: 33, SEQ ID NO: 35, SEQ ID  
NO: 37, SEQ ID NO: 39, SEQ ID NO: 41, SEQ ID NO: 43, SEQ ID NO: 45, SEQ ID  
5 NO: 47, SEQ ID NO: 49, SEQ ID NO: 51, SEQ ID NO: 53, SEQ ID NO: 55, SEQ ID  
NO: 57, SEQ ID NO: 59, SEQ ID NO: 61, SEQ ID NO: 63, SEQ ID NO: 65, SEQ ID  
NO: 67, SEQ ID NO: 69, SEQ ID NO: 71, SEQ ID NO: 73, SEQ ID NO: 75, SEQ ID  
NO: 77, SEQ ID NO: 79, SEQ ID NO: 81, SEQ ID NO: 83, SEQ ID NO: 85, SEQ ID  
NO: 87, SEQ ID NO: 89, SEQ ID NO: 91, SEQ ID NO: 93, SEQ ID NO: 95, SEQ ID  
10 NO: 97, SEQ ID NO: 99, SEQ ID NO: 101, SEQ ID NO: 103, SEQ ID NO: 105, SEQ  
ID NO: 107, SEQ ID NO: 109, SEQ ID NO: 111, SEQ ID NO: 113, SEQ ID NO: 115,  
SEQ ID NO: 117, SEQ ID NO: 119, SEQ ID NO: 121, SEQ ID NO: 123, SEQ ID  
NO: 125, SEQ ID NO: 127, SEQ ID NO: 129, SEQ ID NO: 131, SEQ ID NO: 133,  
SEQ ID NO: 135, SEQ ID NO: 137, SEQ ID NO: 139, SEQ ID NO: 141, SEQ ID  
15 NO: 143, SEQ ID NO: 145, SEQ ID NO: 147, SEQ ID NO: 149, SEQ ID NO: 151,  
SEQ ID NO: 153, SEQ ID NO: 155, SEQ ID NO: 157, SEQ ID NO: 159, SEQ ID  
NO: 161, SEQ ID NO: 163, SEQ ID NO: 165, SEQ ID NO: 167, SEQ ID NO: 169,  
SEQ ID NO: 171, SEQ ID NO: 173, SEQ ID NO: 175, SEQ ID NO: 177, SEQ ID  
NO: 179, SEQ ID NO: 181, SEQ ID NO: 183, SEQ ID NO: 185, SEQ ID NO: 187,  
20 SEQ ID NO: 189, SEQ ID NO: 191, SEQ ID NO: 193, SEQ ID NO: 195, SEQ ID  
NO: 197, SEQ ID NO: 199, SEQ ID NO: 201, SEQ ID NO: 203, SEQ ID NO: 205,  
SEQ ID NO: 207, SEQ ID NO: 209, SEQ ID NO: 211, SEQ ID NO: 213, SEQ ID  
NO: 215, SEQ ID NO: 217, SEQ ID NO: 219, SEQ ID NO: 221, SEQ ID NO: 223,  
SEQ ID NO: 225, SEQ ID NO: 227, SEQ ID NO: 229, SEQ ID NO: 231, SEQ ID  
25 NO: 233, SEQ ID NO: 235, SEQ ID NO: 237, SEQ ID NO: 239, SEQ ID NO: 241,  
SEQ ID NO: 243, SEQ ID NO: 245, SEQ ID NO: 247, SEQ ID NO: 249, SEQ ID  
NO: 251, SEQ ID NO: 253, SEQ ID NO: 255, SEQ ID NO: 257, SEQ ID NO: 259,  
SEQ ID NO: 261, SEQ ID NO: 263, SEQ ID NO: 265, SEQ ID NO: 267, SEQ ID  
NO: 269, SEQ ID NO: 271, SEQ ID NO: 273, SEQ ID NO: 275, SEQ ID NO: 277,  
30 SEQ ID NO: 279, SEQ ID NO: 281, SEQ ID NO: 283, SEQ ID NO: 285, SEQ ID  
NO: 287, SEQ ID NO: 289, SEQ ID NO: 291, SEQ ID NO: 293, SEQ ID NO: 295,  
SEQ ID NO: 297, SEQ ID NO: 299, SEQ ID NO: 301, SEQ ID NO: 303, SEQ ID  
NO: 305, SEQ ID NO: 307, SEQ ID NO: 309, SEQ ID NO: 311, SEQ ID NO: 313,

SEQ ID NO: 315, SEQ ID NO: 317, SEQ ID NO: 319, SEQ ID NO: 321, SEQ ID NO: 323, SEQ ID NO: 325, SEQ ID NO: 327, SEQ ID NO: 329, SEQ ID NO: 331, SEQ ID NO: 333, SEQ ID NO: 335, SEQ ID NO: 337, SEQ ID NO: 339, SEQ ID NO: 341, SEQ ID NO: 343, SEQ ID NO: 345, SEQ ID NO: 347, SEQ ID NO: 349, SEQ ID NO: 351, SEQ ID NO: 353, SEQ ID NO: 355, SEQ ID NO: 357, SEQ ID NO: 359, SEQ ID NO: 361, SEQ ID NO: 363, SEQ ID NO: 365, SEQ ID NO: 367, SEQ ID NO: 369, SEQ ID NO: 371, SEQ ID NO: 373, SEQ ID NO: 375, SEQ ID NO: 377, SEQ ID NO: 379, SEQ ID NO: 381, SEQ ID NO: 383, SEQ ID NO: 385, SEQ ID NO: 387, SEQ ID NO: 389, SEQ ID NO: 391, SEQ ID NO: 393, SEQ ID NO: 395, SEQ ID NO: 397, SEQ ID NO: 399, SEQ ID NO: 401, SEQ ID NO: 403, SEQ ID NO: 405, SEQ ID NO: 407, SEQ ID NO: 409, SEQ ID NO: 411, SEQ ID NO: 413, SEQ ID NO: 415, SEQ ID NO: 417, SEQ ID NO: 419, SEQ ID NO: 421, SEQ ID NO: 423, SEQ ID NO: 425, SEQ ID NO: 427, SEQ ID NO: 429, SEQ ID NO: 431, SEQ ID NO: 433, SEQ ID NO: 435, SEQ ID NO: 437, SEQ ID NO: 439, SEQ ID NO: 441, SEQ ID NO: 443, SEQ ID NO: 445, SEQ ID NO: 447, SEQ ID NO: 449, SEQ ID NO: 451, SEQ ID NO: 453, SEQ ID NO: 455, SEQ ID NO: 457, SEQ ID NO: 459, SEQ ID NO: 461, SEQ ID NO: 463, SEQ ID NO: 465, SEQ ID NO: 467, SEQ ID NO: 469, SEQ ID NO: 471, SEQ ID NO: 473, SEQ ID NO: 475, SEQ ID NO: 477, SEQ ID NO: 479, SEQ ID NO: 481, SEQ ID NO: 483, SEQ ID NO: 485, SEQ ID NO: 487, SEQ ID NO: 489, SEQ ID NO: 491, SEQ ID NO: 493, SEQ ID NO: 495, SEQ ID NO: 497, SEQ ID NO: 499, SEQ ID NO: 501, SEQ ID NO: 503, SEQ ID NO: 505, SEQ ID NO: 507, SEQ ID NO: 509 and SEQ ID NO: 511.

25 21. The method of Claim 20, wherein the ligand is a primary odorant.

22. A compound which blocks activation of an olfactory receptor identified by Claim 20.